(lp0
(dp1
S'line'
p2
VOur results demonstrated that hsa-miR-483-5p, hsa-miR-675, hsa-miR-139-3p, hsa-miR-598, hsa-miR-625 and hsa-miR-187 could serve as prognostic and predictive markers for survival of BDC patients and could potentially be provided as targets for future therapy.
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I104
sS'uniprot'
p8
S''
p9
sS'lengthInChars'
p10
I11
sS'name'
p11
Vhsa-miR-187
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I75
sg8
g9
sg10
I11
sg11
Vhsa-miR-598
p15
sg13
I1
sa(dp16
g7
I46
sg8
g9
sg10
I11
sg11
Vhsa-miR-675
p17
sg13
I1
sa(dp18
g7
I30
sg8
g9
sg10
I14
sg11
Vhsa-miR-483-5p
p19
sg13
I1
sa(dp20
g7
I88
sg8
g9
sg10
I11
sg11
Vhsa-miR-625
p21
sg13
I1
sa(dp22
g7
I59
sg8
g9
sg10
I14
sg11
Vhsa-miR-139-3p
p23
sg13
I1
sasS'diseases'
p24
(lp25
(dp26
g7
I30
sS'cui'
p27
VC0393754
p28
sg10
I3
sg11
Vhsa
p29
sg13
I1
sa(dp30
g7
I30
sg27
VC0393754
p31
sg10
I3
sg11
Vhsa
p32
sg13
I1
sa(dp33
g7
I30
sg27
VC0393754
p34
sg10
I3
sg11
Vhsa
p35
sg13
I1
sa(dp36
g7
I181
sg27
VC1266044
p37
sg10
I3
sg11
VBDC
p38
sg13
I1
sa(dp39
g7
I30
sg27
VC0393754
p40
sg10
I3
sg11
Vhsa
p41
sg13
I1
sa(dp42
g7
I30
sg27
VC0393754
p43
sg10
I3
sg11
Vhsa
p44
sg13
I1
sa(dp45
g7
I30
sg27
VC0393754
p46
sg10
I3
sg11
Vhsa
p47
sg13
I1
sasa(dp48
g2
VTargeting the centromeres of chromosomes 3, 7, 17 (CEP3, 7, 17) and the 9p21-locus (LSI9p21) for diagnosing bladder cancer (BC) is time- and cost-intensive and requires a manual investigation of the sample by a well-trained investigator thus overall limiting its use in clinical diagnostics and large-scaled epidemiological studies.
p49
sg4
(lp50
sg24
(lp51
(dp52
g7
I108
sg27
VC0699885
p53
sg10
I14
sg11
Vbladder cancer
p54
sg13
I2
sa(dp55
g7
I124
sg27
VC0699885
p56
sg10
I2
sg11
VBC
p57
sg13
I1
sasa(dp58
g2
VOssification of the ligamentum flavum (OLF) causing compressive cervical myelopathy or radiculopathy is rare.
p59
sg4
(lp60
sg24
(lp61
(dp62
g7
I87
sg27
VC0700594
p63
sg10
I13
sg11
Vradiculopathy
p64
sg13
I1
sa(dp65
g7
I64
sg27
VC0149645
p66
sg10
I19
sg11
Vcervical myelopathy
p67
sg13
I2
sasa(dp68
g2
VHowever, thoracic OLF rarely causes radiculopathy.
p69
sg4
(lp70
sg24
(lp71
(dp72
g7
I36
sg27
VC0700594
p73
sg10
I13
sg11
Vradiculopathy
p74
sg13
I1
sa(dp75
g7
I9
sg27
VC0729233
p76
sg10
I8
sg11
Vthoracic
p77
sg13
I1
sasa(dp78
g2
VWe report a rare case of thoracic radiculopathy caused by OLF.
p79
sg4
(lp80
sg24
(lp81
(dp82
g7
I25
sg27
VC0154737
p83
sg10
I22
sg11
Vthoracic radiculopathy
p84
sg13
I2
sasa(dp85
g2
VThoracic radiculopathy caused by OLF was suspected.
p86
sg4
(lp87
sg24
(lp88
(dp89
g7
I0
sg27
VC0154737
p90
sg10
I22
sg11
VThoracic radiculopathy
p91
sg13
I2
sasa(dp92
g2
VThoracic OLF rarely causes radiculopathy, but it should be considered as a differential diagnosis of thoracic radicular pain.
p93
sg4
(lp94
sg24
(lp95
(dp96
g7
I101
sg27
VC0729233
p97
sg10
I8
sg11
Vthoracic
p98
sg13
I1
sa(dp99
g7
I0
sg27
VC0729233
p100
sg10
I8
sg11
VThoracic
p101
sg13
I1
sa(dp102
g7
I27
sg27
VC0700594
p103
sg10
I13
sg11
Vradiculopathy
p104
sg13
I1
sa(dp105
g7
I110
sg27
VC0278147
p106
sg10
I14
sg11
Vradicular pain
p107
sg13
I2
sasa(dp108
g2
VOLF should be kept in mind if a patient presents with radiculopathy, particularly in the cervical region, for which surgical intervention is contemplated.
p109
sg4
(lp110
(dp111
g7
I0
sg8
g9
sg10
I3
sg11
VOLF
p112
sg13
I1
sasg24
(lp113
(dp114
g7
I54
sg27
VC0700594
p115
sg10
I13
sg11
Vradiculopathy
p116
sg13
I1
sasa(dp117
g2
VRadiculopathy resulting from ossification of the ligamentum flavum (OLF) is extremely rare and concerns only intercostal neuralgias.
p118
sg4
(lp119
sg24
(lp120
(dp121
g7
I121
sg27
VC0027796
p122
sg10
I10
sg11
Vneuralgias
p123
sg13
I1
sa(dp124
g7
I0
sg27
VC0700594
p125
sg10
I13
sg11
VRadiculopathy
p126
sg13
I1
sasa(dp127
g2
VWe describe a 37-year-old Caucasian woman with a lumbar radiculopathy revealing an OLF.
p128
sg4
(lp129
sg24
(lp130
(dp131
g7
I49
sg27
VC1263855
p132
sg10
I20
sg11
Vlumbar radiculopathy
p133
sg13
I2
sasa(dp134
g2
VPancreatitis was induced in C57Bl/6 wild-type (control), cathepsin B-knockout, and cathepsin L-knockout mice by partial pancreatic duct ligation with supramaximal caerulein injection, or by repetitive supramaximal caerulein injections alone.
p135
sg4
(lp136
(dp137
g7
I57
sg8
VP07858
p138
sg10
I11
sg11
Vcathepsin B
p139
sg13
I2
sa(dp140
g7
I83
sg8
VP07711
p141
sg10
I11
sg11
Vcathepsin L
p142
sg13
I2
sasg24
(lp143
(dp144
g7
I0
sg27
VC0030305
p145
sg10
I12
sg11
VPancreatitis
p146
sg13
I1
sasa(dp147
g2
VTrypsinogen became activated in macrophages cultured with purified trypsinogen or co-cultured with pancreatic acini and in pancreata of mice with pancreatitis; trypsinogen activation required macrophage endocytosis and expression and activity of cathepsin B, and was sensitive to pH.
p148
sg4
(lp149
(dp150
g7
I67
sg8
VP07478
p151
sg10
I11
sg11
Vtrypsinogen
p152
sg13
I1
sa(dp153
g7
I246
sg8
VP07858
p154
sg10
I11
sg11
Vcathepsin B
p155
sg13
I2
sa(dp156
g7
I67
sg8
VP07478
p157
sg10
I11
sg11
Vtrypsinogen
p158
sg13
I1
sa(dp159
g7
I0
sg8
VP07478
p160
sg10
I11
sg11
VTrypsinogen
p161
sg13
I1
sasg24
(lp162
(dp163
g7
I146
sg27
VC0030305
p164
sg10
I12
sg11
Vpancreatitis
p165
sg13
I1
sasa(dp166
g2
VActivation of trypsinogen in macrophages resulted in translocation of NF-kB and production of inflammatory cytokines; mice without trypsinogen activation (cathepsin B-knockout mice) in macrophages developed less severe pancreatitis compared with control mice.
p167
sg4
(lp168
(dp169
g7
I131
sg8
VP07478
p170
sg10
I22
sg11
Vtrypsinogen activation
p171
sg13
I2
sa(dp172
g7
I14
sg8
VP07478
p173
sg10
I11
sg11
Vtrypsinogen
p174
sg13
I1
sa(dp175
g7
I155
sg8
VP07858
p176
sg10
I11
sg11
Vcathepsin B
p177
sg13
I2
sasg24
(lp178
(dp179
g7
I53
sg27
VC0040715
p180
sg10
I13
sg11
Vtranslocation
p181
sg13
I1
sa(dp182
g7
I219
sg27
VC0030305
p183
sg10
I12
sg11
Vpancreatitis
p184
sg13
I1
sasa(dp185
g2
VTransfer of macrophage from control mice to cathepsin B-knockout mice increased the severity of pancreatitis.
p186
sg4
(lp187
(dp188
g7
I44
sg8
VP07858
p189
sg10
I11
sg11
Vcathepsin B
p190
sg13
I2
sasg24
(lp191
(dp192
g7
I96
sg27
VC0030305
p193
sg10
I12
sg11
Vpancreatitis
p194
sg13
I1
sasa(dp195
g2
VExperimental studies in acute pancreatitis (AP) suggest a strong association of acinar cell injury with cathepsin B-dependent intracellular activation of trypsin.
p196
sg4
(lp197
(dp198
g7
I154
sg8
VP35030
p199
sg10
I7
sg11
Vtrypsin
p200
sg13
I1
sasg24
(lp201
(dp202
g7
I44
sg27
VC0001339
p203
sg10
I2
sg11
VAP
p204
sg13
I1
sa(dp205
g7
I87
sg27
VC0599732
p206
sg10
I11
sg11
Vcell injury
p207
sg13
I2
sa(dp208
g7
I24
sg27
VC0001339
p209
sg10
I18
sg11
Vacute pancreatitis
p210
sg13
I2
sasa(dp211
g2
VPancreas, lung, and serum was harvested up to 48 h after pancreatitis induction and used for histopathology, amylase, lipase, cathepsin B, trypsin, and elastase activity measurements, myeloperoxidase (MPO) content and cytokine concentrations.
p212
sg4
(lp213
(dp214
g7
I126
sg8
VP07858
p215
sg10
I11
sg11
Vcathepsin B
p216
sg13
I2
sa(dp217
g7
I152
sg8
VP30740
p218
sg10
I8
sg11
Velastase
p219
sg13
I1
sa(dp220
g7
I184
sg8
VP05164
p221
sg10
I15
sg11
Vmyeloperoxidase
p222
sg13
I1
sa(dp223
g7
I118
sg8
VP04118
p224
sg10
I6
sg11
Vlipase
p225
sg13
I1
sa(dp226
g7
I201
sg8
VP05164
p227
sg10
I3
sg11
VMPO
p228
sg13
I1
sa(dp229
g7
I109
sg8
VP04746
p230
sg10
I7
sg11
Vamylase
p231
sg13
I1
sa(dp232
g7
I139
sg8
VP35030
p233
sg10
I7
sg11
Vtrypsin
p234
sg13
I1
sasg24
(lp235
(dp236
g7
I57
sg27
VC0030305
p237
sg10
I12
sg11
Vpancreatitis
p238
sg13
I1
sasa(dp239
g2
VIn taurocholate-pancreatitis AZD8309 reduced cathepsin B activity and MPO.
p240
sg4
(lp241
(dp242
g7
I45
sg8
VP07858
p243
sg10
I11
sg11
Vcathepsin B
p244
sg13
I2
sa(dp245
g7
I70
sg8
VP05164
p246
sg10
I3
sg11
VMPO
p247
sg13
I1
sasg24
(lp248
(dp249
g7
I16
sg27
VC0030305
p250
sg10
I12
sg11
Vpancreatitis
p251
sg13
I1
sasa(dp252
g2
VThe lysosomal hydrolase cathepsin B (CTSB) is a known activator of trypsinogen, and its deletion reduces disease severity in experimental pancreatitis.
p253
sg4
(lp254
(dp255
g7
I4
sg8
VP07858
p256
sg10
I31
sg11
Vlysosomal hydrolase cathepsin B
p257
sg13
I4
sa(dp258
g7
I37
sg8
VP07858
p259
sg10
I4
sg11
VCTSB
p260
sg13
I1
sa(dp261
g7
I67
sg8
VP07478
p262
sg10
I11
sg11
Vtrypsinogen
p263
sg13
I1
sasg24
(lp264
(dp265
g7
I138
sg27
VC0030305
p266
sg10
I12
sg11
Vpancreatitis
p267
sg13
I1
sasa(dp268
g2
VIn summary, CTSB in pancreatitis undergoes activation in a secretory, vesicular, and acidic compartment where it activates trypsinogen.
p269
sg4
(lp270
(dp271
g7
I123
sg8
VP07478
p272
sg10
I11
sg11
Vtrypsinogen
p273
sg13
I1
sasg24
(lp274
(dp275
g7
I20
sg27
VC0030305
p276
sg10
I12
sg11
Vpancreatitis
p277
sg13
I1
sasa(dp278
g2
VC3F was also significantly increased in 20 chronic renal failure (CRF) patients as compared to 196 controls; this would support the existence of functional differences between C3F and C3S alleles.
p279
sg4
(lp280
(dp281
g7
I0
sg8
g9
sg10
I3
sg11
VC3F
p282
sg13
I1
sa(dp283
g7
I0
sg8
g9
sg10
I3
sg11
VC3F
p284
sg13
I1
sasg24
(lp285
(dp286
g7
I66
sg27
VC0022661
p287
sg10
I3
sg11
VCRF
p288
sg13
I1
sa(dp289
g7
I43
sg27
VC0022661
p290
sg10
I21
sg11
Vchronic renal failure
p291
sg13
I3
sasa(dp292
g2
VEctopic expression of Fgfr2c, a gene implicated in craniosynostosis in mice and humans, and that of Runx2 was detected within the affected sutures of Bcl11b(-/-) mice.
p293
sg4
(lp294
(dp295
g7
I150
sg8
g9
sg10
I11
sg11
VBcl11b(-/-)
p296
sg13
I1
sa(dp297
g7
I100
sg8
g9
sg10
I5
sg11
VRunx2
p298
sg13
I1
sasg24
(lp299
(dp300
g7
I51
sg27
VC0010278
p301
sg10
I16
sg11
Vcraniosynostosis
p302
sg13
I1
sasa(dp303
g2
VThese data suggest that ectopic expression of Fgfr2c in the sutural mesenchyme, without concomitant changes in the expression of FGF ligands, appears to induce the RUNX2-dependent osteogenic program and craniosynostosis in Bcl11b(-/-) mice.
p304
sg4
(lp305
(dp306
g7
I223
sg8
g9
sg10
I11
sg11
VBcl11b(-/-)
p307
sg13
I1
sa(dp308
g7
I129
sg8
g9
sg10
I11
sg11
VFGF ligands
p309
sg13
I2
sa(dp310
g7
I164
sg8
g9
sg10
I5
sg11
VRUNX2
p311
sg13
I1
sasg24
(lp312
(dp313
g7
I203
sg27
VC0010278
p314
sg10
I16
sg11
Vcraniosynostosis
p315
sg13
I1
sasa(dp316
g2
V(2) An analysis of all published HLA data for patients of European origin indicated a weak association of pernicious anemia with HLA-B7.
p317
sg4
(lp318
(dp319
g7
I129
sg8
VP30486
p320
sg10
I6
sg11
VHLA-B7
p321
sg13
I1
sa(dp322
g7
I33
sg8
VP30486
p323
sg10
I3
sg11
VHLA
p324
sg13
I1
sasg24
(lp325
(dp326
g7
I106
sg27
VC0002892
p327
sg10
I17
sg11
Vpernicious anemia
p328
sg13
I2
sasa(dp329
g2
VSpecifically, studies have demonstrated miR-221/-222 function as oncogenes, and promote PCa cell proliferation and the development of castration-resistant prostate cancer (CRPC).
p330
sg4
(lp331
sg24
(lp332
(dp333
g7
I88
sg27
VC0268398
p334
sg10
I3
sg11
VPCa
p335
sg13
I1
sa(dp336
g7
I155
sg27
VC0600139
p337
sg10
I15
sg11
Vprostate cancer
p338
sg13
I2
sa(dp339
g7
I97
sg27
VC0334094
p340
sg10
I13
sg11
Vproliferation
p341
sg13
I1
sasa(dp342
g2
VSOCS3 was found significantly declined, while microRNA-221 (miR-221) obviously up-regulated in bladder cancer tissue.
p343
sg4
(lp344
(dp345
g7
I0
sg8
g9
sg10
I5
sg11
VSOCS3
p346
sg13
I1
sasg24
(lp347
(dp348
g7
I95
sg27
VC0699885
p349
sg10
I14
sg11
Vbladder cancer
p350
sg13
I2
sasa(dp351
g2
VThis study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.
p352
sg4
(lp353
(dp354
g7
I68
sg8
VP40763
p355
sg10
I5
sg11
VSTAT3
p356
sg13
I1
sa(dp357
g7
I58
sg8
g9
sg10
I5
sg11
VSOCS3
p358
sg13
I1
sa(dp359
g7
I36
sg8
g9
sg10
I7
sg11
VmiR-221
p360
sg13
I1
sasg24
(lp361
(dp362
g7
I96
sg27
VC0699885
p363
sg10
I14
sg11
Vbladder cancer
p364
sg13
I2
sa(dp365
g7
I116
sg27
VC0334094
p366
sg10
I13
sg11
Vproliferation
p367
sg13
I1
sasa(dp368
g2
VBladder cancer tumor tissue and para-carcinoma tissue were collected from patients to test miR-221 and SOCS3 expressions.
p369
sg4
(lp370
(dp371
g7
I91
sg8
g9
sg10
I7
sg11
VmiR-221
p372
sg13
I1
sa(dp373
g7
I103
sg8
g9
sg10
I5
sg11
VSOCS3
p374
sg13
I1
sasg24
(lp375
(dp376
g7
I0
sg27
VC0699885
p377
sg10
I14
sg11
VBladder cancer
p378
sg13
I2
sa(dp379
g7
I15
sg27
VC0027651
p380
sg10
I5
sg11
Vtumor
p381
sg13
I1
sa(dp382
g7
I37
sg27
VC0007097
p383
sg10
I9
sg11
Vcarcinoma
p384
sg13
I1
sasa(dp385
g2
VMiR-221 significantly increased, while SOCS3 obviously reduced in bladder cancer tissue compared with para-carcinoma tissue.
p386
sg4
(lp387
(dp388
g7
I0
sg8
g9
sg10
I7
sg11
VMiR-221
p389
sg13
I1
sa(dp390
g7
I39
sg8
g9
sg10
I5
sg11
VSOCS3
p391
sg13
I1
sasg24
(lp392
(dp393
g7
I107
sg27
VC0007097
p394
sg10
I9
sg11
Vcarcinoma
p395
sg13
I1
sa(dp396
g7
I66
sg27
VC0699885
p397
sg10
I14
sg11
Vbladder cancer
p398
sg13
I2
sasa(dp399
g2
VMiR-221 elevated, while SOCS3 reduced in bladder cancer tissue.
p400
sg4
(lp401
(dp402
g7
I0
sg8
g9
sg10
I29
sg11
VMiR-221 elevated, while SOCS3
p403
sg13
I4
sasg24
(lp404
(dp405
g7
I41
sg27
VC0699885
p406
sg10
I14
sg11
Vbladder cancer
p407
sg13
I2
sasa(dp408
g2
VAs miR-221 targets several regulators of the PI3K-AKT-mTOR pathway and a link between this pathway and CD44 has been previously shown in prostate cancer, we considered miR-221 regulation of CD44 may be through this pathway.
p409
sg4
(lp410
(dp411
g7
I54
sg8
VP42345
p412
sg10
I4
sg11
VmTOR
p413
sg13
I1
sa(dp414
g7
I50
sg8
g9
sg10
I3
sg11
VAKT
p415
sg13
I1
sa(dp416
g7
I45
sg8
VP42336
p417
sg10
I4
sg11
VPI3K
p418
sg13
I1
sasg24
(lp419
(dp420
g7
I137
sg27
VC0600139
p421
sg10
I15
sg11
Vprostate cancer
p422
sg13
I2
sasa(dp423
g2
VThe aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
p424
sg4
(lp425
(dp426
g7
I249
sg8
VP55786
p427
sg10
I9
sg11
Vserum PSA
p428
sg13
I2
sa(dp429
g7
I190
sg8
g9
sg10
I7
sg11
VmiR-221
p430
sg13
I1
sa(dp431
g7
I65
sg8
VP11308
p432
sg10
I3
sg11
VERG
p433
sg13
I1
sa(dp434
g7
I162
sg8
VP78358
p435
sg10
I4
sg11
VPCA3
p436
sg13
I1
sa(dp437
g7
I129
sg8
VP55786
p438
sg10
I3
sg11
VPSA
p439
sg13
I1
sa(dp440
g7
I89
sg8
VP07288
p441
sg10
I38
sg11
Vtumor tissue prostate-specific antigen
p442
sg13
I4
sa(dp443
g7
I135
sg8
VP78358
p444
sg10
I25
sg11
Vprostate cancer antigen 3
p445
sg13
I4
sa(dp446
g7
I178
sg8
g9
sg10
I7
sg11
VmiR-26a
p447
sg13
I1
sa(dp448
g7
I57
sg8
g9
sg10
I7
sg11
VTMPRSS2
p449
sg13
I1
sa(dp450
g7
I169
sg8
g9
sg10
I7
sg11
VmiR-23b
p451
sg13
I1
sasg24
(lp452
(dp453
g7
I280
sg27
VC0268398
p454
sg10
I3
sg11
VPCa
p455
sg13
I1
sa(dp456
g7
I89
sg27
VC0027651
p457
sg10
I5
sg11
Vtumor
p458
sg13
I1
sa(dp459
g7
I284
sg27
VC1458156
p460
sg10
I10
sg11
Vrecurrence
p461
sg13
I1
sa(dp462
g7
I135
sg27
VC0600139
p463
sg10
I15
sg11
Vprostate cancer
p464
sg13
I2
sa(dp465
g7
I129
sg27
VC1519176
p466
sg10
I3
sg11
VPSA
p467
sg13
I1
sa(dp468
g7
I102
sg27
VC1519176
p469
sg10
I25
sg11
Vprostate-specific antigen
p470
sg13
I2
sa(dp471
g7
I129
sg27
VC1519176
p472
sg10
I3
sg11
VPSA
p473
sg13
I1
sasa(dp474
g2
VOnly 5 genes were significantly up-regulated in MS patients vs control subjects; namely TNF-AIP6, IL-1RA, OASL, CLC and DOCK4 (p &lt; 0.05).
p475
sg4
(lp476
(dp477
g7
I88
sg8
VP01375
p478
sg10
I8
sg11
VTNF-AIP6
p479
sg13
I1
sa(dp480
g7
I120
sg8
g9
sg10
I5
sg11
VDOCK4
p481
sg13
I1
sa(dp482
g7
I106
sg8
g9
sg10
I4
sg11
VOASL
p483
sg13
I1
sa(dp484
g7
I112
sg8
g9
sg10
I3
sg11
VCLC
p485
sg13
I1
sa(dp486
g7
I98
sg8
VP18510
p487
sg10
I6
sg11
VIL-1RA
p488
sg13
I1
sasg24
(lp489
sa(dp490
g2
VAnalysis of the effector molecules of the up-regulated genes revealed that 83 MS patients had positive serum level of OASL, 87 MS patients had positive serum levels of IL-1RA, and none of the 88 MS patients showed detectable serum levels of TNF-AIP6, CLC or DOCK4.
p491
sg4
(lp492
(dp493
g7
I258
sg8
g9
sg10
I5
sg11
VDOCK4
p494
sg13
I1
sa(dp495
g7
I168
sg8
VP18510
p496
sg10
I6
sg11
VIL-1RA
p497
sg13
I1
sa(dp498
g7
I241
sg8
VP01375
p499
sg10
I3
sg11
VTNF
p500
sg13
I1
sa(dp501
g7
I251
sg8
g9
sg10
I3
sg11
VCLC
p502
sg13
I1
sasg24
(lp503
sa(dp504
g2
VOASL and IL-1RA genes were strongly expressed in MS patients and that their effector molecules may be considered as biomarkers associated with the inflammatory process of the disease and possibly treatment response.
p505
sg4
(lp506
(dp507
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p508
sg13
I1
sa(dp509
g7
I9
sg8
VP18510
p510
sg10
I12
sg11
VIL-1RA genes
p511
sg13
I2
sasg24
(lp512
sa(dp513
g2
VHowever, IRF1, IFNK and viral restriction factors (IFIT1, 2, 3, 5, OASL, CD74, RTP4) were up-regulated.
p514
sg4
(lp515
(dp516
g7
I73
sg8
VP04233
p517
sg10
I4
sg11
VCD74
p518
sg13
I1
sa(dp519
g7
I51
sg8
VP09914
p520
sg10
I5
sg11
VIFIT1
p521
sg13
I1
sa(dp522
g7
I9
sg8
VP10914
p523
sg10
I4
sg11
VIRF1
p524
sg13
I1
sa(dp525
g7
I79
sg8
g9
sg10
I4
sg11
VRTP4
p526
sg13
I1
sa(dp527
g7
I67
sg8
g9
sg10
I4
sg11
VOASL
p528
sg13
I1
sa(dp529
g7
I24
sg8
VP19883
p530
sg10
I25
sg11
Vviral restriction factors
p531
sg13
I3
sa(dp532
g7
I15
sg8
g9
sg10
I4
sg11
VIFNK
p533
sg13
I1
sasg24
(lp534
sa(dp535
g2
VThe signature's genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5).
p536
sg4
(lp537
(dp538
g7
I127
sg8
g9
sg10
I4
sg11
VOASL
p539
sg13
I1
sa(dp540
g7
I66
sg8
g9
sg10
I14
sg11
VInterleukin 16
p541
sg13
I2
sa(dp542
g7
I89
sg8
g9
sg10
I36
sg11
V2',5'-Oligoadenylate Synthetase Like
p543
sg13
I3
sa(dp544
g7
I82
sg8
g9
sg10
I4
sg11
VIL16
p545
sg13
I1
sa(dp546
g7
I27
sg8
g9
sg10
I29
sg11
VInterferon Stimulated Gene 15
p547
sg13
I4
sa(dp548
g7
I58
sg8
VP05161
p549
sg10
I5
sg11
VISG15
p550
sg13
I1
sasg24
(lp551
(dp552
g7
I138
sg27
VC0001511
p553
sg10
I8
sg11
VAdhesion
p554
sg13
I1
sasa(dp555
g2
VPrevious work has identified that following viral infection, type I IFN signaling induces the production of the 2'-5'-oligoadenylate synthetase (OAS) family, which include OAS1, OAS2, OAS3, and OAS-like (OASL) protein.
p556
sg4
(lp557
(dp558
g7
I68
sg8
VP01562
p559
sg10
I3
sg11
VIFN
p560
sg13
I1
sa(dp561
g7
I194
sg8
g9
sg10
I8
sg11
VOAS-like
p562
sg13
I1
sa(dp563
g7
I112
sg8
g9
sg10
I31
sg11
V2'-5'-oligoadenylate synthetase
p564
sg13
I2
sa(dp565
g7
I204
sg8
g9
sg10
I4
sg11
VOASL
p566
sg13
I1
sa(dp567
g7
I184
sg8
g9
sg10
I4
sg11
VOAS3
p568
sg13
I1
sa(dp569
g7
I178
sg8
VP29728
p570
sg10
I4
sg11
VOAS2
p571
sg13
I1
sa(dp572
g7
I145
sg8
g9
sg10
I3
sg11
VOAS
p573
sg13
I1
sasg24
(lp574
(dp575
g7
I145
sg27
VC0599973
p576
sg10
I3
sg11
VOAS
p577
sg13
I1
sa(dp578
g7
I112
sg27
VC0599973
p579
sg10
I31
sg11
V2'-5'-oligoadenylate synthetase
p580
sg13
I2
sa(dp581
g7
I145
sg27
VC0599973
p582
sg10
I3
sg11
VOAS
p583
sg13
I1
sa(dp584
g7
I44
sg27
VC0042769
p585
sg10
I15
sg11
Vviral infection
p586
sg13
I2
sasa(dp587
g2
VOASL was identified to be strongly induced following viral infection through engaging the RNA sensor RIG-I and increasing signaling through this pathway to enhance the anti-viral type I IFN response.
p588
sg4
(lp589
(dp590
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p591
sg13
I1
sa(dp592
g7
I101
sg8
g9
sg10
I5
sg11
VRIG-I
p593
sg13
I1
sa(dp594
g7
I186
sg8
VP01562
p595
sg10
I3
sg11
VIFN
p596
sg13
I1
sasg24
(lp597
(dp598
g7
I53
sg27
VC0042769
p599
sg10
I15
sg11
Vviral infection
p600
sg13
I2
sasa(dp601
g2
VSurprisingly, infection with viral dsDNA revealed an IFN inhibitory role and therefore pro-viral function of OASL through the inhibition of the cGAS cytosolic DNA sensing mechanism.
p602
sg4
(lp603
(dp604
g7
I53
sg8
VP01562
p605
sg10
I3
sg11
VIFN
p606
sg13
I1
sa(dp607
g7
I109
sg8
g9
sg10
I4
sg11
VOASL
p608
sg13
I1
sasg24
(lp609
(dp610
g7
I14
sg27
VC0009450
p611
sg10
I9
sg11
Vinfection
p612
sg13
I1
sasa(dp613
g2
VIntracellular bacteria are able to activate the cytosolic DNA sensing pathway, however the role of OASL during bacterial infection is largely unknown.
p614
sg4
(lp615
(dp616
g7
I99
sg8
g9
sg10
I4
sg11
VOASL
p617
sg13
I1
sasg24
(lp618
(dp619
g7
I111
sg27
VC0004623
p620
sg10
I19
sg11
Vbacterial infection
p621
sg13
I2
sasa(dp622
g2
VVacuolar pathogenic microbes such as mycobacteria induce OASL early post infection, where it functions in a prosurvival fashion by inhibiting autophagic mechanisms and antimicrobial peptide expression.
p623
sg4
(lp624
(dp625
g7
I57
sg8
g9
sg10
I4
sg11
VOASL
p626
sg13
I1
sasg24
(lp627
(dp628
g7
I73
sg27
VC0009450
p629
sg10
I9
sg11
Vinfection
p630
sg13
I1
sasa(dp631
g2
VThis suggests an underestimated role of OASL in the innate immune response to infection with a variety of pathogens and points to OASL-associated modulation of the type I IFN response.
p632
sg4
(lp633
(dp634
g7
I40
sg8
g9
sg10
I4
sg11
VOASL
p635
sg13
I1
sa(dp636
g7
I40
sg8
g9
sg10
I4
sg11
VOASL
p637
sg13
I1
sa(dp638
g7
I164
sg8
VP01562
p639
sg10
I10
sg11
Vtype I IFN
p640
sg13
I3
sasg24
(lp641
(dp642
g7
I78
sg27
VC0009450
p643
sg10
I9
sg11
Vinfection
p644
sg13
I1
sa(dp645
g7
I52
sg27
VC1155265
p646
sg10
I22
sg11
Vinnate immune response
p647
sg13
I3
sasa(dp648
g2
VOASL may therefore play a critical role in defining the outcome of infection.
p649
sg4
(lp650
(dp651
g7
I0
sg8
g9
sg10
I4
sg11
VOASL
p652
sg13
I1
sasg24
(lp653
(dp654
g7
I67
sg27
VC0009450
p655
sg10
I9
sg11
Vinfection
p656
sg13
I1
sasa(dp657
g2
VWe earlier nominated 16 genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2) as predictors of response to remission induction therapy against MPA.
p658
sg4
(lp659
(dp660
g7
I120
sg8
VP59665
p661
sg10
I5
sg11
VDEFA1
p662
sg13
I1
sa(dp663
g7
I31
sg8
g9
sg10
I4
sg11
VIRF7
p664
sg13
I1
sa(dp665
g7
I57
sg8
g9
sg10
I3
sg11
VCLC
p666
sg13
I1
sa(dp667
g7
I83
sg8
VP32246
p668
sg10
I4
sg11
VCCR1
p669
sg13
I1
sa(dp670
g7
I144
sg8
g9
sg10
I6
sg11
VCOL9A2
p671
sg13
I1
sa(dp672
g7
I112
sg8
g9
sg10
I6
sg11
VPLSCR1
p673
sg13
I1
sa(dp674
g7
I133
sg8
VP12838
p675
sg10
I5
sg11
VDEFA4
p676
sg13
I1
sa(dp677
g7
I103
sg8
g9
sg10
I7
sg11
VBIRC4BP
p678
sg13
I1
sa(dp679
g7
I126
sg8
VP59665
p680
sg10
I5
sg11
VDEFA3
p681
sg13
I1
sa(dp682
g7
I76
sg8
g9
sg10
I5
sg11
VHERC5
p683
sg13
I1
sa(dp684
g7
I37
sg8
VP09914
p685
sg10
I5
sg11
VIFIT1
p686
sg13
I1
sa(dp687
g7
I51
sg8
g9
sg10
I4
sg11
VOASL
p688
sg13
I1
sa(dp689
g7
I44
sg8
g9
sg10
I5
sg11
VIFIT5
p690
sg13
I1
sa(dp691
g7
I69
sg8
VP28065
p692
sg10
I5
sg11
VPSMB9
p693
sg13
I1
sa(dp694
g7
I62
sg8
VP32455
p695
sg10
I5
sg11
VGBP-1
p696
sg13
I1
sa(dp697
g7
I95
sg8
g9
sg10
I6
sg11
VMS4A4A
p698
sg13
I1
sasg24
(lp699
(dp700
g7
I181
sg27
VC0687702
p701
sg10
I9
sg11
Vremission
p702
sg13
I1
sasa(dp703
g2
VThe 2'5'-oligoadenylate synthetase (OAS) is an interferon (IFN)-induced protein that plays an important role in the antiviral action of IFN, with OAS3 being one of the four OAS classes (OAS1, OAS2, OAS3, OASL).
p704
sg4
(lp705
(dp706
g7
I146
sg8
g9
sg10
I4
sg11
VOAS3
p707
sg13
I1
sa(dp708
g7
I4
sg8
g9
sg10
I30
sg11
V2'5'-oligoadenylate synthetase
p709
sg13
I2
sa(dp710
g7
I47
sg8
VP01563
p711
sg10
I10
sg11
Vinterferon
p712
sg13
I1
sa(dp713
g7
I59
sg8
VP01562
p714
sg10
I3
sg11
VIFN
p715
sg13
I1
sa(dp716
g7
I146
sg8
g9
sg10
I4
sg11
VOAS3
p717
sg13
I1
sa(dp718
g7
I204
sg8
g9
sg10
I4
sg11
VOASL
p719
sg13
I1
sa(dp720
g7
I36
sg8
g9
sg10
I3
sg11
VOAS
p721
sg13
I1
sa(dp722
g7
I192
sg8
VP29728
p723
sg10
I4
sg11
VOAS2
p724
sg13
I1
sa(dp725
g7
I59
sg8
VP01562
p726
sg10
I3
sg11
VIFN
p727
sg13
I1
sa(dp728
g7
I36
sg8
g9
sg10
I3
sg11
VOAS
p729
sg13
I1
sasg24
(lp730
(dp731
g7
I36
sg27
VC0599973
p732
sg10
I3
sg11
VOAS
p733
sg13
I1
sa(dp734
g7
I4
sg27
VC0599973
p735
sg10
I30
sg11
V2'5'-oligoadenylate synthetase
p736
sg13
I2
sa(dp737
g7
I36
sg27
VC0599973
p738
sg10
I3
sg11
VOAS
p739
sg13
I1
sasa(dp740
g2
VIn a pooled analysis of 105 candidate genes and two genome-wide association studies, we observed associations of single nucleotide polymorphisms from nine genes (EIF2AK2, IFNAR2, ITPA, MBL2, MX1, OASL, SPP1, TGFB1, TNK2) with response to interferon-based therapy.
p741
sg4
(lp742
(dp743
g7
I191
sg8
VP20591
p744
sg10
I3
sg11
VMX1
p745
sg13
I1
sa(dp746
g7
I196
sg8
g9
sg10
I4
sg11
VOASL
p747
sg13
I1
sa(dp748
g7
I208
sg8
VP01137
p749
sg10
I5
sg11
VTGFB1
p750
sg13
I1
sa(dp751
g7
I202
sg8
VP10451
p752
sg10
I4
sg11
VSPP1
p753
sg13
I1
sa(dp754
g7
I215
sg8
g9
sg10
I4
sg11
VTNK2
p755
sg13
I1
sa(dp756
g7
I162
sg8
VP19525
p757
sg10
I7
sg11
VEIF2AK2
p758
sg13
I1
sa(dp759
g7
I185
sg8
VP11226
p760
sg10
I4
sg11
VMBL2
p761
sg13
I1
sa(dp762
g7
I179
sg8
g9
sg10
I4
sg11
VITPA
p763
sg13
I1
sa(dp764
g7
I171
sg8
VP48551
p765
sg10
I6
sg11
VIFNAR2
p766
sg13
I1
sa(dp767
g7
I238
sg8
VP01563
p768
sg10
I10
sg11
Vinterferon
p769
sg13
I1
sasg24
(lp770
sa(dp771
g2
VSingle nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747), OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients.
p772
sg4
(lp773
(dp774
g7
I93
sg8
g9
sg10
I17
sg11
VOASL (rs10849829)
p775
sg13
I2
sa(dp776
g7
I57
sg8
VP29728
p777
sg10
I4
sg11
VOAS2
p778
sg13
I1
sa(dp779
g7
I75
sg8
g9
sg10
I4
sg11
VOAS3
p780
sg13
I1
sa(dp781
g7
I227
sg8
VP01562
p782
sg10
I3
sg11
VIFN
p783
sg13
I1
sa(dp784
g7
I115
sg8
g9
sg10
I5
sg11
VIL28B
p785
sg13
I1
sasg24
(lp786
sa(dp787
g2
VThe association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).
p788
sg4
(lp789
(dp790
g7
I151
sg8
g9
sg10
I15
sg11
VOASL rs10849829
p791
sg13
I2
sa(dp792
g7
I63
sg8
g9
sg10
I16
sg11
VIL28B rs12979860
p793
sg13
I2
sasg24
(lp794
sa(dp795
g2
VThe aim of the present study was to evaluate agreement between three pairs formed by one of three mania scales (Young Mania Rating Scale [YMRS], Bech-Rafaelsen Mania Scale [BRMS], or the Clinician-Administered Rating Scale for Mania [CARS-M]) and a single depression scale (21-item Hamilton Depression Rating Scale [21-HAM-D]) for evaluation of response to mood stabilizers in patients with mixed bipolar disorder.
p796
sg4
(lp797
sg24
(lp798
(dp799
g7
I118
sg27
VC0338831
p800
sg10
I5
sg11
VMania
p801
sg13
I1
sa(dp802
g7
I118
sg27
VC0338831
p803
sg10
I5
sg11
VMania
p804
sg13
I1
sa(dp805
g7
I391
sg27
VC2937260
p806
sg10
I22
sg11
Vmixed bipolar disorder
p807
sg13
I3
sa(dp808
g7
I319
sg27
VC0030481
p809
sg10
I3
sg11
VHAM
p810
sg13
I1
sa(dp811
g7
I256
sg27
VC0011581
p812
sg10
I10
sg11
Vdepression
p813
sg13
I1
sa(dp814
g7
I291
sg27
VC0011581
p815
sg10
I10
sg11
VDepression
p816
sg13
I1
sa(dp817
g7
I98
sg27
VC0338831
p818
sg10
I5
sg11
Vmania
p819
sg13
I1
sa(dp820
g7
I118
sg27
VC0338831
p821
sg10
I5
sg11
VMania
p822
sg13
I1
sasa(dp823
g2
VThe present study suggests that any one of the three tested mania rating scales (YMRS, BRMS, and CARS-M) can be combined with the 21-HAM-D to assess treatment response in patients with mixed bipolar disorder.
p824
sg4
(lp825
(dp826
g7
I97
sg8
VP49589
p827
sg10
I6
sg11
VCARS-M
p828
sg13
I1
sasg24
(lp829
(dp830
g7
I133
sg27
VC0030481
p831
sg10
I3
sg11
VHAM
p832
sg13
I1
sa(dp833
g7
I60
sg27
VC0338831
p834
sg10
I5
sg11
Vmania
p835
sg13
I1
sa(dp836
g7
I185
sg27
VC2937260
p837
sg10
I22
sg11
Vmixed bipolar disorder
p838
sg13
I3
sasa(dp839
g2
VOlder adults and patients with dementia often have disrupted circadian activity rhythms (CARs).
p840
sg4
(lp841
sg24
(lp842
(dp843
g7
I31
sg27
VC0497327
p844
sg10
I8
sg11
Vdementia
p845
sg13
I1
sasa(dp846
g2
VClinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93.
p847
sg4
(lp848
(dp849
g7
I130
sg8
g9
sg10
I6
sg11
VmiR-25
p850
sg13
I1
sa(dp851
g7
I32
sg8
VP10645
p852
sg10
I4
sg11
VcGAS
p853
sg13
I1
sasg24
(lp854
(dp855
g7
I90
sg27
VC0678222
p856
sg10
I13
sg11
Vbreast cancer
p857
sg13
I2
sasa(dp858
g2
VIn our analysis, we found that increased expression of 12 mature miRNAs-hsa-miR-320a, hsa-miR-361-5p, hsa-miR-103a-3p, hsa-miR-21-5p, hsa-miR-374b-5p, hsa-miR-140-3p, hsa-miR-25-3p, hsa-miR-651-5p, hsa-miR-200c-3p, hsa-miR-30a-5p, hsa-miR-30c-5p, and hsa-let-7i-5p -each predicted improved breast cancer survival.
p859
sg4
(lp860
(dp861
g7
I134
sg8
g9
sg10
I15
sg11
Vhsa-miR-374b-5p
p862
sg13
I1
sa(dp863
g7
I151
sg8
g9
sg10
I14
sg11
Vhsa-miR-140-3p
p864
sg13
I1
sa(dp865
g7
I86
sg8
g9
sg10
I14
sg11
Vhsa-miR-361-5p
p866
sg13
I1
sa(dp867
g7
I182
sg8
g9
sg10
I14
sg11
Vhsa-miR-651-5p
p868
sg13
I1
sa(dp869
g7
I215
sg8
g9
sg10
I14
sg11
Vhsa-miR-30a-5p
p870
sg13
I1
sa(dp871
g7
I102
sg8
g9
sg10
I15
sg11
Vhsa-miR-103a-3p
p872
sg13
I1
sa(dp873
g7
I198
sg8
g9
sg10
I15
sg11
Vhsa-miR-200c-3p
p874
sg13
I1
sa(dp875
g7
I119
sg8
g9
sg10
I13
sg11
Vhsa-miR-21-5p
p876
sg13
I1
sa(dp877
g7
I65
sg8
g9
sg10
I3
sg11
VmiR
p878
sg13
I1
sa(dp879
g7
I251
sg8
g9
sg10
I13
sg11
Vhsa-let-7i-5p
p880
sg13
I1
sa(dp881
g7
I231
sg8
g9
sg10
I14
sg11
Vhsa-miR-30c-5p
p882
sg13
I1
sa(dp883
g7
I167
sg8
g9
sg10
I13
sg11
Vhsa-miR-25-3p
p884
sg13
I1
sa(dp885
g7
I72
sg8
g9
sg10
I3
sg11
Vhsa
p886
sg13
I1
sasg24
(lp887
(dp888
g7
I72
sg27
VC0393754
p889
sg10
I3
sg11
Vhsa
p890
sg13
I1
sa(dp891
g7
I72
sg27
VC0393754
p892
sg10
I3
sg11
Vhsa
p893
sg13
I1
sa(dp894
g7
I72
sg27
VC0393754
p895
sg10
I3
sg11
Vhsa
p896
sg13
I1
sa(dp897
g7
I72
sg27
VC0393754
p898
sg10
I3
sg11
Vhsa
p899
sg13
I1
sa(dp900
g7
I290
sg27
VC0678222
p901
sg10
I13
sg11
Vbreast cancer
p902
sg13
I2
sa(dp903
g7
I72
sg27
VC0393754
p904
sg10
I3
sg11
Vhsa
p905
sg13
I1
sa(dp906
g7
I72
sg27
VC0393754
p907
sg10
I3
sg11
Vhsa
p908
sg13
I1
sa(dp909
g7
I72
sg27
VC0393754
p910
sg10
I3
sg11
Vhsa
p911
sg13
I1
sa(dp912
g7
I72
sg27
VC0393754
p913
sg10
I3
sg11
Vhsa
p914
sg13
I1
sa(dp915
g7
I72
sg27
VC0393754
p916
sg10
I3
sg11
Vhsa
p917
sg13
I1
sa(dp918
g7
I72
sg27
VC0393754
p919
sg10
I3
sg11
Vhsa
p920
sg13
I1
sa(dp921
g7
I72
sg27
VC0393754
p922
sg10
I3
sg11
Vhsa
p923
sg13
I1
sa(dp924
g7
I72
sg27
VC0393754
p925
sg10
I3
sg11
Vhsa
p926
sg13
I1
sasa(dp927
g2
VHere, we report a novel function of isoliquiritigenin (ISL) as a natural inhibitor of autophagy-related miR-25 in killing drug-resistant breast cancer cells.
p928
sg4
(lp929
(dp930
g7
I104
sg8
g9
sg10
I6
sg11
VmiR-25
p931
sg13
I1
sasg24
(lp932
(dp933
g7
I137
sg27
VC0678222
p934
sg10
I13
sg11
Vbreast cancer
p935
sg13
I2
sasa(dp936
g2
VOverall, our results not only indicate that ISL acts as a natural autophagy inducer to increase breast cancer chemosensitivity, but also reveal that miR-25 functions as a novel regulator of autophagy by targeting ULK1.
p937
sg4
(lp938
(dp939
g7
I149
sg8
g9
sg10
I6
sg11
VmiR-25
p940
sg13
I1
sa(dp941
g7
I213
sg8
g9
sg10
I4
sg11
VULK1
p942
sg13
I1
sa(dp943
g7
I44
sg8
g9
sg10
I3
sg11
VISL
p944
sg13
I1
sasg24
(lp945
(dp946
g7
I96
sg27
VC0678222
p947
sg10
I13
sg11
Vbreast cancer
p948
sg13
I2
sasa(dp949
g2
VExpression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.
p950
sg4
(lp951
(dp952
g7
I67
sg8
g9
sg10
I10
sg11
Vhsa-miR-17
p953
sg13
I1
sa(dp954
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p955
sg13
I1
sa(dp956
g7
I194
sg8
g9
sg10
I14
sg11
VDFFA, and EGFR
p957
sg13
I3
sa(dp958
g7
I46
sg8
g9
sg10
I3
sg11
VmiR
p959
sg13
I1
sa(dp960
g7
I91
sg8
g9
sg10
I11
sg11
Vhsa-miR-221
p961
sg13
I1
sa(dp962
g7
I187
sg8
g9
sg10
I5
sg11
VPDCD4
p963
sg13
I1
sa(dp964
g7
I180
sg8
VP41221
p965
sg10
I5
sg11
VWNT5A
p966
sg13
I1
sa(dp967
g7
I55
sg8
g9
sg10
I10
sg11
Vhsa-miR-16
p968
sg13
I1
sa(dp969
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p970
sg13
I1
sa(dp971
g7
I104
sg8
g9
sg10
I11
sg11
Vhsa-miR-326
p972
sg13
I1
sa(dp973
g7
I42
sg8
g9
sg10
I3
sg11
Vhsa
p974
sg13
I1
sa(dp975
g7
I173
sg8
g9
sg10
I5
sg11
VTOM34
p976
sg13
I1
sa(dp977
g7
I159
sg8
g9
sg10
I4
sg11
VE2F3
p978
sg13
I1
sasg24
(lp979
(dp980
g7
I42
sg27
VC0393754
p981
sg10
I3
sg11
Vhsa
p982
sg13
I1
sa(dp983
g7
I280
sg27
VC0006826
p984
sg10
I6
sg11
Vcancer
p985
sg13
I1
sa(dp986
g7
I42
sg27
VC0393754
p987
sg10
I3
sg11
Vhsa
p988
sg13
I1
sa(dp989
g7
I216
sg27
VC1621958
p990
sg10
I23
sg11
Vglioblastoma multiforme
p991
sg13
I2
sa(dp992
g7
I42
sg27
VC0393754
p993
sg10
I3
sg11
Vhsa
p994
sg13
I1
sa(dp995
g7
I42
sg27
VC0393754
p996
sg10
I3
sg11
Vhsa
p997
sg13
I1
sa(dp998
g7
I42
sg27
VC0393754
p999
sg10
I3
sg11
Vhsa
p1000
sg13
I1
sa(dp1001
g7
I42
sg27
VC0393754
p1002
sg10
I3
sg11
Vhsa
p1003
sg13
I1
sa(dp1004
g7
I42
sg27
VC0393754
p1005
sg10
I3
sg11
Vhsa
p1006
sg13
I1
sasa(dp1007
g2
VThe present study examined whether it could be possible to quantify the expression of TOMM34 and RNF43 in colorectal cancer and liver metastasis samples prepared from paraffin blocks.
p1008
sg4
(lp1009
(dp1010
g7
I97
sg8
g9
sg10
I5
sg11
VRNF43
p1011
sg13
I1
sa(dp1012
g7
I86
sg8
g9
sg10
I6
sg11
VTOMM34
p1013
sg13
I1
sasg24
(lp1014
(dp1015
g7
I106
sg27
VC1527249
p1016
sg10
I17
sg11
Vcolorectal cancer
p1017
sg13
I2
sa(dp1018
g7
I128
sg27
VC0494165
p1019
sg10
I16
sg11
Vliver metastasis
p1020
sg13
I2
sasa(dp1021
g2
VQuantification of TOMM34 and RNF43 gene expression in several-year-old paraffin-embedded colorectal cancer specimens was possible by qPCR using the Universal ProbeLibrary.
p1022
sg4
(lp1023
(dp1024
g7
I18
sg8
g9
sg10
I6
sg11
VTOMM34
p1025
sg13
I1
sa(dp1026
g7
I29
sg8
g9
sg10
I10
sg11
VRNF43 gene
p1027
sg13
I2
sasg24
(lp1028
(dp1029
g7
I89
sg27
VC1527249
p1030
sg10
I17
sg11
Vcolorectal cancer
p1031
sg13
I2
sasa(dp1032
g2
VThe mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed.
p1033
sg4
(lp1034
(dp1035
g7
I82
sg8
g9
sg10
I5
sg11
VKNTC2
p1036
sg13
I1
sa(dp1037
g7
I203
sg8
g9
sg10
I63
sg11
V34-kDa translocase of the outer mitochondrial membrane (TOMM34)
p1038
sg13
I8
sa(dp1039
g7
I132
sg8
g9
sg10
I24
sg11
VM phase phosphoprotein-1
p1040
sg13
I3
sa(dp1041
g7
I169
sg8
g9
sg10
I23
sg11
VDEP domain-containing 1
p1042
sg13
I3
sa(dp1043
g7
I271
sg8
VP62877
p1044
sg10
I22
sg11
Vring finger protein-43
p1045
sg13
I3
sa(dp1046
g7
I194
sg8
g9
sg10
I6
sg11
VDEPDC1
p1047
sg13
I1
sa(dp1048
g7
I295
sg8
g9
sg10
I5
sg11
VRNF43
p1049
sg13
I1
sa(dp1050
g7
I158
sg8
g9
sg10
I8
sg11
VMPHOSPH1
p1051
sg13
I1
sa(dp1052
g7
I31
sg8
g9
sg10
I49
sg11
VWilms' tumor gene (WT1), kinetochore associated-2
p1053
sg13
I6
sasg24
(lp1054
(dp1055
g7
I31
sg27
VC0027708
p1056
sg10
I12
sg11
VWilms' tumor
p1057
sg13
I2
sa(dp1058
g7
I50
sg27
VC0027708
p1059
sg10
I3
sg11
VWT1
p1060
sg13
I1
sasa(dp1061
g2
VThese antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43 [RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2).
p1062
sg4
(lp1063
(dp1064
g7
I255
sg8
g9
sg10
I37
sg11
Vholliday junction recognition protein
p1065
sg13
I4
sa(dp1066
g7
I293
sg8
g9
sg10
I5
sg11
VHJURP
p1067
sg13
I1
sa(dp1068
g7
I240
sg8
g9
sg10
I9
sg11
VM1[FOXM1]
p1069
sg13
I1
sa(dp1070
g7
I351
sg8
VP17948
p1071
sg10
I6
sg11
VVEGFR1
p1072
sg13
I1
sa(dp1073
g7
I306
sg8
g9
sg10
I44
sg11
Vvascular endothelial growth factor receptors
p1074
sg13
I5
sa(dp1075
g7
I220
sg8
g9
sg10
I4
sg11
VMELK
p1076
sg13
I1
sa(dp1077
g7
I362
sg8
VP35968
p1078
sg10
I6
sg11
VVEGFR2
p1079
sg13
I1
sa(dp1080
g7
I91
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1081
sg13
I4
sa(dp1082
g7
I179
sg8
VP30740
p1083
sg10
I40
sg11
Vmaternal embryonic leucine zipper kinase
p1084
sg13
I5
sa(dp1085
g7
I68
sg8
VP15735
p1086
sg10
I22
sg11
Vcancer-testis antigens
p1087
sg13
I2
sasg24
(lp1088
(dp1089
g7
I68
sg27
VC0006826
p1090
sg10
I6
sg11
Vcancer
p1091
sg13
I1
sasa(dp1092
g2
VTo evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial membrane (TOMM34), and insulin-like growth factor-II mRNA binding protein 3 (KOC1), and the remaining two from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
p1093
sg4
(lp1094
(dp1095
g7
I406
sg8
g9
sg10
I4
sg11
VKOC1
p1096
sg13
I1
sa(dp1097
g7
I251
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1098
sg13
I4
sa(dp1099
g7
I352
sg8
VP01308
p1100
sg10
I52
sg11
Vinsulin-like growth factor-II mRNA binding protein 3
p1101
sg13
I7
sa(dp1102
g7
I339
sg8
g9
sg10
I6
sg11
VTOMM34
p1103
sg13
I1
sa(dp1104
g7
I509
sg8
VP17948
p1105
sg10
I6
sg11
VVEGFR1
p1106
sg13
I1
sa(dp1107
g7
I177
sg8
VP30447
p1108
sg10
I10
sg11
VHLA-A*2402
p1109
sg13
I1
sa(dp1110
g7
I462
sg8
VP17948
p1111
sg10
I45
sg11
Vvascular endothelial growth factor receptor 1
p1112
sg13
I6
sa(dp1113
g7
I275
sg8
g9
sg10
I5
sg11
VRNF43
p1114
sg13
I1
sa(dp1115
g7
I521
sg8
VP35968
p1116
sg10
I6
sg11
VVEGFR2
p1117
sg13
I1
sasg24
(lp1118
(dp1119
g7
I142
sg27
VC1527249
p1120
sg10
I17
sg11
Vcolorectal cancer
p1121
sg13
I2
sasa(dp1122
g2
VThese antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34).
p1123
sg4
(lp1124
(dp1125
g7
I114
sg8
g9
sg10
I46
sg11
Vtranslocase of outer mitochondrial membrane 34
p1126
sg13
I6
sa(dp1127
g7
I55
sg8
VP15735
p1128
sg10
I22
sg11
Vcancer-testis antigens
p1129
sg13
I2
sa(dp1130
g7
I79
sg8
g9
sg10
I22
sg11
Vring finger protein 43
p1131
sg13
I4
sa(dp1132
g7
I103
sg8
g9
sg10
I5
sg11
VRNF43
p1133
sg13
I1
sa(dp1134
g7
I162
sg8
g9
sg10
I6
sg11
VTOMM34
p1135
sg13
I1
sasg24
(lp1136
(dp1137
g7
I55
sg27
VC0006826
p1138
sg10
I6
sg11
Vcancer
p1139
sg13
I1
sasa(dp1140
g2
VWe conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer.
p1141
sg4
(lp1142
(dp1143
g7
I69
sg8
g9
sg10
I5
sg11
VRNF43
p1144
sg13
I1
sa(dp1145
g7
I33
sg8
VP31749
p1146
sg10
I34
sg11
Vcolorectal cancer-specific peptide
p1147
sg13
I3
sa(dp1148
g7
I76
sg8
g9
sg10
I6
sg11
VTOMM34
p1149
sg13
I1
sasg24
(lp1150
(dp1151
g7
I168
sg27
VC0854750
p1152
sg10
I27
sg11
Vrecurrent colorectal cancer
p1153
sg13
I3
sa(dp1154
g7
I33
sg27
VC1527249
p1155
sg10
I17
sg11
Vcolorectal cancer
p1156
sg13
I2
sasa(dp1157
g2
VWe started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.
p1158
sg4
(lp1159
(dp1160
g7
I164
sg8
g9
sg10
I37
sg11
Vholliday junction recognition protein
p1161
sg13
I4
sa(dp1162
g7
I82
sg8
g9
sg10
I31
sg11
Vforkhead box protein M1 [FOXM1]
p1163
sg13
I5
sa(dp1164
g7
I157
sg8
g9
sg10
I4
sg11
VMELK
p1165
sg13
I1
sa(dp1166
g7
I202
sg8
g9
sg10
I5
sg11
VHJURP
p1167
sg13
I1
sa(dp1168
g7
I210
sg8
VP17948
p1169
sg10
I65
sg11
Vvascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2
p1170
sg13
I8
sa(dp1171
g7
I67
sg8
g9
sg10
I5
sg11
VRNF43
p1172
sg13
I1
sa(dp1173
g7
I74
sg8
g9
sg10
I6
sg11
VTOMM34
p1174
sg13
I1
sa(dp1175
g7
I115
sg8
VP30740
p1176
sg10
I40
sg11
Vmaternal embryonic leucine zipper kinase
p1177
sg13
I5
sasg24
(lp1178
(dp1179
g7
I310
sg27
VC0854750
p1180
sg10
I27
sg11
Vrecurrent colorectal cancer
p1181
sg13
I3
sasa(dp1182
g2
VRecently, analysis of tumor antigens using micro-arrays has revealed upregulation             of cancer-testis antigens RNF43 and TOMM34 and vascular endothelial growth factor             receptors VEGFR1 and VEGFR2 in colorectal cancer.
p1183
sg4
(lp1184
(dp1185
g7
I130
sg8
g9
sg10
I6
sg11
VTOMM34
p1186
sg13
I1
sa(dp1187
g7
I120
sg8
g9
sg10
I5
sg11
VRNF43
p1188
sg13
I1
sa(dp1189
g7
I141
sg8
VP17948
p1190
sg10
I74
sg11
Vvascular endothelial growth factor             receptors VEGFR1 and VEGFR2
p1191
sg13
I20
sasg24
(lp1192
(dp1193
g7
I97
sg27
VC0006826
p1194
sg10
I6
sg11
Vcancer
p1195
sg13
I1
sa(dp1196
g7
I22
sg27
VC0027651
p1197
sg10
I5
sg11
Vtumor
p1198
sg13
I1
sa(dp1199
g7
I219
sg27
VC1527249
p1200
sg10
I17
sg11
Vcolorectal cancer
p1201
sg13
I2
sasa(dp1202
g2
VOur aim was to analyze the dynamic modulation, determined by ADT, of the expression of selected genes involved in the pathogenesis and progression of prostate cancer (TMPRSS2:ERG, WNT11, SPINK1, CHGA, AR, and SPDEF) using real-time polymerase chain reaction in a series of 59 surgical samples of prostate carcinomas, including 37 cases preoperatively treated with ADT and 22 untreated cases, and in 43 corresponding biopsies.
p1203
sg4
(lp1204
(dp1205
g7
I187
sg8
VP00995
p1206
sg10
I6
sg11
VSPINK1
p1207
sg13
I1
sa(dp1208
g7
I209
sg8
g9
sg10
I5
sg11
VSPDEF
p1209
sg13
I1
sa(dp1210
g7
I175
sg8
VP11308
p1211
sg10
I3
sg11
VERG
p1212
sg13
I1
sa(dp1213
g7
I195
sg8
VP10645
p1214
sg10
I4
sg11
VCHGA
p1215
sg13
I1
sa(dp1216
g7
I180
sg8
g9
sg10
I5
sg11
VWNT11
p1217
sg13
I1
sasg24
(lp1218
(dp1219
g7
I305
sg27
VC0007097
p1220
sg10
I10
sg11
Vcarcinomas
p1221
sg13
I1
sa(dp1222
g7
I118
sg27
VC0699748
p1223
sg10
I12
sg11
Vpathogenesis
p1224
sg13
I1
sa(dp1225
g7
I135
sg27
VC1739135
p1226
sg10
I30
sg11
Vprogression of prostate cancer
p1227
sg13
I4
sasa(dp1228
g2
VHowever, Wnt-11 expression in cervical cancer has not been well investigated.
p1229
sg4
(lp1230
sg24
(lp1231
(dp1232
g7
I30
sg27
VC0302592
p1233
sg10
I15
sg11
Vcervical cancer
p1234
sg13
I2
sasa(dp1235
g2
VWnt-11 and HR-HPV E6 expression increased in a manner that corresponded with the progression of cervical cancer and was significantly correlated with the International Federation of Gynecology and Obstetrics cancer stage, lymph node metastasis, tumor size, and HPV infection.
p1236
sg4
(lp1237
sg24
(lp1238
(dp1239
g7
I96
sg27
VC0302592
p1240
sg10
I15
sg11
Vcervical cancer
p1241
sg13
I2
sa(dp1242
g7
I245
sg27
VC0027651
p1243
sg10
I5
sg11
Vtumor
p1244
sg13
I1
sa(dp1245
g7
I222
sg27
VC0686619
p1246
sg10
I21
sg11
Vlymph node metastasis
p1247
sg13
I3
sa(dp1248
g7
I105
sg27
VC0006826
p1249
sg10
I6
sg11
Vcancer
p1250
sg13
I1
sa(dp1251
g7
I265
sg27
VC0009450
p1252
sg10
I9
sg11
Vinfection
p1253
sg13
I1
sasa(dp1254
g2
VWnt-11 protein expression was positively associated with HR-HPV E6 protein expression in all 78 cervical cancer samples (P &lt; 0.001).
p1255
sg4
(lp1256
sg24
(lp1257
(dp1258
g7
I96
sg27
VC0302592
p1259
sg10
I15
sg11
Vcervical cancer
p1260
sg13
I2
sasa(dp1261
g2
VFurthermore, Wnt-11 was positively associated with P-JNK1 expression and promoted cervical cancer cell proliferation and invasion.
p1262
sg4
(lp1263
(dp1264
g7
I53
sg8
VP45983
p1265
sg10
I4
sg11
VJNK1
p1266
sg13
I1
sasg24
(lp1267
(dp1268
g7
I103
sg27
VC0334094
p1269
sg10
I13
sg11
Vproliferation
p1270
sg13
I1
sa(dp1271
g7
I121
sg27
VC2699153
p1272
sg10
I8
sg11
Vinvasion
p1273
sg13
I1
sa(dp1274
g7
I82
sg27
VC0302592
p1275
sg10
I15
sg11
Vcervical cancer
p1276
sg13
I2
sasa(dp1277
g2
VThese observations suggest that the increased Wnt-11 expression observed in cervical cancer cells may lead to the phosphorylation and activation of JNK-1 and significantly promote tumor cell proliferation and cell migration/invasion through activation of the Wnt/JNK pathway.
p1278
sg4
(lp1279
(dp1280
g7
I148
sg8
VP53779
p1281
sg10
I5
sg11
VJNK-1
p1282
sg13
I1
sa(dp1283
g7
I148
sg8
VP53779
p1284
sg10
I3
sg11
VJNK
p1285
sg13
I1
sasg24
(lp1286
(dp1287
g7
I191
sg27
VC0334094
p1288
sg10
I13
sg11
Vproliferation
p1289
sg13
I1
sa(dp1290
g7
I180
sg27
VC0027651
p1291
sg10
I5
sg11
Vtumor
p1292
sg13
I1
sa(dp1293
g7
I76
sg27
VC0302592
p1294
sg10
I15
sg11
Vcervical cancer
p1295
sg13
I2
sa(dp1296
g7
I224
sg27
VC2699153
p1297
sg10
I8
sg11
Vinvasion
p1298
sg13
I1
sasa(dp1299
g2
VConsequently, Wnt-11 may serve as a novel target for cervical cancer therapy.
p1300
sg4
(lp1301
sg24
(lp1302
(dp1303
g7
I53
sg27
VC0302592
p1304
sg10
I15
sg11
Vcervical cancer
p1305
sg13
I2
sasa(dp1306
g2
VIn this study, we aimed to explore the association among gene variants of five cytokines, tumor necrosis factor alpha (TNF-Alfa), transforming growth factor beta-1 (TGF-Beta1), interferon gamma (IFN-Gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10), and clinical parameters and prognosis in patients with multiple myeloma (MM) treated with novel therapeutic drugs in Turkish population for the first time except TNF-Alfa.
p1307
sg4
(lp1308
(dp1309
g7
I249
sg8
VP22301
p1310
sg10
I5
sg11
VIL-10
p1311
sg13
I1
sa(dp1312
g7
I207
sg8
VP05231
p1313
sg10
I13
sg11
Vinterleukin-6
p1314
sg13
I1
sa(dp1315
g7
I130
sg8
VP01137
p1316
sg10
I33
sg11
Vtransforming growth factor beta-1
p1317
sg13
I4
sa(dp1318
g7
I119
sg8
VP01375
p1319
sg10
I8
sg11
VTNF-Alfa
p1320
sg13
I1
sa(dp1321
g7
I90
sg8
VP01375
p1322
sg10
I27
sg11
Vtumor necrosis factor alpha
p1323
sg13
I4
sa(dp1324
g7
I165
sg8
VP01137
p1325
sg10
I9
sg11
VTGF-Beta1
p1326
sg13
I1
sa(dp1327
g7
I195
sg8
VP01579
p1328
sg10
I9
sg11
VIFN-Gamma
p1329
sg13
I1
sa(dp1330
g7
I177
sg8
VP01579
p1331
sg10
I16
sg11
Vinterferon gamma
p1332
sg13
I2
sa(dp1333
g7
I222
sg8
VP05231
p1334
sg10
I4
sg11
VIL-6
p1335
sg13
I1
sa(dp1336
g7
I233
sg8
VP22301
p1337
sg10
I14
sg11
Vinterleukin-10
p1338
sg13
I1
sasg24
(lp1339
(dp1340
g7
I312
sg27
VC0026764
p1341
sg10
I16
sg11
Vmultiple myeloma
p1342
sg13
I2
sa(dp1343
g7
I90
sg27
VC0333516
p1344
sg10
I14
sg11
Vtumor necrosis
p1345
sg13
I2
sasa(dp1346
g2
VUsing absolute value of log2 fold-change &gt; 2 or extremely small P value (10-20) as a criterion, we identified nine significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in heart failure.
p1347
sg4
(lp1348
(dp1349
g7
I166
sg8
g9
sg10
I4
sg11
VMYL7
p1350
sg13
I1
sa(dp1351
g7
I159
sg8
VP30711
p1352
sg10
I5
sg11
VGSTT1
p1353
sg13
I1
sa(dp1354
g7
I137
sg8
VP69905
p1355
sg10
I4
sg11
VHBA1
p1356
sg13
I1
sa(dp1357
g7
I143
sg8
VP02042
p1358
sg10
I3
sg11
VHBB
p1359
sg13
I1
sa(dp1360
g7
I172
sg8
VP01160
p1361
sg10
I4
sg11
VNPPA
p1362
sg13
I1
sa(dp1363
g7
I178
sg8
VP16860
p1364
sg10
I4
sg11
VNPPB
p1365
sg13
I1
sa(dp1366
g7
I148
sg8
g9
sg10
I9
sg11
VHIST1H2AC
p1367
sg13
I1
sa(dp1368
g7
I184
sg8
g9
sg10
I4
sg11
VPDK4
p1369
sg13
I1
sa(dp1370
g7
I190
sg8
VP14555
p1371
sg10
I7
sg11
VPLA2G2A
p1372
sg13
I1
sasg24
(lp1373
(dp1374
g7
I257
sg27
VC0007193
p1375
sg10
I22
sg11
Vdilated cardiomyopathy
p1376
sg13
I2
sa(dp1377
g7
I202
sg27
VC0149721
p1378
sg10
I3
sg11
VLVH
p1379
sg13
I1
sa(dp1380
g7
I283
sg27
VC0018802
p1381
sg10
I13
sg11
Vheart failure
p1382
sg13
I2
sasa(dp1383
g2
VTolerized cow's milk protein (CMP)-sensitive atopic dermatitis had, in particular, decreased kappa-casein-specific IgG(1) levels, compared with clinically reactive patients.
p1384
sg4
(lp1385
(dp1386
g7
I93
sg8
VP07498
p1387
sg10
I28
sg11
Vkappa-casein-specific IgG(1)
p1388
sg13
I2
sasg24
(lp1389
(dp1390
g7
I45
sg27
VC0011615
p1391
sg10
I17
sg11
Vatopic dermatitis
p1392
sg13
I2
sasa(dp1393
g2
VTolerised patients, particularly those with atopic dermatitis, had decreased responses to kappa-casein which were restored after Treg depletion.
p1394
sg4
(lp1395
(dp1396
g7
I90
sg8
VP07498
p1397
sg10
I12
sg11
Vkappa-casein
p1398
sg13
I1
sasg24
(lp1399
(dp1400
g7
I44
sg27
VC0011615
p1401
sg10
I17
sg11
Vatopic dermatitis
p1402
sg13
I2
sasa(dp1403
g2
VA markedly decreased proliferative response to kappa-casein in tolerised IgE-mediated CMA patients with atopic dermatitis, which was abrogated by Treg depletion, suggested a role for kappa-casein in tolerance induction.
p1404
sg4
(lp1405
(dp1406
g7
I47
sg8
VP07498
p1407
sg10
I12
sg11
Vkappa-casein
p1408
sg13
I1
sa(dp1409
g7
I73
sg8
VP01854
p1410
sg10
I3
sg11
VIgE
p1411
sg13
I1
sa(dp1412
g7
I47
sg8
VP07498
p1413
sg10
I12
sg11
Vkappa-casein
p1414
sg13
I1
sasg24
(lp1415
(dp1416
g7
I21
sg27
VC0334094
p1417
sg10
I13
sg11
Vproliferative
p1418
sg13
I1
sa(dp1419
g7
I73
sg27
VC0270850
p1420
sg10
I3
sg11
VIgE
p1421
sg13
I1
sa(dp1422
g7
I104
sg27
VC0011615
p1423
sg10
I17
sg11
Vatopic dermatitis
p1424
sg13
I2
sa(dp1425
g7
I199
sg27
VC0020963
p1426
sg10
I9
sg11
Vtolerance
p1427
sg13
I1
sasa(dp1428
g2
VIn order to investigate the role of food antigen-specific T cells circulating in the blood of patients with food allergy, we compared T cell response to three casein components (alpha s-, beta- and, kappa-casein) with specificities of IgG and IgE binding to the casein components in four milk-allergic patients (P1-4) with atopic dermatitis.
p1429
sg4
(lp1430
(dp1431
g7
I243
sg8
VP01854
p1432
sg10
I3
sg11
VIgE
p1433
sg13
I1
sasg24
(lp1434
(dp1435
g7
I323
sg27
VC0011615
p1436
sg10
I17
sg11
Vatopic dermatitis
p1437
sg13
I2
sa(dp1438
g7
I108
sg27
VC0016470
p1439
sg10
I12
sg11
Vfood allergy
p1440
sg13
I2
sa(dp1441
g7
I243
sg27
VC0270850
p1442
sg10
I3
sg11
VIgE
p1443
sg13
I1
sasa(dp1444
g2
VStudies have identified that PKM2 is related to the development of glucose intolerance and insulin resistance in rodents and humans.
p1445
sg4
(lp1446
(dp1447
g7
I91
sg8
VP01308
p1448
sg10
I7
sg11
Vinsulin
p1449
sg13
I1
sasg24
(lp1450
(dp1451
g7
I91
sg27
VC0021655
p1452
sg10
I18
sg11
Vinsulin resistance
p1453
sg13
I2
sa(dp1454
g7
I67
sg27
VC0271650
p1455
sg10
I19
sg11
Vglucose intolerance
p1456
sg13
I2
sasa(dp1457
g2
VMechanistically, we showed that hyperglycemia and diabetes decreased PKM2 tetramer formation and activity by sulfenylation in mouse glomeruli and cultured podocytes.
p1458
sg4
(lp1459
sg24
(lp1460
(dp1461
g7
I50
sg27
VC0011849
p1462
sg10
I8
sg11
Vdiabetes
p1463
sg13
I1
sa(dp1464
g7
I32
sg27
VC0020456
p1465
sg10
I13
sg11
Vhyperglycemia
p1466
sg13
I1
sasa(dp1467
g2
VPodocyte-specific Pkm2-knockout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.
p1468
sg4
(lp1469
sg24
(lp1470
(dp1471
g7
I47
sg27
VC0011849
p1472
sg10
I8
sg11
Vdiabetes
p1473
sg13
I1
sa(dp1474
g7
I99
sg27
VC0677042
p1475
sg10
I9
sg11
Vpathology
p1476
sg13
I1
sasa(dp1477
g2
VConversely, we found that pharmacological activation of PKM2 by a small-molecule PKM2 activator, TEPP-46, reversed hyperglycemia-induced elevation in toxic glucose metabolites and mitochondrial dysfunction, partially by increasing glycolytic flux and PGC-1Alfa mRNA in cultured podocytes.
p1478
sg4
(lp1479
(dp1480
g7
I251
sg8
VP20142
p1481
sg10
I14
sg11
VPGC-1Alfa mRNA
p1482
sg13
I2
sa(dp1483
g7
I97
sg8
g9
sg10
I7
sg11
VTEPP-46
p1484
sg13
I1
sa(dp1485
g7
I66
sg8
VP05154
p1486
sg10
I29
sg11
Vsmall-molecule PKM2 activator
p1487
sg13
I3
sasg24
(lp1488
(dp1489
g7
I115
sg27
VC0020456
p1490
sg10
I13
sg11
Vhyperglycemia
p1491
sg13
I1
sasa(dp1492
g2
VTo identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155.
p1493
sg4
(lp1494
(dp1495
g7
I16
sg8
g9
sg10
I7
sg11
VmiR-155
p1496
sg13
I1
sasg24
(lp1497
(dp1498
g7
I117
sg27
VC0019829
p1499
sg10
I16
sg11
VHodgkin lymphoma
p1500
sg13
I2
sa(dp1501
g7
I45
sg27
VC0079731
p1502
sg10
I15
sg11
VB-cell lymphoma
p1503
sg13
I2
sa(dp1504
g7
I135
sg27
VC0019829
p1505
sg10
I2
sg11
VHL
p1506
sg13
I1
sasa(dp1507
g2
VFurther research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.
p1508
sg4
(lp1509
(dp1510
g7
I182
sg8
VP24385
p1511
sg10
I5
sg11
VCCND1
p1512
sg13
I1
sa(dp1513
g7
I173
sg8
VP11802
p1514
sg10
I4
sg11
VCDK4
p1515
sg13
I1
sa(dp1516
g7
I167
sg8
g9
sg10
I4
sg11
VCDK6
p1517
sg13
I1
sasg24
(lp1518
(dp1519
g7
I66
sg27
VC0334094
p1520
sg10
I13
sg11
Vproliferation
p1521
sg13
I1
sa(dp1522
g7
I83
sg27
VC0699885
p1523
sg10
I14
sg11
Vbladder cancer
p1524
sg13
I2
sasa(dp1525
g2
VmiR-29c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6.
p1526
sg4
(lp1527
(dp1528
g7
I103
sg8
g9
sg10
I4
sg11
VCDK6
p1529
sg13
I1
sa(dp1530
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-29c
p1531
sg13
I1
sasg24
(lp1532
(dp1533
g7
I67
sg27
VC0699885
p1534
sg10
I14
sg11
Vbladder cancer
p1535
sg13
I2
sa(dp1536
g7
I55
sg27
VC2699153
p1537
sg10
I8
sg11
Vinvasion
p1538
sg13
I1
sa(dp1539
g7
I26
sg27
VC0334094
p1540
sg10
I13
sg11
Vproliferation
p1541
sg13
I1
sasa(dp1542
g2
Vp34cdc2, collapsin response mediator protein 4 (CRMP4), doublecortin (DCX), HuD, and NeuN expression was assessed in tuber (n = 16) and subependymal giant cell astrocytoma (SEGA; n = 6) specimens in tuberous sclerosis complex to define the developmental phenotype and lineage of giant cells (CGs) in these lesions.
p1543
sg4
(lp1544
(dp1545
g7
I85
sg8
g9
sg10
I4
sg11
VNeuN
p1546
sg13
I1
sa(dp1547
g7
I48
sg8
g9
sg10
I5
sg11
VCRMP4
p1548
sg13
I1
sa(dp1549
g7
I70
sg8
g9
sg10
I3
sg11
VDCX
p1550
sg13
I1
sa(dp1551
g7
I9
sg8
g9
sg10
I37
sg11
Vcollapsin response mediator protein 4
p1552
sg13
I5
sa(dp1553
g7
I76
sg8
VP26378
p1554
sg10
I3
sg11
VHuD
p1555
sg13
I1
sa(dp1556
g7
I0
sg8
VP06493
p1557
sg10
I7
sg11
Vp34cdc2
p1558
sg13
I1
sa(dp1559
g7
I56
sg8
g9
sg10
I12
sg11
Vdoublecortin
p1560
sg13
I1
sasg24
(lp1561
(dp1562
g7
I199
sg27
VC0041341
p1563
sg10
I26
sg11
Vtuberous sclerosis complex
p1564
sg13
I3
sa(dp1565
g7
I136
sg27
VC0205768
p1566
sg10
I35
sg11
Vsubependymal giant cell astrocytoma
p1567
sg13
I4
sa(dp1568
g7
I149
sg27
VC0017547
p1569
sg10
I5
sg11
Vgiant
p1570
sg13
I1
sa(dp1571
g7
I173
sg27
VC0205768
p1572
sg10
I4
sg11
VSEGA
p1573
sg13
I1
sasa(dp1574
g2
VFirst, logistic regression analysis in two human prostate gene expression datasets revealed that expression levels of five genes (CXCL14, ITGAX, LPCAT2, RNASEH2A, and ZNF322) were positively correlated with aggressive prostate cancer and two genes (CCL19 and HIST1H1A) were protective for aggressive prostate cancer.
p1575
sg4
(lp1576
(dp1577
g7
I153
sg8
g9
sg10
I8
sg11
VRNASEH2A
p1578
sg13
I1
sa(dp1579
g7
I130
sg8
g9
sg10
I6
sg11
VCXCL14
p1580
sg13
I1
sa(dp1581
g7
I167
sg8
g9
sg10
I6
sg11
VZNF322
p1582
sg13
I1
sa(dp1583
g7
I138
sg8
VP20702
p1584
sg10
I5
sg11
VITGAX
p1585
sg13
I1
sa(dp1586
g7
I145
sg8
g9
sg10
I6
sg11
VLPCAT2
p1587
sg13
I1
sa(dp1588
g7
I259
sg8
g9
sg10
I8
sg11
VHIST1H1A
p1589
sg13
I1
sa(dp1590
g7
I249
sg8
g9
sg10
I5
sg11
VCCL19
p1591
sg13
I1
sasg24
(lp1592
(dp1593
g7
I218
sg27
VC0600139
p1594
sg10
I15
sg11
Vprostate cancer
p1595
sg13
I2
sa(dp1596
g7
I207
sg27
VC0001807
p1597
sg10
I10
sg11
Vaggressive
p1598
sg13
I1
sa(dp1599
g7
I218
sg27
VC0600139
p1600
sg10
I15
sg11
Vprostate cancer
p1601
sg13
I2
sa(dp1602
g7
I207
sg27
VC0001807
p1603
sg10
I10
sg11
Vaggressive
p1604
sg13
I1
sasa(dp1605
g2
VSecond generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis.
p1606
sg4
(lp1607
(dp1608
g7
I18
sg8
VP08620
p1609
sg10
I17
sg11
VH1 antihistamines
p1610
sg13
I2
sa(dp1611
g7
I37
sg8
g9
sg10
I3
sg11
VH1A
p1612
sg13
I1
sasg24
(lp1613
(dp1614
g7
I122
sg27
VC0861155
p1615
sg10
I19
sg11
Vrhinoconjunctivitis
p1616
sg13
I1
sa(dp1617
g7
I100
sg27
VC2607914
p1618
sg10
I17
sg11
Vallergic rhinitis
p1619
sg13
I2
sasa(dp1620
g2
VConsecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed prospectively for 30 days from the prescription of a second generation H1A in monotherapy.
p1621
sg4
(lp1622
(dp1623
g7
I175
sg8
g9
sg10
I3
sg11
VH1A
p1624
sg13
I1
sasg24
(lp1625
(dp1626
g7
I57
sg27
VC0861155
p1627
sg10
I19
sg11
Vrhinoconjunctivitis
p1628
sg13
I1
sa(dp1629
g7
I21
sg27
VC0683278
p1630
sg10
I9
sg11
Vsuffering
p1631
sg13
I1
sa(dp1632
g7
I36
sg27
VC2607914
p1633
sg10
I17
sg11
Vallergic rhinitis
p1634
sg13
I2
sasa(dp1635
g2
VAntibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.
p1636
sg4
(lp1637
(dp1638
g7
I143
sg8
VP16401
p1639
sg10
I3
sg11
VH1b
p1640
sg13
I1
sasg24
(lp1641
(dp1642
g7
I34
sg27
VC0021400
p1643
sg10
I9
sg11
Vinfluenza
p1644
sg13
I1
sasa(dp1645
g2
VWe have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.
p1646
sg4
(lp1647
(dp1648
g7
I22
sg8
VP32243
p1649
sg10
I4
sg11
VOTX2
p1650
sg13
I1
sa(dp1651
g7
I163
sg8
g9
sg10
I5
sg11
VMertk
p1652
sg13
I1
sasg24
(lp1653
(dp1654
g7
I119
sg27
VC0035334
p1655
sg10
I20
sg11
Vretinitis pigmentosa
p1656
sg13
I2
sasa(dp1657
g2
VTransplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
p1658
sg4
(lp1659
(dp1660
g7
I19
sg8
VP32243
p1661
sg10
I4
sg11
VOTX2
p1662
sg13
I1
sasg24
(lp1663
(dp1664
g7
I88
sg27
VC0035309
p1665
sg10
I16
sg11
Vretinal diseases
p1666
sg13
I2
sa(dp1667
g7
I151
sg27
VC0242383
p1668
sg10
I32
sg11
Vage-related macular degeneration
p1669
sg13
I3
sasa(dp1670
g2
VTherapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.
p1671
sg4
(lp1672
(dp1673
g7
I27
sg8
VP32243
p1674
sg10
I4
sg11
VOTX2
p1675
sg13
I1
sasg24
(lp1676
(dp1677
g7
I88
sg27
VC0035309
p1678
sg10
I16
sg11
Vretinal diseases
p1679
sg13
I2
sa(dp1680
g7
I113
sg27
VC0242383
p1681
sg10
I3
sg11
VAMD
p1682
sg13
I1
sasa(dp1683
g2
VThe retinal disease resembles conditional mice models that show slow photoreceptor degeneration secondary to loss of Otx2 function in the adult RPE.
p1684
sg4
(lp1685
(dp1686
g7
I117
sg8
VP32243
p1687
sg10
I4
sg11
VOtx2
p1688
sg13
I1
sasg24
(lp1689
(dp1690
g7
I83
sg27
VC0043020
p1691
sg10
I22
sg11
Vdegeneration secondary
p1692
sg13
I2
sa(dp1693
g7
I4
sg27
VC0035309
p1694
sg10
I15
sg11
Vretinal disease
p1695
sg13
I2
sa(dp1696
g7
I69
sg27
VC1998028
p1697
sg10
I26
sg11
Vphotoreceptor degeneration
p1698
sg13
I2
sasa(dp1699
g2
VWhen the beads were coated with amelogenin gene splice products (A+4 or A-4), the expression of osteo-chondrogenic markers (RP59, Sox9, or BSP) was also observed.
p1700
sg4
(lp1701
(dp1702
g7
I32
sg8
g9
sg10
I31
sg11
Vamelogenin gene splice products
p1703
sg13
I4
sa(dp1704
g7
I130
sg8
VP48436
p1705
sg10
I4
sg11
VSox9
p1706
sg13
I1
sasg24
(lp1707
(dp1708
g7
I124
sg27
VC3151227
p1709
sg10
I4
sg11
VRP59
p1710
sg13
I1
sasa(dp1711
g2
VThis study has provided evidence that the regulation of the SVCT2 transporter plays an important role not only in T1D osteoporosis but also in other oxidative stress-related musculoskeletal complications.
p1712
sg4
(lp1713
(dp1714
g7
I60
sg8
g9
sg10
I17
sg11
VSVCT2 transporter
p1715
sg13
I2
sasg24
(lp1716
(dp1717
g7
I118
sg27
VC0029456
p1718
sg10
I12
sg11
Vosteoporosis
p1719
sg13
I1
sa(dp1720
g7
I149
sg27
VC0242606
p1721
sg10
I16
sg11
Voxidative stress
p1722
sg13
I2
sasa(dp1723
g2
VAutosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness.
p1724
sg4
(lp1725
(dp1726
g7
I20
sg8
VP54868
p1727
sg10
I16
sg11
VHMG-CoA synthase
p1728
sg13
I2
sasg24
(lp1729
(dp1730
g7
I90
sg27
VC0020615
p1731
sg10
I12
sg11
Vhypoglycemia
p1732
sg13
I1
sa(dp1733
g7
I104
sg27
VC0042963
p1734
sg10
I8
sg11
Vvomiting
p1735
sg13
I1
sa(dp1736
g7
I128
sg27
VC0019209
p1737
sg10
I12
sg11
Vhepatomegaly
p1738
sg13
I1
sa(dp1739
g7
I24
sg27
VC2678439
p1740
sg10
I3
sg11
VCoA
p1741
sg13
I1
sa(dp1742
g7
I114
sg27
VC0023380
p1743
sg10
I8
sg11
Vlethargy
p1744
sg13
I1
sasa(dp1745
g2
VMost frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 +/- 10.0 years).
p1746
sg4
(lp1747
sg24
(lp1748
(dp1749
g7
I94
sg27
VC2242577
p1750
sg10
I22
sg11
Voromandibular dystonia
p1751
sg13
I2
sa(dp1752
g7
I118
sg27
VC3150833
p1753
sg10
I3
sg11
VOMD
p1754
sg13
I1
sa(dp1755
g7
I143
sg27
VC1848954
p1756
sg10
I20
sg11
Vgeneralized dystonia
p1757
sg13
I2
sasa(dp1758
g2
VEight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course.
p1759
sg4
(lp1760
sg24
(lp1761
(dp1762
g7
I72
sg27
VC1848954
p1763
sg10
I20
sg11
Vgeneralized dystonia
p1764
sg13
I2
sa(dp1765
g7
I139
sg27
VC0575081
p1766
sg10
I17
sg11
Vgait difficulties
p1767
sg13
I2
sa(dp1768
g7
I67
sg27
VC3150833
p1769
sg10
I3
sg11
VOMD
p1770
sg13
I1
sa(dp1771
g7
I106
sg27
VC0011168
p1772
sg10
I9
sg11
Vdysphagia
p1773
sg13
I1
sa(dp1774
g7
I94
sg27
VC0013362
p1775
sg10
I10
sg11
Vdysarthria
p1776
sg13
I1
sasa(dp1777
g2
VA smoothelin-deficient mouse model may help to establish the role of smoothelin-A in intestinal contraction and provide a model for myogenic chronic intestinal pseudo-obstruction.
p1778
sg4
(lp1779
sg24
(lp1780
(dp1781
g7
I96
sg27
VC1140999
p1782
sg10
I11
sg11
Vcontraction
p1783
sg13
I1
sa(dp1784
g7
I141
sg27
VC0238062
p1785
sg10
I37
sg11
Vchronic intestinal pseudo-obstruction
p1786
sg13
I3
sasa(dp1787
g2
VThe pathology of mice lacking smoothelin-A is reminiscent of that seen in patients with chronic intestinal pseudo-obstruction.
p1788
sg4
(lp1789
sg24
(lp1790
(dp1791
g7
I4
sg27
VC0677042
p1792
sg10
I9
sg11
Vpathology
p1793
sg13
I1
sa(dp1794
g7
I88
sg27
VC0238062
p1795
sg10
I37
sg11
Vchronic intestinal pseudo-obstruction
p1796
sg13
I3
sasa(dp1797
g2
VHereditary tyrosinemia type 1 (HT1) is characterized by severe progressive liver disease and renal tubular dysfunction.
p1798
sg4
(lp1799
sg24
(lp1800
(dp1801
g7
I0
sg27
VC0268483
p1802
sg10
I22
sg11
VHereditary tyrosinemia
p1803
sg13
I2
sa(dp1804
g7
I93
sg27
VC0151747
p1805
sg10
I25
sg11
Vrenal tubular dysfunction
p1806
sg13
I3
sa(dp1807
g7
I75
sg27
VC0023895
p1808
sg10
I13
sg11
Vliver disease
p1809
sg13
I2
sasa(dp1810
g2
VIf left untreated this deficiency of functional FAH leads to a buildup of toxic metabolites that can cause liver disease, kidney dysfunction and high mortality.
p1811
sg4
(lp1812
(dp1813
g7
I48
sg8
VP16930
p1814
sg10
I3
sg11
VFAH
p1815
sg13
I1
sasg24
(lp1816
(dp1817
g7
I113
sg27
VC0022658
p1818
sg10
I15
sg11
Vdisease, kidney
p1819
sg13
I2
sa(dp1820
g7
I122
sg27
VC0151746
p1821
sg10
I18
sg11
Vkidney dysfunction
p1822
sg13
I2
sasa(dp1823
g2
VIn this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH-/-) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease.
p1824
sg4
(lp1825
(dp1826
g7
I39
sg8
VP16930
p1827
sg10
I29
sg11
Vfumarylacetoacetate hydrolase
p1828
sg13
I2
sasg24
(lp1829
(dp1830
g7
I150
sg27
VC0023890
p1831
sg10
I9
sg11
Vcirrhosis
p1832
sg13
I1
sa(dp1833
g7
I137
sg27
VC0016059
p1834
sg10
I8
sg11
Vfibrosis
p1835
sg13
I1
sasa(dp1836
g2
VUnder conditions of low-dose NTBC, FAH-/- pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-animal model of chronic liver disease.
p1837
sg4
(lp1838
sg24
(lp1839
(dp1840
g7
I57
sg27
VC0239946
p1841
sg10
I14
sg11
Vliver fibrosis
p1842
sg13
I2
sa(dp1843
g7
I76
sg27
VC0020541
p1844
sg10
I19
sg11
Vportal hypertension
p1845
sg13
I2
sa(dp1846
g7
I143
sg27
VC0341439
p1847
sg10
I21
sg11
Vchronic liver disease
p1848
sg13
I3
sasa(dp1849
g2
VFah-deficient mice and pigs are phenotypically analogous to human HT1, but do not recapitulate all the chronic features of the human disorder, especially liver fibrosis and cirrhosis.
p1850
sg4
(lp1851
(dp1852
g7
I0
sg8
VP16930
p1853
sg10
I3
sg11
VFah
p1854
sg13
I1
sasg24
(lp1855
(dp1856
g7
I154
sg27
VC0239946
p1857
sg10
I14
sg11
Vliver fibrosis
p1858
sg13
I2
sa(dp1859
g7
I173
sg27
VC0023890
p1860
sg10
I9
sg11
Vcirrhosis
p1861
sg13
I1
sasa(dp1862
g2
VMore importantly, the Fah(-/-) rats developed remarkable liver fibrosis and cirrhosis, which have not been observed in Fah mutant mice or pigs.
p1863
sg4
(lp1864
(dp1865
g7
I22
sg8
VP16930
p1866
sg10
I8
sg11
VFah(-/-)
p1867
sg13
I1
sa(dp1868
g7
I119
sg8
VP16930
p1869
sg10
I10
sg11
VFah mutant
p1870
sg13
I2
sasg24
(lp1871
(dp1872
g7
I57
sg27
VC0239946
p1873
sg10
I14
sg11
Vliver fibrosis
p1874
sg13
I2
sa(dp1875
g7
I76
sg27
VC0023890
p1876
sg10
I9
sg11
Vcirrhosis
p1877
sg13
I1
sa(dp1878
g7
I123
sg27
VC0596988
p1879
sg10
I6
sg11
Vmutant
p1880
sg13
I1
sasa(dp1881
g2
VMoreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture.
p1882
sg4
(lp1883
(dp1884
g7
I62
sg8
VP16930
p1885
sg10
I8
sg11
VFah(-/-)
p1886
sg13
I1
sasg24
(lp1887
(dp1888
g7
I125
sg27
VC0023890
p1889
sg10
I9
sg11
Vcirrhosis
p1890
sg13
I1
sa(dp1891
g7
I107
sg27
VC0239946
p1892
sg10
I14
sg11
Vliver fibrosis
p1893
sg13
I2
sasa(dp1894
g2
VThese results indicate that Fah(-/-) rats may be used as an animal model of HT1 with liver cirrhosis.
p1895
sg4
(lp1896
(dp1897
g7
I28
sg8
VP16930
p1898
sg10
I3
sg11
VFah
p1899
sg13
I1
sasg24
(lp1900
(dp1901
g7
I85
sg27
VC0023890
p1902
sg10
I15
sg11
Vliver cirrhosis
p1903
sg13
I2
sasa(dp1904
g2
VRecent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
p1905
sg4
(lp1906
(dp1907
g7
I178
sg8
g9
sg10
I8
sg11
VARHGEF12
p1908
sg13
I1
sa(dp1909
g7
I268
sg8
g9
sg10
I5
sg11
VGLIS3
p1910
sg13
I1
sa(dp1911
g7
I201
sg8
g9
sg10
I5
sg11
VATXN2
p1912
sg13
I1
sa(dp1913
g7
I150
sg8
g9
sg10
I4
sg11
VGMDS
p1914
sg13
I1
sa(dp1915
g7
I255
sg8
g9
sg10
I5
sg11
VEPDR1
p1916
sg13
I1
sa(dp1917
g7
I194
sg8
g9
sg10
I5
sg11
VFOXC1
p1918
sg13
I1
sa(dp1919
g7
I162
sg8
g9
sg10
I6
sg11
VTGFBR3
p1920
sg13
I1
sa(dp1921
g7
I283
sg8
g9
sg10
I11
sg11
VDPM2-FAM102
p1922
sg13
I1
sa(dp1923
g7
I275
sg8
g9
sg10
I6
sg11
VFERMT2
p1924
sg13
I1
sa(dp1925
g7
I156
sg8
g9
sg10
I4
sg11
VPMM2
p1926
sg13
I1
sa(dp1927
g7
I188
sg8
g9
sg10
I4
sg11
VGAS7
p1928
sg13
I1
sa(dp1929
g7
I262
sg8
VP28329
p1930
sg10
I4
sg11
VCHAT
p1931
sg13
I1
sa(dp1932
g7
I143
sg8
g9
sg10
I5
sg11
VAFAP1
p1933
sg13
I1
sasg24
(lp1934
(dp1935
g7
I60
sg27
VC0017601
p1936
sg10
I8
sg11
Vglaucoma
p1937
sg13
I1
sa(dp1938
g7
I114
sg27
VC0017612
p1939
sg10
I19
sg11
Vopen-angle glaucoma
p1940
sg13
I2
sa(dp1941
g7
I323
sg27
VC0206368
p1942
sg10
I3
sg11
VXFS
p1943
sg13
I1
sa(dp1944
g7
I100
sg27
VC0339573
p1945
sg10
I4
sg11
VPOAG
p1946
sg13
I1
sa(dp1947
g7
I301
sg27
VC0206368
p1948
sg10
I20
sg11
Vexfoliation syndrome
p1949
sg13
I2
sa(dp1950
g7
I223
sg27
VC0017606
p1951
sg10
I30
sg11
Vprimary angle-closure glaucoma
p1952
sg13
I3
sa(dp1953
g7
I60
sg27
VC0017601
p1954
sg10
I8
sg11
Vglaucoma
p1955
sg13
I1
sasa(dp1956
g2
VRecently, a genome-wide association study identified genetic variations in ITGA4 and HLA-DRB1 that affect the LMR levels and were widely believed to be susceptibility genes for autoimmune diseases, including rheumatoid arthritis (RA).
p1957
sg4
(lp1958
(dp1959
g7
I85
sg8
VP30486
p1960
sg10
I3
sg11
VHLA
p1961
sg13
I1
sa(dp1962
g7
I89
sg8
g9
sg10
I4
sg11
VDRB1
p1963
sg13
I1
sa(dp1964
g7
I75
sg8
VP13612
p1965
sg10
I5
sg11
VITGA4
p1966
sg13
I1
sasg24
(lp1967
(dp1968
g7
I208
sg27
VC0003873
p1969
sg10
I20
sg11
Vrheumatoid arthritis
p1970
sg13
I2
sa(dp1971
g7
I230
sg27
VC0003873
p1972
sg10
I2
sg11
VRA
p1973
sg13
I1
sa(dp1974
g7
I177
sg27
VC0004364
p1975
sg10
I19
sg11
Vautoimmune diseases
p1976
sg13
I2
sasa(dp1977
g2
VTo evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).
p1978
sg4
(lp1979
(dp1980
g7
I140
sg8
VP20701
p1981
sg10
I5
sg11
VCD11a
p1982
sg13
I1
sa(dp1983
g7
I150
sg8
VP13612
p1984
sg10
I5
sg11
VCD49d
p1985
sg13
I1
sa(dp1986
g7
I107
sg8
VP02741
p1987
sg10
I3
sg11
VCRP
p1988
sg13
I1
sa(dp1989
g7
I87
sg8
VP02741
p1990
sg10
I18
sg11
VC-reactive protein
p1991
sg13
I2
sasg24
(lp1992
(dp1993
g7
I211
sg27
VC0036421
p1994
sg10
I3
sg11
VSSc
p1995
sg13
I1
sa(dp1996
g7
I191
sg27
VC0036421
p1997
sg10
I18
sg11
Vsystemic sclerosis
p1998
sg13
I2
sasa(dp1999
g2
VProstaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.
p2000
sg4
(lp2001
(dp2002
g7
I78
sg8
VP13612
p2003
sg10
I5
sg11
VCD49d
p2004
sg13
I1
sa(dp2005
g7
I68
sg8
VP20701
p2006
sg10
I5
sg11
VCD11a
p2007
sg13
I1
sasg24
(lp2008
(dp2009
g7
I223
sg27
VC0036421
p2010
sg10
I18
sg11
Vsystemic sclerosis
p2011
sg13
I2
sasa(dp2012
g2
VMR-1S directly phosphorylates and activates the MEK-ERK-RSK pathway to accelerate cancer growth and facilitates metastasis by activating the MLC2-FAK-AKT pathway.
p2013
sg4
(lp2014
(dp2015
g7
I141
sg8
VP24844
p2016
sg10
I4
sg11
VMLC2
p2017
sg13
I1
sa(dp2018
g7
I150
sg8
g9
sg10
I3
sg11
VAKT
p2019
sg13
I1
sa(dp2020
g7
I48
sg8
VP45985
p2021
sg10
I3
sg11
VMEK
p2022
sg13
I1
sa(dp2023
g7
I52
sg8
VP29323
p2024
sg10
I3
sg11
VERK
p2025
sg13
I1
sa(dp2026
g7
I146
sg8
g9
sg10
I3
sg11
VFAK
p2027
sg13
I1
sa(dp2028
g7
I0
sg8
VP08235
p2029
sg10
I5
sg11
VMR-1S
p2030
sg13
I1
sa(dp2031
g7
I56
sg8
VP51812
p2032
sg10
I3
sg11
VRSK
p2033
sg13
I1
sasg24
(lp2034
(dp2035
g7
I112
sg27
VC0027627
p2036
sg10
I10
sg11
Vmetastasis
p2037
sg13
I1
sa(dp2038
g7
I82
sg27
VC0006826
p2039
sg10
I6
sg11
Vcancer
p2040
sg13
I1
sasa(dp2041
g2
VAfter overexpressing TMEM17, levels of p-ERK and its downstream molecules, p-P90RSK and Snail, were down-regulated, while levels of Occludin and Zo-1 were up-regulated, which result in the inhibition of invasion and migration ability of lung cancer cells.
p2042
sg4
(lp2043
(dp2044
g7
I132
sg8
g9
sg10
I8
sg11
VOccludin
p2045
sg13
I1
sa(dp2046
g7
I41
sg8
VP29323
p2047
sg10
I3
sg11
VERK
p2048
sg13
I1
sa(dp2049
g7
I145
sg8
g9
sg10
I4
sg11
VZo-1
p2050
sg13
I1
sa(dp2051
g7
I21
sg8
g9
sg10
I6
sg11
VTMEM17
p2052
sg13
I1
sasg24
(lp2053
(dp2054
g7
I203
sg27
VC2699153
p2055
sg10
I8
sg11
Vinvasion
p2056
sg13
I1
sa(dp2057
g7
I237
sg27
VC0684249
p2058
sg10
I11
sg11
Vlung cancer
p2059
sg13
I2
sasa(dp2060
g2
VHerein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions.
p2061
sg4
(lp2062
(dp2063
g7
I114
sg8
VP41159
p2064
sg10
I6
sg11
Vleptin
p2065
sg13
I1
sa(dp2066
g7
I151
sg8
VP14555
p2067
sg10
I9
sg11
VsPLA2-IIA
p2068
sg13
I1
sasg24
(lp2069
(dp2070
g7
I164
sg27
VC0004114
p2071
sg10
I11
sg11
Vastrocytoma
p2072
sg13
I1
sa(dp2073
g7
I70
sg27
VC0006118
p2074
sg10
I12
sg11
Vbrain tumors
p2075
sg13
I2
sa(dp2076
g7
I58
sg27
VC0028754
p2077
sg10
I7
sg11
Vobesity
p2078
sg13
I1
sasa(dp2079
g2
VPLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity.
p2080
sg4
(lp2081
(dp2082
g7
I0
sg8
VP14555
p2083
sg10
I7
sg11
VPLA2g2a
p2084
sg13
I1
sasg24
(lp2085
(dp2086
g7
I26
sg27
VC0020676
p2087
sg10
I14
sg11
Vhypothyroidism
p2088
sg13
I1
sa(dp2089
g7
I26
sg27
VC0020676
p2090
sg10
I14
sg11
Vhypothyroidism
p2091
sg13
I1
sa(dp2092
g7
I98
sg27
VC0021368
p2093
sg10
I12
sg11
Vinflammation
p2094
sg13
I1
sa(dp2095
g7
I159
sg27
VC0028754
p2096
sg10
I7
sg11
Vobesity
p2097
sg13
I1
sasa(dp2098
g2
VThere were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00).
p2099
sg4
(lp2100
(dp2101
g7
I67
sg8
VP05164
p2102
sg10
I3
sg11
VMPO
p2103
sg13
I1
sa(dp2104
g7
I72
sg8
VP14555
p2105
sg10
I5
sg11
VsPLA2
p2106
sg13
I1
sasg24
(lp2107
(dp2108
g7
I49
sg27
VC2936179
p2109
sg10
I16
sg11
Vvisceral obesity
p2110
sg13
I2
sasa(dp2111
g2
VWe suggest that pla2g2a may have a causal relationship with chronic adiposity and metabolic syndrome and that its inhibition in vivo may be a valuable new approach to treat obesity, type 2 diabetes, and metabolic dysfunction in humans.
p2112
sg4
(lp2113
(dp2114
g7
I16
sg8
VP14555
p2115
sg10
I7
sg11
Vpla2g2a
p2116
sg13
I1
sasg24
(lp2117
(dp2118
g7
I182
sg27
VC0011860
p2119
sg10
I15
sg11
Vtype 2 diabetes
p2120
sg13
I3
sa(dp2121
g7
I68
sg27
VC0028754
p2122
sg10
I9
sg11
Vadiposity
p2123
sg13
I1
sa(dp2124
g7
I173
sg27
VC0028754
p2125
sg10
I7
sg11
Vobesity
p2126
sg13
I1
sa(dp2127
g7
I82
sg27
VC0524620
p2128
sg10
I18
sg11
Vmetabolic syndrome
p2129
sg13
I2
sasa(dp2130
g2
VTrypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival.
p2131
sg4
(lp2132
(dp2133
g7
I133
sg8
VP11926
p2134
sg10
I23
sg11
Vornithine decarboxylase
p2135
sg13
I2
sa(dp2136
g7
I158
sg8
VP11926
p2137
sg10
I3
sg11
VODC
p2138
sg13
I1
sa(dp2139
g7
I82
sg8
g9
sg10
I3
sg11
VHAT
p2140
sg13
I1
sa(dp2141
g7
I51
sg8
g9
sg10
I29
sg11
Vhuman African trypanosomiasis
p2142
sg13
I3
sasg24
(lp2143
(dp2144
g7
I57
sg27
VC0041228
p2145
sg10
I23
sg11
VAfrican trypanosomiasis
p2146
sg13
I2
sasa(dp2147
g2
VFurthermore, the molecular dynamics simulation work reveals that ZINC67909154 could be a potent inhibitor and this compound can be used to combat VL disease Conclusion: This study concludes that ZINC67909154 has the great potential to inhibit L. donovani ODC and would add to the drug discovery process against visceral leishmaniasis.
p2148
sg4
(lp2149
sg24
(lp2150
(dp2151
g7
I311
sg27
VC0023290
p2152
sg10
I22
sg11
Vvisceral leishmaniasis
p2153
sg13
I2
sa(dp2154
g7
I269
sg27
VC0004269
p2155
sg10
I3
sg11
Vadd
p2156
sg13
I1
sasa(dp2157
g2
Varginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SpdS), trypanothione synthetase (TryS or TSA), trypanothione reductase (TryR or TR), tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are promising targets for the development of new drugs against leishmaniasis.
p2158
sg4
(lp2159
(dp2160
g7
I0
sg8
VP11926
p2161
sg10
I39
sg11
Varginase (ARG), ornithine decarboxylase
p2162
sg13
I4
sa(dp2163
g7
I266
sg8
g9
sg10
I25
sg11
Vdeoxyhypusine hydroxylase
p2164
sg13
I2
sa(dp2165
g7
I115
sg8
VP35453
p2166
sg10
I4
sg11
VSpdS
p2167
sg13
I1
sa(dp2168
g7
I225
sg8
VP30041
p2169
sg10
I5
sg11
VTXNPx
p2170
sg13
I1
sa(dp2171
g7
I83
sg8
VP17707
p2172
sg10
I8
sg11
VAdoMetDC
p2173
sg13
I1
sa(dp2174
g7
I156
sg8
VP32119
p2175
sg10
I3
sg11
VTSA
p2176
sg13
I1
sa(dp2177
g7
I94
sg8
VP19623
p2178
sg10
I19
sg11
Vspermidine synthase
p2179
sg13
I2
sa(dp2180
g7
I257
sg8
VP49366
p2181
sg10
I3
sg11
VDHS
p2182
sg13
I1
sa(dp2183
g7
I41
sg8
VP11926
p2184
sg10
I3
sg11
VODC
p2185
sg13
I1
sa(dp2186
g7
I162
sg8
g9
sg10
I23
sg11
Vtrypanothione reductase
p2187
sg13
I2
sa(dp2188
g7
I200
sg8
VP30041
p2189
sg10
I23
sg11
Vtryparedoxin peroxidase
p2190
sg13
I2
sa(dp2191
g7
I293
sg8
g9
sg10
I4
sg11
VDOHH
p2192
sg13
I1
sa(dp2193
g7
I47
sg8
VP17707
p2194
sg10
I34
sg11
VS-adenosylmethionine decarboxylase
p2195
sg13
I2
sa(dp2196
g7
I233
sg8
VP49366
p2197
sg10
I22
sg11
Vdeoxyhypusine synthase
p2198
sg13
I2
sasg24
(lp2199
(dp2200
g7
I257
sg27
VC0272051
p2201
sg10
I3
sg11
VDHS
p2202
sg13
I1
sa(dp2203
g7
I362
sg27
VC0023281
p2204
sg10
I13
sg11
Vleishmaniasis
p2205
sg13
I1
sasa(dp2206
g2
VThe plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth factor Beta (TGF-Beta), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity.
p2207
sg4
(lp2208
(dp2209
g7
I33
sg8
VP11926
p2210
sg10
I23
sg11
Vornithine decarboxylase
p2211
sg13
I2
sa(dp2212
g7
I21
sg8
VP05089
p2213
sg10
I10
sg11
Varginase I
p2214
sg13
I2
sa(dp2215
g7
I64
sg8
VP18075
p2216
sg10
I31
sg11
Vtransforming growth factor Beta
p2217
sg13
I4
sa(dp2218
g7
I58
sg8
VP11926
p2219
sg10
I3
sg11
VODC
p2220
sg13
I1
sa(dp2221
g7
I97
sg8
VP18075
p2222
sg10
I8
sg11
VTGF-Beta
p2223
sg13
I1
sasg24
(lp2224
(dp2225
g7
I208
sg27
VC0023283
p2226
sg10
I23
sg11
Vcutaneous leishmaniasis
p2227
sg13
I2
sasa(dp2228
g2
VImmunohistochemistry confirmed that arginase I, ODC, and cyclooxygenase2 expression was higher in lesion biopsy specimens from patients with DCL than in those from patients with LCL.
p2229
sg4
(lp2230
(dp2231
g7
I48
sg8
VP11926
p2232
sg10
I3
sg11
VODC
p2233
sg13
I1
sa(dp2234
g7
I36
sg8
VP05089
p2235
sg10
I10
sg11
Varginase I
p2236
sg13
I2
sasg24
(lp2237
sa(dp2238
g2
VOur data implicate arginase I, ODC, PGE2, and TGF-Beta in the failure to mount an efficient immune response and suggest perspectives in the development of new strategies for therapeutic intervention for patients with DCL.
p2239
sg4
(lp2240
(dp2241
g7
I31
sg8
VP11926
p2242
sg10
I3
sg11
VODC
p2243
sg13
I1
sa(dp2244
g7
I19
sg8
VP05089
p2245
sg10
I10
sg11
Varginase I
p2246
sg13
I2
sa(dp2247
g7
I46
sg8
VP18075
p2248
sg10
I8
sg11
VTGF-Beta
p2249
sg13
I1
sasg24
(lp2250
sa(dp2251
g2
VThe active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
p2252
sg4
(lp2253
(dp2254
g7
I335
sg8
VP34896
p2255
sg10
I31
sg11
Vserine hydroxymethyltransferase
p2256
sg13
I2
sa(dp2257
g7
I281
sg8
VP17174
p2258
sg10
I5
sg11
VAspAT
p2259
sg13
I1
sa(dp2260
g7
I218
sg8
VP11926
p2261
sg10
I3
sg11
VODC
p2262
sg13
I1
sa(dp2263
g7
I193
sg8
VP11926
p2264
sg10
I23
sg11
Vornithine decarboxylase
p2265
sg13
I2
sa(dp2266
g7
I253
sg8
VP17174
p2267
sg10
I26
sg11
Vaspartate aminotransferase
p2268
sg13
I2
sa(dp2269
g7
I368
sg8
VP34896
p2270
sg10
I4
sg11
VSHMT
p2271
sg13
I1
sasg24
(lp2272
(dp2273
g7
I157
sg27
VC0024530
p2274
sg10
I7
sg11
Vmalaria
p2275
sg13
I1
sasa(dp2276
g2
VAlfa-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis.
p2277
sg4
(lp2278
(dp2279
g7
I135
sg8
VP11926
p2280
sg10
I23
sg11
Vornithine decarboxylase
p2281
sg13
I2
sa(dp2282
g7
I160
sg8
VP11926
p2283
sg10
I3
sg11
VODC
p2284
sg13
I1
sasg24
(lp2285
(dp2286
g7
I77
sg27
VC0041228
p2287
sg10
I25
sg11
VAfrican sleeping sickness
p2288
sg13
I3
sasa(dp2289
g2
VThis is the first study from north India reporting CYP1B1 mutations in Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma.
p2290
sg4
(lp2291
(dp2292
g7
I35
sg8
g9
sg10
I22
sg11
VIndia reporting CYP1B1
p2293
sg13
I3
sasg24
(lp2294
(dp2295
g7
I71
sg27
VC0265341
p2296
sg10
I24
sg11
VAxenfeld-Rieger syndrome
p2297
sg13
I2
sa(dp2298
g7
I139
sg27
VC0017601
p2299
sg10
I8
sg11
Vglaucoma
p2300
sg13
I1
sa(dp2301
g7
I111
sg27
VC0020302
p2302
sg10
I11
sg11
Vbuphthalmos
p2303
sg13
I1
sasa(dp2304
g2
VPurported BS2 cases may be divided into: (1) Bardet-Biedl syndrome with fortuitous coloboma or aniridia, (2) BS2 sensu stricto, a recessively inherited syndrome of sexual infantilism, short stature, coloboma, and preaxial polydactyly without obesity, only known from the original report, (3) a "new" dominantly inherited form of colobomatous microphthalmia occasionally associated with obesity, hypogonadism, and mental retardation, to which our observations belong.
p2305
sg4
(lp2306
sg24
(lp2307
(dp2308
g7
I58
sg27
VC0039082
p2309
sg10
I8
sg11
Vsyndrome
p2310
sg13
I1
sa(dp2311
g7
I213
sg27
VC0345354
p2312
sg10
I20
sg11
Vpreaxial polydactyly
p2313
sg13
I2
sa(dp2314
g7
I184
sg27
VC0013336
p2315
sg10
I13
sg11
Vshort stature
p2316
sg13
I2
sa(dp2317
g7
I164
sg27
VC0242341
p2318
sg10
I18
sg11
Vsexual infantilism
p2319
sg13
I2
sa(dp2320
g7
I45
sg27
VC0752166
p2321
sg10
I21
sg11
VBardet-Biedl syndrome
p2322
sg13
I2
sa(dp2323
g7
I95
sg27
VC0003076
p2324
sg10
I8
sg11
Vaniridia
p2325
sg13
I1
sa(dp2326
g7
I413
sg27
VC0025362
p2327
sg10
I18
sg11
Vmental retardation
p2328
sg13
I2
sa(dp2329
g7
I83
sg27
VC0009363
p2330
sg10
I8
sg11
Vcoloboma
p2331
sg13
I1
sa(dp2332
g7
I83
sg27
VC0009363
p2333
sg10
I8
sg11
Vcoloboma
p2334
sg13
I1
sa(dp2335
g7
I242
sg27
VC0028754
p2336
sg10
I7
sg11
Vobesity
p2337
sg13
I1
sa(dp2338
g7
I329
sg27
VC2931500
p2339
sg10
I27
sg11
Vcolobomatous microphthalmia
p2340
sg13
I2
sa(dp2341
g7
I395
sg27
VC0020619
p2342
sg10
I12
sg11
Vhypogonadism
p2343
sg13
I1
sa(dp2344
g7
I242
sg27
VC0028754
p2345
sg10
I7
sg11
Vobesity
p2346
sg13
I1
sasa(dp2347
g2
VGanglioneuromas (GNs) are benign tumors resulting from neural crest tissue.
p2348
sg4
(lp2349
sg24
(lp2350
(dp2351
g7
I17
sg27
VC0017075
p2352
sg10
I3
sg11
VGNs
p2353
sg13
I1
sa(dp2354
g7
I26
sg27
VC0086692
p2355
sg10
I13
sg11
Vbenign tumors
p2356
sg13
I2
sa(dp2357
g7
I0
sg27
VC0017075
p2358
sg10
I15
sg11
VGanglioneuromas
p2359
sg13
I1
sa(dp2360
g7
I62
sg27
VC0206138
p2361
sg10
I5
sg11
Vcrest
p2362
sg13
I1
sasa(dp2363
g2
VAdrenal ganglioneuromas (GNs) constitute rare, differentiated tumors which originate from neural crest cells.
p2364
sg4
(lp2365
sg24
(lp2366
(dp2367
g7
I62
sg27
VC0027651
p2368
sg10
I6
sg11
Vtumors
p2369
sg13
I1
sa(dp2370
g7
I97
sg27
VC0206138
p2371
sg10
I5
sg11
Vcrest
p2372
sg13
I1
sa(dp2373
g7
I8
sg27
VC0017075
p2374
sg10
I15
sg11
Vganglioneuromas
p2375
sg13
I1
sa(dp2376
g7
I25
sg27
VC0017075
p2377
sg10
I3
sg11
VGNs
p2378
sg13
I1
sasa(dp2379
g2
VGanglioneuromas (GNs) are hamartomatous tumors derived from the autonomic nervous system.
p2380
sg4
(lp2381
sg24
(lp2382
(dp2383
g7
I74
sg27
VC0027769
p2384
sg10
I7
sg11
Vnervous
p2385
sg13
I1
sa(dp2386
g7
I17
sg27
VC0017075
p2387
sg10
I3
sg11
VGNs
p2388
sg13
I1
sa(dp2389
g7
I0
sg27
VC0017075
p2390
sg10
I15
sg11
VGanglioneuromas
p2391
sg13
I1
sa(dp2392
g7
I40
sg27
VC0027651
p2393
sg10
I6
sg11
Vtumors
p2394
sg13
I1
sa(dp2395
g7
I26
sg27
VC0018552
p2396
sg10
I13
sg11
Vhamartomatous
p2397
sg13
I1
sasa(dp2398
g2
VGNs are categorized into three different morphological subtypes, namely, polypoid GN, ganglioneuromatous polyposis, and diffuse ganglioneuromatosis.
p2399
sg4
(lp2400
(dp2401
g7
I0
sg8
VP15586
p2402
sg10
I3
sg11
VGNs
p2403
sg13
I1
sasg24
(lp2404
(dp2405
g7
I105
sg27
VC0334108
p2406
sg10
I9
sg11
Vpolyposis
p2407
sg13
I1
sa(dp2408
g7
I128
sg27
VC0334595
p2409
sg10
I19
sg11
Vganglioneuromatosis
p2410
sg13
I1
sasa(dp2411
g2
VGanglioneuromas (GNs) arising from neural crest sympathogonia are rare benign neurogenic tumors.
p2412
sg4
(lp2413
sg24
(lp2414
(dp2415
g7
I89
sg27
VC0027651
p2416
sg10
I6
sg11
Vtumors
p2417
sg13
I1
sa(dp2418
g7
I17
sg27
VC0017075
p2419
sg10
I3
sg11
VGNs
p2420
sg13
I1
sa(dp2421
g7
I0
sg27
VC0017075
p2422
sg10
I15
sg11
VGanglioneuromas
p2423
sg13
I1
sa(dp2424
g7
I42
sg27
VC0206138
p2425
sg10
I5
sg11
Vcrest
p2426
sg13
I1
sasa(dp2427
g2
VGanglioneuromas (GNs) are neural crest cell-derived tumors and rarely occur in the adrenal gland.
p2428
sg4
(lp2429
sg24
(lp2430
(dp2431
g7
I17
sg27
VC0017075
p2432
sg10
I3
sg11
VGNs
p2433
sg13
I1
sa(dp2434
g7
I0
sg27
VC0017075
p2435
sg10
I15
sg11
VGanglioneuromas
p2436
sg13
I1
sa(dp2437
g7
I52
sg27
VC0027651
p2438
sg10
I6
sg11
Vtumors
p2439
sg13
I1
sa(dp2440
g7
I33
sg27
VC0206138
p2441
sg10
I5
sg11
Vcrest
p2442
sg13
I1
sasa(dp2443
g2
VGanglioneuromas (GNs) are the rarest and most benign of the neuroblastic tumors.
p2444
sg4
(lp2445
sg24
(lp2446
(dp2447
g7
I17
sg27
VC0017075
p2448
sg10
I3
sg11
VGNs
p2449
sg13
I1
sa(dp2450
g7
I0
sg27
VC0017075
p2451
sg10
I15
sg11
VGanglioneuromas
p2452
sg13
I1
sa(dp2453
g7
I73
sg27
VC0027651
p2454
sg10
I6
sg11
Vtumors
p2455
sg13
I1
sasa(dp2456
g2
VGanglioneuromas (GNs) are rare benign tumors and their association with neurofibromatosis type 1 (NF-1) is especially uncommon.
p2457
sg4
(lp2458
(dp2459
g7
I72
sg8
VP21359
p2460
sg10
I24
sg11
Vneurofibromatosis type 1
p2461
sg13
I3
sa(dp2462
g7
I98
sg8
VP21359
p2463
sg10
I4
sg11
VNF-1
p2464
sg13
I1
sasg24
(lp2465
(dp2466
g7
I72
sg27
VC0027831
p2467
sg10
I24
sg11
Vneurofibromatosis type 1
p2468
sg13
I3
sa(dp2469
g7
I17
sg27
VC0017075
p2470
sg10
I3
sg11
VGNs
p2471
sg13
I1
sa(dp2472
g7
I98
sg27
VC0027831
p2473
sg10
I4
sg11
VNF-1
p2474
sg13
I1
sa(dp2475
g7
I31
sg27
VC0086692
p2476
sg10
I13
sg11
Vbenign tumors
p2477
sg13
I2
sa(dp2478
g7
I0
sg27
VC0017075
p2479
sg10
I15
sg11
VGanglioneuromas
p2480
sg13
I1
sasa(dp2481
g2
VFour of eight T1D-specific regions contained known type 2 diabetes (T2D) candidate genes (COBL, GLIS3, RNLS and BCAR1), suggesting a shared cellular etiology.
p2482
sg4
(lp2483
(dp2484
g7
I103
sg8
g9
sg10
I4
sg11
VRNLS
p2485
sg13
I1
sa(dp2486
g7
I90
sg8
g9
sg10
I4
sg11
VCOBL
p2487
sg13
I1
sa(dp2488
g7
I96
sg8
g9
sg10
I5
sg11
VGLIS3
p2489
sg13
I1
sa(dp2490
g7
I112
sg8
VP56945
p2491
sg10
I5
sg11
VBCAR1
p2492
sg13
I1
sasg24
(lp2493
(dp2494
g7
I68
sg27
VC0011860
p2495
sg10
I3
sg11
VT2D
p2496
sg13
I1
sa(dp2497
g7
I51
sg27
VC0011860
p2498
sg10
I15
sg11
Vtype 2 diabetes
p2499
sg13
I3
sasa(dp2500
g2
VAutoantibodies to insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured in follow-up sera, and genotyping for type 1 diabetes susceptibility genes (HLA-DR/HLA-DQ, INS variable number of tandem repeats [VNTR] and single nucleotide polymorphisms at PTPN22, PTPN2, ERBB3, IL2, SH2B3, CTLA4, IFIH1, KIAA0350 [also known as CLEC16A], CD25, IL18RAP, IL10, COBL) was performed on the DNA samples of children born to a parent with type 1 diabetes and prospectively followed from birth for up to 22 years.
p2501
sg4
(lp2502
(dp2503
g7
I353
sg8
g9
sg10
I8
sg11
VKIAA0350
p2504
sg13
I1
sa(dp2505
g7
I206
sg8
VP30486
p2506
sg10
I6
sg11
VHLA-DR
p2507
sg13
I1
sa(dp2508
g7
I393
sg8
g9
sg10
I7
sg11
VIL18RAP
p2509
sg13
I1
sa(dp2510
g7
I320
sg8
VP21860
p2511
sg10
I5
sg11
VERBB3
p2512
sg13
I1
sa(dp2513
g7
I89
sg8
g9
sg10
I18
sg11
Vzinc transporter 8
p2514
sg13
I3
sa(dp2515
g7
I305
sg8
VP17706
p2516
sg10
I5
sg11
VPTPN2
p2517
sg13
I1
sa(dp2518
g7
I206
sg8
VP30486
p2519
sg10
I3
sg11
VHLA
p2520
sg13
I1
sa(dp2521
g7
I305
sg8
g9
sg10
I6
sg11
VPTPN22
p2522
sg13
I1
sa(dp2523
g7
I377
sg8
g9
sg10
I7
sg11
VCLEC16A
p2524
sg13
I1
sa(dp2525
g7
I339
sg8
VP16410
p2526
sg10
I5
sg11
VCTLA4
p2527
sg13
I1
sa(dp2528
g7
I402
sg8
VP22301
p2529
sg10
I4
sg11
VIL10
p2530
sg13
I1
sa(dp2531
g7
I408
sg8
g9
sg10
I4
sg11
VCOBL
p2532
sg13
I1
sa(dp2533
g7
I332
sg8
g9
sg10
I5
sg11
VSH2B3
p2534
sg13
I1
sa(dp2535
g7
I346
sg8
g9
sg10
I5
sg11
VIFIH1
p2536
sg13
I1
sa(dp2537
g7
I387
sg8
VP01589
p2538
sg10
I4
sg11
VCD25
p2539
sg13
I1
sa(dp2540
g7
I327
sg8
VP60568
p2541
sg10
I3
sg11
VIL2
p2542
sg13
I1
sa(dp2543
g7
I18
sg8
VP01308
p2544
sg10
I7
sg11
Vinsulin
p2545
sg13
I1
sasg24
(lp2546
(dp2547
g7
I33
sg27
VC0270549
p2548
sg10
I3
sg11
VGAD
p2549
sg13
I1
sa(dp2550
g7
I45
sg27
VC0021670
p2551
sg10
I10
sg11
Vinsulinoma
p2552
sg13
I1
sa(dp2553
g7
I221
sg27
VC1533172
p2554
sg10
I3
sg11
VINS
p2555
sg13
I1
sa(dp2556
g7
I168
sg27
VC0011854
p2557
sg10
I15
sg11
Vtype 1 diabetes
p2558
sg13
I3
sa(dp2559
g7
I168
sg27
VC0011854
p2560
sg10
I15
sg11
Vtype 1 diabetes
p2561
sg13
I3
sasa(dp2562
g2
VChildren of parents with type 1 diabetes and prospectively followed from birth for the development of islet autoantibodies and diabetes were genotyped for single-nucleotide polymorphisms at 12 type 1 diabetes susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10 and COBL).
p2563
sg4
(lp2564
(dp2565
g7
I290
sg8
VP60568
p2566
sg10
I3
sg11
VIL2
p2567
sg13
I1
sa(dp2568
g7
I260
sg8
g9
sg10
I8
sg11
VKIAA0350
p2569
sg13
I1
sa(dp2570
g7
I231
sg8
VP21860
p2571
sg10
I5
sg11
VERBB3
p2572
sg13
I1
sa(dp2573
g7
I313
sg8
g9
sg10
I4
sg11
VCOBL
p2574
sg13
I1
sa(dp2575
g7
I276
sg8
VP16410
p2576
sg10
I5
sg11
VCTLA4
p2577
sg13
I1
sa(dp2578
g7
I295
sg8
g9
sg10
I7
sg11
VIL18RAP
p2579
sg13
I1
sa(dp2580
g7
I252
sg8
g9
sg10
I6
sg11
VPTPN22
p2581
sg13
I1
sa(dp2582
g7
I245
sg8
g9
sg10
I5
sg11
VIFIH1
p2583
sg13
I1
sa(dp2584
g7
I283
sg8
g9
sg10
I5
sg11
VSH2B3
p2585
sg13
I1
sa(dp2586
g7
I238
sg8
VP17706
p2587
sg10
I5
sg11
VPTPN2
p2588
sg13
I1
sa(dp2589
g7
I270
sg8
VP01589
p2590
sg10
I4
sg11
VCD25
p2591
sg13
I1
sa(dp2592
g7
I304
sg8
VP22301
p2593
sg10
I4
sg11
VIL10
p2594
sg13
I1
sasg24
(lp2595
(dp2596
g7
I25
sg27
VC0011854
p2597
sg10
I15
sg11
Vtype 1 diabetes
p2598
sg13
I3
sa(dp2599
g7
I25
sg27
VC0011854
p2600
sg10
I15
sg11
Vtype 1 diabetes
p2601
sg13
I3
sa(dp2602
g7
I32
sg27
VC0011849
p2603
sg10
I8
sg11
Vdiabetes
p2604
sg13
I1
sasa(dp2605
g2
VThe greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.
p2606
sg4
(lp2607
(dp2608
g7
I165
sg8
VP30486
p2609
sg10
I3
sg11
VHLA
p2610
sg13
I1
sa(dp2611
g7
I101
sg8
VP16410
p2612
sg10
I5
sg11
VCTLA4
p2613
sg13
I1
sa(dp2614
g7
I116
sg8
g9
sg10
I7
sg11
VIL18RAP
p2615
sg13
I1
sa(dp2616
g7
I108
sg8
g9
sg10
I6
sg11
VPTPN22
p2617
sg13
I1
sa(dp2618
g7
I142
sg8
g9
sg10
I4
sg11
VCOBL
p2619
sg13
I1
sa(dp2620
g7
I94
sg8
g9
sg10
I5
sg11
VIFIH1
p2621
sg13
I1
sa(dp2622
g7
I125
sg8
g9
sg10
I5
sg11
VSH2B3
p2623
sg13
I1
sa(dp2624
g7
I132
sg8
g9
sg10
I8
sg11
VKIAA0350
p2625
sg13
I1
sa(dp2626
g7
I151
sg8
VP21860
p2627
sg10
I5
sg11
VERBB3
p2628
sg13
I1
sasg24
(lp2629
(dp2630
g7
I13
sg27
VC0011849
p2631
sg10
I8
sg11
Vdiabetes
p2632
sg13
I1
sasa(dp2633
g2
VHowever, all of the eosinophil-activating cytokines, such as IL-5, IL-3, and GM-CSF, are typically present in atopic diseases, including allergic asthma.
p2634
sg4
(lp2635
(dp2636
g7
I61
sg8
VP05113
p2637
sg10
I4
sg11
VIL-5
p2638
sg13
I1
sa(dp2639
g7
I67
sg8
VP08700
p2640
sg10
I4
sg11
VIL-3
p2641
sg13
I1
sa(dp2642
g7
I77
sg8
VP04141
p2643
sg10
I6
sg11
VGM-CSF
p2644
sg13
I1
sasg24
(lp2645
(dp2646
g7
I137
sg27
VC0155877
p2647
sg10
I15
sg11
Vallergic asthma
p2648
sg13
I2
sa(dp2649
g7
I110
sg27
VC0392707
p2650
sg10
I6
sg11
Vatopic
p2651
sg13
I1
sasa(dp2652
g2
VIn a murine model of allergic asthma, we found that Tyk-2((-/-)) asthmatic mice have induced peribronchial collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD4(+) effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13.
p2653
sg4
(lp2654
(dp2655
g7
I254
sg8
VP05113
p2656
sg10
I4
sg11
VIL-5
p2657
sg13
I1
sa(dp2658
g7
I165
sg8
g9
sg10
I4
sg11
VIRF4
p2659
sg13
I1
sa(dp2660
g7
I242
sg8
VP08700
p2661
sg10
I4
sg11
VIL-3
p2662
sg13
I1
sa(dp2663
g7
I248
sg8
VP05112
p2664
sg10
I4
sg11
VIL-4
p2665
sg13
I1
sa(dp2666
g7
I174
sg8
VP01730
p2667
sg10
I31
sg11
Vhyperproliferative lung Th2 CD4
p2668
sg13
I4
sa(dp2669
g7
I270
sg8
VP35225
p2670
sg10
I5
sg11
VIL-13
p2671
sg13
I1
sasg24
(lp2672
(dp2673
g7
I21
sg27
VC0155877
p2674
sg10
I15
sg11
Vallergic asthma
p2675
sg13
I2
sa(dp2676
g7
I65
sg27
VC0004096
p2677
sg10
I9
sg11
Vasthmatic
p2678
sg13
I1
sasa(dp2679
g2
VHeterologous or homologous Nrf2 deletion (Nrf2+/- or Nrf2-/-) rescued the pancreatic phenotypes, weight loss and hypoglycemia in KC::Keap1 mice, suggesting that Nrf2 is a major downstream target of Keap1.
p2680
sg4
(lp2681
(dp2682
g7
I27
sg8
g9
sg10
I4
sg11
VNrf2
p2683
sg13
I1
sa(dp2684
g7
I27
sg8
g9
sg10
I4
sg11
VNrf2
p2685
sg13
I1
sa(dp2686
g7
I133
sg8
g9
sg10
I5
sg11
VKeap1
p2687
sg13
I1
sa(dp2688
g7
I133
sg8
g9
sg10
I5
sg11
VKeap1
p2689
sg13
I1
sasg24
(lp2690
(dp2691
g7
I113
sg27
VC0020615
p2692
sg10
I12
sg11
Vhypoglycemia
p2693
sg13
I1
sasa(dp2694
g2
VDisrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer's and Parkinson's.
p2695
sg4
(lp2696
(dp2697
g7
I21
sg8
g9
sg10
I4
sg11
VNrf2
p2698
sg13
I1
sa(dp2699
g7
I21
sg8
g9
sg10
I4
sg11
VNrf2
p2700
sg13
I1
sa(dp2701
g7
I15
sg8
g9
sg10
I5
sg11
VKeap1
p2702
sg13
I1
sasg24
(lp2703
(dp2704
g7
I222
sg27
VC0006826
p2705
sg10
I6
sg11
Vcancer
p2706
sg13
I1
sa(dp2707
g7
I230
sg27
VC0011849
p2708
sg10
I8
sg11
Vdiabetes
p2709
sg13
I1
sa(dp2710
g7
I167
sg27
VC0242606
p2711
sg10
I16
sg11
Voxidative stress
p2712
sg13
I2
sa(dp2713
g7
I188
sg27
VC0021368
p2714
sg10
I12
sg11
Vinflammation
p2715
sg13
I1
sa(dp2716
g7
I141
sg27
VC0008679
p2717
sg10
I16
sg11
Vchronic diseases
p2718
sg13
I2
sasa(dp2719
g2
VThis study investigates the role of ACSVL3 in the maintenance of glioblastoma multiforme (GBM) stem cell self-renewal and the capacity of GBM stem cells to initiate tumor xenograft formation.
p2720
sg4
(lp2721
sg24
(lp2722
(dp2723
g7
I90
sg27
VC1621958
p2724
sg10
I3
sg11
VGBM
p2725
sg13
I1
sa(dp2726
g7
I90
sg27
VC1621958
p2727
sg10
I3
sg11
VGBM
p2728
sg13
I1
sa(dp2729
g7
I65
sg27
VC1621958
p2730
sg10
I23
sg11
Vglioblastoma multiforme
p2731
sg13
I2
sa(dp2732
g7
I165
sg27
VC0027651
p2733
sg10
I5
sg11
Vtumor
p2734
sg13
I1
sasa(dp2735
g2
VWe examined ACSVL3 expression during differentiation of several GBM stem cell enriched neurosphere cultures.
p2736
sg4
(lp2737
sg24
(lp2738
(dp2739
g7
I64
sg27
VC0017636
p2740
sg10
I3
sg11
VGBM
p2741
sg13
I1
sasa(dp2742
g2
VACSVL3 expression levels were substantially increased in GBM stem cell enriched neurosphere cultures and decreased after differentiation of the neurospheres.
p2743
sg4
(lp2744
sg24
(lp2745
(dp2746
g7
I57
sg27
VC0017636
p2747
sg10
I3
sg11
VGBM
p2748
sg13
I1
sasa(dp2749
g2
VFurthermore, ACSVL3 knockdown reduced anchorage-independent neurosphere cell growth, neurosphere-forming capacity as well as self-renewal of these GBM stem cell enriched neurosphere cultures.
p2750
sg4
(lp2751
sg24
(lp2752
(dp2753
g7
I147
sg27
VC0017636
p2754
sg10
I3
sg11
VGBM
p2755
sg13
I1
sasa(dp2756
g2
VA link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.
p2757
sg4
(lp2758
(dp2759
g7
I133
sg8
VP29401
p2760
sg10
I24
sg11
Vreceptor tyrosine kinase
p2761
sg13
I3
sa(dp2762
g7
I252
sg8
VP08581
p2763
sg10
I5
sg11
Vc-Met
p2764
sg13
I1
sa(dp2765
g7
I248
sg8
VP05231
p2766
sg10
I3
sg11
VHGF
p2767
sg13
I1
sasg24
(lp2768
(dp2769
g7
I180
sg27
VC0017636
p2770
sg10
I3
sg11
VGBM
p2771
sg13
I1
sa(dp2772
g7
I26
sg27
VC0006826
p2773
sg10
I6
sg11
Vcancer
p2774
sg13
I1
sa(dp2775
g7
I248
sg27
VC0399440
p2776
sg10
I3
sg11
VHGF
p2777
sg13
I1
sa(dp2778
g7
I211
sg27
VC0598935
p2779
sg10
I16
sg11
Vtumor initiation
p2780
sg13
I2
sasa(dp2781
g2
VOur findings indicate that the lipid metabolism enzyme ACSVL3 is involved in GBM stem cell maintenance and the tumor-initiating capacity of GBM stem cell enriched-neurospheres in animals.
p2782
sg4
(lp2783
sg24
(lp2784
(dp2785
g7
I77
sg27
VC0017636
p2786
sg10
I3
sg11
VGBM
p2787
sg13
I1
sa(dp2788
g7
I111
sg27
VC0027651
p2789
sg10
I5
sg11
Vtumor
p2790
sg13
I1
sa(dp2791
g7
I77
sg27
VC0017636
p2792
sg10
I3
sg11
VGBM
p2793
sg13
I1
sasa(dp2794
g2
VA significant association was detected between TLR9 genotypes and some of the disease manifestations as myositis (p = 0.032), psychosis (p = 0.014), photosensitivity (p = 0.002), and pleurisy (p = &lt;0.001).
p2795
sg4
(lp2796
(dp2797
g7
I47
sg8
g9
sg10
I14
sg11
VTLR9 genotypes
p2798
sg13
I2
sasg24
(lp2799
(dp2800
g7
I149
sg27
VC0393720
p2801
sg10
I16
sg11
Vphotosensitivity
p2802
sg13
I1
sa(dp2803
g7
I183
sg27
VC0497354
p2804
sg10
I8
sg11
Vpleurisy
p2805
sg13
I1
sa(dp2806
g7
I104
sg27
VC0027121
p2807
sg10
I8
sg11
Vmyositis
p2808
sg13
I1
sa(dp2809
g7
I126
sg27
VC0349204
p2810
sg10
I9
sg11
Vpsychosis
p2811
sg13
I1
sasa(dp2812
g2
VIn addition, rLj-HMGB2 could induce the generation of proinflammatory mediators in the activated human acute monocytic leukemia cell line (THP1), which suggested that Lj-HMGB2 may participate in the immune response of the lampreys.
p2813
sg4
(lp2814
(dp2815
g7
I139
sg8
VP10070
p2816
sg10
I4
sg11
VTHP1
p2817
sg13
I1
sa(dp2818
g7
I13
sg8
VP26583
p2819
sg10
I9
sg11
VrLj-HMGB2
p2820
sg13
I1
sa(dp2821
g7
I14
sg8
VP26583
p2822
sg10
I8
sg11
VLj-HMGB2
p2823
sg13
I1
sasg24
(lp2824
(dp2825
g7
I103
sg27
VC1318544
p2826
sg10
I24
sg11
Vacute monocytic leukemia
p2827
sg13
I3
sasa(dp2828
g2
VNut consumption was independently associated with a decreased risk of overall and vascular-disease mortality, particularly in women.
p2829
sg4
(lp2830
(dp2831
g7
I0
sg8
g9
sg10
I3
sg11
VNut
p2832
sg13
I1
sasg24
(lp2833
sa(dp2834
g2
VNut consumption has been inconsistently associated with risk of stroke.
p2835
sg4
(lp2836
(dp2837
g7
I0
sg8
g9
sg10
I3
sg11
VNut
p2838
sg13
I1
sasg24
(lp2839
(dp2840
g7
I64
sg27
VC0038454
p2841
sg10
I6
sg11
Vstroke
p2842
sg13
I1
sasa(dp2843
g2
VUlcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-Alfa.
p2844
sg4
(lp2845
(dp2846
g7
I86
sg8
VP05534
p2847
sg10
I35
sg11
Vmonocyte human leukocyte antigen-DR
p2848
sg13
I4
sa(dp2849
g7
I123
sg8
VP30486
p2850
sg10
I3
sg11
VHLA
p2851
sg13
I1
sa(dp2852
g7
I220
sg8
VP01375
p2853
sg10
I33
sg11
Vtumour necrosis factor [TNF]-Alfa
p2854
sg13
I4
sa(dp2855
g7
I173
sg8
g9
sg10
I42
sg11
Vgut-homing C-C chemokine receptor 9 [CCR9]
p2856
sg13
I6
sasg24
(lp2857
(dp2858
g7
I0
sg27
VC0009324
p2859
sg10
I18
sg11
VUlcerative colitis
p2860
sg13
I2
sa(dp2861
g7
I220
sg27
VC0333516
p2862
sg10
I15
sg11
Vtumour necrosis
p2863
sg13
I2
sasa(dp2864
g2
VThe aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response.
p2865
sg4
(lp2866
(dp2867
g7
I132
sg8
VP51686
p2868
sg10
I4
sg11
VCCR9
p2869
sg13
I1
sasg24
(lp2870
(dp2871
g7
I211
sg27
VC0009324
p2872
sg10
I18
sg11
Vulcerative colitis
p2873
sg13
I2
sa(dp2874
g7
I39
sg27
VC0456909
p2875
sg10
I5
sg11
Vblind
p2876
sg13
I1
sasa(dp2877
g2
VPatients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column.
p2878
sg4
(lp2879
(dp2880
g7
I110
sg8
VP55773
p2881
sg10
I23
sg11
VC-C chemokine ligand 25
p2882
sg13
I4
sa(dp2883
g7
I142
sg8
VP51686
p2884
sg10
I4
sg11
VCCR9
p2885
sg13
I1
sa(dp2886
g7
I135
sg8
g9
sg10
I5
sg11
VCCL25
p2887
sg13
I1
sasg24
(lp2888
(dp2889
g7
I14
sg27
VC0009324
p2890
sg10
I18
sg11
Vulcerative colitis
p2891
sg13
I2
sasa(dp2892
g2
VCC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key role in leukocyte recruitment to the gut and represents a therapeutic target in inflammatory bowel disease.
p2893
sg4
(lp2894
(dp2895
g7
I0
sg8
g9
sg10
I28
sg11
VCC chemokine receptor type 9
p2896
sg13
I5
sa(dp2897
g7
I30
sg8
VP51686
p2898
sg10
I4
sg11
VCCR9
p2899
sg13
I1
sa(dp2900
g7
I50
sg8
g9
sg10
I5
sg11
VCCL25
p2901
sg13
I1
sasg24
(lp2902
(dp2903
g7
I148
sg27
VC0021390
p2904
sg10
I26
sg11
Vinflammatory bowel disease
p2905
sg13
I3
sa(dp2906
g7
I86
sg27
VC0271510
p2907
sg10
I11
sg11
Vrecruitment
p2908
sg13
I1
sasa(dp2909
g2
VThe selective CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need for very high doses to block receptor activation.
p2910
sg4
(lp2911
(dp2912
g7
I14
sg8
VP51686
p2913
sg10
I4
sg11
VCCR9
p2914
sg13
I1
sasg24
(lp2915
(dp2916
g7
I81
sg27
VC0010346
p2917
sg10
I15
sg11
VCrohn's disease
p2918
sg13
I2
sasa(dp2919
g2
VTo investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions.#\u3000METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ.#\u3000Colitis was evaluated by body weight decreases and by histological score.#\u3000Also colonic mRNA expression was measured by RT-PCR.#\u3000To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation.#\u3000Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry.#\u3000Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA.#\u3000Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry.#\u3000RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis.#\u3000In the colons of IMQ-treated mice, mRNA expression of TNF-Alfa was decreased, and strong expressions of IL-6, IFN-Beta and TGF-Beta were detected.#\u3000IL-10 and TGF-Beta productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells.#\u3000In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-Beta, TGF-Beta and Foxp3 mRNA were detected.#\u3000IL-10 production from MLN cells was also increased in the IMQ-treated group.#\u3000Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.#\u3000CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.
p2920
sg4
(lp2921
(dp2922
g7
I613
sg8
VP01730
p2923
sg10
I4
sg11
VCD4+
p2924
sg13
I1
sa(dp2925
g7
I1267
sg8
VP01375
p2926
sg10
I8
sg11
VTNF-Alfa
p2927
sg13
I1
sa(dp2928
g7
I849
sg8
VP12872
p2929
sg10
I3
sg11
VMLN
p2930
sg13
I1
sa(dp2931
g7
I520
sg8
VP01562
p2932
sg10
I10
sg11
Vtype-1 IFN
p2933
sg13
I2
sa(dp2934
g7
I1336
sg8
VP18075
p2935
sg10
I8
sg11
VTGF-Beta
p2936
sg13
I1
sa(dp2937
g7
I1785
sg8
VP51686
p2938
sg10
I4
sg11
VCCR9
p2939
sg13
I1
sa(dp2940
g7
I1323
sg8
VP01574
p2941
sg10
I8
sg11
VIFN-Beta
p2942
sg13
I1
sa(dp2943
g7
I1639
sg8
g9
sg10
I10
sg11
VFoxp3 mRNA
p2944
sg13
I2
sa(dp2945
g7
I1317
sg8
VP05231
p2946
sg10
I4
sg11
VIL-6
p2947
sg13
I1
sa(dp2948
g7
I42
sg8
g9
sg10
I11
sg11
VTLR7 ligand
p2949
sg13
I2
sa(dp2950
g7
I825
sg8
VP12872
p2951
sg10
I22
sg11
Vmesenteric lymph nodes
p2952
sg13
I3
sa(dp2953
g7
I1336
sg8
VP18075
p2954
sg10
I8
sg11
VTGF-Beta
p2955
sg13
I1
sa(dp2956
g7
I1336
sg8
VP18075
p2957
sg10
I8
sg11
VTGF-Beta
p2958
sg13
I1
sa(dp2959
g7
I1785
sg8
VP51686
p2960
sg10
I4
sg11
VCCR9
p2961
sg13
I1
sa(dp2962
g7
I42
sg8
g9
sg10
I4
sg11
VTLR7
p2963
sg13
I1
sa(dp2964
g7
I1323
sg8
VP01574
p2965
sg10
I8
sg11
VIFN-Beta
p2966
sg13
I1
sasg24
(lp2967
(dp2968
g7
I178
sg27
VC0009319
p2969
sg10
I7
sg11
Vcolitis
p2970
sg13
I1
sa(dp2971
g7
I178
sg27
VC0009319
p2972
sg10
I7
sg11
Vcolitis
p2973
sg13
I1
sa(dp2974
g7
I81
sg27
VC0021368
p2975
sg10
I12
sg11
Vinflammation
p2976
sg13
I1
sa(dp2977
g7
I332
sg27
VC0009319
p2978
sg10
I8
sg11
V\u3000Colitis
p2979
sg13
I1
sa(dp2980
g7
I178
sg27
VC0009319
p2981
sg10
I7
sg11
Vcolitis
p2982
sg13
I1
sa(dp2983
g7
I178
sg27
VC0009319
p2984
sg10
I7
sg11
Vcolitis
p2985
sg13
I1
sa(dp2986
g7
I81
sg27
VC0021368
p2987
sg10
I12
sg11
Vinflammation
p2988
sg13
I1
sasa(dp2989
g2
VWe here showed that CCR9+ CD11b+ macrophages play an important role during the course of Concanavalin A-induced murine acute liver injury as well as human acute hepatitis via the production of inflammatory cytokines and the Th1 induction.
p2990
sg4
(lp2991
(dp2992
g7
I20
sg8
VP51686
p2993
sg10
I12
sg11
VCCR9+ CD11b+
p2994
sg13
I2
sasg24
(lp2995
(dp2996
g7
I155
sg27
VC0267797
p2997
sg10
I15
sg11
Vacute hepatitis
p2998
sg13
I2
sasa(dp2999
g2
VWe found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses (10-4&gt;P&gt;5.8x10-6).
p3000
sg4
(lp3001
(dp3002
g7
I126
sg8
VP51686
p3003
sg10
I4
sg11
VCCR9
p3004
sg13
I1
sa(dp3005
g7
I109
sg8
g9
sg10
I5
sg11
VRGS21
p3006
sg13
I1
sa(dp3007
g7
I116
sg8
VP08567
p3008
sg10
I4
sg11
VPLEK
p3009
sg13
I1
sa(dp3010
g7
I101
sg8
g9
sg10
I6
sg11
VIL18R1
p3011
sg13
I1
sa(dp3012
g7
I94
sg8
g9
sg10
I5
sg11
VTAGAP
p3013
sg13
I1
sasg24
(lp3014
(dp3015
g7
I78
sg27
VC0007570
p3016
sg10
I14
sg11
Vceliac disease
p3017
sg13
I2
sa(dp3018
g7
I78
sg27
VC0007570
p3019
sg10
I14
sg11
Vceliac disease
p3020
sg13
I2
sasa(dp3021
g2
VIncluding chemokines [C-C motif ligand (CCL) 19, CCL20, CCL21, C-X-C motif ligand (CXCL) 6, CXCL10, and CXCL11] and soluble cytokine and chemokine receptors [soluble (s) interleukin (IL) 6 receptor (R), soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, and sIL-R2], ten inflammation-related markers, were nominally associated with diabetes (P&lt;0.05).
p3022
sg4
(lp3023
(dp3024
g7
I56
sg8
g9
sg10
I5
sg11
VCCL21
p3025
sg13
I1
sa(dp3026
g7
I92
sg8
VP02778
p3027
sg10
I6
sg11
VCXCL10
p3028
sg13
I1
sa(dp3029
g7
I211
sg8
VP01375
p3030
sg10
I40
sg11
Vtumor necrosis factor receptor (sTNFR) 1
p3031
sg13
I6
sa(dp3032
g7
I265
sg8
VP40967
p3033
sg10
I6
sg11
VsIL-R2
p3034
sg13
I1
sa(dp3035
g7
I104
sg8
g9
sg10
I6
sg11
VCXCL11
p3036
sg13
I1
sa(dp3037
g7
I49
sg8
VP78556
p3038
sg10
I5
sg11
VCCL20
p3039
sg13
I1
sasg24
(lp3040
(dp3041
g7
I339
sg27
VC0011849
p3042
sg10
I8
sg11
Vdiabetes
p3043
sg13
I1
sa(dp3044
g7
I21
sg27
VC1852438
p3045
sg10
I17
sg11
V[C-C motif ligand
p3046
sg13
I3
sa(dp3047
g7
I40
sg27
VC1852438
p3048
sg10
I3
sg11
VCCL
p3049
sg13
I1
sa(dp3050
g7
I265
sg27
VC0333873
p3051
sg10
I3
sg11
VsIL
p3052
sg13
I1
sa(dp3053
g7
I278
sg27
VC0021368
p3054
sg10
I12
sg11
Vinflammation
p3055
sg13
I1
sa(dp3056
g7
I211
sg27
VC0333516
p3057
sg10
I14
sg11
Vtumor necrosis
p3058
sg13
I2
sasa(dp3059
g2
VWe identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.
p3060
sg4
(lp3061
(dp3062
g7
I27
sg8
g9
sg10
I30
sg11
Vmelanoma-associated antigen D2
p3063
sg13
I3
sasg24
(lp3064
(dp3065
g7
I27
sg27
VC0025202
p3066
sg10
I8
sg11
Vmelanoma
p3067
sg13
I1
sasa(dp3068
g2
VMAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.We distinguish two types of hereditary NDI: a 'pure' type with loss of water only and a complex type with loss of water and ions.
p3069
sg4
(lp3070
(dp3071
g7
I0
sg8
g9
sg10
I6
sg11
VMAGED2
p3072
sg13
I1
sasg24
(lp3073
(dp3074
g7
I33
sg27
VC0020224
p3075
sg10
I14
sg11
Vpolyhydramnios
p3076
sg13
I1
sa(dp3077
g7
I168
sg27
VC1563705
p3078
sg10
I3
sg11
VNDI
p3079
sg13
I1
sa(dp3080
g7
I110
sg27
VC0004775
p3081
sg10
I18
sg11
VBartter's syndrome
p3082
sg13
I2
sasa(dp3083
g2
VA new variant of this was recently identified: seven families were described with transient antenatal Bartter's syndrome, polyhydramnios and MAGED2 mutations.Multiple compounds have been identified experimentally that may stimulate urinary concentration independently of the vasopressin V2 receptor.
p3084
sg4
(lp3085
(dp3086
g7
I275
sg8
VP30518
p3087
sg10
I23
sg11
Vvasopressin V2 receptor
p3088
sg13
I3
sa(dp3089
g7
I141
sg8
g9
sg10
I6
sg11
VMAGED2
p3090
sg13
I1
sasg24
(lp3091
(dp3092
g7
I122
sg27
VC0020224
p3093
sg10
I14
sg11
Vpolyhydramnios
p3094
sg13
I1
sa(dp3095
g7
I102
sg27
VC0004775
p3096
sg10
I18
sg11
VBartter's syndrome
p3097
sg13
I2
sasa(dp3098
g2
VFluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically engineered models of cancer development and treatment.
p3099
sg4
(lp3100
(dp3101
g7
I69
sg8
VP20151
p3102
sg10
I3
sg11
VhK2
p3103
sg13
I1
sasg24
(lp3104
(dp3105
g7
I187
sg27
VC0006826
p3106
sg10
I6
sg11
Vcancer
p3107
sg13
I1
sasa(dp3108
g2
VHumanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers.
p3109
sg4
(lp3110
(dp3111
g7
I0
sg8
g9
sg10
I14
sg11
VHumanized 11B6
p3112
sg13
I2
sasg24
(lp3113
(dp3114
g7
I135
sg27
VC0006826
p3115
sg10
I7
sg11
Vcancers
p3116
sg13
I1
sasa(dp3117
g2
VMAGE-D2 is new gene found to cause severe polyhydramnios and transient postnatal Bartter-like syndrome.
p3118
sg4
(lp3119
(dp3120
g7
I0
sg8
g9
sg10
I7
sg11
VMAGE-D2
p3121
sg13
I1
sasg24
(lp3122
(dp3123
g7
I42
sg27
VC0020224
p3124
sg10
I14
sg11
Vpolyhydramnios
p3125
sg13
I1
sa(dp3126
g7
I94
sg27
VC0039082
p3127
sg10
I8
sg11
Vsyndrome
p3128
sg13
I1
sasa(dp3129
g2
VThese women were divided into two after breast cancer groups (BCG1 and BCG2) and a control group (CG).
p3130
sg4
(lp3131
(dp3132
g7
I62
sg8
g9
sg10
I4
sg11
VBCG1
p3133
sg13
I1
sasg24
(lp3134
(dp3135
g7
I40
sg27
VC0678222
p3136
sg10
I13
sg11
Vbreast cancer
p3137
sg13
I2
sasa(dp3138
g2
VGroup BCG1 consisted of women who had undergone breast cancer surgery within the last 18months and BCG2 those whose postoperative periods were more than 18months.
p3139
sg4
(lp3140
sg24
(lp3141
(dp3142
g7
I48
sg27
VC0678222
p3143
sg10
I13
sg11
Vbreast cancer
p3144
sg13
I2
sasa(dp3145
g2
VThe indices in millisecond, RMSSD (BCG1=19.83; BCG2=14.99; CG=31.46), SD1 (BCG1=14.03; BCG2=10.61; CG=22.27), SD2 (BCG1=39.17; BCG2=35.28; CG=61.16), SDNN (BCG1=29.58; BCG2=26.12; CG=46.36) and HF in milliseconds squared (BCG1=194.2; BCG2=91.07; CG=449.4) showed statistically significant reductions in the breast cancer groups compared to the CG (p&lt;=0.0001).
p3146
sg4
(lp3147
sg24
(lp3148
(dp3149
g7
I307
sg27
VC0678222
p3150
sg10
I13
sg11
Vbreast cancer
p3151
sg13
I2
sa(dp3152
g7
I70
sg27
VC1861380
p3153
sg10
I3
sg11
VSD1
p3154
sg13
I1
sasa(dp3155
g2
VThe discovery that mutations in MAGED2 cause a rare and transient form of antenatal Bartter's Syndrome may have implications beyond the very small number of affected families.
p3156
sg4
(lp3157
(dp3158
g7
I32
sg8
g9
sg10
I6
sg11
VMAGED2
p3159
sg13
I1
sasg24
(lp3160
(dp3161
g7
I84
sg27
VC0004775
p3162
sg10
I18
sg11
VBartter's Syndrome
p3163
sg13
I2
sasa(dp3164
g2
VWe identified a mutation in MAGED2 in each of the 13 infants in our analysis who had transient antenatal Bartter's syndrome.
p3165
sg4
(lp3166
(dp3167
g7
I28
sg8
g9
sg10
I6
sg11
VMAGED2
p3168
sg13
I1
sasg24
(lp3169
(dp3170
g7
I105
sg27
VC0004775
p3171
sg10
I18
sg11
VBartter's syndrome
p3172
sg13
I2
sasa(dp3173
g2
VMAGED2 encodes melanoma-associated antigen D2 (MAGE-D2) and maps to the X chromosome.
p3174
sg4
(lp3175
(dp3176
g7
I0
sg8
g9
sg10
I6
sg11
VMAGED2
p3177
sg13
I1
sa(dp3178
g7
I47
sg8
g9
sg10
I7
sg11
VMAGE-D2
p3179
sg13
I1
sa(dp3180
g7
I15
sg8
g9
sg10
I30
sg11
Vmelanoma-associated antigen D2
p3181
sg13
I3
sasg24
(lp3182
(dp3183
g7
I15
sg27
VC0025202
p3184
sg10
I8
sg11
Vmelanoma
p3185
sg13
I1
sasa(dp3186
g2
VWe also identified two different MAGED2 mutations in two families with idiopathic polyhydramnios.
p3187
sg4
(lp3188
(dp3189
g7
I33
sg8
g9
sg10
I16
sg11
VMAGED2 mutations
p3190
sg13
I2
sasg24
(lp3191
(dp3192
g7
I82
sg27
VC0020224
p3193
sg10
I14
sg11
Vpolyhydramnios
p3194
sg13
I1
sasa(dp3195
g2
VWe found that MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.
p3196
sg4
(lp3197
(dp3198
g7
I14
sg8
g9
sg10
I6
sg11
VMAGED2
p3199
sg13
I1
sasg24
(lp3200
(dp3201
g7
I124
sg27
VC0004775
p3202
sg10
I18
sg11
VBartter's syndrome
p3203
sg13
I2
sa(dp3204
g7
I47
sg27
VC0020224
p3205
sg10
I14
sg11
Vpolyhydramnios
p3206
sg13
I1
sasa(dp3207
g2
VVirulence factors profiling showed that most of MRSA isolates in our center carried the virulence factor pattern of cna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld (214/239, 89.54%).
p3208
sg4
(lp3209
(dp3210
g7
I116
sg8
g9
sg10
I66
sg11
Vcna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld
p3211
sg13
I1
sasg24
(lp3212
(dp3213
g7
I48
sg27
VC0343401
p3214
sg10
I4
sg11
VMRSA
p3215
sg13
I1
sasa(dp3216
g2
VThe main virulence genes in these strains were hlg (33.3%), scn (23.3%), cna (20%), hlb (20%), and clfA (18.3%), others including icaA, fnbA, tst, seb, hld, eta and sea.
p3217
sg4
(lp3218
(dp3219
g7
I152
sg8
VP35670
p3220
sg10
I3
sg11
Vhld
p3221
sg13
I1
sa(dp3222
g7
I142
sg8
g9
sg10
I3
sg11
Vtst
p3223
sg13
I1
sa(dp3224
g7
I157
sg8
VP25101
p3225
sg10
I3
sg11
Veta
p3226
sg13
I1
sa(dp3227
g7
I147
sg8
g9
sg10
I3
sg11
Vseb
p3228
sg13
I1
sasg24
(lp3229
sa(dp3230
g2
VOther virulence genes detected were (number of strains): tsst-1 (6), hla (15), hlb (9), hld (15), hlg (6), hlgv (9), cna (2), aur (14), and egc-like cluster (3).
p3231
sg4
(lp3232
sg24
(lp3233
sa(dp3234
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases: CENTRAL (2007, Issue 1); MEDLINE via PUBMED (1966 to March 2007); EMBASE (2005 to April 2007); CINAHL (1982 to March 2007); LILACS (1982 to March 2007); PsycINFO (1887 to March 2007); ERIC (1966 to March 2007); CCT (March 2007); Academic Search Elite (to March 2007), C2- SPECTR (to March 2007 ), NRR (2007 Issue 1), ClinicalTrials.gov (accessed March 2007) and within supplements of Medicine and Science in Sports and Exercise.
p3235
sg4
(lp3236
sg24
(lp3237
(dp3238
g7
I322
sg27
VC2752078
p3239
sg10
I3
sg11
VCCT
p3240
sg13
I1
sa(dp3241
g7
I54
sg27
VC0013080
p3242
sg10
I13
sg11
VDown syndrome
p3243
sg13
I2
sasa(dp3244
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases:CENTRAL (2005, Issue 2); MEDLINE (1966 to March 2005); EMBASE (2005 to April 2005); CINAHL (1982 to March 2005); LILACS (1982 to March 2005); PsycINFO (1887 to March 2005); ERIC (1966 to March 2005); CCT (March 2005); Academic Search Elite (to March 2005), C2- SPECTR (to March 2005 ), NRR (2005 Issue 1), ClinicalTrials.gov (accessed March 2005)and within supplements of Medicine and Science in Sports and Exercise.
p3245
sg4
(lp3246
sg24
(lp3247
(dp3248
g7
I54
sg27
VC0013080
p3249
sg10
I13
sg11
VDown syndrome
p3250
sg13
I2
sa(dp3251
g7
I310
sg27
VC2752078
p3252
sg10
I3
sg11
VCCT
p3253
sg13
I1
sasa(dp3254
g2
VFMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.
p3255
sg4
(lp3256
(dp3257
g7
I0
sg8
g9
sg10
I3
sg11
VFMT
p3258
sg13
I1
sasg24
(lp3259
(dp3260
g7
I36
sg27
VC0021390
p3261
sg10
I3
sg11
VIBD
p3262
sg13
I1
sa(dp3263
g7
I68
sg27
VC0022104
p3264
sg10
I3
sg11
VIBS
p3265
sg13
I1
sa(dp3266
g7
I42
sg27
VC0022104
p3267
sg10
I24
sg11
Virritable bowel syndrome
p3268
sg13
I3
sa(dp3269
g7
I77
sg27
VC0524620
p3270
sg10
I18
sg11
Vmetabolic syndrome
p3271
sg13
I2
sa(dp3272
g7
I7
sg27
VC0021390
p3273
sg10
I27
sg11
Vinflammatory bowel diseases
p3274
sg13
I3
sasa(dp3275
g2
VBlockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma.
p3276
sg4
(lp3277
(dp3278
g7
I12
sg8
g9
sg10
I4
sg11
VCD69
p3279
sg13
I1
sa(dp3280
g7
I17
sg8
VP24844
p3281
sg10
I4
sg11
VMyl9
p3282
sg13
I1
sasg24
(lp3283
(dp3284
g7
I143
sg27
VC0004096
p3285
sg10
I6
sg11
Vasthma
p3286
sg13
I1
sa(dp3287
g7
I65
sg27
VC0021368
p3288
sg10
I12
sg11
Vinflammation
p3289
sg13
I1
sasa(dp3290
g2
VA greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells.
p3291
sg4
(lp3292
(dp3293
g7
I24
sg8
VP13535
p3294
sg10
I6
sg11
Vmyosin
p3295
sg13
I1
sa(dp3296
g7
I102
sg8
g9
sg10
I25
sg11
Vmyosin light chain kinase
p3297
sg13
I4
sasg24
(lp3298
(dp3299
g7
I192
sg27
VC0004096
p3300
sg10
I9
sg11
Vasthmatic
p3301
sg13
I1
sasa(dp3302
g2
VSome of the differentially expressed lncRNAs that were upregulated, such as AK124776, lincRNA-RAB12-1, KRT8P25, RP11-474J18.4, AC000110.1, KRT8P13, KRT8P10, BC072678, and downregulated, such as nc-HOXB9-206, RP11-160A10.2, nc-HOXA11-86, nc-HOXD10-7, nc-HOXB9-205, CES4, nc-HOXD12-3, systematic research on these lncRNAs will help clarify the mechanisms of urothelial carcinoma of the bladder and guide the early diagnosis and treatment of this cancer in the future.
p3303
sg4
(lp3304
(dp3305
g7
I223
sg8
VP31270
p3306
sg10
I12
sg11
Vnc-HOXA11-86
p3307
sg13
I1
sa(dp3308
g7
I112
sg8
g9
sg10
I25
sg11
VRP11-474J18.4, AC000110.1
p3309
sg13
I2
sa(dp3310
g7
I250
sg8
VP17482
p3311
sg10
I12
sg11
Vnc-HOXB9-205
p3312
sg13
I1
sa(dp3313
g7
I197
sg8
VP17482
p3314
sg10
I9
sg11
VHOXB9-206
p3315
sg13
I1
sa(dp3316
g7
I86
sg8
g9
sg10
I15
sg11
VlincRNA-RAB12-1
p3317
sg13
I1
sa(dp3318
g7
I208
sg8
g9
sg10
I13
sg11
VRP11-160A10.2
p3319
sg13
I1
sa(dp3320
g7
I237
sg8
VP28358
p3321
sg10
I11
sg11
Vnc-HOXD10-7
p3322
sg13
I1
sa(dp3323
g7
I270
sg8
VP35452
p3324
sg10
I11
sg11
Vnc-HOXD12-3
p3325
sg13
I1
sa(dp3326
g7
I264
sg8
g9
sg10
I4
sg11
VCES4
p3327
sg13
I1
sasg24
(lp3328
(dp3329
g7
I112
sg27
VC1838601
p3330
sg10
I4
sg11
VRP11
p3331
sg13
I1
sa(dp3332
g7
I367
sg27
VC0699885
p3333
sg10
I24
sg11
Vcarcinoma of the bladder
p3334
sg13
I4
sa(dp3335
g7
I444
sg27
VC0006826
p3336
sg10
I6
sg11
Vcancer
p3337
sg13
I1
sa(dp3338
g7
I112
sg27
VC1838601
p3339
sg10
I4
sg11
VRP11
p3340
sg13
I1
sasa(dp3341
g2
VProteins labeled with LCA were Rab-3, Rab-12, Rab-16, and M-Ras.
p3342
sg4
(lp3343
(dp3344
g7
I46
sg8
VP52594
p3345
sg10
I6
sg11
VRab-16
p3346
sg13
I1
sa(dp3347
g7
I38
sg8
VP52594
p3348
sg10
I6
sg11
VRab-12
p3349
sg13
I1
sa(dp3350
g7
I31
sg8
VP52594
p3351
sg10
I5
sg11
VRab-3
p3352
sg13
I1
sa(dp3353
g7
I58
sg8
g9
sg10
I5
sg11
VM-Ras
p3354
sg13
I1
sasg24
(lp3355
(dp3356
g7
I22
sg27
VC0339527
p3357
sg10
I3
sg11
VLCA
p3358
sg13
I1
sasa(dp3359
g2
VMoreover, the ANT2 precursors were observed to change in oncocytomas.
p3360
sg4
(lp3361
(dp3362
g7
I14
sg8
VP05141
p3363
sg10
I15
sg11
VANT2 precursors
p3364
sg13
I2
sasg24
(lp3365
(dp3366
g7
I57
sg27
VC0949541
p3367
sg10
I11
sg11
Voncocytomas
p3368
sg13
I1
sasa(dp3369
g2
VIn particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor.
p3370
sg4
(lp3371
(dp3372
g7
I89
sg8
VP05141
p3373
sg10
I4
sg11
VANT2
p3374
sg13
I1
sa(dp3375
g7
I47
sg8
g9
sg10
I41
sg11
Vadenine nucleotide translocator isoform 2
p3376
sg13
I5
sasg24
(lp3377
(dp3378
g7
I173
sg27
VC0949541
p3379
sg10
I10
sg11
Voncocytoma
p3380
sg13
I1
sa(dp3381
g7
I209
sg27
VC0022665
p3382
sg10
I11
sg11
Vrenal tumor
p3383
sg13
I2
sasa(dp3384
g2
VThis study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX.
p3385
sg4
(lp3386
sg24
(lp3387
(dp3388
g7
I88
sg27
VC0678222
p3389
sg10
I13
sg11
Vbreast cancer
p3390
sg13
I2
sasa(dp3391
g2
VBased on the results, we conclude that breast cancer and co-treatment of CYP and DOX interfere with various biological markers, thereby, showing the physiological imbalance.
p3392
sg4
(lp3393
sg24
(lp3394
(dp3395
g7
I39
sg27
VC0678222
p3396
sg10
I13
sg11
Vbreast cancer
p3397
sg13
I2
sa(dp3398
g7
I163
sg27
VC1397014
p3399
sg10
I9
sg11
Vimbalance
p3400
sg13
I1
sasa(dp3401
g2
VEpoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer.
p3402
sg4
(lp3403
(dp3404
g7
I46
sg8
VP20853
p3405
sg10
I15
sg11
Vcytochrome P450
p3406
sg13
I2
sa(dp3407
g7
I63
sg8
VP20853
p3408
sg10
I3
sg11
VCYP
p3409
sg13
I1
sasg24
(lp3410
(dp3411
g7
I124
sg27
VC0678222
p3412
sg10
I13
sg11
Vbreast cancer
p3413
sg13
I2
sasa(dp3414
g2
VHere, we found that CYP3A4 expression and its epoxy-product, 11,12-epoxyeicosatrienoic acid (11,12-EET) was enhanced in tamoxifen (TAM)-resistant MCF-7 (TAMR-MCF-7) breast cancer cells compared to control MCF-7 cells.
p3415
sg4
(lp3416
(dp3417
g7
I20
sg8
VP08684
p3418
sg10
I6
sg11
VCYP3A4
p3419
sg13
I1
sasg24
(lp3420
(dp3421
g7
I165
sg27
VC0678222
p3422
sg10
I13
sg11
Vbreast cancer
p3423
sg13
I2
sa(dp3424
g7
I131
sg27
VC1834582
p3425
sg10
I3
sg11
VTAM
p3426
sg13
I1
sa(dp3427
g7
I120
sg27
VC1834582
p3428
sg10
I9
sg11
Vtamoxifen
p3429
sg13
I1
sasa(dp3430
g2
VOur findings suggest that the CYP3A4-mediated EET pathway represents a potential therapeutic target for the treatment of tamoxifen-resistant breast cancer.
p3431
sg4
(lp3432
(dp3433
g7
I30
sg8
VP08684
p3434
sg10
I6
sg11
VCYP3A4
p3435
sg13
I1
sasg24
(lp3436
(dp3437
g7
I141
sg27
VC0678222
p3438
sg10
I13
sg11
Vbreast cancer
p3439
sg13
I2
sasa(dp3440
g2
VCYP3A4 was unexpectedly associated with breast cancer mitochondria and synthesized arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), which promoted the electron transport chain/respiration and inhibited AMPKAlfa.
p3441
sg4
(lp3442
(dp3443
g7
I0
sg8
VP08684
p3444
sg10
I6
sg11
VCYP3A4
p3445
sg13
I1
sasg24
(lp3446
(dp3447
g7
I40
sg27
VC0678222
p3448
sg10
I13
sg11
Vbreast cancer
p3449
sg13
I2
sasa(dp3450
g2
VCYP3A4 knockdown activated AMPKAlfa, promoted autophagy, and prevented mammary tumor formation.
p3451
sg4
(lp3452
(dp3453
g7
I0
sg8
VP08684
p3454
sg10
I6
sg11
VCYP3A4
p3455
sg13
I1
sasg24
(lp3456
(dp3457
g7
I71
sg27
VC1458155
p3458
sg10
I13
sg11
Vmammary tumor
p3459
sg13
I2
sasa(dp3460
g2
VComprehensive genotyping of CYP enzymes and transporters was performed using the iPLEX ADME PGx Pro Panel in 302 tamoxifen-treated breast cancer patients.
p3461
sg4
(lp3462
(dp3463
g7
I28
sg8
g9
sg10
I11
sg11
VCYP enzymes
p3464
sg13
I2
sasg24
(lp3465
(dp3466
g7
I131
sg27
VC0678222
p3467
sg10
I13
sg11
Vbreast cancer
p3468
sg13
I2
sasa(dp3469
g2
VIt has been recently reported that CD38 was highly expressed in adipose tissues from obese people and CD38-deficient mice were resistant to high-fat diet (HFD)-induced obesity.
p3470
sg4
(lp3471
(dp3472
g7
I35
sg8
VP28907
p3473
sg10
I4
sg11
VCD38
p3474
sg13
I1
sa(dp3475
g7
I35
sg8
VP28907
p3476
sg10
I4
sg11
VCD38
p3477
sg13
I1
sasg24
(lp3478
(dp3479
g7
I168
sg27
VC0028754
p3480
sg10
I7
sg11
Vobesity
p3481
sg13
I1
sa(dp3482
g7
I85
sg27
VC0028754
p3483
sg10
I5
sg11
Vobese
p3484
sg13
I1
sasa(dp3485
g2
VIn this study, to explore the roles of CD38 in adipogenesis and lipogenesis in vivo and in vitro, obesity models were generated with male CD38-/- and WT mice fed with HFD.
p3486
sg4
(lp3487
(dp3488
g7
I39
sg8
VP28907
p3489
sg10
I4
sg11
VCD38
p3490
sg13
I1
sa(dp3491
g7
I39
sg8
VP28907
p3492
sg10
I4
sg11
VCD38
p3493
sg13
I1
sasg24
(lp3494
(dp3495
g7
I98
sg27
VC0028754
p3496
sg10
I7
sg11
Vobesity
p3497
sg13
I1
sasa(dp3498
g2
VThe results showed that CD38-/- male mice were significantly resistant to HFD-induced obesity.
p3499
sg4
(lp3500
(dp3501
g7
I24
sg8
VP28907
p3502
sg10
I4
sg11
VCD38
p3503
sg13
I1
sasg24
(lp3504
(dp3505
g7
I86
sg27
VC0028754
p3506
sg10
I7
sg11
Vobesity
p3507
sg13
I1
sasa(dp3508
g2
VThese results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARGamma-FASN signalling pathway during the development of obesity.
p3509
sg4
(lp3510
(dp3511
g7
I27
sg8
VP28907
p3512
sg10
I4
sg11
VCD38
p3513
sg13
I1
sa(dp3514
g7
I99
sg8
g9
sg10
I5
sg11
VSirt1
p3515
sg13
I1
sasg24
(lp3516
(dp3517
g7
I165
sg27
VC0028754
p3518
sg10
I7
sg11
Vobesity
p3519
sg13
I1
sasa(dp3520
g2
VWe also found that obesity development was associated with an increase in the number of CD38+ adipose progenitors, this effect being more pronounced in intra-abdominal than in subcutaneous fat, suggesting a higher rate of adipocyte commitment in visceral depots.
p3521
sg4
(lp3522
(dp3523
g7
I88
sg8
VP28907
p3524
sg10
I5
sg11
VCD38+
p3525
sg13
I1
sasg24
(lp3526
(dp3527
g7
I19
sg27
VC0028754
p3528
sg10
I7
sg11
Vobesity
p3529
sg13
I1
sasa(dp3530
g2
VIn this study, we show that CD45RO+CD38+ Beta cell Ag-specific CD4+ T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects.
p3531
sg4
(lp3532
(dp3533
g7
I28
sg8
VP28907
p3534
sg10
I25
sg11
VCD45RO+CD38+ Beta cell Ag
p3535
sg13
I4
sa(dp3536
g7
I63
sg8
VP01730
p3537
sg10
I4
sg11
VCD4+
p3538
sg13
I1
sasg24
(lp3539
(dp3540
g7
I114
sg27
VC0011854
p3541
sg10
I15
sg11
Vtype 1 diabetes
p3542
sg13
I3
sasa(dp3543
g2
VRegulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance.
p3544
sg4
(lp3545
(dp3546
g7
I86
sg8
g9
sg10
I6
sg11
VNMNAT2
p3547
sg13
I1
sa(dp3548
g7
I68
sg8
g9
sg10
I5
sg11
VSIRT7
p3549
sg13
I1
sa(dp3550
g7
I136
sg8
VP28907
p3551
sg10
I4
sg11
VCD38
p3552
sg13
I1
sa(dp3553
g7
I61
sg8
g9
sg10
I5
sg11
VSIRT4
p3554
sg13
I1
sa(dp3555
g7
I111
sg8
g9
sg10
I6
sg11
VNMNAT3
p3556
sg13
I1
sa(dp3557
g7
I75
sg8
g9
sg10
I6
sg11
VNAPRT1
p3558
sg13
I1
sasg24
(lp3559
(dp3560
g7
I145
sg27
VC0271650
p3561
sg10
I19
sg11
Vglucose intolerance
p3562
sg13
I2
sa(dp3563
g7
I23
sg27
VC1850380
p3564
sg10
I3
sg11
VNAD
p3565
sg13
I1
sasa(dp3566
g2
VA total of eleven of genes were differently expressed in celiac patients compared with disease controls of which CD36, CD38, FOXP1, SELL, PPARA, PPARG, AGT previously associated with type 2 diabetes and AKAP6, NTNG1 with anorexia nervosa remained significant after correction for multiple testing.
p3567
sg4
(lp3568
(dp3569
g7
I152
sg8
VP21549
p3570
sg10
I3
sg11
VAGT
p3571
sg13
I1
sa(dp3572
g7
I119
sg8
VP28907
p3573
sg10
I4
sg11
VCD38
p3574
sg13
I1
sa(dp3575
g7
I145
sg8
g9
sg10
I5
sg11
VPPARG
p3576
sg13
I1
sa(dp3577
g7
I132
sg8
VP14151
p3578
sg10
I4
sg11
VSELL
p3579
sg13
I1
sa(dp3580
g7
I138
sg8
g9
sg10
I5
sg11
VPPARA
p3581
sg13
I1
sa(dp3582
g7
I210
sg8
g9
sg10
I5
sg11
VNTNG1
p3583
sg13
I1
sa(dp3584
g7
I125
sg8
g9
sg10
I5
sg11
VFOXP1
p3585
sg13
I1
sa(dp3586
g7
I203
sg8
g9
sg10
I5
sg11
VAKAP6
p3587
sg13
I1
sasg24
(lp3588
(dp3589
g7
I183
sg27
VC0011860
p3590
sg10
I15
sg11
Vtype 2 diabetes
p3591
sg13
I3
sa(dp3592
g7
I221
sg27
VC0003125
p3593
sg10
I16
sg11
Vanorexia nervosa
p3594
sg13
I2
sasa(dp3595
g2
VPF significantly increased the expression of nuclear factor-YA (NF-YA), which strongly upregulated the molecules involved in the proteolytic machinery [molecular chaperones, carboxyl terminus of Hsc70-interacting protein and transcription factor EB], which thus mitigated the behavioral and pathological impairments in an SBMA mouse model through the upregulation of pathogenic androgen receptor protein clearance in motor neurons and muscles.
p3596
sg4
(lp3597
(dp3598
g7
I195
sg8
VP50502
p3599
sg10
I25
sg11
VHsc70-interacting protein
p3600
sg13
I2
sa(dp3601
g7
I378
sg8
VP10275
p3602
sg10
I25
sg11
Vandrogen receptor protein
p3603
sg13
I3
sa(dp3604
g7
I45
sg8
VP01160
p3605
sg10
I17
sg11
Vnuclear factor-YA
p3606
sg13
I2
sa(dp3607
g7
I225
sg8
VP19484
p3608
sg10
I23
sg11
Vtranscription factor EB
p3609
sg13
I3
sa(dp3610
g7
I64
sg8
VP23511
p3611
sg10
I5
sg11
VNF-YA
p3612
sg13
I1
sasg24
(lp3613
(dp3614
g7
I322
sg27
VC1839259
p3615
sg10
I4
sg11
VSBMA
p3616
sg13
I1
sasa(dp3617
g2
VOne hundred and seven patients (49.3%) had no significant change in BP; 30.9% had intradialytic hypertension (IDHT) while 19.8% had intradialytic hypotension (IDH).
p3618
sg4
(lp3619
sg24
(lp3620
(dp3621
g7
I96
sg27
VC0020538
p3622
sg10
I12
sg11
Vhypertension
p3623
sg13
I1
sasa(dp3624
g2
VThis week's articles describe ways to treat arthritis caused by chikungunya virus, IDH-mutant cancers, and hypertension.
p3625
sg4
(lp3626
sg24
(lp3627
(dp3628
g7
I94
sg27
VC0006826
p3629
sg10
I7
sg11
Vcancers
p3630
sg13
I1
sa(dp3631
g7
I107
sg27
VC0020538
p3632
sg10
I12
sg11
Vhypertension
p3633
sg13
I1
sa(dp3634
g7
I64
sg27
VC0008055
p3635
sg10
I11
sg11
Vchikungunya
p3636
sg13
I1
sa(dp3637
g7
I87
sg27
VC0596988
p3638
sg10
I6
sg11
Vmutant
p3639
sg13
I1
sa(dp3640
g7
I44
sg27
VC0003864
p3641
sg10
I9
sg11
Varthritis
p3642
sg13
I1
sasa(dp3643
g2
VOn univariate analysis, diabetes mellitus, hypertension (HTN), cerebrovascular accident (CVA), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), smoking, hepatitis C, inadequate dialysis, intradialytic hypotension (IDH), interdialytic weight gain, low serum creatinine &lt;4 mg/dL, and anemia (Hb &lt;10 g/dL) were found to be statistically significantly different between frail and nonfrail groups On multivariate regression analysis, only HTN, PVD, CVA, anemia, smoking, and IDH were found to be significant.
p3644
sg4
(lp3645
(dp3646
g7
I57
sg8
VP24821
p3647
sg10
I3
sg11
VHTN
p3648
sg13
I1
sa(dp3649
g7
I209
sg8
VP48735
p3650
sg10
I25
sg11
Vintradialytic hypotension
p3651
sg13
I2
sa(dp3652
g7
I43
sg8
VP24821
p3653
sg10
I12
sg11
Vhypertension
p3654
sg13
I1
sa(dp3655
g7
I236
sg8
VP48735
p3656
sg10
I3
sg11
VIDH
p3657
sg13
I1
sasg24
(lp3658
(dp3659
g7
I160
sg27
VC0085096
p3660
sg10
I3
sg11
VPVD
p3661
sg13
I1
sa(dp3662
g7
I43
sg27
VC0020538
p3663
sg10
I12
sg11
Vhypertension
p3664
sg13
I1
sa(dp3665
g7
I89
sg27
VC0038454
p3666
sg10
I3
sg11
VCVA
p3667
sg13
I1
sa(dp3668
g7
I57
sg27
VC0020538
p3669
sg10
I3
sg11
VHTN
p3670
sg13
I1
sa(dp3671
g7
I125
sg27
VC0242698
p3672
sg10
I3
sg11
VLVD
p3673
sg13
I1
sa(dp3674
g7
I95
sg27
VC0242698
p3675
sg10
I28
sg11
Vleft ventricular dysfunction
p3676
sg13
I3
sa(dp3677
g7
I160
sg27
VC0085096
p3678
sg10
I3
sg11
VPVD
p3679
sg13
I1
sa(dp3680
g7
I307
sg27
VC0002871
p3681
sg10
I6
sg11
Vanemia
p3682
sg13
I1
sa(dp3683
g7
I63
sg27
VC0038454
p3684
sg10
I24
sg11
Vcerebrovascular accident
p3685
sg13
I2
sa(dp3686
g7
I307
sg27
VC0002871
p3687
sg10
I6
sg11
Vanemia
p3688
sg13
I1
sa(dp3689
g7
I57
sg27
VC0020538
p3690
sg10
I3
sg11
VHTN
p3691
sg13
I1
sa(dp3692
g7
I24
sg27
VC0011849
p3693
sg10
I17
sg11
Vdiabetes mellitus
p3694
sg13
I2
sa(dp3695
g7
I131
sg27
VC0085096
p3696
sg10
I27
sg11
Vperipheral vascular disease
p3697
sg13
I3
sa(dp3698
g7
I175
sg27
VC0019196
p3699
sg10
I11
sg11
Vhepatitis C
p3700
sg13
I2
sa(dp3701
g7
I89
sg27
VC0038454
p3702
sg10
I3
sg11
VCVA
p3703
sg13
I1
sasa(dp3704
g2
VFactors predicting frailty include HTN, smoking, LVD, PVD, CVA, smoking, anemia, and IDH.
p3705
sg4
(lp3706
(dp3707
g7
I85
sg8
VP48735
p3708
sg10
I3
sg11
VIDH
p3709
sg13
I1
sasg24
(lp3710
(dp3711
g7
I59
sg27
VC0038454
p3712
sg10
I3
sg11
VCVA
p3713
sg13
I1
sa(dp3714
g7
I73
sg27
VC0002871
p3715
sg10
I6
sg11
Vanemia
p3716
sg13
I1
sa(dp3717
g7
I35
sg27
VC0020538
p3718
sg10
I3
sg11
VHTN
p3719
sg13
I1
sa(dp3720
g7
I54
sg27
VC0085096
p3721
sg10
I3
sg11
VPVD
p3722
sg13
I1
sasa(dp3723
g2
VIntradialytic hypertension (IDH) increases morbidity and mortality.
p3724
sg4
(lp3725
sg24
(lp3726
(dp3727
g7
I14
sg27
VC0020538
p3728
sg10
I12
sg11
Vhypertension
p3729
sg13
I1
sasa(dp3730
g2
VIntradialytic hypertension (ID-HTN) is an increasingly recognized phenomenon and although less common than IDH, portends poor cardiovascular prognosis as well as reflects higher hypertension burden in the dialysis population.
p3731
sg4
(lp3732
sg24
(lp3733
(dp3734
g7
I31
sg27
VC0020538
p3735
sg10
I3
sg11
VHTN
p3736
sg13
I1
sa(dp3737
g7
I14
sg27
VC0020538
p3738
sg10
I12
sg11
Vhypertension
p3739
sg13
I1
sa(dp3740
g7
I14
sg27
VC0020538
p3741
sg10
I12
sg11
Vhypertension
p3742
sg13
I1
sasa(dp3743
g2
VDry weight, hypertension, and phosphorus levels are modifiable risk factors to possibly reduce the rate of IDH episodes.
p3744
sg4
(lp3745
sg24
(lp3746
(dp3747
g7
I12
sg27
VC0020538
p3748
sg10
I12
sg11
Vhypertension
p3749
sg13
I1
sasa(dp3750
g2
VWe believe that all hypertension guidelines should follow the National Institute for Health and Excellence (NICE) and make IDP and CTD first choice 'thiazide-like diuretics.'
p3751
sg4
(lp3752
sg24
(lp3753
(dp3754
g7
I20
sg27
VC0020538
p3755
sg10
I12
sg11
Vhypertension
p3756
sg13
I1
sasa(dp3757
g2
VImmunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex.
p3758
sg4
(lp3759
(dp3760
g7
I43
sg8
VP35712
p3761
sg10
I4
sg11
VSOX6
p3762
sg13
I1
sa(dp3763
g7
I38
sg8
VP35712
p3764
sg10
I18
sg11
Vanti-SOX6 antibody
p3765
sg13
I2
sa(dp3766
g7
I43
sg8
VP35712
p3767
sg10
I4
sg11
VSOX6
p3768
sg13
I1
sasg24
(lp3769
(dp3770
g7
I134
sg27
VC0004114
p3771
sg10
I12
sg11
Vastrocytomas
p3772
sg13
I1
sa(dp3773
g7
I77
sg27
VC0017638
p3774
sg10
I6
sg11
Vglioma
p3775
sg13
I1
sa(dp3776
g7
I272
sg27
VC0027651
p3777
sg10
I5
sg11
Vtumor
p3778
sg13
I1
sa(dp3779
g7
I105
sg27
VC0017636
p3780
sg10
I13
sg11
Vglioblastomas
p3781
sg13
I1
sa(dp3782
g7
I231
sg27
VC0334583
p3783
sg10
I21
sg11
Vpilocytic astrocytoma
p3784
sg13
I2
sa(dp3785
g7
I206
sg27
VC0028945
p3786
sg10
I17
sg11
Voligodendroglioma
p3787
sg13
I1
sa(dp3788
g7
I123
sg27
VC0334579
p3789
sg10
I23
sg11
Vanaplastic astrocytomas
p3790
sg13
I2
sasa(dp3791
g2
VTo address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1alpha, Il1beta, Il6, and Tnfalpha and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids.
p3792
sg4
(lp3793
(dp3794
g7
I200
sg8
VP05231
p3795
sg10
I3
sg11
VIl6
p3796
sg13
I1
sa(dp3797
g7
I233
sg8
VP35354
p3798
sg10
I4
sg11
VCox2
p3799
sg13
I1
sa(dp3800
g7
I209
sg8
VP01375
p3801
sg10
I8
sg11
VTnfalpha
p3802
sg13
I1
sa(dp3803
g7
I181
sg8
VP01583
p3804
sg10
I8
sg11
VIl1alpha
p3805
sg13
I1
sa(dp3806
g7
I254
sg8
VP51808
p3807
sg10
I3
sg11
VRP3
p3808
sg13
I1
sa(dp3809
g7
I191
sg8
VP01584
p3810
sg10
I7
sg11
VIl1beta
p3811
sg13
I1
sasg24
(lp3812
(dp3813
g7
I254
sg27
VC1845667
p3814
sg10
I3
sg11
VRP3
p3815
sg13
I1
sasa(dp3816
g2
VWith a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population.
p3817
sg4
(lp3818
sg24
(lp3819
(dp3820
g7
I226
sg27
VC0007222
p3821
sg10
I23
sg11
Vdisease, cardiovascular
p3822
sg13
I2
sa(dp3823
g7
I209
sg27
VC0011849
p3824
sg10
I8
sg11
Vdiabetes
p3825
sg13
I1
sa(dp3826
g7
I195
sg27
VC0020538
p3827
sg10
I12
sg11
Vhypertension
p3828
sg13
I1
sasa(dp3829
g2
VEndostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents progression of atherosclerosis.
p3830
sg4
(lp3831
sg24
(lp3832
(dp3833
g7
I107
sg27
VC0004153
p3834
sg10
I15
sg11
Vatherosclerosis
p3835
sg13
I1
sasa(dp3836
g2
VFor ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) &gt;4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P&lt;0.0001) and endostatin &gt;4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model.
p3837
sg4
(lp3838
sg24
(lp3839
(dp3840
g7
I20
sg27
VC0553692
p3841
sg10
I19
sg11
Vhemorrhagic strokes
p3842
sg13
I2
sa(dp3843
g7
I32
sg27
VC0038454
p3844
sg10
I6
sg11
Vstroke
p3845
sg13
I1
sa(dp3846
g7
I352
sg27
VC0020538
p3847
sg10
I12
sg11
Vhypertension
p3848
sg13
I1
sa(dp3849
g7
I327
sg27
VC0004238
p3850
sg10
I19
sg11
Vatrial fibrillation
p3851
sg13
I2
sasa(dp3852
g2
VIn patients with coronary heart disease, the count of endothelial progenitor cells was lower by 4 times, the level of VEGF was higher by 52%, and the level of endostatin was lower by 13% than in healthy volunteers.
p3853
sg4
(lp3854
sg24
(lp3855
(dp3856
g7
I17
sg27
VC0010054
p3857
sg10
I22
sg11
Vcoronary heart disease
p3858
sg13
I3
sasa(dp3859
g2
VTo examine the association between the serum endostatin levels and subclinical atherosclerosis independent of traditional risk factors in a healthy Japanese population.
p3860
sg4
(lp3861
(dp3862
g7
I39
sg8
VP39059
p3863
sg10
I16
sg11
Vserum endostatin
p3864
sg13
I2
sasg24
(lp3865
(dp3866
g7
I79
sg27
VC0004153
p3867
sg10
I15
sg11
Vatherosclerosis
p3868
sg13
I1
sasa(dp3869
g2
VA higher serum endostatin level reflected subclinical atherosclerosis in this Japanese population.
p3870
sg4
(lp3871
sg24
(lp3872
(dp3873
g7
I54
sg27
VC0004153
p3874
sg10
I15
sg11
Vatherosclerosis
p3875
sg13
I1
sasa(dp3876
g2
VThe most common diseases among humanitarian cases were benign tumors (29%, 5/17), cranioplasty (23%, 4/17), obstructive hydrocephalus (11%, 2/17), nonobstructive hydrocephalus (11%, 2/17), hemifacial spasm (11%, 2/17), and cerebral angiography (11%, 2/17).
p3877
sg4
(lp3878
sg24
(lp3879
(dp3880
g7
I200
sg27
VC0037763
p3881
sg10
I5
sg11
Vspasm
p3882
sg13
I1
sa(dp3883
g7
I108
sg27
VC0549423
p3884
sg10
I25
sg11
Vobstructive hydrocephalus
p3885
sg13
I2
sa(dp3886
g7
I55
sg27
VC0086692
p3887
sg10
I13
sg11
Vbenign tumors
p3888
sg13
I2
sa(dp3889
g7
I120
sg27
VC0020255
p3890
sg10
I13
sg11
Vhydrocephalus
p3891
sg13
I1
sasa(dp3892
g2
VTwenty-seven (33.8%) patients developed ARE, 5 (6%) developed hydrocephalus, 10 (12.5%) reported new ataxia, 17 (21%) developed trigeminal dysfunction, 3 (3.75%) had facial weakness, and 1 patient developed hemifacial spasm.
p3893
sg4
(lp3894
sg24
(lp3895
(dp3896
g7
I101
sg27
VC0004134
p3897
sg10
I6
sg11
Vataxia
p3898
sg13
I1
sa(dp3899
g7
I166
sg27
VC0427055
p3900
sg10
I15
sg11
Vfacial weakness
p3901
sg13
I2
sa(dp3902
g7
I62
sg27
VC0020255
p3903
sg10
I13
sg11
Vhydrocephalus
p3904
sg13
I1
sa(dp3905
g7
I218
sg27
VC0037763
p3906
sg10
I5
sg11
Vspasm
p3907
sg13
I1
sasa(dp3908
g2
VTwelve factors, including gender, hypertension, intracranial aneurysm, cerebral vascular spasm, hydrocephalus and conscious disturbance during hospitalization, smoking, age, WFNS (World Federation of Neurological Surgeons) scale, Fisher grade, white blood cell count and blood glucose level at admission, were analyzed by using Chi-square test, t test, and Logistic multiple regression analysis.
p3909
sg4
(lp3910
sg24
(lp3911
(dp3912
g7
I61
sg27
VC0917996
p3913
sg10
I18
sg11
Vaneurysm, cerebral
p3914
sg13
I2
sa(dp3915
g7
I34
sg27
VC0151740
p3916
sg10
I26
sg11
Vhypertension, intracranial
p3917
sg13
I2
sa(dp3918
g7
I96
sg27
VC0020255
p3919
sg10
I13
sg11
Vhydrocephalus
p3920
sg13
I1
sa(dp3921
g7
I80
sg27
VC0085616
p3922
sg10
I14
sg11
Vvascular spasm
p3923
sg13
I2
sasa(dp3924
g2
VWe studied 37 patients with spasm, trisomy 21, prematurity, epilepsy, psychomotor retardation, and/or hydrocephalus (study group) and 67 control patients, all between 14 months and 14 years of age.
p3925
sg4
(lp3926
sg24
(lp3927
(dp3928
g7
I60
sg27
VC0085417
p3929
sg10
I21
sg11
Vepilepsy, psychomotor
p3930
sg13
I2
sa(dp3931
g7
I102
sg27
VC0020255
p3932
sg10
I13
sg11
Vhydrocephalus
p3933
sg13
I1
sa(dp3934
g7
I28
sg27
VC0037763
p3935
sg10
I5
sg11
Vspasm
p3936
sg13
I1
sa(dp3937
g7
I35
sg27
VC0013080
p3938
sg10
I10
sg11
Vtrisomy 21
p3939
sg13
I2
sasa(dp3940
g2
VSurgical treatment after radiosurgery or radiotherapy may be necessary for tumors that continue to grow, or for patients who develop brainstem compressive symptoms, disabling hemifacial spasm, or hydrocephalus.
p3941
sg4
(lp3942
sg24
(lp3943
(dp3944
g7
I186
sg27
VC0037763
p3945
sg10
I5
sg11
Vspasm
p3946
sg13
I1
sa(dp3947
g7
I75
sg27
VC0027651
p3948
sg10
I6
sg11
Vtumors
p3949
sg13
I1
sa(dp3950
g7
I196
sg27
VC0020255
p3951
sg10
I13
sg11
Vhydrocephalus
p3952
sg13
I1
sasa(dp3953
g2
VAmong these, 236 differentially expressed genes (DEGs) were statistically significant, including many DEGs that were novel in cervical cancer, including gastrulation brain homeobox 2,5-hydroxytryptamine receptor 1D and endothelin 3.
p3954
sg4
(lp3955
(dp3956
g7
I49
sg8
g9
sg10
I4
sg11
VDEGs
p3957
sg13
I1
sa(dp3958
g7
I219
sg8
VP14138
p3959
sg10
I12
sg11
Vendothelin 3
p3960
sg13
I2
sa(dp3961
g7
I166
sg8
VP52954
p3962
sg10
I48
sg11
Vbrain homeobox 2,5-hydroxytryptamine receptor 1D
p3963
sg13
I5
sa(dp3964
g7
I17
sg8
g9
sg10
I30
sg11
Vdifferentially expressed genes
p3965
sg13
I3
sasg24
(lp3966
(dp3967
g7
I126
sg27
VC0302592
p3968
sg10
I15
sg11
Vcervical cancer
p3969
sg13
I2
sasa(dp3970
g2
VA total of 5 overlapping genes [dipeptidyl peptidase 4 (DPP4); endothelin 3 (EDN3); fibroblast growth factor 14 (FGF14); tachykinin, precursor 1 (TAC1); and wingless-type MMTV integration site family, member 16 (WNT16)] between the 561 overlapping differentially methylated genes and the 242 DEGs were identified, which were downregulated and hypermethylated simultaneously in cervical cancer samples.
p3971
sg4
(lp3972
(dp3973
g7
I121
sg8
VP29401
p3974
sg10
I23
sg11
Vtachykinin, precursor 1
p3975
sg13
I3
sa(dp3976
g7
I157
sg8
g9
sg10
I53
sg11
Vwingless-type MMTV integration site family, member 16
p3977
sg13
I7
sa(dp3978
g7
I31
sg8
VP27487
p3979
sg10
I23
sg11
V[dipeptidyl peptidase 4
p3980
sg13
I3
sa(dp3981
g7
I56
sg8
VP27487
p3982
sg10
I4
sg11
VDPP4
p3983
sg13
I1
sa(dp3984
g7
I84
sg8
g9
sg10
I27
sg11
Vfibroblast growth factor 14
p3985
sg13
I4
sa(dp3986
g7
I212
sg8
g9
sg10
I5
sg11
VWNT16
p3987
sg13
I1
sa(dp3988
g7
I113
sg8
g9
sg10
I5
sg11
VFGF14
p3989
sg13
I1
sa(dp3990
g7
I63
sg8
VP14138
p3991
sg10
I12
sg11
Vendothelin 3
p3992
sg13
I2
sa(dp3993
g7
I77
sg8
VP14138
p3994
sg10
I4
sg11
VEDN3
p3995
sg13
I1
sasg24
(lp3996
(dp3997
g7
I377
sg27
VC0302592
p3998
sg10
I15
sg11
Vcervical cancer
p3999
sg13
I2
sasa(dp4000
g2
VEmploying functions of several bioinformatics tools, we selected 143 differentially expressed genes (DEGs) associated with the cervical cancer.
p4001
sg4
(lp4002
(dp4003
g7
I101
sg8
g9
sg10
I4
sg11
VDEGs
p4004
sg13
I1
sa(dp4005
g7
I69
sg8
g9
sg10
I30
sg11
Vdifferentially expressed genes
p4006
sg13
I3
sasg24
(lp4007
(dp4008
g7
I127
sg27
VC0302592
p4009
sg10
I15
sg11
Vcervical cancer
p4010
sg13
I2
sasa(dp4011
g2
VThe results of bioinformatics analysis show that these DEGs play important roles in the development of cervical cancer.
p4012
sg4
(lp4013
(dp4014
g7
I55
sg8
g9
sg10
I4
sg11
VDEGs
p4015
sg13
I1
sasg24
(lp4016
(dp4017
g7
I103
sg27
VC0302592
p4018
sg10
I15
sg11
Vcervical cancer
p4019
sg13
I2
sasa(dp4020
g2
VA total of 1,160 and 756 DEGs were identified in the pre-invasive and invasive stages of cervical cancer, respectively.
p4021
sg4
(lp4022
sg24
(lp4023
(dp4024
g7
I89
sg27
VC0302592
p4025
sg10
I15
sg11
Vcervical cancer
p4026
sg13
I2
sasa(dp4027
g2
VSurvival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma.
p4028
sg4
(lp4029
(dp4030
g7
I170
sg8
g9
sg10
I6
sg11
VDNMT3B
p4031
sg13
I1
sa(dp4032
g7
I91
sg8
g9
sg10
I15
sg11
Vzeste homolog 1
p4033
sg13
I3
sa(dp4034
g7
I159
sg8
g9
sg10
I6
sg11
VDNMT3A
p4035
sg13
I1
sa(dp4036
g7
I136
sg8
g9
sg10
I21
sg11
VPHD finger protein 19
p4037
sg13
I4
sa(dp4038
g7
I130
sg8
g9
sg10
I4
sg11
VEZH2
p4039
sg13
I1
sasg24
(lp4040
(dp4041
g7
I243
sg27
VC0017638
p4042
sg10
I6
sg11
Vglioma
p4043
sg13
I1
sasa(dp4044
g2
VIn this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-Epsilon-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC).
p4045
sg4
(lp4046
(dp4047
g7
I129
sg8
g9
sg10
I4
sg11
VPCL3
p4048
sg13
I1
sa(dp4049
g7
I102
sg8
g9
sg10
I25
sg11
Vpoly-Epsilon-caprolactone
p4050
sg13
I1
sasg24
(lp4051
(dp4052
g7
I227
sg27
VC0678222
p4053
sg10
I13
sg11
Vbreast cancer
p4054
sg13
I2
sasa(dp4055
g2
VInterestingly, changes in EZH2, PHF19, CBX7, CBX6 and EZH1 occurred progressively as astrocytoma grade increased.
p4056
sg4
(lp4057
(dp4058
g7
I26
sg8
g9
sg10
I4
sg11
VEZH2
p4059
sg13
I1
sa(dp4060
g7
I39
sg8
g9
sg10
I4
sg11
VCBX7
p4061
sg13
I1
sa(dp4062
g7
I54
sg8
g9
sg10
I4
sg11
VEZH1
p4063
sg13
I1
sa(dp4064
g7
I45
sg8
g9
sg10
I4
sg11
VCBX6
p4065
sg13
I1
sa(dp4066
g7
I32
sg8
g9
sg10
I5
sg11
VPHF19
p4067
sg13
I1
sasg24
(lp4068
(dp4069
g7
I85
sg27
VC0004114
p4070
sg10
I11
sg11
Vastrocytoma
p4071
sg13
I1
sasa(dp4072
g2
VIn this report, we show that PHF19 silencing reduces the cell proliferation rate and increases the transendothelial migration capacities of melanoma cell lines.
p4073
sg4
(lp4074
(dp4075
g7
I29
sg8
g9
sg10
I5
sg11
VPHF19
p4076
sg13
I1
sasg24
(lp4077
(dp4078
g7
I140
sg27
VC0025202
p4079
sg10
I8
sg11
Vmelanoma
p4080
sg13
I1
sa(dp4081
g7
I62
sg27
VC0334094
p4082
sg10
I13
sg11
Vproliferation
p4083
sg13
I1
sasa(dp4084
g2
VOur data therefore indicate the role of PHF19 and its upstream regulator, Akt, in the phenotype switch of melanoma cells from proliferative to invasive states.
p4085
sg4
(lp4086
(dp4087
g7
I40
sg8
g9
sg10
I5
sg11
VPHF19
p4088
sg13
I1
sa(dp4089
g7
I74
sg8
g9
sg10
I3
sg11
VAkt
p4090
sg13
I1
sasg24
(lp4091
(dp4092
g7
I106
sg27
VC0025202
p4093
sg10
I8
sg11
Vmelanoma
p4094
sg13
I1
sa(dp4095
g7
I126
sg27
VC0334094
p4096
sg10
I13
sg11
Vproliferative
p4097
sg13
I1
sasa(dp4098
g2
VInterestingly, the products of the hPCL3 gene, particularly the short form, hPCL3S, are markedly overexpressed in many types of cancers, including colon, skin, lung, rectal, cervical, uterus, and liver cancers.
p4099
sg4
(lp4100
(dp4101
g7
I76
sg8
g9
sg10
I6
sg11
VhPCL3S
p4102
sg13
I1
sa(dp4103
g7
I35
sg8
g9
sg10
I10
sg11
VhPCL3 gene
p4104
sg13
I2
sasg24
(lp4105
(dp4106
g7
I128
sg27
VC0006826
p4107
sg10
I7
sg11
Vcancers
p4108
sg13
I1
sa(dp4109
g7
I196
sg27
VC0345904
p4110
sg10
I13
sg11
Vliver cancers
p4111
sg13
I2
sasa(dp4112
g2
VBoth hPCL3S and hPCL3L messages were increased dramatically in most cell lines derived from various stages of melanoma and glioma tumor progression.
p4113
sg4
(lp4114
(dp4115
g7
I5
sg8
g9
sg10
I6
sg11
VhPCL3S
p4116
sg13
I1
sasg24
(lp4117
(dp4118
g7
I123
sg27
VC0017638
p4119
sg10
I6
sg11
Vglioma
p4120
sg13
I1
sa(dp4121
g7
I110
sg27
VC0025202
p4122
sg10
I8
sg11
Vmelanoma
p4123
sg13
I1
sa(dp4124
g7
I130
sg27
VC0178874
p4125
sg10
I17
sg11
Vtumor progression
p4126
sg13
I2
sasa(dp4127
g2
VFifty patients (19 males and 31 females, mean age 52.4 y) showed sagging posterior layer TLF, and 32 of them developed &gt;=1 junctional problems, such as retrolistheses (n=25), compression fractures (n=5), spondylolistheses (n=4), progressive scoliosis (n=4), and segmental instability with bone marrow change (n=2).
p4128
sg4
(lp4129
sg24
(lp4130
(dp4131
g7
I244
sg27
VC0700208
p4132
sg10
I9
sg11
Vscoliosis
p4133
sg13
I1
sa(dp4134
g7
I178
sg27
VC0521169
p4135
sg10
I21
sg11
Vcompression fractures
p4136
sg13
I2
sa(dp4137
g7
I207
sg27
VC0038016
p4138
sg10
I17
sg11
Vspondylolistheses
p4139
sg13
I1
sasa(dp4140
g2
VHowever, the patients with thoracolumbar fracture (TLF) had significantly more MSCs than those with degenerative disc disease (DDD), but not for NCs.
p4141
sg4
(lp4142
sg24
(lp4143
(dp4144
g7
I127
sg27
VC0406811
p4145
sg10
I3
sg11
VDDD
p4146
sg13
I1
sa(dp4147
g7
I100
sg27
VC0158266
p4148
sg10
I25
sg11
Vdegenerative disc disease
p4149
sg13
I3
sasa(dp4150
g2
VCommon physiological pathways are involved in several ARCA, such as DNA repair deficiency (AOA1, ataxia telangiectasia [AT]...), RNA termination disorder (AOA2), mitochondrial defect (FRDA, sensory ataxic neuropathy with dysarthria and ophthalmoplegia [Sando]...), lipoprotein assembly defects (AVED, abetalipoproteinemia [ABL]), chaperon protein disorders (ARSACS, Marinesco-Sjoegren syndrome [MSS]) or peroxysomal diseases (Refsum disease [RD]).
p4151
sg4
(lp4152
(dp4153
g7
I184
sg8
g9
sg10
I4
sg11
VFRDA
p4154
sg13
I1
sasg24
(lp4155
(dp4156
g7
I236
sg27
VC0029089
p4157
sg10
I15
sg11
Vophthalmoplegia
p4158
sg13
I1
sa(dp4159
g7
I323
sg27
VC0000744
p4160
sg10
I3
sg11
VABL
p4161
sg13
I1
sa(dp4162
g7
I385
sg27
VC0039082
p4163
sg10
I8
sg11
Vsyndrome
p4164
sg13
I1
sa(dp4165
g7
I301
sg27
VC0000744
p4166
sg10
I20
sg11
Vabetalipoproteinemia
p4167
sg13
I1
sa(dp4168
g7
I184
sg27
VC1856689
p4169
sg10
I4
sg11
VFRDA
p4170
sg13
I1
sa(dp4171
g7
I221
sg27
VC0013362
p4172
sg10
I10
sg11
Vdysarthria
p4173
sg13
I1
sa(dp4174
g7
I155
sg27
VC1853761
p4175
sg10
I4
sg11
VAOA2
p4176
sg13
I1
sa(dp4177
g7
I253
sg27
VC1843851
p4178
sg10
I5
sg11
VSando
p4179
sg13
I1
sa(dp4180
g7
I205
sg27
VC0442874
p4181
sg10
I10
sg11
Vneuropathy
p4182
sg13
I1
sa(dp4183
g7
I358
sg27
VC1849140
p4184
sg10
I6
sg11
VARSACS
p4185
sg13
I1
sa(dp4186
g7
I97
sg27
VC0004135
p4187
sg10
I21
sg11
Vataxia telangiectasia
p4188
sg13
I2
sa(dp4189
g7
I198
sg27
VC0234366
p4190
sg10
I6
sg11
Vataxic
p4191
sg13
I1
sa(dp4192
g7
I91
sg27
VC1859598
p4193
sg10
I4
sg11
VAOA1
p4194
sg13
I1
sa(dp4195
g7
I426
sg27
VC0034960
p4196
sg10
I14
sg11
VRefsum disease
p4197
sg13
I2
sa(dp4198
g7
I68
sg27
VC0268134
p4199
sg10
I21
sg11
VDNA repair deficiency
p4200
sg13
I3
sa(dp4201
g7
I295
sg27
VC1848533
p4202
sg10
I4
sg11
VAVED
p4203
sg13
I1
sa(dp4204
g7
I395
sg27
VC0024814
p4205
sg10
I3
sg11
VMSS
p4206
sg13
I1
sasa(dp4207
g2
VWhile Friedreich's ataxia (FRDA) and ataxia telangiectasia (AT) are known to be the two most frequent forms of autosomal recessive cerebellar ataxia (ARCA), knowledge on the other forms of ARCA has been obtained only recently, and they appear to be rarer.
p4208
sg4
(lp4209
sg24
(lp4210
(dp4211
g7
I60
sg27
VC0004135
p4212
sg10
I2
sg11
VAT
p4213
sg13
I1
sa(dp4214
g7
I37
sg27
VC0004135
p4215
sg10
I21
sg11
Vataxia telangiectasia
p4216
sg13
I2
sa(dp4217
g7
I6
sg27
VC0016719
p4218
sg10
I19
sg11
VFriedreich's ataxia
p4219
sg13
I2
sa(dp4220
g7
I111
sg27
VC0007758
p4221
sg10
I37
sg11
Vautosomal recessive cerebellar ataxia
p4222
sg13
I4
sa(dp4223
g7
I27
sg27
VC1856689
p4224
sg10
I4
sg11
VFRDA
p4225
sg13
I1
sa(dp4226
g7
I150
sg27
VC0007758
p4227
sg10
I4
sg11
VARCA
p4228
sg13
I1
sa(dp4229
g7
I150
sg27
VC0007758
p4230
sg10
I4
sg11
VARCA
p4231
sg13
I1
sasa(dp4232
g2
VTranscription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy.
p4233
sg4
(lp4234
(dp4235
g7
I0
sg8
VP35398
p4236
sg10
I26
sg11
VTranscription factor MEF2C
p4237
sg13
I3
sa(dp4238
g7
I98
sg8
g9
sg10
I11
sg11
Vhuman MEF2C
p4239
sg13
I2
sasg24
(lp4240
(dp4241
g7
I174
sg27
VC0014544
p4242
sg10
I8
sg11
Vepilepsy
p4243
sg13
I1
sa(dp4244
g7
I88
sg27
VC1510586
p4245
sg10
I3
sg11
VASD
p4246
sg13
I1
sa(dp4247
g7
I145
sg27
VC0025362
p4248
sg10
I23
sg11
Vintellectual disability
p4249
sg13
I2
sa(dp4250
g7
I88
sg27
VC1510586
p4251
sg10
I3
sg11
VASD
p4252
sg13
I1
sa(dp4253
g7
I62
sg27
VC1510586
p4254
sg10
I24
sg11
Vautism spectrum disorder
p4255
sg13
I3
sasa(dp4256
g2
VThe microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C.
p4257
sg4
(lp4258
(dp4259
g7
I108
sg8
VP21579
p4260
sg10
I4
sg11
VSYT1
p4261
sg13
I1
sa(dp4262
g7
I122
sg8
g9
sg10
I6
sg11
VGRIN2B
p4263
sg13
I1
sa(dp4264
g7
I99
sg8
g9
sg10
I7
sg11
VSLC12A5
p4265
sg13
I1
sa(dp4266
g7
I137
sg8
g9
sg10
I5
sg11
VSCN2A
p4267
sg13
I1
sa(dp4268
g7
I154
sg8
g9
sg10
I5
sg11
VMEF2C
p4269
sg13
I1
sa(dp4270
g7
I114
sg8
g9
sg10
I6
sg11
VGRIN2A
p4271
sg13
I1
sa(dp4272
g7
I130
sg8
g9
sg10
I5
sg11
VKCNB1
p4273
sg13
I1
sa(dp4274
g7
I144
sg8
g9
sg10
I4
sg11
VTSC1
p4275
sg13
I1
sasg24
(lp4276
(dp4277
g7
I144
sg27
VC1854465
p4278
sg10
I4
sg11
VTSC1
p4279
sg13
I1
sa(dp4280
g7
I74
sg27
VC0014544
p4281
sg10
I8
sg11
Vepilepsy
p4282
sg13
I1
sasa(dp4283
g2
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p4284
sg4
(lp4285
(dp4286
g7
I292
sg8
g9
sg10
I6
sg11
VPICALM
p4287
sg13
I1
sa(dp4288
g7
I176
sg8
g9
sg10
I5
sg11
VCD2AP
p4289
sg13
I1
sa(dp4290
g7
I270
sg8
g9
sg10
I6
sg11
VMS4A4E
p4291
sg13
I1
sa(dp4292
g7
I255
sg8
g9
sg10
I5
sg11
VMEF2C
p4293
sg13
I1
sa(dp4294
g7
I227
sg8
VP30486
p4295
sg10
I3
sg11
VHLA
p4296
sg13
I1
sa(dp4297
g7
I206
sg8
g9
sg10
I4
sg11
VDSG2
p4298
sg13
I1
sa(dp4299
g7
I189
sg8
g9
sg10
I5
sg11
VCELF1
p4300
sg13
I1
sa(dp4301
g7
I157
sg8
VP02649
p4302
sg10
I4
sg11
VAPOE
p4303
sg13
I1
sa(dp4304
g7
I150
sg8
g9
sg10
I5
sg11
VABCA7
p4305
sg13
I1
sa(dp4306
g7
I313
sg8
g9
sg10
I4
sg11
VRIN3
p4307
sg13
I1
sa(dp4308
g7
I328
sg8
g9
sg10
I5
sg11
VSORL1
p4309
sg13
I1
sa(dp4310
g7
I319
sg8
g9
sg10
I7
sg11
VSLC24A4
p4311
sg13
I1
sa(dp4312
g7
I247
sg8
g9
sg10
I6
sg11
VINPP5D
p4313
sg13
I1
sa(dp4314
g7
I262
sg8
g9
sg10
I6
sg11
VMS4A4A
p4315
sg13
I1
sa(dp4316
g7
I183
sg8
VP20138
p4317
sg10
I4
sg11
VCD33
p4318
sg13
I1
sa(dp4319
g7
I300
sg8
g9
sg10
I4
sg11
VPLD3
p4320
sg13
I1
sa(dp4321
g7
I219
sg8
g9
sg10
I6
sg11
VFERMT2
p4322
sg13
I1
sa(dp4323
g7
I169
sg8
g9
sg10
I5
sg11
VCASS4
p4324
sg13
I1
sa(dp4325
g7
I196
sg8
VP10909
p4326
sg10
I3
sg11
VCLU
p4327
sg13
I1
sa(dp4328
g7
I306
sg8
g9
sg10
I5
sg11
VPTK2B
p4329
sg13
I1
sa(dp4330
g7
I212
sg8
VP21709
p4331
sg10
I5
sg11
VEPHA1
p4332
sg13
I1
sa(dp4333
g7
I278
sg8
g9
sg10
I6
sg11
VMS4A6E
p4334
sg13
I1
sa(dp4335
g7
I227
sg8
VP30486
p4336
sg10
I3
sg11
VHLA
p4337
sg13
I1
sa(dp4338
g7
I201
sg8
VP17927
p4339
sg10
I3
sg11
VCR1
p4340
sg13
I1
sa(dp4341
g7
I339
sg8
g9
sg10
I12
sg11
VZCWPW1 genes
p4342
sg13
I2
sa(dp4343
g7
I286
sg8
g9
sg10
I4
sg11
VNME8
p4344
sg13
I1
sa(dp4345
g7
I231
sg8
g9
sg10
I4
sg11
VDRB1
p4346
sg13
I1
sasg24
(lp4347
(dp4348
g7
I95
sg27
VC0002395
p4349
sg10
I20
sg11
VAlzheimer's diseases
p4350
sg13
I2
sa(dp4351
g7
I117
sg27
VC0002395
p4352
sg10
I2
sg11
VAD
p4353
sg13
I1
sasa(dp4354
g2
VEpilepsy-causing SIK1 sequence variations resulted in abnormalities in the MEF2C-ARC pathway of neuronal development and synapse activity response.
p4355
sg4
(lp4356
(dp4357
g7
I17
sg8
VP57059
p4358
sg10
I13
sg11
VSIK1 sequence
p4359
sg13
I2
sa(dp4360
g7
I81
sg8
g9
sg10
I3
sg11
VARC
p4361
sg13
I1
sa(dp4362
g7
I75
sg8
g9
sg10
I5
sg11
VMEF2C
p4363
sg13
I1
sasg24
(lp4364
(dp4365
g7
I81
sg27
VC0001857
p4366
sg10
I3
sg11
VARC
p4367
sg13
I1
sa(dp4368
g7
I0
sg27
VC0014544
p4369
sg10
I8
sg11
VEpilepsy
p4370
sg13
I1
sasa(dp4371
g2
VThis work provides the first insights into the mechanisms of pathogenesis in SIK1 syndrome, and extends the ARX-MEF2C pathway in the pathogenesis of developmental epilepsy.
p4372
sg4
(lp4373
(dp4374
g7
I112
sg8
g9
sg10
I5
sg11
VMEF2C
p4375
sg13
I1
sa(dp4376
g7
I108
sg8
g9
sg10
I3
sg11
VARX
p4377
sg13
I1
sasg24
(lp4378
(dp4379
g7
I61
sg27
VC0699748
p4380
sg10
I12
sg11
Vpathogenesis
p4381
sg13
I1
sa(dp4382
g7
I82
sg27
VC0039082
p4383
sg10
I8
sg11
Vsyndrome
p4384
sg13
I1
sa(dp4385
g7
I163
sg27
VC0014544
p4386
sg10
I8
sg11
Vepilepsy
p4387
sg13
I1
sa(dp4388
g7
I61
sg27
VC0699748
p4389
sg10
I12
sg11
Vpathogenesis
p4390
sg13
I1
sasa(dp4391
g2
VA common single nucleotide polymorphism (SNP, rs190982) in MEF2C gene was identified to be related to late-onset Alzheimer's disease (LOAD) in Caucasians in a large meta-analysis of genome-wide association studies (GWAS).
p4392
sg4
(lp4393
(dp4394
g7
I59
sg8
g9
sg10
I10
sg11
VMEF2C gene
p4395
sg13
I2
sasg24
(lp4396
(dp4397
g7
I113
sg27
VC1521724
p4398
sg10
I19
sg11
VAlzheimer's disease
p4399
sg13
I2
sasa(dp4400
g2
VA key factor protecting from oxidative stress in gestational diabetes mellitus (GDM) and in type 2 diabetes (T2D) is paraoxonase-1 (PON1).
p4401
sg4
(lp4402
(dp4403
g7
I132
sg8
VP27169
p4404
sg10
I4
sg11
VPON1
p4405
sg13
I1
sa(dp4406
g7
I117
sg8
VP14222
p4407
sg10
I13
sg11
Vparaoxonase-1
p4408
sg13
I1
sasg24
(lp4409
(dp4410
g7
I49
sg27
VC0085207
p4411
sg10
I29
sg11
Vgestational diabetes mellitus
p4412
sg13
I3
sa(dp4413
g7
I80
sg27
VC0085207
p4414
sg10
I3
sg11
VGDM
p4415
sg13
I1
sa(dp4416
g7
I109
sg27
VC0011860
p4417
sg10
I3
sg11
VT2D
p4418
sg13
I1
sa(dp4419
g7
I29
sg27
VC0242606
p4420
sg10
I16
sg11
Voxidative stress
p4421
sg13
I2
sa(dp4422
g7
I92
sg27
VC0011860
p4423
sg10
I15
sg11
Vtype 2 diabetes
p4424
sg13
I3
sasa(dp4425
g2
VIn this study our aim was to evaluate paraoxonase (PON1) activity and free sulfhydryl groups (-SH) as antioxidative parameters and lipid hydroperoxide (LOOH) as oxidative parameter in the serum of women with gestational diabetes mellitus (GDM) and determine their relation with the degree of subclinical atherosclerosis.
p4426
sg4
(lp4427
(dp4428
g7
I38
sg8
VP14222
p4429
sg10
I11
sg11
Vparaoxonase
p4430
sg13
I1
sa(dp4431
g7
I51
sg8
VP27169
p4432
sg10
I4
sg11
VPON1
p4433
sg13
I1
sasg24
(lp4434
(dp4435
g7
I304
sg27
VC0004153
p4436
sg10
I15
sg11
Vatherosclerosis
p4437
sg13
I1
sa(dp4438
g7
I208
sg27
VC0085207
p4439
sg10
I29
sg11
Vgestational diabetes mellitus
p4440
sg13
I3
sa(dp4441
g7
I239
sg27
VC0085207
p4442
sg10
I3
sg11
VGDM
p4443
sg13
I1
sasa(dp4444
g2
VTo clarify the levels of protein oxidation markers such as protein carbonyl (PCO), protein hydroperoxides (P-OOH), advanced oxidation protein products (AOPP) and nitrotyrosine (NT), as well as antioxidative enzymes such as paraoxonase (PON-1) in women with and without gestational diabetes mellitus (GDM).
p4445
sg4
(lp4446
(dp4447
g7
I223
sg8
VP14222
p4448
sg10
I11
sg11
Vparaoxonase
p4449
sg13
I1
sa(dp4450
g7
I236
sg8
VP27169
p4451
sg10
I5
sg11
VPON-1
p4452
sg13
I1
sasg24
(lp4453
(dp4454
g7
I269
sg27
VC0085207
p4455
sg10
I29
sg11
Vgestational diabetes mellitus
p4456
sg13
I3
sa(dp4457
g7
I59
sg27
VC0032460
p4458
sg10
I16
sg11
Vprotein carbonyl
p4459
sg13
I2
sa(dp4460
g7
I300
sg27
VC0085207
p4461
sg10
I3
sg11
VGDM
p4462
sg13
I1
sa(dp4463
g7
I77
sg27
VC0032460
p4464
sg10
I3
sg11
VPCO
p4465
sg13
I1
sasa(dp4466
g2
VRecently, numerous new antibodies defining the characteristic clinical phenotype have been described as anti-MDA5 antibodies associated with interstitial lung disease and amyopathic dermatomyositis or anti-TIF1Gamma antibodies as markers for paraneoplastic dermatomyositis.
p4467
sg4
(lp4468
(dp4469
g7
I104
sg8
g9
sg10
I20
sg11
Vanti-MDA5 antibodies
p4470
sg13
I2
sa(dp4471
g7
I201
sg8
g9
sg10
I25
sg11
Vanti-TIF1Gamma antibodies
p4472
sg13
I2
sasg24
(lp4473
(dp4474
g7
I242
sg27
VC1735598
p4475
sg10
I30
sg11
Vparaneoplastic dermatomyositis
p4476
sg13
I2
sa(dp4477
g7
I171
sg27
VC0406645
p4478
sg10
I26
sg11
Vamyopathic dermatomyositis
p4479
sg13
I2
sa(dp4480
g7
I141
sg27
VC0206062
p4481
sg10
I25
sg11
Vinterstitial lung disease
p4482
sg13
I3
sasa(dp4483
g2
VPM is associated with anti-synthetase antibodies (anti-Jo-1, PL-7, PL-12, OJ, and EJ) and DM with anti-Mi-2, anti-SAE, anti-TIF-1-Gamma and anti-NXP2 (both associated with cancer) or anti-MDA5 antibodies (associated with interstitial lung disease).
p4484
sg4
(lp4485
(dp4486
g7
I98
sg8
g9
sg10
I9
sg11
Vanti-Mi-2
p4487
sg13
I1
sa(dp4488
g7
I140
sg8
g9
sg10
I9
sg11
Vanti-NXP2
p4489
sg13
I1
sa(dp4490
g7
I183
sg8
g9
sg10
I20
sg11
Vanti-MDA5 antibodies
p4491
sg13
I2
sa(dp4492
g7
I119
sg8
g9
sg10
I16
sg11
Vanti-TIF-1-Gamma
p4493
sg13
I1
sasg24
(lp4494
(dp4495
g7
I172
sg27
VC0006826
p4496
sg10
I6
sg11
Vcancer
p4497
sg13
I1
sa(dp4498
g7
I221
sg27
VC0206062
p4499
sg10
I25
sg11
Vinterstitial lung disease
p4500
sg13
I3
sasa(dp4501
g2
VTwenty-six (43.3%) PM/DM-ILD patients were anti-aminoacyl tRNA-synthetase antibody-positive (anti-ARS-positive), 15 (25.0%) were anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5-positive), 3 (5%) were anti-signal recognition particle antibody-positive, 1 (1.7%) was anti-transcriptional intermediary factor 1-gamma antibody-positive, and 15 (25%) were MSA-negative.
p4502
sg4
(lp4503
(dp4504
g7
I196
sg8
g9
sg10
I9
sg11
Vanti-MDA5
p4505
sg13
I1
sa(dp4506
g7
I129
sg8
g9
sg10
I56
sg11
Vanti-melanoma differentiation-associated gene 5 antibody
p4507
sg13
I5
sa(dp4508
g7
I229
sg8
VP61011
p4509
sg10
I41
sg11
Vanti-signal recognition particle antibody
p4510
sg13
I4
sa(dp4511
g7
I294
sg8
g9
sg10
I57
sg11
Vanti-transcriptional intermediary factor 1-gamma antibody
p4512
sg13
I5
sasg24
(lp4513
(dp4514
g7
I134
sg27
VC0025202
p4515
sg10
I8
sg11
Vmelanoma
p4516
sg13
I1
sa(dp4517
g7
I380
sg27
VC0393571
p4518
sg10
I3
sg11
VMSA
p4519
sg13
I1
sasa(dp4520
g2
VAntibodies to transcription intermediary factor 1Gamma/Alfa (TIF1Gamma/Alfa, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD.
p4521
sg4
(lp4522
(dp4523
g7
I61
sg8
g9
sg10
I9
sg11
VTIF1Gamma
p4524
sg13
I1
sa(dp4525
g7
I147
sg8
g9
sg10
I47
sg11
Vanti-melanoma differentiation-associated gene 5
p4526
sg13
I4
sa(dp4527
g7
I14
sg8
g9
sg10
I40
sg11
Vtranscription intermediary factor 1Gamma
p4528
sg13
I4
sa(dp4529
g7
I77
sg8
g9
sg10
I8
sg11
Vp155/140
p4530
sg13
I1
sa(dp4531
g7
I196
sg8
g9
sg10
I4
sg11
VMDA5
p4532
sg13
I1
sasg24
(lp4533
(dp4534
g7
I130
sg27
VC0006826
p4535
sg10
I10
sg11
Vmalignancy
p4536
sg13
I1
sa(dp4537
g7
I152
sg27
VC0025202
p4538
sg10
I8
sg11
Vmelanoma
p4539
sg13
I1
sasa(dp4540
g2
VAnti-TIF-1Gamma positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia.
p4541
sg4
(lp4542
(dp4543
g7
I0
sg8
g9
sg10
I15
sg11
VAnti-TIF-1Gamma
p4544
sg13
I1
sasg24
(lp4545
(dp4546
g7
I114
sg27
VC0034735
p4547
sg10
I18
sg11
VRaynaud phenomenon
p4548
sg13
I2
sa(dp4549
g7
I148
sg27
VC0003862
p4550
sg10
I10
sg11
Varthralgia
p4551
sg13
I1
sa(dp4552
g7
I138
sg27
VC0003864
p4553
sg10
I9
sg11
Varthritis
p4554
sg13
I1
sa(dp4555
g7
I87
sg27
VC0206062
p4556
sg10
I25
sg11
Vinterstitial lung disease
p4557
sg13
I3
sasa(dp4558
g2
VThe frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1Gamma, anti-NXP2 and anti-SAE, respectively.
p4559
sg4
(lp4560
(dp4561
g7
I108
sg8
g9
sg10
I9
sg11
Vanti-NXP2
p4562
sg13
I1
sa(dp4563
g7
I92
sg8
g9
sg10
I14
sg11
Vanti-TIF1Gamma
p4564
sg13
I1
sasg24
(lp4565
(dp4566
g7
I47
sg27
VC0242656
p4567
sg10
I19
sg11
Vdisease progression
p4568
sg13
I2
sa(dp4569
g7
I17
sg27
VC0034069
p4570
sg10
I18
sg11
Vpulmonary fibrosis
p4571
sg13
I2
sasa(dp4572
g2
VEach of the identified mutations altered the equilibrium between alternative GR conformations distinctively, indicating that the Hsp90 dependence of SRs may correlate with differences in the conformational dynamics of these receptors.
p4573
sg4
(lp4574
(dp4575
g7
I129
sg8
VP07900
p4576
sg10
I5
sg11
VHsp90
p4577
sg13
I1
sa(dp4578
g7
I149
sg8
VP35270
p4579
sg10
I3
sg11
VSRs
p4580
sg13
I1
sa(dp4581
g7
I77
sg8
VP00390
p4582
sg10
I2
sg11
VGR
p4583
sg13
I1
sasg24
(lp4584
(dp4585
g7
I135
sg27
VC0439857
p4586
sg10
I10
sg11
Vdependence
p4587
sg13
I1
sa(dp4588
g7
I149
sg27
VC0175693
p4589
sg10
I3
sg11
VSRs
p4590
sg13
I1
sasa(dp4591
g2
VThe ubiquitous heat shock protein 90 (hsp90) has been shown to participate directly in the function of a wide variety of cellular signal transduction components, including steroid receptors (SRs).
p4592
sg4
(lp4593
(dp4594
g7
I172
sg8
VP52788
p4595
sg10
I17
sg11
Vsteroid receptors
p4596
sg13
I2
sa(dp4597
g7
I15
sg8
VP07900
p4598
sg10
I21
sg11
Vheat shock protein 90
p4599
sg13
I4
sa(dp4600
g7
I38
sg8
VP07900
p4601
sg10
I5
sg11
Vhsp90
p4602
sg13
I1
sa(dp4603
g7
I191
sg8
VP35270
p4604
sg10
I3
sg11
VSRs
p4605
sg13
I1
sasg24
(lp4606
(dp4607
g7
I172
sg27
VC0175693
p4608
sg10
I17
sg11
Vsteroid receptors
p4609
sg13
I2
sa(dp4610
g7
I191
sg27
VC0175693
p4611
sg10
I3
sg11
VSRs
p4612
sg13
I1
sasa(dp4613
g2
VHowever, there is still no direct evidence for an in vivo association of SRs with hsp90.
p4614
sg4
(lp4615
(dp4616
g7
I82
sg8
VP07900
p4617
sg10
I5
sg11
Vhsp90
p4618
sg13
I1
sa(dp4619
g7
I73
sg8
VP35270
p4620
sg10
I3
sg11
VSRs
p4621
sg13
I1
sasg24
(lp4622
(dp4623
g7
I73
sg27
VC0175693
p4624
sg10
I3
sg11
VSRs
p4625
sg13
I1
sasa(dp4626
g2
VThe results suggest that the interaction of SRs with the hsp90 is minimal when compared to a bona fide type of interaction with the co-factors.
p4627
sg4
(lp4628
(dp4629
g7
I57
sg8
VP07900
p4630
sg10
I5
sg11
Vhsp90
p4631
sg13
I1
sa(dp4632
g7
I44
sg8
VP35270
p4633
sg10
I3
sg11
VSRs
p4634
sg13
I1
sasg24
(lp4635
(dp4636
g7
I44
sg27
VC0175693
p4637
sg10
I3
sg11
VSRs
p4638
sg13
I1
sasa(dp4639
g2
VTo address the role of endothelial Cx43 in this process, we analyzed Cx43 regulation in human umbilical vein endothelial cells in the proximity of Cx43high (DU-145 and MAT-LyLu) and Cx43low prostate cancer cells (PC-3 and AT-2).
p4640
sg4
(lp4641
(dp4642
g7
I168
sg8
VP24752
p4643
sg10
I8
sg11
VMAT-LyLu
p4644
sg13
I1
sa(dp4645
g7
I35
sg8
VP17302
p4646
sg10
I4
sg11
VCx43
p4647
sg13
I1
sa(dp4648
g7
I35
sg8
VP17302
p4649
sg10
I4
sg11
VCx43
p4650
sg13
I1
sa(dp4651
g7
I213
sg8
g9
sg10
I4
sg11
VPC-3
p4652
sg13
I1
sasg24
(lp4653
(dp4654
g7
I190
sg27
VC0600139
p4655
sg10
I15
sg11
Vprostate cancer
p4656
sg13
I2
sasa(dp4657
g2
VThe data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy.
p4658
sg4
(lp4659
(dp4660
g7
I26
sg8
VP50052
p4661
sg10
I5
sg11
VAT2-R
p4662
sg13
I1
sasg24
(lp4663
(dp4664
g7
I145
sg27
VC1458156
p4665
sg10
I10
sg11
Vrecurrence
p4666
sg13
I1
sa(dp4667
g7
I65
sg27
VC0600139
p4668
sg10
I15
sg11
Vprostate cancer
p4669
sg13
I2
sasa(dp4670
g2
VThe present study found that, similarly to 5-fluorouracil, low concentrations (1-10 myM) of 9-aminoacridine (9-AAA) inhibited the growth of the two rat prostate cancer AT-2 and Mat-LyLu cell lines and the human melanoma A375 cell line.
p4671
sg4
(lp4672
(dp4673
g7
I177
sg8
VP24752
p4674
sg10
I3
sg11
VMat
p4675
sg13
I1
sa(dp4676
g7
I148
sg8
g9
sg10
I24
sg11
Vrat prostate cancer AT-2
p4677
sg13
I4
sasg24
(lp4678
(dp4679
g7
I211
sg27
VC0025202
p4680
sg10
I8
sg11
Vmelanoma
p4681
sg13
I1
sa(dp4682
g7
I111
sg27
VC0162871
p4683
sg10
I3
sg11
VAAA
p4684
sg13
I1
sa(dp4685
g7
I152
sg27
VC0600139
p4686
sg10
I15
sg11
Vprostate cancer
p4687
sg13
I2
sasa(dp4688
g2
VFurthermore, our previous studies indicate that increased expression of Ang II type 2 receptor (AT2R) alone induced apoptosis in human prostate cancer lines, an effect that did not require Ang II.
p4689
sg4
(lp4690
(dp4691
g7
I72
sg8
VP01019
p4692
sg10
I22
sg11
VAng II type 2 receptor
p4693
sg13
I5
sa(dp4694
g7
I72
sg8
VP01019
p4695
sg10
I6
sg11
VAng II
p4696
sg13
I2
sa(dp4697
g7
I96
sg8
VP50052
p4698
sg10
I4
sg11
VAT2R
p4699
sg13
I1
sasg24
(lp4700
(dp4701
g7
I135
sg27
VC0600139
p4702
sg10
I15
sg11
Vprostate cancer
p4703
sg13
I2
sasa(dp4704
g2
VHuman prostate cancer DU145 xenograft mouse model was used to assess the effect of AT2R on tumor growth in vivo.
p4705
sg4
(lp4706
(dp4707
g7
I83
sg8
VP50052
p4708
sg10
I4
sg11
VAT2R
p4709
sg13
I1
sasg24
(lp4710
(dp4711
g7
I91
sg27
VC0598934
p4712
sg10
I12
sg11
Vtumor growth
p4713
sg13
I2
sa(dp4714
g7
I6
sg27
VC0600139
p4715
sg10
I15
sg11
Vprostate cancer
p4716
sg13
I2
sasa(dp4717
g2
VThe results showed that AT2R overexpression can inhibit tumor growth of prostate cancer in vivo by inhibiting proliferation and inducing apoptosis of tumor cells.
p4718
sg4
(lp4719
(dp4720
g7
I24
sg8
VP50052
p4721
sg10
I4
sg11
VAT2R
p4722
sg13
I1
sasg24
(lp4723
(dp4724
g7
I56
sg27
VC0598934
p4725
sg10
I12
sg11
Vtumor growth
p4726
sg13
I2
sa(dp4727
g7
I110
sg27
VC0334094
p4728
sg10
I13
sg11
Vproliferation
p4729
sg13
I1
sa(dp4730
g7
I72
sg27
VC0600139
p4731
sg10
I15
sg11
Vprostate cancer
p4732
sg13
I2
sa(dp4733
g7
I56
sg27
VC0027651
p4734
sg10
I5
sg11
Vtumor
p4735
sg13
I1
sasa(dp4736
g2
VThe aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers.
p4737
sg4
(lp4738
(dp4739
g7
I51
sg8
VP30556
p4740
sg10
I3
sg11
VAT1
p4741
sg13
I1
sa(dp4742
g7
I59
sg8
VP50052
p4743
sg10
I3
sg11
VAT2
p4744
sg13
I1
sasg24
(lp4745
(dp4746
g7
I51
sg27
VC0004135
p4747
sg10
I3
sg11
VAT1
p4748
sg13
I1
sa(dp4749
g7
I84
sg27
VC0376358
p4750
sg10
I16
sg11
Vprostate cancers
p4751
sg13
I2
sasa(dp4752
g2
VThe data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis.
p4753
sg4
(lp4754
(dp4755
g7
I76
sg8
VP01116
p4756
sg10
I3
sg11
VRAS
p4757
sg13
I1
sa(dp4758
g7
I20
sg8
VP50052
p4759
sg10
I12
sg11
VAT2 receptor
p4760
sg13
I2
sa(dp4761
g7
I12
sg8
VP30556
p4762
sg10
I3
sg11
VAT1
p4763
sg13
I1
sasg24
(lp4764
(dp4765
g7
I12
sg27
VC0004135
p4766
sg10
I3
sg11
VAT1
p4767
sg13
I1
sasa(dp4768
g2
Vsartanes) and/or AT2 agonists in prostate cancer prophylaxis and/or treatment.
p4769
sg4
(lp4770
sg24
(lp4771
(dp4772
g7
I33
sg27
VC0600139
p4773
sg10
I15
sg11
Vprostate cancer
p4774
sg13
I2
sasa(dp4775
g2
VThe results indicate that CEGA using the new circular stapling device in surgery of the esophageal carcinoma is a very effective procedure to improve the anastomotic technique from a traditional hand-sewn anastomosis to a stapled anastomosis and can reduce the incidence of complications.
p4776
sg4
(lp4777
sg24
(lp4778
(dp4779
g7
I205
sg27
VC0332853
p4780
sg10
I11
sg11
Vanastomosis
p4781
sg13
I1
sa(dp4782
g7
I88
sg27
VC0152018
p4783
sg10
I20
sg11
Vesophageal carcinoma
p4784
sg13
I2
sa(dp4785
g7
I205
sg27
VC0332853
p4786
sg10
I11
sg11
Vanastomosis
p4787
sg13
I1
sasa(dp4788
g2
VAn unusual retinal pigment epitheliopathy resembling ophthalmomyiasis interna posterior (OMI) is endemic to Guam.
p4789
sg4
(lp4790
sg24
(lp4791
(dp4792
g7
I11
sg27
VC0860552
p4793
sg10
I30
sg11
Vretinal pigment epitheliopathy
p4794
sg13
I3
sa(dp4795
g7
I53
sg27
VC0027034
p4796
sg10
I16
sg11
Vophthalmomyiasis
p4797
sg13
I1
sasa(dp4798
g2
VToxicity, such as mucositis, leukocytopenia and neutropenia, was higher in ConcCRTx than in CTx followed by RTx.
p4799
sg4
(lp4800
sg24
(lp4801
(dp4802
g7
I92
sg27
VC0238052
p4803
sg10
I3
sg11
VCTx
p4804
sg13
I1
sa(dp4805
g7
I29
sg27
VC0023530
p4806
sg10
I14
sg11
Vleukocytopenia
p4807
sg13
I1
sa(dp4808
g7
I18
sg27
VC0333355
p4809
sg10
I9
sg11
Vmucositis
p4810
sg13
I1
sasa(dp4811
g2
VAt the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia.
p4812
sg4
(lp4813
sg24
(lp4814
(dp4815
g7
I104
sg27
VC0333355
p4816
sg10
I9
sg11
Vmucositis
p4817
sg13
I1
sa(dp4818
g7
I23
sg27
VC0238052
p4819
sg10
I3
sg11
VCtx
p4820
sg13
I1
sasa(dp4821
g2
VTherefore, the effect of CKD on the disposition of CYP1A2-metabolized, CYP2C8-metabolized, CYP2C9-metabolized, CYP2C19-metabolized, and organic anion-transporting polypeptide (OATP)-transported drugs was investigated.
p4822
sg4
(lp4823
(dp4824
g7
I91
sg8
VP11712
p4825
sg10
I6
sg11
VCYP2C9
p4826
sg13
I1
sa(dp4827
g7
I111
sg8
VP33261
p4828
sg10
I7
sg11
VCYP2C19
p4829
sg13
I1
sa(dp4830
g7
I71
sg8
VP10632
p4831
sg10
I6
sg11
VCYP2C8
p4832
sg13
I1
sa(dp4833
g7
I51
sg8
VP05177
p4834
sg10
I6
sg11
VCYP1A2
p4835
sg13
I1
sasg24
(lp4836
sa(dp4837
g2
VWe identified dedicated CKD studies with 6, 5, 6, 4, and 12 "model" substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, respectively.
p4838
sg4
(lp4839
(dp4840
g7
I99
sg8
VP11712
p4841
sg10
I6
sg11
VCYP2C9
p4842
sg13
I1
sa(dp4843
g7
I83
sg8
VP05177
p4844
sg10
I6
sg11
VCYP1A2
p4845
sg13
I1
sa(dp4846
g7
I107
sg8
VP33261
p4847
sg10
I7
sg11
VCYP2C19
p4848
sg13
I1
sa(dp4849
g7
I91
sg8
VP10632
p4850
sg10
I6
sg11
VCYP2C8
p4851
sg13
I1
sasg24
(lp4852
sa(dp4853
g2
VIn contrast, the effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.
p4854
sg4
(lp4855
(dp4856
g7
I54
sg8
VP33261
p4857
sg10
I7
sg11
VCYP2C19
p4858
sg13
I1
sa(dp4859
g7
I42
sg8
VP11712
p4860
sg10
I6
sg11
VCYP2C9
p4861
sg13
I1
sa(dp4862
g7
I109
sg8
VP46721
p4863
sg10
I4
sg11
VOATP
p4864
sg13
I1
sa(dp4865
g7
I34
sg8
VP05177
p4866
sg10
I6
sg11
VCYP1A2
p4867
sg13
I1
sa(dp4868
g7
I98
sg8
VP10632
p4869
sg10
I6
sg11
VCYP2C8
p4870
sg13
I1
sasg24
(lp4871
sa(dp4872
g2
VTo investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1 and GSTP1 on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis.
p4873
sg4
(lp4874
(dp4875
g7
I74
sg8
VP30711
p4876
sg10
I5
sg11
VGSTT1
p4877
sg13
I1
sa(dp4878
g7
I81
sg8
VP09488
p4879
sg10
I5
sg11
VGSTM1
p4880
sg13
I1
sa(dp4881
g7
I49
sg8
VP11712
p4882
sg10
I6
sg11
VCYP2C9
p4883
sg13
I1
sa(dp4884
g7
I91
sg8
VP09211
p4885
sg10
I5
sg11
VGSTP1
p4886
sg13
I1
sa(dp4887
g7
I57
sg8
VP33261
p4888
sg10
I7
sg11
VCYP2C19
p4889
sg13
I1
sa(dp4890
g7
I66
sg8
VP08684
p4891
sg10
I6
sg11
VCYP3A4
p4892
sg13
I1
sasg24
(lp4893
(dp4894
g7
I164
sg27
VC0024143
p4895
sg10
I15
sg11
Vlupus nephritis
p4896
sg13
I2
sasa(dp4897
g2
VChronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity.
p4898
sg4
(lp4899
(dp4900
g7
I98
sg8
VP11712
p4901
sg10
I6
sg11
VCYP2C9
p4902
sg13
I1
sasg24
(lp4903
(dp4904
g7
I0
sg27
VC1561643
p4905
sg10
I22
sg11
VChronic kidney disease
p4906
sg13
I3
sa(dp4907
g7
I24
sg27
VC1561643
p4908
sg10
I3
sg11
VCKD
p4909
sg13
I1
sasa(dp4910
g2
VCKD increased the effect of CYP2C9 genetic variation on (S)-warfarin and (R,S)-warfarin metabolism.
p4911
sg4
(lp4912
(dp4913
g7
I28
sg8
VP11712
p4914
sg10
I6
sg11
VCYP2C9
p4915
sg13
I1
sasg24
(lp4916
sa(dp4917
g2
VTecarfarin exposure was similar between the HVs and the CKD subjects regardless of CYP2C9 genotype.
p4918
sg4
(lp4919
(dp4920
g7
I83
sg8
VP11712
p4921
sg10
I15
sg11
VCYP2C9 genotype
p4922
sg13
I2
sasg24
(lp4923
sa(dp4924
g2
VThe CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance) was similar in all the patients with CKD and was concordant with previous reports of patients with end-stage renal disease (ESRD) and healthy controls.
p4925
sg4
(lp4926
(dp4927
g7
I4
sg8
VP11712
p4928
sg10
I6
sg11
VCYP2C9
p4929
sg13
I1
sasg24
(lp4930
(dp4931
g7
I187
sg27
VC0022661
p4932
sg10
I4
sg11
VESRD
p4933
sg13
I1
sa(dp4934
g7
I162
sg27
VC0022661
p4935
sg10
I23
sg11
Vend-stage renal disease
p4936
sg13
I3
sasa(dp4937
g2
VFor flurbiprofen, patients with glomerulonephritis had higher oral clearance than those with nonglomerular CKD, suggesting higher unbound fraction and enhanced metabolism through other (non-CYP2C9) routes.
p4938
sg4
(lp4939
(dp4940
g7
I190
sg8
VP11712
p4941
sg10
I6
sg11
VCYP2C9
p4942
sg13
I1
sasg24
(lp4943
(dp4944
g7
I32
sg27
VC0017658
p4945
sg10
I18
sg11
Vglomerulonephritis
p4946
sg13
I1
sasa(dp4947
g2
VThe current study suggests no statistically significant differences in the in vivo activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or nonglomerular CKD.
p4948
sg4
(lp4949
(dp4950
g7
I95
sg8
VP08684
p4951
sg10
I17
sg11
VCYP2C9 and CYP3A4
p4952
sg13
I3
sasg24
(lp4953
(dp4954
g7
I137
sg27
VC0017658
p4955
sg10
I18
sg11
Vglomerulonephritis
p4956
sg13
I1
sasa(dp4957
g2
VWe examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy.
p4958
sg4
(lp4959
(dp4960
g7
I24
sg8
VP00797
p4961
sg10
I5
sg11
Vrenin
p4962
sg13
I1
sa(dp4963
g7
I96
sg8
VP12821
p4964
sg10
I3
sg11
VACE
p4965
sg13
I1
sasg24
(lp4966
(dp4967
g7
I182
sg27
VC0027686
p4968
sg10
I15
sg11
Vneoangiogenesis
p4969
sg13
I1
sa(dp4970
g7
I143
sg27
VC0035309
p4971
sg10
I11
sg11
Vretinopathy
p4972
sg13
I1
sa(dp4973
g7
I120
sg27
VC0334094
p4974
sg10
I13
sg11
Vproliferative
p4975
sg13
I1
sa(dp4976
g7
I116
sg27
VC0004606
p4977
sg10
I38
sg11
Vnon-proliferative diabetic retinopathy
p4978
sg13
I3
sasa(dp4979
g2
VTo assess angiotensin-converting enzyme (ACE) levels in aqueous humor and plasma of patients with nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) as another potent ischemia-induced angiogenic factor.
p4980
sg4
(lp4981
(dp4982
g7
I41
sg8
VP12821
p4983
sg10
I3
sg11
VACE
p4984
sg13
I1
sa(dp4985
g7
I223
sg8
g9
sg10
I17
sg11
Vangiogenic factor
p4986
sg13
I2
sa(dp4987
g7
I10
sg8
VP12821
p4988
sg10
I29
sg11
Vangiotensin-converting enzyme
p4989
sg13
I2
sasg24
(lp4990
(dp4991
g7
I98
sg27
VC0004606
p4992
sg10
I37
sg11
Vnonproliferative diabetic retinopathy
p4993
sg13
I3
sa(dp4994
g7
I56
sg27
VC0595936
p4995
sg10
I13
sg11
Vaqueous humor
p4996
sg13
I2
sa(dp4997
g7
I137
sg27
VC0004606
p4998
sg10
I4
sg11
VNPDR
p4999
sg13
I1
sa(dp5000
g7
I138
sg27
VC0154830
p5001
sg10
I3
sg11
VPDR
p5002
sg13
I1
sa(dp5003
g7
I206
sg27
VC0022116
p5004
sg10
I8
sg11
Vischemia
p5005
sg13
I1
sa(dp5006
g7
I101
sg27
VC0154830
p5007
sg10
I34
sg11
Vproliferative diabetic retinopathy
p5008
sg13
I3
sasa(dp5009
g2
VWe observed significantly elevated ACE level in aqueous humor of patients with PDR compared with the patients with NPDR and normal subjects (P = 0.023), but no significant difference was detected between nonproliferative diabetics and control group (P = 0.239).
p5010
sg4
(lp5011
(dp5012
g7
I35
sg8
VP12821
p5013
sg10
I3
sg11
VACE
p5014
sg13
I1
sasg24
(lp5015
(dp5016
g7
I79
sg27
VC1845050
p5017
sg10
I3
sg11
VPDR
p5018
sg13
I1
sa(dp5019
g7
I48
sg27
VC0595936
p5020
sg10
I13
sg11
Vaqueous humor
p5021
sg13
I2
sasa(dp5022
g2
VStudies exploring the association between ACE I/D polymorphism and BDR or PDR may help us better understand the genetics of DR.
p5023
sg4
(lp5024
(dp5025
g7
I42
sg8
VP12821
p5026
sg10
I7
sg11
VACE I/D
p5027
sg13
I2
sasg24
(lp5028
(dp5029
g7
I74
sg27
VC1845050
p5030
sg10
I3
sg11
VPDR
p5031
sg13
I1
sasa(dp5032
g2
VTo evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients.
p5033
sg4
(lp5034
(dp5035
g7
I69
sg8
VP12821
p5036
sg10
I5
sg11
VACE-I
p5037
sg13
I1
sa(dp5038
g7
I27
sg8
VP12821
p5039
sg10
I40
sg11
Vangiotensin-converting enzyme inhibitors
p5040
sg13
I3
sasg24
(lp5041
(dp5042
g7
I111
sg27
VC0004606
p5043
sg10
I38
sg11
Vnon-proliferative diabetic retinopathy
p5044
sg13
I3
sa(dp5045
g7
I151
sg27
VC0004606
p5046
sg10
I4
sg11
VNPDR
p5047
sg13
I1
sasa(dp5048
g2
VThis was a retrospective case control study of 128 patients with normotensive type 2 diabetes with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99).
p5049
sg4
(lp5050
(dp5051
g7
I185
sg8
VP12821
p5052
sg10
I5
sg11
VACE-I
p5053
sg13
I1
sa(dp5054
g7
I185
sg8
VP12821
p5055
sg10
I5
sg11
VACE-I
p5056
sg13
I1
sasg24
(lp5057
(dp5058
g7
I78
sg27
VC0011860
p5059
sg10
I15
sg11
Vtype 2 diabetes
p5060
sg13
I3
sa(dp5061
g7
I138
sg27
VC0730278
p5062
sg10
I11
sg11
Vsevere NPDR
p5063
sg13
I2
sasa(dp5064
g2
VSmall doses of ACE-I did not yield any beneficial effects in retarding the progression of severe NPDR.
p5065
sg4
(lp5066
(dp5067
g7
I15
sg8
VP12821
p5068
sg10
I5
sg11
VACE-I
p5069
sg13
I1
sasg24
(lp5070
(dp5071
g7
I90
sg27
VC0730278
p5072
sg10
I11
sg11
Vsevere NPDR
p5073
sg13
I2
sasa(dp5074
g2
VA7730C variant which showed a high mutation frequency in cervical cancer was predicted to be a binding site for the cellular transcription factor PHOX2A.
p5075
sg4
(lp5076
(dp5077
g7
I146
sg8
g9
sg10
I6
sg11
VPHOX2A
p5078
sg13
I1
sasg24
(lp5079
(dp5080
g7
I57
sg27
VC0302592
p5081
sg10
I15
sg11
Vcervical cancer
p5082
sg13
I2
sasa(dp5083
g2
VmiR-326 regulates cell proliferation and migration in lung cancer by targeting Phox2a and is regulated by HOTAIR.
p5084
sg4
(lp5085
(dp5086
g7
I0
sg8
g9
sg10
I3
sg11
VmiR
p5087
sg13
I1
sa(dp5088
g7
I79
sg8
g9
sg10
I6
sg11
VPhox2a
p5089
sg13
I1
sasg24
(lp5090
(dp5091
g7
I54
sg27
VC0684249
p5092
sg10
I11
sg11
Vlung cancer
p5093
sg13
I2
sa(dp5094
g7
I23
sg27
VC0334094
p5095
sg10
I13
sg11
Vproliferation
p5096
sg13
I1
sasa(dp5097
g2
VPHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma (NB), because of their over-expression in different NB cell lines and tumour samples.
p5098
sg4
(lp5099
(dp5100
g7
I0
sg8
g9
sg10
I6
sg11
VPHOX2B
p5101
sg13
I1
sa(dp5102
g7
I30
sg8
g9
sg10
I6
sg11
VPHOX2A
p5103
sg13
I1
sa(dp5104
g7
I45
sg8
g9
sg10
I20
sg11
Vhomeodomain proteins
p5105
sg13
I2
sasg24
(lp5106
(dp5107
g7
I195
sg27
VC0027819
p5108
sg10
I2
sg11
VNB
p5109
sg13
I1
sa(dp5110
g7
I195
sg27
VC0027819
p5111
sg10
I2
sg11
VNB
p5112
sg13
I1
sa(dp5113
g7
I264
sg27
VC0027651
p5114
sg10
I6
sg11
Vtumour
p5115
sg13
I1
sa(dp5116
g7
I164
sg27
VC0699748
p5117
sg10
I12
sg11
Vpathogenesis
p5118
sg13
I1
sa(dp5119
g7
I180
sg27
VC0027819
p5120
sg10
I13
sg11
Vneuroblastoma
p5121
sg13
I1
sasa(dp5122
g2
VTo identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP).
p5123
sg4
(lp5124
(dp5125
g7
I189
sg8
g9
sg10
I6
sg11
VPHOX2A
p5126
sg13
I1
sa(dp5127
g7
I176
sg8
VP43235
p5128
sg10
I3
sg11
VOC2
p5129
sg13
I1
sa(dp5130
g7
I197
sg8
g9
sg10
I5
sg11
VPITX2
p5131
sg13
I1
sa(dp5132
g7
I170
sg8
VP23409
p5133
sg10
I4
sg11
VMYF6
p5134
sg13
I1
sa(dp5135
g7
I181
sg8
VP16234
p5136
sg10
I6
sg11
VPDGFRA
p5137
sg13
I1
sa(dp5138
g7
I226
sg8
g9
sg10
I4
sg11
VSOX1
p5139
sg13
I1
sa(dp5140
g7
I216
sg8
g9
sg10
I5
sg11
VSMPD3
p5141
sg13
I1
sa(dp5142
g7
I204
sg8
VP10826
p5143
sg10
I4
sg11
VRARB
p5144
sg13
I1
sa(dp5145
g7
I164
sg8
g9
sg10
I4
sg11
VHPP1
p5146
sg13
I1
sa(dp5147
g7
I145
sg8
g9
sg10
I4
sg11
VALX1
p5148
sg13
I1
sa(dp5149
g7
I210
sg8
g9
sg10
I4
sg11
VSIX6
p5150
sg13
I1
sa(dp5151
g7
I151
sg8
VP10415
p5152
sg10
I4
sg11
VBCL2
p5153
sg13
I1
sa(dp5154
g7
I157
sg8
VP58012
p5155
sg10
I5
sg11
VFOXL2
p5156
sg13
I1
sasg24
(lp5157
(dp5158
g7
I89
sg27
VC0007131
p5159
sg10
I5
sg11
VNSCLC
p5160
sg13
I1
sa(dp5161
g7
I81
sg27
VC0006826
p5162
sg10
I6
sg11
Vcancer
p5163
sg13
I1
sa(dp5164
g7
I61
sg27
VC0007131
p5165
sg10
I26
sg11
Vnon-small cell lung cancer
p5166
sg13
I4
sa(dp5167
g7
I339
sg27
VC0024115
p5168
sg10
I12
sg11
Vlung disease
p5169
sg13
I2
sa(dp5170
g7
I268
sg27
VC0278504
p5171
sg10
I13
sg11
Vstage I NSCLC
p5172
sg13
I3
sasa(dp5173
g2
VThe methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P&lt;0.05).
p5174
sg4
(lp5175
(dp5176
g7
I85
sg8
g9
sg10
I6
sg11
VPHOX2A
p5177
sg13
I1
sa(dp5178
g7
I55
sg8
VP23409
p5179
sg10
I4
sg11
VMYF6
p5180
sg13
I1
sa(dp5181
g7
I61
sg8
g9
sg10
I4
sg11
VSIX6
p5182
sg13
I1
sa(dp5183
g7
I79
sg8
VP10415
p5184
sg10
I4
sg11
VBCL2
p5185
sg13
I1
sa(dp5186
g7
I67
sg8
g9
sg10
I4
sg11
VSOX1
p5187
sg13
I1
sa(dp5188
g7
I73
sg8
VP10826
p5189
sg10
I4
sg11
VRARB
p5190
sg13
I1
sasg24
(lp5191
(dp5192
g7
I106
sg27
VC0278504
p5193
sg10
I13
sg11
Vstage I NSCLC
p5194
sg13
I3
sa(dp5195
g7
I183
sg27
VC0024115
p5196
sg10
I12
sg11
Vlung disease
p5197
sg13
I2
sasa(dp5198
g2
VFurthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively.
p5199
sg4
(lp5200
(dp5201
g7
I90
sg8
VP42857
p5202
sg10
I3
sg11
VP21
p5203
sg13
I1
sa(dp5204
g7
I101
sg8
VP10645
p5205
sg10
I4
sg11
VCHGA
p5206
sg13
I1
sa(dp5207
g7
I274
sg8
VP10415
p5208
sg10
I4
sg11
VBCL2
p5209
sg13
I1
sa(dp5210
g7
I101
sg8
VP10645
p5211
sg10
I4
sg11
VCHGA
p5212
sg13
I1
sa(dp5213
g7
I107
sg8
VP17600
p5214
sg10
I3
sg11
VSYN
p5215
sg13
I1
sa(dp5216
g7
I293
sg8
g9
sg10
I6
sg11
VPHOX2A
p5217
sg13
I1
sa(dp5218
g7
I221
sg8
VP42771
p5219
sg10
I3
sg11
Vp53
p5220
sg13
I1
sa(dp5221
g7
I85
sg8
VP42771
p5222
sg10
I3
sg11
VP53
p5223
sg13
I1
sa(dp5224
g7
I78
sg8
VP04626
p5225
sg10
I5
sg11
VHER-2
p5226
sg13
I1
sa(dp5227
g7
I115
sg8
VP13804
p5228
sg10
I3
sg11
VEMA
p5229
sg13
I1
sasg24
(lp5230
(dp5231
g7
I141
sg27
VC0278504
p5232
sg10
I13
sg11
Vstage I NSCLC
p5233
sg13
I3
sa(dp5234
g7
I123
sg27
VC0006826
p5235
sg10
I6
sg11
Vcancer
p5236
sg13
I1
sa(dp5237
g7
I115
sg27
VC0268596
p5238
sg10
I3
sg11
VEMA
p5239
sg13
I1
sasa(dp5240
g2
VIn this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC.
p5241
sg4
(lp5242
(dp5243
g7
I168
sg8
g9
sg10
I4
sg11
VSOX1
p5244
sg13
I1
sa(dp5245
g7
I138
sg8
VP23409
p5246
sg10
I4
sg11
VMYF6
p5247
sg13
I1
sa(dp5248
g7
I144
sg8
g9
sg10
I4
sg11
VSIX6
p5249
sg13
I1
sa(dp5250
g7
I150
sg8
g9
sg10
I6
sg11
VPHOX2A
p5251
sg13
I1
sasg24
(lp5252
(dp5253
g7
I72
sg27
VC0278504
p5254
sg10
I13
sg11
Vstage I NSCLC
p5255
sg13
I3
sa(dp5256
g7
I114
sg27
VC0024115
p5257
sg10
I13
sg11
Vlung diseases
p5258
sg13
I2
sa(dp5259
g7
I80
sg27
VC0007131
p5260
sg10
I5
sg11
VNSCLC
p5261
sg13
I1
sasa(dp5262
g2
VHeteroplasmic m.3697G&gt;A has been reported in patients with Leber's hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes and Stuve-Wiedemann syndrome.
p5263
sg4
(lp5264
sg24
(lp5265
(dp5266
g7
I132
sg27
VC0001125
p5267
sg10
I15
sg11
Vlactic acidosis
p5268
sg13
I2
sa(dp5269
g7
I177
sg27
VC0796176
p5270
sg10
I24
sg11
VStuve-Wiedemann syndrome
p5271
sg13
I2
sa(dp5272
g7
I99
sg27
VC0162666
p5273
sg10
I31
sg11
Vmitochondrial encephalomyopathy
p5274
sg13
I2
sa(dp5275
g7
I152
sg27
VC0038454
p5276
sg10
I6
sg11
Vstroke
p5277
sg13
I1
sa(dp5278
g7
I62
sg27
VC0917796
p5279
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p5280
sg13
I4
sasa(dp5281
g2
VThese can be grouped into disorders with reduced papillae (Machado-Joseph disease, Stuve-Wiedemann syndrome, familial dysautonomia, dystonia musculorum, and Behcet's disease) and those with taste defects only (Alzheimer's disease, Huntington's disease, hereditary sensory and autonomic neuropathy type IV, and diabetes mellitus).
p5282
sg4
(lp5283
sg24
(lp5284
(dp5285
g7
I310
sg27
VC0011849
p5286
sg10
I17
sg11
Vdiabetes mellitus
p5287
sg13
I2
sa(dp5288
g7
I132
sg27
VC0393593
p5289
sg10
I8
sg11
Vdystonia
p5290
sg13
I1
sa(dp5291
g7
I210
sg27
VC1521724
p5292
sg10
I19
sg11
VAlzheimer's disease
p5293
sg13
I2
sa(dp5294
g7
I253
sg27
VC0020074
p5295
sg10
I51
sg11
Vhereditary sensory and autonomic neuropathy type IV
p5296
sg13
I7
sa(dp5297
g7
I109
sg27
VC0013364
p5298
sg10
I21
sg11
Vfamilial dysautonomia
p5299
sg13
I2
sa(dp5300
g7
I59
sg27
VC0024408
p5301
sg10
I22
sg11
VMachado-Joseph disease
p5302
sg13
I2
sa(dp5303
g7
I231
sg27
VC0020179
p5304
sg10
I20
sg11
VHuntington's disease
p5305
sg13
I2
sa(dp5306
g7
I83
sg27
VC0796176
p5307
sg10
I24
sg11
VStuve-Wiedemann syndrome
p5308
sg13
I2
sa(dp5309
g7
I157
sg27
VC0004943
p5310
sg10
I16
sg11
VBehcet's disease
p5311
sg13
I2
sasa(dp5312
g2
VWe used in-situ hybridization to analyze the expression patterns of three known members (a, b and c) of the RGM ("repulsive guidance molecule") gene family and of the RGMa receptor neogenin in a glaucoma mouse model (DBA/2J strain) and the C57BL/6J strain, which served as a control.
p5313
sg4
(lp5314
(dp5315
g7
I167
sg8
g9
sg10
I22
sg11
VRGMa receptor neogenin
p5316
sg13
I3
sasg24
(lp5317
(dp5318
g7
I195
sg27
VC0017601
p5319
sg10
I8
sg11
Vglaucoma
p5320
sg13
I1
sa(dp5321
g7
I217
sg27
VC0398550
p5322
sg10
I3
sg11
VDBA
p5323
sg13
I1
sasa(dp5324
g2
VIn order to understand the role of the RGMs and neogenin in glaucoma, we characterized their expression patterns in the developing and mature mouse retina and in the optic nerve.
p5325
sg4
(lp5326
(dp5327
g7
I39
sg8
g9
sg10
I17
sg11
VRGMs and neogenin
p5328
sg13
I3
sasg24
(lp5329
(dp5330
g7
I60
sg27
VC0017601
p5331
sg10
I8
sg11
Vglaucoma
p5332
sg13
I1
sasa(dp5333
g2
VInterestingly, we found a higher expression of RGMa, RGMb and neogenin in the retinas of all glaucoma-affected mice than in the age-matched control strain.
p5334
sg4
(lp5335
(dp5336
g7
I53
sg8
g9
sg10
I17
sg11
VRGMb and neogenin
p5337
sg13
I3
sa(dp5338
g7
I47
sg8
g9
sg10
I4
sg11
VRGMa
p5339
sg13
I1
sasg24
(lp5340
(dp5341
g7
I93
sg27
VC0017601
p5342
sg10
I8
sg11
Vglaucoma
p5343
sg13
I1
sasa(dp5344
g2
VA tool developed for their use--DeAR GP (Dementia Assessment Referral to GP)--empowers care home staff, makes more efficient use of GPs' and specialist memory nurses' time, and improves diagnosis of dementia.
p5345
sg4
(lp5346
(dp5347
g7
I132
sg8
g9
sg10
I3
sg11
VGPs
p5348
sg13
I1
sasg24
(lp5349
(dp5350
g7
I41
sg27
VC0497327
p5351
sg10
I8
sg11
VDementia
p5352
sg13
I1
sa(dp5353
g7
I199
sg27
VC0497327
p5354
sg10
I8
sg11
Vdementia
p5355
sg13
I1
sa(dp5356
g7
I132
sg27
VC0272302
p5357
sg10
I3
sg11
VGPs
p5358
sg13
I1
sasa(dp5359
g2
VUsing homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection.
p5360
sg4
(lp5361
(dp5362
g7
I114
sg8
VP09958
p5363
sg10
I5
sg11
Vfurin
p5364
sg13
I1
sa(dp5365
g7
I73
sg8
g9
sg10
I5
sg11
VFGF23
p5366
sg13
I1
sa(dp5367
g7
I200
sg8
VP01270
p5368
sg10
I3
sg11
VPTH
p5369
sg13
I1
sasg24
(lp5370
(dp5371
g7
I29
sg27
VC0342642
p5372
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p5373
sg13
I4
sasa(dp5374
g2
VWe discuss in this review the current implications of GRx and/or glutathionylation in the inflammatory response and in diseases associated with chronic inflammation, namely diabetes, atherosclerosis, inflammatory lung disease, cancer, and Alzheimer's disease, and in viral infections.
p5375
sg4
(lp5376
sg24
(lp5377
(dp5378
g7
I239
sg27
VC1521724
p5379
sg10
I19
sg11
VAlzheimer's disease
p5380
sg13
I2
sa(dp5381
g7
I90
sg27
VC1155266
p5382
sg10
I21
sg11
Vinflammatory response
p5383
sg13
I2
sa(dp5384
g7
I144
sg27
VC0021376
p5385
sg10
I20
sg11
Vchronic inflammation
p5386
sg13
I2
sa(dp5387
g7
I183
sg27
VC0004153
p5388
sg10
I15
sg11
Vatherosclerosis
p5389
sg13
I1
sa(dp5390
g7
I213
sg27
VC0024115
p5391
sg10
I12
sg11
Vlung disease
p5392
sg13
I2
sa(dp5393
g7
I267
sg27
VC0042769
p5394
sg10
I16
sg11
Vviral infections
p5395
sg13
I2
sa(dp5396
g7
I173
sg27
VC0011849
p5397
sg10
I8
sg11
Vdiabetes
p5398
sg13
I1
sa(dp5399
g7
I227
sg27
VC0006826
p5400
sg10
I6
sg11
Vcancer
p5401
sg13
I1
sasa(dp5402
g2
VIn addition to arising from the procedure per se, a genetic or cytogenetic abnormality in offspring of an ICSI pregnancy could arise as result of offspring inheriting the mutant gene or chromosomal abnormality conferring paternal infertility: Y deletions (DAZ) in oligospermia males, cystic fibrosis in offspring of males with congenital bilateral absence vas deferens (CBAVD), and sex chromosomal abnormalities in offspring of Klinefelter syndrome (47,XXY) males.
p5403
sg4
(lp5404
sg24
(lp5405
(dp5406
g7
I284
sg27
VC0010674
p5407
sg10
I15
sg11
Vcystic fibrosis
p5408
sg13
I2
sa(dp5409
g7
I186
sg27
VC0008625
p5410
sg10
I23
sg11
Vchromosomal abnormality
p5411
sg13
I2
sa(dp5412
g7
I428
sg27
VC0022735
p5413
sg10
I20
sg11
VKlinefelter syndrome
p5414
sg13
I2
sa(dp5415
g7
I382
sg27
VC0036868
p5416
sg10
I29
sg11
Vsex chromosomal abnormalities
p5417
sg13
I3
sa(dp5418
g7
I370
sg27
VC0403814
p5419
sg10
I5
sg11
VCBAVD
p5420
sg13
I1
sa(dp5421
g7
I230
sg27
VC0021359
p5422
sg10
I11
sg11
Vinfertility
p5423
sg13
I1
sa(dp5424
g7
I171
sg27
VC0596988
p5425
sg10
I6
sg11
Vmutant
p5426
sg13
I1
sa(dp5427
g7
I327
sg27
VC0403814
p5428
sg10
I41
sg11
Vcongenital bilateral absence vas deferens
p5429
sg13
I5
sa(dp5430
g7
I264
sg27
VC0028960
p5431
sg10
I12
sg11
Voligospermia
p5432
sg13
I1
sa(dp5433
g7
I63
sg27
VC0008625
p5434
sg10
I23
sg11
Vcytogenetic abnormality
p5435
sg13
I2
sasa(dp5436
g2
VTwo recent candidate genes, ErbB3 and Fgfr1, are growth factors whose mRNA levels have been found to be altered in the leukocytes of patients that are affected by bipolar disorder in a depressive state.
p5437
sg4
(lp5438
(dp5439
g7
I28
sg8
VP21860
p5440
sg10
I5
sg11
VErbB3
p5441
sg13
I1
sa(dp5442
g7
I38
sg8
VP20930
p5443
sg10
I5
sg11
VFgfr1
p5444
sg13
I1
sasg24
(lp5445
(dp5446
g7
I163
sg27
VC0005586
p5447
sg10
I16
sg11
Vbipolar disorder
p5448
sg13
I2
sa(dp5449
g7
I185
sg27
VC0011570
p5450
sg10
I16
sg11
Vdepressive state
p5451
sg13
I2
sasa(dp5452
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p5453
sg4
(lp5454
(dp5455
g7
I94
sg8
g9
sg10
I8
sg11
VARHGEF10
p5456
sg13
I1
sa(dp5457
g7
I186
sg8
VP07197
p5458
sg10
I4
sg11
VNEF3
p5459
sg13
I1
sa(dp5460
g7
I210
sg8
VP48454
p5461
sg10
I6
sg11
VPPP3CC
p5462
sg13
I1
sa(dp5463
g7
I142
sg8
g9
sg10
I4
sg11
VEGR3
p5464
sg13
I1
sa(dp5465
g7
I120
sg8
g9
sg10
I6
sg11
VCHRNB3
p5466
sg13
I1
sa(dp5467
g7
I86
sg8
VP25100
p5468
sg10
I6
sg11
VADRA1A
p5469
sg13
I1
sa(dp5470
g7
I234
sg8
VP54219
p5471
sg10
I7
sg11
VSLC18A1
p5472
sg13
I1
sa(dp5473
g7
I228
sg8
VP54219
p5474
sg10
I5
sg11
VVMAT1
p5475
sg13
I1
sa(dp5476
g7
I180
sg8
VP18440
p5477
sg10
I4
sg11
VNAT2
p5478
sg13
I1
sa(dp5479
g7
I128
sg8
g9
sg10
I4
sg11
VDKK4
p5480
sg13
I1
sa(dp5481
g7
I162
sg8
VP20930
p5482
sg10
I5
sg11
VFGFR1
p5483
sg13
I1
sa(dp5484
g7
I104
sg8
g9
sg10
I6
sg11
VCHRNA2
p5485
sg13
I1
sa(dp5486
g7
I134
sg8
g9
sg10
I6
sg11
VDPYSL2
p5487
sg13
I1
sa(dp5488
g7
I169
sg8
g9
sg10
I4
sg11
VFZD3
p5489
sg13
I1
sa(dp5490
g7
I148
sg8
g9
sg10
I5
sg11
VFGF17
p5491
sg13
I1
sa(dp5492
g7
I155
sg8
g9
sg10
I5
sg11
VFGF20
p5493
sg13
I1
sa(dp5494
g7
I218
sg8
g9
sg10
I5
sg11
VSFRP1
p5495
sg13
I1
sa(dp5496
g7
I198
sg8
g9
sg10
I4
sg11
VPCM1
p5497
sg13
I1
sa(dp5498
g7
I112
sg8
g9
sg10
I6
sg11
VCHRNA6
p5499
sg13
I1
sasg24
(lp5500
(dp5501
g7
I436
sg27
VC0006826
p5502
sg10
I6
sg11
Vcancer
p5503
sg13
I1
sa(dp5504
g7
I309
sg27
VC0036341
p5505
sg10
I13
sg11
Vschizophrenia
p5506
sg13
I1
sa(dp5507
g7
I332
sg27
VC0005586
p5508
sg10
I16
sg11
Vbipolar disorder
p5509
sg13
I2
sa(dp5510
g7
I324
sg27
VC0004352
p5511
sg10
I6
sg11
Vautism
p5512
sg13
I1
sa(dp5513
g7
I366
sg27
VC0524851
p5514
sg10
I27
sg11
Vneurodegenerative disorders
p5515
sg13
I2
sa(dp5516
g7
I353
sg27
VC0011581
p5517
sg10
I10
sg11
Vdepression
p5518
sg13
I1
sa(dp5519
g7
I411
sg27
VC1521724
p5520
sg10
I19
sg11
VAlzheimer's disease
p5521
sg13
I2
sasa(dp5522
g2
VThe region on chromosome 3p13-p14 known to contain several chromosomal translocation breakpoints in families with "pure familial renal cell carcinoma" is quite proximal to the VHL locus in 3p25-p26 we have identified.
p5523
sg4
(lp5524
(dp5525
g7
I176
sg8
VP40337
p5526
sg10
I9
sg11
VVHL locus
p5527
sg13
I2
sa(dp5528
g7
I30
sg8
VP03971
p5529
sg10
I3
sg11
Vp14
p5530
sg13
I1
sasg24
(lp5531
(dp5532
g7
I176
sg27
VC0019562
p5533
sg10
I3
sg11
VVHL
p5534
sg13
I1
sa(dp5535
g7
I120
sg27
VC2931352
p5536
sg10
I29
sg11
Vfamilial renal cell carcinoma
p5537
sg13
I4
sa(dp5538
g7
I59
sg27
VC0040715
p5539
sg10
I25
sg11
Vchromosomal translocation
p5540
sg13
I2
sasa(dp5541
g2
VImmunohistochemical studies and TCR gamma gene rearrangement analysis using a polymerase chain reaction with primers specific for V gamma 1-8 and V gamma 9 gene segments in combination with denaturing gradient gel electrophoresis (PCR/ DGGE) were performed on frozen material of 11 pseudo-T-cell lymphomas and 17 CTCLs, including 9 cases of mycosis fungoides (MF) and 8 pleomorphic CTCLs.
p5542
sg4
(lp5543
(dp5544
g7
I130
sg8
g9
sg10
I39
sg11
VV gamma 1-8 and V gamma 9 gene segments
p5545
sg13
I9
sasg24
(lp5546
(dp5547
g7
I341
sg27
VC0026948
p5548
sg10
I17
sg11
Vmycosis fungoides
p5549
sg13
I2
sa(dp5550
g7
I289
sg27
VC0079772
p5551
sg10
I16
sg11
VT-cell lymphomas
p5552
sg13
I2
sa(dp5553
g7
I360
sg27
VC0026948
p5554
sg10
I2
sg11
VMF
p5555
sg13
I1
sasa(dp5556
g2
VUnclassifiable cutaneous T-cell lymphoma was also diagnosed in the second patient: it was associated with a monoclonal proliferation of T-cell receptor V gamma 9, delta + large granular T lymphocytes and finally developed into frank, acute pre-T lymphatic leukemia.
p5557
sg4
(lp5558
(dp5559
g7
I136
sg8
g9
sg10
I32
sg11
VT-cell receptor V gamma 9, delta
p5560
sg13
I6
sasg24
(lp5561
(dp5562
g7
I119
sg27
VC0334094
p5563
sg10
I13
sg11
Vproliferation
p5564
sg13
I1
sa(dp5565
g7
I15
sg27
VC0079773
p5566
sg10
I25
sg11
Vcutaneous T-cell lymphoma
p5567
sg13
I3
sa(dp5568
g7
I246
sg27
VC0023448
p5569
sg10
I18
sg11
Vlymphatic leukemia
p5570
sg13
I2
sasa(dp5571
g2
VIn addition to providing insight into Pol I transcription and ES control, Pol I transcription inhibitors potentially also provide new approaches to treat trypanosomiasis.
p5572
sg4
(lp5573
(dp5574
g7
I38
sg8
VP10266
p5575
sg10
I5
sg11
VPol I
p5576
sg13
I2
sa(dp5577
g7
I38
sg8
VP10266
p5578
sg10
I5
sg11
VPol I
p5579
sg13
I2
sasg24
(lp5580
(dp5581
g7
I154
sg27
VC0041227
p5582
sg10
I15
sg11
Vtrypanosomiasis
p5583
sg13
I1
sasa(dp5584
g2
VIn the unicellular parasite Trypanosoma brucei, which causes African sleeping sickness, TbISWI down-regulates RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs), which are monoallelically expressed.
p5585
sg4
(lp5586
(dp5587
g7
I110
sg8
VP24928
p5588
sg10
I16
sg11
VRNA polymerase I
p5589
sg13
I3
sa(dp5590
g7
I128
sg8
VP10266
p5591
sg10
I5
sg11
VPol I
p5592
sg13
I2
sasg24
(lp5593
(dp5594
g7
I61
sg27
VC0041228
p5595
sg10
I25
sg11
VAfrican sleeping sickness
p5596
sg13
I3
sasa(dp5597
g2
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p5598
sg4
(lp5599
(dp5600
g7
I48
sg8
g9
sg10
I19
sg11
Vperilipin rs1052700
p5601
sg13
I2
sasg24
(lp5602
(dp5603
g7
I85
sg27
VC0011860
p5604
sg10
I3
sg11
VT2D
p5605
sg13
I1
sa(dp5606
g7
I85
sg27
VC0011860
p5607
sg10
I3
sg11
VT2D
p5608
sg13
I1
sa(dp5609
g7
I137
sg27
VC0028754
p5610
sg10
I7
sg11
Vobesity
p5611
sg13
I1
sasa(dp5612
g2
VThe perilipin rs1052700 polymorphism is related to T2D but not obesity.
p5613
sg4
(lp5614
(dp5615
g7
I51
sg8
g9
sg10
I3
sg11
VT2D
p5616
sg13
I1
sa(dp5617
g7
I4
sg8
g9
sg10
I19
sg11
Vperilipin rs1052700
p5618
sg13
I2
sasg24
(lp5619
(dp5620
g7
I51
sg27
VC0011860
p5621
sg10
I3
sg11
VT2D
p5622
sg13
I1
sa(dp5623
g7
I63
sg27
VC0028754
p5624
sg10
I7
sg11
Vobesity
p5625
sg13
I1
sasa(dp5626
g2
VThis prospective study recruited 22 patients with ESRD who underwent a first living kidney allograft transplantation, comprising 12 patients with CYP3A5*1 allele (CYP3A5*1/*1 or *1/*3) and 10 patients without CYP3A5*1 allele (CYP3A5*3/*3).
p5627
sg4
(lp5628
(dp5629
g7
I146
sg8
VP20815
p5630
sg10
I8
sg11
VCYP3A5*1
p5631
sg13
I1
sa(dp5632
g7
I226
sg8
VP20815
p5633
sg10
I11
sg11
VCYP3A5*3/*3
p5634
sg13
I1
sa(dp5635
g7
I146
sg8
VP20815
p5636
sg10
I15
sg11
VCYP3A5*1 allele
p5637
sg13
I2
sa(dp5638
g7
I146
sg8
VP20815
p5639
sg10
I15
sg11
VCYP3A5*1 allele
p5640
sg13
I2
sasg24
(lp5641
(dp5642
g7
I50
sg27
VC0022661
p5643
sg10
I4
sg11
VESRD
p5644
sg13
I1
sasa(dp5645
g2
VNineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47).
p5646
sg4
(lp5647
(dp5648
g7
I35
sg8
VP35504
p5649
sg10
I6
sg11
VUGT1A1
p5650
sg13
I1
sa(dp5651
g7
I55
sg8
VP20815
p5652
sg10
I12
sg11
VCYP3A5 genes
p5653
sg13
I2
sa(dp5654
g7
I21
sg8
VP08183
p5655
sg10
I5
sg11
VABCB1
p5656
sg13
I1
sa(dp5657
g7
I43
sg8
g9
sg10
I7
sg11
VSLCO1B1
p5658
sg13
I1
sasg24
(lp5659
(dp5660
g7
I133
sg27
VC0392525
p5661
sg10
I15
sg11
Vnephrolithiasis
p5662
sg13
I1
sasa(dp5663
g2
VCalcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD.
p5664
sg4
(lp5665
(dp5666
g7
I425
sg8
VP08183
p5667
sg10
I11
sg11
VABCB1 3435C
p5668
sg13
I2
sa(dp5669
g7
I249
sg8
g9
sg10
I22
sg11
VCNI-transporting ABCB1
p5670
sg13
I2
sa(dp5671
g7
I210
sg8
g9
sg10
I30
sg11
VCNI-metabolizing enzyme CYP3A5
p5672
sg13
I3
sa(dp5673
g7
I23
sg8
g9
sg10
I3
sg11
VCNI
p5674
sg13
I1
sa(dp5675
g7
I0
sg8
g9
sg10
I21
sg11
VCalcineurin inhibitor
p5676
sg13
I2
sa(dp5677
g7
I440
sg8
g9
sg10
I6
sg11
VT SNPs
p5678
sg13
I2
sa(dp5679
g7
I403
sg8
VP20815
p5680
sg10
I12
sg11
VCYP3A5 6986A
p5681
sg13
I2
sasg24
(lp5682
sa(dp5683
g2
VNeither did we find a correlation between the investigated SNPs in either donor or recipient ABCB1 and CYP3A5 genes (or combinations thereof) and the development of CKD.
p5684
sg4
(lp5685
(dp5686
g7
I93
sg8
VP08183
p5687
sg10
I5
sg11
VABCB1
p5688
sg13
I1
sa(dp5689
g7
I103
sg8
VP20815
p5690
sg10
I12
sg11
VCYP3A5 genes
p5691
sg13
I2
sasg24
(lp5692
sa(dp5693
g2
VAn individual's risk of developing CKD after LT is not associated with genetic variation in either recipient or donor CYP3A5 or ABCB1 genotype status.
p5694
sg4
(lp5695
(dp5696
g7
I118
sg8
VP20815
p5697
sg10
I6
sg11
VCYP3A5
p5698
sg13
I1
sa(dp5699
g7
I128
sg8
VP08183
p5700
sg10
I14
sg11
VABCB1 genotype
p5701
sg13
I2
sasg24
(lp5702
sa(dp5703
g2
VIn conclusion, these results suggest that CYP3A5 polymorphism and plasma concentration of 3-INDS may account for the interindividual variability of CYP3A activity, and that plasma concentration of 3-INDS may partially explain the gap in CYP3A activity that cannot be explained by genetic contribution in patients with renal failure.
p5704
sg4
(lp5705
(dp5706
g7
I42
sg8
VP08684
p5707
sg10
I5
sg11
VCYP3A
p5708
sg13
I1
sa(dp5709
g7
I42
sg8
VP20815
p5710
sg10
I6
sg11
VCYP3A5
p5711
sg13
I1
sa(dp5712
g7
I42
sg8
VP08684
p5713
sg10
I5
sg11
VCYP3A
p5714
sg13
I1
sasg24
(lp5715
(dp5716
g7
I318
sg27
VC0035078
p5717
sg10
I13
sg11
Vrenal failure
p5718
sg13
I2
sasa(dp5719
g2
V#\u76ee#\u7684#\uff1a #\u63a2#\u8ba8FGD6  (faciogenital dysplasia) #\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u7684#\u4f5c#\u7528#\u3002 #\u65b9#\u6cd5#\uff1a #\u9009#\u53d6FGD6#\u57fa#\u56e0#\u5e72#\u6270#\u9776#\u5e8f#\u5217, #\u4f7f#\u7528AdEasy#\u7cfb#\u7edf#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53, #\u5305#\u88c5#\u5e76#\u6269#\u589e#\u91cd#\u7ec4#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA, #\u611f#\u67d3HP14.5#\u7ec6#\u80de#\u3002#\u7ec6#\u80de#\u514d#\u75ab#\u8367#\u5149#\u68c0#\u6d4bFGD6#\u86cb#\u767d#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe#\u6c34#\u5e73, #\u5b9e#\u65f6#\u8367#\u5149#\u5b9a#\u91cfPCR#\u68c0#\u6d4bFGD6#\u3001#\u7532#\u80ce#\u86cb#\u767d (AFP) #\u53ca#\u767d#\u86cb#\u767d (Alb) #\u7684mRNA#\u6c34#\u5e73, Western blot#\u68c0#\u6d4bFGD6#\u3001AFP#\u53caAlb#\u7684#\u86cb#\u767d#\u8868#\u8fbe#\u6c34#\u5e73#\u3002#\u6bcf#\u7ec4#\u7ec6#\u80de#\u5747#\u8bbe#\u7f6epSES-Ad-RFP#\u817a#\u75c5#\u6bd2#\u7a7a#\u8f7d#\u4f53#\u611f#\u67d3#\u8fdb#\u884c#\u5bf9#\u7167#\u3002#\u6240#\u6709#\u6570#\u636e#\u7528#\u5747#\u6570+/-#\u6807#\u51c6#\u5dee (x+/-s) #\u8868#\u793a, #\u91c7#\u7528#\u5355#\u56e0#\u7d20#\u65b9#\u5dee#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a FGD6#\u86cb#\u767d#\u4e3b#\u8981#\u8868#\u8fbe#\u4e8eHP14.5#\u7ec6#\u80de#\u80de#\u6838#\u4e2d#\u3002#\u6210#\u529f#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA#\u3002#\u4e0b#\u8c03FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u964d#\u4f4eAFP#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe, #\u800c#\u5347#\u9ad8Alb#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe (P&lt;0.01) #\u3002 #\u7ed3#\u8bba#\uff1a #\u6291#\u5236FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u4f7fHP14.5#\u7ec6#\u80de#\u5411#\u809d#\u7ec6#\u80de#\u65b9#\u5411#\u5206#\u5316, #\u56e0#\u6b64, FGD6#\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u53ef#\u80fd#\u8d77#\u7740#\u91cd#\u8981#\u4f5c#\u7528#\u3002.
p5720
sg4
(lp5721
(dp5722
g7
I11
sg8
g9
sg10
I4
sg11
VFGD6
p5723
sg13
I1
sa(dp5724
g7
I376
sg8
VP25090
p5725
sg10
I3
sg11
VRFP
p5726
sg13
I1
sa(dp5727
g7
I11
sg8
g9
sg10
I4
sg11
VFGD6
p5728
sg13
I1
sa(dp5729
g7
I329
sg8
VP02771
p5730
sg10
I4
sg11
V\u3001AFP
p5731
sg13
I1
sa(dp5732
g7
I11
sg8
g9
sg10
I4
sg11
VFGD6
p5733
sg13
I1
sa(dp5734
g7
I11
sg8
g9
sg10
I4
sg11
VFGD6
p5735
sg13
I1
sasg24
(lp5736
(dp5737
g7
I18
sg27
VC0175701
p5738
sg10
I22
sg11
Vfaciogenital dysplasia
p5739
sg13
I2
sasa(dp5740
g2
VFiltered albumin has been suggested to be a cause of the glomerular and tubular injuries observed at advanced stages of Alport syndrome.
p5741
sg4
(lp5742
(dp5743
g7
I9
sg8
VP00441
p5744
sg10
I7
sg11
Valbumin
p5745
sg13
I1
sasg24
(lp5746
(dp5747
g7
I120
sg27
VC1567741
p5748
sg10
I15
sg11
VAlport syndrome
p5749
sg13
I2
sasa(dp5750
g2
VTo directly investigate the role that albumin plays in the progression of disease in Alport syndrome, we generated albumin knockout (Alb(-/-)) mice to use as a tool for removing albuminuria as a component of kidney disease.
p5751
sg4
(lp5752
(dp5753
g7
I38
sg8
VP00441
p5754
sg10
I7
sg11
Valbumin
p5755
sg13
I1
sa(dp5756
g7
I38
sg8
VP00441
p5757
sg10
I7
sg11
Valbumin
p5758
sg13
I1
sa(dp5759
g7
I133
sg8
g9
sg10
I3
sg11
VAlb
p5760
sg13
I1
sasg24
(lp5761
(dp5762
g7
I85
sg27
VC1567741
p5763
sg10
I15
sg11
VAlport syndrome
p5764
sg13
I2
sa(dp5765
g7
I208
sg27
VC0022658
p5766
sg10
I14
sg11
Vkidney disease
p5767
sg13
I2
sasa(dp5768
g2
VAlb mutant mice were bred to collagen-Alfa3(IV) knockout (Col4a3(-/-)) mice, which are a model for human Alport syndrome.
p5769
sg4
(lp5770
(dp5771
g7
I0
sg8
g9
sg10
I3
sg11
VAlb
p5772
sg13
I1
sasg24
(lp5773
(dp5774
g7
I105
sg27
VC1567741
p5775
sg10
I15
sg11
VAlport syndrome
p5776
sg13
I2
sa(dp5777
g7
I4
sg27
VC0596988
p5778
sg10
I6
sg11
Vmutant
p5779
sg13
I1
sasa(dp5780
g2
VWe conclude that filtered albumin is injurious to kidney cells in Alport syndrome and perhaps in other proteinuric kidney diseases, including diabetic nephropathy.
p5781
sg4
(lp5782
(dp5783
g7
I26
sg8
VP00441
p5784
sg10
I7
sg11
Valbumin
p5785
sg13
I1
sasg24
(lp5786
(dp5787
g7
I142
sg27
VC0011881
p5788
sg10
I20
sg11
Vdiabetic nephropathy
p5789
sg13
I2
sa(dp5790
g7
I115
sg27
VC0022658
p5791
sg10
I15
sg11
Vkidney diseases
p5792
sg13
I2
sa(dp5793
g7
I66
sg27
VC1567741
p5794
sg10
I15
sg11
VAlport syndrome
p5795
sg13
I2
sasa(dp5796
g2
VOn the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.
p5797
sg4
(lp5798
(dp5799
g7
I81
sg8
VP49767
p5800
sg10
I6
sg11
VVEGF-C
p5801
sg13
I1
sasg24
(lp5802
(dp5803
g7
I183
sg27
VC0558353
p5804
sg10
I13
sg11
Vtongue cancer
p5805
sg13
I2
sa(dp5806
g7
I35
sg27
VC0027651
p5807
sg10
I5
sg11
Vtumor
p5808
sg13
I1
sa(dp5809
g7
I50
sg27
VC2699153
p5810
sg10
I8
sg11
Vinvasion
p5811
sg13
I1
sasa(dp5812
g2
VThe use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.
p5813
sg4
(lp5814
(dp5815
g7
I80
sg8
VP49767
p5816
sg10
I6
sg11
VVEGF-C
p5817
sg13
I1
sa(dp5818
g7
I91
sg8
g9
sg10
I6
sg11
VVEGF-D
p5819
sg13
I1
sasg24
(lp5820
(dp5821
g7
I156
sg27
VC0558353
p5822
sg10
I13
sg11
Vtongue cancer
p5823
sg13
I2
sasa(dp5824
g2
VVEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.
p5825
sg4
(lp5826
(dp5827
g7
I14
sg8
g9
sg10
I6
sg11
VVEGF-D
p5828
sg13
I1
sa(dp5829
g7
I6
sg8
VP49767
p5830
sg10
I6
sg11
VVEGF-C
p5831
sg13
I1
sa(dp5832
g7
I206
sg8
g9
sg10
I9
sg11
VMIA siRNA
p5833
sg13
I2
sa(dp5834
g7
I25
sg8
g9
sg10
I3
sg11
VMIA
p5835
sg13
I1
sa(dp5836
g7
I14
sg8
g9
sg10
I6
sg11
VVEGF-D
p5837
sg13
I1
sa(dp5838
g7
I6
sg8
VP49767
p5839
sg10
I6
sg11
VVEGF-C
p5840
sg13
I1
sasg24
(lp5841
(dp5842
g7
I61
sg27
VC0558353
p5843
sg10
I13
sg11
Vtongue cancer
p5844
sg13
I2
sasa(dp5845
g2
VVascular endothelial growth factor and Notch1 expression are significantly related to cervical lymph node metastasis and depth of invasion in tongue cancer patients.
p5846
sg4
(lp5847
(dp5848
g7
I0
sg8
g9
sg10
I34
sg11
VVascular endothelial growth factor
p5849
sg13
I4
sa(dp5850
g7
I39
sg8
VP46531
p5851
sg10
I6
sg11
VNotch1
p5852
sg13
I1
sasg24
(lp5853
(dp5854
g7
I130
sg27
VC2699153
p5855
sg10
I8
sg11
Vinvasion
p5856
sg13
I1
sa(dp5857
g7
I95
sg27
VC0686619
p5858
sg10
I21
sg11
Vlymph node metastasis
p5859
sg13
I3
sa(dp5860
g7
I142
sg27
VC0558353
p5861
sg10
I13
sg11
Vtongue cancer
p5862
sg13
I2
sasa(dp5863
g2
VMutant-type p53 and VEGF are known to be related to angiogenesis, and maspin is a potent angiogenic inhibitor but its role in tongue cancer has scarcely been examined.
p5864
sg4
(lp5865
(dp5866
g7
I12
sg8
VP42771
p5867
sg10
I3
sg11
Vp53
p5868
sg13
I1
sasg24
(lp5869
(dp5870
g7
I0
sg27
VC0596988
p5871
sg10
I6
sg11
VMutant
p5872
sg13
I1
sa(dp5873
g7
I126
sg27
VC0558353
p5874
sg10
I13
sg11
Vtongue cancer
p5875
sg13
I2
sasa(dp5876
g2
VWe observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer.
p5877
sg4
(lp5878
(dp5879
g7
I30
sg8
VP36952
p5880
sg10
I6
sg11
Vmaspin
p5881
sg13
I1
sa(dp5882
g7
I38
sg8
VP42771
p5883
sg10
I15
sg11
Vmutant-type p53
p5884
sg13
I2
sasg24
(lp5885
(dp5886
g7
I128
sg27
VC0558353
p5887
sg10
I13
sg11
Vtongue cancer
p5888
sg13
I2
sa(dp5889
g7
I38
sg27
VC0596988
p5890
sg10
I6
sg11
Vmutant
p5891
sg13
I1
sasa(dp5892
g2
VIn an experimental autoimmune encephalomyelitis model of CNS autoimmunity, we found activation-induced cytidine deaminase, a GC-defining enzyme, in meningeal ELT (mELT) densely populated by B and T cells.
p5893
sg4
(lp5894
(dp5895
g7
I103
sg8
VP32320
p5896
sg10
I18
sg11
Vcytidine deaminase
p5897
sg13
I2
sasg24
(lp5898
(dp5899
g7
I30
sg27
VC0014070
p5900
sg10
I17
sg11
Vencephalomyelitis
p5901
sg13
I1
sa(dp5902
g7
I61
sg27
VC0004368
p5903
sg10
I12
sg11
Vautoimmunity
p5904
sg13
I1
sa(dp5905
g7
I19
sg27
VC0443146
p5906
sg10
I10
sg11
Vautoimmune
p5907
sg13
I1
sasa(dp5908
g2
VA prospective randomized survey of 113 abortions carried out by 1 operator using a single technique among women in the 7th-10th week of amenorrhea was undertaken to test the effectiveness of systemically administered oxytocins to reduce bleeding during therapeutic abortion by suction.
p5909
sg4
(lp5910
sg24
(lp5911
(dp5912
g7
I136
sg27
VC0002453
p5913
sg10
I10
sg11
Vamenorrhea
p5914
sg13
I1
sa(dp5915
g7
I237
sg27
VC0019080
p5916
sg10
I8
sg11
Vbleeding
p5917
sg13
I1
sasa(dp5918
g2
VThis cross-sectional study includes 304 patients with type 2 diabetes treated with oral antidiabetic drugs (ADOs) and a glomerular filtration rate (estimated GFR) &amp;lt;60ml/min/1.73m2.
p5919
sg4
(lp5920
sg24
(lp5921
(dp5922
g7
I54
sg27
VC0011860
p5923
sg10
I15
sg11
Vtype 2 diabetes
p5924
sg13
I3
sasa(dp5925
g2
VThe purpose of this study was to evaluate the hypothesis that acute hyperglycaemia in hearts of rats without diabetes alters coronary vascular responses to nitric oxide (NO), adenosine (ADO) and phenylephrine (PHE).
p5926
sg4
(lp5927
sg24
(lp5928
(dp5929
g7
I62
sg27
VC0342301
p5930
sg10
I20
sg11
Vacute hyperglycaemia
p5931
sg13
I2
sa(dp5932
g7
I109
sg27
VC0011849
p5933
sg10
I8
sg11
Vdiabetes
p5934
sg13
I1
sasa(dp5935
g2
VIn conclusion, STZ-diabetes mellitus enhances the antiphosphaturic effect of ADO by mechanisms unrelated to ADO A1 receptor stimulation.
p5936
sg4
(lp5937
(dp5938
g7
I108
sg8
g9
sg10
I15
sg11
VADO A1 receptor
p5939
sg13
I3
sasg24
(lp5940
(dp5941
g7
I19
sg27
VC0011849
p5942
sg10
I17
sg11
Vdiabetes mellitus
p5943
sg13
I2
sasa(dp5944
g2
VBradykinin type 1 receptor antagonism could represent a promising therapeutic tool in combination with TZD for the treatment of T2D, obesity and insulin resistance.
p5945
sg4
(lp5946
(dp5947
g7
I0
sg8
VP01042
p5948
sg10
I26
sg11
VBradykinin type 1 receptor
p5949
sg13
I4
sa(dp5950
g7
I145
sg8
VP01308
p5951
sg10
I7
sg11
Vinsulin
p5952
sg13
I1
sasg24
(lp5953
(dp5954
g7
I133
sg27
VC0028754
p5955
sg10
I7
sg11
Vobesity
p5956
sg13
I1
sa(dp5957
g7
I145
sg27
VC0021655
p5958
sg10
I18
sg11
Vinsulin resistance
p5959
sg13
I2
sa(dp5960
g7
I128
sg27
VC0011860
p5961
sg10
I3
sg11
VT2D
p5962
sg13
I1
sasa(dp5963
g2
VThe aim of this study was to analyze the acute responses of bradykinin, insulin, and glycemia to exercise performed above and below lactate threshold (LT) in individuals with type 2 diabetes mellitus (T2D).
p5964
sg4
(lp5965
(dp5966
g7
I60
sg8
VP01042
p5967
sg10
I10
sg11
Vbradykinin
p5968
sg13
I1
sa(dp5969
g7
I72
sg8
VP01308
p5970
sg10
I7
sg11
Vinsulin
p5971
sg13
I1
sasg24
(lp5972
(dp5973
g7
I175
sg27
VC0011860
p5974
sg10
I24
sg11
Vtype 2 diabetes mellitus
p5975
sg13
I4
sa(dp5976
g7
I201
sg27
VC0011860
p5977
sg10
I3
sg11
VT2D
p5978
sg13
I1
sasa(dp5979
g2
VTo examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).
p5980
sg4
(lp5981
(dp5982
g7
I30
sg8
VP01042
p5983
sg10
I10
sg11
Vbradykinin
p5984
sg13
I1
sa(dp5985
g7
I171
sg8
VP00797
p5986
sg10
I5
sg11
VRenin
p5987
sg13
I1
sa(dp5988
g7
I177
sg8
VP21549
p5989
sg10
I11
sg11
VAngiotensin
p5990
sg13
I1
sasg24
(lp5991
(dp5992
g7
I86
sg27
VC0011881
p5993
sg10
I20
sg11
Vdiabetic nephropathy
p5994
sg13
I2
sa(dp5995
g7
I157
sg27
VC0011854
p5996
sg10
I3
sg11
VT1D
p5997
sg13
I1
sa(dp5998
g7
I140
sg27
VC0011854
p5999
sg10
I15
sg11
Vtype 1 diabetes
p6000
sg13
I3
sasa(dp6001
g2
VHeterozygosity for missense mutations in Seipin, namely N88S and S90L, leads to a broad spectrum of motor neuropathy, while a number of loss-of-function mutations in Seipin are associated with the Berardinelli-Seip congenital generalized lipodystrophy type 2 (CGL2, BSCL2), a condition that is characterized by severe lipoatrophy, insulin resistance, and intellectual impairment.
p6002
sg4
(lp6003
(dp6004
g7
I331
sg8
VP01308
p6005
sg10
I7
sg11
Vinsulin
p6006
sg13
I1
sa(dp6007
g7
I266
sg8
g9
sg10
I5
sg11
VBSCL2
p6008
sg13
I1
sa(dp6009
g7
I260
sg8
VP20718
p6010
sg10
I4
sg11
VCGL2
p6011
sg13
I1
sa(dp6012
g7
I41
sg8
g9
sg10
I6
sg11
VSeipin
p6013
sg13
I1
sa(dp6014
g7
I215
sg8
VP20718
p6015
sg10
I43
sg11
Vcongenital generalized lipodystrophy type 2
p6016
sg13
I5
sa(dp6017
g7
I41
sg8
g9
sg10
I6
sg11
VSeipin
p6018
sg13
I1
sasg24
(lp6019
(dp6020
g7
I318
sg27
VC1280433
p6021
sg10
I11
sg11
Vlipoatrophy
p6022
sg13
I1
sa(dp6023
g7
I331
sg27
VC0021655
p6024
sg10
I18
sg11
Vinsulin resistance
p6025
sg13
I2
sa(dp6026
g7
I276
sg27
VC0012634
p6027
sg10
I9
sg11
Vcondition
p6028
sg13
I1
sa(dp6029
g7
I100
sg27
VC0235025
p6030
sg10
I16
sg11
Vmotor neuropathy
p6031
sg13
I2
sa(dp6032
g7
I260
sg27
VC1720863
p6033
sg10
I4
sg11
VCGL2
p6034
sg13
I1
sa(dp6035
g7
I215
sg27
VC1720863
p6036
sg10
I43
sg11
Vcongenital generalized lipodystrophy type 2
p6037
sg13
I5
sa(dp6038
g7
I355
sg27
VC0683322
p6039
sg10
I23
sg11
Vintellectual impairment
p6040
sg13
I2
sasa(dp6041
g2
VIn comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29.
p6042
sg4
(lp6043
(dp6044
g7
I171
sg8
g9
sg10
I5
sg11
VIL-29
p6045
sg13
I1
sasg24
(lp6046
(dp6047
g7
I65
sg27
VC0023895
p6048
sg10
I14
sg11
Vdisease, liver
p6049
sg13
I2
sasa(dp6050
g2
VHere, we demonstrate a key regulatory role of IL-28A in T-cell-mediated hepatitis.
p6051
sg4
(lp6052
sg24
(lp6053
(dp6054
g7
I72
sg27
VC0019159
p6055
sg10
I9
sg11
Vhepatitis
p6056
sg13
I1
sasa(dp6057
g2
VIL-28A induced TH1 cytokine production by CD4+ T lymphocytes in a T-bet-dependent manner and was up-regulated in a murine model of T-cell-mediated hepatitis upon Con A administration.
p6058
sg4
(lp6059
(dp6060
g7
I42
sg8
VP01730
p6061
sg10
I4
sg11
VCD4+
p6062
sg13
I1
sa(dp6063
g7
I15
sg8
VP13236
p6064
sg10
I12
sg11
VTH1 cytokine
p6065
sg13
I2
sasg24
(lp6066
(dp6067
g7
I147
sg27
VC0019159
p6068
sg10
I9
sg11
Vhepatitis
p6069
sg13
I1
sasa(dp6070
g2
VIn addition, IL-28A-transgenic mice showed markedly augmented Con A-induced hepatitis with up-regulated interferon-gamma cytokine production, as compared with wild-type mice.
p6071
sg4
(lp6072
(dp6073
g7
I104
sg8
VP01579
p6074
sg10
I16
sg11
Vinterferon-gamma
p6075
sg13
I1
sasg24
(lp6076
(dp6077
g7
I76
sg27
VC0019159
p6078
sg10
I9
sg11
Vhepatitis
p6079
sg13
I1
sasa(dp6080
g2
VIn addition, in vivo blockade of interferon-gamma but not IL-4 suppressed augmented liver inflammation in transgenic mice, suggesting that IL-28A induces the T-bet signaling pathway in T-cell-induced hepatitis.
p6081
sg4
(lp6082
(dp6083
g7
I58
sg8
VP05112
p6084
sg10
I4
sg11
VIL-4
p6085
sg13
I1
sa(dp6086
g7
I158
sg8
g9
sg10
I5
sg11
VT-bet
p6087
sg13
I1
sa(dp6088
g7
I33
sg8
VP01579
p6089
sg10
I16
sg11
Vinterferon-gamma
p6090
sg13
I1
sasg24
(lp6091
(dp6092
g7
I90
sg27
VC0021368
p6093
sg10
I12
sg11
Vinflammation
p6094
sg13
I1
sa(dp6095
g7
I200
sg27
VC0019159
p6096
sg10
I9
sg11
Vhepatitis
p6097
sg13
I1
sasa(dp6098
g2
VThus, targeting of IL-28A represents a potential novel approach for therapy of Th1-mediated inflammatory diseases such as T-cell-mediated hepatitis.
p6099
sg4
(lp6100
sg24
(lp6101
(dp6102
g7
I138
sg27
VC0019159
p6103
sg10
I9
sg11
Vhepatitis
p6104
sg13
I1
sasa(dp6105
g2
VThe present study therefore indicated that NOD receptor and TLR9 may modulate the inflammatory response and further impact upon intestinal injury of SAP, via the regulation of NF-KB expression and the oxidation/antioxidation balance, suggesting therapeutically targeting NOD receptor and TLR9 might be a useful approach for the treatment of severe acute pancreatitis.
p6106
sg4
(lp6107
(dp6108
g7
I60
sg8
g9
sg10
I4
sg11
VTLR9
p6109
sg13
I1
sa(dp6110
g7
I60
sg8
g9
sg10
I4
sg11
VTLR9
p6111
sg13
I1
sa(dp6112
g7
I43
sg8
VP54259
p6113
sg10
I12
sg11
VNOD receptor
p6114
sg13
I2
sa(dp6115
g7
I43
sg8
VP54259
p6116
sg10
I12
sg11
VNOD receptor
p6117
sg13
I2
sasg24
(lp6118
(dp6119
g7
I82
sg27
VC1155266
p6120
sg10
I21
sg11
Vinflammatory response
p6121
sg13
I2
sa(dp6122
g7
I43
sg27
VC0751781
p6123
sg10
I3
sg11
VNOD
p6124
sg13
I1
sa(dp6125
g7
I348
sg27
VC0001339
p6126
sg10
I18
sg11
Vacute pancreatitis
p6127
sg13
I2
sa(dp6128
g7
I43
sg27
VC0751781
p6129
sg10
I3
sg11
VNOD
p6130
sg13
I1
sasa(dp6131
g2
VIt also has efficacy in limiting TLR9-mediated sterile inflammation in in vivo models of acute liver injury and acute pancreatitis.
p6132
sg4
(lp6133
(dp6134
g7
I33
sg8
g9
sg10
I4
sg11
VTLR9
p6135
sg13
I1
sasg24
(lp6136
(dp6137
g7
I47
sg27
VC0678108
p6138
sg10
I7
sg11
Vsterile
p6139
sg13
I1
sa(dp6140
g7
I55
sg27
VC0021368
p6141
sg10
I12
sg11
Vinflammation
p6142
sg13
I1
sa(dp6143
g7
I112
sg27
VC0001339
p6144
sg10
I18
sg11
Vacute pancreatitis
p6145
sg13
I2
sasa(dp6146
g2
VGenetic deletion and pharmacologic antagonism demonstrate that specific DAMP receptors, including Toll-like receptor (TLR) 4, TLR9, and P2X7, are also required for inflammation in experimental acute pancreatitis.
p6147
sg4
(lp6148
(dp6149
g7
I63
sg8
g9
sg10
I23
sg11
Vspecific DAMP receptors
p6150
sg13
I3
sa(dp6151
g7
I98
sg8
g9
sg10
I26
sg11
VToll-like receptor (TLR) 4
p6152
sg13
I4
sa(dp6153
g7
I126
sg8
g9
sg10
I4
sg11
VTLR9
p6154
sg13
I1
sa(dp6155
g7
I136
sg8
g9
sg10
I4
sg11
VP2X7
p6156
sg13
I1
sasg24
(lp6157
(dp6158
g7
I164
sg27
VC0021368
p6159
sg10
I12
sg11
Vinflammation
p6160
sg13
I1
sa(dp6161
g7
I193
sg27
VC0001339
p6162
sg10
I18
sg11
Vacute pancreatitis
p6163
sg13
I2
sasa(dp6164
g2
VAcute pancreatitis was induced by caerulein stimulation in wild-type mice and mice deficient in components of the inflammasome (apoptosis-associated speck-like protein containing a caspase recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor P2X(7).
p6165
sg4
(lp6166
(dp6167
g7
I256
sg8
g9
sg10
I4
sg11
VTLR9
p6168
sg13
I1
sa(dp6169
g7
I270
sg8
VP51575
p6170
sg10
I26
sg11
Vpurinergic receptor P2X(7)
p6171
sg13
I3
sa(dp6172
g7
I234
sg8
g9
sg10
I20
sg11
VToll-like receptor 9
p6173
sg13
I3
sa(dp6174
g7
I181
sg8
VP39880
p6175
sg10
I7
sg11
Vcaspase
p6176
sg13
I1
sa(dp6177
g7
I222
sg8
VP29466
p6178
sg10
I9
sg11
Vcaspase-1
p6179
sg13
I1
sasg24
(lp6180
(dp6181
g7
I189
sg27
VC0271510
p6182
sg10
I11
sg11
Vrecruitment
p6183
sg13
I1
sa(dp6184
g7
I0
sg27
VC0001339
p6185
sg10
I18
sg11
VAcute pancreatitis
p6186
sg13
I2
sasa(dp6187
g2
VAdditionally, wild-type mice were pretreated with a TLR9 antagonist before induction of acute pancreatitis by caerulein or retrograde bile duct infusion of taurolithocholic acid 3-sulfate.
p6188
sg4
(lp6189
(dp6190
g7
I52
sg8
g9
sg10
I4
sg11
VTLR9
p6191
sg13
I1
sasg24
(lp6192
(dp6193
g7
I88
sg27
VC0001339
p6194
sg10
I18
sg11
Vacute pancreatitis
p6195
sg13
I2
sasa(dp6196
g2
VTLR9 and P2X(7) are important DAMP receptors upstream of inflammasome activation, and their antagonism could provide a new therapeutic strategy for treating acute pancreatitis.
p6197
sg4
(lp6198
(dp6199
g7
I0
sg8
g9
sg10
I4
sg11
VTLR9
p6200
sg13
I1
sa(dp6201
g7
I9
sg8
VP51575
p6202
sg10
I6
sg11
VP2X(7)
p6203
sg13
I1
sasg24
(lp6204
(dp6205
g7
I157
sg27
VC0001339
p6206
sg10
I18
sg11
Vacute pancreatitis
p6207
sg13
I2
sasa(dp6208
g2
VWe are currently screening the 113 candidate DFNB79 genes for mutations and have excluded CACNA1B, EDF1, PTGDS, EHMT1, QSOX2, NOTCH1, MIR126 and MIR602.
p6209
sg4
(lp6210
(dp6211
g7
I112
sg8
g9
sg10
I5
sg11
VEHMT1
p6212
sg13
I1
sa(dp6213
g7
I90
sg8
g9
sg10
I7
sg11
VCACNA1B
p6214
sg13
I1
sa(dp6215
g7
I119
sg8
g9
sg10
I5
sg11
VQSOX2
p6216
sg13
I1
sa(dp6217
g7
I99
sg8
g9
sg10
I4
sg11
VEDF1
p6218
sg13
I1
sa(dp6219
g7
I45
sg8
g9
sg10
I12
sg11
VDFNB79 genes
p6220
sg13
I2
sa(dp6221
g7
I126
sg8
VP46531
p6222
sg10
I6
sg11
VNOTCH1
p6223
sg13
I1
sa(dp6224
g7
I105
sg8
VP41222
p6225
sg10
I5
sg11
VPTGDS
p6226
sg13
I1
sasg24
(lp6227
(dp6228
g7
I45
sg27
VC2750082
p6229
sg10
I6
sg11
VDFNB79
p6230
sg13
I1
sasa(dp6231
g2
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p6232
sg4
(lp6233
(dp6234
g7
I79
sg8
VP22083
p6235
sg10
I4
sg11
VCD15
p6236
sg13
I1
sa(dp6237
g7
I194
sg8
VP04198
p6238
sg10
I12
sg11
VNMYC protein
p6239
sg13
I2
sa(dp6240
g7
I17
sg8
VP18075
p6241
sg10
I29
sg11
Vmorphogenetic protein (BMP)-4
p6242
sg13
I3
sa(dp6243
g7
I85
sg8
VP61073
p6244
sg10
I5
sg11
VCD184
p6245
sg13
I1
sasg24
(lp6246
(dp6247
g7
I92
sg27
VC0027819
p6248
sg10
I13
sg11
Vneuroblastoma
p6249
sg13
I1
sasa(dp6250
g2
VRecent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.
p6251
sg4
(lp6252
(dp6253
g7
I29
sg8
VP51679
p6254
sg10
I32
sg11
VC-X-C motif chemokine receptor 4
p6255
sg13
I5
sa(dp6256
g7
I119
sg8
VP48061
p6257
sg10
I6
sg11
VCXCL12
p6258
sg13
I1
sa(dp6259
g7
I63
sg8
VP61073
p6260
sg10
I5
sg11
VCXCR4
p6261
sg13
I1
sa(dp6262
g7
I86
sg8
VP55773
p6263
sg10
I31
sg11
VC-X-C motif chemokine ligand 12
p6264
sg13
I5
sa(dp6265
g7
I186
sg8
VP24385
p6266
sg10
I9
sg11
VCyclin D1
p6267
sg13
I2
sasg24
(lp6268
(dp6269
g7
I230
sg27
VC0751690
p6270
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p6271
sg13
I5
sa(dp6272
g7
I199
sg27
VC0027831
p6273
sg10
I19
sg11
Vneurofibromatosis 1
p6274
sg13
I2
sa(dp6275
g7
I302
sg27
VC0334094
p6276
sg10
I13
sg11
Vproliferation
p6277
sg13
I1
sa(dp6278
g7
I271
sg27
VC0751690
p6279
sg10
I5
sg11
VMPNST
p6280
sg13
I1
sasa(dp6281
g2
VWestern blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.
p6282
sg4
(lp6283
(dp6284
g7
I58
sg8
VP61073
p6285
sg10
I14
sg11
VCXCR4 isoforms
p6286
sg13
I2
sasg24
(lp6287
(dp6288
g7
I76
sg27
VC0027819
p6289
sg10
I13
sg11
Vneuroblastoma
p6290
sg13
I1
sasa(dp6291
g2
VOur data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.
p6292
sg4
(lp6293
(dp6294
g7
I81
sg8
VP61073
p6295
sg10
I20
sg11
V47 kDa CXCR4 isoform
p6296
sg13
I4
sasg24
(lp6297
(dp6298
g7
I132
sg27
VC0027819
p6299
sg10
I13
sg11
Vneuroblastoma
p6300
sg13
I1
sa(dp6301
g7
I106
sg27
VC2699153
p6302
sg10
I8
sg11
Vinvasion
p6303
sg13
I1
sasa(dp6304
g2
VIn this study, we investigated the role of NF-KB signaling pathway in the regulation of CXC chemokine receptor-4 (CXCR4) in neuroblastoma metastasis.
p6305
sg4
(lp6306
(dp6307
g7
I114
sg8
VP61073
p6308
sg10
I5
sg11
VCXCR4
p6309
sg13
I1
sa(dp6310
g7
I88
sg8
VP61073
p6311
sg10
I24
sg11
VCXC chemokine receptor-4
p6312
sg13
I3
sasg24
(lp6313
(dp6314
g7
I124
sg27
VC0027819
p6315
sg10
I13
sg11
Vneuroblastoma
p6316
sg13
I1
sa(dp6317
g7
I138
sg27
VC0027627
p6318
sg10
I10
sg11
Vmetastasis
p6319
sg13
I1
sasa(dp6320
g2
VTargeting NF-KB signalling pathways and ultimately CXCR4 could be a strategy in neuroblastoma therapy.
p6321
sg4
(lp6322
(dp6323
g7
I51
sg8
VP61073
p6324
sg10
I5
sg11
VCXCR4
p6325
sg13
I1
sasg24
(lp6326
(dp6327
g7
I80
sg27
VC0027819
p6328
sg10
I13
sg11
Vneuroblastoma
p6329
sg13
I1
sasa(dp6330
g2
VThe FAM3C interleukin-like epithelial-to-mesenchymal-transition (EMT) inducer (ILEI) has been shown to be strongly up-regulated in several cancers and to be essential for tumor formation and metastasis in epithelial cells, correlating with a significant decrease in overall survival in colon and breast cancer patients.
p6331
sg4
(lp6332
(dp6333
g7
I79
sg8
g9
sg10
I4
sg11
VILEI
p6334
sg13
I1
sa(dp6335
g7
I4
sg8
g9
sg10
I5
sg11
VFAM3C
p6336
sg13
I1
sa(dp6337
g7
I10
sg8
VP60568
p6338
sg10
I16
sg11
Vinterleukin-like
p6339
sg13
I1
sasg24
(lp6340
(dp6341
g7
I139
sg27
VC0006826
p6342
sg10
I7
sg11
Vcancers
p6343
sg13
I1
sa(dp6344
g7
I296
sg27
VC0678222
p6345
sg10
I13
sg11
Vbreast cancer
p6346
sg13
I2
sa(dp6347
g7
I171
sg27
VC0027651
p6348
sg10
I5
sg11
Vtumor
p6349
sg13
I1
sa(dp6350
g7
I53
sg27
VC0599156
p6351
sg10
I10
sg11
Vtransition
p6352
sg13
I1
sa(dp6353
g7
I191
sg27
VC0027627
p6354
sg10
I10
sg11
Vmetastasis
p6355
sg13
I1
sasa(dp6356
g2
VInterleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor survival in human breast cancer.
p6357
sg4
(lp6358
(dp6359
g7
I0
sg8
VP60568
p6360
sg10
I16
sg11
VInterleukin-like
p6361
sg13
I1
sasg24
(lp6362
(dp6363
g7
I237
sg27
VC0678222
p6364
sg10
I13
sg11
Vbreast cancer
p6365
sg13
I2
sa(dp6366
g7
I97
sg27
VC0178874
p6367
sg10
I17
sg11
Vtumor progression
p6368
sg13
I2
sa(dp6369
g7
I43
sg27
VC0599156
p6370
sg10
I10
sg11
Vtransition
p6371
sg13
I1
sa(dp6372
g7
I146
sg27
VC0006826
p6373
sg10
I7
sg11
Vcancers
p6374
sg13
I1
sasa(dp6375
g2
VMurine mammary tumor and metastasis models of EpC40 and 4T1 cells overexpressing different mutant forms of ILEI were used-extended with in vivo aprotinin treatment for the inhibition of ILEI-processing proteases-to test the in vivo relevance of proteolytic cleavage.
p6376
sg4
(lp6377
(dp6378
g7
I107
sg8
g9
sg10
I4
sg11
VILEI
p6379
sg13
I1
sa(dp6380
g7
I107
sg8
g9
sg10
I4
sg11
VILEI
p6381
sg13
I1
sasg24
(lp6382
(dp6383
g7
I25
sg27
VC0027627
p6384
sg10
I10
sg11
Vmetastasis
p6385
sg13
I1
sa(dp6386
g7
I91
sg27
VC0596988
p6387
sg10
I6
sg11
Vmutant
p6388
sg13
I1
sa(dp6389
g7
I7
sg27
VC1458155
p6390
sg10
I13
sg11
Vmammary tumor
p6391
sg13
I2
sasa(dp6392
g2
VImmunohistochemistry for ILEI localization and uPAR expression was performed on two human breast cancer arrays, and ILEI and uPAR scores were correlated with the metastasis-free survival of patients.
p6393
sg4
(lp6394
(dp6395
g7
I25
sg8
g9
sg10
I4
sg11
VILEI
p6396
sg13
I1
sa(dp6397
g7
I25
sg8
g9
sg10
I4
sg11
VILEI
p6398
sg13
I1
sasg24
(lp6399
(dp6400
g7
I162
sg27
VC0027627
p6401
sg10
I10
sg11
Vmetastasis
p6402
sg13
I1
sa(dp6403
g7
I90
sg27
VC0678222
p6404
sg10
I13
sg11
Vbreast cancer
p6405
sg13
I2
sasa(dp6406
g2
VMoreover, altered subcellular ILEI localization strongly correlates with high tumor cell-associated uPAR protein expression, as well as with poor survival, in human breast cancer.
p6407
sg4
(lp6408
sg24
(lp6409
(dp6410
g7
I78
sg27
VC0027651
p6411
sg10
I5
sg11
Vtumor
p6412
sg13
I1
sa(dp6413
g7
I165
sg27
VC0678222
p6414
sg10
I13
sg11
Vbreast cancer
p6415
sg13
I2
sasa(dp6416
g2
VOur findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer.
p6417
sg4
(lp6418
(dp6419
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6420
sg13
I1
sa(dp6421
g7
I23
sg8
VP30740
p6422
sg10
I30
sg11
Vextracellular serine proteases
p6423
sg13
I3
sa(dp6424
g7
I69
sg8
VP00747
p6425
sg10
I7
sg11
Vplasmin
p6426
sg13
I1
sa(dp6427
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6428
sg13
I1
sa(dp6429
g7
I127
sg8
g9
sg10
I4
sg11
VILEI
p6430
sg13
I1
sasg24
(lp6431
(dp6432
g7
I139
sg27
VC0178874
p6433
sg10
I17
sg11
Vtumor progression
p6434
sg13
I2
sa(dp6435
g7
I267
sg27
VC0678222
p6436
sg10
I13
sg11
Vbreast cancer
p6437
sg13
I2
sasa(dp6438
g2
VILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
p6439
sg4
(lp6440
(dp6441
g7
I134
sg8
g9
sg10
I3
sg11
VEMT
p6442
sg13
I1
sa(dp6443
g7
I0
sg8
g9
sg10
I4
sg11
VILEI
p6444
sg13
I1
sasg24
(lp6445
(dp6446
g7
I139
sg27
VC0027627
p6447
sg10
I10
sg11
Vmetastasis
p6448
sg13
I1
sa(dp6449
g7
I125
sg27
VC2699153
p6450
sg10
I8
sg11
Vinvasion
p6451
sg13
I1
sa(dp6452
g7
I85
sg27
VC0027651
p6453
sg10
I6
sg11
Vtumors
p6454
sg13
I1
sa(dp6455
g7
I193
sg27
VC0678222
p6456
sg10
I13
sg11
Vbreast cancer
p6457
sg13
I2
sasa(dp6458
g2
VKeeping in view the fact that molecular basis of Burkitt's lymphoma (BL) is poorly understood, we attempted to explore the small interfering RNA (siRNA) mediated c-myc gene regulation using BL-derived EB-3 cell line as archetype cellular model.
p6459
sg4
(lp6460
(dp6461
g7
I162
sg8
VP12524
p6462
sg10
I10
sg11
Vc-myc gene
p6463
sg13
I2
sasg24
(lp6464
(dp6465
g7
I49
sg27
VC0006413
p6466
sg10
I18
sg11
VBurkitt's lymphoma
p6467
sg13
I2
sa(dp6468
g7
I69
sg27
VC0006413
p6469
sg10
I2
sg11
VBL
p6470
sg13
I1
sa(dp6471
g7
I69
sg27
VC0006413
p6472
sg10
I2
sg11
VBL
p6473
sg13
I1
sasa(dp6474
g2
VWith other procedures, as anti-complement immunoperoxidase (ACIP) and anti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen (EBNA) was detected precisely in EB3, Jijoye and Raji lymphocytes using anti-EBNA antibodies from patients with nasopharyngeal carcinoma or Burkitt lymphoma, in dilution 1:10-1:5120.
p6475
sg4
(lp6476
(dp6477
g7
I169
sg8
g9
sg10
I3
sg11
VEB3
p6478
sg13
I1
sa(dp6479
g7
I60
sg8
g9
sg10
I4
sg11
VACIP
p6480
sg13
I1
sa(dp6481
g7
I26
sg8
g9
sg10
I32
sg11
Vanti-complement immunoperoxidase
p6482
sg13
I2
sa(dp6483
g7
I70
sg8
VP14209
p6484
sg10
I65
sg11
Vanti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen
p6485
sg13
I7
sasg24
(lp6486
(dp6487
g7
I248
sg27
VC2931822
p6488
sg10
I24
sg11
Vnasopharyngeal carcinoma
p6489
sg13
I2
sa(dp6490
g7
I276
sg27
VC0006413
p6491
sg10
I16
sg11
VBurkitt lymphoma
p6492
sg13
I2
sasa(dp6493
g2
VThe virus in the EB-3 cell line derived from a Burkitt lymphoma was partially purified by digestion with proteolytic enzyme and by density-gradient centrifugation on potassium tartrate.
p6494
sg4
(lp6495
sg24
(lp6496
(dp6497
g7
I47
sg27
VC0006413
p6498
sg10
I16
sg11
VBurkitt lymphoma
p6499
sg13
I2
sasa(dp6500
g2
VThis conjugate proved to be a potent cytotoxin for surface Ig positive Burkitt lymphoma EB-3 cells, growing in vitro and produced 50% inhibition of protein synthesis at level of 1.4 x 10(-9) M. When tested for cytotoxic action on target cells, the composite conjugate molecule was at least 100 times more effective than antibodies alone, ricin A-chain alone or a conjugate ricin A-chain--normal rabbit IgG.
p6501
sg4
(lp6502
(dp6503
g7
I395
sg8
g9
sg10
I10
sg11
Vrabbit IgG
p6504
sg13
I2
sa(dp6505
g7
I338
sg8
g9
sg10
I13
sg11
Vricin A-chain
p6506
sg13
I2
sasg24
(lp6507
(dp6508
g7
I71
sg27
VC0006413
p6509
sg10
I16
sg11
VBurkitt lymphoma
p6510
sg13
I2
sasa(dp6511
g2
VThe interaction of poly- and monoclonal antibodies against the L-chain of human Ig with Burkitt lymphoma EB-3 cells was studied using a fluorescent lipid probe, anthrylvinyl-labelled sphingomyelin, incorporated into the cell plasma membrane.
p6512
sg4
(lp6513
sg24
(lp6514
(dp6515
g7
I88
sg27
VC0006413
p6516
sg10
I16
sg11
VBurkitt lymphoma
p6517
sg13
I2
sasa(dp6518
g2
VThe only gangliosides in Burkitt's lymphoma EB-3 cells is GM3.
p6519
sg4
(lp6520
sg24
(lp6521
(dp6522
g7
I25
sg27
VC0006413
p6523
sg10
I18
sg11
VBurkitt's lymphoma
p6524
sg13
I2
sasa(dp6525
g2
VTreatment of Burkitt's lymphoma EB-3 cells with gangliosides GM1 or GM3 results in their binding to and partial incorporation into the cell membrane.
p6526
sg4
(lp6527
sg24
(lp6528
(dp6529
g7
I13
sg27
VC0006413
p6530
sg10
I18
sg11
VBurkitt's lymphoma
p6531
sg13
I2
sasa(dp6532
g2
VWe sought to investigate the renoprotection of CIRP in a rat model of deep hypothermic circulatory arrest.
p6533
sg4
(lp6534
(dp6535
g7
I47
sg8
g9
sg10
I4
sg11
VCIRP
p6536
sg13
I1
sasg24
(lp6537
(dp6538
g7
I87
sg27
VC0444720
p6539
sg10
I18
sg11
Vcirculatory arrest
p6540
sg13
I2
sasa(dp6541
g2
VOverexpression and knockdown of CIRP were achieved in vivo by directly injecting lentivirus vectors containing packaging lentivirus (pL)/internal ribosome entry site (IRES)/green fluorescent protein (GFP)-CIRP or pL/short hairpin RNA (shRNA)/F-cold inducible RNA binding protein (F-CIRP)-A into the renal parenchyma of rats 7 days before deep hypothermic circulatory arrest under the ultrasound guidance.
p6542
sg4
(lp6543
(dp6544
g7
I173
sg8
g9
sg10
I25
sg11
Vgreen fluorescent protein
p6545
sg13
I3
sa(dp6546
g7
I241
sg8
g9
sg10
I37
sg11
V/F-cold inducible RNA binding protein
p6547
sg13
I5
sa(dp6548
g7
I280
sg8
g9
sg10
I6
sg11
VF-CIRP
p6549
sg13
I1
sa(dp6550
g7
I32
sg8
g9
sg10
I4
sg11
VCIRP
p6551
sg13
I1
sasg24
(lp6552
(dp6553
g7
I244
sg27
VC0024117
p6554
sg10
I4
sg11
Vcold
p6555
sg13
I1
sa(dp6556
g7
I355
sg27
VC0444720
p6557
sg10
I18
sg11
Vcirculatory arrest
p6558
sg13
I2
sasa(dp6559
g2
VOur findings suggest that the CIRP exerts a robust renoprotective effect by inhibiting apoptosis in the rat model of deep hypothermic circulatory arrest.
p6560
sg4
(lp6561
(dp6562
g7
I30
sg8
g9
sg10
I4
sg11
VCIRP
p6563
sg13
I1
sasg24
(lp6564
(dp6565
g7
I134
sg27
VC0444720
p6566
sg10
I18
sg11
Vcirculatory arrest
p6567
sg13
I2
sasa(dp6568
g2
VCompared with baseline, rats resuscitated from cardiac arrest showed increased expression of CIRP, Bax, Caspase 9, and Caspase 3 and decreased expression of Bcl-2 in hippocampus (P &lt; 0.05).
p6569
sg4
(lp6570
(dp6571
g7
I157
sg8
VP10415
p6572
sg10
I5
sg11
VBcl-2
p6573
sg13
I1
sa(dp6574
g7
I119
sg8
VP42574
p6575
sg10
I9
sg11
VCaspase 3
p6576
sg13
I2
sa(dp6577
g7
I93
sg8
g9
sg10
I4
sg11
VCIRP
p6578
sg13
I1
sa(dp6579
g7
I104
sg8
VP55211
p6580
sg10
I9
sg11
VCaspase 9
p6581
sg13
I2
sasg24
(lp6582
(dp6583
g7
I47
sg27
VC0018790
p6584
sg10
I14
sg11
Vcardiac arrest
p6585
sg13
I2
sasa(dp6586
g2
VOur findings suggest that 32 C therapeutic hypothermia exerts an important neuroprotective effects by up-regulating CIRP expression and inhibiting mitochondrial apoptosis factor production in the cardiac arrest rat model.
p6587
sg4
(lp6588
(dp6589
g7
I116
sg8
g9
sg10
I4
sg11
VCIRP
p6590
sg13
I1
sasg24
(lp6591
(dp6592
g7
I196
sg27
VC0018790
p6593
sg10
I14
sg11
Vcardiac arrest
p6594
sg13
I2
sasa(dp6595
g2
VA previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.
p6596
sg4
(lp6597
(dp6598
g7
I74
sg8
g9
sg10
I5
sg11
VVGLL3
p6599
sg13
I1
sa(dp6600
g7
I59
sg8
VP17936
p6601
sg10
I6
sg11
VIGFBP3
p6602
sg13
I1
sasg24
(lp6603
(dp6604
g7
I194
sg27
VC0600139
p6605
sg10
I15
sg11
Vprostate cancer
p6606
sg13
I2
sa(dp6607
g7
I267
sg27
VC0700198
p6608
sg10
I10
sg11
VAspiration
p6609
sg13
I1
sa(dp6610
g7
I152
sg27
VC0006826
p6611
sg10
I6
sg11
Vcancer
p6612
sg13
I1
sasa(dp6613
g2
VMultiple biopsy samples from 43 patients were evaluated using a previously reported gene signature of IGFBP3, F3 and VGLL3 with potential prognostic value in estimating overall survival at diagnosis of prostate cancer.
p6614
sg4
(lp6615
(dp6616
g7
I117
sg8
g9
sg10
I5
sg11
VVGLL3
p6617
sg13
I1
sa(dp6618
g7
I102
sg8
VP17936
p6619
sg10
I6
sg11
VIGFBP3
p6620
sg13
I1
sasg24
(lp6621
(dp6622
g7
I202
sg27
VC0600139
p6623
sg10
I15
sg11
Vprostate cancer
p6624
sg13
I2
sasa(dp6625
g2
VThe gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-containing tissue representing the primary and secondary Gleason patterns were high and consistent, while the low expressed VGLL3 showed more variation in its expression levels.
p6626
sg4
(lp6627
(dp6628
g7
I203
sg8
g9
sg10
I5
sg11
VVGLL3
p6629
sg13
I1
sa(dp6630
g7
I30
sg8
VP17936
p6631
sg10
I6
sg11
VIGFBP3
p6632
sg13
I1
sasg24
(lp6633
(dp6634
g7
I47
sg27
VC0600139
p6635
sg10
I15
sg11
Vprostate cancer
p6636
sg13
I2
sasa(dp6637
g2
VPrevious studies have implicated vestigial like 3 (VGLL3), a chromosome 3p12.3 gene that encodes a putative transcription co-factor, as a candidate tumor suppressor gene (TSG) in high-grade serous ovarian carcinomas (HGSC), the most common type of epithelial ovarian cancer.
p6638
sg4
(lp6639
(dp6640
g7
I171
sg8
g9
sg10
I3
sg11
VTSG
p6641
sg13
I1
sa(dp6642
g7
I33
sg8
g9
sg10
I16
sg11
Vvestigial like 3
p6643
sg13
I3
sa(dp6644
g7
I148
sg8
VP25054
p6645
sg10
I21
sg11
Vtumor suppressor gene
p6646
sg13
I3
sa(dp6647
g7
I51
sg8
g9
sg10
I5
sg11
VVGLL3
p6648
sg13
I1
sasg24
(lp6649
(dp6650
g7
I248
sg27
VC0677886
p6651
sg10
I25
sg11
Vepithelial ovarian cancer
p6652
sg13
I3
sa(dp6653
g7
I148
sg27
VC0027651
p6654
sg10
I5
sg11
Vtumor
p6655
sg13
I1
sa(dp6656
g7
I197
sg27
VC0029925
p6657
sg10
I18
sg11
Vovarian carcinomas
p6658
sg13
I2
sasa(dp6659
g2
VA complementation analysis based on microcell-mediated chromosome transfer (MMCT) using a centric fragment of chromosome 3 (der3p12-q12.1) into the OV-90 ovarian cancer cell line haploinsufficient for 3p and lacking VGLL3 expression was performed to assess the effect on tumorigenic potential and growth characteristics.
p6660
sg4
(lp6661
(dp6662
g7
I216
sg8
g9
sg10
I5
sg11
VVGLL3
p6663
sg13
I1
sasg24
(lp6664
(dp6665
g7
I154
sg27
VC1140680
p6666
sg10
I14
sg11
Vovarian cancer
p6667
sg13
I2
sasa(dp6668
g2
VInterestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
p6669
sg4
(lp6670
(dp6671
g7
I44
sg8
g9
sg10
I6
sg11
VZNF654
p6672
sg13
I1
sa(dp6673
g7
I34
sg8
g9
sg10
I5
sg11
VVGLL3
p6674
sg13
I1
sasg24
(lp6675
(dp6676
g7
I68
sg27
VC1140680
p6677
sg10
I23
sg11
Vmalignant ovarian tumor
p6678
sg13
I3
sa(dp6679
g7
I180
sg27
VC0004997
p6680
sg10
I21
sg11
Vbenign ovarian tumors
p6681
sg13
I3
sasa(dp6682
g2
VWe tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers.
p6683
sg4
(lp6684
(dp6685
g7
I90
sg8
VP56524
p6686
sg10
I4
sg11
VHDAC
p6687
sg13
I1
sa(dp6688
g7
I29
sg8
VP45985
p6689
sg10
I3
sg11
VMEK
p6690
sg13
I1
sa(dp6691
g7
I56
sg8
g9
sg10
I3
sg11
VAkt
p6692
sg13
I1
sasg24
(lp6693
(dp6694
g7
I206
sg27
VC0699791
p6695
sg10
I17
sg11
Vgastric carcinoma
p6696
sg13
I2
sa(dp6697
g7
I187
sg27
VC2239176
p6698
sg10
I17
sg11
Vhepatic carcinoma
p6699
sg13
I2
sa(dp6700
g7
I146
sg27
VC0006826
p6701
sg10
I6
sg11
Vcancer
p6702
sg13
I1
sa(dp6703
g7
I225
sg27
VC0699790
p6704
sg10
I15
sg11
Vcolon carcinoma
p6705
sg13
I2
sa(dp6706
g7
I177
sg27
VC0025202
p6707
sg10
I8
sg11
Vmelanoma
p6708
sg13
I1
sa(dp6709
g7
I264
sg27
VC0153633
p6710
sg10
I13
sg11
Vbrain cancers
p6711
sg13
I2
sa(dp6712
g7
I242
sg27
VC0678222
p6713
sg10
I16
sg11
Vbreast carcinoma
p6714
sg13
I2
sasa(dp6715
g2
VHere, we report that escape of human T-cell acute lymphoblastic leukemia (T-ALL) cells or colorectal cancer cells from dormancy is associated with Dll4 expression in the tumor microenvironment and increased Notch3 signaling in tumor cells.
p6716
sg4
(lp6717
(dp6718
g7
I207
sg8
g9
sg10
I6
sg11
VNotch3
p6719
sg13
I1
sa(dp6720
g7
I147
sg8
g9
sg10
I4
sg11
VDll4
p6721
sg13
I1
sasg24
(lp6722
(dp6723
g7
I170
sg27
VC0027651
p6724
sg10
I5
sg11
Vtumor
p6725
sg13
I1
sa(dp6726
g7
I37
sg27
VC1961099
p6727
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p6728
sg13
I4
sa(dp6729
g7
I170
sg27
VC0027651
p6730
sg10
I5
sg11
Vtumor
p6731
sg13
I1
sa(dp6732
g7
I90
sg27
VC1527249
p6733
sg10
I17
sg11
Vcolorectal cancer
p6734
sg13
I2
sa(dp6735
g7
I74
sg27
VC1961099
p6736
sg10
I5
sg11
VT-ALL
p6737
sg13
I1
sasa(dp6738
g2
VAPOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
p6739
sg4
(lp6740
(dp6741
g7
I0
sg8
VP41238
p6742
sg10
I7
sg11
VAPOBEC1
p6743
sg13
I1
sasg24
(lp6744
(dp6745
g7
I142
sg27
VC0012634
p6746
sg10
I9
sg11
Vcondition
p6747
sg13
I1
sa(dp6748
g7
I74
sg27
VC0596263
p6749
sg10
I14
sg11
Vcarcinogenesis
p6750
sg13
I1
sa(dp6751
g7
I29
sg27
VC0006826
p6752
sg10
I6
sg11
Vcancer
p6753
sg13
I1
sa(dp6754
g7
I174
sg27
VC0279628
p6755
sg10
I25
sg11
Vesophageal adenocarcinoma
p6756
sg13
I2
sa(dp6757
g7
I119
sg27
VC0004763
p6758
sg10
I19
sg11
VBarrett's esophagus
p6759
sg13
I2
sasa(dp6760
g2
VThe differential diagnosis includes Klippel-Trenaunay-Weber syndrome, neurofibromatosis, Milroy disease, and Proteus syndrome.
p6761
sg4
(lp6762
sg24
(lp6763
(dp6764
g7
I109
sg27
VC0085261
p6765
sg10
I16
sg11
VProteus syndrome
p6766
sg13
I2
sa(dp6767
g7
I60
sg27
VC0162678
p6768
sg10
I27
sg11
Vsyndrome, neurofibromatosis
p6769
sg13
I2
sa(dp6770
g7
I89
sg27
VC1704423
p6771
sg10
I14
sg11
VMilroy disease
p6772
sg13
I2
sa(dp6773
g7
I36
sg27
VC0022739
p6774
sg10
I32
sg11
VKlippel-Trenaunay-Weber syndrome
p6775
sg13
I2
sasa(dp6776
g2
VNotably, new experimental data have shown protective immune responses of bee venom group III sPLA2 against a wide range of diseases including asthma, Parkinson's disease, and drug-induced organ inflammation.
p6777
sg4
(lp6778
sg24
(lp6779
(dp6780
g7
I194
sg27
VC0021368
p6781
sg10
I12
sg11
Vinflammation
p6782
sg13
I1
sa(dp6783
g7
I142
sg27
VC0004096
p6784
sg10
I6
sg11
Vasthma
p6785
sg13
I1
sa(dp6786
g7
I150
sg27
VC0030567
p6787
sg10
I19
sg11
VParkinson's disease
p6788
sg13
I2
sasa(dp6789
g2
VSnake venom are known containing PLA2s (svPLA2s) which exhibit a wide variety of pharmacological effects including neurotoxicity, cardiotoxicity, myotoxicity and hemorrhage.
p6790
sg4
(lp6791
(dp6792
g7
I33
sg8
VP04054
p6793
sg10
I5
sg11
VPLA2s
p6794
sg13
I1
sasg24
(lp6795
(dp6796
g7
I162
sg27
VC0019080
p6797
sg10
I10
sg11
Vhemorrhage
p6798
sg13
I1
sasa(dp6799
g2
VThis study was aimed to assess regulation of surface-membrane enzymes such as Delta-6-desaturase (FADS2), secretory Phospholipase A2(sPLA2) by hemp seed and evening primrose oils as well as Hot-natured dietary intervention in relapsing remitting multiple sclerosis (RRMS) patients.
p6800
sg4
(lp6801
(dp6802
g7
I78
sg8
g9
sg10
I18
sg11
VDelta-6-desaturase
p6803
sg13
I1
sa(dp6804
g7
I116
sg8
VP04054
p6805
sg10
I16
sg11
VPhospholipase A2
p6806
sg13
I2
sa(dp6807
g7
I133
sg8
VP14555
p6808
sg10
I5
sg11
VsPLA2
p6809
sg13
I1
sa(dp6810
g7
I98
sg8
g9
sg10
I5
sg11
VFADS2
p6811
sg13
I1
sasg24
(lp6812
(dp6813
g7
I266
sg27
VC0751967
p6814
sg10
I4
sg11
VRRMS
p6815
sg13
I1
sa(dp6816
g7
I226
sg27
VC0751967
p6817
sg10
I38
sg11
Vrelapsing remitting multiple sclerosis
p6818
sg13
I4
sasa(dp6819
g2
VPhospholipases A2 (PLA2s) are enzymes responsible for inflammatory effects, edema formation, myotoxicity, neurotoxicity and other manifestations from envenoming.
p6820
sg4
(lp6821
(dp6822
g7
I0
sg8
VP04054
p6823
sg10
I17
sg11
VPhospholipases A2
p6824
sg13
I2
sa(dp6825
g7
I19
sg8
VP04054
p6826
sg10
I5
sg11
VPLA2s
p6827
sg13
I1
sasg24
(lp6828
(dp6829
g7
I76
sg27
VC0013604
p6830
sg10
I5
sg11
Vedema
p6831
sg13
I1
sasa(dp6832
g2
VDefects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.
p6833
sg4
(lp6834
(dp6835
g7
I30
sg8
g9
sg10
I26
sg11
Vintegrin-binding protein 2
p6836
sg13
I3
sa(dp6837
g7
I11
sg8
g9
sg10
I4
sg11
VCIB2
p6838
sg13
I1
sasg24
(lp6839
(dp6840
g7
I116
sg27
VC0271097
p6841
sg10
I14
sg11
VUsher syndrome
p6842
sg13
I2
sa(dp6843
g7
I207
sg27
VC0456909
p6844
sg10
I9
sg11
Vblindness
p6845
sg13
I1
sa(dp6846
g7
I95
sg27
VC0011053
p6847
sg10
I8
sg11
Vdeafness
p6848
sg13
I1
sa(dp6849
g7
I105
sg27
VC1836199
p6850
sg10
I6
sg11
VDFNB48
p6851
sg13
I1
sa(dp6852
g7
I95
sg27
VC0011053
p6853
sg10
I8
sg11
Vdeafness
p6854
sg13
I1
sasa(dp6855
g2
VHere, we report that mutations in CIB2, which encodes a calcium- and integrin-binding protein, are associated with nonsyndromic deafness (DFNB48) and Usher syndrome type 1J (USH1J).
p6856
sg4
(lp6857
(dp6858
g7
I34
sg8
g9
sg10
I4
sg11
VCIB2
p6859
sg13
I1
sa(dp6860
g7
I69
sg8
g9
sg10
I24
sg11
Vintegrin-binding protein
p6861
sg13
I2
sasg24
(lp6862
(dp6863
g7
I150
sg27
VC0271097
p6864
sg10
I14
sg11
VUsher syndrome
p6865
sg13
I2
sa(dp6866
g7
I138
sg27
VC1836199
p6867
sg10
I6
sg11
VDFNB48
p6868
sg13
I1
sa(dp6869
g7
I128
sg27
VC0011053
p6870
sg10
I8
sg11
Vdeafness
p6871
sg13
I1
sasa(dp6872
g2
VIn polymyositis and inclusion body myositis, KIF4 cells were mainly located around individual muscle fibers, whereas in dermatomyositis, they were also near blood vessels.
p6873
sg4
(lp6874
(dp6875
g7
I45
sg8
g9
sg10
I4
sg11
VKIF4
p6876
sg13
I1
sasg24
(lp6877
(dp6878
g7
I3
sg27
VC0085655
p6879
sg10
I12
sg11
Vpolymyositis
p6880
sg13
I1
sa(dp6881
g7
I120
sg27
VC0221056
p6882
sg10
I15
sg11
Vdermatomyositis
p6883
sg13
I1
sa(dp6884
g7
I20
sg27
VC0238190
p6885
sg10
I23
sg11
Vinclusion body myositis
p6886
sg13
I3
sasa(dp6887
g2
VCD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin.
p6888
sg4
(lp6889
(dp6890
g7
I0
sg8
VP21926
p6891
sg10
I3
sg11
VCD9
p6892
sg13
I1
sasg24
(lp6893
(dp6894
g7
I123
sg27
VC0001511
p6895
sg10
I8
sg11
Vadhesion
p6896
sg13
I1
sa(dp6897
g7
I123
sg27
VC0001511
p6898
sg10
I8
sg11
Vadhesion
p6899
sg13
I1
sasa(dp6900
g2
VThe immunoprofiles of MOLP-6 and MOLP-7 correspond to that seen typically in primary MM cells: positive for cytoplasmic immunoglobulin (Ig) chains, a heavy and kappa light chains, CD9, CD28, CD40, CD44, CD45, CD56, and PCA-1; the cells were negative for surface Igs and various other B-cell, T-cell and myelomonocyte associated markers.
p6901
sg4
(lp6902
(dp6903
g7
I203
sg8
VP08575
p6904
sg10
I4
sg11
VCD45
p6905
sg13
I1
sa(dp6906
g7
I219
sg8
g9
sg10
I5
sg11
VPCA-1
p6907
sg13
I1
sa(dp6908
g7
I180
sg8
VP21926
p6909
sg10
I3
sg11
VCD9
p6910
sg13
I1
sa(dp6911
g7
I191
sg8
VP25942
p6912
sg10
I4
sg11
VCD40
p6913
sg13
I1
sa(dp6914
g7
I150
sg8
g9
sg10
I28
sg11
Vheavy and kappa light chains
p6915
sg13
I5
sa(dp6916
g7
I185
sg8
VP33681
p6917
sg10
I4
sg11
VCD28
p6918
sg13
I1
sa(dp6919
g7
I262
sg8
g9
sg10
I3
sg11
VIgs
p6920
sg13
I1
sa(dp6921
g7
I108
sg8
g9
sg10
I38
sg11
Vcytoplasmic immunoglobulin (Ig) chains
p6922
sg13
I4
sasg24
(lp6923
(dp6924
g7
I262
sg27
VC1306856
p6925
sg10
I3
sg11
VIgs
p6926
sg13
I1
sa(dp6927
g7
I219
sg27
VC0268398
p6928
sg10
I3
sg11
VPCA
p6929
sg13
I1
sasa(dp6930
g2
VThe univariate analysis showed that five parameters had an adverse effect on both complete remission (CR) and survival: advanced age (greater than 60 years), anemia (hemoglobin concentration (Hb) less than 10g/dl), the expression of the antigens detected by the anti-megakaryocytic antibodies (CDw41/CDw42), the monocytic antibodies (CD14), and the CD9 (FMC56, FMC8) antigen.
p6931
sg4
(lp6932
(dp6933
g7
I166
sg8
g9
sg10
I10
sg11
Vhemoglobin
p6934
sg13
I1
sa(dp6935
g7
I349
sg8
VP21926
p6936
sg10
I3
sg11
VCD9
p6937
sg13
I1
sa(dp6938
g7
I334
sg8
VP08571
p6939
sg10
I4
sg11
VCD14
p6940
sg13
I1
sasg24
(lp6941
(dp6942
g7
I59
sg27
VC0879626
p6943
sg10
I14
sg11
Vadverse effect
p6944
sg13
I2
sa(dp6945
g7
I158
sg27
VC0002871
p6946
sg10
I6
sg11
Vanemia
p6947
sg13
I1
sa(dp6948
g7
I91
sg27
VC0687702
p6949
sg10
I9
sg11
Vremission
p6950
sg13
I1
sasa(dp6951
g2
VIn this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).
p6952
sg4
(lp6953
(dp6954
g7
I382
sg8
VP61278
p6955
sg10
I12
sg11
Vsomatostatin
p6956
sg13
I1
sa(dp6957
g7
I370
sg8
VP06881
p6958
sg10
I10
sg11
Vcalcitonin
p6959
sg13
I1
sa(dp6960
g7
I400
sg8
VP01282
p6961
sg10
I3
sg11
VVIP
p6962
sg13
I1
sasg24
(lp6963
(dp6964
g7
I216
sg27
VC0020615
p6965
sg10
I13
sg11
Vhypoglycaemia
p6966
sg13
I1
sa(dp6967
g7
I176
sg27
VC0010481
p6968
sg10
I18
sg11
VCushing's syndrome
p6969
sg13
I2
sa(dp6970
g7
I204
sg27
VC0001206
p6971
sg10
I10
sg11
Vacromegaly
p6972
sg13
I1
sa(dp6973
g7
I84
sg27
VC0020437
p6974
sg10
I14
sg11
Vhypercalcaemia
p6975
sg13
I1
sa(dp6976
g7
I66
sg27
VC0039082
p6977
sg10
I9
sg11
Vsyndromes
p6978
sg13
I1
sa(dp6979
g7
I237
sg27
VC0027651
p6980
sg10
I7
sg11
Vtumours
p6981
sg13
I1
sa(dp6982
g7
I304
sg27
VC0018418
p6983
sg10
I13
sg11
Vgynaecomastia
p6984
sg13
I1
sasa(dp6985
g2
VProtrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).
p6986
sg4
(lp6987
(dp6988
g7
I138
sg8
g9
sg10
I5
sg11
VSPG31
p6989
sg13
I1
sa(dp6990
g7
I187
sg8
VP33176
p6991
sg10
I5
sg11
VKif5B
p6992
sg13
I1
sa(dp6993
g7
I146
sg8
g9
sg10
I5
sg11
VREEP5
p6994
sg13
I1
sa(dp6995
g7
I111
sg8
g9
sg10
I10
sg11
Vatlastin-1
p6996
sg13
I1
sa(dp6997
g7
I74
sg8
VP60201
p6998
sg10
I28
sg11
Vmyelin proteolipid protein 1
p6999
sg13
I4
sa(dp7000
g7
I43
sg8
g9
sg10
I20
sg11
VHSP-related proteins
p7001
sg13
I2
sa(dp7002
g7
I131
sg8
g9
sg10
I5
sg11
VREEP1
p7003
sg13
I1
sa(dp7004
g7
I179
sg8
g9
sg10
I5
sg11
VSPG10
p7005
sg13
I1
sa(dp7006
g7
I172
sg8
g9
sg10
I5
sg11
VKif5A
p7007
sg13
I1
sa(dp7008
g7
I123
sg8
g9
sg10
I5
sg11
VSPG3A
p7009
sg13
I1
sa(dp7010
g7
I131
sg8
g9
sg10
I5
sg11
VREEP1
p7011
sg13
I1
sa(dp7012
g7
I194
sg8
g9
sg10
I5
sg11
VKif5C
p7013
sg13
I1
sa(dp7014
g7
I104
sg8
VP60201
p7015
sg10
I4
sg11
VSPG2
p7016
sg13
I1
sasg24
(lp7017
(dp7018
g7
I138
sg27
VC1853247
p7019
sg10
I5
sg11
VSPG31
p7020
sg13
I1
sa(dp7021
g7
I179
sg27
VC1858712
p7022
sg10
I5
sg11
VSPG10
p7023
sg13
I1
sa(dp7024
g7
I123
sg27
VC2931355
p7025
sg10
I5
sg11
VSPG3A
p7026
sg13
I1
sa(dp7027
g7
I104
sg27
VC1839264
p7028
sg10
I4
sg11
VSPG2
p7029
sg13
I1
sa(dp7030
g7
I43
sg27
VC0034152
p7031
sg10
I3
sg11
VHSP
p7032
sg13
I1
sa(dp7033
g7
I252
sg27
VC1858106
p7034
sg10
I5
sg11
VSPG12
p7035
sg13
I1
sasa(dp7036
g2
VDownregulation of ACE2 is always associated with the ALI or ARDS induced by avian influenza virus, severe acute respiratory syndrome-coronavirus, respiratory syncytial virus and sepsis.
p7037
sg4
(lp7038
(dp7039
g7
I18
sg8
g9
sg10
I4
sg11
VACE2
p7040
sg13
I1
sasg24
(lp7041
(dp7042
g7
I178
sg27
VC0243026
p7043
sg10
I6
sg11
Vsepsis
p7044
sg13
I1
sa(dp7045
g7
I60
sg27
VC0035222
p7046
sg10
I4
sg11
VARDS
p7047
sg13
I1
sa(dp7048
g7
I99
sg27
VC1175175
p7049
sg10
I33
sg11
Vsevere acute respiratory syndrome
p7050
sg13
I4
sa(dp7051
g7
I76
sg27
VC0016627
p7052
sg10
I15
sg11
Vavian influenza
p7053
sg13
I2
sasa(dp7054
g2
VA virus infection assay showed that rWIV1-DeltaX replicated as efficiently as rWIV1 in Vero E6, Calu-3, and HeLa-hACE2 cells.
p7055
sg4
(lp7056
(dp7057
g7
I96
sg8
g9
sg10
I6
sg11
VCalu-3
p7058
sg13
I1
sasg24
(lp7059
(dp7060
g7
I2
sg27
VC0042769
p7061
sg10
I15
sg11
Vvirus infection
p7062
sg13
I2
sasa(dp7063
g2
VResults show that 106 cases of tetanus occurred in Aceh, with a case fatality ratio (CFR) of 18.9%; 71 cases occurred in Yogyakarta, with CFR of 36.6%.
p7064
sg4
(lp7065
sg24
(lp7066
(dp7067
g7
I31
sg27
VC0039614
p7068
sg10
I7
sg11
Vtetanus
p7069
sg13
I1
sasa(dp7070
g2
VTreatment of (DR-BB x WF)F1 x WF animals (all lyp+/+) using a standard induction protocol caused type 1 diabetes in 58% of progeny.
p7071
sg4
(lp7072
sg24
(lp7073
(dp7074
g7
I97
sg27
VC0011854
p7075
sg10
I15
sg11
Vtype 1 diabetes
p7076
sg13
I3
sasa(dp7077
g2
VAll genetic analyses of BB rat diabetes to date have backcrossed to the DP-BB strain or used (DP-BB x non-BB)F2 animals to ensure that a fraction of progeny are homozygous for lyp.
p7078
sg4
(lp7079
(dp7080
g7
I176
sg8
g9
sg10
I3
sg11
Vlyp
p7081
sg13
I1
sasg24
(lp7082
(dp7083
g7
I31
sg27
VC0011849
p7084
sg10
I8
sg11
Vdiabetes
p7085
sg13
I1
sa(dp7086
g7
I176
sg27
VC1868674
p7087
sg10
I3
sg11
Vlyp
p7088
sg13
I1
sasa(dp7089
g2
VSince, type 1 diabetes is characterised by hyperglycaemia we analysed 22 diabetic and 43 non-diabetic [(BB x SHR)FI x BB] backcross hybrids (28M:37F) which were already homozygous for Iddml and Iddm2 to search for quantitative trait loci (QTLs) affecting blood glucose in BB/OK rats.
p7090
sg4
(lp7091
(dp7092
g7
I194
sg8
VP01308
p7093
sg10
I5
sg11
VIddm2
p7094
sg13
I1
sasg24
(lp7095
(dp7096
g7
I43
sg27
VC0020456
p7097
sg10
I14
sg11
Vhyperglycaemia
p7098
sg13
I1
sa(dp7099
g7
I7
sg27
VC0011854
p7100
sg10
I15
sg11
Vtype 1 diabetes
p7101
sg13
I3
sa(dp7102
g7
I194
sg27
VC1852092
p7103
sg10
I5
sg11
VIddm2
p7104
sg13
I1
sasa(dp7105
g2
VThis prompted us to investigate the inheritance of IDDM in two subpopulations of BB rats (BB/OK and BB/PhiK) by crossing studies with the production of (diabetic BB x LEW 1.A) F1, F2 generations and of first backcross hybrids onto BB (B1BB) and LEW.1A (B1A) rats respectively.
p7106
sg4
(lp7107
sg24
(lp7108
(dp7109
g7
I51
sg27
VC0011854
p7110
sg10
I4
sg11
VIDDM
p7111
sg13
I1
sasa(dp7112
g2
VLRRK2 selectively interacts with three Beta-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4).
p7113
sg4
(lp7114
(dp7115
g7
I79
sg8
g9
sg10
I5
sg11
VTUBB6
p7116
sg13
I1
sa(dp7117
g7
I0
sg8
g9
sg10
I5
sg11
VLRRK2
p7118
sg13
I1
sa(dp7119
g7
I39
sg8
VP68371
p7120
sg10
I21
sg11
VBeta-tubulin isoforms
p7121
sg13
I2
sa(dp7122
g7
I68
sg8
VP04350
p7123
sg10
I5
sg11
VTUBB4
p7124
sg13
I1
sa(dp7125
g7
I62
sg8
VP04350
p7126
sg10
I4
sg11
VTUBB
p7127
sg13
I1
sa(dp7128
g7
I68
sg8
VP04350
p7129
sg10
I5
sg11
VTUBB4
p7130
sg13
I1
sasg24
(lp7131
(dp7132
g7
I125
sg27
VC0026650
p7133
sg10
I17
sg11
Vmovement disorder
p7134
sg13
I2
sa(dp7135
g7
I160
sg27
VC1851943
p7136
sg10
I4
sg11
VDYT4
p7137
sg13
I1
sa(dp7138
g7
I143
sg27
VC1851943
p7139
sg10
I15
sg11
Vdystonia type 4
p7140
sg13
I3
sasa(dp7141
g2
VIn this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).
p7142
sg4
(lp7143
(dp7144
g7
I209
sg8
VP32245
p7145
sg10
I4
sg11
VMC4R
p7146
sg13
I1
sa(dp7147
g7
I188
sg8
g9
sg10
I3
sg11
VFTO
p7148
sg13
I1
sa(dp7149
g7
I222
sg8
g9
sg10
I5
sg11
VNEGR1
p7150
sg13
I1
sa(dp7151
g7
I175
sg8
VP41161
p7152
sg10
I4
sg11
VETV5
p7153
sg13
I1
sa(dp7154
g7
I229
sg8
g9
sg10
I6
sg11
VSEC16B
p7155
sg13
I1
sa(dp7156
g7
I181
sg8
g9
sg10
I5
sg11
VFAIM2
p7157
sg13
I1
sa(dp7158
g7
I193
sg8
g9
sg10
I6
sg11
VGNPDA2
p7159
sg13
I1
sa(dp7160
g7
I237
sg8
g9
sg10
I5
sg11
VSH2B1
p7161
sg13
I1
sa(dp7162
g7
I248
sg8
g9
sg10
I6
sg11
VTMEM18
p7163
sg13
I1
sa(dp7164
g7
I201
sg8
g9
sg10
I6
sg11
VKCTD15
p7165
sg13
I1
sa(dp7166
g7
I215
sg8
g9
sg10
I5
sg11
VMTCH2
p7167
sg13
I1
sasg24
(lp7168
(dp7169
g7
I160
sg27
VC0028754
p7170
sg10
I7
sg11
Vobesity
p7171
sg13
I1
sasa(dp7172
g2
VIn total, 15 loci reached genome-wide significance (P-value &lt; 5 x 10(-8)) in the joint discovery and replication analysis, of which 12 are previously identified loci in or close to ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B, TNNI3K, MC4R, GPR61, LMX1B and OLFM4 associated with adult body mass index or childhood obesity.
p7173
sg4
(lp7174
(dp7175
g7
I256
sg8
g9
sg10
I5
sg11
VLMX1B
p7176
sg13
I1
sa(dp7177
g7
I222
sg8
g9
sg10
I3
sg11
VFTO
p7178
sg13
I1
sa(dp7179
g7
I199
sg8
g9
sg10
I6
sg11
VTMEM18
p7180
sg13
I1
sa(dp7181
g7
I215
sg8
g9
sg10
I5
sg11
VFAIM2
p7182
sg13
I1
sa(dp7183
g7
I266
sg8
g9
sg10
I5
sg11
VOLFM4
p7184
sg13
I1
sa(dp7185
g7
I227
sg8
g9
sg10
I6
sg11
VTFAP2B
p7186
sg13
I1
sa(dp7187
g7
I243
sg8
VP32245
p7188
sg10
I4
sg11
VMC4R
p7189
sg13
I1
sa(dp7190
g7
I191
sg8
g9
sg10
I6
sg11
VGNPDA2
p7191
sg13
I1
sa(dp7192
g7
I207
sg8
g9
sg10
I6
sg11
VSEC16B
p7193
sg13
I1
sa(dp7194
g7
I184
sg8
VP40145
p7195
sg10
I5
sg11
VADCY3
p7196
sg13
I1
sa(dp7197
g7
I249
sg8
g9
sg10
I5
sg11
VGPR61
p7198
sg13
I1
sa(dp7199
g7
I235
sg8
g9
sg10
I6
sg11
VTNNI3K
p7200
sg13
I1
sasg24
(lp7201
(dp7202
g7
I313
sg27
VC2362324
p7203
sg10
I17
sg11
Vchildhood obesity
p7204
sg13
I2
sasa(dp7205
g2
VAn obesity-related gene, Fas apoptotic inhibitory molecule 2 (FAIM2), is regulated by nutritional state and the methylation levels of the FAIM2 promoter are significantly associated with obesity.
p7206
sg4
(lp7207
(dp7208
g7
I25
sg8
g9
sg10
I35
sg11
VFas apoptotic inhibitory molecule 2
p7209
sg13
I5
sa(dp7210
g7
I138
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7211
sg13
I2
sa(dp7212
g7
I62
sg8
g9
sg10
I5
sg11
VFAIM2
p7213
sg13
I1
sasg24
(lp7214
(dp7215
g7
I3
sg27
VC0028754
p7216
sg10
I7
sg11
Vobesity
p7217
sg13
I1
sa(dp7218
g7
I3
sg27
VC0028754
p7219
sg10
I7
sg11
Vobesity
p7220
sg13
I1
sa(dp7221
g7
I25
sg27
VC0015923
p7222
sg10
I3
sg11
VFas
p7223
sg13
I1
sasa(dp7224
g2
VWhether the molecular mechanisms by which FAIM2 affects obesity are involved in lifestyle is unclear.
p7225
sg4
(lp7226
(dp7227
g7
I42
sg8
g9
sg10
I5
sg11
VFAIM2
p7228
sg13
I1
sasg24
(lp7229
(dp7230
g7
I56
sg27
VC0028754
p7231
sg10
I7
sg11
Vobesity
p7232
sg13
I1
sasa(dp7233
g2
VOur results suggest that lifestyle may possibly be mediating the process of the FAIM2 involved in obesity.
p7234
sg4
(lp7235
(dp7236
g7
I80
sg8
g9
sg10
I5
sg11
VFAIM2
p7237
sg13
I1
sasg24
(lp7238
(dp7239
g7
I98
sg27
VC0028754
p7240
sg10
I7
sg11
Vobesity
p7241
sg13
I1
sasa(dp7242
g2
VFas apoptotic inhibitory molecule 2 (FAIM2) is an obesity-related gene, but the mechanisms by which FAIM2 is involved in obesity are not understood.
p7243
sg4
(lp7244
(dp7245
g7
I37
sg8
g9
sg10
I5
sg11
VFAIM2
p7246
sg13
I1
sa(dp7247
g7
I37
sg8
g9
sg10
I5
sg11
VFAIM2
p7248
sg13
I1
sa(dp7249
g7
I0
sg8
g9
sg10
I35
sg11
VFas apoptotic inhibitory molecule 2
p7250
sg13
I5
sasg24
(lp7251
(dp7252
g7
I0
sg27
VC0015923
p7253
sg10
I3
sg11
VFas
p7254
sg13
I1
sa(dp7255
g7
I50
sg27
VC0028754
p7256
sg10
I7
sg11
Vobesity
p7257
sg13
I1
sa(dp7258
g7
I50
sg27
VC0028754
p7259
sg10
I7
sg11
Vobesity
p7260
sg13
I1
sasa(dp7261
g2
VThe purpose of this study was to investigate the potential associations of FAIM2 promoter methylation with obesity and components of dyslipidaemia in Chinese children.
p7262
sg4
(lp7263
(dp7264
g7
I75
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7265
sg13
I2
sasg24
(lp7266
(dp7267
g7
I107
sg27
VC0028754
p7268
sg10
I7
sg11
Vobesity
p7269
sg13
I1
sa(dp7270
g7
I133
sg27
VC0242339
p7271
sg10
I13
sg11
Vdyslipidaemia
p7272
sg13
I1
sasa(dp7273
g2
VThis study provides the first evidence that the methylation levels of the FAIM2 promoter are significantly associated with obesity and are independently associated with dyslipidaemia and its components in Chinese children.
p7274
sg4
(lp7275
(dp7276
g7
I74
sg8
g9
sg10
I14
sg11
VFAIM2 promoter
p7277
sg13
I2
sasg24
(lp7278
(dp7279
g7
I169
sg27
VC0242339
p7280
sg10
I13
sg11
Vdyslipidaemia
p7281
sg13
I1
sa(dp7282
g7
I123
sg27
VC0028754
p7283
sg10
I7
sg11
Vobesity
p7284
sg13
I1
sasa(dp7285
g2
VThe association of FTO rs9939609-A, MC4R rs17782313-C, GNPDA2 rs10938397-G, and FAIM2 rs7138803-A with higher BMI, fat mass percentage, waist circumference, and waist-to height ratio and risk of obesity, and BDNF rs6265-G allele may increase BMI and obesity risk in Chinese children.
p7286
sg4
(lp7287
(dp7288
g7
I80
sg8
g9
sg10
I17
sg11
VFAIM2 rs7138803-A
p7289
sg13
I2
sa(dp7290
g7
I36
sg8
VP32245
p7291
sg10
I17
sg11
VMC4R rs17782313-C
p7292
sg13
I2
sa(dp7293
g7
I55
sg8
g9
sg10
I19
sg11
VGNPDA2 rs10938397-G
p7294
sg13
I2
sa(dp7295
g7
I19
sg8
g9
sg10
I15
sg11
VFTO rs9939609-A
p7296
sg13
I2
sasg24
(lp7297
(dp7298
g7
I195
sg27
VC0028754
p7299
sg10
I7
sg11
Vobesity
p7300
sg13
I1
sa(dp7301
g7
I195
sg27
VC0028754
p7302
sg10
I7
sg11
Vobesity
p7303
sg13
I1
sasa(dp7304
g2
VHere we aim to see whether variants in obesity-associated genes--NEGR1, FTO, MTCH2, MC4R, LRRN6C, MAP2K5, FAIM2, SEC16B, ETV5, BDNF-AS, ATXN2L, ATP2A1, KCTD15, and TNN13K--are associated with white matter microstructural properties, assessed by high angular resolution diffusion imaging (HARDI) in young healthy adults between 20 and 30 years of age from the Queensland Twin Imaging study (QTIM).
p7305
sg4
(lp7306
(dp7307
g7
I65
sg8
g9
sg10
I5
sg11
VNEGR1
p7308
sg13
I1
sa(dp7309
g7
I144
sg8
g9
sg10
I6
sg11
VATP2A1
p7310
sg13
I1
sa(dp7311
g7
I72
sg8
g9
sg10
I3
sg11
VFTO
p7312
sg13
I1
sa(dp7313
g7
I98
sg8
g9
sg10
I6
sg11
VMAP2K5
p7314
sg13
I1
sa(dp7315
g7
I106
sg8
g9
sg10
I5
sg11
VFAIM2
p7316
sg13
I1
sa(dp7317
g7
I113
sg8
g9
sg10
I6
sg11
VSEC16B
p7318
sg13
I1
sa(dp7319
g7
I152
sg8
g9
sg10
I6
sg11
VKCTD15
p7320
sg13
I1
sa(dp7321
g7
I121
sg8
VP41161
p7322
sg10
I4
sg11
VETV5
p7323
sg13
I1
sa(dp7324
g7
I77
sg8
g9
sg10
I5
sg11
VMTCH2
p7325
sg13
I1
sa(dp7326
g7
I84
sg8
VP32245
p7327
sg10
I4
sg11
VMC4R
p7328
sg13
I1
sa(dp7329
g7
I90
sg8
g9
sg10
I6
sg11
VLRRN6C
p7330
sg13
I1
sasg24
(lp7331
(dp7332
g7
I39
sg27
VC0028754
p7333
sg10
I7
sg11
Vobesity
p7334
sg13
I1
sasa(dp7335
g2
VOur results reflect an epigenetic regulation of Rbl2/p130 expression in breast cancer.
p7336
sg4
(lp7337
(dp7338
g7
I48
sg8
g9
sg10
I4
sg11
VRbl2
p7339
sg13
I1
sa(dp7340
g7
I53
sg8
g9
sg10
I4
sg11
Vp130
p7341
sg13
I1
sasg24
(lp7342
(dp7343
g7
I72
sg27
VC0678222
p7344
sg10
I13
sg11
Vbreast cancer
p7345
sg13
I2
sasa(dp7346
g2
VThis highlights the importance of Rbl2/p130 promoter methylation in breast cancer pathogenesis.
p7347
sg4
(lp7348
(dp7349
g7
I39
sg8
g9
sg10
I4
sg11
Vp130
p7350
sg13
I1
sa(dp7351
g7
I34
sg8
g9
sg10
I4
sg11
VRbl2
p7352
sg13
I1
sasg24
(lp7353
(dp7354
g7
I68
sg27
VC0678222
p7355
sg10
I13
sg11
Vbreast cancer
p7356
sg13
I2
sa(dp7357
g7
I82
sg27
VC0699748
p7358
sg10
I12
sg11
Vpathogenesis
p7359
sg13
I1
sasa(dp7360
g2
VHere, we report that ER-beta and pRb2/p130 proteins co-immunoprecipitate in both nucleus and cytoplasm of MCF-7 breast cancer cells.
p7361
sg4
(lp7362
(dp7363
g7
I38
sg8
g9
sg10
I4
sg11
Vp130
p7364
sg13
I1
sa(dp7365
g7
I33
sg8
VP02812
p7366
sg10
I4
sg11
VpRb2
p7367
sg13
I1
sasg24
(lp7368
(dp7369
g7
I112
sg27
VC0678222
p7370
sg10
I13
sg11
Vbreast cancer
p7371
sg13
I2
sasa(dp7372
g2
VHere we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells.
p7373
sg4
(lp7374
(dp7375
g7
I81
sg8
VP02812
p7376
sg10
I4
sg11
VpRb2
p7377
sg13
I1
sa(dp7378
g7
I42
sg8
g9
sg10
I13
sg11
VER-alpha gene
p7379
sg13
I2
sa(dp7380
g7
I86
sg8
g9
sg10
I4
sg11
Vp130
p7381
sg13
I1
sasg24
(lp7382
(dp7383
g7
I106
sg27
VC0678222
p7384
sg10
I13
sg11
Vbreast cancer
p7385
sg13
I2
sa(dp7386
g7
I56
sg27
VC0544461
p7387
sg10
I12
sg11
Vinactivation
p7388
sg13
I1
sasa(dp7389
g2
VThese findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
p7390
sg4
(lp7391
(dp7392
g7
I33
sg8
g9
sg10
I4
sg11
Vp130
p7393
sg13
I1
sa(dp7394
g7
I104
sg8
g9
sg10
I13
sg11
VER-alpha gene
p7395
sg13
I2
sa(dp7396
g7
I28
sg8
VP02812
p7397
sg10
I4
sg11
VpRb2
p7398
sg13
I1
sasg24
(lp7399
(dp7400
g7
I240
sg27
VC0678222
p7401
sg10
I13
sg11
Vbreast cancer
p7402
sg13
I2
sa(dp7403
g7
I276
sg27
VC0027651
p7404
sg10
I6
sg11
Vtumors
p7405
sg13
I1
sasa(dp7406
g2
VIn order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed for expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16, p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status, Ki67, and HER2/neu immunoreactivity.
p7407
sg4
(lp7408
(dp7409
g7
I347
sg8
g9
sg10
I3
sg11
VRb2
p7410
sg13
I1
sa(dp7411
g7
I324
sg8
VP42771
p7412
sg10
I3
sg11
Vp16
p7413
sg13
I1
sa(dp7414
g7
I334
sg8
VP40305
p7415
sg10
I3
sg11
Vp27
p7416
sg13
I1
sa(dp7417
g7
I415
sg8
VP04626
p7418
sg10
I3
sg11
Vneu
p7419
sg13
I1
sa(dp7420
g7
I40
sg8
VP13688
p7421
sg10
I7
sg11
VCEACAM1
p7422
sg13
I1
sa(dp7423
g7
I329
sg8
VP42857
p7424
sg10
I3
sg11
Vp21
p7425
sg13
I1
sa(dp7426
g7
I314
sg8
VP24864
p7427
sg10
I8
sg11
Vcyclin E
p7428
sg13
I2
sa(dp7429
g7
I410
sg8
VP04626
p7430
sg10
I4
sg11
VHER2
p7431
sg13
I1
sa(dp7432
g7
I303
sg8
VP24385
p7433
sg10
I9
sg11
Vcyclin D1
p7434
sg13
I2
sa(dp7435
g7
I367
sg8
VP22736
p7436
sg10
I24
sg11
Vsteroid hormone receptor
p7437
sg13
I3
sasg24
(lp7438
(dp7439
g7
I70
sg27
VC0678222
p7440
sg10
I13
sg11
Vbreast cancer
p7441
sg13
I2
sa(dp7442
g7
I214
sg27
VC0007097
p7443
sg10
I10
sg11
Vcarcinomas
p7444
sg13
I1
sasa(dp7445
g2
VWeak or absent Rb2 expression was more often found in endometrial (59%) than in mammary carcinomas (24%).
p7446
sg4
(lp7447
(dp7448
g7
I15
sg8
g9
sg10
I3
sg11
VRb2
p7449
sg13
I1
sasg24
(lp7450
(dp7451
g7
I88
sg27
VC0007097
p7452
sg10
I10
sg11
Vcarcinomas
p7453
sg13
I1
sasa(dp7454
g2
VWe found significant positive correlations of Rb2 expression with Rb, ER, and PR-B in breast cancer samples, and of Rb2 with Rb, PR-A, PR-B, and younger age in endometrial carcinomas.
p7455
sg4
(lp7456
(dp7457
g7
I46
sg8
g9
sg10
I3
sg11
VRb2
p7458
sg13
I1
sa(dp7459
g7
I46
sg8
g9
sg10
I3
sg11
VRb2
p7460
sg13
I1
sasg24
(lp7461
(dp7462
g7
I86
sg27
VC0678222
p7463
sg10
I13
sg11
Vbreast cancer
p7464
sg13
I2
sa(dp7465
g7
I160
sg27
VC0476089
p7466
sg10
I22
sg11
Vendometrial carcinomas
p7467
sg13
I2
sasa(dp7468
g2
VOur results indicate that loss of Rb2 expression, mostly by transcriptional down-regulation, may be associated with the development and dedifferentiation of most endometrial and a subset of mammary carcinomas.
p7469
sg4
(lp7470
(dp7471
g7
I34
sg8
g9
sg10
I3
sg11
VRb2
p7472
sg13
I1
sasg24
(lp7473
(dp7474
g7
I198
sg27
VC0007097
p7475
sg10
I10
sg11
Vcarcinomas
p7476
sg13
I1
sa(dp7477
g7
I136
sg27
VC0002793
p7478
sg10
I17
sg11
Vdedifferentiation
p7479
sg13
I1
sasa(dp7480
g2
VWe have developed a novel glycocancer biomarker, fucosylated haptoglobin (Fuc-Hpt), and have investigated its usefulness for the diagnosis of pancreatic cancer over approximately 10 years.
p7481
sg4
(lp7482
(dp7483
g7
I74
sg8
VP00738
p7484
sg10
I7
sg11
VFuc-Hpt
p7485
sg13
I1
sa(dp7486
g7
I49
sg8
VP00738
p7487
sg10
I23
sg11
Vfucosylated haptoglobin
p7488
sg13
I2
sasg24
(lp7489
(dp7490
g7
I142
sg27
VC0235974
p7491
sg10
I17
sg11
Vpancreatic cancer
p7492
sg13
I2
sasa(dp7493
g2
VIn this review, we provide a historical summary of our research on Fuc-Hpt as a cancer biomarker, and discuss a potential early detection system for pancreatic cancer.
p7494
sg4
(lp7495
(dp7496
g7
I67
sg8
VP00738
p7497
sg10
I7
sg11
VFuc-Hpt
p7498
sg13
I1
sasg24
(lp7499
(dp7500
g7
I80
sg27
VC0006826
p7501
sg10
I6
sg11
Vcancer
p7502
sg13
I1
sa(dp7503
g7
I149
sg27
VC0235974
p7504
sg10
I17
sg11
Vpancreatic cancer
p7505
sg13
I2
sasa(dp7506
g2
VWe developed a lectin-antibody ELISA kit using PhoSL to determine core-Fuc-Hpt levels in sera from colorectal or pancreatic cancer patients.
p7507
sg4
(lp7508
(dp7509
g7
I66
sg8
VP00738
p7510
sg10
I12
sg11
Vcore-Fuc-Hpt
p7511
sg13
I1
sa(dp7512
g7
I15
sg8
g9
sg10
I15
sg11
Vlectin-antibody
p7513
sg13
I1
sasg24
(lp7514
(dp7515
g7
I113
sg27
VC0235974
p7516
sg10
I17
sg11
Vpancreatic cancer
p7517
sg13
I2
sasa(dp7518
g2
VSerum levels of AAL-reactive Hpt are higher in pancreatic cancer patients, whereas those of PhoSL-reactive Hpt are higher in colorectal cancer patients.
p7519
sg4
(lp7520
(dp7521
g7
I92
sg8
VP00738
p7522
sg10
I18
sg11
VPhoSL-reactive Hpt
p7523
sg13
I2
sa(dp7524
g7
I16
sg8
VP00738
p7525
sg10
I16
sg11
VAAL-reactive Hpt
p7526
sg13
I2
sasg24
(lp7527
(dp7528
g7
I47
sg27
VC0235974
p7529
sg10
I17
sg11
Vpancreatic cancer
p7530
sg13
I2
sa(dp7531
g7
I125
sg27
VC1527249
p7532
sg10
I17
sg11
Vcolorectal cancer
p7533
sg13
I2
sasa(dp7534
g2
VFucosylated haptoglobin (Fuc-Hpt) has been identified as a novel biomarker for pancreatic cancer.
p7535
sg4
(lp7536
(dp7537
g7
I25
sg8
VP00738
p7538
sg10
I7
sg11
VFuc-Hpt
p7539
sg13
I1
sa(dp7540
g7
I0
sg8
VP00738
p7541
sg10
I23
sg11
VFucosylated haptoglobin
p7542
sg13
I2
sasg24
(lp7543
(dp7544
g7
I79
sg27
VC0235974
p7545
sg10
I17
sg11
Vpancreatic cancer
p7546
sg13
I2
sasa(dp7547
g2
VWe previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.
p7548
sg4
(lp7549
(dp7550
g7
I38
sg8
VP00738
p7551
sg10
I7
sg11
VFuc-Hpt
p7552
sg13
I1
sa(dp7553
g7
I153
sg8
g9
sg10
I23
sg11
VAleuria aurantia lectin
p7554
sg13
I3
sa(dp7555
g7
I125
sg8
g9
sg10
I15
sg11
Vlectin antibody
p7556
sg13
I2
sasg24
(lp7557
(dp7558
g7
I88
sg27
VC0235974
p7559
sg10
I17
sg11
Vpancreatic cancer
p7560
sg13
I2
sasa(dp7561
g2
VUsing the model checking method, we verified several Alzheimer's disease and cancer-related properties, and also identified important proteins (NFKB, ATF4, ASK1 and TRAF2) in the ER-Golgi network, which might be responsible for the pathogenesis of cancer and AD.
p7562
sg4
(lp7563
(dp7564
g7
I156
sg8
g9
sg10
I4
sg11
VASK1
p7565
sg13
I1
sa(dp7566
g7
I144
sg8
g9
sg10
I4
sg11
VNFKB
p7567
sg13
I1
sa(dp7568
g7
I165
sg8
g9
sg10
I5
sg11
VTRAF2
p7569
sg13
I1
sa(dp7570
g7
I150
sg8
VP18848
p7571
sg10
I4
sg11
VATF4
p7572
sg13
I1
sasg24
(lp7573
(dp7574
g7
I77
sg27
VC0006826
p7575
sg10
I6
sg11
Vcancer
p7576
sg13
I1
sa(dp7577
g7
I53
sg27
VC1521724
p7578
sg10
I19
sg11
VAlzheimer's disease
p7579
sg13
I2
sa(dp7580
g7
I232
sg27
VC0699748
p7581
sg10
I12
sg11
Vpathogenesis
p7582
sg13
I1
sa(dp7583
g7
I77
sg27
VC0006826
p7584
sg10
I6
sg11
Vcancer
p7585
sg13
I1
sasa(dp7586
g2
VWe genotyped 107 AIH-1 children and up to 326 healthy subjects for TNFA G-308A, TNFA G-238A, LTA A+252G, LTA A+80C, NFKBIL1 T-63A, BAT1 C-348T, BAT1 G-22C, MICA, and HLA-B polymorphisms.
p7587
sg4
(lp7588
(dp7589
g7
I105
sg8
VP10515
p7590
sg10
I9
sg11
VLTA A+80C
p7591
sg13
I2
sa(dp7592
g7
I166
sg8
VP30461
p7593
sg10
I5
sg11
VHLA-B
p7594
sg13
I1
sa(dp7595
g7
I131
sg8
VP82251
p7596
sg10
I11
sg11
VBAT1 C-348T
p7597
sg13
I2
sa(dp7598
g7
I144
sg8
VP82251
p7599
sg10
I10
sg11
VBAT1 G-22C
p7600
sg13
I2
sa(dp7601
g7
I93
sg8
VP10515
p7602
sg10
I10
sg11
VLTA A+252G
p7603
sg13
I2
sa(dp7604
g7
I67
sg8
VP01375
p7605
sg10
I11
sg11
VTNFA G-308A
p7606
sg13
I2
sa(dp7607
g7
I116
sg8
g9
sg10
I13
sg11
VNFKBIL1 T-63A
p7608
sg13
I2
sa(dp7609
g7
I80
sg8
VP01375
p7610
sg10
I11
sg11
VTNFA G-238A
p7611
sg13
I2
sasg24
(lp7612
(dp7613
g7
I156
sg27
VC0700319
p7614
sg10
I4
sg11
VMICA
p7615
sg13
I1
sasa(dp7616
g2
VTandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.
p7617
sg4
(lp7618
(dp7619
g7
I155
sg8
g9
sg10
I6
sg11
VZNF261
p7620
sg13
I1
sa(dp7621
g7
I142
sg8
g9
sg10
I4
sg11
VRAMP
p7622
sg13
I1
sa(dp7623
g7
I147
sg8
VP28329
p7624
sg10
I3
sg11
VFIM
p7625
sg13
I1
sa(dp7626
g7
I162
sg8
g9
sg10
I8
sg11
VDXS6673E
p7627
sg13
I1
sasg24
(lp7628
(dp7629
g7
I147
sg27
VC0393929
p7630
sg10
I3
sg11
VFIM
p7631
sg13
I1
sasa(dp7632
g2
VFrom 2005 to 2010, our unit performed testing for IL2RG, JAK3, IL7R, RAG1, RAG2, DCLRE1C, LIG4, AK2, and ZAP70 mutations in 42 Chinese and Southeast Asian infants with SCID adopting a candidate gene approach, based on patient's gender, immune phenotype, and inheritance pattern.
p7633
sg4
(lp7634
(dp7635
g7
I50
sg8
VP31785
p7636
sg10
I5
sg11
VIL2RG
p7637
sg13
I1
sa(dp7638
g7
I96
sg8
g9
sg10
I3
sg11
VAK2
p7639
sg13
I1
sa(dp7640
g7
I105
sg8
VP43403
p7641
sg10
I15
sg11
VZAP70 mutations
p7642
sg13
I2
sa(dp7643
g7
I69
sg8
VP15918
p7644
sg10
I4
sg11
VRAG1
p7645
sg13
I1
sa(dp7646
g7
I75
sg8
VP55895
p7647
sg10
I4
sg11
VRAG2
p7648
sg13
I1
sa(dp7649
g7
I57
sg8
VP52333
p7650
sg10
I4
sg11
VJAK3
p7651
sg13
I1
sa(dp7652
g7
I90
sg8
VP49917
p7653
sg10
I4
sg11
VLIG4
p7654
sg13
I1
sasg24
(lp7655
(dp7656
g7
I168
sg27
VC0085110
p7657
sg10
I4
sg11
VSCID
p7658
sg13
I1
sasa(dp7659
g2
VMutations were identified in 26 patients, including IL2RG (n = 19), IL7R (n = 2), JAK3 (n = 2), RAG1 (n = 1), RAG2 (n = 1), and DCLRE1C (n = 1).
p7660
sg4
(lp7661
(dp7662
g7
I82
sg8
VP52333
p7663
sg10
I4
sg11
VJAK3
p7664
sg13
I1
sa(dp7665
g7
I52
sg8
VP31785
p7666
sg10
I5
sg11
VIL2RG
p7667
sg13
I1
sa(dp7668
g7
I110
sg8
VP55895
p7669
sg10
I4
sg11
VRAG2
p7670
sg13
I1
sa(dp7671
g7
I96
sg8
VP15918
p7672
sg10
I4
sg11
VRAG1
p7673
sg13
I1
sasg24
(lp7674
sa(dp7675
g2
VMutations in any of eight known genes: IL2RG, ARTEMIS, RAG1, RAG2, ADA, CD45, JAK3, and IL7R cause SCID.
p7676
sg4
(lp7677
(dp7678
g7
I39
sg8
VP31785
p7679
sg10
I5
sg11
VIL2RG
p7680
sg13
I1
sa(dp7681
g7
I78
sg8
VP52333
p7682
sg10
I4
sg11
VJAK3
p7683
sg13
I1
sa(dp7684
g7
I55
sg8
VP15918
p7685
sg10
I4
sg11
VRAG1
p7686
sg13
I1
sa(dp7687
g7
I72
sg8
VP08575
p7688
sg10
I4
sg11
VCD45
p7689
sg13
I1
sa(dp7690
g7
I67
sg8
VP00813
p7691
sg10
I3
sg11
VADA
p7692
sg13
I1
sa(dp7693
g7
I61
sg8
VP55895
p7694
sg10
I4
sg11
VRAG2
p7695
sg13
I1
sasg24
(lp7696
(dp7697
g7
I99
sg27
VC0085110
p7698
sg10
I4
sg11
VSCID
p7699
sg13
I1
sasa(dp7700
g2
VPrevious studies have reported that Nit2, a member of the nitrilase superfamily, is a potential tumor suppressor, although its function remains elusive in colon cancer.
p7701
sg4
(lp7702
(dp7703
g7
I36
sg8
g9
sg10
I4
sg11
VNit2
p7704
sg13
I1
sasg24
(lp7705
(dp7706
g7
I155
sg27
VC0699790
p7707
sg10
I12
sg11
Vcolon cancer
p7708
sg13
I2
sa(dp7709
g7
I96
sg27
VC0027651
p7710
sg10
I5
sg11
Vtumor
p7711
sg13
I1
sasa(dp7712
g2
VIn the present study, we employed an RNA interference lentivirus system to silence endogenous NIT2 expression in the colon cancer cell line, HCT116.
p7713
sg4
(lp7714
(dp7715
g7
I94
sg8
g9
sg10
I4
sg11
VNIT2
p7716
sg13
I1
sasg24
(lp7717
(dp7718
g7
I75
sg27
VC0858952
p7719
sg10
I7
sg11
Vsilence
p7720
sg13
I1
sa(dp7721
g7
I117
sg27
VC0699790
p7722
sg10
I12
sg11
Vcolon cancer
p7723
sg13
I2
sasa(dp7724
g2
VThe depletion of NIT2 markedly inhibited colon cancer cell proliferation and colony formation and induced cell cycle arrest in the G0/G1 phase, as shown by MTT assay, colony formation assay and flow cytometric analysis, respectively.
p7725
sg4
(lp7726
(dp7727
g7
I17
sg8
g9
sg10
I4
sg11
VNIT2
p7728
sg13
I1
sasg24
(lp7729
(dp7730
g7
I59
sg27
VC0334094
p7731
sg10
I13
sg11
Vproliferation
p7732
sg13
I1
sa(dp7733
g7
I41
sg27
VC0699790
p7734
sg10
I12
sg11
Vcolon cancer
p7735
sg13
I2
sasa(dp7736
g2
VFurther investigation with an intracellular signaling array demonstrated that the depletion of NIT2 triggered the apoptosis of colon cancer cells through the caspase-3 and poly(ADP-ribose) polymerase (PARP) pathways.
p7737
sg4
(lp7738
(dp7739
g7
I95
sg8
g9
sg10
I4
sg11
VNIT2
p7740
sg13
I1
sa(dp7741
g7
I201
sg8
VP09874
p7742
sg10
I4
sg11
VPARP
p7743
sg13
I1
sa(dp7744
g7
I158
sg8
VP42574
p7745
sg10
I9
sg11
Vcaspase-3
p7746
sg13
I1
sa(dp7747
g7
I172
sg8
VP09874
p7748
sg10
I27
sg11
Vpoly(ADP-ribose) polymerase
p7749
sg13
I2
sasg24
(lp7750
(dp7751
g7
I127
sg27
VC0699790
p7752
sg10
I12
sg11
Vcolon cancer
p7753
sg13
I2
sasa(dp7754
g2
VOur findings suggest that NIT2 may be an oncogene in human colon cancer and may thus serve as a promising therapeutic target for the treatment of colon cancer.
p7755
sg4
(lp7756
(dp7757
g7
I26
sg8
g9
sg10
I4
sg11
VNIT2
p7758
sg13
I1
sasg24
(lp7759
(dp7760
g7
I59
sg27
VC0699790
p7761
sg10
I12
sg11
Vcolon cancer
p7762
sg13
I2
sa(dp7763
g7
I59
sg27
VC0699790
p7764
sg10
I12
sg11
Vcolon cancer
p7765
sg13
I2
sasa(dp7766
g2
VOur report may provide clues regarding the nature of the biological amidase substrate(s) of Nit1 (another member of the Nit family), which is a well-established tumor suppressor protein), and emphasizes a) the crucial role of Nit2 in nitrogen and sulfur metabolism, and b) the possible link of Nit2 to cancer biology.
p7767
sg4
(lp7768
(dp7769
g7
I226
sg8
g9
sg10
I4
sg11
VNit2
p7770
sg13
I1
sa(dp7771
g7
I92
sg8
g9
sg10
I4
sg11
VNit1
p7772
sg13
I1
sa(dp7773
g7
I226
sg8
g9
sg10
I4
sg11
VNit2
p7774
sg13
I1
sasg24
(lp7775
(dp7776
g7
I161
sg27
VC0027651
p7777
sg10
I5
sg11
Vtumor
p7778
sg13
I1
sa(dp7779
g7
I302
sg27
VC0006826
p7780
sg10
I6
sg11
Vcancer
p7781
sg13
I1
sasa(dp7782
g2
VThe purpose of this study was to retrospectively characterize benign and malignant prostate peripheral zone tissue by using endorectal MRI and 3D 1H MRS. Fifty-two men with untreated biopsy-proven prostate cancer underwent combined endorectal MRI and MRSI.
p7783
sg4
(lp7784
sg24
(lp7785
(dp7786
g7
I197
sg27
VC0600139
p7787
sg10
I15
sg11
Vprostate cancer
p7788
sg13
I2
sa(dp7789
g7
I149
sg27
VC0025235
p7790
sg10
I3
sg11
VMRS
p7791
sg13
I1
sasa(dp7792
g2
VThe addition of 3D1H MRSI to MRI can improve diagnosis of prostate cancer contributing indirectly to improve local staging.
p7793
sg4
(lp7794
sg24
(lp7795
(dp7796
g7
I58
sg27
VC0600139
p7797
sg10
I15
sg11
Vprostate cancer
p7798
sg13
I2
sasa(dp7799
g2
VIn addition, the correlation between metabolic 3D1H MRSI data with pathological Gleason grade may offer a non-invasive means to better predict prostate cancer aggressiveness.
p7800
sg4
(lp7801
sg24
(lp7802
(dp7803
g7
I143
sg27
VC1853195
p7804
sg10
I30
sg11
Vprostate cancer aggressiveness
p7805
sg13
I3
sasa(dp7806
g2
VThe objective of our study was to establish the sensitivity and specificity for prostate cancer detection using a combined 1H MR spectroscopy and diffusion-weighted MRI approach.
p7807
sg4
(lp7808
sg24
(lp7809
(dp7810
g7
I80
sg27
VC0600139
p7811
sg10
I15
sg11
Vprostate cancer
p7812
sg13
I2
sasa(dp7813
g2
VMRI, dynamic MRI, and 1H-MR spectroscopic imaging were performed in 10 patients with prostate cancer on 1.5T and 3T whole-body scanners.
p7814
sg4
(lp7815
sg24
(lp7816
(dp7817
g7
I85
sg27
VC0600139
p7818
sg10
I15
sg11
Vprostate cancer
p7819
sg13
I2
sasa(dp7820
g2
VInitial results of endorectal 3T 1H-MR spectroscopic imaging in prostate cancer patients showed potential advantages: the increase in spatial, temporal, and spectral resolution at higher field strength may result in an improved accuracy in delineating and staging prostate cancer.
p7821
sg4
(lp7822
sg24
(lp7823
(dp7824
g7
I64
sg27
VC0600139
p7825
sg10
I15
sg11
Vprostate cancer
p7826
sg13
I2
sa(dp7827
g7
I64
sg27
VC0600139
p7828
sg10
I15
sg11
Vprostate cancer
p7829
sg13
I2
sasa(dp7830
g2
VTo establish an experimental setting for monitoring perfusion and metabolism in orthotopic prostate cancer at 1.5 T using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 1H-MR spectroscopy (MRS).
p7831
sg4
(lp7832
sg24
(lp7833
(dp7834
g7
I91
sg27
VC0600139
p7835
sg10
I15
sg11
Vprostate cancer
p7836
sg13
I2
sa(dp7837
g7
I209
sg27
VC0025235
p7838
sg10
I3
sg11
VMRS
p7839
sg13
I1
sa(dp7840
g7
I189
sg27
VC0025235
p7841
sg10
I18
sg11
V1H-MR spectroscopy
p7842
sg13
I2
sasa(dp7843
g2
VDCE MRI and 1H-MRS has potential to characterize orthotopic Dunning prostate cancer in rats, which is a promising model similar to human prostate carcinomas.
p7844
sg4
(lp7845
sg24
(lp7846
(dp7847
g7
I15
sg27
VC0025235
p7848
sg10
I3
sg11
VMRS
p7849
sg13
I1
sa(dp7850
g7
I68
sg27
VC0600139
p7851
sg10
I15
sg11
Vprostate cancer
p7852
sg13
I2
sa(dp7853
g7
I146
sg27
VC0007097
p7854
sg10
I10
sg11
Vcarcinomas
p7855
sg13
I1
sasa(dp7856
g2
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p7857
sg4
(lp7858
(dp7859
g7
I117
sg8
g9
sg10
I7
sg11
VFam107A
p7860
sg13
I1
sa(dp7861
g7
I111
sg8
g9
sg10
I4
sg11
VDRR1
p7862
sg13
I1
sa(dp7863
g7
I39
sg8
VP48506
p7864
sg10
I29
sg11
Vglucocorticoid-regulated gene
p7865
sg13
I2
sasg24
(lp7866
(dp7867
g7
I88
sg27
VC0007134
p7868
sg10
I20
sg11
Vrenal cell carcinoma
p7869
sg13
I3
sasa(dp7870
g2
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p7871
sg4
(lp7872
(dp7873
g7
I0
sg8
g9
sg10
I4
sg11
VTU3A
p7874
sg13
I1
sasg24
(lp7875
(dp7876
g7
I91
sg27
VC0007134
p7877
sg10
I20
sg11
Vrenal cell carcinoma
p7878
sg13
I3
sa(dp7879
g7
I66
sg27
VC0027651
p7880
sg10
I5
sg11
Vtumor
p7881
sg13
I1
sa(dp7882
g7
I113
sg27
VC0007134
p7883
sg10
I3
sg11
VRCC
p7884
sg13
I1
sasa(dp7885
g2
VIn our search for tumor suppressor genes from this region, we have cloned a gene that we have called DRR 1 (downregulated in renal cell carcinoma).
p7886
sg4
(lp7887
(dp7888
g7
I101
sg8
g9
sg10
I5
sg11
VDRR 1
p7889
sg13
I2
sasg24
(lp7890
(dp7891
g7
I18
sg27
VC0027651
p7892
sg10
I5
sg11
Vtumor
p7893
sg13
I1
sa(dp7894
g7
I125
sg27
VC0007134
p7895
sg10
I20
sg11
Vrenal cell carcinoma
p7896
sg13
I3
sasa(dp7897
g2
VOur results suggest that loss of expression of the DRR 1 gene may play an important role in the development of renal cell carcinoma and possibly other tumors.
p7898
sg4
(lp7899
(dp7900
g7
I51
sg8
g9
sg10
I10
sg11
VDRR 1 gene
p7901
sg13
I3
sasg24
(lp7902
(dp7903
g7
I151
sg27
VC0027651
p7904
sg10
I6
sg11
Vtumors
p7905
sg13
I1
sa(dp7906
g7
I111
sg27
VC0007134
p7907
sg10
I20
sg11
Vrenal cell carcinoma
p7908
sg13
I3
sasa(dp7909
g2
VE2F5 was identified as one of the most deregulated genes in prostate cancer tissues, predominantly in samples with Gleason-score 6.
p7910
sg4
(lp7911
(dp7912
g7
I0
sg8
g9
sg10
I4
sg11
VE2F5
p7913
sg13
I1
sasg24
(lp7914
(dp7915
g7
I60
sg27
VC0600139
p7916
sg10
I15
sg11
Vprostate cancer
p7917
sg13
I2
sasa(dp7918
g2
VFunction of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
p7919
sg4
(lp7920
(dp7921
g7
I21
sg8
VP46108
p7922
sg10
I3
sg11
Vp38
p7923
sg13
I1
sa(dp7924
g7
I12
sg8
g9
sg10
I4
sg11
VE2F5
p7925
sg13
I1
sasg24
(lp7926
(dp7927
g7
I28
sg27
VC0600139
p7928
sg10
I15
sg11
Vprostate cancer
p7929
sg13
I2
sasa(dp7930
g2
VOur findings unearthed that E2F5/p38 axis played a cardinal role in uncontrolled cellular proliferation in prostate cancer through pSMAD3L activation.
p7931
sg4
(lp7932
(dp7933
g7
I33
sg8
VP46108
p7934
sg10
I3
sg11
Vp38
p7935
sg13
I1
sa(dp7936
g7
I28
sg8
g9
sg10
I4
sg11
VE2F5
p7937
sg13
I1
sasg24
(lp7938
(dp7939
g7
I81
sg27
VC0020507
p7940
sg10
I22
sg11
Vcellular proliferation
p7941
sg13
I2
sa(dp7942
g7
I107
sg27
VC0600139
p7943
sg10
I15
sg11
Vprostate cancer
p7944
sg13
I2
sasa(dp7945
g2
VIt also underscores a strong potential for E2F5 to be incorporated as a tool in early detection of prostate cancer.
p7946
sg4
(lp7947
(dp7948
g7
I43
sg8
g9
sg10
I4
sg11
VE2F5
p7949
sg13
I1
sasg24
(lp7950
(dp7951
g7
I99
sg27
VC0600139
p7952
sg10
I15
sg11
Vprostate cancer
p7953
sg13
I2
sasa(dp7954
g2
VWe report the coexistence of otitis media and epididymo-orchitis owing to Hemophilus influenzae, type b in 2 children.
p7955
sg4
(lp7956
sg24
(lp7957
(dp7958
g7
I29
sg27
VC0029882
p7959
sg10
I12
sg11
Votitis media
p7960
sg13
I2
sa(dp7961
g7
I46
sg27
VC0149881
p7962
sg10
I18
sg11
Vepididymo-orchitis
p7963
sg13
I1
sasa(dp7964
g2
VOverexpression of tau rescued the Nogo-66-induced inhibition of neurite outgrowth in neuroblastoma 2a (N2a) cells and primary cortical neurons.
p7965
sg4
(lp7966
sg24
(lp7967
(dp7968
g7
I85
sg27
VC0027819
p7969
sg10
I13
sg11
Vneuroblastoma
p7970
sg13
I1
sasa(dp7971
g2
VTaken together, we suggest that Nogo-A is closely involved in the neuronal response to hypoxic and oxidative stress, an observation that may be of relevance not only in stroke-induced ischaemia, but also in neuroblastoma formation.
p7972
sg4
(lp7973
sg24
(lp7974
(dp7975
g7
I99
sg27
VC0242606
p7976
sg10
I16
sg11
Voxidative stress
p7977
sg13
I2
sa(dp7978
g7
I184
sg27
VC0022116
p7979
sg10
I9
sg11
Vischaemia
p7980
sg13
I1
sa(dp7981
g7
I87
sg27
VC0242184
p7982
sg10
I7
sg11
Vhypoxic
p7983
sg13
I1
sa(dp7984
g7
I169
sg27
VC0038454
p7985
sg10
I6
sg11
Vstroke
p7986
sg13
I1
sa(dp7987
g7
I207
sg27
VC0027819
p7988
sg10
I13
sg11
Vneuroblastoma
p7989
sg13
I1
sasa(dp7990
g2
VIn the present study, we report on the role of GSK-3Beta signaling on Nogo-66-treated mouse neuroblastoma N2a cells.
p7991
sg4
(lp7992
(dp7993
g7
I47
sg8
VP49841
p7994
sg10
I9
sg11
VGSK-3Beta
p7995
sg13
I1
sasg24
(lp7996
(dp7997
g7
I86
sg27
VC1524043
p7998
sg10
I19
sg11
Vmouse neuroblastoma
p7999
sg13
I2
sasa(dp8000
g2
VBrain-derived neurotrophic factor stimulates the phosphorylation, suppressing Nogo-dependent inhibition of neurite outgrowth from neuroblastoma-derived neural cells.
p8001
sg4
(lp8002
(dp8003
g7
I0
sg8
g9
sg10
I33
sg11
VBrain-derived neurotrophic factor
p8004
sg13
I3
sasg24
(lp8005
(dp8006
g7
I130
sg27
VC0027819
p8007
sg10
I13
sg11
Vneuroblastoma
p8008
sg13
I1
sasa(dp8009
g2
VIn our per-SNP analysis, eight myopia gene associations were replicated successfully: GJD2, RASGRF1, BICC1, KCNQ5, CD55, CYP26A1, LRRC4C, and B4GALNT2.Seven additional gene associations were replicated in our gene-based analyses: GRIA4, BMP2, QKI, BMP4, SFRP1, SH3GL2, and EHBP1L1.
p8010
sg4
(lp8011
(dp8012
g7
I254
sg8
g9
sg10
I5
sg11
VSFRP1
p8013
sg13
I1
sa(dp8014
g7
I261
sg8
g9
sg10
I6
sg11
VSH3GL2
p8015
sg13
I1
sa(dp8016
g7
I130
sg8
g9
sg10
I6
sg11
VLRRC4C
p8017
sg13
I1
sa(dp8018
g7
I237
sg8
VP12643
p8019
sg10
I4
sg11
VBMP2
p8020
sg13
I1
sa(dp8021
g7
I86
sg8
g9
sg10
I4
sg11
VGJD2
p8022
sg13
I1
sa(dp8023
g7
I121
sg8
g9
sg10
I7
sg11
VCYP26A1
p8024
sg13
I1
sa(dp8025
g7
I273
sg8
g9
sg10
I7
sg11
VEHBP1L1
p8026
sg13
I1
sa(dp8027
g7
I108
sg8
g9
sg10
I5
sg11
VKCNQ5
p8028
sg13
I1
sa(dp8029
g7
I101
sg8
g9
sg10
I5
sg11
VBICC1
p8030
sg13
I1
sa(dp8031
g7
I115
sg8
VP08174
p8032
sg10
I4
sg11
VCD55
p8033
sg13
I1
sa(dp8034
g7
I230
sg8
VP48058
p8035
sg10
I5
sg11
VGRIA4
p8036
sg13
I1
sa(dp8037
g7
I248
sg8
VP12644
p8038
sg10
I4
sg11
VBMP4
p8039
sg13
I1
sa(dp8040
g7
I142
sg8
g9
sg10
I8
sg11
VB4GALNT2
p8041
sg13
I1
sa(dp8042
g7
I92
sg8
g9
sg10
I7
sg11
VRASGRF1
p8043
sg13
I1
sasg24
(lp8044
(dp8045
g7
I31
sg27
VC0027092
p8046
sg10
I6
sg11
Vmyopia
p8047
sg13
I1
sasa(dp8048
g2
VThe aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients.
p8049
sg4
(lp8050
(dp8051
g7
I68
sg8
VP60903
p8052
sg10
I7
sg11
VS100A10
p8053
sg13
I1
sasg24
(lp8054
(dp8055
g7
I115
sg27
VC0001418
p8056
sg10
I15
sg11
Vadenocarcinomas
p8057
sg13
I1
sasa(dp8058
g2
VS100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated.
p8059
sg4
(lp8060
(dp8061
g7
I0
sg8
VP60903
p8062
sg10
I7
sg11
VS100A10
p8063
sg13
I1
sasg24
(lp8064
(dp8065
g7
I86
sg27
VC0001418
p8066
sg10
I15
sg11
Vadenocarcinomas
p8067
sg13
I1
sasa(dp8068
g2
VS100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030).
p8069
sg4
(lp8070
(dp8071
g7
I0
sg8
VP60903
p8072
sg10
I7
sg11
VS100A10
p8073
sg13
I1
sasg24
(lp8074
(dp8075
g7
I62
sg27
VC0001418
p8076
sg10
I15
sg11
Vadenocarcinomas
p8077
sg13
I1
sa(dp8078
g7
I260
sg27
VC2699153
p8079
sg10
I8
sg11
Vinvasion
p8080
sg13
I1
sasa(dp8081
g2
VThe present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
p8082
sg4
(lp8083
(dp8084
g7
I31
sg8
VP60903
p8085
sg10
I7
sg11
VS100A10
p8086
sg13
I1
sa(dp8087
g7
I31
sg8
VP60903
p8088
sg10
I7
sg11
VS100A10
p8089
sg13
I1
sasg24
(lp8090
(dp8091
g7
I72
sg27
VC0001418
p8092
sg10
I15
sg11
Vadenocarcinomas
p8093
sg13
I1
sa(dp8094
g7
I67
sg27
VC0152013
p8095
sg10
I19
sg11
Vlung adenocarcinoma
p8096
sg13
I2
sasa(dp8097
g2
VUsing mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10.
p8098
sg4
(lp8099
(dp8100
g7
I260
sg8
VP14406
p8101
sg10
I6
sg11
VCOX7A2
p8102
sg13
I1
sa(dp8103
g7
I271
sg8
VP04271
p8104
sg10
I4
sg11
VS100
p8105
sg13
I1
sasg24
(lp8106
(dp8107
g7
I209
sg27
VC1332460
p8108
sg10
I24
sg11
VBarrett's adenocarcinoma
p8109
sg13
I2
sasa(dp8110
g2
VIn the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.
p8111
sg4
(lp8112
(dp8113
g7
I74
sg8
VP14406
p8114
sg10
I6
sg11
VCOX7A2
p8115
sg13
I1
sa(dp8116
g7
I85
sg8
VP37802
p8117
sg10
I6
sg11
VTAGLN2
p8118
sg13
I1
sasg24
(lp8119
(dp8120
g7
I212
sg27
VC1332460
p8121
sg10
I24
sg11
VBarrett's adenocarcinoma
p8122
sg13
I2
sasa(dp8123
g2
VS100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.
p8124
sg4
(lp8125
(dp8126
g7
I25
sg8
VP04271
p8127
sg10
I11
sg11
VS100 family
p8128
sg13
I2
sa(dp8129
g7
I0
sg8
VP60903
p8130
sg10
I7
sg11
VS100A10
p8131
sg13
I1
sa(dp8132
g7
I128
sg8
VP00747
p8133
sg10
I11
sg11
Vplasminogen
p8134
sg13
I1
sasg24
(lp8135
(dp8136
g7
I101
sg27
VC2699153
p8137
sg10
I8
sg11
Vinvasion
p8138
sg13
I1
sa(dp8139
g7
I114
sg27
VC0027627
p8140
sg10
I10
sg11
Vmetastasis
p8141
sg13
I1
sa(dp8142
g7
I91
sg27
VC0007097
p8143
sg10
I9
sg11
Vcarcinoma
p8144
sg13
I1
sasa(dp8145
g2
VCells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.
p8146
sg4
(lp8147
(dp8148
g7
I85
sg8
VP07355
p8149
sg10
I10
sg11
Vannexin II
p8150
sg13
I2
sa(dp8151
g7
I73
sg8
VP60903
p8152
sg10
I7
sg11
VS100A10
p8153
sg13
I1
sasg24
(lp8154
(dp8155
g7
I58
sg27
VC0007097
p8156
sg10
I10
sg11
Vcarcinomas
p8157
sg13
I1
sasa(dp8158
g2
VS100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.
p8159
sg4
(lp8160
(dp8161
g7
I12
sg8
VP07355
p8162
sg10
I10
sg11
Vannexin II
p8163
sg13
I2
sa(dp8164
g7
I0
sg8
VP60903
p8165
sg10
I7
sg11
VS100A10
p8166
sg13
I1
sasg24
(lp8167
(dp8168
g7
I45
sg27
VC0007133
p8169
sg10
I20
sg11
Vpapillary carcinomas
p8170
sg13
I2
sa(dp8171
g7
I55
sg27
VC0007097
p8172
sg10
I10
sg11
Vcarcinomas
p8173
sg13
I1
sasa(dp8174
g2
VThese findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.
p8175
sg4
(lp8176
(dp8177
g7
I40
sg8
VP07355
p8178
sg10
I10
sg11
Vannexin II
p8179
sg13
I2
sa(dp8180
g7
I28
sg8
VP60903
p8181
sg10
I7
sg11
VS100A10
p8182
sg13
I1
sasg24
(lp8183
(dp8184
g7
I69
sg27
VC0001807
p8185
sg10
I10
sg11
Vaggressive
p8186
sg13
I1
sa(dp8187
g7
I99
sg27
VC0205698
p8188
sg10
I20
sg11
Vanaplastic carcinoma
p8189
sg13
I2
sa(dp8190
g7
I158
sg27
VC0007133
p8191
sg10
I19
sg11
Vpapillary carcinoma
p8192
sg13
I2
sasa(dp8193
g2
VThe spin-labeled derivative of podophyllotoxin, N'-podophyllic acid-N-[3-(2,2,5,5-tetramethyl pyrrolinenyloxy)] semicarbazide (GP-11), was synthesized and tested for its antitumor activity against mouse transplantable tumors, Sarcoma-180, Hepatoma-A, P388 leukemia and Ehrlich ascites carcinoma.
p8194
sg4
(lp8195
sg24
(lp8196
(dp8197
g7
I239
sg27
VC0023903
p8198
sg10
I8
sg11
VHepatoma
p8199
sg13
I1
sa(dp8200
g7
I285
sg27
VC0007097
p8201
sg10
I9
sg11
Vcarcinoma
p8202
sg13
I1
sa(dp8203
g7
I226
sg27
VC1261473
p8204
sg10
I7
sg11
VSarcoma
p8205
sg13
I1
sa(dp8206
g7
I256
sg27
VC0023418
p8207
sg10
I8
sg11
Vleukemia
p8208
sg13
I1
sa(dp8209
g7
I218
sg27
VC0027651
p8210
sg10
I6
sg11
Vtumors
p8211
sg13
I1
sasa(dp8212
g2
VRemote parenchymal hemorrhage (rPH) after intravenous thrombolysis with recombinant tissue-type plasminogen activator may be associated with cerebral amyloid angiopathy, although supportive data are limited.
p8213
sg4
(lp8214
(dp8215
g7
I84
sg8
VP00747
p8216
sg10
I33
sg11
Vtissue-type plasminogen activator
p8217
sg13
I3
sasg24
(lp8218
(dp8219
g7
I141
sg27
VC0085220
p8220
sg10
I27
sg11
Vcerebral amyloid angiopathy
p8221
sg13
I3
sa(dp8222
g7
I7
sg27
VC0747264
p8223
sg10
I22
sg11
Vparenchymal hemorrhage
p8224
sg13
I2
sasa(dp8225
g2
VWe here review the data with respect to the activation of tPA by fibrin and its multiple other cofactors, in relation to tPA's role in pathophysiology, notably fibrinolysis and amyloidosis, with emphasis on Alzheimer's disease.
p8226
sg4
(lp8227
(dp8228
g7
I65
sg8
VP22087
p8229
sg10
I6
sg11
Vfibrin
p8230
sg13
I1
sasg24
(lp8231
(dp8232
g7
I177
sg27
VC0002726
p8233
sg10
I11
sg11
Vamyloidosis
p8234
sg13
I1
sa(dp8235
g7
I207
sg27
VC1521724
p8236
sg10
I19
sg11
VAlzheimer's disease
p8237
sg13
I2
sasa(dp8238
g2
VCerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy.
p8239
sg4
(lp8240
(dp8241
g7
I158
sg8
VP00747
p8242
sg10
I5
sg11
Vrt-PA
p8243
sg13
I1
sa(dp8244
g7
I111
sg8
VP00747
p8245
sg10
I45
sg11
Vrecombinant tissue-type plasminogen activator
p8246
sg13
I4
sasg24
(lp8247
(dp8248
g7
I29
sg27
VC1842937
p8249
sg10
I3
sg11
VCAA
p8250
sg13
I1
sa(dp8251
g7
I0
sg27
VC0085220
p8252
sg10
I27
sg11
VCerebral amyloid angiopathy
p8253
sg13
I3
sasa(dp8254
g2
VThe purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice.
p8255
sg4
(lp8256
(dp8257
g7
I180
sg8
VP36222
p8258
sg10
I14
sg11
Vglycoprotein B
p8259
sg13
I2
sa(dp8260
g7
I196
sg8
g9
sg10
I3
sg11
VgBs
p8261
sg13
I1
sasg24
(lp8262
(dp8263
g7
I196
sg27
VC1841700
p8264
sg10
I3
sg11
VgBs
p8265
sg13
I1
sa(dp8266
g7
I112
sg27
VC0333262
p8267
sg10
I8
sg11
Vvesicles
p8268
sg13
I1
sa(dp8269
g7
I330
sg27
VC0019372
p8270
sg10
I16
sg11
Vherpes infection
p8271
sg13
I2
sa(dp8272
g7
I204
sg27
VC0019348
p8273
sg10
I14
sg11
Vherpes simplex
p8274
sg13
I2
sasa(dp8275
g2
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p8276
sg4
(lp8277
(dp8278
g7
I57
sg8
VP35398
p8279
sg10
I36
sg11
VT-cell-specific transcription factor
p8280
sg13
I3
sa(dp8281
g7
I276
sg8
VP11473
p8282
sg10
I18
sg11
Vvitamin D receptor
p8283
sg13
I3
sa(dp8284
g7
I109
sg8
VP00519
p8285
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p8286
sg13
I3
sa(dp8287
g7
I399
sg8
g9
sg10
I31
sg11
VPR domain zinc finger protein 1
p8288
sg13
I6
sa(dp8289
g7
I322
sg8
VP29323
p8290
sg10
I3
sg11
VERK
p8291
sg13
I1
sa(dp8292
g7
I362
sg8
VP20823
p8293
sg10
I35
sg11
Vrunt-related transcription factor 1
p8294
sg13
I4
sa(dp8295
g7
I477
sg8
VP01584
p8296
sg10
I13
sg11
Vinterleukin 1
p8297
sg13
I2
sa(dp8298
g7
I152
sg8
VP12931
p8299
sg10
I8
sg11
Vsarcoma"
p8300
sg13
I1
sa(dp8301
g7
I163
sg8
VP10914
p8302
sg10
I30
sg11
Vinterferon regulatory factor 1
p8303
sg13
I4
sa(dp8304
g7
I227
sg8
VP49336
p8305
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p8306
sg13
I4
sa(dp8307
g7
I296
sg8
VP56524
p8308
sg10
I19
sg11
Vhistone deacetylase
p8309
sg13
I2
sa(dp8310
g7
I95
sg8
VP12931
p8311
sg10
I3
sg11
VSrc
p8312
sg13
I1
sa(dp8313
g7
I217
sg8
VP14635
p8314
sg10
I8
sg11
Vcyclin B
p8315
sg13
I2
sa(dp8316
g7
I334
sg8
VP10415
p8317
sg10
I26
sg11
Vbcl-2-associated X protein
p8318
sg13
I3
sa(dp8319
g7
I317
sg8
VP53779
p8320
sg10
I4
sg11
VMAPK
p8321
sg13
I1
sa(dp8322
g7
I432
sg8
VP09619
p8323
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p8324
sg13
I4
sa(dp8325
g7
I265
sg8
VP29466
p8326
sg10
I9
sg11
Vcaspase-1
p8327
sg13
I1
sa(dp8328
g7
I195
sg8
VP04818
p8329
sg10
I20
sg11
Vthymidylate synthase
p8330
sg13
I2
sa(dp8331
g7
I252
sg8
VP24941
p8332
sg10
I3
sg11
VCDK
p8333
sg13
I1
sasg24
(lp8334
(dp8335
g7
I152
sg27
VC1261473
p8336
sg10
I7
sg11
Vsarcoma
p8337
sg13
I1
sa(dp8338
g7
I362
sg27
VC0013336
p8339
sg10
I4
sg11
Vrunt
p8340
sg13
I1
sasa(dp8341
g2
VThe IRF-1 priming of TEXs enhances antitumour immune response.British Journal of Cancer advance online publication, 7 November 2017; doi:10.1038/bjc.2017.389 www.bjcancer.com.
p8342
sg4
(lp8343
(dp8344
g7
I4
sg8
VP10914
p8345
sg10
I5
sg11
VIRF-1
p8346
sg13
I1
sasg24
(lp8347
(dp8348
g7
I81
sg27
VC0006826
p8349
sg10
I6
sg11
VCancer
p8350
sg13
I1
sasa(dp8351
g2
VInterferon regulatory factor 1 (IRF1) has been suggested to act as a tumor suppressor in human cancers.
p8352
sg4
(lp8353
(dp8354
g7
I0
sg8
VP10914
p8355
sg10
I30
sg11
VInterferon regulatory factor 1
p8356
sg13
I4
sa(dp8357
g7
I32
sg8
VP10914
p8358
sg10
I4
sg11
VIRF1
p8359
sg13
I1
sasg24
(lp8360
(dp8361
g7
I69
sg27
VC0027651
p8362
sg10
I5
sg11
Vtumor
p8363
sg13
I1
sa(dp8364
g7
I95
sg27
VC0006826
p8365
sg10
I7
sg11
Vcancers
p8366
sg13
I1
sasa(dp8367
g2
VHowever, the clinical significance and biological function of IRF1 in cholangiocarcinoma is poorly understood.
p8368
sg4
(lp8369
(dp8370
g7
I62
sg8
VP10914
p8371
sg10
I4
sg11
VIRF1
p8372
sg13
I1
sasg24
(lp8373
(dp8374
g7
I70
sg27
VC0206698
p8375
sg10
I18
sg11
Vcholangiocarcinoma
p8376
sg13
I1
sasa(dp8377
g2
VIn our results, IRF1 mRNA and protein expressions were decreased in cholangiocarcinoma tissues and cell lines compared with paired normal hepatic tissues and intrahepatic bile duct epithelial cell line.
p8378
sg4
(lp8379
(dp8380
g7
I16
sg8
VP10914
p8381
sg10
I9
sg11
VIRF1 mRNA
p8382
sg13
I2
sasg24
(lp8383
(dp8384
g7
I68
sg27
VC0206698
p8385
sg10
I18
sg11
Vcholangiocarcinoma
p8386
sg13
I1
sasa(dp8387
g2
VIRF1 protein low-expression was associated with tumor stage, tumor size, vascular invasion and metastasis and served as a poor independent prognostic parameter in cholangiocarcinoma patients.
p8388
sg4
(lp8389
(dp8390
g7
I0
sg8
VP10914
p8391
sg10
I4
sg11
VIRF1
p8392
sg13
I1
sasg24
(lp8393
(dp8394
g7
I95
sg27
VC0027627
p8395
sg10
I10
sg11
Vmetastasis
p8396
sg13
I1
sa(dp8397
g7
I163
sg27
VC0206698
p8398
sg10
I18
sg11
Vcholangiocarcinoma
p8399
sg13
I1
sa(dp8400
g7
I48
sg27
VC0027651
p8401
sg10
I5
sg11
Vtumor
p8402
sg13
I1
sa(dp8403
g7
I82
sg27
VC2699153
p8404
sg10
I8
sg11
Vinvasion
p8405
sg13
I1
sa(dp8406
g7
I48
sg27
VC0027651
p8407
sg10
I5
sg11
Vtumor
p8408
sg13
I1
sasa(dp8409
g2
VUp-regulation of IRF1 expression suppressed cholangiocarcinoma cells proliferation, migration and invasion, and blocked cell cycle progression, but has no effect on apoptosis.
p8410
sg4
(lp8411
(dp8412
g7
I17
sg8
VP10914
p8413
sg10
I4
sg11
VIRF1
p8414
sg13
I1
sasg24
(lp8415
(dp8416
g7
I44
sg27
VC0206698
p8417
sg10
I18
sg11
Vcholangiocarcinoma
p8418
sg13
I1
sa(dp8419
g7
I69
sg27
VC0334094
p8420
sg10
I13
sg11
Vproliferation
p8421
sg13
I1
sa(dp8422
g7
I98
sg27
VC2699153
p8423
sg10
I8
sg11
Vinvasion
p8424
sg13
I1
sasa(dp8425
g2
VIn conclusion, IRF1 is low-expressed in cholangiocarcinoma tissues and cell lines, and correlated with malignant status and prognosis in cholangiocarcinoma patients.
p8426
sg4
(lp8427
(dp8428
g7
I15
sg8
VP10914
p8429
sg10
I4
sg11
VIRF1
p8430
sg13
I1
sasg24
(lp8431
(dp8432
g7
I40
sg27
VC0206698
p8433
sg10
I18
sg11
Vcholangiocarcinoma
p8434
sg13
I1
sa(dp8435
g7
I40
sg27
VC0206698
p8436
sg10
I18
sg11
Vcholangiocarcinoma
p8437
sg13
I1
sasa(dp8438
g2
VIRF1 served as tumor suppressor in the regulation of cholangiocarcinoma cells proliferation, cell cycle, migration and invasion.
p8439
sg4
(lp8440
(dp8441
g7
I0
sg8
VP10914
p8442
sg10
I4
sg11
VIRF1
p8443
sg13
I1
sasg24
(lp8444
(dp8445
g7
I119
sg27
VC2699153
p8446
sg10
I8
sg11
Vinvasion
p8447
sg13
I1
sa(dp8448
g7
I15
sg27
VC0027651
p8449
sg10
I5
sg11
Vtumor
p8450
sg13
I1
sa(dp8451
g7
I53
sg27
VC0206698
p8452
sg10
I18
sg11
Vcholangiocarcinoma
p8453
sg13
I1
sa(dp8454
g7
I78
sg27
VC0334094
p8455
sg10
I13
sg11
Vproliferation
p8456
sg13
I1
sasa(dp8457
g2
VTo examine genetic defects of the IFNGamma-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.
p8458
sg4
(lp8459
(dp8460
g7
I43
sg8
VP10914
p8461
sg10
I4
sg11
VIRF1
p8462
sg13
I1
sasg24
(lp8463
(dp8464
g7
I111
sg27
VC0006826
p8465
sg10
I6
sg11
VCancer
p8466
sg13
I1
sa(dp8467
g7
I59
sg27
VC0007131
p8468
sg10
I26
sg11
Vnon-small cell lung cancer
p8469
sg13
I4
sa(dp8470
g7
I169
sg27
VC0149782
p8471
sg10
I28
sg11
Vlung squamous cell carcinoma
p8472
sg13
I4
sa(dp8473
g7
I199
sg27
VC0149782
p8474
sg10
I4
sg11
VLuSc
p8475
sg13
I1
sa(dp8476
g7
I138
sg27
VC0152013
p8477
sg10
I19
sg11
Vlung adenocarcinoma
p8478
sg13
I2
sa(dp8479
g7
I87
sg27
VC0007131
p8480
sg10
I5
sg11
VNSCLC
p8481
sg13
I1
sa(dp8482
g7
I159
sg27
VC0152013
p8483
sg10
I4
sg11
VLuAd
p8484
sg13
I1
sasa(dp8485
g2
VIRF1 expression was correlated with immune cytolytic activity markers GZMA and PRF1 in NSCLC.
p8486
sg4
(lp8487
(dp8488
g7
I79
sg8
VP14222
p8489
sg10
I4
sg11
VPRF1
p8490
sg13
I1
sa(dp8491
g7
I70
sg8
VP12544
p8492
sg10
I4
sg11
VGZMA
p8493
sg13
I1
sa(dp8494
g7
I0
sg8
VP10914
p8495
sg10
I4
sg11
VIRF1
p8496
sg13
I1
sasg24
(lp8497
(dp8498
g7
I87
sg27
VC0007131
p8499
sg10
I5
sg11
VNSCLC
p8500
sg13
I1
sasa(dp8501
g2
VDeletion of JAK2 or inhibition of the JAK2 kinase activity resulted in loss of IFNGamma-induced IRF1 and cell surface HLA-ABC in JAK2 wildtype NSCLC cells, whereas expression of exogenous JAK2 in H1573 cells restored the IFNGamma responses.
p8502
sg4
(lp8503
(dp8504
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8505
sg13
I1
sa(dp8506
g7
I96
sg8
VP10914
p8507
sg10
I4
sg11
VIRF1
p8508
sg13
I1
sa(dp8509
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8510
sg13
I1
sa(dp8511
g7
I118
sg8
VP30486
p8512
sg10
I7
sg11
VHLA-ABC
p8513
sg13
I1
sa(dp8514
g7
I12
sg8
g9
sg10
I4
sg11
VJAK2
p8515
sg13
I1
sa(dp8516
g7
I38
sg8
g9
sg10
I11
sg11
VJAK2 kinase
p8517
sg13
I2
sasg24
(lp8518
(dp8519
g7
I143
sg27
VC0007131
p8520
sg10
I5
sg11
VNSCLC
p8521
sg13
I1
sasa(dp8522
g2
VThese findings show that JAK2 deficiency is the major mechanism of genetic defects of the IFNGamma-IRF1 pathway in NSCLC and reveal a previously unrecognized significance of chromosome 9p deletion in NSCLC.
p8523
sg4
(lp8524
(dp8525
g7
I25
sg8
g9
sg10
I4
sg11
VJAK2
p8526
sg13
I1
sa(dp8527
g7
I90
sg8
VP10914
p8528
sg10
I13
sg11
VIFNGamma-IRF1
p8529
sg13
I1
sasg24
(lp8530
(dp8531
g7
I115
sg27
VC0007131
p8532
sg10
I5
sg11
VNSCLC
p8533
sg13
I1
sa(dp8534
g7
I115
sg27
VC0007131
p8535
sg10
I5
sg11
VNSCLC
p8536
sg13
I1
sasa(dp8537
g2
VPerformance of the investigational use only-labeled GeneXpert(R) (Cepheid, Sunnyvale, CA) Bladder Cancer Assay, an assay for detection of the five mRNAs (ABL1, CRH, IGF2, ANXA10, and UPK1B), was evaluated in an independent test cohort (n=450).
p8538
sg4
(lp8539
(dp8540
g7
I171
sg8
g9
sg10
I6
sg11
VANXA10
p8541
sg13
I1
sa(dp8542
g7
I160
sg8
VP06850
p8543
sg10
I3
sg11
VCRH
p8544
sg13
I1
sa(dp8545
g7
I165
sg8
VP01344
p8546
sg10
I4
sg11
VIGF2
p8547
sg13
I1
sa(dp8548
g7
I183
sg8
g9
sg10
I5
sg11
VUPK1B
p8549
sg13
I1
sa(dp8550
g7
I154
sg8
VP00519
p8551
sg10
I4
sg11
VABL1
p8552
sg13
I1
sasg24
(lp8553
(dp8554
g7
I90
sg27
VC0699885
p8555
sg10
I14
sg11
VBladder Cancer
p8556
sg13
I2
sasa(dp8557
g2
VOur previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells.
p8558
sg4
(lp8559
(dp8560
g7
I81
sg8
g9
sg10
I6
sg11
VANXA10
p8561
sg13
I1
sa(dp8562
g7
I68
sg8
g9
sg10
I11
sg11
Vannexin A10
p8563
sg13
I2
sa(dp8564
g7
I130
sg8
VP25063
p8565
sg10
I4
sg11
VCD24
p8566
sg13
I1
sasg24
(lp8567
(dp8568
g7
I136
sg27
VC0001418
p8569
sg10
I14
sg11
Vadenocarcinoma
p8570
sg13
I1
sasa(dp8571
g2
VThe correlation between ANXA10 expression and the progression of pancreatic cancer remains unknown.
p8572
sg4
(lp8573
(dp8574
g7
I24
sg8
g9
sg10
I6
sg11
VANXA10
p8575
sg13
I1
sasg24
(lp8576
(dp8577
g7
I65
sg27
VC0235974
p8578
sg10
I17
sg11
Vpancreatic cancer
p8579
sg13
I2
sasa(dp8580
g2
VIn this study, we performed an immunostaining assay to evaluate ANXA10 expression in 155 primary human tissue specimens, including normal pancreas, chronic pancreatitis (CP), pancreatic adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN, the most important precursor of PDAC), and intraductal papillary mucinous neoplasm (IPMN).
p8581
sg4
(lp8582
(dp8583
g7
I64
sg8
g9
sg10
I6
sg11
VANXA10
p8584
sg13
I1
sasg24
(lp8585
(dp8586
g7
I209
sg27
VC1301034
p8587
sg10
I36
sg11
Vpancreatic intraepithelial neoplasia
p8588
sg13
I3
sa(dp8589
g7
I297
sg27
VC3160815
p8590
sg10
I39
sg11
Vintraductal papillary mucinous neoplasm
p8591
sg13
I4
sa(dp8592
g7
I175
sg27
VC0281361
p8593
sg10
I25
sg11
Vpancreatic adenocarcinoma
p8594
sg13
I2
sa(dp8595
g7
I148
sg27
VC0149521
p8596
sg10
I20
sg11
Vchronic pancreatitis
p8597
sg13
I2
sa(dp8598
g7
I202
sg27
VC0281361
p8599
sg10
I4
sg11
VPDAC
p8600
sg13
I1
sa(dp8601
g7
I202
sg27
VC0281361
p8602
sg10
I4
sg11
VPDAC
p8603
sg13
I1
sa(dp8604
g7
I170
sg27
VC0149521
p8605
sg10
I2
sg11
VCP
p8606
sg13
I1
sa(dp8607
g7
I247
sg27
VC1301034
p8608
sg10
I5
sg11
VPanIN
p8609
sg13
I1
sa(dp8610
g7
I338
sg27
VC3160815
p8611
sg10
I4
sg11
VIPMN
p8612
sg13
I1
sasa(dp8613
g2
VSince PDAC develops through a series of PanINs which in turn arise from pancreatic ducts, the consistent overexpression of ANXA10 in ductal epithelial cells in PanINs and PDACs but negative in normal pancreatic ducts suggests that ANXA10 could serve as a potential marker indicating the presence of PDAC at its earliest precancerous stages.
p8614
sg4
(lp8615
(dp8616
g7
I123
sg8
g9
sg10
I6
sg11
VANXA10
p8617
sg13
I1
sa(dp8618
g7
I123
sg8
g9
sg10
I6
sg11
VANXA10
p8619
sg13
I1
sasg24
(lp8620
sa(dp8621
g2
VIn this study, we evaluated the effects of simvastatin on ANXA10 signaling in androgen-independent prostate cancer cells.
p8622
sg4
(lp8623
(dp8624
g7
I58
sg8
g9
sg10
I6
sg11
VANXA10
p8625
sg13
I1
sa(dp8626
g7
I43
sg8
g9
sg10
I11
sg11
Vsimvastatin
p8627
sg13
I1
sasg24
(lp8628
(dp8629
g7
I99
sg27
VC0600139
p8630
sg10
I15
sg11
Vprostate cancer
p8631
sg13
I2
sasa(dp8632
g2
VIn human prostate biopsy samples, ANXA10 mRNA expression was significantly lower in the prostate cancer group than in the BPH group.
p8633
sg4
(lp8634
(dp8635
g7
I34
sg8
g9
sg10
I11
sg11
VANXA10 mRNA
p8636
sg13
I2
sasg24
(lp8637
(dp8638
g7
I122
sg27
VC0005001
p8639
sg10
I3
sg11
VBPH
p8640
sg13
I1
sa(dp8641
g7
I88
sg27
VC0600139
p8642
sg10
I15
sg11
Vprostate cancer
p8643
sg13
I2
sasa(dp8644
g2
VNext, we found that up-regulation of ANXA10 in PC-3 resulted in down-regulation of S100 calcium binding protein A4 (S100A4), which is reportedly correlated with aggressiveness and a worse prognosis for patients with different types of carcinomas.
p8645
sg4
(lp8646
(dp8647
g7
I116
sg8
VP26447
p8648
sg10
I6
sg11
VS100A4
p8649
sg13
I1
sa(dp8650
g7
I83
sg8
VP26447
p8651
sg10
I31
sg11
VS100 calcium binding protein A4
p8652
sg13
I5
sa(dp8653
g7
I47
sg8
g9
sg10
I4
sg11
VPC-3
p8654
sg13
I1
sa(dp8655
g7
I37
sg8
g9
sg10
I6
sg11
VANXA10
p8656
sg13
I1
sasg24
(lp8657
(dp8658
g7
I235
sg27
VC0007097
p8659
sg10
I10
sg11
Vcarcinomas
p8660
sg13
I1
sa(dp8661
g7
I161
sg27
VC0001807
p8662
sg10
I14
sg11
Vaggressiveness
p8663
sg13
I1
sasa(dp8664
g2
VOur results suggest that statins inhibit the proliferation, migration, and invasion of androgen-independent prostate cancer cells by up-regulation of ANXA10.
p8665
sg4
(lp8666
(dp8667
g7
I150
sg8
g9
sg10
I6
sg11
VANXA10
p8668
sg13
I1
sasg24
(lp8669
(dp8670
g7
I75
sg27
VC2699153
p8671
sg10
I8
sg11
Vinvasion
p8672
sg13
I1
sa(dp8673
g7
I108
sg27
VC0600139
p8674
sg10
I15
sg11
Vprostate cancer
p8675
sg13
I2
sa(dp8676
g7
I45
sg27
VC0334094
p8677
sg10
I13
sg11
Vproliferation
p8678
sg13
I1
sasa(dp8679
g2
VImmunohistochemistry for 7 gastric-type markers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC, and MUC6) and 2 intestinal-type markers (CDX2 and CK20) was performed in 36 normal gastric/colorectal mucosa tissues, 163 colorectal polyps, and 175 microsatellite-unstable colorectal carcinomas (MSI-H CRCs).
p8680
sg4
(lp8681
(dp8682
g7
I133
sg8
g9
sg10
I4
sg11
VCDX2
p8683
sg13
I1
sa(dp8684
g7
I57
sg8
g9
sg10
I5
sg11
VVSIG1
p8685
sg13
I1
sa(dp8686
g7
I64
sg8
VP56856
p8687
sg10
I6
sg11
VCLDN18
p8688
sg13
I1
sa(dp8689
g7
I142
sg8
VP35900
p8690
sg10
I4
sg11
VCK20
p8691
sg13
I1
sa(dp8692
g7
I78
sg8
g9
sg10
I4
sg11
VTFF2
p8693
sg13
I1
sa(dp8694
g7
I72
sg8
VP14091
p8695
sg10
I4
sg11
VCTSE
p8696
sg13
I1
sa(dp8697
g7
I96
sg8
g9
sg10
I4
sg11
VMUC6
p8698
sg13
I1
sa(dp8699
g7
I49
sg8
g9
sg10
I6
sg11
VANXA10
p8700
sg13
I1
sasg24
(lp8701
(dp8702
g7
I265
sg27
VC0009402
p8703
sg10
I21
sg11
Vcolorectal carcinomas
p8704
sg13
I2
sa(dp8705
g7
I214
sg27
VC0949059
p8706
sg10
I17
sg11
Vcolorectal polyps
p8707
sg13
I2
sa(dp8708
g7
I288
sg27
VC0920269
p8709
sg10
I3
sg11
VMSI
p8710
sg13
I1
sasa(dp8711
g2
VTwo decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue.
p8712
sg4
(lp8713
(dp8714
g7
I17
sg8
VP09382
p8715
sg10
I10
sg11
VGalectin-8
p8716
sg13
I1
sasg24
(lp8717
(dp8718
g7
I47
sg27
VC0600139
p8719
sg10
I18
sg11
Vprostate carcinoma
p8720
sg13
I2
sasa(dp8721
g2
VIn this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages.
p8722
sg4
(lp8723
(dp8724
g7
I26
sg8
VP09382
p8725
sg10
I10
sg11
VGalectin-8
p8726
sg13
I1
sa(dp8727
g7
I78
sg8
VP42025
p8728
sg10
I3
sg11
VPC3
p8729
sg13
I1
sa(dp8730
g7
I86
sg8
g9
sg10
I8
sg11
VIGR-CaP1
p8731
sg13
I1
sasg24
(lp8732
(dp8733
g7
I170
sg27
VC0677042
p8734
sg10
I9
sg11
Vpathology
p8735
sg13
I1
sa(dp8736
g7
I50
sg27
VC0600139
p8737
sg10
I15
sg11
Vprostate cancer
p8738
sg13
I2
sasa(dp8739
g2
VWe show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.
p8740
sg4
(lp8741
(dp8742
g7
I72
sg8
VP16278
p8743
sg10
I5
sg11
VGal-8
p8744
sg13
I1
sasg24
(lp8745
(dp8746
g7
I81
sg27
VC0027651
p8747
sg10
I6
sg11
Vtumour
p8748
sg13
I1
sa(dp8749
g7
I141
sg27
VC0600139
p8750
sg10
I15
sg11
Vprostate cancer
p8751
sg13
I2
sasa(dp8752
g2
VCollectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.
p8753
sg4
(lp8754
(dp8755
g7
I36
sg8
VP09382
p8756
sg10
I10
sg11
VGalectin-8
p8757
sg13
I1
sasg24
(lp8758
(dp8759
g7
I105
sg27
VC0600139
p8760
sg10
I15
sg11
Vprostate cancer
p8761
sg13
I2
sasa(dp8762
g2
VImmunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.
p8763
sg4
(lp8764
(dp8765
g7
I24
sg8
VP49221
p8766
sg10
I33
sg11
Vprostate carcinoma tumour antigen
p8767
sg13
I4
sasg24
(lp8768
(dp8769
g7
I24
sg27
VC0600139
p8770
sg10
I18
sg11
Vprostate carcinoma
p8771
sg13
I2
sa(dp8772
g7
I43
sg27
VC0027651
p8773
sg10
I6
sg11
Vtumour
p8774
sg13
I1
sasa(dp8775
g2
VGalectin-8 levels of expression positively correlate with certain human neoplasms, prostate cancer being the best example studied thus far.
p8776
sg4
(lp8777
(dp8778
g7
I0
sg8
VP09382
p8779
sg10
I10
sg11
VGalectin-8
p8780
sg13
I1
sasg24
(lp8781
(dp8782
g7
I72
sg27
VC0033578
p8783
sg10
I19
sg11
Vneoplasms, prostate
p8784
sg13
I2
sa(dp8785
g7
I92
sg27
VC0006826
p8786
sg10
I6
sg11
Vcancer
p8787
sg13
I1
sasa(dp8788
g2
VThe Prostate Carcinoma Tumor Antigen-1 (PCTA-1) is located at the prostate cancer susceptibility locus on chromosome 1q42.2-43 (PCaP).
p8789
sg4
(lp8790
(dp8791
g7
I13
sg8
VP14209
p8792
sg10
I25
sg11
VCarcinoma Tumor Antigen-1
p8793
sg13
I3
sa(dp8794
g7
I66
sg8
g9
sg10
I30
sg11
Vprostate cancer susceptibility
p8795
sg13
I3
sasg24
(lp8796
(dp8797
g7
I66
sg27
VC1864472
p8798
sg10
I60
sg11
Vprostate cancer susceptibility locus on chromosome 1q42.2-43
p8799
sg13
I7
sa(dp8800
g7
I23
sg27
VC0027651
p8801
sg10
I5
sg11
VTumor
p8802
sg13
I1
sa(dp8803
g7
I4
sg27
VC0600139
p8804
sg10
I18
sg11
VProstate Carcinoma
p8805
sg13
I2
sa(dp8806
g7
I128
sg27
VC1864472
p8807
sg10
I4
sg11
VPCaP
p8808
sg13
I1
sasa(dp8809
g2
VSeventy-seven familial prostate cancer cases from 36 German and French pedigrees were screened for germline mutations in the PCTA-1 gene using enzymatic mutation detection (EMD).
p8810
sg4
(lp8811
sg24
(lp8812
(dp8813
g7
I143
sg27
VC0340861
p8814
sg10
I28
sg11
Venzymatic mutation detection
p8815
sg13
I3
sa(dp8816
g7
I173
sg27
VC0340861
p8817
sg10
I3
sg11
VEMD
p8818
sg13
I1
sa(dp8819
g7
I23
sg27
VC0600139
p8820
sg10
I15
sg11
Vprostate cancer
p8821
sg13
I2
sasa(dp8822
g2
VPCTA-1 is not a classical high risk gene with deleterious mutations predisposing to hereditary prostate cancer.
p8823
sg4
(lp8824
sg24
(lp8825
(dp8826
g7
I84
sg27
VC2931456
p8827
sg10
I26
sg11
Vhereditary prostate cancer
p8828
sg13
I3
sasa(dp8829
g2
VThe isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination with expression screening.
p8830
sg4
(lp8831
(dp8832
g7
I26
sg8
VP14209
p8833
sg10
I25
sg11
VCarcinoma Tumor Antigen-1
p8834
sg13
I3
sa(dp8835
g7
I102
sg8
VP09382
p8836
sg10
I10
sg11
VGalectin-8
p8837
sg13
I1
sasg24
(lp8838
(dp8839
g7
I36
sg27
VC0027651
p8840
sg10
I5
sg11
VTumor
p8841
sg13
I1
sa(dp8842
g7
I150
sg27
VC0600139
p8843
sg10
I15
sg11
Vprostate cancer
p8844
sg13
I2
sa(dp8845
g7
I244
sg27
VC0432222
p8846
sg10
I23
sg11
VSurface Epitope Masking
p8847
sg13
I3
sa(dp8848
g7
I17
sg27
VC0600139
p8849
sg10
I18
sg11
VProstate Carcinoma
p8850
sg13
I2
sa(dp8851
g7
I269
sg27
VC0432222
p8852
sg10
I3
sg11
VSEM
p8853
sg13
I1
sasa(dp8854
g2
VPCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer.
p8855
sg4
(lp8856
sg24
(lp8857
(dp8858
g7
I66
sg27
VC0600139
p8859
sg10
I15
sg11
Vprostate cancer
p8860
sg13
I2
sasa(dp8861
g2
VScreening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1).
p8862
sg4
(lp8863
(dp8864
g7
I73
sg8
VP63125
p8865
sg10
I11
sg11
VPro 1.5 mAb
p8866
sg13
I3
sa(dp8867
g7
I104
sg8
VP49221
p8868
sg10
I34
sg11
Vprostate carcinoma tumor antigen-1
p8869
sg13
I4
sa(dp8870
g7
I140
sg8
VP49221
p8871
sg10
I6
sg11
VPCTA-1
p8872
sg13
I1
sasg24
(lp8873
(dp8874
g7
I24
sg27
VC0600139
p8875
sg10
I15
sg11
Vprostate cancer
p8876
sg13
I2
sa(dp8877
g7
I123
sg27
VC0027651
p8878
sg10
I5
sg11
Vtumor
p8879
sg13
I1
sa(dp8880
g7
I104
sg27
VC0600139
p8881
sg10
I18
sg11
Vprostate carcinoma
p8882
sg13
I2
sasa(dp8883
g2
VPrimer pairs within the 3' untranslated region of PCTA-1 and reverse transcription-PCR demonstrate selective expression of PCTA-1 by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.
p8884
sg4
(lp8885
sg24
(lp8886
(dp8887
g7
I142
sg27
VC0007097
p8888
sg10
I10
sg11
Vcarcinomas
p8889
sg13
I1
sa(dp8890
g7
I180
sg27
VC0005001
p8891
sg10
I28
sg11
Vbenign prostatic hypertrophy
p8892
sg13
I3
sasa(dp8893
g2
VMoreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.
p8894
sg4
(lp8895
(dp8896
g7
I76
sg8
VP17542
p8897
sg10
I4
sg11
VTAL1
p8898
sg13
I1
sa(dp8899
g7
I36
sg8
VP25791
p8900
sg10
I4
sg11
VLMO2
p8901
sg13
I1
sa(dp8902
g7
I10
sg8
g9
sg10
I5
sg11
VFoxp3
p8903
sg13
I1
sasg24
(lp8904
(dp8905
g7
I127
sg27
VC1961099
p8906
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p8907
sg13
I4
sasa(dp8908
g2
VOverexpression of LMO2 is known to be one of the causes of T-cell acute lymphoblastic leukemia (T-ALL) development; however, the mechanisms behind its oncogenic activity are incompletely understood.
p8909
sg4
(lp8910
(dp8911
g7
I18
sg8
VP25791
p8912
sg10
I4
sg11
VLMO2
p8913
sg13
I1
sasg24
(lp8914
(dp8915
g7
I96
sg27
VC1961099
p8916
sg10
I5
sg11
VT-ALL
p8917
sg13
I1
sa(dp8918
g7
I59
sg27
VC1961099
p8919
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p8920
sg13
I4
sasa(dp8921
g2
VExpression of LMO2 has been evaluated in B-cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia; however, information concerning its role in breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) negative B-cell acute lymphoblastic leukemia (B-ALL) remains limited.
p8922
sg4
(lp8923
(dp8924
g7
I14
sg8
VP25791
p8925
sg10
I4
sg11
VLMO2
p8926
sg13
I1
sa(dp8927
g7
I246
sg8
VP55157
p8928
sg10
I3
sg11
VABL
p8929
sg13
I1
sa(dp8930
g7
I242
sg8
VP11274
p8931
sg10
I3
sg11
VBCR
p8932
sg13
I1
sa(dp8933
g7
I207
sg8
VP35125
p8934
sg10
I33
sg11
Vleukemia viral oncogene homolog 1
p8935
sg13
I5
sasg24
(lp8936
(dp8937
g7
I98
sg27
VC0023467
p8938
sg10
I22
sg11
Vacute myeloid leukemia
p8939
sg13
I3
sa(dp8940
g7
I85
sg27
VC0023418
p8941
sg10
I8
sg11
Vleukemia
p8942
sg13
I1
sa(dp8943
g7
I246
sg27
VC0000744
p8944
sg10
I3
sg11
VABL
p8945
sg13
I1
sa(dp8946
g7
I297
sg27
VC0006413
p8947
sg10
I5
sg11
VB-ALL
p8948
sg13
I1
sa(dp8949
g7
I260
sg27
VC1292769
p8950
sg10
I35
sg11
VB-cell acute lymphoblastic leukemia
p8951
sg13
I4
sa(dp8952
g7
I58
sg27
VC1961099
p8953
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p8954
sg13
I4
sasa(dp8955
g2
VOncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL).
p8956
sg4
(lp8957
(dp8958
g7
I216
sg8
VP25791
p8959
sg10
I4
sg11
VLMO2
p8960
sg13
I1
sa(dp8961
g7
I204
sg8
g9
sg10
I10
sg11
VLIM-only 2
p8962
sg13
I2
sasg24
(lp8963
(dp8964
g7
I58
sg27
VC0085669
p8965
sg10
I15
sg11
Vacute leukemias
p8966
sg13
I2
sa(dp8967
g7
I262
sg27
VC1961099
p8968
sg10
I5
sg11
VT-ALL
p8969
sg13
I1
sa(dp8970
g7
I225
sg27
VC1961099
p8971
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p8972
sg13
I4
sasa(dp8973
g2
VT-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex.
p8974
sg4
(lp8975
(dp8976
g7
I93
sg8
VP17542
p8977
sg10
I35
sg11
VT-cell acute lymphocytic leukemia 1
p8978
sg13
I5
sa(dp8979
g7
I134
sg8
VP25791
p8980
sg10
I4
sg11
VLMO2
p8981
sg13
I1
sa(dp8982
g7
I0
sg8
g9
sg10
I12
sg11
VT-cell acute
p8983
sg13
I2
sa(dp8984
g7
I87
sg8
VP17542
p8985
sg10
I4
sg11
VTAL1
p8986
sg13
I1
sa(dp8987
g7
I165
sg8
VP17542
p8988
sg10
I28
sg11
VTAL1 transcriptional complex
p8989
sg13
I3
sasg24
(lp8990
(dp8991
g7
I0
sg27
VC1961099
p8992
sg10
I35
sg11
VT-cell acute lymphoblastic leukemia
p8993
sg13
I4
sa(dp8994
g7
I37
sg27
VC1961099
p8995
sg10
I5
sg11
VT-ALL
p8996
sg13
I1
sa(dp8997
g7
I93
sg27
VC1961099
p8998
sg10
I33
sg11
VT-cell acute lymphocytic leukemia
p8999
sg13
I4
sasa(dp9000
g2
VLmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL).
p9001
sg4
(lp9002
(dp9003
g7
I160
sg8
g9
sg10
I3
sg11
VETP
p9004
sg13
I1
sa(dp9005
g7
I137
sg8
VP01275
p9006
sg10
I21
sg11
VT-cell precursor-like
p9007
sg13
I2
sa(dp9008
g7
I0
sg8
VP25791
p9009
sg10
I4
sg11
VLmo2
p9010
sg13
I1
sasg24
(lp9011
(dp9012
g7
I85
sg27
VC0085669
p9013
sg10
I15
sg11
Vacute leukemias
p9014
sg13
I2
sa(dp9015
g7
I196
sg27
VC1961102
p9016
sg10
I3
sg11
VALL
p9017
sg13
I1
sa(dp9018
g7
I166
sg27
VC1961102
p9019
sg10
I28
sg11
Vacute lymphoblastic leukemia
p9020
sg13
I3
sasa(dp9021
g2
VParticipants (N = 4,901) were from Look AHEAD, a randomized controlled trial that compared ILI to diabetes support and education (DSE).
p9022
sg4
(lp9023
sg24
(lp9024
(dp9025
g7
I98
sg27
VC0011849
p9026
sg10
I8
sg11
Vdiabetes
p9027
sg13
I1
sasa(dp9028
g2
VA multidomain intensive lifestyle intervention (ILI) to induce weight loss and increase physical activity for 8 to 11 years or diabetes support and education (DSE), a control condition.
p9029
sg4
(lp9030
sg24
(lp9031
(dp9032
g7
I175
sg27
VC0012634
p9033
sg10
I9
sg11
Vcondition
p9034
sg13
I1
sa(dp9035
g7
I127
sg27
VC0011849
p9036
sg10
I8
sg11
Vdiabetes
p9037
sg13
I1
sasa(dp9038
g2
VOverweight and obese (BMI &gt;=25 kg/m 2) middle-aged and older adults (aged 45-76 years at enrollment) with type 2 diabetes enrolled in Look AHEAD, a trial evaluating an intensive lifestyle intervention (ILI) designed to achieve weight loss through caloric restriction and increased physical activity compared to diabetes support and education (DSE), underwent standardized assessments of performance-based physical function including a 4- and 400-m walk, lower extremity physical performance (expanded Short Physical Performance Battery, SPPBexp), and grip strength approximately 11 years post-randomization and 1.5 years after the intervention was stopped (n=3,783).
p9039
sg4
(lp9040
sg24
(lp9041
(dp9042
g7
I116
sg27
VC0011849
p9043
sg10
I8
sg11
Vdiabetes
p9044
sg13
I1
sa(dp9045
g7
I15
sg27
VC0028754
p9046
sg10
I5
sg11
Vobese
p9047
sg13
I1
sa(dp9048
g7
I0
sg27
VC0497406
p9049
sg10
I10
sg11
VOverweight
p9050
sg13
I1
sa(dp9051
g7
I109
sg27
VC0011860
p9052
sg10
I15
sg11
Vtype 2 diabetes
p9053
sg13
I3
sasa(dp9054
g2
VTo address the unique nature of prions, our group targets epitopes, termed disease specific epitopes (DSEs), whose exposure for antibody binding depends on disease-associated misfolding of PrPC into PrPSc.
p9055
sg4
(lp9056
(dp9057
g7
I189
sg8
VP48637
p9058
sg10
I4
sg11
VPrPC
p9059
sg13
I1
sasg24
(lp9060
sa(dp9061
g2
VDuring 5 years spanning the end of intervention and post-intervention follow-up, repeated cognitive assessments were obtained in 1,091 individuals who had been assigned to ILI or a control condition of diabetes support and education (DSE).
p9062
sg4
(lp9063
sg24
(lp9064
(dp9065
g7
I189
sg27
VC0012634
p9066
sg10
I9
sg11
Vcondition
p9067
sg13
I1
sa(dp9068
g7
I202
sg27
VC0011849
p9069
sg10
I8
sg11
Vdiabetes
p9070
sg13
I1
sasa(dp9071
g2
VA total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain &gt;=7% weight loss or to diabetes support and education intervention (DSE).
p9072
sg4
(lp9073
sg24
(lp9074
(dp9075
g7
I244
sg27
VC0011849
p9076
sg10
I8
sg11
Vdiabetes
p9077
sg13
I1
sasa(dp9078
g2
VThe purpose of this study was to assess range of motion (ROM), pain, and incidence of radiographic degenerative joint disease (DJD) after volar radioscapholunate (RSL) arthrodesis and distal scaphoidectomy (DSE) following malunited distal radius fractures (DRF).
p9079
sg4
(lp9080
sg24
(lp9081
(dp9082
g7
I127
sg27
VC0029408
p9083
sg10
I3
sg11
VDJD
p9084
sg13
I1
sa(dp9085
g7
I99
sg27
VC0029408
p9086
sg10
I26
sg11
Vdegenerative joint disease
p9087
sg13
I3
sasa(dp9088
g2
VFourteen patients with malunited DRF and DJD limited to the radiocarpal joint underwent RSL arthrodesis and DSE between 2006 and 2014.
p9089
sg4
(lp9090
sg24
(lp9091
sa(dp9092
g2
VThe impact of a static electric field (EF) on amyloid peptide aggregation has been much less studied, although EFs may have some applications to treat Parkinson's disease symptoms.
p9093
sg4
(lp9094
sg24
(lp9095
(dp9096
g7
I46
sg27
VC0011560
p9097
sg10
I7
sg11
Vamyloid
p9098
sg13
I1
sa(dp9099
g7
I151
sg27
VC0030567
p9100
sg10
I19
sg11
VParkinson's disease
p9101
sg13
I2
sasa(dp9102
g2
VCognitive impairments occur frequently and early in multiple sclerosis (MS) and contribute significantly to a reduced quality of life of patients with MS. Executive functions (EFs) play a pivotal role for the behavioral adaption to the environment and are also crucial for compensatory processes of cognitive impairments.
p9103
sg4
(lp9104
sg24
(lp9105
(dp9106
g7
I299
sg27
VC0338656
p9107
sg10
I21
sg11
Vcognitive impairments
p9108
sg13
I2
sa(dp9109
g7
I72
sg27
VC0036429
p9110
sg10
I2
sg11
VMS
p9111
sg13
I1
sa(dp9112
g7
I72
sg27
VC0036429
p9113
sg10
I2
sg11
VMS
p9114
sg13
I1
sa(dp9115
g7
I0
sg27
VC0338656
p9116
sg10
I21
sg11
VCognitive impairments
p9117
sg13
I2
sa(dp9118
g7
I52
sg27
VC0026769
p9119
sg10
I18
sg11
Vmultiple sclerosis
p9120
sg13
I2
sasa(dp9121
g2
VSeveral recent studies have pointed out that early impairment of executive functions (EFs) in Parkinson's Disease (PD) may be a crucial marker to detect patients at risk for developing dementia.
p9122
sg4
(lp9123
sg24
(lp9124
(dp9125
g7
I51
sg27
VC0684336
p9126
sg10
I10
sg11
Vimpairment
p9127
sg13
I1
sa(dp9128
g7
I94
sg27
VC0030567
p9129
sg10
I19
sg11
VParkinson's Disease
p9130
sg13
I2
sa(dp9131
g7
I115
sg27
VC0030567
p9132
sg10
I2
sg11
VPD
p9133
sg13
I1
sa(dp9134
g7
I185
sg27
VC0497327
p9135
sg10
I8
sg11
Vdementia
p9136
sg13
I1
sasa(dp9137
g2
VImportantly, analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers of EVs that contained high levels of miR-27a as compared with healthy controls.
p9138
sg4
(lp9139
(dp9140
g7
I149
sg8
g9
sg10
I7
sg11
VmiR-27a
p9141
sg13
I1
sasg24
(lp9142
(dp9143
g7
I56
sg27
VC0019187
p9144
sg10
I19
sg11
Valcoholic hepatitis
p9145
sg13
I2
sasa(dp9146
g2
VThe following associations were found: auto-immune thyroid disease (4.3% of DH patients and 6.0% of CD patients), insulin dependent diabetes (1.0% DH and 5.5% CD), lupus erythematosus (1.3% DH and 0.3% CD), Sjoegren's syndrome (1.0% DH and 2.9% CD), sarcoidosis (1.3% DH and 1.8% CD), and vitiligo or alopecia areata (1.6% DH and 0% CD).
p9147
sg4
(lp9148
(dp9149
g7
I114
sg8
VP01308
p9150
sg10
I7
sg11
Vinsulin
p9151
sg13
I1
sasg24
(lp9152
(dp9153
g7
I51
sg27
VC0040128
p9154
sg10
I15
sg11
Vthyroid disease
p9155
sg13
I2
sa(dp9156
g7
I114
sg27
VC0011854
p9157
sg10
I26
sg11
Vinsulin dependent diabetes
p9158
sg13
I3
sa(dp9159
g7
I164
sg27
VC0409974
p9160
sg10
I19
sg11
Vlupus erythematosus
p9161
sg13
I2
sa(dp9162
g7
I250
sg27
VC0036202
p9163
sg10
I11
sg11
Vsarcoidosis
p9164
sg13
I1
sa(dp9165
g7
I301
sg27
VC0002171
p9166
sg10
I15
sg11
Valopecia areata
p9167
sg13
I2
sa(dp9168
g7
I207
sg27
VC1527336
p9169
sg10
I19
sg11
VSjoegren's syndrome
p9170
sg13
I2
sa(dp9171
g7
I289
sg27
VC0042900
p9172
sg10
I8
sg11
Vvitiligo
p9173
sg13
I1
sasa(dp9174
g2
VRarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the Beta-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.
p9175
sg4
(lp9176
(dp9177
g7
I331
sg8
g9
sg10
I5
sg11
VATXN3
p9178
sg13
I1
sa(dp9179
g7
I511
sg8
VP04062
p9180
sg10
I3
sg11
VGBA
p9181
sg13
I1
sa(dp9182
g7
I486
sg8
VP02774
p9183
sg10
I23
sg11
VBeta-glucocerebrosidase
p9184
sg13
I1
sa(dp9185
g7
I557
sg8
g9
sg10
I9
sg11
VLYST gene
p9186
sg13
I2
sa(dp9187
g7
I388
sg8
g9
sg10
I12
sg11
VATP13A2 gene
p9188
sg13
I2
sa(dp9189
g7
I321
sg8
g9
sg10
I8
sg11
Vataxin-3
p9190
sg13
I1
sasg24
(lp9191
(dp9192
g7
I344
sg27
VC1847640
p9193
sg10
I20
sg11
VKufor-Rakeb syndrome
p9194
sg13
I2
sa(dp9195
g7
I75
sg27
VC0524851
p9196
sg10
I26
sg11
Vneurodegenerative diseases
p9197
sg13
I2
sa(dp9198
g7
I525
sg27
VC0007965
p9199
sg10
I24
sg11
VChediak-Higashi syndrome
p9200
sg13
I2
sa(dp9201
g7
I149
sg27
VC0039082
p9202
sg10
I8
sg11
Vsyndrome
p9203
sg13
I1
sa(dp9204
g7
I219
sg27
VC0025362
p9205
sg10
I18
sg11
Vmental retardation
p9206
sg13
I2
sa(dp9207
g7
I142
sg27
VC0004134
p9208
sg10
I6
sg11
Vataxia
p9209
sg13
I1
sa(dp9210
g7
I26
sg27
VC0242422
p9211
sg10
I12
sg11
Vparkinsonism
p9212
sg13
I1
sa(dp9213
g7
I131
sg27
VC0040822
p9214
sg10
I6
sg11
Vtremor
p9215
sg13
I1
sa(dp9216
g7
I251
sg27
VC0024408
p9217
sg10
I22
sg11
VMachado-Joseph disease
p9218
sg13
I2
sa(dp9219
g7
I446
sg27
VC0017205
p9220
sg10
I15
sg11
VGaucher disease
p9221
sg13
I2
sasa(dp9222
g2
VWe also identified the mutation of the LYST gene, that is causative gene for Chediak-Higashi syndrome, for the autosomal recessive complicated spastic paraplegia with cerebellar ataxia and neuropathy.
p9223
sg4
(lp9224
(dp9225
g7
I39
sg8
g9
sg10
I9
sg11
VLYST gene
p9226
sg13
I2
sasg24
(lp9227
(dp9228
g7
I167
sg27
VC0007758
p9229
sg10
I17
sg11
Vcerebellar ataxia
p9230
sg13
I2
sa(dp9231
g7
I189
sg27
VC0442874
p9232
sg10
I10
sg11
Vneuropathy
p9233
sg13
I1
sa(dp9234
g7
I143
sg27
VC0037772
p9235
sg10
I18
sg11
Vspastic paraplegia
p9236
sg13
I2
sa(dp9237
g7
I77
sg27
VC0007965
p9238
sg10
I24
sg11
VChediak-Higashi syndrome
p9239
sg13
I2
sasa(dp9240
g2
VTo our knowledge, this is the first study on spina bifida to determine the nucleotide sequences of breakpoints for trisomy 2p24.3-pter and monosomy 5p14.3-pter.
p9241
sg4
(lp9242
sg24
(lp9243
(dp9244
g7
I45
sg27
VC0080178
p9245
sg10
I12
sg11
Vspina bifida
p9246
sg13
I2
sa(dp9247
g7
I139
sg27
VC0026499
p9248
sg10
I8
sg11
Vmonosomy
p9249
sg13
I1
sa(dp9250
g7
I115
sg27
VC0041107
p9251
sg10
I7
sg11
Vtrisomy
p9252
sg13
I1
sasa(dp9253
g2
VOur report serves to emphasize the consistency in the prenatal sonographic feature of spina bifida in consecutive pregnancies with fetuses associated with partial trisomy 3q (3q26.1-qter) and partial monosomy 5p (5p13.33-pter).
p9254
sg4
(lp9255
sg24
(lp9256
(dp9257
g7
I155
sg27
VC1297882
p9258
sg10
I15
sg11
Vpartial trisomy
p9259
sg13
I2
sa(dp9260
g7
I163
sg27
VC0795809
p9261
sg10
I10
sg11
Vtrisomy 3q
p9262
sg13
I2
sa(dp9263
g7
I192
sg27
VC0008628
p9264
sg10
I16
sg11
Vpartial monosomy
p9265
sg13
I2
sa(dp9266
g7
I86
sg27
VC0080178
p9267
sg10
I12
sg11
Vspina bifida
p9268
sg13
I2
sasa(dp9269
g2
VThese are classified into ten different types (NDNC1-10), which are described in OMIM.1 The genes described for isolated nail disorders include PLCD1 (MIM 602142), RSPO4 (MIM 610573), FZD6 (MIM 603409), COL7A1 (MIM 120120), HPGD (MIM 601688) and SLCO2A1 (MIM 601460).
p9270
sg4
(lp9271
(dp9272
g7
I151
sg8
g9
sg10
I10
sg11
VMIM 602142
p9273
sg13
I2
sa(dp9274
g7
I255
sg8
g9
sg10
I10
sg11
VMIM 601460
p9275
sg13
I2
sa(dp9276
g7
I203
sg8
g9
sg10
I6
sg11
VCOL7A1
p9277
sg13
I1
sa(dp9278
g7
I190
sg8
g9
sg10
I10
sg11
VMIM 603409
p9279
sg13
I2
sa(dp9280
g7
I184
sg8
g9
sg10
I4
sg11
VFZD6
p9281
sg13
I1
sa(dp9282
g7
I211
sg8
g9
sg10
I10
sg11
VMIM 120120
p9283
sg13
I2
sa(dp9284
g7
I144
sg8
VP51178
p9285
sg10
I5
sg11
VPLCD1
p9286
sg13
I1
sa(dp9287
g7
I171
sg8
g9
sg10
I10
sg11
VMIM 610573
p9288
sg13
I2
sa(dp9289
g7
I164
sg8
g9
sg10
I5
sg11
VRSPO4
p9290
sg13
I1
sa(dp9291
g7
I246
sg8
g9
sg10
I7
sg11
VSLCO2A1
p9292
sg13
I1
sasg24
(lp9293
(dp9294
g7
I121
sg27
VC0027339
p9295
sg10
I14
sg11
Vnail disorders
p9296
sg13
I2
sa(dp9297
g7
I47
sg27
VC0406443
p9298
sg10
I5
sg11
VNDNC1
p9299
sg13
I1
sasa(dp9300
g2
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence (anonychia) or hypoplasia (hyponuchia) of finger- and/or toenails frequently caused by mutations in the R-spondin 4 (RSPO4) gene.
p9301
sg4
(lp9302
(dp9303
g7
I217
sg8
g9
sg10
I11
sg11
VR-spondin 4
p9304
sg13
I2
sa(dp9305
g7
I230
sg8
g9
sg10
I5
sg11
VRSPO4
p9306
sg13
I1
sasg24
(lp9307
(dp9308
g7
I128
sg27
VC0243069
p9309
sg10
I10
sg11
Vhypoplasia
p9310
sg13
I1
sa(dp9311
g7
I0
sg27
VC0265998
p9312
sg10
I112
sg11
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence
p9313
sg13
I13
sa(dp9314
g7
I114
sg27
VC0265998
p9315
sg10
I9
sg11
Vanonychia
p9316
sg13
I1
sasa(dp9317
g2
VBecause there were no other congenital abnormalities, this was considered to be anonychia congenita; probably caused by a recessive defect of the R-spondin 4-coding gene.
p9318
sg4
(lp9319
(dp9320
g7
I146
sg8
g9
sg10
I23
sg11
VR-spondin 4-coding gene
p9321
sg13
I3
sasg24
(lp9322
(dp9323
g7
I80
sg27
VC0265998
p9324
sg10
I19
sg11
Vanonychia congenita
p9325
sg13
I2
sa(dp9326
g7
I28
sg27
VC0000768
p9327
sg10
I24
sg11
Vcongenital abnormalities
p9328
sg13
I2
sasa(dp9329
g2
VTo investigate whether receipt of any antithrombin concentrate improves laboratory and clinical outcomes in children undergoing extracorporeal membrane oxygenation for respiratory failure during their hospitalization compared with those who did not receive antithrombin.
p9330
sg4
(lp9331
(dp9332
g7
I38
sg8
VP05546
p9333
sg10
I12
sg11
Vantithrombin
p9334
sg13
I1
sa(dp9335
g7
I38
sg8
VP05546
p9336
sg10
I12
sg11
Vantithrombin
p9337
sg13
I1
sasg24
(lp9338
(dp9339
g7
I168
sg27
VC1145670
p9340
sg10
I19
sg11
Vrespiratory failure
p9341
sg13
I2
sasa(dp9342
g2
VIntermittent, on-demand dosing of antithrombin concentrate in pediatric patients on extracorporeal membrane oxygenation for respiratory failure increased antithrombin levels, but not typically to the targeted level.
p9343
sg4
(lp9344
(dp9345
g7
I34
sg8
VP05546
p9346
sg10
I12
sg11
Vantithrombin
p9347
sg13
I1
sa(dp9348
g7
I34
sg8
VP05546
p9349
sg10
I12
sg11
Vantithrombin
p9350
sg13
I1
sasg24
(lp9351
(dp9352
g7
I124
sg27
VC1145670
p9353
sg10
I19
sg11
Vrespiratory failure
p9354
sg13
I2
sasa(dp9355
g2
VWe hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS.
p9356
sg4
(lp9357
(dp9358
g7
I75
sg8
VP05546
p9359
sg10
I4
sg11
VrhAT
p9360
sg13
I1
sa(dp9361
g7
I75
sg8
VP05546
p9362
sg10
I4
sg11
VrhAT
p9363
sg13
I1
sa(dp9364
g7
I43
sg8
VP05546
p9365
sg10
I30
sg11
Vrecombinant human antithrombin
p9366
sg13
I3
sa(dp9367
g7
I145
sg8
VP00747
p9368
sg10
I3
sg11
VTPA
p9369
sg13
I1
sa(dp9370
g7
I75
sg8
VP05546
p9371
sg10
I4
sg11
VrhAT
p9372
sg13
I1
sa(dp9373
g7
I115
sg8
VP00747
p9374
sg10
I28
sg11
Vtissue plasminogen activator
p9375
sg13
I3
sasg24
(lp9376
(dp9377
g7
I299
sg27
VC0035222
p9378
sg10
I4
sg11
VARDS
p9379
sg13
I1
sasa(dp9380
g2
VAfter 12 months, bonds fell from 43.9 +/- 9.5 MPa to 20.1 +/- 5.4 MPa and from 39.6 +/- 9.4 MPa to 14.2 +/- 5.0 MPa in control specimens for SB1 and XPB respectively, while bond fell only from 41.9 +/- 9.6MPa to 33.2 +/- 8.3 MPa and 38.3 +/- 8.9 MPa to 26.5 +/- 10.9 (for SB1 and XPB, respectively) when 0.2% CHX was previously used.
p9381
sg4
(lp9382
(dp9383
g7
I141
sg8
g9
sg10
I3
sg11
VSB1
p9384
sg13
I1
sa(dp9385
g7
I149
sg8
VP19447
p9386
sg10
I3
sg11
VXPB
p9387
sg13
I1
sasg24
(lp9388
(dp9389
g7
I149
sg27
VC0268136
p9390
sg10
I3
sg11
VXPB
p9391
sg13
I1
sa(dp9392
g7
I149
sg27
VC0268136
p9393
sg10
I3
sg11
VXPB
p9394
sg13
I1
sasa(dp9395
g2
VPrimary SFs from patients with rheumatoid arthritis (RA) were treated with recombinant human bone morphogenetic protein-2 or transduced with a constitutively active mutant of the ALK3 gene (ALK3CA) with or without TNF-Alfa, and then cultured in pellets.
p9396
sg4
(lp9397
(dp9398
g7
I179
sg8
VP36894
p9399
sg10
I9
sg11
VALK3 gene
p9400
sg13
I2
sa(dp9401
g7
I214
sg8
VP01375
p9402
sg10
I8
sg11
VTNF-Alfa
p9403
sg13
I1
sasg24
(lp9404
(dp9405
g7
I53
sg27
VC0003873
p9406
sg10
I2
sg11
VRA
p9407
sg13
I1
sa(dp9408
g7
I165
sg27
VC0596988
p9409
sg10
I6
sg11
Vmutant
p9410
sg13
I1
sa(dp9411
g7
I31
sg27
VC0003873
p9412
sg10
I20
sg11
Vrheumatoid arthritis
p9413
sg13
I2
sasa(dp9414
g2
VWe describe a patient with ALK-negative ALCL presenting with clinical and radiographic findings suggesting osteomyelitis 6 months after left rotator cuff repair surgery.
p9415
sg4
(lp9416
sg24
(lp9417
(dp9418
g7
I40
sg27
VC0206180
p9419
sg10
I4
sg11
VALCL
p9420
sg13
I1
sa(dp9421
g7
I107
sg27
VC0029443
p9422
sg10
I13
sg11
Vosteomyelitis
p9423
sg13
I1
sasa(dp9424
g2
VWe compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and GABA(B) receptor 2 (GABBR2) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with autism and matched controls.
p9425
sg4
(lp9426
(dp9427
g7
I80
sg8
g9
sg10
I18
sg11
VGABA(B) receptor 2
p9428
sg13
I3
sa(dp9429
g7
I100
sg8
g9
sg10
I6
sg11
VGABBR2
p9430
sg13
I1
sa(dp9431
g7
I48
sg8
g9
sg10
I18
sg11
VGABA(B) receptor 1
p9432
sg13
I3
sa(dp9433
g7
I22
sg8
g9
sg10
I16
sg11
VGABA(B) receptor
p9434
sg13
I2
sa(dp9435
g7
I68
sg8
g9
sg10
I6
sg11
VGABBR1
p9436
sg13
I1
sasg24
(lp9437
(dp9438
g7
I174
sg27
VC0004352
p9439
sg10
I6
sg11
Vautism
p9440
sg13
I1
sasa(dp9441
g2
VSclerosteosis is caused by loss-of-function mutations in the SOST gene which encodes a secreted glycoprotein, sclerostin.
p9442
sg4
(lp9443
(dp9444
g7
I61
sg8
g9
sg10
I9
sg11
VSOST gene
p9445
sg13
I2
sasg24
(lp9446
(dp9447
g7
I0
sg27
VC0265301
p9448
sg10
I13
sg11
VSclerosteosis
p9449
sg13
I1
sa(dp9450
g7
I61
sg27
VC0265301
p9451
sg10
I4
sg11
VSOST
p9452
sg13
I1
sasa(dp9453
g2
VVBD is caused by a noncoding deletion that removes a SOST-specific regulatory element in bone.
p9454
sg4
(lp9455
sg24
(lp9456
(dp9457
g7
I53
sg27
VC0265301
p9458
sg10
I4
sg11
VSOST
p9459
sg13
I1
sasa(dp9460
g2
VHere we describe how human genetics studies in sclerosteosis and VBD patients, in combination with the generation of transgenic and knockout mice, has led to a better understanding of the role of sclerostin in bone metabolism.
p9461
sg4
(lp9462
(dp9463
g7
I196
sg8
g9
sg10
I10
sg11
Vsclerostin
p9464
sg13
I1
sasg24
(lp9465
(dp9466
g7
I47
sg27
VC0265301
p9467
sg10
I13
sg11
Vsclerosteosis
p9468
sg13
I1
sasa(dp9469
g2
VIn addition, expression of SOST is delayed or suppressed; resulting in active WNT signaling and enhanced periosteal bone formation, and the combined outcome is generalized hyperostosis.
p9470
sg4
(lp9471
(dp9472
g7
I27
sg8
g9
sg10
I4
sg11
VSOST
p9473
sg13
I1
sasg24
(lp9474
(dp9475
g7
I27
sg27
VC0265301
p9476
sg10
I4
sg11
VSOST
p9477
sg13
I1
sa(dp9478
g7
I172
sg27
VC0020492
p9479
sg10
I12
sg11
Vhyperostosis
p9480
sg13
I1
sasa(dp9481
g2
VInitially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin.
p9482
sg4
(lp9483
(dp9484
g7
I97
sg8
g9
sg10
I4
sg11
VSOST
p9485
sg13
I1
sasg24
(lp9486
(dp9487
g7
I97
sg27
VC0265301
p9488
sg10
I4
sg11
VSOST
p9489
sg13
I1
sa(dp9490
g7
I39
sg27
VC0265301
p9491
sg10
I13
sg11
Vsclerosteosis
p9492
sg13
I1
sasa(dp9493
g2
VMore recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients.
p9494
sg4
(lp9495
(dp9496
g7
I85
sg8
g9
sg10
I10
sg11
Vsclerostin
p9497
sg13
I1
sa(dp9498
g7
I58
sg8
g9
sg10
I4
sg11
VLRP4
p9499
sg13
I1
sasg24
(lp9500
(dp9501
g7
I106
sg27
VC0265301
p9502
sg10
I13
sg11
Vsclerosteosis
p9503
sg13
I1
sasa(dp9504
g2
VThe positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.
p9505
sg4
(lp9506
sg24
(lp9507
(dp9508
g7
I64
sg27
VC0029401
p9509
sg10
I21
sg11
VPaget disease of bone
p9510
sg13
I4
sasa(dp9511
g2
VSclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin.
p9512
sg4
(lp9513
sg24
(lp9514
(dp9515
g7
I0
sg27
VC0265301
p9516
sg10
I13
sg11
VSclerosteosis
p9517
sg13
I1
sa(dp9518
g7
I18
sg27
VC0432272
p9519
sg10
I18
sg11
Vvan Buchem disease
p9520
sg13
I3
sa(dp9521
g7
I66
sg27
VC0334044
p9522
sg10
I10
sg11
Vdysplasias
p9523
sg13
I1
sasa(dp9524
g2
VIn this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis.
p9525
sg4
(lp9526
(dp9527
g7
I217
sg8
g9
sg10
I10
sg11
Vsclerostin
p9528
sg13
I1
sasg24
(lp9529
(dp9530
g7
I148
sg27
VC0432272
p9531
sg10
I18
sg11
Vvan Buchem disease
p9532
sg13
I3
sa(dp9533
g7
I379
sg27
VC0029456
p9534
sg10
I12
sg11
Vosteoporosis
p9535
sg13
I1
sa(dp9536
g7
I130
sg27
VC0265301
p9537
sg10
I13
sg11
Vsclerosteosis
p9538
sg13
I1
sasa(dp9539
g2
VAfter discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation.
p9540
sg4
(lp9541
(dp9542
g7
I36
sg8
g9
sg10
I10
sg11
Vsclerostin
p9543
sg13
I1
sa(dp9544
g7
I31
sg8
g9
sg10
I4
sg11
VSost
p9545
sg13
I1
sasg24
(lp9546
(dp9547
g7
I132
sg27
VC0265301
p9548
sg10
I13
sg11
Vsclerosteosis
p9549
sg13
I1
sa(dp9550
g7
I99
sg27
VC0039082
p9551
sg10
I9
sg11
Vsyndromes
p9552
sg13
I1
sa(dp9553
g7
I31
sg27
VC0265301
p9554
sg10
I4
sg11
VSost
p9555
sg13
I1
sa(dp9556
g7
I109
sg27
VC0432272
p9557
sg10
I18
sg11
VVan Buchem disease
p9558
sg13
I3
sasa(dp9559
g2
VLoss-of-function mutations of the sclerostin gene (SOST) cause sclerosteosis and Van Buchem disease characterized by bone overgrowth.
p9560
sg4
(lp9561
(dp9562
g7
I34
sg8
g9
sg10
I15
sg11
Vsclerostin gene
p9563
sg13
I2
sa(dp9564
g7
I51
sg8
g9
sg10
I4
sg11
VSOST
p9565
sg13
I1
sasg24
(lp9566
(dp9567
g7
I34
sg27
VC0265301
p9568
sg10
I15
sg11
Vsclerostin gene
p9569
sg13
I2
sa(dp9570
g7
I63
sg27
VC0265301
p9571
sg10
I13
sg11
Vsclerosteosis
p9572
sg13
I1
sa(dp9573
g7
I51
sg27
VC0265301
p9574
sg10
I4
sg11
VSOST
p9575
sg13
I1
sa(dp9576
g7
I81
sg27
VC0432272
p9577
sg10
I18
sg11
VVan Buchem disease
p9578
sg13
I3
sasa(dp9579
g2
VMutations in the human sclerostin gene (SOST) lead to sclerosteosis with progressive skeletal overgrowth, whereas sclerostin-deficient (Sost(-/-)) mice exhibit increased bone mass and strength.
p9580
sg4
(lp9581
(dp9582
g7
I17
sg8
g9
sg10
I21
sg11
Vhuman sclerostin gene
p9583
sg13
I3
sa(dp9584
g7
I40
sg8
g9
sg10
I4
sg11
VSOST
p9585
sg13
I1
sasg24
(lp9586
(dp9587
g7
I23
sg27
VC0265301
p9588
sg10
I15
sg11
Vsclerostin gene
p9589
sg13
I2
sa(dp9590
g7
I136
sg27
VC0265301
p9591
sg10
I4
sg11
VSost
p9592
sg13
I1
sa(dp9593
g7
I40
sg27
VC0265301
p9594
sg10
I4
sg11
VSOST
p9595
sg13
I1
sa(dp9596
g7
I54
sg27
VC0265301
p9597
sg10
I13
sg11
Vsclerosteosis
p9598
sg13
I1
sasa(dp9599
g2
VTherefore, this study provides additional support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.
p9600
sg4
(lp9601
(dp9602
g7
I61
sg8
g9
sg10
I3
sg11
VOGA
p9603
sg13
I1
sasg24
(lp9604
(dp9605
g7
I143
sg27
VC0949664
p9606
sg10
I11
sg11
Vtauopathies
p9607
sg13
I1
sa(dp9608
g7
I95
sg27
VC1521724
p9609
sg10
I19
sg11
VAlzheimer's disease
p9610
sg13
I2
sasa(dp9611
g2
VTo identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis.
p9612
sg4
(lp9613
(dp9614
g7
I79
sg8
g9
sg10
I28
sg11
VUDP-glucuronosyltransferases
p9615
sg13
I1
sa(dp9616
g7
I109
sg8
g9
sg10
I4
sg11
VUGTs
p9617
sg13
I1
sasg24
(lp9618
(dp9619
g7
I53
sg27
VC0007097
p9620
sg10
I10
sg11
Vcarcinomas
p9621
sg13
I1
sasa(dp9622
g2
VIn this study, the expression and regulation of two androgen-inactivating enzymes, the UDP-glucuronosyltransferases UGT2B15 and UGT2B17, was assessed in breast cancer.
p9623
sg4
(lp9624
(dp9625
g7
I128
sg8
g9
sg10
I7
sg11
VUGT2B17
p9626
sg13
I1
sa(dp9627
g7
I87
sg8
VP54855
p9628
sg10
I36
sg11
VUDP-glucuronosyltransferases UGT2B15
p9629
sg13
I2
sasg24
(lp9630
(dp9631
g7
I153
sg27
VC0678222
p9632
sg10
I13
sg11
Vbreast cancer
p9633
sg13
I2
sasa(dp9634
g2
VGlobal ablation of INSL3 hormone or its receptor RXFP2 in male mice results in cryptorchidism and infertility.
p9635
sg4
(lp9636
(dp9637
g7
I49
sg8
g9
sg10
I5
sg11
VRXFP2
p9638
sg13
I1
sa(dp9639
g7
I19
sg8
VP51460
p9640
sg10
I13
sg11
VINSL3 hormone
p9641
sg13
I2
sasg24
(lp9642
(dp9643
g7
I98
sg27
VC0021359
p9644
sg10
I11
sg11
Vinfertility
p9645
sg13
I1
sa(dp9646
g7
I79
sg27
VC0010417
p9647
sg10
I14
sg11
Vcryptorchidism
p9648
sg13
I1
sasa(dp9649
g2
VWe have also produced shRNA transgenic mice with reduced RXFP2 expression Such males manifested various degree of uni- and bilateral cryptorchidism.
p9650
sg4
(lp9651
(dp9652
g7
I57
sg8
g9
sg10
I5
sg11
VRXFP2
p9653
sg13
I1
sasg24
(lp9654
(dp9655
g7
I123
sg27
VC0431663
p9656
sg10
I24
sg11
Vbilateral cryptorchidism
p9657
sg13
I2
sasa(dp9658
g2
VTo study the consequences of an aberrant testicular environment in cryptorchidism we used a mouse model with a deletion of Rxfp2 gene resulting in a high intra-abdominal testicular position.
p9659
sg4
(lp9660
(dp9661
g7
I123
sg8
g9
sg10
I10
sg11
VRxfp2 gene
p9662
sg13
I2
sasg24
(lp9663
(dp9664
g7
I67
sg27
VC0010417
p9665
sg10
I14
sg11
Vcryptorchidism
p9666
sg13
I1
sasa(dp9667
g2
VDeletion of Insl3 or Rxfp2 genes in mice caused cryptorchidism resulting from a failure of gubernaculum development.
p9668
sg4
(lp9669
(dp9670
g7
I12
sg8
VP51460
p9671
sg10
I5
sg11
VInsl3
p9672
sg13
I1
sa(dp9673
g7
I21
sg8
g9
sg10
I11
sg11
VRxfp2 genes
p9674
sg13
I2
sasg24
(lp9675
(dp9676
g7
I48
sg27
VC0010417
p9677
sg10
I14
sg11
Vcryptorchidism
p9678
sg13
I1
sasa(dp9679
g2
VUsing Cre transgene driven by retinoic acid receptor beta promoter, conditional gene targeting in gubernacular mesenchymal cells at early embryonic stages caused high intraabdominal cryptorchidism as in males with a global deletion of Rxfp2.
p9680
sg4
(lp9681
(dp9682
g7
I30
sg8
VP10826
p9683
sg10
I36
sg11
Vretinoic acid receptor beta promoter
p9684
sg13
I5
sa(dp9685
g7
I6
sg8
g9
sg10
I13
sg11
VCre transgene
p9686
sg13
I2
sa(dp9687
g7
I235
sg8
g9
sg10
I5
sg11
VRxfp2
p9688
sg13
I1
sasg24
(lp9689
(dp9690
g7
I182
sg27
VC0010417
p9691
sg10
I14
sg11
Vcryptorchidism
p9692
sg13
I1
sasa(dp9693
g2
VPrenatal exposure to diethylstilbestrol affected the expression of LGR8 mRNA in the mouse gubernaculum testis, which suggests that diethylstilbestrol may induce cryptorchidism by interfering with the INSL3-LGR8 signaling system and consequently the development of the gubernaculum testis.
p9694
sg4
(lp9695
(dp9696
g7
I67
sg8
VP51460
p9697
sg10
I4
sg11
VLGR8
p9698
sg13
I1
sa(dp9699
g7
I200
sg8
VP51460
p9700
sg10
I5
sg11
VINSL3
p9701
sg13
I1
sa(dp9702
g7
I67
sg8
VP51460
p9703
sg10
I9
sg11
VLGR8 mRNA
p9704
sg13
I2
sasg24
(lp9705
(dp9706
g7
I161
sg27
VC0010417
p9707
sg10
I14
sg11
Vcryptorchidism
p9708
sg13
I1
sasa(dp9709
g2
VProspectively collected cremaster muscle and/or hernia sac tissues from boys with congenital (79) or acquired (66) nonsyndromic cryptorchidism and hernia/hydrocele (controls, 84) were analyzed for hormone receptor (RXFP2, AR, ESR1, ESR2) and myosin heavy chain specific (MYH1, MYH2, MYH7) mRNA expression using real-time reverse transcriptase polymerase chain reaction.
p9710
sg4
(lp9711
(dp9712
g7
I226
sg8
VP03372
p9713
sg10
I4
sg11
VESR1
p9714
sg13
I1
sa(dp9715
g7
I277
sg8
g9
sg10
I4
sg11
VMYH2
p9716
sg13
I1
sa(dp9717
g7
I242
sg8
VP13535
p9718
sg10
I18
sg11
Vmyosin heavy chain
p9719
sg13
I3
sa(dp9720
g7
I193
sg8
VP22736
p9721
sg10
I20
sg11
Vfor hormone receptor
p9722
sg13
I3
sa(dp9723
g7
I271
sg8
VP12882
p9724
sg10
I4
sg11
VMYH1
p9725
sg13
I1
sa(dp9726
g7
I215
sg8
g9
sg10
I5
sg11
VRXFP2
p9727
sg13
I1
sasg24
(lp9728
(dp9729
g7
I48
sg27
VC0333062
p9730
sg10
I10
sg11
Vhernia sac
p9731
sg13
I2
sa(dp9732
g7
I128
sg27
VC0010417
p9733
sg10
I14
sg11
Vcryptorchidism
p9734
sg13
I1
sa(dp9735
g7
I48
sg27
VC0019270
p9736
sg10
I6
sg11
Vhernia
p9737
sg13
I1
sa(dp9738
g7
I154
sg27
VC1720771
p9739
sg10
I9
sg11
Vhydrocele
p9740
sg13
I1
sasa(dp9741
g2
VExon sequencing of candidate genes identified mutations in mice with cystic kidneys (Bicc1), cryptorchidism (Rxfp2), restricted germ cell deficiency (Plk4), and severe germ cell deficiency (Prdm9).
p9742
sg4
(lp9743
(dp9744
g7
I150
sg8
g9
sg10
I4
sg11
VPlk4
p9745
sg13
I1
sa(dp9746
g7
I109
sg8
g9
sg10
I5
sg11
VRxfp2
p9747
sg13
I1
sa(dp9748
g7
I190
sg8
g9
sg10
I5
sg11
VPrdm9
p9749
sg13
I1
sa(dp9750
g7
I85
sg8
g9
sg10
I5
sg11
VBicc1
p9751
sg13
I1
sasg24
(lp9752
(dp9753
g7
I93
sg27
VC0010417
p9754
sg10
I14
sg11
Vcryptorchidism
p9755
sg13
I1
sa(dp9756
g7
I69
sg27
VC0022679
p9757
sg10
I14
sg11
Vcystic kidneys
p9758
sg13
I2
sasa(dp9759
g2
VPatients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded.
p9760
sg4
(lp9761
(dp9762
g7
I190
sg8
VP02741
p9763
sg10
I18
sg11
VC-reactive protein
p9764
sg13
I2
sa(dp9765
g7
I179
sg8
VP00441
p9766
sg10
I7
sg11
Valbumin
p9767
sg13
I1
sasg24
(lp9768
(dp9769
g7
I96
sg27
VC0034065
p9770
sg10
I18
sg11
Vpulmonary embolism
p9771
sg13
I2
sa(dp9772
g7
I23
sg27
VC0032285
p9773
sg10
I9
sg11
Vpneumonia
p9774
sg13
I1
sa(dp9775
g7
I70
sg27
VC0023212
p9776
sg10
I24
sg11
Vleft-sided heart failure
p9777
sg13
I3
sasa(dp9778
g2
VAnalyzing gene expression signatures in endometrial and stomach adenocarcinomas revealed that tumors with a JAK1 frameshift exhibited reduced expression of interferon response signatures and multiple anti-tumor immune signatures.
p9779
sg4
(lp9780
(dp9781
g7
I156
sg8
VP01563
p9782
sg10
I10
sg11
Vinterferon
p9783
sg13
I1
sa(dp9784
g7
I108
sg8
VP23458
p9785
sg10
I4
sg11
VJAK1
p9786
sg13
I1
sasg24
(lp9787
(dp9788
g7
I64
sg27
VC0001418
p9789
sg10
I15
sg11
Vadenocarcinomas
p9790
sg13
I1
sa(dp9791
g7
I113
sg27
VC0079380
p9792
sg10
I10
sg11
Vframeshift
p9793
sg13
I1
sa(dp9794
g7
I94
sg27
VC0027651
p9795
sg10
I6
sg11
Vtumors
p9796
sg13
I1
sa(dp9797
g7
I94
sg27
VC0027651
p9798
sg10
I5
sg11
Vtumor
p9799
sg13
I1
sasa(dp9800
g2
VFrom these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
p9801
sg4
(lp9802
(dp9803
g7
I358
sg8
VP01563
p9804
sg10
I10
sg11
Vinterferon
p9805
sg13
I1
sa(dp9806
g7
I55
sg8
VP23458
p9807
sg10
I4
sg11
VJAK1
p9808
sg13
I1
sa(dp9809
g7
I55
sg8
VP23458
p9810
sg10
I4
sg11
VJAK1
p9811
sg13
I1
sa(dp9812
g7
I55
sg8
VP23458
p9813
sg10
I4
sg11
VJAK1
p9814
sg13
I1
sasg24
(lp9815
(dp9816
g7
I136
sg27
VC0006826
p9817
sg10
I6
sg11
Vcancer
p9818
sg13
I1
sa(dp9819
g7
I182
sg27
VC0027651
p9820
sg10
I6
sg11
Vtumors
p9821
sg13
I1
sa(dp9822
g7
I285
sg27
VC0282683
p9823
sg10
I20
sg11
Vtumor immune evasion
p9824
sg13
I3
sa(dp9825
g7
I194
sg27
VC0920269
p9826
sg10
I26
sg11
Vmicrosatellite instability
p9827
sg13
I2
sasa(dp9828
g2
VMAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.
p9829
sg4
(lp9830
(dp9831
g7
I69
sg8
VP23458
p9832
sg10
I6
sg11
VJAK1/2
p9833
sg13
I1
sasg24
(lp9834
(dp9835
g7
I129
sg27
VC0032463
p9836
sg10
I17
sg11
Vpolycythemia vera
p9837
sg13
I2
sasa(dp9838
g2
VRuxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.
p9839
sg4
(lp9840
(dp9841
g7
I21
sg8
VP23458
p9842
sg10
I6
sg11
VJAK1/2
p9843
sg13
I1
sasg24
(lp9844
(dp9845
g7
I75
sg27
VC0001815
p9846
sg10
I13
sg11
Vmyelofibrosis
p9847
sg13
I1
sa(dp9848
g7
I96
sg27
VC0032463
p9849
sg10
I17
sg11
Vpolycythemia vera
p9850
sg13
I2
sasa(dp9851
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder that is characterized by episodic yet cumulative heterotopic ossification (HO) in skeletal muscles, tendons, and ligaments over a patient's lifetime.
p9852
sg4
(lp9853
sg24
(lp9854
(dp9855
g7
I157
sg27
VC0029396
p9856
sg10
I2
sg11
VHO
p9857
sg13
I1
sa(dp9858
g7
I0
sg27
VC0016037
p9859
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p9860
sg13
I3
sa(dp9861
g7
I131
sg27
VC0029396
p9862
sg10
I24
sg11
Vheterotopic ossification
p9863
sg13
I2
sa(dp9864
g7
I39
sg27
VC0016037
p9865
sg10
I3
sg11
VFOP
p9866
sg13
I1
sasa(dp9867
g2
VGain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival.
p9868
sg4
(lp9869
(dp9870
g7
I34
sg8
VP29475
p9871
sg10
I31
sg11
VType I Bone Morphogenic Protein
p9872
sg13
I5
sasg24
(lp9873
(dp9874
g7
I329
sg27
VC0220603
p9875
sg10
I21
sg11
Vpediatric brain tumor
p9876
sg13
I3
sa(dp9877
g7
I310
sg27
VC0017638
p9878
sg10
I7
sg11
VGliomas
p9879
sg13
I1
sa(dp9880
g7
I241
sg27
VC0029396
p9881
sg10
I24
sg11
Vheterotopic ossification
p9882
sg13
I2
sa(dp9883
g7
I164
sg27
VC0016037
p9884
sg10
I3
sg11
VFOP
p9885
sg13
I1
sa(dp9886
g7
I125
sg27
VC0016037
p9887
sg10
I37
sg11
VFibrodysplasia Ossificans Progressiva
p9888
sg13
I3
sasa(dp9889
g2
VFibrodysplasia ossificans progressiva is an autosomal dominant disorder due to germline mutations of ACVR1/ALK2 causing progressive heterotopic endochondral ossifications.
p9890
sg4
(lp9891
(dp9892
g7
I107
sg8
g9
sg10
I4
sg11
VALK2
p9893
sg13
I1
sa(dp9894
g7
I101
sg8
g9
sg10
I5
sg11
VACVR1
p9895
sg13
I1
sasg24
(lp9896
(dp9897
g7
I0
sg27
VC0016037
p9898
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p9899
sg13
I3
sasa(dp9900
g2
VIt is an autosomal dominant disease, usually caused by a new mutation in the ACVR1 receptor gene, which is in the signaling pathway for bone morphogenic protein.
p9901
sg4
(lp9902
(dp9903
g7
I77
sg8
g9
sg10
I19
sg11
VACVR1 receptor gene
p9904
sg13
I3
sasg24
(lp9905
(dp9906
g7
I57
sg27
VC2985439
p9907
sg10
I12
sg11
Vnew mutation
p9908
sg13
I2
sasa(dp9909
g2
VFibrodysplasia ossificans progressiva (FOP), characterized by congenital malformation of bones, is an autosomal dominant disorder.
p9910
sg4
(lp9911
sg24
(lp9912
(dp9913
g7
I0
sg27
VC0016037
p9914
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p9915
sg13
I3
sa(dp9916
g7
I62
sg27
VC1705254
p9917
sg10
I23
sg11
Vcongenital malformation
p9918
sg13
I2
sa(dp9919
g7
I39
sg27
VC0016037
p9920
sg10
I3
sg11
VFOP
p9921
sg13
I1
sasa(dp9922
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification in skeletal muscle tissue.
p9923
sg4
(lp9924
sg24
(lp9925
(dp9926
g7
I0
sg27
VC0016037
p9927
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p9928
sg13
I3
sa(dp9929
g7
I111
sg27
VC0029396
p9930
sg10
I24
sg11
Vheterotopic ossification
p9931
sg13
I2
sa(dp9932
g7
I39
sg27
VC0016037
p9933
sg10
I3
sg11
VFOP
p9934
sg13
I1
sasa(dp9935
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification.
p9936
sg4
(lp9937
sg24
(lp9938
(dp9939
g7
I0
sg27
VC0016037
p9940
sg10
I37
sg11
VFibrodysplasia ossificans progressiva
p9941
sg13
I3
sa(dp9942
g7
I111
sg27
VC0029396
p9943
sg10
I24
sg11
Vheterotopic ossification
p9944
sg13
I2
sa(dp9945
g7
I39
sg27
VC0016037
p9946
sg10
I3
sg11
VFOP
p9947
sg13
I1
sasa(dp9948
g2
VLoss of ORAI1 function is linked with rheumatoid arthritis (RA) and hence pharmacological blockers of ORAI1 could be potential therapeutic agents for the treatment of RA.
p9949
sg4
(lp9950
(dp9951
g7
I8
sg8
g9
sg10
I5
sg11
VORAI1
p9952
sg13
I1
sa(dp9953
g7
I8
sg8
g9
sg10
I5
sg11
VORAI1
p9954
sg13
I1
sasg24
(lp9955
(dp9956
g7
I9
sg27
VC0003873
p9957
sg10
I2
sg11
VRA
p9958
sg13
I1
sa(dp9959
g7
I9
sg27
VC0003873
p9960
sg10
I2
sg11
VRA
p9961
sg13
I1
sa(dp9962
g7
I38
sg27
VC0003873
p9963
sg10
I20
sg11
Vrheumatoid arthritis
p9964
sg13
I2
sasa(dp9965
g2
VTo determine whether Ca(2+) release-activated Ca(2+) (CRAC) channels contribute to the abnormal behaviour of T cells in patients with rheumatoid arthritis (RA), we performed a cross-sectional study to characterize the expression and functional status of CRACM1 channels in RA patients.
p9966
sg4
(lp9967
sg24
(lp9968
(dp9969
g7
I87
sg27
VC0233514
p9970
sg10
I18
sg11
Vabnormal behaviour
p9971
sg13
I2
sa(dp9972
g7
I134
sg27
VC0003873
p9973
sg10
I20
sg11
Vrheumatoid arthritis
p9974
sg13
I2
sa(dp9975
g7
I55
sg27
VC0003873
p9976
sg10
I2
sg11
VRA
p9977
sg13
I1
sa(dp9978
g7
I55
sg27
VC0003873
p9979
sg10
I2
sg11
VRA
p9980
sg13
I1
sasa(dp9981
g2
VSince autoreactive T cells play an important role in the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and organ transplantation, Orai1 becomes an attractive therapeutic target for ameliorating autoimmune disease.
p9982
sg4
(lp9983
(dp9984
g7
I169
sg8
g9
sg10
I5
sg11
VOrai1
p9985
sg13
I1
sasg24
(lp9986
(dp9987
g7
I100
sg27
VC0003873
p9988
sg10
I20
sg11
Vrheumatoid arthritis
p9989
sg13
I2
sa(dp9990
g7
I72
sg27
VC0004364
p9991
sg10
I19
sg11
Vautoimmune diseases
p9992
sg13
I2
sa(dp9993
g7
I72
sg27
VC0004364
p9994
sg10
I18
sg11
Vautoimmune disease
p9995
sg13
I2
sa(dp9996
g7
I122
sg27
VC0026769
p9997
sg10
I18
sg11
Vmultiple sclerosis
p9998
sg13
I2
sasa(dp9999
g2
VOur results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activity that represent potential vaccine candidates for immunotherapy of grass pollen allergy.
p10000
sg4
(lp10001
(dp10002
g7
I58
sg8
g9
sg10
I30
sg11
VLol p 5 sequence yield mutants
p10003
sg13
I6
sasg24
(lp10004
(dp10005
g7
I187
sg27
VC0740919
p10006
sg10
I20
sg11
Vgrass pollen allergy
p10007
sg13
I3
sasa(dp10008
g2
VHerein we present data relative to the effect of knocking down BCKDK gene on the real time oxygen consumption rate of fibroblasts obtained from a Maple Syrup Urine Disease (MSUD) patient.
p10009
sg4
(lp10010
(dp10011
g7
I63
sg8
g9
sg10
I10
sg11
VBCKDK gene
p10012
sg13
I2
sasg24
(lp10013
(dp10014
g7
I173
sg27
VC0024776
p10015
sg10
I4
sg11
VMSUD
p10016
sg13
I1
sa(dp10017
g7
I146
sg27
VC0024776
p10018
sg10
I25
sg11
VMaple Syrup Urine Disease
p10019
sg13
I4
sasa(dp10020
g2
VData relative to the effectiveness of the knockdown together with the potentiality of the BCKDK-knockdown to increase the deficient branched-chain Alfa-ketoacid dehydrogenase activity detected in MSUD patients are also shown.
p10021
sg4
(lp10022
(dp10023
g7
I90
sg8
g9
sg10
I5
sg11
VBCKDK
p10024
sg13
I1
sa(dp10025
g7
I147
sg8
VP49366
p10026
sg10
I27
sg11
VAlfa-ketoacid dehydrogenase
p10027
sg13
I2
sasg24
(lp10028
(dp10029
g7
I196
sg27
VC0024776
p10030
sg10
I4
sg11
VMSUD
p10031
sg13
I1
sasa(dp10032
g2
VIn the study, 800 patients with coronary artery disease, cerebrovascular disease, or peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were recruited.
p10033
sg4
(lp10034
sg24
(lp10035
(dp10036
g7
I112
sg27
VC1704436
p10037
sg10
I3
sg11
VPAD
p10038
sg13
I1
sa(dp10039
g7
I32
sg27
VC1956346
p10040
sg10
I23
sg11
Vcoronary artery disease
p10041
sg13
I3
sa(dp10042
g7
I57
sg27
VC0007820
p10043
sg10
I23
sg11
Vcerebrovascular disease
p10044
sg13
I2
sa(dp10045
g7
I85
sg27
VC1704436
p10046
sg10
I25
sg11
Vperipheral artery disease
p10047
sg13
I3
sasa(dp10048
g2
VTo obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany.
p10049
sg4
(lp10050
sg24
(lp10051
(dp10052
g7
I66
sg27
VC1963943
p10053
sg10
I16
sg11
Vatherothrombosis
p10054
sg13
I1
sa(dp10055
g7
I159
sg27
VC0007222
p10056
sg10
I3
sg11
VCVD
p10057
sg13
I1
sa(dp10058
g7
I275
sg27
VC1704436
p10059
sg10
I3
sg11
VPAD
p10060
sg13
I1
sa(dp10061
g7
I246
sg27
VC1704436
p10062
sg10
I27
sg11
Vperipheral arterial disease
p10063
sg13
I3
sa(dp10064
g7
I190
sg27
VC0010054
p10065
sg10
I3
sg11
VCAD
p10066
sg13
I1
sa(dp10067
g7
I134
sg27
VC0007820
p10068
sg10
I23
sg11
Vcerebrovascular disease
p10069
sg13
I2
sa(dp10070
g7
I165
sg27
VC0010054
p10071
sg10
I23
sg11
Vcoronary artery disease
p10072
sg13
I3
sasa(dp10073
g2
VThe stroke relationships of a Chinese character reflect its structure, which can be statistically represented by the neighborhood system and clique potentials within the MRF framework.
p10074
sg4
(lp10075
sg24
(lp10076
(dp10077
g7
I4
sg27
VC0038454
p10078
sg10
I6
sg11
Vstroke
p10079
sg13
I1
sasa(dp10080
g2
VWe penalize the structurally mismatched stroke relationships with MRFs using the prior clique potentials, and derive the likelihood clique potentials from Gaussian mixture models, which encode the large variations of stroke relationships statistically.
p10081
sg4
(lp10082
sg24
(lp10083
(dp10084
g7
I40
sg27
VC0038454
p10085
sg10
I6
sg11
Vstroke
p10086
sg13
I1
sa(dp10087
g7
I40
sg27
VC0038454
p10088
sg10
I6
sg11
Vstroke
p10089
sg13
I1
sasa(dp10090
g2
VIn the proposed HCCR system, we use the single-site likelihood clique potentials to extract many candidate strokes from character images, and use the pairsite clique potentials to determine the best structural match between the input candidate strokes and the MRF-based character models by relaxation labeling.
p10091
sg4
(lp10092
sg24
(lp10093
(dp10094
g7
I107
sg27
VC0038454
p10095
sg10
I7
sg11
Vstrokes
p10096
sg13
I1
sa(dp10097
g7
I107
sg27
VC0038454
p10098
sg10
I7
sg11
Vstrokes
p10099
sg13
I1
sasa(dp10100
g2
VTotal left ventricular stroke volume (TSV), antegrade stroke volume (ASV), and mitral regurgitation volume (MRV) and fraction (MRF) were determined and compared between the two modalities.
p10101
sg4
(lp10102
sg24
(lp10103
(dp10104
g7
I23
sg27
VC0038454
p10105
sg10
I6
sg11
Vstroke
p10106
sg13
I1
sa(dp10107
g7
I23
sg27
VC0038454
p10108
sg10
I6
sg11
Vstroke
p10109
sg13
I1
sa(dp10110
g7
I79
sg27
VC0026266
p10111
sg10
I20
sg11
Vmitral regurgitation
p10112
sg13
I2
sasa(dp10113
g2
VThe reliability of non-invasive quantification of mitral regurgitation (MR) was assessed in 76 patients with angiographically demonstrated MR by comparing the results of different echo-Doppler (ED) indices with angiographic grade and MR fraction (MRF).
p10114
sg4
(lp10115
sg24
(lp10116
(dp10117
g7
I72
sg27
VC0026266
p10118
sg10
I2
sg11
VMR
p10119
sg13
I1
sa(dp10120
g7
I50
sg27
VC0026266
p10121
sg10
I20
sg11
Vmitral regurgitation
p10122
sg13
I2
sa(dp10123
g7
I72
sg27
VC0026266
p10124
sg10
I2
sg11
VMR
p10125
sg13
I1
sa(dp10126
g7
I72
sg27
VC0026266
p10127
sg10
I2
sg11
VMR
p10128
sg13
I1
sasa(dp10129
g2
VAllergic asthma from mint is less well-recognized.
p10130
sg4
(lp10131
sg24
(lp10132
(dp10133
g7
I0
sg27
VC0155877
p10134
sg10
I15
sg11
VAllergic asthma
p10135
sg13
I2
sasa(dp10136
g2
VA case of a 54-year-old woman with dyspnea on exposure to the scent of peppermint is presented in whom mint exposure, as seemingly innocuous as the breath of others who had consumed Tic Tac candies, exacerbated her underlying asthma.
p10137
sg4
(lp10138
(dp10139
g7
I182
sg8
g9
sg10
I7
sg11
VTic Tac
p10140
sg13
I2
sasg24
(lp10141
(dp10142
g7
I35
sg27
VC0013404
p10143
sg10
I7
sg11
Vdyspnea
p10144
sg13
I1
sa(dp10145
g7
I182
sg27
VC0278076
p10146
sg10
I3
sg11
VTic
p10147
sg13
I1
sa(dp10148
g7
I226
sg27
VC0004096
p10149
sg10
I6
sg11
Vasthma
p10150
sg13
I1
sasa(dp10151
g2
VAdditionally, this cases suggests that asthma can result from inhaling the scent of mint and gives consideration to obtaining confirmatory pre- and postexposure pulmonary function data by both impulse oscillometry and spirometry.
p10152
sg4
(lp10153
sg24
(lp10154
(dp10155
g7
I39
sg27
VC0004096
p10156
sg10
I6
sg11
Vasthma
p10157
sg13
I1
sasa(dp10158
g2
VWe review the significance of elevated alpha-fetoprotein levels and discuss the clinical relevance of this unusual presentation of a possible primary Hodgkin's lymphoma.
p10159
sg4
(lp10160
(dp10161
g7
I39
sg8
VP02771
p10162
sg10
I17
sg11
Valpha-fetoprotein
p10163
sg13
I1
sasg24
(lp10164
(dp10165
g7
I150
sg27
VC0019829
p10166
sg10
I18
sg11
VHodgkin's lymphoma
p10167
sg13
I2
sasa(dp10168
g2
VHowever, we have found that exogenous 8-OHdG can paradoxically reduce ROS production, attenuate the nuclear factor-KB signaling pathway, and ameliorate the expression of proinflammatory mediators such as interleukin (IL)-1, IL-6, cyclo-oxygenase-2, and inducible nitric oxide synthase in addition to expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-1, NOX organizer-1 and NOX activator-1 in various conditions of inflammation-based gastrointestinal (GI) diseases including gastritis, inflammatory bowel disease, pancreatitis, and even colitis-associated carcinogenesis.
p10169
sg4
(lp10170
(dp10171
g7
I230
sg8
VP00403
p10172
sg10
I17
sg11
Vcyclo-oxygenase-2
p10173
sg13
I1
sa(dp10174
g7
I395
sg8
VP05154
p10175
sg10
I15
sg11
VNOX activator-1
p10176
sg13
I2
sa(dp10177
g7
I263
sg8
VP29475
p10178
sg10
I21
sg11
Vnitric oxide synthase
p10179
sg13
I3
sa(dp10180
g7
I204
sg8
VP60568
p10181
sg10
I18
sg11
Vinterleukin (IL)-1
p10182
sg13
I2
sa(dp10183
g7
I224
sg8
VP05231
p10184
sg10
I4
sg11
VIL-6
p10185
sg13
I1
sa(dp10186
g7
I100
sg8
VP01160
p10187
sg10
I17
sg11
Vnuclear factor-KB
p10188
sg13
I2
sa(dp10189
g7
I314
sg8
g9
sg10
I59
sg11
Vnicotinamide adenine dinucleotide phosphate oxidase (NOX)-1
p10190
sg13
I6
sasg24
(lp10191
(dp10192
g7
I436
sg27
VC0021368
p10193
sg10
I12
sg11
Vinflammation
p10194
sg13
I1
sa(dp10195
g7
I535
sg27
VC0030305
p10196
sg10
I12
sg11
Vpancreatitis
p10197
sg13
I1
sa(dp10198
g7
I496
sg27
VC0017152
p10199
sg10
I9
sg11
Vgastritis
p10200
sg13
I1
sa(dp10201
g7
I577
sg27
VC0596263
p10202
sg10
I14
sg11
Vcarcinogenesis
p10203
sg13
I1
sa(dp10204
g7
I507
sg27
VC0021390
p10205
sg10
I26
sg11
Vinflammatory bowel disease
p10206
sg13
I3
sa(dp10207
g7
I558
sg27
VC0009319
p10208
sg10
I7
sg11
Vcolitis
p10209
sg13
I1
sasa(dp10210
g2
VWe studied nine patients (56 +/- 7 years) with complete AV-block and permanent dual-chamber pacemaker (DDD) under different pacing modes: ventricle pacing (VVI) 70 bpm, DDD 106 +/- 4 bpm, rate adaptive pacing (VVI-FA) 108 +/- 3 bpm.
p10211
sg4
(lp10212
sg24
(lp10213
(dp10214
g7
I103
sg27
VC0406811
p10215
sg10
I3
sg11
VDDD
p10216
sg13
I1
sa(dp10217
g7
I103
sg27
VC0406811
p10218
sg10
I3
sg11
VDDD
p10219
sg13
I1
sasa(dp10220
g2
VRecently, several reports have demonstrated that dysregulation of miR-4262 is in numerous cancers.
p10221
sg4
(lp10222
(dp10223
g7
I66
sg8
g9
sg10
I8
sg11
VmiR-4262
p10224
sg13
I1
sasg24
(lp10225
(dp10226
g7
I90
sg27
VC0006826
p10227
sg10
I7
sg11
Vcancers
p10228
sg13
I1
sasa(dp10229
g2
VOverexpression of miR-4262 was demonstrated to decrease GALNT4 mRNA and protein expression levels, and thereby suppressed cell viability, growth and cell-cycle progression in SW480 and SW620 colon cancer cells.
p10230
sg4
(lp10231
(dp10232
g7
I18
sg8
g9
sg10
I8
sg11
VmiR-4262
p10233
sg13
I1
sa(dp10234
g7
I56
sg8
g9
sg10
I11
sg11
VGALNT4 mRNA
p10235
sg13
I2
sasg24
(lp10236
(dp10237
g7
I191
sg27
VC0699790
p10238
sg10
I12
sg11
Vcolon cancer
p10239
sg13
I2
sasa(dp10240
g2
VThe expression level of miR-4262 was observed to be downregulated as the expression of GALNT4 was upregulated in colon cancer tissues and cell lines.
p10241
sg4
(lp10242
(dp10243
g7
I87
sg8
g9
sg10
I6
sg11
VGALNT4
p10244
sg13
I1
sa(dp10245
g7
I24
sg8
g9
sg10
I8
sg11
VmiR-4262
p10246
sg13
I1
sasg24
(lp10247
(dp10248
g7
I113
sg27
VC0699790
p10249
sg10
I12
sg11
Vcolon cancer
p10250
sg13
I2
sasa(dp10251
g2
VIn conclusion, the results demonstrated that miR-4262 may be involved in the development of colon cancer via targeting of GALNT4.
p10252
sg4
(lp10253
(dp10254
g7
I122
sg8
g9
sg10
I6
sg11
VGALNT4
p10255
sg13
I1
sa(dp10256
g7
I45
sg8
g9
sg10
I8
sg11
VmiR-4262
p10257
sg13
I1
sasg24
(lp10258
(dp10259
g7
I92
sg27
VC0699790
p10260
sg10
I12
sg11
Vcolon cancer
p10261
sg13
I2
sasa(dp10262
g2
VThe miR-4262/GALNT4 axis may be a novel target for diagnosing and understanding the underlying molecular mechanism of colon cancer.
p10263
sg4
(lp10264
(dp10265
g7
I13
sg8
g9
sg10
I6
sg11
VGALNT4
p10266
sg13
I1
sa(dp10267
g7
I4
sg8
g9
sg10
I8
sg11
VmiR-4262
p10268
sg13
I1
sasg24
(lp10269
(dp10270
g7
I118
sg27
VC0699790
p10271
sg10
I12
sg11
Vcolon cancer
p10272
sg13
I2
sasa(dp10273
g2
VThe aim of this study was to investigate whether miR-4262 was associated with the prognosis of acute myeloid leukemia (AML) patients.
p10274
sg4
(lp10275
sg24
(lp10276
(dp10277
g7
I119
sg27
VC0023467
p10278
sg10
I3
sg11
VAML
p10279
sg13
I1
sa(dp10280
g7
I95
sg27
VC0023467
p10281
sg10
I22
sg11
Vacute myeloid leukemia
p10282
sg13
I3
sasa(dp10283
g2
VIn this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells.
p10284
sg4
(lp10285
sg24
(lp10286
(dp10287
g7
I84
sg27
VC0334094
p10288
sg10
I13
sg11
Vproliferation
p10289
sg13
I1
sa(dp10290
g7
I107
sg27
VC0151779
p10291
sg10
I28
sg11
Vcutaneous malignant melanoma
p10292
sg13
I3
sa(dp10293
g7
I137
sg27
VC0151779
p10294
sg10
I3
sg11
VCMM
p10295
sg13
I1
sasa(dp10296
g2
VThe expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients.
p10297
sg4
(lp10298
sg24
(lp10299
sa(dp10300
g2
VmiR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM.
p10301
sg4
(lp10302
(dp10303
g7
I0
sg8
g9
sg10
I8
sg11
VmiR-4262
p10304
sg13
I1
sa(dp10305
g7
I114
sg8
g9
sg10
I14
sg11
VKruppel-like 6
p10306
sg13
I2
sa(dp10307
g7
I130
sg8
g9
sg10
I4
sg11
VKLF6
p10308
sg13
I1
sasg24
(lp10309
(dp10310
g7
I174
sg27
VC0006826
p10311
sg10
I7
sg11
Vcancers
p10312
sg13
I1
sa(dp10313
g7
I146
sg27
VC0027651
p10314
sg10
I5
sg11
Vtumor
p10315
sg13
I1
sasa(dp10316
g2
VmiR-4262 is a potential tumor promoter in human cancers.
p10317
sg4
(lp10318
(dp10319
g7
I0
sg8
g9
sg10
I8
sg11
VmiR-4262
p10320
sg13
I1
sasg24
(lp10321
(dp10322
g7
I48
sg27
VC0006826
p10323
sg10
I7
sg11
Vcancers
p10324
sg13
I1
sa(dp10325
g7
I24
sg27
VC0027651
p10326
sg10
I5
sg11
Vtumor
p10327
sg13
I1
sasa(dp10328
g2
VIn this study, we first investigated the role of miR-4262 in the proliferation and invasion of human breast cancer cells.
p10329
sg4
(lp10330
sg24
(lp10331
(dp10332
g7
I65
sg27
VC0334094
p10333
sg10
I13
sg11
Vproliferation
p10334
sg13
I1
sa(dp10335
g7
I101
sg27
VC0678222
p10336
sg10
I13
sg11
Vbreast cancer
p10337
sg13
I2
sa(dp10338
g7
I83
sg27
VC2699153
p10339
sg10
I8
sg11
Vinvasion
p10340
sg13
I1
sasa(dp10341
g2
VOur results showed that, compared with the adjacent tissues and MCF-10A normal breast epithelial cells, miR-4262 was markedly increased in the breast cancer tissues and five cell lines, including MDA-MB-231, MDA-MB-468, MDA-MB-435, SKBR3, and MCF-7.
p10342
sg4
(lp10343
(dp10344
g7
I104
sg8
g9
sg10
I8
sg11
VmiR-4262
p10345
sg13
I1
sasg24
(lp10346
(dp10347
g7
I143
sg27
VC0678222
p10348
sg10
I13
sg11
Vbreast cancer
p10349
sg13
I2
sasa(dp10350
g2
VThen the miR-4262 mimic or oligo anta-miR-4262 was transfected into MDA-MB-231 and MCF-7 breast cancer cell lines.
p10351
sg4
(lp10352
sg24
(lp10353
(dp10354
g7
I89
sg27
VC0678222
p10355
sg10
I13
sg11
Vbreast cancer
p10356
sg13
I2
sasa(dp10357
g2
VIn conclusion, miR-4262 positively regulates proliferation and invasion of human breast cancer cells via suppression of KLF6 and KLF15.
p10358
sg4
(lp10359
(dp10360
g7
I15
sg8
g9
sg10
I8
sg11
VmiR-4262
p10361
sg13
I1
sa(dp10362
g7
I129
sg8
g9
sg10
I5
sg11
VKLF15
p10363
sg13
I1
sa(dp10364
g7
I120
sg8
g9
sg10
I4
sg11
VKLF6
p10365
sg13
I1
sasg24
(lp10366
(dp10367
g7
I63
sg27
VC2699153
p10368
sg10
I8
sg11
Vinvasion
p10369
sg13
I1
sa(dp10370
g7
I105
sg27
VC0221103
p10371
sg10
I11
sg11
Vsuppression
p10372
sg13
I1
sa(dp10373
g7
I81
sg27
VC0678222
p10374
sg10
I13
sg11
Vbreast cancer
p10375
sg13
I2
sa(dp10376
g7
I45
sg27
VC0334094
p10377
sg10
I13
sg11
Vproliferation
p10378
sg13
I1
sasa(dp10379
g2
VTogether, our data suggest that suppression of miR-4262 in OS cells may promote OPN-mediated cancer invasion, highlighting miR-4262 as an intriguing therapeutic target to prevent OS metastases.
p10380
sg4
(lp10381
(dp10382
g7
I80
sg8
VP10451
p10383
sg10
I3
sg11
VOPN
p10384
sg13
I1
sasg24
(lp10385
(dp10386
g7
I100
sg27
VC2699153
p10387
sg10
I8
sg11
Vinvasion
p10388
sg13
I1
sa(dp10389
g7
I32
sg27
VC0221103
p10390
sg10
I11
sg11
Vsuppression
p10391
sg13
I1
sa(dp10392
g7
I182
sg27
VC0027627
p10393
sg10
I10
sg11
Vmetastases
p10394
sg13
I1
sa(dp10395
g7
I93
sg27
VC0006826
p10396
sg10
I6
sg11
Vcancer
p10397
sg13
I1
sasa(dp10398
g2
VThose can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).
p10399
sg4
(lp10400
(dp10401
g7
I246
sg8
g9
sg10
I5
sg11
VSARS2
p10402
sg13
I1
sa(dp10403
g7
I324
sg8
VP01133
p10404
sg10
I3
sg11
VEGF
p10405
sg13
I1
sa(dp10406
g7
I108
sg8
g9
sg10
I6
sg11
VCLDN19
p10407
sg13
I1
sa(dp10408
g7
I310
sg8
g9
sg10
I5
sg11
VTRPM6
p10409
sg13
I1
sa(dp10410
g7
I122
sg8
VP51801
p10411
sg10
I6
sg11
VCLCNKB
p10412
sg13
I1
sa(dp10413
g7
I342
sg8
g9
sg10
I7
sg11
VFAM111A
p10414
sg13
I1
sa(dp10415
g7
I335
sg8
g9
sg10
I5
sg11
VKCNA1
p10416
sg13
I1
sa(dp10417
g7
I170
sg8
VP55017
p10418
sg10
I7
sg11
VSLC12A3
p10419
sg13
I1
sa(dp10420
g7
I207
sg8
VP61457
p10421
sg10
I5
sg11
VPCBD1
p10422
sg13
I1
sa(dp10423
g7
I200
sg8
VP35680
p10424
sg10
I5
sg11
VHNF1B
p10425
sg13
I1
sa(dp10426
g7
I179
sg8
g9
sg10
I4
sg11
VBSND
p10427
sg13
I1
sa(dp10428
g7
I185
sg8
VP78508
p10429
sg10
I6
sg11
VKCNJ10
p10430
sg13
I1
sa(dp10431
g7
I100
sg8
g9
sg10
I6
sg11
VCLDN16
p10432
sg13
I1
sa(dp10433
g7
I122
sg8
VP51801
p10434
sg10
I6
sg11
VCLCNKB
p10435
sg13
I1
sa(dp10436
g7
I116
sg8
VP41180
p10437
sg10
I4
sg11
VCASR
p10438
sg13
I1
sasg24
(lp10439
(dp10440
g7
I179
sg27
VC1865270
p10441
sg10
I4
sg11
VBSND
p10442
sg13
I1
sa(dp10443
g7
I260
sg27
VC0022541
p10444
sg10
I21
sg11
VKearns-Sayre syndrome
p10445
sg13
I2
sasa(dp10446
g2
VFor radiculopathy, epidural corticosteroids were associated with greater immediate-term reduction in pain (weighted mean difference on a scale of 0 to 100, -7.55 [95% CI, -11.4 to -3.74]; SOE, moderate), function (standardized mean difference after exclusion of an outlier trial, -0.33 [CI, -0.56 to -0.09]; SOE, low), and short-term surgery risk (relative risk, 0.62 [CI, 0.41 to 0.92]; SOE, low).
p10447
sg4
(lp10448
sg24
(lp10449
(dp10450
g7
I4
sg27
VC0700594
p10451
sg10
I13
sg11
Vradiculopathy
p10452
sg13
I1
sasa(dp10453
g2
VThe final multilevel growth model revealed improvements in RMDQ scores in patients with radiculopathy at the 6-week (-8.1, 95 % CI -12.6 to -2.6; P = 0.006) and 6-month (-4.1, 95 % CI -7.4 to -0.7; P = 0.020) follow-up occasions compared to patients without radiculopathy.
p10454
sg4
(lp10455
sg24
(lp10456
(dp10457
g7
I88
sg27
VC0700594
p10458
sg10
I13
sg11
Vradiculopathy
p10459
sg13
I1
sa(dp10460
g7
I88
sg27
VC0700594
p10461
sg10
I13
sg11
Vradiculopathy
p10462
sg13
I1
sasa(dp10463
g2
VAn interaction between electrodiagnostic status and time revealed faster weekly improvements in RMDQ scores in patients with radiculopathy at the 6-week (-0.72, 95 % CI -1.4 to -0.04; P = 0.040) through the 16-week (-0.30, 95 % CI, -0.57 to -0.04; P = 0.028) follow-up occasions compared to patients without radiculopathy.
p10464
sg4
(lp10465
sg24
(lp10466
(dp10467
g7
I125
sg27
VC0700594
p10468
sg10
I13
sg11
Vradiculopathy
p10469
sg13
I1
sa(dp10470
g7
I125
sg27
VC0700594
p10471
sg10
I13
sg11
Vradiculopathy
p10472
sg13
I1
sasa(dp10473
g2
VFor patients with radiculopathy, a repeated-measures analysis of variance showed a significant decrease in the H reflex amplitude (from 0.81 +/- 0.4 to 0.69 +/- 0.39 mV), an increase in radicular symptoms after reading (from 4.2 +/- 1.3 to 5.6 +/- 1.4 on the visual analog scale), an increase in the H reflex amplitude (from 0.69 +/- 0.39 to 1.01 +/- 0.49 mV), and a decrease in pain intensity (from 5.6 +/- 1.4 to 1.5 +/- 1.3) after repeated neck retractions.
p10474
sg4
(lp10475
sg24
(lp10476
(dp10477
g7
I18
sg27
VC0700594
p10478
sg10
I13
sg11
Vradiculopathy
p10479
sg13
I1
sasa(dp10480
g2
VAlthough some autoinflammatory diseases are due to gain-of-function mutations for caspase-1 activity, common diseases such as gout, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myeloma also are responsive to IL-1Beta neutralization.
p10481
sg4
(lp10482
(dp10483
g7
I82
sg8
VP29466
p10484
sg10
I9
sg11
Vcaspase-1
p10485
sg13
I1
sa(dp10486
g7
I256
sg8
VP01584
p10487
sg10
I8
sg11
VIL-1Beta
p10488
sg13
I1
sasg24
(lp10489
(dp10490
g7
I126
sg27
VC0018099
p10491
sg10
I4
sg11
Vgout
p10492
sg13
I1
sa(dp10493
g7
I214
sg27
VC1531608
p10494
sg10
I18
sg11
Vsmoldering myeloma
p10495
sg13
I2
sa(dp10496
g7
I188
sg27
VC0003873
p10497
sg10
I20
sg11
Vrheumatoid arthritis
p10498
sg13
I2
sa(dp10499
g7
I174
sg27
VC0031046
p10500
sg10
I12
sg11
Vpericarditis
p10501
sg13
I1
sa(dp10502
g7
I132
sg27
VC0011860
p10503
sg10
I15
sg11
Vtype 2 diabetes
p10504
sg13
I3
sa(dp10505
g7
I149
sg27
VC0018802
p10506
sg10
I13
sg11
Vheart failure
p10507
sg13
I2
sasa(dp10508
g2
VInactivation of Ccl2 in an Lkb1-driven mouse model of endometrial cancer slowed tumor progression and increased survival.
p10509
sg4
(lp10510
(dp10511
g7
I16
sg8
VP13500
p10512
sg10
I4
sg11
VCcl2
p10513
sg13
I1
sa(dp10514
g7
I27
sg8
g9
sg10
I4
sg11
VLkb1
p10515
sg13
I1
sasg24
(lp10516
(dp10517
g7
I80
sg27
VC0178874
p10518
sg10
I17
sg11
Vtumor progression
p10519
sg13
I2
sa(dp10520
g7
I54
sg27
VC0476089
p10521
sg10
I18
sg11
Vendometrial cancer
p10522
sg13
I2
sa(dp10523
g7
I0
sg27
VC0544461
p10524
sg10
I12
sg11
VInactivation
p10525
sg13
I1
sasa(dp10526
g2
VIn human primary endometrial cancers, loss of LKB1 protein was strongly associated with increased CCL2 expression by tumor cells as well as increased macrophage density in the tumor microenvironment.
p10527
sg4
(lp10528
(dp10529
g7
I46
sg8
g9
sg10
I12
sg11
VLKB1 protein
p10530
sg13
I2
sa(dp10531
g7
I98
sg8
VP13500
p10532
sg10
I4
sg11
VCCL2
p10533
sg13
I1
sasg24
(lp10534
(dp10535
g7
I117
sg27
VC0027651
p10536
sg10
I5
sg11
Vtumor
p10537
sg13
I1
sa(dp10538
g7
I17
sg27
VC0476089
p10539
sg10
I19
sg11
Vendometrial cancers
p10540
sg13
I2
sa(dp10541
g7
I117
sg27
VC0027651
p10542
sg10
I5
sg11
Vtumor
p10543
sg13
I1
sasa(dp10544
g2
VThese data demonstrate that CCL2 is a potent effector of LKB1 loss in endometrial cancer, creating potential avenues for therapeutic opportunities.
p10545
sg4
(lp10546
(dp10547
g7
I28
sg8
VP13500
p10548
sg10
I4
sg11
VCCL2
p10549
sg13
I1
sa(dp10550
g7
I57
sg8
g9
sg10
I4
sg11
VLKB1
p10551
sg13
I1
sasg24
(lp10552
(dp10553
g7
I70
sg27
VC0476089
p10554
sg10
I18
sg11
Vendometrial cancer
p10555
sg13
I2
sasa(dp10556
g2
VOur results showed that in HEC-1-B (human endometrial cancer) cells, IL-17 stimulation induced mRNA level increases of CCL2, CCL5, CCL20, CXCL2, and IL-8.
p10557
sg4
(lp10558
(dp10559
g7
I131
sg8
VP78556
p10560
sg10
I5
sg11
VCCL20
p10561
sg13
I1
sa(dp10562
g7
I27
sg8
g9
sg10
I7
sg11
VHEC-1-B
p10563
sg13
I1
sa(dp10564
g7
I138
sg8
VP19875
p10565
sg10
I5
sg11
VCXCL2
p10566
sg13
I1
sa(dp10567
g7
I125
sg8
VP13501
p10568
sg10
I4
sg11
VCCL5
p10569
sg13
I1
sa(dp10570
g7
I119
sg8
VP13500
p10571
sg10
I4
sg11
VCCL2
p10572
sg13
I1
sasg24
(lp10573
(dp10574
g7
I42
sg27
VC0476089
p10575
sg10
I18
sg11
Vendometrial cancer
p10576
sg13
I2
sasa(dp10577
g2
VIn this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I polymorphisms with endometrial cancer was investigated using 50 endometrial cancer patients and 211 controls.
p10578
sg4
(lp10579
(dp10580
g7
I67
sg8
VP41597
p10581
sg10
I4
sg11
VCCR2
p10582
sg13
I1
sa(dp10583
g7
I51
sg8
VP13500
p10584
sg10
I11
sg11
VCCL2 A2518G
p10585
sg13
I2
sasg24
(lp10586
(dp10587
g7
I96
sg27
VC0476089
p10588
sg10
I18
sg11
Vendometrial cancer
p10589
sg13
I2
sa(dp10590
g7
I96
sg27
VC0476089
p10591
sg10
I18
sg11
Vendometrial cancer
p10592
sg13
I2
sasa(dp10593
g2
VIn our study, individuals with CCL2 A2518G GG genotype showed a 6.7-fold increased risk for endometrial cancer (p&lt;0.0001) and individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium cancer (p&lt;0.0001).
p10594
sg4
(lp10595
(dp10596
g7
I31
sg8
VP13500
p10597
sg10
I23
sg11
VCCL2 A2518G GG genotype
p10598
sg13
I4
sa(dp10599
g7
I146
sg8
VP13500
p10600
sg10
I20
sg11
VCCL2 A2518G A allele
p10601
sg13
I4
sasg24
(lp10602
(dp10603
g7
I92
sg27
VC0476089
p10604
sg10
I18
sg11
Vendometrial cancer
p10605
sg13
I2
sa(dp10606
g7
I197
sg27
VC0476089
p10607
sg10
I18
sg11
Vendometrium cancer
p10608
sg13
I2
sasa(dp10609
g2
VIn conclusion, we state that there appears to be an association between polymorphism of CCL2 and its receptor CCR2 and endometrial cancer.
p10610
sg4
(lp10611
(dp10612
g7
I110
sg8
VP41597
p10613
sg10
I4
sg11
VCCR2
p10614
sg13
I1
sa(dp10615
g7
I88
sg8
VP13500
p10616
sg10
I4
sg11
VCCL2
p10617
sg13
I1
sasg24
(lp10618
(dp10619
g7
I119
sg27
VC0476089
p10620
sg10
I18
sg11
Vendometrial cancer
p10621
sg13
I2
sasa(dp10622
g2
VA total of 146 cryptorchid and 140 infertile patients without a history of cryptorchidism were screened with a sequence tagged site plus/minus method and further confirmed and characterized by CDY1/DAZ gene dosage and copy analysis.
p10623
sg4
(lp10624
(dp10625
g7
I193
sg8
g9
sg10
I4
sg11
VCDY1
p10626
sg13
I1
sa(dp10627
g7
I198
sg8
g9
sg10
I3
sg11
VDAZ
p10628
sg13
I1
sasg24
(lp10629
(dp10630
g7
I35
sg27
VC0021359
p10631
sg10
I9
sg11
Vinfertile
p10632
sg13
I1
sa(dp10633
g7
I75
sg27
VC0010417
p10634
sg10
I14
sg11
Vcryptorchidism
p10635
sg13
I1
sasa(dp10636
g2
VThe aim of this study is to explore the various modes of action miR-497 has on human cervical cancer (CC) cell behavior.
p10637
sg4
(lp10638
sg24
(lp10639
(dp10640
g7
I85
sg27
VC0302592
p10641
sg10
I15
sg11
Vcervical cancer
p10642
sg13
I2
sasa(dp10643
g2
VIn this study, the expression levels of PVT1 and miR-497 in NSCLC cells were determined by qRT-PCR.
p10644
sg4
(lp10645
(dp10646
g7
I49
sg8
g9
sg10
I7
sg11
VmiR-497
p10647
sg13
I1
sasg24
(lp10648
(dp10649
g7
I60
sg27
VC0007131
p10650
sg10
I5
sg11
VNSCLC
p10651
sg13
I1
sasa(dp10652
g2
VOur findings indicated that PVT1 was significantly upregulated and miR-497 was markedly downregulated in NSCLC cell lines.
p10653
sg4
(lp10654
(dp10655
g7
I67
sg8
g9
sg10
I7
sg11
VmiR-497
p10656
sg13
I1
sasg24
(lp10657
(dp10658
g7
I105
sg27
VC0007131
p10659
sg10
I5
sg11
VNSCLC
p10660
sg13
I1
sasa(dp10661
g2
VMoreover, PVT1 overexpression reversed the inhibitory effect of miR-497 on cell viability, invasion and promotion effect on apoptosis of NSCLC cells.
p10662
sg4
(lp10663
sg24
(lp10664
(dp10665
g7
I137
sg27
VC0007131
p10666
sg10
I5
sg11
VNSCLC
p10667
sg13
I1
sa(dp10668
g7
I91
sg27
VC2699153
p10669
sg10
I8
sg11
Vinvasion
p10670
sg13
I1
sasa(dp10671
g2
VIn conclusion, knockdown of PVT1 inhibited cell viability, invasion and induced apoptosis in NSCLC by regulating miR-497 expression, elucidating the molecular mechanism of the oncogenic role of PVT1 in NSCLC and providing an lncRNA-directed target for NSCLC.
p10672
sg4
(lp10673
sg24
(lp10674
(dp10675
g7
I93
sg27
VC0007131
p10676
sg10
I5
sg11
VNSCLC
p10677
sg13
I1
sa(dp10678
g7
I59
sg27
VC2699153
p10679
sg10
I8
sg11
Vinvasion
p10680
sg13
I1
sa(dp10681
g7
I93
sg27
VC0007131
p10682
sg10
I5
sg11
VNSCLC
p10683
sg13
I1
sa(dp10684
g7
I93
sg27
VC0007131
p10685
sg10
I5
sg11
VNSCLC
p10686
sg13
I1
sasa(dp10687
g2
VMany prominent cancer-associated molecules have been identified over the recent years which include EGFR, CD44, TGFbRII, HER2, miR-497, NMP22, BTA, Fibrin/FDP etc.
p10688
sg4
(lp10689
(dp10690
g7
I127
sg8
g9
sg10
I7
sg11
VmiR-497
p10691
sg13
I1
sa(dp10692
g7
I155
sg8
g9
sg10
I3
sg11
VFDP
p10693
sg13
I1
sa(dp10694
g7
I148
sg8
VP22087
p10695
sg10
I6
sg11
VFibrin
p10696
sg13
I1
sa(dp10697
g7
I121
sg8
VP04626
p10698
sg10
I4
sg11
VHER2
p10699
sg13
I1
sasg24
(lp10700
(dp10701
g7
I15
sg27
VC0006826
p10702
sg10
I6
sg11
Vcancer
p10703
sg13
I1
sasa(dp10704
g2
VThe expression levels of miR-497 in the cancerous and the adjacent noncancerous tissues were detected using reverse transcription-quantitative polymerase chain reaction.
p10705
sg4
(lp10706
sg24
(lp10707
sa(dp10708
g2
VAn miR-497-overexpressing vector was transfected into the T24 and BIU-87 bladder cancer cell lines in order to determine the effect of miR-497 expression on cell migration and invasion using Transwell assays.
p10709
sg4
(lp10710
sg24
(lp10711
(dp10712
g7
I176
sg27
VC2699153
p10713
sg10
I8
sg11
Vinvasion
p10714
sg13
I1
sa(dp10715
g7
I73
sg27
VC0699885
p10716
sg10
I14
sg11
Vbladder cancer
p10717
sg13
I2
sasa(dp10718
g2
VThe findings of the present study revealed that miR-497 was expressed at low levels in the cancer bladder tissue compared with the adjacent noncancerous tissue, and its expression was associated with the pathological classification, TNM stage and metastasis.
p10719
sg4
(lp10720
(dp10721
g7
I48
sg8
g9
sg10
I7
sg11
VmiR-497
p10722
sg13
I1
sasg24
(lp10723
(dp10724
g7
I247
sg27
VC0027627
p10725
sg10
I10
sg11
Vmetastasis
p10726
sg13
I1
sa(dp10727
g7
I91
sg27
VC0006826
p10728
sg10
I6
sg11
Vcancer
p10729
sg13
I1
sasa(dp10730
g2
VThe present study revealed that miR-497 overexpression may be a suppressor of the metastasis of bladder cancer, and may have an important role in the diagnosis of bladder cancer.
p10731
sg4
(lp10732
sg24
(lp10733
(dp10734
g7
I82
sg27
VC0027627
p10735
sg10
I10
sg11
Vmetastasis
p10736
sg13
I1
sa(dp10737
g7
I96
sg27
VC0699885
p10738
sg10
I14
sg11
Vbladder cancer
p10739
sg13
I2
sa(dp10740
g7
I96
sg27
VC0699885
p10741
sg10
I14
sg11
Vbladder cancer
p10742
sg13
I2
sasa(dp10743
g2
VPHR patient portal users (34 percent of eligible persons) were older and more likely to be White, have private health insurance, and develop gestational diabetes than nonusers.
p10744
sg4
(lp10745
sg24
(lp10746
(dp10747
g7
I141
sg27
VC0085207
p10748
sg10
I20
sg11
Vgestational diabetes
p10749
sg13
I2
sasa(dp10750
g2
VWe searched the Internet to review patient-held medical records (PHRs) of patients with diabetes and examine current levels of integration of diabetes and depression care in Japan.
p10751
sg4
(lp10752
sg24
(lp10753
(dp10754
g7
I88
sg27
VC0011849
p10755
sg10
I8
sg11
Vdiabetes
p10756
sg13
I1
sa(dp10757
g7
I155
sg27
VC0011581
p10758
sg10
I10
sg11
Vdepression
p10759
sg13
I1
sa(dp10760
g7
I88
sg27
VC0011849
p10761
sg10
I8
sg11
Vdiabetes
p10762
sg13
I1
sasa(dp10763
g2
VEight sets of PHRs were found for people with diabetes.
p10764
sg4
(lp10765
sg24
(lp10766
(dp10767
g7
I46
sg27
VC0011849
p10768
sg10
I8
sg11
Vdiabetes
p10769
sg13
I1
sasa(dp10770
g2
VAll PHRs included clinical follow-up of diabetes and multidisciplinary clinical pathways for diabetes care.
p10771
sg4
(lp10772
sg24
(lp10773
(dp10774
g7
I40
sg27
VC0011849
p10775
sg10
I8
sg11
Vdiabetes
p10776
sg13
I1
sa(dp10777
g7
I40
sg27
VC0011849
p10778
sg10
I8
sg11
Vdiabetes
p10779
sg13
I1
sasa(dp10780
g2
VIn terms of an integrated PHR for a patient comorbid with diabetes and depression, necessary components include hopes/preferences, educational information on diabetes complications and treatment, medical history, stress and coping, resources, and monitoring diabetes and depression.
p10781
sg4
(lp10782
sg24
(lp10783
(dp10784
g7
I58
sg27
VC0011849
p10785
sg10
I8
sg11
Vdiabetes
p10786
sg13
I1
sa(dp10787
g7
I71
sg27
VC0011581
p10788
sg10
I10
sg11
Vdepression
p10789
sg13
I1
sa(dp10790
g7
I58
sg27
VC0011849
p10791
sg10
I8
sg11
Vdiabetes
p10792
sg13
I1
sa(dp10793
g7
I158
sg27
VC0342257
p10794
sg10
I22
sg11
Vdiabetes complications
p10795
sg13
I2
sa(dp10796
g7
I71
sg27
VC0011581
p10797
sg10
I10
sg11
Vdepression
p10798
sg13
I1
sasa(dp10799
g2
VA new PHR may be suitable for comorbid patients with diabetes and depression.
p10800
sg4
(lp10801
sg24
(lp10802
(dp10803
g7
I66
sg27
VC0011581
p10804
sg10
I10
sg11
Vdepression
p10805
sg13
I1
sa(dp10806
g7
I53
sg27
VC0011849
p10807
sg10
I8
sg11
Vdiabetes
p10808
sg13
I1
sasa(dp10809
g2
Vto evaluate the attitude of patients with Type II diabetes towards using a PHR to manage their condition.
p10810
sg4
(lp10811
sg24
(lp10812
(dp10813
g7
I42
sg27
VC0011860
p10814
sg10
I16
sg11
VType II diabetes
p10815
sg13
I3
sa(dp10816
g7
I95
sg27
VC0012634
p10817
sg10
I9
sg11
Vcondition
p10818
sg13
I1
sasa(dp10819
g2
VThe attitude of patients towards using PHR in management of their diabetes was positive.
p10820
sg4
(lp10821
sg24
(lp10822
(dp10823
g7
I66
sg27
VC0011849
p10824
sg10
I8
sg11
Vdiabetes
p10825
sg13
I1
sasa(dp10826
g2
VPersonal health records (PHRs) have the potential to improve patient self-management for chronic conditions such as diabetes.
p10827
sg4
(lp10828
sg24
(lp10829
(dp10830
g7
I116
sg27
VC0011849
p10831
sg10
I8
sg11
Vdiabetes
p10832
sg13
I1
sasa(dp10833
g2
VThe purpose of this qualitative study was to explore how patients with type 2 diabetes used a PHR to manage their diabetes-related health information for self-care.
p10834
sg4
(lp10835
sg24
(lp10836
(dp10837
g7
I71
sg27
VC0011860
p10838
sg10
I15
sg11
Vtype 2 diabetes
p10839
sg13
I3
sa(dp10840
g7
I78
sg27
VC0011849
p10841
sg10
I8
sg11
Vdiabetes
p10842
sg13
I1
sasa(dp10843
g2
VFifty-nine patients with type 2 diabetes were interviewed 3-6 months after receiving initial training on a free-of-charge, Web-based PHR.
p10844
sg4
(lp10845
sg24
(lp10846
(dp10847
g7
I123
sg27
VC0332875
p10848
sg10
I3
sg11
VWeb
p10849
sg13
I1
sa(dp10850
g7
I25
sg27
VC0011860
p10851
sg10
I15
sg11
Vtype 2 diabetes
p10852
sg13
I3
sasa(dp10853
g2
VThe objective of this paper is to describe the design and implementation of a Personal Health Record System (PHR-S) for supporting monitoring of blood glucose in diabetes mellitus type 2 patients.
p10854
sg4
(lp10855
sg24
(lp10856
(dp10857
g7
I162
sg27
VC0011860
p10858
sg10
I24
sg11
Vdiabetes mellitus type 2
p10859
sg13
I4
sasa(dp10860
g2
VIn this study the different applications and functionalities of the program are demonstrated such as: exhaustive assembly (rDNA region and mitochondrial genome), extracting homologous regions or genes (IGS, RPB1, RPB2 and TEF1a), as well as extracting multiple regions within a single run.
p10861
sg4
(lp10862
(dp10863
g7
I207
sg8
VP24928
p10864
sg10
I4
sg11
VRPB1
p10865
sg13
I1
sa(dp10866
g7
I213
sg8
VP30876
p10867
sg10
I4
sg11
VRPB2
p10868
sg13
I1
sa(dp10869
g7
I202
sg8
g9
sg10
I3
sg11
VIGS
p10870
sg13
I1
sasg24
(lp10871
(dp10872
g7
I202
sg27
VC1306856
p10873
sg10
I3
sg11
VIGS
p10874
sg13
I1
sasa(dp10875
g2
VSequences of the translation elongation factor 1Alfa (tef1Alfa), RNA polymerase II subunit B2 (rpb2), ATP citrate lyase subunit A (acla), and internal transcribed spacer (ITS) regions were monomorphic, while the intergenic spacer (IGS) region showed length polymorphisms at two minisatellites of 23 and 39 nucleotides (nt).
p10876
sg4
(lp10877
(dp10878
g7
I102
sg8
g9
sg10
I27
sg11
VATP citrate lyase subunit A
p10879
sg13
I5
sa(dp10880
g7
I54
sg8
g9
sg10
I8
sg11
Vtef1Alfa
p10881
sg13
I1
sa(dp10882
g7
I95
sg8
VP30876
p10883
sg10
I4
sg11
Vrpb2
p10884
sg13
I1
sa(dp10885
g7
I131
sg8
g9
sg10
I4
sg11
Vacla
p10886
sg13
I1
sa(dp10887
g7
I65
sg8
VP30876
p10888
sg10
I28
sg11
VRNA polymerase II subunit B2
p10889
sg13
I5
sa(dp10890
g7
I17
sg8
g9
sg10
I35
sg11
Vtranslation elongation factor 1Alfa
p10891
sg13
I4
sasg24
(lp10892
(dp10893
g7
I212
sg27
VC1306856
p10894
sg10
I17
sg11
Vintergenic spacer
p10895
sg13
I2
sa(dp10896
g7
I231
sg27
VC1306856
p10897
sg10
I3
sg11
VIGS
p10898
sg13
I1
sasa(dp10899
g2
VThe phylogenetic relationships of these species were determined using sequences from the ITS and IGS region of the nuclear rRNA gene complex, two nuclear genes ( Beta -tubulin (benA) and RNA polymerase II second largest subunit (rpb2)) and two mitochondrial genes (small rRNA subunit (rns) and cytochrome oxidase subunit I (cox1)) and, where available, related sequences from databases.
p10900
sg4
(lp10901
(dp10902
g7
I324
sg8
VP00395
p10903
sg10
I4
sg11
Vcox1
p10904
sg13
I1
sa(dp10905
g7
I294
sg8
VP00395
p10906
sg10
I28
sg11
Vcytochrome oxidase subunit I
p10907
sg13
I4
sa(dp10908
g7
I229
sg8
VP30876
p10909
sg10
I4
sg11
Vrpb2
p10910
sg13
I1
sa(dp10911
g7
I187
sg8
VP19388
p10912
sg10
I17
sg11
VRNA polymerase II
p10913
sg13
I3
sasg24
(lp10914
(dp10915
g7
I285
sg27
VC1850106
p10916
sg10
I3
sg11
Vrns
p10917
sg13
I1
sa(dp10918
g7
I97
sg27
VC1306856
p10919
sg10
I3
sg11
VIGS
p10920
sg13
I1
sasa(dp10921
g2
VThe combined use of the three commonly employed nuclear genes (benA, rpb2, and ITS), the IGS region, and two less often used mitochondrial gene sequences (rns and cox1) as a single unit resolved several taxonomic ambiguities.
p10922
sg4
(lp10923
(dp10924
g7
I155
sg8
g9
sg10
I3
sg11
Vrns
p10925
sg13
I1
sa(dp10926
g7
I163
sg8
VP00395
p10927
sg10
I4
sg11
Vcox1
p10928
sg13
I1
sa(dp10929
g7
I69
sg8
VP30876
p10930
sg10
I4
sg11
Vrpb2
p10931
sg13
I1
sa(dp10932
g7
I89
sg8
g9
sg10
I10
sg11
VIGS region
p10933
sg13
I2
sasg24
(lp10934
(dp10935
g7
I89
sg27
VC1306856
p10936
sg10
I3
sg11
VIGS
p10937
sg13
I1
sa(dp10938
g7
I155
sg27
VC1850106
p10939
sg10
I3
sg11
Vrns
p10940
sg13
I1
sasa(dp10941
g2
VIn order to find other markers that, in combination with the ITS rDNA region can be used for species identification in Cladonia, we studied the loci IGS rDNA, ef1Alfa, rpb2 and cox1.
p10942
sg4
(lp10943
(dp10944
g7
I149
sg8
g9
sg10
I8
sg11
VIGS rDNA
p10945
sg13
I2
sa(dp10946
g7
I168
sg8
VP30876
p10947
sg10
I4
sg11
Vrpb2
p10948
sg13
I1
sa(dp10949
g7
I177
sg8
VP00395
p10950
sg10
I4
sg11
Vcox1
p10951
sg13
I1
sasg24
(lp10952
(dp10953
g7
I149
sg27
VC1306856
p10954
sg10
I3
sg11
VIGS
p10955
sg13
I1
sasa(dp10956
g2
VThree-gene combined analyses (ITS+IGS+rpb2) were performed and the results indicated that the Chinese 'G.
p10957
sg4
(lp10958
sg24
(lp10959
sa(dp10960
g2
VSeven loci were analyzed: the translation elongation factor 1 alpha gene (EF-1Alfa); the nuclear rRNA internal transcribed spacer (ITS), large subunit (LSU), and intergenic spacer (IGS) regions; the second largest subunit of the RNA polymerase gene (RPB2); the calmodulin gene (CAM); and the mitochondrial small subunit (mtSSU) rRNA gene.
p10961
sg4
(lp10962
(dp10963
g7
I30
sg8
g9
sg10
I42
sg11
Vtranslation elongation factor 1 alpha gene
p10964
sg13
I6
sa(dp10965
g7
I250
sg8
VP30876
p10966
sg10
I4
sg11
VRPB2
p10967
sg13
I1
sa(dp10968
g7
I278
sg8
VP01768
p10969
sg10
I3
sg11
VCAM
p10970
sg13
I1
sa(dp10971
g7
I261
sg8
g9
sg10
I15
sg11
Vcalmodulin gene
p10972
sg13
I2
sasg24
(lp10973
(dp10974
g7
I162
sg27
VC1306856
p10975
sg10
I17
sg11
Vintergenic spacer
p10976
sg13
I2
sa(dp10977
g7
I261
sg27
VC1861821
p10978
sg10
I15
sg11
Vcalmodulin gene
p10979
sg13
I2
sa(dp10980
g7
I181
sg27
VC1306856
p10981
sg10
I3
sg11
VIGS
p10982
sg13
I1
sa(dp10983
g7
I278
sg27
VC1861821
p10984
sg10
I3
sg11
VCAM
p10985
sg13
I1
sasa(dp10986
g2
VTwenty-nine IGS, 27 EF-1Alfa, 26 RPB2, 24 CAM, 18 ITS, 19 LSU, and 18 mtSSU haplotypes were identified; 29 were unique, and haplotypes for 24 clinical strains were novel.
p10987
sg4
(lp10988
(dp10989
g7
I12
sg8
g9
sg10
I25
sg11
VIGS, 27 EF-1Alfa, 26 RPB2
p10990
sg13
I5
sasg24
(lp10991
(dp10992
g7
I12
sg27
VC1306856
p10993
sg10
I3
sg11
VIGS
p10994
sg13
I1
sa(dp10995
g7
I42
sg27
VC1861821
p10996
sg10
I3
sg11
VCAM
p10997
sg13
I1
sasa(dp10998
g2
VComplete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).
p10999
sg4
(lp11000
(dp11001
g7
I20
sg8
VP42226
p11002
sg10
I5
sg11
VSTAT6
p11003
sg13
I1
sasg24
(lp11004
(dp11005
g7
I45
sg27
VC0205825
p11006
sg10
I23
sg11
Vpleomorphic liposarcoma
p11007
sg13
I2
sa(dp11008
g7
I73
sg27
VC0206657
p11009
sg10
I26
sg11
Valveolar soft part sarcoma
p11010
sg13
I4
sasa(dp11011
g2
VPatients with ASC due to choledocholithiasis were allocated to two groups: Those who underwent EST immediately and those who underwent EBD followed by EST 1 wk later because they were under anticoagulant therapy, had a coagulopathy (international normalized ratio &gt; 1.3, partial thromboplastin time greater than twice that of control), or had a platelet count &lt; 50000 x 10(3)/myL.
p11012
sg4
(lp11013
(dp11014
g7
I282
sg8
VP13726
p11015
sg10
I14
sg11
Vthromboplastin
p11016
sg13
I1
sa(dp11017
g7
I382
sg8
VP29590
p11018
sg10
I3
sg11
VmyL
p11019
sg13
I1
sasg24
(lp11020
(dp11021
g7
I25
sg27
VC0701818
p11022
sg10
I19
sg11
Vcholedocholithiasis
p11023
sg13
I1
sa(dp11024
g7
I219
sg27
VC0005779
p11025
sg10
I12
sg11
Vcoagulopathy
p11026
sg13
I1
sasa(dp11027
g2
VA cross of the Asd-4 mutant with wild-type resulted in fruiting bodies that appeared to be normal macroscopically but which were complete devoid of asci and ascospores.
p11028
sg4
(lp11029
(dp11030
g7
I15
sg8
VP51689
p11031
sg10
I12
sg11
VAsd-4 mutant
p11032
sg13
I2
sasg24
(lp11033
(dp11034
g7
I15
sg27
VC1510586
p11035
sg10
I3
sg11
VAsd
p11036
sg13
I1
sa(dp11037
g7
I21
sg27
VC0596988
p11038
sg10
I6
sg11
Vmutant
p11039
sg13
I1
sasa(dp11040
g2
VA mutant strain (asd-1) with a recessive crossing defect (apparently caused by the RIP process) was isolated; in this strain, early development is normal and may asci are formed, but ascospores are never delineated.
p11041
sg4
(lp11042
(dp11043
g7
I17
sg8
VP51689
p11044
sg10
I5
sg11
Vasd-1
p11045
sg13
I1
sasg24
(lp11046
(dp11047
g7
I17
sg27
VC1510586
p11048
sg10
I3
sg11
Vasd
p11049
sg13
I1
sa(dp11050
g7
I2
sg27
VC0596988
p11051
sg10
I6
sg11
Vmutant
p11052
sg13
I1
sasa(dp11053
g2
VcPGES and mPGES-2 have been found expressed in normal gastric mucosa, with no change in expression levels seen in gastritis or gastric ulcer tissue.
p11054
sg4
(lp11055
(dp11056
g7
I10
sg8
g9
sg10
I7
sg11
VmPGES-2
p11057
sg13
I1
sa(dp11058
g7
I0
sg8
g9
sg10
I5
sg11
VcPGES
p11059
sg13
I1
sasg24
(lp11060
(dp11061
g7
I114
sg27
VC0017152
p11062
sg10
I9
sg11
Vgastritis
p11063
sg13
I1
sa(dp11064
g7
I127
sg27
VC0038358
p11065
sg10
I13
sg11
Vgastric ulcer
p11066
sg13
I2
sasa(dp11067
g2
VHerein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC).
p11068
sg4
(lp11069
(dp11070
g7
I31
sg8
g9
sg10
I4
sg11
VChk1
p11071
sg13
I1
sa(dp11072
g7
I40
sg8
g9
sg10
I3
sg11
VATM
p11073
sg13
I1
sasg24
(lp11074
(dp11075
g7
I83
sg27
VC0242787
p11076
sg10
I3
sg11
VMBC
p11077
sg13
I1
sa(dp11078
g7
I63
sg27
VC0242787
p11079
sg10
I18
sg11
Vmale breast cancer
p11080
sg13
I3
sasa(dp11081
g2
VWe have previously shown that the1100delC variant of the cell-cycle-checkpoint kinase gene CHEK2, which is carried by approximately 1% of the population confers a two-fold increase in female breast cancer and a 10-fold increase in male breast cancer.
p11082
sg4
(lp11083
sg24
(lp11084
(dp11085
g7
I184
sg27
VC0235653
p11086
sg10
I20
sg11
Vfemale breast cancer
p11087
sg13
I3
sa(dp11088
g7
I186
sg27
VC0242787
p11089
sg10
I18
sg11
Vmale breast cancer
p11090
sg13
I3
sasa(dp11091
g2
VThe purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels with diabetic nephropathy (DN).
p11092
sg4
(lp11093
(dp11094
g7
I70
sg8
g9
sg10
I14
sg11
Vinterleukin-19
p11095
sg13
I1
sa(dp11096
g7
I86
sg8
g9
sg10
I5
sg11
VIL-19
p11097
sg13
I1
sasg24
(lp11098
(dp11099
g7
I105
sg27
VC0011881
p11100
sg10
I20
sg11
Vdiabetic nephropathy
p11101
sg13
I2
sa(dp11102
g7
I127
sg27
VC0011881
p11103
sg10
I2
sg11
VDN
p11104
sg13
I1
sasa(dp11105
g2
VIL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role that contributes to the progression of diabetic nephropathy.
p11106
sg4
(lp11107
(dp11108
g7
I0
sg8
g9
sg10
I5
sg11
VIL-19
p11109
sg13
I1
sa(dp11110
g7
I0
sg8
g9
sg10
I5
sg11
VIL-19
p11111
sg13
I1
sa(dp11112
g7
I56
sg8
VP01034
p11113
sg10
I10
sg11
VCystatin C
p11114
sg13
I2
sasg24
(lp11115
(dp11116
g7
I140
sg27
VC0011881
p11117
sg10
I20
sg11
Vdiabetic nephropathy
p11118
sg13
I2
sasa(dp11119
g2
VWe also demonstrate a large increase in levels of IL-19 in urine of patients with chronic kidney disease, which significantly correlated with estimated glomerular filtration rate levels.
p11120
sg4
(lp11121
(dp11122
g7
I50
sg8
g9
sg10
I5
sg11
VIL-19
p11123
sg13
I1
sasg24
(lp11124
(dp11125
g7
I82
sg27
VC1561643
p11126
sg10
I22
sg11
Vchronic kidney disease
p11127
sg13
I3
sasa(dp11128
g2
VNon-clustered protocadherins (PCDHs) are calcium-dependent adhesion molecules which have attracted attention for their possible roles in the neuronal circuit formation during development and their implications in the neurological disorders such as autism and mental retardation.
p11129
sg4
(lp11130
sg24
(lp11131
(dp11132
g7
I217
sg27
VC0027765
p11133
sg10
I22
sg11
Vneurological disorders
p11134
sg13
I2
sa(dp11135
g7
I59
sg27
VC0001511
p11136
sg10
I8
sg11
Vadhesion
p11137
sg13
I1
sa(dp11138
g7
I248
sg27
VC0004352
p11139
sg10
I6
sg11
Vautism
p11140
sg13
I1
sa(dp11141
g7
I259
sg27
VC0025362
p11142
sg10
I18
sg11
Vmental retardation
p11143
sg13
I2
sasa(dp11144
g2
VMutation screening of 30 individuals with autism identified two PCDH11Y polymorphic amino acid changes, F885V and K980N.
p11145
sg4
(lp11146
sg24
(lp11147
(dp11148
g7
I42
sg27
VC0004352
p11149
sg10
I6
sg11
Vautism
p11150
sg13
I1
sasa(dp11151
g2
VIn the present study, we analyzed the expression levels of LETM1 in bladder cancer tissues and non-cancerous tissues as well as in four bladder cancer cell lines (T24, EJ, 5637 and J82) and a human bladder epithelial immortalized cell line SV-HUC-1.
p11152
sg4
(lp11153
(dp11154
g7
I59
sg8
g9
sg10
I5
sg11
VLETM1
p11155
sg13
I1
sasg24
(lp11156
(dp11157
g7
I68
sg27
VC0699885
p11158
sg10
I14
sg11
Vbladder cancer
p11159
sg13
I2
sa(dp11160
g7
I68
sg27
VC0699885
p11161
sg10
I14
sg11
Vbladder cancer
p11162
sg13
I2
sasa(dp11163
g2
VThe PD-L1 mRNA and protein expression levels were measured in the bladder cancer T24 cell line and the human uroepithelial SV-HUC-1 cell line, following treatment with interleukin (IL)-2, interferon (IFN)-Alfa and IFN-Gamma, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively.
p11164
sg4
(lp11165
(dp11166
g7
I200
sg8
VP01562
p11167
sg10
I3
sg11
VIFN
p11168
sg13
I1
sa(dp11169
g7
I188
sg8
VP01563
p11170
sg10
I10
sg11
Vinterferon
p11171
sg13
I1
sa(dp11172
g7
I214
sg8
VP01579
p11173
sg10
I9
sg11
VIFN-Gamma
p11174
sg13
I1
sa(dp11175
g7
I168
sg8
VP60568
p11176
sg10
I18
sg11
Vinterleukin (IL)-2
p11177
sg13
I2
sasg24
(lp11178
(dp11179
g7
I66
sg27
VC0699885
p11180
sg10
I14
sg11
Vbladder cancer
p11181
sg13
I2
sasa(dp11182
g2
VRT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-Alfa and IFN-Gamma markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P&lt;0.05), but had no significant effect in non-tumor SV-HUC-1 cells.
p11183
sg4
(lp11184
(dp11185
g7
I63
sg8
VP01562
p11186
sg10
I8
sg11
VIFN-Alfa
p11187
sg13
I1
sa(dp11188
g7
I57
sg8
VP60568
p11189
sg10
I4
sg11
VIL-2
p11190
sg13
I1
sa(dp11191
g7
I76
sg8
VP01579
p11192
sg10
I9
sg11
VIFN-Gamma
p11193
sg13
I1
sasg24
(lp11194
(dp11195
g7
I157
sg27
VC0699885
p11196
sg10
I14
sg11
Vbladder cancer
p11197
sg13
I2
sa(dp11198
g7
I232
sg27
VC0027651
p11199
sg10
I5
sg11
Vtumor
p11200
sg13
I1
sasa(dp11201
g2
VOur data showed that miR-6838 was sharply up-regulated in the bladder tissues from bladder cancer patients and 4 human bladder cancer cell lines, compared with the healthy volunteers and SU-HUC-1 human normal bladder epithelial cells.
p11202
sg4
(lp11203
(dp11204
g7
I187
sg8
g9
sg10
I8
sg11
VSU-HUC-1
p11205
sg13
I1
sasg24
(lp11206
(dp11207
g7
I83
sg27
VC0699885
p11208
sg10
I14
sg11
Vbladder cancer
p11209
sg13
I2
sa(dp11210
g7
I83
sg27
VC0699885
p11211
sg10
I14
sg11
Vbladder cancer
p11212
sg13
I2
sasa(dp11213
g2
VTreatment with dioscin decreased viability of BC 5637 and T24 cells, but not non-cancer bladder epithelial cell, SV-HUC-1.
p11214
sg4
(lp11215
sg24
(lp11216
(dp11217
g7
I81
sg27
VC0006826
p11218
sg10
I6
sg11
Vcancer
p11219
sg13
I1
sasa(dp11220
g2
VA primary deficiency of protein C or S is proposed which would produce cerebral thrombosis with exposure of phospholipids; this thrombosis then, like antigens, would generate antibodies acting on the thrombin-thrombomodulin complex, exacerbating the thrombotic process.
p11221
sg4
(lp11222
(dp11223
g7
I24
sg8
VP02810
p11224
sg10
I9
sg11
Vprotein C
p11225
sg13
I2
sa(dp11226
g7
I200
sg8
VP00734
p11227
sg10
I8
sg11
Vthrombin
p11228
sg13
I1
sa(dp11229
g7
I209
sg8
VP07204
p11230
sg10
I14
sg11
Vthrombomodulin
p11231
sg13
I1
sasg24
(lp11232
(dp11233
g7
I71
sg27
VC0795687
p11234
sg10
I19
sg11
Vcerebral thrombosis
p11235
sg13
I2
sa(dp11236
g7
I80
sg27
VC0040053
p11237
sg10
I10
sg11
Vthrombosis
p11238
sg13
I1
sasa(dp11239
g2
VTo investigate whether defects in the SPATA17 gene are associated with azoospermia due to meiotic arrest, a mutational analysis was conducted, in which the SPATA17 coding regions of 18 Japanese patients with this condition were sequenced.
p11240
sg4
(lp11241
(dp11242
g7
I38
sg8
g9
sg10
I12
sg11
VSPATA17 gene
p11243
sg13
I2
sa(dp11244
g7
I38
sg8
g9
sg10
I7
sg11
VSPATA17
p11245
sg13
I1
sasg24
(lp11246
(dp11247
g7
I213
sg27
VC0012634
p11248
sg10
I9
sg11
Vcondition
p11249
sg13
I1
sa(dp11250
g7
I71
sg27
VC1321542
p11251
sg10
I11
sg11
Vazoospermia
p11252
sg13
I1
sasa(dp11253
g2
VThe frequencies of erythrocyte MNSs antigens and certain histocompatibility leukocyte antigen (HLA) specificities (HLA-A, HLA-B, and HLA-DR) were determined in white patients with meningitis or epiglottitis due to Haemophilus influenzae type b and in controls.
p11254
sg4
(lp11255
(dp11256
g7
I19
sg8
VP21333
p11257
sg10
I25
sg11
Verythrocyte MNSs antigens
p11258
sg13
I3
sa(dp11259
g7
I49
sg8
VP14209
p11260
sg10
I44
sg11
Vcertain histocompatibility leukocyte antigen
p11261
sg13
I4
sa(dp11262
g7
I122
sg8
VP30461
p11263
sg10
I5
sg11
VHLA-B
p11264
sg13
I1
sa(dp11265
g7
I133
sg8
VP30486
p11266
sg10
I6
sg11
VHLA-DR
p11267
sg13
I1
sa(dp11268
g7
I115
sg8
VP30447
p11269
sg10
I5
sg11
VHLA-A
p11270
sg13
I1
sa(dp11271
g7
I95
sg8
VP30486
p11272
sg10
I3
sg11
VHLA
p11273
sg13
I1
sasg24
(lp11274
(dp11275
g7
I194
sg27
VC0014541
p11276
sg10
I12
sg11
Vepiglottitis
p11277
sg13
I1
sa(dp11278
g7
I180
sg27
VC0025289
p11279
sg10
I10
sg11
Vmeningitis
p11280
sg13
I1
sasa(dp11281
g2
VAnalysis of antigen expression pattern, the presence or absence of T cell-associated antigen deletion, and the expression of CD10 and CD34 by 4-color flow cytometry can help differentiate thymoma from T-cell ALL/LBL.
p11282
sg4
(lp11283
(dp11284
g7
I125
sg8
VP08473
p11285
sg10
I4
sg11
VCD10
p11286
sg13
I1
sa(dp11287
g7
I134
sg8
VP28906
p11288
sg10
I4
sg11
VCD34
p11289
sg13
I1
sa(dp11290
g7
I67
sg8
VP14209
p11291
sg10
I25
sg11
VT cell-associated antigen
p11292
sg13
I3
sasg24
(lp11293
(dp11294
g7
I188
sg27
VC0040100
p11295
sg10
I7
sg11
Vthymoma
p11296
sg13
I1
sasa(dp11297
g2
VWe found that CYC1 was upregulated in breast tumor tissues, especially in tissues with lymph node metastasis.
p11298
sg4
(lp11299
(dp11300
g7
I14
sg8
VP08574
p11301
sg10
I4
sg11
VCYC1
p11302
sg13
I1
sasg24
(lp11303
(dp11304
g7
I38
sg27
VC1458155
p11305
sg10
I12
sg11
Vbreast tumor
p11306
sg13
I2
sa(dp11307
g7
I87
sg27
VC0686619
p11308
sg10
I21
sg11
Vlymph node metastasis
p11309
sg13
I3
sasa(dp11310
g2
VAnd higher expression of CYC1 correlates with poor prognosis in breast cancer patients using online databases and tools.
p11311
sg4
(lp11312
(dp11313
g7
I25
sg8
VP08574
p11314
sg10
I4
sg11
VCYC1
p11315
sg13
I1
sasg24
(lp11316
(dp11317
g7
I64
sg27
VC0678222
p11318
sg10
I13
sg11
Vbreast cancer
p11319
sg13
I2
sasa(dp11320
g2
VThen we confirmed that CYC1 contributed to metastasis and proliferation in two highly metastatic human breast cancer cell lines.
p11321
sg4
(lp11322
(dp11323
g7
I23
sg8
VP08574
p11324
sg10
I4
sg11
VCYC1
p11325
sg13
I1
sasg24
(lp11326
(dp11327
g7
I43
sg27
VC0027627
p11328
sg10
I10
sg11
Vmetastasis
p11329
sg13
I1
sa(dp11330
g7
I58
sg27
VC0334094
p11331
sg10
I13
sg11
Vproliferation
p11332
sg13
I1
sa(dp11333
g7
I103
sg27
VC0678222
p11334
sg10
I13
sg11
Vbreast cancer
p11335
sg13
I2
sasa(dp11336
g2
VOur results indicated that CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis.
p11337
sg4
(lp11338
(dp11339
g7
I27
sg8
VP08574
p11340
sg10
I4
sg11
VCYC1
p11341
sg13
I1
sasg24
(lp11342
(dp11343
g7
I62
sg27
VC0178874
p11344
sg10
I18
sg11
Vcancer progression
p11345
sg13
I2
sasa(dp11346
g2
VUbiquinol-cytochrome c reductase hinge protein (UQCRH), as a connecter between cytochrome c1 with cytochrome c in complex III of respiratory chain, is top-ranked hypermethylated gene in clear cell renal cell carcinoma (ccRCC).
p11347
sg4
(lp11348
(dp11349
g7
I48
sg8
VP07919
p11350
sg10
I5
sg11
VUQCRH
p11351
sg13
I1
sa(dp11352
g7
I79
sg8
VP08574
p11353
sg10
I13
sg11
Vcytochrome c1
p11354
sg13
I2
sa(dp11355
g7
I10
sg8
VP99999
p11356
sg10
I12
sg11
Vcytochrome c
p11357
sg13
I2
sa(dp11358
g7
I0
sg8
VP99999
p11359
sg10
I46
sg11
VUbiquinol-cytochrome c reductase hinge protein
p11360
sg13
I5
sasg24
(lp11361
(dp11362
g7
I219
sg27
VC0279702
p11363
sg10
I5
sg11
VccRCC
p11364
sg13
I1
sa(dp11365
g7
I186
sg27
VC0279702
p11366
sg10
I31
sg11
Vclear cell renal cell carcinoma
p11367
sg13
I5
sasa(dp11368
g2
VThis study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human glioma of different grades (World Health Organization grades II-IV).
p11369
sg4
(lp11370
(dp11371
g7
I99
sg8
VP08574
p11372
sg10
I4
sg11
VCYC1
p11373
sg13
I1
sa(dp11374
g7
I61
sg8
VP61769
p11375
sg10
I20
sg11
Vbeta-2-microglobulin
p11376
sg13
I1
sa(dp11377
g7
I237
sg8
VP40429
p11378
sg10
I22
sg11
Vribosomal protein L13a
p11379
sg13
I3
sa(dp11380
g7
I295
sg8
VP20226
p11381
sg10
I24
sg11
VTATA-box binding protein
p11382
sg13
I3
sa(dp11383
g7
I83
sg8
VP99999
p11384
sg10
I14
sg11
Vcytochrome c-1
p11385
sg13
I2
sa(dp11386
g7
I261
sg8
VP40429
p11387
sg10
I6
sg11
VRPL13A
p11388
sg13
I1
sa(dp11389
g7
I106
sg8
VP04406
p11390
sg10
I40
sg11
Vglyceraldehyde-3-phosphate dehydrogenase
p11391
sg13
I2
sa(dp11392
g7
I186
sg8
VP00492
p11393
sg10
I49
sg11
Vhypoxanthine guanine phosphoribosyl transferase 1
p11394
sg13
I5
sa(dp11395
g7
I156
sg8
VP08397
p11396
sg10
I28
sg11
Vhydroxymethylbilane synthase
p11397
sg13
I2
sa(dp11398
g7
I148
sg8
VP04406
p11399
sg10
I5
sg11
VGAPDH
p11400
sg13
I1
sa(dp11401
g7
I270
sg8
VP49366
p11402
sg10
I23
sg11
Vsuccinate dehydrogenase
p11403
sg13
I2
sasg24
(lp11404
(dp11405
g7
I436
sg27
VC0017638
p11406
sg10
I6
sg11
Vglioma
p11407
sg13
I1
sasa(dp11408
g2
VAfter analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in glioma compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting.
p11409
sg4
(lp11410
(dp11411
g7
I110
sg8
VP40429
p11412
sg10
I6
sg11
VRPL13A
p11413
sg13
I1
sa(dp11414
g7
I122
sg8
VP08574
p11415
sg10
I4
sg11
VCYC1
p11416
sg13
I1
sa(dp11417
g7
I103
sg8
VP04406
p11418
sg10
I5
sg11
VGAPDH
p11419
sg13
I1
sasg24
(lp11420
(dp11421
g7
I287
sg27
VC0017636
p11422
sg10
I12
sg11
Vglioblastoma
p11423
sg13
I1
sa(dp11424
g7
I261
sg27
VC0334579
p11425
sg10
I22
sg11
Vanaplastic astrocytoma
p11426
sg13
I2
sa(dp11427
g7
I223
sg27
VC0017638
p11428
sg10
I6
sg11
Vglioma
p11429
sg13
I1
sasa(dp11430
g2
VKaplan-Meier plots identified correlations between individual or combined overexpression of E2F1, E2F3a, Mps1/TTK, Nek2, BubR1, or Hec1 and poor overall and relapse-free survival of breast cancer patients.
p11431
sg4
(lp11432
(dp11433
g7
I131
sg8
g9
sg10
I4
sg11
VHec1
p11434
sg13
I1
sa(dp11435
g7
I105
sg8
VP33981
p11436
sg10
I4
sg11
VMps1
p11437
sg13
I1
sa(dp11438
g7
I115
sg8
VP51955
p11439
sg10
I4
sg11
VNek2
p11440
sg13
I1
sa(dp11441
g7
I92
sg8
g9
sg10
I4
sg11
VE2F1
p11442
sg13
I1
sa(dp11443
g7
I110
sg8
VP49841
p11444
sg10
I3
sg11
VTTK
p11445
sg13
I1
sa(dp11446
g7
I98
sg8
g9
sg10
I5
sg11
VE2F3a
p11447
sg13
I1
sasg24
(lp11448
(dp11449
g7
I157
sg27
VC0277556
p11450
sg10
I7
sg11
Vrelapse
p11451
sg13
I1
sa(dp11452
g7
I182
sg27
VC0678222
p11453
sg10
I13
sg11
Vbreast cancer
p11454
sg13
I2
sasa(dp11455
g2
VBy interrogating the METABRIC database, we observed a significant correlation between p53 expression and that of c-Abl and TTK in basal-like breast cancers.
p11456
sg4
(lp11457
(dp11458
g7
I86
sg8
VP42771
p11459
sg10
I3
sg11
Vp53
p11460
sg13
I1
sa(dp11461
g7
I113
sg8
VP00519
p11462
sg10
I5
sg11
Vc-Abl
p11463
sg13
I1
sa(dp11464
g7
I123
sg8
VP49841
p11465
sg10
I3
sg11
VTTK
p11466
sg13
I1
sasg24
(lp11467
(dp11468
g7
I141
sg27
VC0006142
p11469
sg10
I14
sg11
Vbreast cancers
p11470
sg13
I2
sa(dp11471
g7
I115
sg27
VC0000744
p11472
sg10
I3
sg11
VAbl
p11473
sg13
I1
sasa(dp11474
g2
VThe protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a critical component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple negative breast cancer.
p11475
sg4
(lp11476
(dp11477
g7
I46
sg8
VP49841
p11478
sg10
I3
sg11
VTTK
p11479
sg13
I1
sa(dp11480
g7
I4
sg8
VP29401
p11481
sg10
I40
sg11
Vprotein kinase threonine tyrosine kinase
p11482
sg13
I5
sa(dp11483
g7
I65
sg8
VP33981
p11484
sg10
I4
sg11
VMps1
p11485
sg13
I1
sasg24
(lp11486
(dp11487
g7
I190
sg27
VC0006826
p11488
sg10
I7
sg11
Vcancers
p11489
sg13
I1
sa(dp11490
g7
I223
sg27
VC0678222
p11491
sg10
I13
sg11
Vbreast cancer
p11492
sg13
I2
sa(dp11493
g7
I179
sg27
VC0001807
p11494
sg10
I10
sg11
Vaggressive
p11495
sg13
I1
sasa(dp11496
g2
VHigh levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC).
p11497
sg4
(lp11498
(dp11499
g7
I50
sg8
VP49841
p11500
sg10
I3
sg11
VTTK
p11501
sg13
I1
sa(dp11502
g7
I45
sg8
VP33981
p11503
sg10
I4
sg11
VMps1
p11504
sg13
I1
sasg24
(lp11505
(dp11506
g7
I165
sg27
VC0001807
p11507
sg10
I10
sg11
Vaggressive
p11508
sg13
I1
sa(dp11509
g7
I176
sg27
VC0006142
p11510
sg10
I14
sg11
Vbreast cancers
p11511
sg13
I2
sa(dp11512
g7
I100
sg27
VC0006142
p11513
sg10
I13
sg11
Vbreast cancer
p11514
sg13
I2
sa(dp11515
g7
I192
sg27
VC0006142
p11516
sg10
I2
sg11
VBC
p11517
sg13
I1
sasa(dp11518
g2
VThese compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions.
p11519
sg4
(lp11520
(dp11521
g7
I165
sg8
VP33981
p11522
sg10
I4
sg11
VMps1
p11523
sg13
I1
sasg24
(lp11524
(dp11525
g7
I77
sg27
VC0678222
p11526
sg10
I13
sg11
Vbreast cancer
p11527
sg13
I2
sa(dp11528
g7
I39
sg27
VC0334094
p11529
sg10
I13
sg11
Vproliferative
p11530
sg13
I1
sasa(dp11531
g2
VIn addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356myM to 0.809myM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells.
p11532
sg4
(lp11533
(dp11534
g7
I49
sg8
VP33981
p11535
sg10
I4
sg11
VMps1
p11536
sg13
I1
sa(dp11537
g7
I49
sg8
VP33981
p11538
sg10
I11
sg11
VMps1 kinase
p11539
sg13
I2
sasg24
(lp11540
(dp11541
g7
I250
sg27
VC0678222
p11542
sg10
I13
sg11
Vbreast cancer
p11543
sg13
I2
sa(dp11544
g7
I192
sg27
VC1705960
p11545
sg10
I11
sg11
Vduplication
p11546
sg13
I1
sasa(dp11547
g2
VUsing drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.
p11548
sg4
(lp11549
(dp11550
g7
I139
sg8
VP49841
p11551
sg10
I3
sg11
VTTK
p11552
sg13
I1
sa(dp11553
g7
I134
sg8
VP33981
p11554
sg10
I4
sg11
VMps1
p11555
sg13
I1
sasg24
(lp11556
(dp11557
g7
I211
sg27
VC0006142
p11558
sg10
I14
sg11
Vbreast cancers
p11559
sg13
I2
sasa(dp11560
g2
VHowever, high levels of Mps1 are found in many types of human malignancies, including glioblastoma, thyroid carcinoma, breast cancer, and other cancers.
p11561
sg4
(lp11562
(dp11563
g7
I24
sg8
VP33981
p11564
sg10
I4
sg11
VMps1
p11565
sg13
I1
sasg24
(lp11566
(dp11567
g7
I100
sg27
VC0549473
p11568
sg10
I17
sg11
Vthyroid carcinoma
p11569
sg13
I2
sa(dp11570
g7
I86
sg27
VC0017636
p11571
sg10
I12
sg11
Vglioblastoma
p11572
sg13
I1
sa(dp11573
g7
I62
sg27
VC0006826
p11574
sg10
I12
sg11
Vmalignancies
p11575
sg13
I1
sa(dp11576
g7
I144
sg27
VC0006826
p11577
sg10
I7
sg11
Vcancers
p11578
sg13
I1
sa(dp11579
g7
I119
sg27
VC0678222
p11580
sg10
I13
sg11
Vbreast cancer
p11581
sg13
I2
sasa(dp11582
g2
VHere, we employed amphiphilic polymers and silenced the expression of two cell cycle proteins, TTK and CDC20, and the anti-apoptosis protein survivin to determine the efficacy of polymer-mediated siRNA treatment in breast cancer cells as well as side effects in nonmalignant cells in vitro.
p11583
sg4
(lp11584
(dp11585
g7
I95
sg8
VP49841
p11586
sg10
I3
sg11
VTTK
p11587
sg13
I1
sa(dp11588
g7
I103
sg8
g9
sg10
I5
sg11
VCDC20
p11589
sg13
I1
sasg24
(lp11590
(dp11591
g7
I215
sg27
VC0678222
p11592
sg10
I13
sg11
Vbreast cancer
p11593
sg13
I2
sasa(dp11594
g2
VTo explore expressions of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinases-1 (TIMP-1) and transforming growth factor-Beta1 (TGF-Beta1) in valve tissue of rheumatic heart disease (RHD), and to analyzed their roles in RHD.
p11595
sg4
(lp11596
(dp11597
g7
I62
sg8
VP01033
p11598
sg10
I40
sg11
Vtissue inhibitor of metalloproteinases-1
p11599
sg13
I4
sa(dp11600
g7
I150
sg8
VP01137
p11601
sg10
I9
sg11
VTGF-Beta1
p11602
sg13
I1
sa(dp11603
g7
I116
sg8
VP01137
p11604
sg10
I32
sg11
Vtransforming growth factor-Beta1
p11605
sg13
I3
sa(dp11606
g7
I104
sg8
VP01033
p11607
sg10
I6
sg11
VTIMP-1
p11608
sg13
I1
sa(dp11609
g7
I54
sg8
VP03956
p11610
sg10
I5
sg11
VMMP-1
p11611
sg13
I1
sa(dp11612
g7
I26
sg8
VP03956
p11613
sg10
I26
sg11
Vmatrix metalloproteinase-1
p11614
sg13
I2
sasg24
(lp11615
(dp11616
g7
I205
sg27
VC0035439
p11617
sg10
I3
sg11
VRHD
p11618
sg13
I1
sa(dp11619
g7
I180
sg27
VC0035439
p11620
sg10
I23
sg11
Vrheumatic heart disease
p11621
sg13
I3
sa(dp11622
g7
I205
sg27
VC0035439
p11623
sg10
I3
sg11
VRHD
p11624
sg13
I1
sasa(dp11625
g2
VObjectives The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis.
p11626
sg4
(lp11627
sg24
(lp11628
(dp11629
g7
I109
sg27
VC0024143
p11630
sg10
I15
sg11
Vlupus nephritis
p11631
sg13
I2
sa(dp11632
g7
I216
sg27
VC1402315
p11633
sg10
I16
sg11
Vvascular lesions
p11634
sg13
I2
sa(dp11635
g7
I95
sg27
VC0334094
p11636
sg10
I13
sg11
Vproliferative
p11637
sg13
I1
sa(dp11638
g7
I109
sg27
VC0024143
p11639
sg10
I15
sg11
Vlupus nephritis
p11640
sg13
I2
sasa(dp11641
g2
VResults Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 +/- 21% vs. 90 +/- 13%, p = 0.005).
p11642
sg4
(lp11643
sg24
(lp11644
(dp11645
g7
I37
sg27
VC0024143
p11646
sg10
I15
sg11
Vlupus nephritis
p11647
sg13
I2
sasa(dp11648
g2
VConclusions Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores.
p11649
sg4
(lp11650
sg24
(lp11651
(dp11652
g7
I82
sg27
VC0024143
p11653
sg10
I15
sg11
Vlupus nephritis
p11654
sg13
I2
sa(dp11655
g7
I68
sg27
VC0334094
p11656
sg10
I13
sg11
Vproliferative
p11657
sg13
I1
sasa(dp11658
g2
VThe serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P &lt; 0.001, respectively).
p11659
sg4
(lp11660
sg24
(lp11661
(dp11662
g7
I75
sg27
VC0024143
p11663
sg10
I15
sg11
Vlupus nephritis
p11664
sg13
I2
sa(dp11665
g7
I75
sg27
VC0024143
p11666
sg10
I15
sg11
Vlupus nephritis
p11667
sg13
I2
sa(dp11668
g7
I95
sg27
VC1268935
p11669
sg10
I3
sg11
VTTP
p11670
sg13
I1
sasa(dp11671
g2
VThe prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P &lt; 0.001; 6/7, 86% versus 0, P &lt; 0.001, respectively).
p11672
sg4
(lp11673
sg24
(lp11674
(dp11675
g7
I90
sg27
VC0024143
p11676
sg10
I15
sg11
Vlupus nephritis
p11677
sg13
I2
sa(dp11678
g7
I110
sg27
VC1268935
p11679
sg10
I3
sg11
VTTP
p11680
sg13
I1
sa(dp11681
g7
I90
sg27
VC0024143
p11682
sg10
I15
sg11
Vlupus nephritis
p11683
sg13
I2
sasa(dp11684
g2
VADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP-HUS associated with lupus nephritis.
p11685
sg4
(lp11686
(dp11687
g7
I77
sg8
g9
sg10
I7
sg11
VTTP-HUS
p11688
sg13
I1
sasg24
(lp11689
(dp11690
g7
I77
sg27
VC1268935
p11691
sg10
I3
sg11
VTTP
p11692
sg13
I1
sa(dp11693
g7
I101
sg27
VC0024143
p11694
sg10
I15
sg11
Vlupus nephritis
p11695
sg13
I2
sa(dp11696
g7
I61
sg27
VC0699748
p11697
sg10
I12
sg11
Vpathogenesis
p11698
sg13
I1
sasa(dp11699
g2
VPlasma vWF and vWF-CP activities were measured using enzyme-linked immunosorbent assay (ELISA) and residual collagen binding assay respectively in patients with lupus nephritis (n = 31), primary nephritic syndrome (n = 25), diabetic nephropathy (n = 45), chronic glomerulonephritis (n = 38) and 40 normal controls.
p11700
sg4
(lp11701
(dp11702
g7
I15
sg8
VP04275
p11703
sg10
I6
sg11
VvWF-CP
p11704
sg13
I1
sa(dp11705
g7
I7
sg8
VP04275
p11706
sg10
I3
sg11
VvWF
p11707
sg13
I1
sasg24
(lp11708
(dp11709
g7
I195
sg27
VC0268732
p11710
sg10
I18
sg11
Vnephritic syndrome
p11711
sg13
I2
sa(dp11712
g7
I161
sg27
VC0024143
p11713
sg10
I15
sg11
Vlupus nephritis
p11714
sg13
I2
sa(dp11715
g7
I224
sg27
VC0011881
p11716
sg10
I20
sg11
Vdiabetic nephropathy
p11717
sg13
I2
sa(dp11718
g7
I255
sg27
VC0152451
p11719
sg10
I26
sg11
Vchronic glomerulonephritis
p11720
sg13
I2
sasa(dp11721
g2
VRenal biopsy demonstrated that the vWF level in stage IV was higher than in stages II and III while vWF-CP activity was lower in patients with lupus nephritis.
p11722
sg4
(lp11723
(dp11724
g7
I35
sg8
VP04275
p11725
sg10
I3
sg11
VvWF
p11726
sg13
I1
sa(dp11727
g7
I100
sg8
VP04275
p11728
sg10
I6
sg11
VvWF-CP
p11729
sg13
I1
sasg24
(lp11730
(dp11731
g7
I143
sg27
VC0024143
p11732
sg10
I15
sg11
Vlupus nephritis
p11733
sg13
I2
sasa(dp11734
g2
VFurthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis.
p11735
sg4
(lp11736
(dp11737
g7
I42
sg8
VP04275
p11738
sg10
I3
sg11
VvWF
p11739
sg13
I1
sasg24
(lp11740
(dp11741
g7
I108
sg27
VC0024143
p11742
sg10
I15
sg11
Vlupus nephritis
p11743
sg13
I2
sa(dp11744
g7
I88
sg27
VC1268935
p11745
sg10
I3
sg11
VTTP
p11746
sg13
I1
sasa(dp11747
g2
VIn this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients.
p11748
sg4
(lp11749
(dp11750
g7
I83
sg8
g9
sg10
I20
sg11
Vkinesin light chains
p11751
sg13
I3
sa(dp11752
g7
I105
sg8
g9
sg10
I4
sg11
VKLCs
p11753
sg13
I1
sasg24
(lp11754
(dp11755
g7
I210
sg27
VC0012739
p11756
sg10
I3
sg11
VDIC
p11757
sg13
I1
sa(dp11758
g7
I343
sg27
VC1521724
p11759
sg10
I19
sg11
VAlzheimer's disease
p11760
sg13
I2
sa(dp11761
g7
I183
sg27
VC0012739
p11762
sg10
I25
sg11
Vdynein intermediate chain
p11763
sg13
I3
sasa(dp11764
g2
VBy immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients.
p11765
sg4
(lp11766
sg24
(lp11767
(dp11768
g7
I97
sg27
VC0012739
p11769
sg10
I3
sg11
VDIC
p11770
sg13
I1
sa(dp11771
g7
I161
sg27
VC1521724
p11772
sg10
I19
sg11
VAlzheimer's disease
p11773
sg13
I2
sasa(dp11774
g2
VWe suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3Beta-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.
p11775
sg4
(lp11776
(dp11777
g7
I150
sg8
VP49841
p11778
sg10
I9
sg11
VGSK-3Beta
p11779
sg13
I1
sasg24
(lp11780
(dp11781
g7
I266
sg27
VC1521724
p11782
sg10
I19
sg11
VAlzheimer's disease
p11783
sg13
I2
sa(dp11784
g7
I38
sg27
VC0012739
p11785
sg10
I3
sg11
VDIC
p11786
sg13
I1
sasa(dp11787
g2
VChildren with cystic fibrosis (CF) often have suboptimal adherence rates to nebulized medication.
p11788
sg4
(lp11789
sg24
(lp11790
(dp11791
g7
I14
sg27
VC0010674
p11792
sg10
I15
sg11
Vcystic fibrosis
p11793
sg13
I2
sa(dp11794
g7
I31
sg27
VC0010674
p11795
sg10
I2
sg11
VCF
p11796
sg13
I1
sasa(dp11797
g2
VA cocktail of three phages active against Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for a potential nebulized formulation.
p11798
sg4
(lp11799
sg24
(lp11800
(dp11801
g7
I79
sg27
VC0010674
p11802
sg10
I15
sg11
Vcystic fibrosis
p11803
sg13
I2
sasa(dp11804
g2
VTreatment regimen for families of children with cystic fibrosis (CF) is considerable, particularly when nebulised therapies for chronic Pseudomonas aeruginosa airway infection are prescribed.
p11805
sg4
(lp11806
sg24
(lp11807
(dp11808
g7
I166
sg27
VC0009450
p11809
sg10
I9
sg11
Vinfection
p11810
sg13
I1
sa(dp11811
g7
I48
sg27
VC0010674
p11812
sg10
I15
sg11
Vcystic fibrosis
p11813
sg13
I2
sa(dp11814
g7
I65
sg27
VC0010674
p11815
sg10
I2
sg11
VCF
p11816
sg13
I1
sasa(dp11817
g2
VThe time requirements for multiple daily nebulizer treatments are important impediments to the quality of life for most patients with cystic fibrosis (CF).
p11818
sg4
(lp11819
sg24
(lp11820
(dp11821
g7
I134
sg27
VC0010674
p11822
sg10
I15
sg11
Vcystic fibrosis
p11823
sg13
I2
sa(dp11824
g7
I151
sg27
VC0010674
p11825
sg10
I2
sg11
VCF
p11826
sg13
I1
sasa(dp11827
g2
VTherefore, in this study, the author describes for the first time the common feature of oral clefts in patients carrying a microduplication of 15q13.3 encompassing the CHRNA7 gene, which sheds light on the correlation between CHRNA7 and cleft palate.
p11828
sg4
(lp11829
(dp11830
g7
I168
sg8
VP36544
p11831
sg10
I11
sg11
VCHRNA7 gene
p11832
sg13
I2
sasg24
(lp11833
(dp11834
g7
I237
sg27
VC0008925
p11835
sg10
I12
sg11
Vcleft palate
p11836
sg13
I2
sasa(dp11837
g2
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p11838
sg4
(lp11839
(dp11840
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p11841
sg13
I1
sa(dp11842
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p11843
sg13
I1
sa(dp11844
g7
I272
sg8
VP08912
p11845
sg10
I5
sg11
VCHRM5
p11846
sg13
I1
sa(dp11847
g7
I202
sg8
VP68032
p11848
sg10
I4
sg11
VACTC
p11849
sg13
I1
sa(dp11850
g7
I264
sg8
VP36544
p11851
sg10
I6
sg11
VCHRNA7
p11852
sg13
I1
sa(dp11853
g7
I169
sg8
g9
sg10
I5
sg11
VMEIS2
p11854
sg13
I1
sa(dp11855
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p11856
sg13
I1
sa(dp11857
g7
I156
sg8
g9
sg10
I5
sg11
VGREM1
p11858
sg13
I1
sa(dp11859
g7
I163
sg8
g9
sg10
I4
sg11
VCX36
p11860
sg13
I1
sa(dp11861
g7
I253
sg8
g9
sg10
I9
sg11
VARHGAP11A
p11862
sg13
I1
sasg24
(lp11863
(dp11864
g7
I233
sg27
VC0025362
p11865
sg10
I18
sg11
Vmental retardation
p11866
sg13
I2
sa(dp11867
g7
I142
sg27
VC0008925
p11868
sg10
I12
sg11
Vcleft palate
p11869
sg13
I2
sa(dp11870
g7
I34
sg27
VC1855900
p11871
sg10
I3
sg11
VCGH
p11872
sg13
I1
sa(dp11873
g7
I177
sg27
VC0018798
p11874
sg10
I23
sg11
Vcongenital heart defect
p11875
sg13
I3
sasa(dp11876
g2
VComparative deletion mapping shows that this region can be dissected into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced transcript levels in RT-qPCR.
p11877
sg4
(lp11878
(dp11879
g7
I154
sg8
g9
sg10
I4
sg11
VNFIA
p11880
sg13
I1
sa(dp11881
g7
I147
sg8
g9
sg10
I5
sg11
VHOOK1
p11882
sg13
I1
sa(dp11883
g7
I167
sg8
g9
sg10
I6
sg11
VDNAJC6
p11884
sg13
I1
sa(dp11885
g7
I179
sg8
g9
sg10
I5
sg11
VPDE4B
p11886
sg13
I1
sa(dp11887
g7
I141
sg8
g9
sg10
I4
sg11
VDAB1
p11888
sg13
I1
sasg24
(lp11889
(dp11890
g7
I224
sg27
VC0025362
p11891
sg10
I23
sg11
Vintellectual disability
p11892
sg13
I2
sasa(dp11893
g2
VImportantly, one patient with an intragenic microdeletion within NFIA and an additional patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly.
p11894
sg4
(lp11895
(dp11896
g7
I65
sg8
g9
sg10
I4
sg11
VNFIA
p11897
sg13
I1
sa(dp11898
g7
I65
sg8
g9
sg10
I4
sg11
VNFIA
p11899
sg13
I1
sasg24
(lp11900
(dp11901
g7
I150
sg27
VC0025362
p11902
sg10
I23
sg11
Vintellectual disability
p11903
sg13
I2
sa(dp11904
g7
I112
sg27
VC0040715
p11905
sg10
I13
sg11
Vtranslocation
p11906
sg13
I1
sa(dp11907
g7
I187
sg27
VC0221355
p11908
sg10
I12
sg11
Vmacrocephaly
p11909
sg13
I1
sasa(dp11910
g2
VWe propose NFIA is responsible for intellectual disability coupled with macrocephaly, and microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to syndromic intellectual disability.
p11911
sg4
(lp11912
(dp11913
g7
I11
sg8
g9
sg10
I4
sg11
VNFIA
p11914
sg13
I1
sasg24
(lp11915
(dp11916
g7
I72
sg27
VC0221355
p11917
sg10
I12
sg11
Vmacrocephaly
p11918
sg13
I1
sa(dp11919
g7
I149
sg27
VC0039082
p11920
sg10
I8
sg11
Vsyndrome
p11921
sg13
I1
sa(dp11922
g7
I35
sg27
VC0025362
p11923
sg10
I23
sg11
Vintellectual disability
p11924
sg13
I2
sa(dp11925
g7
I35
sg27
VC0025362
p11926
sg10
I23
sg11
Vintellectual disability
p11927
sg13
I2
sasa(dp11928
g2
VNon-progressive cerebellar ataxia with mental retardation (CANPMR, OMIM 614756) and chromosome 1p32-p31 deletion syndrome (OMIM 613735) are two very rare inherited disorders, which are caused by mono-allelic deficiency (haplo-insufficiency) of calmodulin-binding transcription activator 1 (CAMTA1) and, respectively, nuclear factor 1 A (NFIA) genes.
p11929
sg4
(lp11930
(dp11931
g7
I244
sg8
g9
sg10
I44
sg11
Vcalmodulin-binding transcription activator 1
p11932
sg13
I4
sa(dp11933
g7
I317
sg8
VP01160
p11934
sg10
I18
sg11
Vnuclear factor 1 A
p11935
sg13
I4
sa(dp11936
g7
I290
sg8
g9
sg10
I6
sg11
VCAMTA1
p11937
sg13
I1
sa(dp11938
g7
I337
sg8
g9
sg10
I4
sg11
VNFIA
p11939
sg13
I1
sasg24
(lp11940
(dp11941
g7
I4
sg27
VC0393525
p11942
sg10
I29
sg11
Vprogressive cerebellar ataxia
p11943
sg13
I3
sa(dp11944
g7
I84
sg27
VC3151036
p11945
sg10
I37
sg11
Vchromosome 1p32-p31 deletion syndrome
p11946
sg13
I4
sa(dp11947
g7
I39
sg27
VC0025362
p11948
sg10
I18
sg11
Vmental retardation
p11949
sg13
I2
sa(dp11950
g7
I195
sg27
VC0021345
p11951
sg10
I4
sg11
Vmono
p11952
sg13
I1
sasa(dp11953
g2
VAmong these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.
p11954
sg4
(lp11955
(dp11956
g7
I49
sg8
g9
sg10
I5
sg11
VAuts2
p11957
sg13
I1
sa(dp11958
g7
I56
sg8
g9
sg10
I4
sg11
VNfia
p11959
sg13
I1
sa(dp11960
g7
I106
sg8
g9
sg10
I4
sg11
VTBR1
p11961
sg13
I1
sa(dp11962
g7
I62
sg8
VP43354
p11963
sg10
I5
sg11
VNr4a2
p11964
sg13
I1
sasg24
(lp11965
(dp11966
g7
I165
sg27
VC0699748
p11967
sg10
I12
sg11
Vpathogenesis
p11968
sg13
I1
sa(dp11969
g7
I158
sg27
VC0004352
p11970
sg10
I6
sg11
Vautism
p11971
sg13
I1
sasa(dp11972
g2
VSome of these maternal and maternal-child associations were in or adjacent to autism candidate genes including: PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4, and SDK1.
p11973
sg4
(lp11974
(dp11975
g7
I200
sg8
g9
sg10
I4
sg11
VNFIA
p11976
sg13
I1
sa(dp11977
g7
I78
sg8
VP27635
p11978
sg10
I22
sg11
Vautism candidate genes
p11979
sg13
I3
sa(dp11980
g7
I162
sg8
VP35398
p11981
sg10
I4
sg11
VRORA
p11982
sg13
I1
sa(dp11983
g7
I227
sg8
g9
sg10
I4
sg11
VSDK1
p11984
sg13
I1
sa(dp11985
g7
I206
sg8
g9
sg10
I6
sg11
VNLGN4X
p11986
sg13
I1
sa(dp11987
g7
I112
sg8
g9
sg10
I5
sg11
VPCDH9
p11988
sg13
I1
sa(dp11989
g7
I156
sg8
VP49789
p11990
sg10
I4
sg11
VFHIT
p11991
sg13
I1
sa(dp11992
g7
I119
sg8
g9
sg10
I5
sg11
VFOXP1
p11993
sg13
I1
sa(dp11994
g7
I214
sg8
g9
sg10
I7
sg11
VRAPGEF4
p11995
sg13
I1
sa(dp11996
g7
I175
sg8
g9
sg10
I7
sg11
VCNTNAP2
p11997
sg13
I1
sa(dp11998
g7
I184
sg8
g9
sg10
I7
sg11
VFAM135B
p11999
sg13
I1
sa(dp12000
g7
I193
sg8
VP25391
p12001
sg10
I5
sg11
VLAMA1
p12002
sg13
I1
sa(dp12003
g7
I168
sg8
g9
sg10
I5
sg11
VCNTN4
p12004
sg13
I1
sa(dp12005
g7
I147
sg8
g9
sg10
I7
sg11
VMACROD2
p12006
sg13
I1
sa(dp12007
g7
I141
sg8
VP78509
p12008
sg10
I4
sg11
VRELN
p12009
sg13
I1
sa(dp12010
g7
I126
sg8
VP28472
p12011
sg10
I6
sg11
VGABRB3
p12012
sg13
I1
sa(dp12013
g7
I134
sg8
VP58400
p12014
sg10
I5
sg11
VNRXN1
p12015
sg13
I1
sasg24
(lp12016
(dp12017
g7
I78
sg27
VC0004352
p12018
sg10
I6
sg11
Vautism
p12019
sg13
I1
sasa(dp12020
g2
VThese results provided a mechanistic linking between TRPM2-mediated Ca2+ influx and p47 phox signaling to induce excess ROS production and TXNIP-mediated NLRP3 inflammasome activation under HG, and suggested that TRPM2 represented a potential target for alleviating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in Type 2 diabetes Mellitus (T2DM).
p12021
sg4
(lp12022
(dp12023
g7
I53
sg8
VP10909
p12024
sg10
I5
sg11
VTRPM2
p12025
sg13
I1
sa(dp12026
g7
I139
sg8
g9
sg10
I5
sg11
VTXNIP
p12027
sg13
I1
sa(dp12028
g7
I88
sg8
VP19878
p12029
sg10
I4
sg11
Vphox
p12030
sg13
I1
sa(dp12031
g7
I53
sg8
VP10909
p12032
sg10
I5
sg11
VTRPM2
p12033
sg13
I1
sa(dp12034
g7
I84
sg8
VP08567
p12035
sg10
I3
sg11
Vp47
p12036
sg13
I1
sasg24
(lp12037
(dp12038
g7
I349
sg27
VC0011860
p12039
sg10
I24
sg11
VType 2 diabetes Mellitus
p12040
sg13
I4
sa(dp12041
g7
I375
sg27
VC0011860
p12042
sg10
I4
sg11
VT2DM
p12043
sg13
I1
sa(dp12044
g7
I307
sg27
VC0020456
p12045
sg10
I13
sg11
Vhyperglycemia
p12046
sg13
I1
sa(dp12047
g7
I329
sg27
VC0242606
p12048
sg10
I16
sg11
Voxidative stress
p12049
sg13
I2
sasa(dp12050
g2
VSOX3 mutations have been associated with growth hormone deficiency, variable degrees of additional pituitary hormone deficiencies, and mental retardation.
p12051
sg4
(lp12052
(dp12053
g7
I41
sg8
VP01242
p12054
sg10
I14
sg11
Vgrowth hormone
p12055
sg13
I2
sa(dp12056
g7
I99
sg8
VP18509
p12057
sg10
I17
sg11
Vpituitary hormone
p12058
sg13
I2
sa(dp12059
g7
I0
sg8
VP41225
p12060
sg10
I4
sg11
VSOX3
p12061
sg13
I1
sasg24
(lp12062
(dp12063
g7
I41
sg27
VC0271561
p12064
sg10
I25
sg11
Vgrowth hormone deficiency
p12065
sg13
I3
sa(dp12066
g7
I135
sg27
VC0025362
p12067
sg10
I18
sg11
Vmental retardation
p12068
sg13
I2
sasa(dp12069
g2
VSOX3 involvement should be considered in a male with short stature due to GH deficiency associated with intellectual disability.
p12070
sg4
(lp12071
(dp12072
g7
I0
sg8
VP41225
p12073
sg10
I4
sg11
VSOX3
p12074
sg13
I1
sasg24
(lp12075
(dp12076
g7
I104
sg27
VC0025362
p12077
sg10
I23
sg11
Vintellectual disability
p12078
sg13
I2
sa(dp12079
g7
I53
sg27
VC0013336
p12080
sg10
I13
sg11
Vshort stature
p12081
sg13
I2
sasa(dp12082
g2
VA further XX male, ascertained because of intellectual disability, carried a de novo cryptic duplication at Xq27.1, involving SOX3.
p12083
sg4
(lp12084
(dp12085
g7
I126
sg8
VP41225
p12086
sg10
I4
sg11
VSOX3
p12087
sg13
I1
sasg24
(lp12088
(dp12089
g7
I42
sg27
VC0025362
p12090
sg10
I23
sg11
Vintellectual disability
p12091
sg13
I2
sa(dp12092
g7
I93
sg27
VC1705960
p12093
sg10
I11
sg11
Vduplication
p12094
sg13
I1
sa(dp12095
g7
I10
sg27
VC0432475
p12096
sg10
I7
sg11
VXX male
p12097
sg13
I2
sasa(dp12098
g2
VIn humans, over- and underdosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated GH deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases, with reported pituitary imaging, an ectopic/undescended posterior pituitary.
p12099
sg4
(lp12100
(dp12101
g7
I36
sg8
VP41225
p12102
sg10
I4
sg11
VSOX3
p12103
sg13
I1
sasg24
(lp12104
(dp12105
g7
I191
sg27
VC0025362
p12106
sg10
I18
sg11
Vmental retardation
p12107
sg13
I2
sa(dp12108
g7
I147
sg27
VC0271561
p12109
sg10
I3
sg11
VGHD
p12110
sg13
I1
sa(dp12111
g7
I155
sg27
VC0242343
p12112
sg10
I18
sg11
Vpanhypopituitarism
p12113
sg13
I1
sa(dp12114
g7
I69
sg27
VC0020635
p12115
sg10
I15
sg11
Vhypopituitarism
p12116
sg13
I1
sa(dp12117
g7
I132
sg27
VC0271561
p12118
sg10
I13
sg11
VGH deficiency
p12119
sg13
I2
sasa(dp12120
g2
VScreening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings, including clefts and a persistent craniopharyngeal canal, with or without mental retardation.
p12121
sg4
(lp12122
(dp12123
g7
I14
sg8
VP41225
p12124
sg10
I4
sg11
VSOX3
p12125
sg13
I1
sasg24
(lp12126
(dp12127
g7
I265
sg27
VC0025362
p12128
sg10
I18
sg11
Vmental retardation
p12129
sg13
I2
sasa(dp12130
g2
VBoth duplications encompassing SOX3 and loss-of function mutations in SOX3 have been reported in a minor portion of X-linked isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD) patients with or without mental retardation.
p12131
sg4
(lp12132
(dp12133
g7
I169
sg8
VP18509
p12134
sg10
I26
sg11
Vcombined pituitary hormone
p12135
sg13
I3
sa(dp12136
g7
I134
sg8
VP01242
p12137
sg10
I14
sg11
Vgrowth hormone
p12138
sg13
I2
sa(dp12139
g7
I31
sg8
VP41225
p12140
sg10
I4
sg11
VSOX3
p12141
sg13
I1
sasg24
(lp12142
(dp12143
g7
I239
sg27
VC0025362
p12144
sg10
I18
sg11
Vmental retardation
p12145
sg13
I2
sa(dp12146
g7
I161
sg27
VC0271561
p12147
sg10
I3
sg11
VGHD
p12148
sg13
I1
sa(dp12149
g7
I141
sg27
VC0599750
p12150
sg10
I18
sg11
Vhormone deficiency
p12151
sg13
I2
sa(dp12152
g7
I125
sg27
VC0271563
p12153
sg10
I34
sg11
Visolated growth hormone deficiency
p12154
sg13
I4
sasa(dp12155
g2
VIn humans, duplication of SOX3 and polyalanine expansions at its C-terminus may cause intellectual disability and hypopituitarism.
p12156
sg4
(lp12157
(dp12158
g7
I26
sg8
VP41225
p12159
sg10
I4
sg11
VSOX3
p12160
sg13
I1
sasg24
(lp12161
(dp12162
g7
I11
sg27
VC1705960
p12163
sg10
I11
sg11
Vduplication
p12164
sg13
I1
sa(dp12165
g7
I114
sg27
VC0020635
p12166
sg10
I15
sg11
Vhypopituitarism
p12167
sg13
I1
sa(dp12168
g7
I86
sg27
VC0025362
p12169
sg10
I23
sg11
Vintellectual disability
p12170
sg13
I2
sasa(dp12171
g2
VThe UNH159 marker as well as RNA-binding motif protein, X-linked (rbmx), SRY-box containing gene 3 (sox3) and alpha-thalassemia/mental retardation syndrome X-linked (atrx) genes were mapped to linkage group 2.
p12172
sg4
(lp12173
(dp12174
g7
I100
sg8
VP41225
p12175
sg10
I4
sg11
Vsox3
p12176
sg13
I1
sa(dp12177
g7
I73
sg8
VP41225
p12178
sg10
I25
sg11
VSRY-box containing gene 3
p12179
sg13
I4
sasg24
(lp12180
(dp12181
g7
I110
sg27
VC1845055
p12182
sg10
I54
sg11
Valpha-thalassemia/mental retardation syndrome X-linked
p12183
sg13
I4
sa(dp12184
g7
I166
sg27
VC1845055
p12185
sg10
I4
sg11
Vatrx
p12186
sg13
I1
sasa(dp12187
g2
VBoth overdosage of SOX3, as a result of gene duplication, and loss of function resulting from expansion of the first polyalanine (PA) tract are associated with variable degrees of hypopituitarism, with or without mental retardation.
p12188
sg4
(lp12189
(dp12190
g7
I19
sg8
VP41225
p12191
sg10
I4
sg11
VSOX3
p12192
sg13
I1
sasg24
(lp12193
(dp12194
g7
I213
sg27
VC0025362
p12195
sg10
I18
sg11
Vmental retardation
p12196
sg13
I2
sa(dp12197
g7
I180
sg27
VC0020635
p12198
sg10
I15
sg11
Vhypopituitarism
p12199
sg13
I1
sa(dp12200
g7
I40
sg27
VC1705960
p12201
sg10
I16
sg11
Vgene duplication
p12202
sg13
I2
sasa(dp12203
g2
VDuplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia.
p12204
sg4
(lp12205
(dp12206
g7
I220
sg8
VP48431
p12207
sg10
I4
sg11
VSOX2
p12208
sg13
I1
sa(dp12209
g7
I72
sg8
VP41225
p12210
sg10
I4
sg11
VSOX3
p12211
sg13
I1
sasg24
(lp12212
(dp12213
g7
I151
sg27
VC0020635
p12214
sg10
I15
sg11
Vhypopituitarism
p12215
sg13
I1
sa(dp12216
g7
I139
sg27
VC0243069
p12217
sg10
I10
sg11
Vhypoplasia
p12218
sg13
I1
sa(dp12219
g7
I337
sg27
VC0003119
p12220
sg10
I12
sg11
Vanophthalmia
p12221
sg13
I1
sa(dp12222
g7
I180
sg27
VC0025362
p12223
sg10
I18
sg11
Vmental retardation
p12224
sg13
I2
sa(dp12225
g7
I151
sg27
VC0020635
p12226
sg10
I15
sg11
Vhypopituitarism
p12227
sg13
I1
sa(dp12228
g7
I313
sg27
VC0014850
p12229
sg10
I19
sg11
Voesophageal atresia
p12230
sg13
I2
sasa(dp12231
g2
VUsing mouse P19 embryonal carcinoma cells, which divide rapidly, yet in retinoic acid adopt a neuronal phenotype, admixed with occasional (approximately 10%) fibroblast-like cells, together with a panel of peptide-specific antibodies raised to 7 of the 8 CCT subunits we show that; (1) adoption of a post mitotic phenotype is accompanied by reduced CCT protein expression, significantly more so for CCTbeta, CCTdelta, CCTepsilon, and CCTtheta than for CCTalpha (TCP-1), CCTgamma and CCTzeta; (2) CCTalpha is detected preferentially over other subunits in neurites of P19 neurons; (3) small amounts of CCTalpha and gamma are localised in nuclei (i.e.
p12232
sg4
(lp12233
(dp12234
g7
I462
sg8
VP00995
p12235
sg10
I5
sg11
VTCP-1
p12236
sg13
I1
sa(dp12237
g7
I349
sg8
g9
sg10
I11
sg11
VCCT protein
p12238
sg13
I2
sasg24
(lp12239
(dp12240
g7
I16
sg27
VC0206659
p12241
sg10
I19
sg11
Vembryonal carcinoma
p12242
sg13
I2
sa(dp12243
g7
I255
sg27
VC2752078
p12244
sg10
I3
sg11
VCCT
p12245
sg13
I1
sa(dp12246
g7
I462
sg27
VC1842402
p12247
sg10
I3
sg11
VTCP
p12248
sg13
I1
sa(dp12249
g7
I255
sg27
VC2752078
p12250
sg10
I3
sg11
VCCT
p12251
sg13
I1
sasa(dp12252
g2
VIn line with these observations, in preclinical models, SIRT2 deficiency increases survival of mice with chronic staphylococcal infection, while having no effect on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic candidiasis.
p12253
sg4
(lp12254
(dp12255
g7
I216
sg8
VP01375
p12256
sg10
I3
sg11
VTNF
p12257
sg13
I1
sa(dp12258
g7
I56
sg8
g9
sg10
I5
sg11
VSIRT2
p12259
sg13
I1
sasg24
(lp12260
(dp12261
g7
I179
sg27
VC0600327
p12262
sg10
I20
sg11
Vtoxic shock syndrome
p12263
sg13
I3
sa(dp12264
g7
I262
sg27
VC0031154
p12265
sg10
I11
sg11
Vperitonitis
p12266
sg13
I1
sa(dp12267
g7
I209
sg27
VC0175697
p12268
sg10
I3
sg11
VLPS
p12269
sg13
I1
sa(dp12270
g7
I286
sg27
VC0519030
p12271
sg10
I31
sg11
VKlebsiella pneumoniae pneumonia
p12272
sg13
I3
sa(dp12273
g7
I323
sg27
VC0857069
p12274
sg10
I19
sg11
Vchronic candidiasis
p12275
sg13
I2
sa(dp12276
g7
I113
sg27
VC0038160
p12277
sg10
I24
sg11
Vstaphylococcal infection
p12278
sg13
I2
sasa(dp12279
g2
VLung injury was studied by measuring: vascular permeability-related pulmonary edema; histopathologic scores, neutrophil infiltration and concentrations of inflammatory cytokines in bronchoalveolar fluid; expression of inflammatory enzymes and sirtuin (SIRT) 1 as well as nuclear factor-kappa B (NF-KB) activity in pulmonary tissues.
p12280
sg4
(lp12281
(dp12282
g7
I295
sg8
VP01160
p12283
sg10
I5
sg11
VNF-KB
p12284
sg13
I1
sa(dp12285
g7
I271
sg8
VP01160
p12286
sg10
I22
sg11
Vnuclear factor-kappa B
p12287
sg13
I3
sasg24
(lp12288
(dp12289
g7
I120
sg27
VC0332448
p12290
sg10
I12
sg11
Vinfiltration
p12291
sg13
I1
sa(dp12292
g7
I68
sg27
VC0034063
p12293
sg10
I15
sg11
Vpulmonary edema
p12294
sg13
I2
sasa(dp12295
g2
VThe aim of our study was to compare the expression of sirtuin in large and small airways in nonsmokers, asymptomatic smokers, and smokers with chronic obstructive pulmonary disease.
p12296
sg4
(lp12297
(dp12298
g7
I54
sg8
g9
sg10
I7
sg11
Vsirtuin
p12299
sg13
I1
sasg24
(lp12300
(dp12301
g7
I143
sg27
VC0024117
p12302
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12303
sg13
I4
sasa(dp12304
g2
VSmokers both with and without chronic obstructive pulmonary disease had decreased sirtuin expression in large airways.
p12305
sg4
(lp12306
(dp12307
g7
I82
sg8
g9
sg10
I7
sg11
Vsirtuin
p12308
sg13
I1
sasg24
(lp12309
(dp12310
g7
I30
sg27
VC0024117
p12311
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12312
sg13
I4
sasa(dp12313
g2
VHowever, in small airways, sirtuin expression was decreased only in patients with chronic obstructive pulmonary disease.
p12314
sg4
(lp12315
sg24
(lp12316
(dp12317
g7
I82
sg27
VC0024117
p12318
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12319
sg13
I4
sasa(dp12320
g2
VSmoking is characterized by suppressed sirtuin expression in large airways, whereas chronic obstructive pulmonary disease is characterized by more severe suppression of sirtuin expression both in large and small airways.
p12321
sg4
(lp12322
(dp12323
g7
I39
sg8
g9
sg10
I7
sg11
Vsirtuin
p12324
sg13
I1
sa(dp12325
g7
I39
sg8
g9
sg10
I7
sg11
Vsirtuin
p12326
sg13
I1
sasg24
(lp12327
(dp12328
g7
I154
sg27
VC0221103
p12329
sg10
I11
sg11
Vsuppression
p12330
sg13
I1
sa(dp12331
g7
I84
sg27
VC0024117
p12332
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12333
sg13
I4
sasa(dp12334
g2
VHuman equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).
p12335
sg4
(lp12336
(dp12337
g7
I83
sg8
g9
sg10
I7
sg11
VSLC29A2
p12338
sg13
I1
sa(dp12339
g7
I71
sg8
g9
sg10
I7
sg11
VSLC29A1
p12340
sg13
I1
sa(dp12341
g7
I0
sg8
g9
sg10
I43
sg11
VHuman equilibrative nucleoside transporters
p12342
sg13
I4
sa(dp12343
g7
I45
sg8
g9
sg10
I4
sg11
VhENT
p12344
sg13
I1
sasg24
(lp12345
(dp12346
g7
I254
sg27
VC1527249
p12347
sg10
I3
sg11
VCRC
p12348
sg13
I1
sa(dp12349
g7
I235
sg27
VC1527249
p12350
sg10
I17
sg11
Vcolorectal cancer
p12351
sg13
I2
sasa(dp12352
g2
VThe purpose of this study was to evaluate the expression profiles of SLC29A1 and SLC29A2 in human cancer cell lines.
p12353
sg4
(lp12354
(dp12355
g7
I81
sg8
g9
sg10
I7
sg11
VSLC29A2
p12356
sg13
I1
sa(dp12357
g7
I69
sg8
g9
sg10
I7
sg11
VSLC29A1
p12358
sg13
I1
sasg24
(lp12359
(dp12360
g7
I98
sg27
VC0006826
p12361
sg10
I6
sg11
Vcancer
p12362
sg13
I1
sasa(dp12363
g2
VUsing quantitative real-time polymerase chain reaction, we comprehensively profiled the transcription levels of SLC29A1 and SLC29A2 in 16 colon cancer cell lines.
p12364
sg4
(lp12365
(dp12366
g7
I124
sg8
g9
sg10
I7
sg11
VSLC29A2
p12367
sg13
I1
sa(dp12368
g7
I112
sg8
g9
sg10
I7
sg11
VSLC29A1
p12369
sg13
I1
sasg24
(lp12370
(dp12371
g7
I138
sg27
VC0699790
p12372
sg10
I12
sg11
Vcolon cancer
p12373
sg13
I2
sasa(dp12374
g2
VWe validated the ubiquitous and heterogeneous distribution of SLC29A1 and SLC29A2 in human colon cancer cell lines and demonstrated that SLC29A1 was highly expressed in 25% of metastatic cell lines (Colo201 and Colo205) and 62.5% of primary cell lines (Caco2, Colo320, HCT116, RKO, and SW48).
p12375
sg4
(lp12376
(dp12377
g7
I62
sg8
g9
sg10
I7
sg11
VSLC29A1
p12378
sg13
I1
sa(dp12379
g7
I74
sg8
g9
sg10
I7
sg11
VSLC29A2
p12380
sg13
I1
sa(dp12381
g7
I62
sg8
g9
sg10
I7
sg11
VSLC29A1
p12382
sg13
I1
sasg24
(lp12383
(dp12384
g7
I91
sg27
VC0699790
p12385
sg10
I12
sg11
Vcolon cancer
p12386
sg13
I2
sasa(dp12387
g2
VFor the first time, we showed that both SLC29A1 and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites.
p12388
sg4
(lp12389
(dp12390
g7
I40
sg8
g9
sg10
I7
sg11
VSLC29A1
p12391
sg13
I1
sa(dp12392
g7
I52
sg8
g9
sg10
I7
sg11
VSLC29A2
p12393
sg13
I1
sasg24
(lp12394
(dp12395
g7
I94
sg27
VC0699790
p12396
sg10
I12
sg11
Vcolon cancer
p12397
sg13
I2
sasa(dp12398
g2
VAs ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition.
p12399
sg4
(lp12400
(dp12401
g7
I196
sg8
g9
sg10
I4
sg11
VENT1
p12402
sg13
I1
sa(dp12403
g7
I205
sg8
g9
sg10
I4
sg11
VENT2
p12404
sg13
I1
sasg24
(lp12405
(dp12406
g7
I91
sg27
VC0006826
p12407
sg10
I6
sg11
Vcancer
p12408
sg13
I1
sasa(dp12409
g2
VThe most significant changes common to HLHS-RV versus control-RV and control-LV sample groups is observed for Anti mullerian hormone receptor 2 (AMHR2) (+18.79 control-RV, +3.38 control-LV), and the BMP antagonist Inhibin alpha (INHA) (+11.47 control-RV, +5.73 control-LV).
p12410
sg4
(lp12411
(dp12412
g7
I110
sg8
VP22736
p12413
sg10
I33
sg11
VAnti mullerian hormone receptor 2
p12414
sg13
I5
sa(dp12415
g7
I145
sg8
g9
sg10
I5
sg11
VAMHR2
p12416
sg13
I1
sa(dp12417
g7
I229
sg8
VP05111
p12418
sg10
I4
sg11
VINHA
p12419
sg13
I1
sa(dp12420
g7
I39
sg8
VP17302
p12421
sg10
I7
sg11
VHLHS-RV
p12422
sg13
I1
sa(dp12423
g7
I199
sg8
VP18075
p12424
sg10
I28
sg11
VBMP antagonist Inhibin alpha
p12425
sg13
I4
sasg24
(lp12426
(dp12427
g7
I39
sg27
VC0152101
p12428
sg10
I4
sg11
VHLHS
p12429
sg13
I1
sasa(dp12430
g2
VWe have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration.
p12431
sg4
(lp12432
(dp12433
g7
I55
sg8
VP41161
p12434
sg10
I4
sg11
VETV5
p12435
sg13
I1
sa(dp12436
g7
I51
sg8
VP41161
p12437
sg10
I3
sg11
VERM
p12438
sg13
I1
sa(dp12439
g7
I33
sg8
VP20908
p12440
sg10
I17
sg11
VEts family member
p12441
sg13
I3
sasg24
(lp12442
(dp12443
g7
I156
sg27
VC0332448
p12444
sg10
I12
sg11
Vinfiltration
p12445
sg13
I1
sa(dp12446
g7
I124
sg27
VC1851841
p12447
sg10
I3
sg11
VEEC
p12448
sg13
I1
sa(dp12449
g7
I100
sg27
VC0206687
p12450
sg10
I22
sg11
Vendometrioid carcinoma
p12451
sg13
I2
sasa(dp12452
g2
VWe have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration.
p12453
sg4
(lp12454
(dp12455
g7
I68
sg8
VP41161
p12456
sg10
I4
sg11
VETV5
p12457
sg13
I1
sa(dp12458
g7
I64
sg8
VP41161
p12459
sg10
I3
sg11
VERM
p12460
sg13
I1
sa(dp12461
g7
I31
sg8
VP35398
p12462
sg10
I31
sg11
VEts family transcription factor
p12463
sg13
I4
sasg24
(lp12464
(dp12465
g7
I175
sg27
VC0332448
p12466
sg10
I12
sg11
Vinfiltration
p12467
sg13
I1
sa(dp12468
g7
I116
sg27
VC0476089
p12469
sg10
I21
sg11
Vendometrial carcinoma
p12470
sg13
I2
sa(dp12471
g7
I139
sg27
VC1851841
p12472
sg10
I3
sg11
VEEC
p12473
sg13
I1
sasa(dp12474
g2
VFinally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination.
p12475
sg4
(lp12476
(dp12477
g7
I42
sg8
VP41161
p12478
sg10
I4
sg11
VETV5
p12479
sg13
I1
sa(dp12480
g7
I38
sg8
VP41161
p12481
sg10
I3
sg11
VERM
p12482
sg13
I1
sa(dp12483
g7
I38
sg8
VP41161
p12484
sg10
I3
sg11
VERM
p12485
sg13
I1
sa(dp12486
g7
I51
sg8
VP08253
p12487
sg10
I5
sg11
VMMP-2
p12488
sg13
I1
sa(dp12489
g7
I42
sg8
VP41161
p12490
sg10
I4
sg11
VETV5
p12491
sg13
I1
sasg24
(lp12492
(dp12493
g7
I93
sg27
VC0332448
p12494
sg10
I12
sg11
Vinfiltrating
p12495
sg13
I1
sa(dp12496
g7
I112
sg27
VC0476089
p12497
sg10
I22
sg11
Vendometrial carcinomas
p12498
sg13
I2
sasa(dp12499
g2
VMost importantly, the defects seen in Gfi1 deficient mice also point to roles of Gfi1 in diseases of the immune system that involve auto-immune responses and acute lymphoid leukemia and lymphoma.
p12500
sg4
(lp12501
(dp12502
g7
I38
sg8
g9
sg10
I4
sg11
VGfi1
p12503
sg13
I1
sa(dp12504
g7
I38
sg8
g9
sg10
I4
sg11
VGfi1
p12505
sg13
I1
sasg24
(lp12506
(dp12507
g7
I186
sg27
VC0024299
p12508
sg10
I8
sg11
Vlymphoma
p12509
sg13
I1
sa(dp12510
g7
I158
sg27
VC1961102
p12511
sg10
I23
sg11
Vacute lymphoid leukemia
p12512
sg13
I3
sasa(dp12513
g2
VThe results showed that the gfi-1 expression level in all leukemia patients was significantly higher than that in normal group (p &lt; 0.05); the gfi-1 mRNA expression in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) patients was significantly higher than that in normal group (p &lt; 0.05); but the difference of gfi-1 mRNA expression between AL and CML or ALL and AML was not significant.
p12514
sg4
(lp12515
(dp12516
g7
I28
sg8
g9
sg10
I5
sg11
Vgfi-1
p12517
sg13
I1
sa(dp12518
g7
I146
sg8
g9
sg10
I10
sg11
Vgfi-1 mRNA
p12519
sg13
I2
sasg24
(lp12520
(dp12521
g7
I238
sg27
VC1961102
p12522
sg10
I23
sg11
Vacute lymphoid leukemia
p12523
sg13
I3
sa(dp12524
g7
I206
sg27
VC0023467
p12525
sg10
I22
sg11
Vacute myeloid leukemia
p12526
sg13
I3
sa(dp12527
g7
I171
sg27
VC0023473
p12528
sg10
I24
sg11
Vchronic myeloid leukemia
p12529
sg13
I3
sa(dp12530
g7
I263
sg27
VC1961102
p12531
sg10
I3
sg11
VALL
p12532
sg13
I1
sa(dp12533
g7
I230
sg27
VC0023467
p12534
sg10
I3
sg11
VAML
p12535
sg13
I1
sa(dp12536
g7
I197
sg27
VC0023473
p12537
sg10
I3
sg11
VCML
p12538
sg13
I1
sa(dp12539
g7
I197
sg27
VC0023473
p12540
sg10
I3
sg11
VCML
p12541
sg13
I1
sa(dp12542
g7
I58
sg27
VC0023418
p12543
sg10
I8
sg11
Vleukemia
p12544
sg13
I1
sa(dp12545
g7
I230
sg27
VC0023467
p12546
sg10
I3
sg11
VAML
p12547
sg13
I1
sa(dp12548
g7
I263
sg27
VC1961102
p12549
sg10
I3
sg11
VALL
p12550
sg13
I1
sasa(dp12551
g2
VThe MDM2 309GG genotype was linked to a higher risk of acute G3-4 dermatitis.
p12552
sg4
(lp12553
sg24
(lp12554
(dp12555
g7
I66
sg27
VC0011603
p12556
sg10
I10
sg11
Vdermatitis
p12557
sg13
I1
sasa(dp12558
g2
VIn an antibody microarray chip analysis, MDM2 expression was increased in atopic dermatitis patients.
p12559
sg4
(lp12560
sg24
(lp12561
(dp12562
g7
I74
sg27
VC0011615
p12563
sg10
I17
sg11
Vatopic dermatitis
p12564
sg13
I2
sasa(dp12565
g2
VAll doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors.
p12566
sg4
(lp12567
(dp12568
g7
I137
sg8
g9
sg10
I6
sg11
VLRP5/6
p12569
sg13
I1
sasg24
(lp12570
(dp12571
g7
I66
sg27
VC0006826
p12572
sg10
I6
sg11
Vcancer
p12573
sg13
I1
sa(dp12574
g7
I32
sg27
VC0027651
p12575
sg10
I6
sg11
Vtumors
p12576
sg13
I1
sa(dp12577
g7
I32
sg27
VC0027651
p12578
sg10
I6
sg11
Vtumors
p12579
sg13
I1
sasa(dp12580
g2
VOur results showed that simultaneous binding to LRP5/6 and uPAR by the dual receptor targeted IONPs was required to inhibit breast cancer cell invasion.
p12581
sg4
(lp12582
(dp12583
g7
I48
sg8
g9
sg10
I6
sg11
VLRP5/6
p12584
sg13
I1
sasg24
(lp12585
(dp12586
g7
I138
sg27
VC2699153
p12587
sg10
I13
sg11
Vcell invasion
p12588
sg13
I2
sa(dp12589
g7
I124
sg27
VC0678222
p12590
sg10
I13
sg11
Vbreast cancer
p12591
sg13
I2
sasa(dp12592
g2
VSTAT5 LKO caused hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated free fatty acid and cholesterol concentrations under HFD feeding but induced only hyperglycemia on normal diet.
p12593
sg4
(lp12594
(dp12595
g7
I0
sg8
VP42229
p12596
sg10
I5
sg11
VSTAT5
p12597
sg13
I1
sasg24
(lp12598
(dp12599
g7
I32
sg27
VC0020459
p12600
sg10
I16
sg11
Vhyperinsulinemia
p12601
sg13
I1
sa(dp12602
g7
I17
sg27
VC0020456
p12603
sg10
I13
sg11
Vhyperglycemia
p12604
sg13
I1
sa(dp12605
g7
I17
sg27
VC0020456
p12606
sg10
I13
sg11
Vhyperglycemia
p12607
sg13
I1
sasa(dp12608
g2
VPrx2 is a key cytoprotector against IO that is induced either by iron supplementation or due to chronic hemolysis as in Beta-thalassemia.
p12609
sg4
(lp12610
(dp12611
g7
I0
sg8
VP32119
p12612
sg10
I4
sg11
VPrx2
p12613
sg13
I1
sasg24
(lp12614
(dp12615
g7
I104
sg27
VC0019054
p12616
sg10
I9
sg11
Vhemolysis
p12617
sg13
I1
sa(dp12618
g7
I120
sg27
VC0005283
p12619
sg10
I16
sg11
VBeta-thalassemia
p12620
sg13
I1
sasa(dp12621
g2
VPeroxiredoxin-2 (Prx2), a typical 2-cysteine peroxiredoxin, is upregulated during Beta-thalassemic erythropoiesis, but its contribution to stress erythropoiesis, a common feature of thalassemia, is yet to be fully defined.
p12622
sg4
(lp12623
(dp12624
g7
I0
sg8
VP32119
p12625
sg10
I15
sg11
VPeroxiredoxin-2
p12626
sg13
I1
sa(dp12627
g7
I17
sg8
VP32119
p12628
sg10
I4
sg11
VPrx2
p12629
sg13
I1
sasg24
(lp12630
(dp12631
g7
I182
sg27
VC0039730
p12632
sg10
I11
sg11
Vthalassemia
p12633
sg13
I1
sasa(dp12634
g2
VIn the present study, we aimed to investigate plasma levels of peroxiredoxin 2 (Prx2) and thioredoxin 1 (Trx1), and the activity of thioredoxin reductase (TrxR), in thalassemia major (TM) patients living in the Antalya region, Turkey.
p12635
sg4
(lp12636
(dp12637
g7
I80
sg8
VP32119
p12638
sg10
I4
sg11
VPrx2
p12639
sg13
I1
sa(dp12640
g7
I90
sg8
VP10599
p12641
sg10
I13
sg11
Vthioredoxin 1
p12642
sg13
I2
sa(dp12643
g7
I132
sg8
VP10599
p12644
sg10
I21
sg11
Vthioredoxin reductase
p12645
sg13
I2
sa(dp12646
g7
I105
sg8
VP60606
p12647
sg10
I4
sg11
VTrx1
p12648
sg13
I1
sa(dp12649
g7
I63
sg8
VP32119
p12650
sg10
I15
sg11
Vperoxiredoxin 2
p12651
sg13
I2
sa(dp12652
g7
I155
sg8
VP30044
p12653
sg10
I4
sg11
VTrxR
p12654
sg13
I1
sasg24
(lp12655
(dp12656
g7
I184
sg27
VC0002875
p12657
sg10
I2
sg11
VTM
p12658
sg13
I1
sa(dp12659
g7
I165
sg27
VC0002875
p12660
sg10
I17
sg11
Vthalassemia major
p12661
sg13
I2
sasa(dp12662
g2
VProteomic analysis of microparticles released from thalassemia intermedia erythrocytes indicated that, besides hemichromes and clustered band 3, the microparticles contain a characteristic set of proteins that includes catalase, heat shock protein 70, peroxiredoxin 2 and carbonic anhydrase.
p12663
sg4
(lp12664
(dp12665
g7
I219
sg8
VP04040
p12666
sg10
I8
sg11
Vcatalase
p12667
sg13
I1
sa(dp12668
g7
I229
sg8
VP34932
p12669
sg10
I21
sg11
Vheat shock protein 70
p12670
sg13
I4
sa(dp12671
g7
I252
sg8
VP32119
p12672
sg10
I15
sg11
Vperoxiredoxin 2
p12673
sg13
I2
sa(dp12674
g7
I272
sg8
VP35218
p12675
sg10
I18
sg11
Vcarbonic anhydrase
p12676
sg13
I2
sasg24
(lp12677
(dp12678
g7
I51
sg27
VC0271979
p12679
sg10
I22
sg11
Vthalassemia intermedia
p12680
sg13
I2
sasa(dp12681
g2
VInterestingly, Prx II interacted with Hb in mouse RBCs, and their interaction, in particular, was severely impaired in RBCs of patients with thalassemia (THAL) and sickle cell anemia (SCA).
p12682
sg4
(lp12683
(dp12684
g7
I15
sg8
VP30041
p12685
sg10
I6
sg11
VPrx II
p12686
sg13
I2
sasg24
(lp12687
(dp12688
g7
I141
sg27
VC0039730
p12689
sg10
I11
sg11
Vthalassemia
p12690
sg13
I1
sa(dp12691
g7
I184
sg27
VC0002895
p12692
sg10
I3
sg11
VSCA
p12693
sg13
I1
sa(dp12694
g7
I164
sg27
VC0002895
p12695
sg10
I18
sg11
Vsickle cell anemia
p12696
sg13
I3
sa(dp12697
g7
I154
sg27
VC0039730
p12698
sg10
I4
sg11
VTHAL
p12699
sg13
I1
sa(dp12700
g7
I107
sg27
VC0684336
p12701
sg10
I8
sg11
Vimpaired
p12702
sg13
I1
sasa(dp12703
g2
VThe cover image, by Lihadh Al Gazali et al., is based on the Original Article A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene, DOI:10.1002/ajmg.a.37741.
p12704
sg4
(lp12705
(dp12706
g7
I223
sg8
g9
sg10
I9
sg11
VFIBP gene
p12707
sg13
I2
sasg24
(lp12708
(dp12709
g7
I102
sg27
VC0025362
p12710
sg10
I23
sg11
Vintellectual disability
p12711
sg13
I2
sa(dp12712
g7
I152
sg27
VC0266313
p12713
sg10
I15
sg11
Vrenal dysplasia
p12714
sg13
I2
sa(dp12715
g7
I90
sg27
VC0039082
p12716
sg10
I8
sg11
Vsyndrome
p12717
sg13
I1
sa(dp12718
g7
I184
sg27
VC0027708
p12719
sg10
I11
sg11
VWilms tumor
p12720
sg13
I2
sasa(dp12721
g2
VDifferent observational clinical studies reported that circulating levels of ANGPTL2 increase significantly in various chronic inflammatory diseases and showed associations between ANGPTL2 levels and diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.
p12722
sg4
(lp12723
(dp12724
g7
I77
sg8
g9
sg10
I7
sg11
VANGPTL2
p12725
sg13
I1
sa(dp12726
g7
I77
sg8
g9
sg10
I7
sg11
VANGPTL2
p12727
sg13
I1
sasg24
(lp12728
(dp12729
g7
I255
sg27
VC0011849
p12730
sg10
I8
sg11
Vdiabetes
p12731
sg13
I1
sa(dp12732
g7
I310
sg27
VC0006826
p12733
sg10
I7
sg11
Vcancers
p12734
sg13
I1
sa(dp12735
g7
I230
sg27
VC0007222
p12736
sg10
I23
sg11
Vcardiovascular diseases
p12737
sg13
I2
sa(dp12738
g7
I265
sg27
VC1561643
p12739
sg10
I22
sg11
Vchronic kidney disease
p12740
sg13
I3
sasa(dp12741
g2
VCirculating ANGPTL2 is increased in chronic kidney disease (CKD), where the risk of CVD is amplified.
p12742
sg4
(lp12743
(dp12744
g7
I12
sg8
g9
sg10
I7
sg11
VANGPTL2
p12745
sg13
I1
sasg24
(lp12746
(dp12747
g7
I60
sg27
VC1561643
p12748
sg10
I3
sg11
VCKD
p12749
sg13
I1
sa(dp12750
g7
I36
sg27
VC1561643
p12751
sg10
I22
sg11
Vchronic kidney disease
p12752
sg13
I3
sa(dp12753
g7
I84
sg27
VC0007222
p12754
sg10
I3
sg11
VCVD
p12755
sg13
I1
sasa(dp12756
g2
VThe positive association between post-KTx ANGPTL2, aortic stiffness and mortality, suggests that ANGPTL2 may play a biological role in CKD-related CVD.
p12757
sg4
(lp12758
(dp12759
g7
I42
sg8
g9
sg10
I7
sg11
VANGPTL2
p12760
sg13
I1
sa(dp12761
g7
I42
sg8
g9
sg10
I7
sg11
VANGPTL2
p12762
sg13
I1
sasg24
(lp12763
(dp12764
g7
I147
sg27
VC0007222
p12765
sg10
I3
sg11
VCVD
p12766
sg13
I1
sa(dp12767
g7
I51
sg27
VC3178782
p12768
sg10
I16
sg11
Vaortic stiffness
p12769
sg13
I2
sasa(dp12770
g2
VHistological analysis of human kidneys indicated abundant expression of angiopoietin-like protein 2 (ANGPTL2) in renal tubule epithelial cells during progression of renal fibrosis.
p12771
sg4
(lp12772
(dp12773
g7
I72
sg8
g9
sg10
I27
sg11
Vangiopoietin-like protein 2
p12774
sg13
I3
sa(dp12775
g7
I101
sg8
g9
sg10
I7
sg11
VANGPTL2
p12776
sg13
I1
sasg24
(lp12777
(dp12778
g7
I165
sg27
VC0151650
p12779
sg10
I14
sg11
Vrenal fibrosis
p12780
sg13
I2
sasa(dp12781
g2
VFurthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.
p12782
sg4
(lp12783
(dp12784
g7
I132
sg8
VP01137
p12785
sg10
I9
sg11
VTGF-Beta1
p12786
sg13
I1
sa(dp12787
g7
I13
sg8
g9
sg10
I7
sg11
VANGPTL2
p12788
sg13
I1
sasg24
(lp12789
(dp12790
g7
I103
sg27
VC0151650
p12791
sg10
I14
sg11
Vrenal fibrosis
p12792
sg13
I2
sa(dp12793
g7
I54
sg27
VC0041956
p12794
sg10
I20
sg11
Vureteral obstruction
p12795
sg13
I2
sa(dp12796
g7
I149
sg27
VC1705759
p12797
sg10
I13
sg11
Vamplification
p12798
sg13
I1
sasa(dp12799
g2
VThus, ANGPTL2 and TGF-Beta1 positively regulate each other as renal fibrosis progresses.
p12800
sg4
(lp12801
(dp12802
g7
I6
sg8
g9
sg10
I7
sg11
VANGPTL2
p12803
sg13
I1
sa(dp12804
g7
I18
sg8
VP01137
p12805
sg10
I9
sg11
VTGF-Beta1
p12806
sg13
I1
sasg24
(lp12807
(dp12808
g7
I62
sg27
VC0151650
p12809
sg10
I14
sg11
Vrenal fibrosis
p12810
sg13
I2
sasa(dp12811
g2
Vdemonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.
p12812
sg4
(lp12813
(dp12814
g7
I160
sg8
g9
sg10
I7
sg11
VANGPTL2
p12815
sg13
I1
sa(dp12816
g7
I39
sg8
g9
sg10
I7
sg11
VAngptl2
p12817
sg13
I1
sa(dp12818
g7
I232
sg8
VP18075
p12819
sg10
I31
sg11
Vtransforming growth factor-Beta
p12820
sg13
I3
sasg24
(lp12821
(dp12822
g7
I81
sg27
VC0151650
p12823
sg10
I15
sg11
Vkidney fibrosis
p12824
sg13
I2
sa(dp12825
g7
I121
sg27
VC0041956
p12826
sg10
I20
sg11
Vureteral obstruction
p12827
sg13
I2
sasa(dp12828
g2
VIn the present study, we tested whether there is a correlation between increased ANGPTL2 expression and inflammation in response to Staphylococcus aureus in murine mastitis and the mechanisms involved.
p12829
sg4
(lp12830
(dp12831
g7
I81
sg8
g9
sg10
I7
sg11
VANGPTL2
p12832
sg13
I1
sasg24
(lp12833
(dp12834
g7
I104
sg27
VC0021368
p12835
sg10
I12
sg11
Vinflammation
p12836
sg13
I1
sa(dp12837
g7
I164
sg27
VC3251795
p12838
sg10
I8
sg11
Vmastitis
p12839
sg13
I1
sasa(dp12840
g2
VThe present findings indicate ANGPTL2 may mediate the inflammation in murine mastitis through the activation of IL-6 and TNF-Alfa.
p12841
sg4
(lp12842
(dp12843
g7
I112
sg8
VP05231
p12844
sg10
I4
sg11
VIL-6
p12845
sg13
I1
sa(dp12846
g7
I121
sg8
VP01375
p12847
sg10
I8
sg11
VTNF-Alfa
p12848
sg13
I1
sa(dp12849
g7
I30
sg8
g9
sg10
I7
sg11
VANGPTL2
p12850
sg13
I1
sasg24
(lp12851
(dp12852
g7
I54
sg27
VC0021368
p12853
sg10
I12
sg11
Vinflammation
p12854
sg13
I1
sa(dp12855
g7
I77
sg27
VC3251795
p12856
sg10
I8
sg11
Vmastitis
p12857
sg13
I1
sasa(dp12858
g2
VThe aim of this study was to investigate the relationship between serum Angptl2 level and chronic kidney disease (CKD).
p12859
sg4
(lp12860
(dp12861
g7
I72
sg8
g9
sg10
I7
sg11
VAngptl2
p12862
sg13
I1
sasg24
(lp12863
(dp12864
g7
I90
sg27
VC1561643
p12865
sg10
I22
sg11
Vchronic kidney disease
p12866
sg13
I3
sa(dp12867
g7
I114
sg27
VC1561643
p12868
sg10
I3
sg11
VCKD
p12869
sg13
I1
sasa(dp12870
g2
VThe age- and sex-adjusted ORs for the presence of CKD increased with higher serum Angptl2 level.
p12871
sg4
(lp12872
(dp12873
g7
I82
sg8
g9
sg10
I7
sg11
VAngptl2
p12874
sg13
I1
sasg24
(lp12875
sa(dp12876
g2
VElevated serum Angptl2 is associated with the likelihood of CKD in the general population.
p12877
sg4
(lp12878
(dp12879
g7
I9
sg8
g9
sg10
I13
sg11
Vserum Angptl2
p12880
sg13
I2
sasg24
(lp12881
sa(dp12882
g2
VWe investigated whether serum Angptl2 levels are associated with diabetic nephropathy in patients with type 2 diabetes.
p12883
sg4
(lp12884
(dp12885
g7
I30
sg8
g9
sg10
I7
sg11
VAngptl2
p12886
sg13
I1
sasg24
(lp12887
(dp12888
g7
I103
sg27
VC0011860
p12889
sg10
I15
sg11
Vtype 2 diabetes
p12890
sg13
I3
sa(dp12891
g7
I65
sg27
VC0011881
p12892
sg10
I20
sg11
Vdiabetic nephropathy
p12893
sg13
I2
sasa(dp12894
g2
VThis suggests a possible role of Angptl2 in progressive nephropathy in patients with type 2 diabetes.
p12895
sg4
(lp12896
(dp12897
g7
I33
sg8
g9
sg10
I7
sg11
VAngptl2
p12898
sg13
I1
sasg24
(lp12899
(dp12900
g7
I85
sg27
VC0011860
p12901
sg10
I15
sg11
Vtype 2 diabetes
p12902
sg13
I3
sa(dp12903
g7
I56
sg27
VC0022658
p12904
sg10
I11
sg11
Vnephropathy
p12905
sg13
I1
sasa(dp12906
g2
VImprovements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described.
p12907
sg4
(lp12908
(dp12909
g7
I146
sg8
VP22830
p12910
sg10
I21
sg11
Vbovine ferrochelatase
p12911
sg13
I2
sa(dp12912
g7
I172
sg8
VP11217
p12913
sg10
I16
sg11
Vmyophosphorylase
p12914
sg13
I1
sasg24
(lp12915
(dp12916
g7
I247
sg27
VC0238357
p12917
sg10
I4
sg11
VHYPP
p12918
sg13
I1
sa(dp12919
g7
I214
sg27
VC0238357
p12920
sg10
I31
sg11
Vhyperkalemic periodic paralysis
p12921
sg13
I3
sasa(dp12922
g2
VThus, peripheral changes of TOAG-1 and RHAMM expression can be used to predict clinical response to Alefacept treatment in psoriasis patients.
p12923
sg4
(lp12924
(dp12925
g7
I39
sg8
g9
sg10
I5
sg11
VRHAMM
p12926
sg13
I1
sasg24
(lp12927
(dp12928
g7
I123
sg27
VC0033860
p12929
sg10
I9
sg11
Vpsoriasis
p12930
sg13
I1
sasa(dp12931
g2
VIn this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.
p12932
sg4
(lp12933
(dp12934
g7
I73
sg8
VP09874
p12935
sg10
I4
sg11
VPARP
p12936
sg13
I1
sasg24
(lp12937
(dp12938
g7
I220
sg27
VC0028778
p12939
sg10
I9
sg11
Vocclusion
p12940
sg13
I1
sa(dp12941
g7
I138
sg27
VC0038454
p12942
sg10
I19
sg11
Vcerebral infarction
p12943
sg13
I2
sasa(dp12944
g2
VOur data thus suggest that the tested PARP polymorphisms do not principally contribute to cerebral infarction, although extensive searches would be required to clarify whether the PARP gene plays an important role in the pathogenesis of human stroke.
p12945
sg4
(lp12946
(dp12947
g7
I180
sg8
VP09874
p12948
sg10
I9
sg11
VPARP gene
p12949
sg13
I2
sa(dp12950
g7
I38
sg8
VP09874
p12951
sg10
I4
sg11
VPARP
p12952
sg13
I1
sasg24
(lp12953
(dp12954
g7
I221
sg27
VC0699748
p12955
sg10
I12
sg11
Vpathogenesis
p12956
sg13
I1
sa(dp12957
g7
I90
sg27
VC0038454
p12958
sg10
I19
sg11
Vcerebral infarction
p12959
sg13
I2
sa(dp12960
g7
I243
sg27
VC0038454
p12961
sg10
I6
sg11
Vstroke
p12962
sg13
I1
sasa(dp12963
g2
VThe OR of breast cancer for the percentage BPE measure (BPE%) quantified from SUB1 was 3.5 (95% Confidence Interval: 1.3, 9.8; p = 0.015) for 20% increments.
p12964
sg4
(lp12965
(dp12966
g7
I78
sg8
VP53999
p12967
sg10
I4
sg11
VSUB1
p12968
sg13
I1
sasg24
(lp12969
(dp12970
g7
I10
sg27
VC0678222
p12971
sg10
I13
sg11
Vbreast cancer
p12972
sg13
I2
sasa(dp12973
g2
VIn this study, we show elevated expression of SUB1 in aggressive prostate cancer.
p12974
sg4
(lp12975
(dp12976
g7
I46
sg8
VP53999
p12977
sg10
I4
sg11
VSUB1
p12978
sg13
I1
sasg24
(lp12979
(dp12980
g7
I54
sg27
VC0001807
p12981
sg10
I10
sg11
Vaggressive
p12982
sg13
I1
sa(dp12983
g7
I65
sg27
VC0600139
p12984
sg10
I15
sg11
Vprostate cancer
p12985
sg13
I2
sasa(dp12986
g2
VKnockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo.
p12987
sg4
(lp12988
(dp12989
g7
I13
sg8
VP53999
p12990
sg10
I4
sg11
VSUB1
p12991
sg13
I1
sasg24
(lp12992
(dp12993
g7
I120
sg27
VC0598934
p12994
sg10
I12
sg11
Vtumor growth
p12995
sg13
I2
sa(dp12996
g7
I137
sg27
VC0027627
p12997
sg10
I10
sg11
Vmetastasis
p12998
sg13
I1
sa(dp12999
g7
I68
sg27
VC0334094
p13000
sg10
I13
sg11
Vproliferation
p13001
sg13
I1
sa(dp13002
g7
I21
sg27
VC0600139
p13003
sg10
I15
sg11
Vprostate cancer
p13004
sg13
I2
sa(dp13005
g7
I83
sg27
VC2699153
p13006
sg10
I8
sg11
Vinvasion
p13007
sg13
I1
sasa(dp13008
g2
VPLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells.
p13009
sg4
(lp13010
(dp13011
g7
I75
sg8
VP53999
p13012
sg10
I4
sg11
VSUB1
p13013
sg13
I1
sa(dp13014
g7
I0
sg8
VP53350
p13015
sg10
I4
sg11
VPLK1
p13016
sg13
I1
sa(dp13017
g7
I0
sg8
VP53350
p13018
sg10
I4
sg11
VPLK1
p13019
sg13
I1
sasg24
(lp13020
(dp13021
g7
I90
sg27
VC0600139
p13022
sg10
I15
sg11
Vprostate cancer
p13023
sg13
I2
sasa(dp13024
g2
VThus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis.
p13025
sg4
(lp13026
(dp13027
g7
I64
sg8
VP53999
p13028
sg10
I4
sg11
VSUB1
p13029
sg13
I1
sa(dp13030
g7
I30
sg8
g9
sg10
I12
sg11
VmiR-101 loss
p13031
sg13
I2
sasg24
(lp13032
(dp13033
g7
I142
sg27
VC0178874
p13034
sg10
I18
sg11
Vcancer progression
p13035
sg13
I2
sa(dp13036
g7
I165
sg27
VC0027627
p13037
sg10
I10
sg11
Vmetastasis
p13038
sg13
I1
sasa(dp13039
g2
VThis study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.
p13040
sg4
(lp13041
(dp13042
g7
I53
sg8
VP53999
p13043
sg10
I4
sg11
VSUB1
p13044
sg13
I1
sa(dp13045
g7
I53
sg8
VP53999
p13046
sg10
I4
sg11
VSUB1
p13047
sg13
I1
sasg24
(lp13048
(dp13049
g7
I61
sg27
VC0600139
p13050
sg10
I15
sg11
Vprostate cancer
p13051
sg13
I2
sa(dp13052
g7
I61
sg27
VC0600139
p13053
sg10
I15
sg11
Vprostate cancer
p13054
sg13
I2
sasa(dp13055
g2
VThe proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma.
p13056
sg4
(lp13057
(dp13058
g7
I63
sg8
VP49767
p13059
sg10
I6
sg11
VVEGF-C
p13060
sg13
I1
sa(dp13061
g7
I77
sg8
VP35968
p13062
sg10
I5
sg11
VVEGFR
p13063
sg13
I1
sasg24
(lp13064
(dp13065
g7
I147
sg27
VC0152013
p13066
sg10
I19
sg11
Vlung adenocarcinoma
p13067
sg13
I2
sa(dp13068
g7
I118
sg27
VC0686619
p13069
sg10
I21
sg11
Vlymph node metastasis
p13070
sg13
I3
sasa(dp13071
g2
VHere, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model.
p13072
sg4
(lp13073
(dp13074
g7
I98
sg8
VP49767
p13075
sg10
I6
sg11
VVEGF-C
p13076
sg13
I1
sa(dp13077
g7
I86
sg8
VP53999
p13078
sg10
I3
sg11
VPC4
p13079
sg13
I1
sa(dp13080
g7
I112
sg8
VP35916
p13081
sg10
I7
sg11
VVEGFR-3
p13082
sg13
I1
sasg24
(lp13083
(dp13084
g7
I128
sg27
VC0152013
p13085
sg10
I19
sg11
Vlung adenocarcinoma
p13086
sg13
I2
sa(dp13087
g7
I170
sg27
VC0027651
p13088
sg10
I5
sg11
Vtumor
p13089
sg13
I1
sasa(dp13090
g2
VPC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.
p13091
sg4
(lp13092
(dp13093
g7
I45
sg8
VP49767
p13094
sg10
I6
sg11
VVEGF-C
p13095
sg13
I1
sa(dp13096
g7
I53
sg8
g9
sg10
I6
sg11
VVEGF-D
p13097
sg13
I1
sa(dp13098
g7
I0
sg8
VP53999
p13099
sg10
I3
sg11
VPC4
p13100
sg13
I1
sa(dp13101
g7
I64
sg8
VP35916
p13102
sg10
I7
sg11
VVEGFR-3
p13103
sg13
I1
sasg24
(lp13104
(dp13105
g7
I144
sg27
VC0152013
p13106
sg10
I19
sg11
Vlung adenocarcinoma
p13107
sg13
I2
sa(dp13108
g7
I282
sg27
VC0027651
p13109
sg10
I6
sg11
Vtumors
p13110
sg13
I1
sa(dp13111
g7
I120
sg27
VC0024232
p13112
sg10
I20
sg11
Vlymphatic metastasis
p13113
sg13
I2
sa(dp13114
g7
I120
sg27
VC0024232
p13115
sg10
I20
sg11
Vlymphatic metastasis
p13116
sg13
I2
sasa(dp13117
g2
VTo test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder.
p13118
sg4
(lp13119
(dp13120
g7
I75
sg8
g9
sg10
I11
sg11
VsE-cadherin
p13121
sg13
I1
sa(dp13122
g7
I55
sg8
g9
sg10
I18
sg11
Vsoluble E-cadherin
p13123
sg13
I2
sasg24
(lp13124
(dp13125
g7
I118
sg27
VC0007138
p13126
sg10
I27
sg11
Vtransitional cell carcinoma
p13127
sg13
I3
sa(dp13128
g7
I147
sg27
VC1861305
p13129
sg10
I3
sg11
VTCC
p13130
sg13
I1
sasa(dp13131
g2
VWe propose potential pathogenic pathways for transitional cell carcinoma of the bladder in diabetic patients based on altered integrin and cadherin distribution in urothelial cells in diabetic patients.
p13132
sg4
(lp13133
(dp13134
g7
I139
sg8
g9
sg10
I8
sg11
Vcadherin
p13135
sg13
I1
sasg24
(lp13136
(dp13137
g7
I45
sg27
VC0279680
p13138
sg10
I42
sg11
Vtransitional cell carcinoma of the bladder
p13139
sg13
I6
sasa(dp13140
g2
VTo evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT).
p13141
sg4
(lp13142
(dp13143
g7
I12
sg8
VP35558
p13144
sg10
I18
sg11
Vsoluble E-cadherin
p13145
sg13
I2
sa(dp13146
g7
I32
sg8
g9
sg10
I11
sg11
VsE-cadherin
p13147
sg13
I1
sasg24
(lp13148
(dp13149
g7
I60
sg27
VC0027651
p13150
sg10
I6
sg11
Vtumour
p13151
sg13
I1
sa(dp13152
g7
I120
sg27
VC1861305
p13153
sg10
I3
sg11
VTCC
p13154
sg13
I1
sa(dp13155
g7
I60
sg27
VC0027651
p13156
sg10
I6
sg11
Vtumour
p13157
sg13
I1
sa(dp13158
g7
I91
sg27
VC0007138
p13159
sg10
I27
sg11
Vtransitional cell carcinoma
p13160
sg13
I3
sa(dp13161
g7
I60
sg27
VC0027651
p13162
sg10
I6
sg11
Vtumour
p13163
sg13
I1
sa(dp13164
g7
I206
sg27
VC0027651
p13165
sg10
I7
sg11
Vtumours
p13166
sg13
I1
sasa(dp13167
g2
VElevated mRNA expression of liver IL-6, IL-17A, IL-17F, TGF-Beta1, Alfa-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in ANIT-induced cholestasis but were attenuated or normalized by YCHT.
p13168
sg4
(lp13169
(dp13170
g7
I34
sg8
VP05231
p13171
sg10
I4
sg11
VIL-6
p13172
sg13
I1
sa(dp13173
g7
I67
sg8
g9
sg10
I8
sg11
VAlfa-SMA
p13174
sg13
I1
sa(dp13175
g7
I83
sg8
g9
sg10
I4
sg11
VNTCP
p13176
sg13
I1
sa(dp13177
g7
I140
sg8
VP23945
p13178
sg10
I3
sg11
VFXR
p13179
sg13
I1
sa(dp13180
g7
I155
sg8
g9
sg10
I4
sg11
VBSEP
p13181
sg13
I1
sa(dp13182
g7
I150
sg8
VP11473
p13183
sg10
I3
sg11
VVDR
p13184
sg13
I1
sa(dp13185
g7
I173
sg8
g9
sg10
I4
sg11
VMRP4
p13186
sg13
I1
sa(dp13187
g7
I56
sg8
VP01137
p13188
sg10
I9
sg11
VTGF-Beta1
p13189
sg13
I1
sa(dp13190
g7
I77
sg8
g9
sg10
I4
sg11
VTGR5
p13191
sg13
I1
sa(dp13192
g7
I161
sg8
g9
sg10
I4
sg11
VMRP2
p13193
sg13
I1
sasg24
(lp13194
(dp13195
g7
I145
sg27
VC2607929
p13196
sg10
I3
sg11
VCAR
p13197
sg13
I1
sa(dp13198
g7
I212
sg27
VC0008370
p13199
sg10
I11
sg11
Vcholestasis
p13200
sg13
I1
sa(dp13201
g7
I72
sg27
VC0026847
p13202
sg10
I3
sg11
VSMA
p13203
sg13
I1
sasa(dp13204
g2
VThe objective of the present study is to evaluate whether IL-6, TNF-Alfa, IL-10 are associated with nutritional status in patients with cirrhosis secondary to biliary atresia and compare to healthy controls.
p13205
sg4
(lp13206
(dp13207
g7
I58
sg8
VP05231
p13208
sg10
I4
sg11
VIL-6
p13209
sg13
I1
sa(dp13210
g7
I64
sg8
VP01375
p13211
sg10
I8
sg11
VTNF-Alfa
p13212
sg13
I1
sasg24
(lp13213
(dp13214
g7
I136
sg27
VC0023890
p13215
sg10
I9
sg11
Vcirrhosis
p13216
sg13
I1
sa(dp13217
g7
I159
sg27
VC0005411
p13218
sg10
I15
sg11
Vbiliary atresia
p13219
sg13
I2
sasa(dp13220
g2
VThe authors suggest that, in patients with cirrhosis secondary to biliary atresia, IL-6 could be used as a possible supporting biomarker of deficient nutritional status and elevated IL-10 levels could be used as a possible early-stage supporting biomarker of deteriorating nutritional status.
p13221
sg4
(lp13222
(dp13223
g7
I83
sg8
VP05231
p13224
sg10
I4
sg11
VIL-6
p13225
sg13
I1
sasg24
(lp13226
(dp13227
g7
I66
sg27
VC0005411
p13228
sg10
I15
sg11
Vbiliary atresia
p13229
sg13
I2
sa(dp13230
g7
I43
sg27
VC0023890
p13231
sg10
I9
sg11
Vcirrhosis
p13232
sg13
I1
sasa(dp13233
g2
VIn a prospective study, 47 patients with obstructive jaundice secondary to malignant lesions were evaluated before, at the fifth hour after, and on the fifth day after PTBD for neopterin, nitrate, tumor necrosis factor (TNF)-Alfa, interleukin (IL)-6, IL-10, CRP levels, and liver function.
p13234
sg4
(lp13235
(dp13236
g7
I197
sg8
VP01375
p13237
sg10
I32
sg11
Vtumor necrosis factor (TNF)-Alfa
p13238
sg13
I4
sa(dp13239
g7
I231
sg8
VP60568
p13240
sg10
I18
sg11
Vinterleukin (IL)-6
p13241
sg13
I2
sa(dp13242
g7
I258
sg8
VP02741
p13243
sg10
I3
sg11
VCRP
p13244
sg13
I1
sasg24
(lp13245
(dp13246
g7
I41
sg27
VC0022354
p13247
sg10
I20
sg11
Vobstructive jaundice
p13248
sg13
I2
sa(dp13249
g7
I197
sg27
VC0333516
p13250
sg10
I14
sg11
Vtumor necrosis
p13251
sg13
I2
sasa(dp13252
g2
VIt has been reported that the hypermethylation of APAF-1, DAPK-1 and other tumor suppressive genes (TSGs) correlates with progression of renal cell carcinoma and exerts prognostic and diagnostic relevance in renal cell carcinoma.
p13253
sg4
(lp13254
(dp13255
g7
I58
sg8
VP53355
p13256
sg10
I6
sg11
VDAPK-1
p13257
sg13
I1
sasg24
(lp13258
(dp13259
g7
I137
sg27
VC0007134
p13260
sg10
I20
sg11
Vrenal cell carcinoma
p13261
sg13
I3
sa(dp13262
g7
I137
sg27
VC0007134
p13263
sg10
I20
sg11
Vrenal cell carcinoma
p13264
sg13
I3
sa(dp13265
g7
I75
sg27
VC0027651
p13266
sg10
I5
sg11
Vtumor
p13267
sg13
I1
sasa(dp13268
g2
VThe present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.
p13269
sg4
(lp13270
(dp13271
g7
I33
sg8
VP57775
p13272
sg10
I3
sg11
VDAC
p13273
sg13
I1
sasg24
(lp13274
(dp13275
g7
I83
sg27
VC0007134
p13276
sg10
I15
sg11
Vrenal carcinoma
p13277
sg13
I2
sa(dp13278
g7
I83
sg27
VC0007134
p13279
sg10
I15
sg11
Vrenal carcinoma
p13280
sg13
I2
sasa(dp13281
g2
VThe aim of this study was to investigate the occurrence and relevance of promoter methylation of the tumor suppressor DAPK-1, APAF-1 () and SPARC in relation to different pathological stages and histological grades of tumor progression that might act as possible independent prognostic factor in the susceptibility towards renal cell carcinoma (RCC) in North Indian population.
p13282
sg4
(lp13283
(dp13284
g7
I118
sg8
VP53355
p13285
sg10
I6
sg11
VDAPK-1
p13286
sg13
I1
sa(dp13287
g7
I140
sg8
VP09486
p13288
sg10
I5
sg11
VSPARC
p13289
sg13
I1
sasg24
(lp13290
(dp13291
g7
I101
sg27
VC0027651
p13292
sg10
I5
sg11
Vtumor
p13293
sg13
I1
sa(dp13294
g7
I323
sg27
VC0007134
p13295
sg10
I20
sg11
Vrenal cell carcinoma
p13296
sg13
I3
sa(dp13297
g7
I218
sg27
VC0178874
p13298
sg10
I17
sg11
Vtumor progression
p13299
sg13
I2
sa(dp13300
g7
I345
sg27
VC0007134
p13301
sg10
I3
sg11
VRCC
p13302
sg13
I1
sasa(dp13303
g2
VTo examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.
p13304
sg4
(lp13305
(dp13306
g7
I186
sg8
VP53355
p13307
sg10
I6
sg11
VDAPK-1
p13308
sg13
I1
sa(dp13309
g7
I60
sg8
g9
sg10
I77
sg11
Vp53 target and tumour suppressor genes apoptotic protease activating factor-1
p13310
sg13
I10
sa(dp13311
g7
I151
sg8
VP53355
p13312
sg10
I33
sg11
Vdeath-associated protein kinase-1
p13313
sg13
I3
sasg24
(lp13314
(dp13315
g7
I75
sg27
VC0027651
p13316
sg10
I6
sg11
Vtumour
p13317
sg13
I1
sa(dp13318
g7
I75
sg27
VC0027651
p13319
sg10
I6
sg11
Vtumour
p13320
sg13
I1
sa(dp13321
g7
I344
sg27
VC0007134
p13322
sg10
I3
sg11
VRCC
p13323
sg13
I1
sa(dp13324
g7
I264
sg27
VC1861305
p13325
sg10
I3
sg11
VTCC
p13326
sg13
I1
sa(dp13327
g7
I235
sg27
VC0007138
p13328
sg10
I27
sg11
Vtransitional cell carcinoma
p13329
sg13
I3
sa(dp13330
g7
I75
sg27
VC0027651
p13331
sg10
I6
sg11
Vtumour
p13332
sg13
I1
sa(dp13333
g7
I322
sg27
VC0007134
p13334
sg10
I20
sg11
Vrenal cell carcinoma
p13335
sg13
I3
sasa(dp13336
g2
VQuantification of mRNA expression of HNF1B, six of its potential target genes (PKHD1, PKD1, PKD2, IFT88, TMEM27 and UMOD) and three genes involved in the Mg(2+) renal homeostasis (ATP1A1, FXYD2 and CLDN16) in the urinary sediment of 11 individuals with mutation of HNF1B and in 9 controls (non-invasive assessment of the renal transcriptome).
p13337
sg4
(lp13338
(dp13339
g7
I105
sg8
g9
sg10
I6
sg11
VTMEM27
p13340
sg13
I1
sa(dp13341
g7
I188
sg8
VP54710
p13342
sg10
I5
sg11
VFXYD2
p13343
sg13
I1
sa(dp13344
g7
I37
sg8
VP35680
p13345
sg10
I5
sg11
VHNF1B
p13346
sg13
I1
sa(dp13347
g7
I92
sg8
g9
sg10
I4
sg11
VPKD2
p13348
sg13
I1
sa(dp13349
g7
I180
sg8
VP05023
p13350
sg10
I6
sg11
VATP1A1
p13351
sg13
I1
sa(dp13352
g7
I37
sg8
VP35680
p13353
sg10
I5
sg11
VHNF1B
p13354
sg13
I1
sa(dp13355
g7
I98
sg8
g9
sg10
I5
sg11
VIFT88
p13356
sg13
I1
sa(dp13357
g7
I116
sg8
VP07911
p13358
sg10
I4
sg11
VUMOD
p13359
sg13
I1
sa(dp13360
g7
I79
sg8
VP08F94
p13361
sg10
I5
sg11
VPKHD1
p13362
sg13
I1
sa(dp13363
g7
I198
sg8
g9
sg10
I6
sg11
VCLDN16
p13364
sg13
I1
sa(dp13365
g7
I86
sg8
VP98161
p13366
sg10
I4
sg11
VPKD1
p13367
sg13
I1
sasg24
(lp13368
(dp13369
g7
I79
sg27
VC0085548
p13370
sg10
I5
sg11
VPKHD1
p13371
sg13
I1
sa(dp13372
g7
I92
sg27
VC2751306
p13373
sg10
I4
sg11
VPKD2
p13374
sg13
I1
sa(dp13375
g7
I86
sg27
VC3149841
p13376
sg10
I4
sg11
VPKD1
p13377
sg13
I1
sasa(dp13378
g2
VCollectrin is a downstream target of the transcription factor hepatocyte nuclear factor-1alpha (HNF-1alpha), which is mutated in maturity-onset diabetes of the young subtype 3 (MODY3).
p13379
sg4
(lp13380
(dp13381
g7
I62
sg8
VP20823
p13382
sg10
I32
sg11
Vhepatocyte nuclear factor-1alpha
p13383
sg13
I3
sa(dp13384
g7
I177
sg8
VP20823
p13385
sg10
I5
sg11
VMODY3
p13386
sg13
I1
sa(dp13387
g7
I0
sg8
g9
sg10
I10
sg11
VCollectrin
p13388
sg13
I1
sa(dp13389
g7
I96
sg8
VP20823
p13390
sg10
I10
sg11
VHNF-1alpha
p13391
sg13
I1
sa(dp13392
g7
I129
sg8
VP20823
p13393
sg10
I46
sg11
Vmaturity-onset diabetes of the young subtype 3
p13394
sg13
I7
sasg24
(lp13395
(dp13396
g7
I177
sg27
VC1838100
p13397
sg10
I5
sg11
VMODY3
p13398
sg13
I1
sa(dp13399
g7
I129
sg27
VC1838100
p13400
sg10
I46
sg11
Vmaturity-onset diabetes of the young subtype 3
p13401
sg13
I7
sasa(dp13402
g2
VSeveral forms of ichthyosis are associated with neurologic manifestations, including Sjoegren-Larsson syndrome, Refsum disease, and mental retardation-enteropathy-deafness-neuropathy-ichthyosis-keratoderma (MEDNIK) syndrome.
p13403
sg4
(lp13404
sg24
(lp13405
(dp13406
g7
I194
sg27
VC0022579
p13407
sg10
I11
sg11
Vkeratoderma
p13408
sg13
I1
sa(dp13409
g7
I85
sg27
VC0037231
p13410
sg10
I25
sg11
VSjoegren-Larsson syndrome
p13411
sg13
I2
sa(dp13412
g7
I163
sg27
VC0011053
p13413
sg10
I8
sg11
Vdeafness
p13414
sg13
I1
sa(dp13415
g7
I17
sg27
VC0020758
p13416
sg10
I10
sg11
Vichthyosis
p13417
sg13
I1
sa(dp13418
g7
I112
sg27
VC0034960
p13419
sg10
I14
sg11
VRefsum disease
p13420
sg13
I2
sa(dp13421
g7
I17
sg27
VC0020758
p13422
sg10
I10
sg11
Vichthyosis
p13423
sg13
I1
sa(dp13424
g7
I102
sg27
VC0039082
p13425
sg10
I8
sg11
Vsyndrome
p13426
sg13
I1
sa(dp13427
g7
I132
sg27
VC0025362
p13428
sg10
I18
sg11
Vmental retardation
p13429
sg13
I2
sa(dp13430
g7
I151
sg27
VC0021831
p13431
sg10
I11
sg11
Venteropathy
p13432
sg13
I1
sa(dp13433
g7
I172
sg27
VC0442874
p13434
sg10
I10
sg11
Vneuropathy
p13435
sg13
I1
sasa(dp13436
g2
VTo determine the difference in thrombomodulin expression in the myometrium and in myoma; and to understand the correlation of anticoagulation/fibrinolytic function and the mechanism of uterine artery occlusion in the treatment of leiomyoma.
p13437
sg4
(lp13438
(dp13439
g7
I31
sg8
VP07204
p13440
sg10
I14
sg11
Vthrombomodulin
p13441
sg13
I1
sasg24
(lp13442
(dp13443
g7
I230
sg27
VC0023267
p13444
sg10
I9
sg11
Vleiomyoma
p13445
sg13
I1
sa(dp13446
g7
I82
sg27
VC0027086
p13447
sg10
I5
sg11
Vmyoma
p13448
sg13
I1
sa(dp13449
g7
I193
sg27
VC0264995
p13450
sg10
I16
sg11
Vartery occlusion
p13451
sg13
I2
sasa(dp13452
g2
VThe relative transcription of thrombomodulin mRNA was 1.28 times higher in myometrial tissue than in myomal tissue (P &lt; 0.05).
p13453
sg4
(lp13454
(dp13455
g7
I30
sg8
VP07204
p13456
sg10
I19
sg11
Vthrombomodulin mRNA
p13457
sg13
I2
sasg24
(lp13458
sa(dp13459
g2
VSimilarly, leiomyoma-associated endometrium expressed less PAI-1 and thrombomodulin in vivo.
p13460
sg4
(lp13461
(dp13462
g7
I59
sg8
VP05121
p13463
sg10
I5
sg11
VPAI-1
p13464
sg13
I1
sa(dp13465
g7
I69
sg8
VP07204
p13466
sg10
I14
sg11
Vthrombomodulin
p13467
sg13
I1
sasg24
(lp13468
(dp13469
g7
I11
sg27
VC0023267
p13470
sg10
I9
sg11
Vleiomyoma
p13471
sg13
I1
sasa(dp13472
g2
VAlfa-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).
p13473
sg4
(lp13474
(dp13475
g7
I48
sg8
VP01308
p13476
sg10
I52
sg11
Vinsulin-like growth factor-II mRNA-binding protein 3
p13477
sg13
I6
sa(dp13478
g7
I102
sg8
g9
sg10
I4
sg11
VIMP3
p13479
sg13
I1
sa(dp13480
g7
I37
sg8
g9
sg10
I5
sg11
VAMACR
p13481
sg13
I1
sa(dp13482
g7
I0
sg8
g9
sg10
I35
sg11
VAlfa-methylacyl coenzyme A racemase
p13483
sg13
I4
sasg24
(lp13484
(dp13485
g7
I194
sg27
VC0004763
p13486
sg10
I2
sg11
VBE
p13487
sg13
I1
sa(dp13488
g7
I162
sg27
VC0334044
p13489
sg10
I9
sg11
Vdysplasia
p13490
sg13
I1
sa(dp13491
g7
I175
sg27
VC0004763
p13492
sg10
I17
sg11
VBarrett esophagus
p13493
sg13
I2
sasa(dp13494
g2
VTo investigate the value of Alfa-methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO).
p13495
sg4
(lp13496
(dp13497
g7
I28
sg8
g9
sg10
I28
sg11
VAlfa-methylacyl-CoA racemase
p13498
sg13
I2
sa(dp13499
g7
I58
sg8
g9
sg10
I5
sg11
VAMACR
p13500
sg13
I1
sasg24
(lp13501
(dp13502
g7
I44
sg27
VC2678439
p13503
sg10
I3
sg11
VCoA
p13504
sg13
I1
sa(dp13505
g7
I127
sg27
VC0004763
p13506
sg10
I20
sg11
VBarrett's oesophagus
p13507
sg13
I2
sa(dp13508
g7
I101
sg27
VC0178874
p13509
sg10
I22
sg11
Vneoplastic progression
p13510
sg13
I2
sa(dp13511
g7
I149
sg27
VC0004763
p13512
sg10
I2
sg11
VBO
p13513
sg13
I1
sasa(dp13514
g2
VThe aim of this study was to evaluate AMACR expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus (BE), ulcerative colitis (UC), and Crohn's disease (CD) and to determine whether its expression can be used to detect dysplastic epithelium in these conditions.
p13515
sg4
(lp13516
sg24
(lp13517
(dp13518
g7
I160
sg27
VC0010346
p13519
sg10
I15
sg11
VCrohn's disease
p13520
sg13
I2
sa(dp13521
g7
I243
sg27
VC0334044
p13522
sg10
I10
sg11
Vdysplastic
p13523
sg13
I1
sa(dp13524
g7
I62
sg27
VC0025568
p13525
sg10
I10
sg11
Vmetaplasia
p13526
sg13
I1
sa(dp13527
g7
I73
sg27
VC0334044
p13528
sg10
I9
sg11
Vdysplasia
p13529
sg13
I1
sa(dp13530
g7
I83
sg27
VC0007097
p13531
sg10
I9
sg11
Vcarcinoma
p13532
sg13
I1
sa(dp13533
g7
I105
sg27
VC0004763
p13534
sg10
I19
sg11
VBarrett's esophagus
p13535
sg13
I2
sa(dp13536
g7
I126
sg27
VC0004763
p13537
sg10
I2
sg11
VBE
p13538
sg13
I1
sa(dp13539
g7
I177
sg27
VC0010346
p13540
sg10
I2
sg11
VCD
p13541
sg13
I1
sa(dp13542
g7
I131
sg27
VC0009324
p13543
sg10
I18
sg11
Vulcerative colitis
p13544
sg13
I2
sa(dp13545
g7
I151
sg27
VC0009324
p13546
sg10
I2
sg11
VUC
p13547
sg13
I1
sasa(dp13548
g2
VThese associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.
p13549
sg4
(lp13550
(dp13551
g7
I221
sg8
VP27487
p13552
sg10
I4
sg11
VDPP4
p13553
sg13
I1
sa(dp13554
g7
I125
sg8
g9
sg10
I5
sg11
VFBXW8
p13555
sg13
I1
sa(dp13556
g7
I76
sg8
g9
sg10
I4
sg11
VWIF1
p13557
sg13
I1
sasg24
(lp13558
(dp13559
g7
I199
sg27
VC0011849
p13560
sg10
I8
sg11
Vdiabetes
p13561
sg13
I1
sa(dp13562
g7
I329
sg27
VC0497327
p13563
sg10
I8
sg11
Vdementia
p13564
sg13
I1
sa(dp13565
g7
I83
sg27
VC0242606
p13566
sg10
I16
sg11
Voxidative stress
p13567
sg13
I2
sa(dp13568
g7
I307
sg27
VC0338656
p13569
sg10
I17
sg11
Vcognitive decline
p13570
sg13
I2
sasa(dp13571
g2
VHistomorphometrical analysis of experimental implants inserted in the femurs of CKD mice revealed a trend of decreased BIC ratio at 2-week healing.
p13572
sg4
(lp13573
sg24
(lp13574
sa(dp13575
g2
VA Cochrane Collaboration review (Roderick, Cochrane Data base of systemic reviews 2007, DOI 10.1002/14651858.CD0018.90.pub3) reported that there was no evidence for correction of acidosis by sodium bicarbonate in pre-end-stage renal disease (ESRD) patients, and concluded that randomized controlled trials (RCTs) are necessary to evaluate the benefits and harms of correcting metabolic acidosis in pre-ESRD patients.
p13576
sg4
(lp13577
sg24
(lp13578
(dp13579
g7
I376
sg27
VC0220981
p13580
sg10
I18
sg11
Vmetabolic acidosis
p13581
sg13
I2
sa(dp13582
g7
I179
sg27
VC0001122
p13583
sg10
I8
sg11
Vacidosis
p13584
sg13
I1
sa(dp13585
g7
I213
sg27
VC0022661
p13586
sg10
I27
sg11
Vpre-end-stage renal disease
p13587
sg13
I3
sa(dp13588
g7
I242
sg27
VC0022661
p13589
sg10
I4
sg11
VESRD
p13590
sg13
I1
sa(dp13591
g7
I242
sg27
VC0022661
p13592
sg10
I4
sg11
VESRD
p13593
sg13
I1
sasa(dp13594
g2
VWe will randomize 600 patients with chronic kidney disease (CKD) stages 3b and 4; 300 of these patients will be included in the bicarbonate study group (Bic), in which levels of bicarbonate should be kept &gt;24 mEq/L; the other 300 patients will be included in the usual-treatment group (no-Bic).
p13595
sg4
(lp13596
sg24
(lp13597
(dp13598
g7
I60
sg27
VC1561643
p13599
sg10
I3
sg11
VCKD
p13600
sg13
I1
sa(dp13601
g7
I36
sg27
VC1561643
p13602
sg10
I22
sg11
Vchronic kidney disease
p13603
sg13
I3
sasa(dp13604
g2
VAcid-Base Disorders in CKD: Moderate metabolic acidosis (Bic 16-20) mEq/L is common with glomerular filtration rates below 20 ml/min, and favors bone demineralization due to the release of calcium and phosphate from the bone, chronic hyperventilation, and muscular weakness and atrophy.
p13605
sg4
(lp13606
(dp13607
g7
I0
sg8
g9
sg10
I9
sg11
VAcid-Base
p13608
sg13
I1
sasg24
(lp13609
(dp13610
g7
I0
sg27
VC0740265
p13611
sg10
I19
sg11
VAcid-Base Disorders
p13612
sg13
I2
sa(dp13613
g7
I256
sg27
VC0151786
p13614
sg10
I17
sg11
Vmuscular weakness
p13615
sg13
I2
sa(dp13616
g7
I145
sg27
VC0242699
p13617
sg10
I21
sg11
Vbone demineralization
p13618
sg13
I2
sa(dp13619
g7
I226
sg27
VC0268054
p13620
sg10
I24
sg11
Vchronic hyperventilation
p13621
sg13
I2
sa(dp13622
g7
I37
sg27
VC0220981
p13623
sg10
I18
sg11
Vmetabolic acidosis
p13624
sg13
I2
sa(dp13625
g7
I278
sg27
VC0333641
p13626
sg10
I7
sg11
Vatrophy
p13627
sg13
I1
sasa(dp13628
g2
VIn a prospective randomized crossover trial, patients with acute renal failure received CRRT with either sodium bicarbonate (Bic) or sodium lactate (Lac) as a buffering agent over 2 consecutive 24-h periods.
p13629
sg4
(lp13630
(dp13631
g7
I140
sg8
VP09848
p13632
sg10
I7
sg11
Vlactate
p13633
sg13
I1
sa(dp13634
g7
I149
sg8
VP09848
p13635
sg10
I3
sg11
VLac
p13636
sg13
I1
sasg24
(lp13637
(dp13638
g7
I59
sg27
VC0022660
p13639
sg10
I19
sg11
Vacute renal failure
p13640
sg13
I3
sasa(dp13641
g2
VThe combination of bicarbonate and mannitol (BIC/MAN) is commonly used to prevent renal failure (RF) in patients with rhabdomyolysis despite the absence of sufficient evidence validating its use.
p13642
sg4
(lp13643
sg24
(lp13644
(dp13645
g7
I118
sg27
VC0035410
p13646
sg10
I14
sg11
Vrhabdomyolysis
p13647
sg13
I1
sa(dp13648
g7
I82
sg27
VC0035078
p13649
sg10
I13
sg11
Vrenal failure
p13650
sg13
I2
sa(dp13651
g7
I97
sg27
VC0035078
p13652
sg10
I2
sg11
VRF
p13653
sg13
I1
sasa(dp13654
g2
VTo unmask weak inputs from outside the conventional RF (CRF), cell excitability was raised by iontophoretic application of glutamate (GLU) and/or bicuculline methiodide (BIC) or by light stimulation of the CRF.
p13655
sg4
(lp13656
(dp13657
g7
I56
sg8
VP06850
p13658
sg10
I3
sg11
VCRF
p13659
sg13
I1
sa(dp13660
g7
I39
sg8
VP06850
p13661
sg10
I15
sg11
Vconventional RF
p13662
sg13
I2
sasg24
(lp13663
(dp13664
g7
I56
sg27
VC0022661
p13665
sg10
I3
sg11
VCRF
p13666
sg13
I1
sa(dp13667
g7
I67
sg27
VC0235169
p13668
sg10
I12
sg11
Vexcitability
p13669
sg13
I1
sa(dp13670
g7
I56
sg27
VC0022661
p13671
sg10
I3
sg11
VCRF
p13672
sg13
I1
sa(dp13673
g7
I39
sg27
VC0022661
p13674
sg10
I15
sg11
Vconventional RF
p13675
sg13
I2
sasa(dp13676
g2
VBicarbonate-buffered replacement fluid (RF-bic) in continuous venovenous hemofiltration (CVVH) may be superior to lactate-buffered replacement fluid (RF-lac) in acute renal failure.
p13677
sg4
(lp13678
sg24
(lp13679
(dp13680
g7
I161
sg27
VC0022660
p13681
sg10
I19
sg11
Vacute renal failure
p13682
sg13
I3
sasa(dp13683
g2
VIn an open, randomized, multicenter study, we investigated the effects of RF-bic and RF-lac on cardiovascular outcome in patients requiring CVVH following acute renal failure.
p13684
sg4
(lp13685
(dp13686
g7
I85
sg8
VP09848
p13687
sg10
I6
sg11
VRF-lac
p13688
sg13
I1
sasg24
(lp13689
(dp13690
g7
I155
sg27
VC0022660
p13691
sg10
I19
sg11
Vacute renal failure
p13692
sg13
I3
sasa(dp13693
g2
VThe data also suggest that the use of RF-bic during CVVH reduces cardiovascular events in critically ill patients with acute renal failure, particularly those with previous cardiovascular disease or heart failure.
p13694
sg4
(lp13695
sg24
(lp13696
(dp13697
g7
I119
sg27
VC0022660
p13698
sg10
I19
sg11
Vacute renal failure
p13699
sg13
I3
sa(dp13700
g7
I199
sg27
VC0018802
p13701
sg10
I13
sg11
Vheart failure
p13702
sg13
I2
sa(dp13703
g7
I173
sg27
VC0007222
p13704
sg10
I22
sg11
Vcardiovascular disease
p13705
sg13
I2
sa(dp13706
g7
I90
sg27
VC0010340
p13707
sg10
I14
sg11
Vcritically ill
p13708
sg13
I2
sasa(dp13709
g2
VThe effect of BIC on whisker-evoked responses was a preferential enhancement in the responses elicited by the whisker giving rise to the highest probability response (center receptive field whisker or CRF).
p13710
sg4
(lp13711
sg24
(lp13712
(dp13713
g7
I201
sg27
VC0022661
p13714
sg10
I3
sg11
VCRF
p13715
sg13
I1
sasa(dp13716
g2
VThe primary influence of BIC and, to a lesser degree, 2-OH-S was to prolong the response duration of VPM neurons to CRF whisker stimulation.
p13717
sg4
(lp13718
(dp13719
g7
I116
sg8
VP06850
p13720
sg10
I3
sg11
VCRF
p13721
sg13
I1
sasg24
(lp13722
(dp13723
g7
I116
sg27
VC0022661
p13724
sg10
I3
sg11
VCRF
p13725
sg13
I1
sasa(dp13726
g2
VSelective PDE5 inhibitors have shown potential in treating kidney fibrosis in patients with chronic kidney disease (CKD), via their downstream signaling, and these inhibitors also have known activity as antithrombotic and anticancer agents.
p13727
sg4
(lp13728
(dp13729
g7
I10
sg8
g9
sg10
I4
sg11
VPDE5
p13730
sg13
I1
sasg24
(lp13731
(dp13732
g7
I92
sg27
VC1561643
p13733
sg10
I22
sg11
Vchronic kidney disease
p13734
sg13
I3
sa(dp13735
g7
I116
sg27
VC1561643
p13736
sg10
I3
sg11
VCKD
p13737
sg13
I1
sa(dp13738
g7
I59
sg27
VC0151650
p13739
sg10
I15
sg11
Vkidney fibrosis
p13740
sg13
I2
sasa(dp13741
g2
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p13742
sg4
(lp13743
(dp13744
g7
I4
sg8
VP31371
p13745
sg10
I14
sg11
VFGF9 subfamily
p13746
sg13
I2
sa(dp13747
g7
I4
sg8
VP31371
p13748
sg10
I4
sg11
VFGF9
p13749
sg13
I1
sa(dp13750
g7
I36
sg8
g9
sg10
I5
sg11
VFGF16
p13751
sg13
I1
sa(dp13752
g7
I47
sg8
g9
sg10
I5
sg11
VFGF20
p13753
sg13
I1
sasg24
(lp13754
(dp13755
g7
I169
sg27
VC2239176
p13756
sg10
I24
sg11
Vhepatocellular carcinoma
p13757
sg13
I2
sa(dp13758
g7
I195
sg27
VC2239176
p13759
sg10
I3
sg11
VHCC
p13760
sg13
I1
sa(dp13761
g7
I127
sg27
VC0334094
p13762
sg10
I13
sg11
Vproliferation
p13763
sg13
I1
sasa(dp13764
g2
VFurthermore, the results indicate that exogenous rhFGF9- and rhFGF20-activated ERK/NF-KB signal transduction pathways play important roles in the regulation of HCC cell proliferation and migration, and this discovery helps to find the potential for new solutions of the treatment of liver cancer.
p13765
sg4
(lp13766
(dp13767
g7
I79
sg8
VP29323
p13768
sg10
I3
sg11
VERK
p13769
sg13
I1
sasg24
(lp13770
(dp13771
g7
I169
sg27
VC0334094
p13772
sg10
I13
sg11
Vproliferation
p13773
sg13
I1
sa(dp13774
g7
I160
sg27
VC2239176
p13775
sg10
I3
sg11
VHCC
p13776
sg13
I1
sa(dp13777
g7
I283
sg27
VC0345904
p13778
sg10
I12
sg11
Vliver cancer
p13779
sg13
I2
sasa(dp13780
g2
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p13781
sg4
(lp13782
(dp13783
g7
I120
sg8
g9
sg10
I5
sg11
VFGF10
p13784
sg13
I1
sa(dp13785
g7
I277
sg8
g9
sg10
I5
sg11
VFGF23
p13786
sg13
I1
sa(dp13787
g7
I38
sg8
VP55075
p13788
sg10
I4
sg11
VFGF8
p13789
sg13
I1
sa(dp13790
g7
I212
sg8
g9
sg10
I5
sg11
VFGF14
p13791
sg13
I1
sa(dp13792
g7
I101
sg8
VP31371
p13793
sg10
I4
sg11
VFGF9
p13794
sg13
I1
sa(dp13795
g7
I14
sg8
VP11487
p13796
sg10
I4
sg11
VFGF3
p13797
sg13
I1
sasg24
(lp13798
(dp13799
g7
I254
sg27
VC0030567
p13800
sg10
I17
sg11
VParkinson disease
p13801
sg13
I2
sa(dp13802
g7
I29
sg27
VC0243065
p13803
sg10
I7
sg11
Vaplasia
p13804
sg13
I1
sa(dp13805
g7
I171
sg27
VC0265269
p13806
sg10
I39
sg11
Vlacrimo-auriculo-dento-digital syndrome
p13807
sg13
I2
sa(dp13808
g7
I46
sg27
VC0158646
p13809
sg10
I16
sg11
Vcleft lip/palate
p13810
sg13
I2
sa(dp13811
g7
I309
sg27
VC1704375
p13812
sg10
I24
sg11
Vhypophosphatemic rickets
p13813
sg13
I2
sa(dp13814
g7
I286
sg27
VC0263628
p13815
sg10
I18
sg11
Vtumoral calcinosis
p13816
sg13
I2
sa(dp13817
g7
I109
sg27
VC0007097
p13818
sg10
I9
sg11
Vcarcinoma
p13819
sg13
I1
sa(dp13820
g7
I29
sg27
VC0243065
p13821
sg10
I7
sg11
Vaplasia
p13822
sg13
I1
sa(dp13823
g7
I70
sg27
VC0022735
p13824
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p13825
sg13
I2
sa(dp13826
g7
I221
sg27
VC0087012
p13827
sg10
I22
sg11
Vspinocerebellar ataxia
p13828
sg13
I2
sasa(dp13829
g2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p13830
sg4
(lp13831
(dp13832
g7
I94
sg8
g9
sg10
I8
sg11
VARHGEF10
p13833
sg13
I1
sa(dp13834
g7
I186
sg8
VP07197
p13835
sg10
I4
sg11
VNEF3
p13836
sg13
I1
sa(dp13837
g7
I210
sg8
VP48454
p13838
sg10
I6
sg11
VPPP3CC
p13839
sg13
I1
sa(dp13840
g7
I142
sg8
g9
sg10
I4
sg11
VEGR3
p13841
sg13
I1
sa(dp13842
g7
I120
sg8
g9
sg10
I6
sg11
VCHRNB3
p13843
sg13
I1
sa(dp13844
g7
I86
sg8
VP25100
p13845
sg10
I6
sg11
VADRA1A
p13846
sg13
I1
sa(dp13847
g7
I234
sg8
VP54219
p13848
sg10
I7
sg11
VSLC18A1
p13849
sg13
I1
sa(dp13850
g7
I228
sg8
VP54219
p13851
sg10
I5
sg11
VVMAT1
p13852
sg13
I1
sa(dp13853
g7
I180
sg8
VP18440
p13854
sg10
I4
sg11
VNAT2
p13855
sg13
I1
sa(dp13856
g7
I128
sg8
g9
sg10
I4
sg11
VDKK4
p13857
sg13
I1
sa(dp13858
g7
I162
sg8
VP20930
p13859
sg10
I5
sg11
VFGFR1
p13860
sg13
I1
sa(dp13861
g7
I104
sg8
g9
sg10
I6
sg11
VCHRNA2
p13862
sg13
I1
sa(dp13863
g7
I134
sg8
g9
sg10
I6
sg11
VDPYSL2
p13864
sg13
I1
sa(dp13865
g7
I169
sg8
g9
sg10
I4
sg11
VFZD3
p13866
sg13
I1
sa(dp13867
g7
I148
sg8
g9
sg10
I5
sg11
VFGF17
p13868
sg13
I1
sa(dp13869
g7
I155
sg8
g9
sg10
I5
sg11
VFGF20
p13870
sg13
I1
sa(dp13871
g7
I218
sg8
g9
sg10
I5
sg11
VSFRP1
p13872
sg13
I1
sa(dp13873
g7
I198
sg8
g9
sg10
I4
sg11
VPCM1
p13874
sg13
I1
sa(dp13875
g7
I112
sg8
g9
sg10
I6
sg11
VCHRNA6
p13876
sg13
I1
sasg24
(lp13877
(dp13878
g7
I436
sg27
VC0006826
p13879
sg10
I6
sg11
Vcancer
p13880
sg13
I1
sa(dp13881
g7
I309
sg27
VC0036341
p13882
sg10
I13
sg11
Vschizophrenia
p13883
sg13
I1
sa(dp13884
g7
I332
sg27
VC0005586
p13885
sg10
I16
sg11
Vbipolar disorder
p13886
sg13
I2
sa(dp13887
g7
I324
sg27
VC0004352
p13888
sg10
I6
sg11
Vautism
p13889
sg13
I1
sa(dp13890
g7
I366
sg27
VC0524851
p13891
sg10
I27
sg11
Vneurodegenerative disorders
p13892
sg13
I2
sa(dp13893
g7
I353
sg27
VC0011581
p13894
sg10
I10
sg11
Vdepression
p13895
sg13
I1
sa(dp13896
g7
I411
sg27
VC1521724
p13897
sg10
I19
sg11
VAlzheimer's disease
p13898
sg13
I2
sasa(dp13899
g2
VEphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.
p13900
sg4
(lp13901
(dp13902
g7
I10
sg8
VP01588
p13903
sg10
I14
sg11
Verythropoietin
p13904
sg13
I1
sa(dp13905
g7
I0
sg8
VP52799
p13906
sg10
I8
sg11
VEphrinB2
p13907
sg13
I1
sasg24
(lp13908
(dp13909
g7
I35
sg27
VC0023903
p13910
sg10
I8
sg11
Vhepatoma
p13911
sg13
I1
sa(dp13912
g7
I188
sg27
VC0242656
p13913
sg10
I19
sg11
Vdisease progression
p13914
sg13
I2
sasa(dp13915
g2
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p13916
sg4
(lp13917
(dp13918
g7
I128
sg8
g9
sg10
I14
sg11
Vangiopoietin 2
p13919
sg13
I2
sa(dp13920
g7
I85
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p13921
sg13
I4
sa(dp13922
g7
I151
sg8
VP52799
p13923
sg10
I8
sg11
VephrinB2
p13924
sg13
I1
sa(dp13925
g7
I224
sg8
VP58294
p13926
sg10
I7
sg11
VEG-VEGF
p13927
sg13
I1
sa(dp13928
g7
I164
sg8
VP58294
p13929
sg10
I58
sg11
Vendocrine gland-derived vascular endothelial growth factor
p13930
sg13
I6
sa(dp13931
g7
I144
sg8
g9
sg10
I4
sg11
VAng2
p13932
sg13
I1
sa(dp13933
g7
I121
sg8
g9
sg10
I4
sg11
VVEGF
p13934
sg13
I1
sasg24
(lp13935
(dp13936
g7
I334
sg27
VC2239176
p13937
sg10
I3
sg11
VHCC
p13938
sg13
I1
sa(dp13939
g7
I237
sg27
VC0596263
p13940
sg10
I14
sg11
Vcarcinogenesis
p13941
sg13
I1
sa(dp13942
g7
I267
sg27
VC3163918
p13943
sg10
I14
sg11
Vtumor thrombus
p13944
sg13
I2
sa(dp13945
g7
I308
sg27
VC2239176
p13946
sg10
I24
sg11
Vhepatocellular carcinoma
p13947
sg13
I2
sasa(dp13948
g2
VWe investigated whether the human MBX gene was associated with susceptibility to microphthalmia by analyzing four Korean families demonstrating microphthalmia with congenital cataract.
p13949
sg4
(lp13950
(dp13951
g7
I28
sg8
g9
sg10
I14
sg11
Vhuman MBX gene
p13952
sg13
I3
sasg24
(lp13953
(dp13954
g7
I81
sg27
VC0026010
p13955
sg10
I14
sg11
Vmicrophthalmia
p13956
sg13
I1
sa(dp13957
g7
I81
sg27
VC0026010
p13958
sg10
I14
sg11
Vmicrophthalmia
p13959
sg13
I1
sa(dp13960
g7
I164
sg27
VC0009691
p13961
sg10
I19
sg11
Vcongenital cataract
p13962
sg13
I2
sasa(dp13963
g2
VTherefore, no indications were found for an association between the MBX gene and microphthalmia with congenital cataract in humans.
p13964
sg4
(lp13965
(dp13966
g7
I68
sg8
g9
sg10
I8
sg11
VMBX gene
p13967
sg13
I2
sasg24
(lp13968
(dp13969
g7
I81
sg27
VC0026010
p13970
sg10
I14
sg11
Vmicrophthalmia
p13971
sg13
I1
sa(dp13972
g7
I101
sg27
VC0009691
p13973
sg10
I19
sg11
Vcongenital cataract
p13974
sg13
I2
sasa(dp13975
g2
VSequence changes have been observed for both NCKX1 and NCKX2 in patients with retinal diseases, but a definitive association with retinal disease has not been shown.
p13976
sg4
(lp13977
(dp13978
g7
I55
sg8
g9
sg10
I5
sg11
VNCKX2
p13979
sg13
I1
sa(dp13980
g7
I45
sg8
g9
sg10
I5
sg11
VNCKX1
p13981
sg13
I1
sasg24
(lp13982
(dp13983
g7
I78
sg27
VC0035309
p13984
sg10
I15
sg11
Vretinal disease
p13985
sg13
I2
sa(dp13986
g7
I78
sg27
VC0035309
p13987
sg10
I16
sg11
Vretinal diseases
p13988
sg13
I2
sasa(dp13989
g2
VTo study the possible involvement of the rod (SLC24A1) and cone (SLC24A2) Na-Ca+K exchanger (NCKX) genes in retinal diseases.
p13990
sg4
(lp13991
(dp13992
g7
I74
sg8
g9
sg10
I30
sg11
VNa-Ca+K exchanger (NCKX) genes
p13993
sg13
I4
sa(dp13994
g7
I65
sg8
g9
sg10
I7
sg11
VSLC24A2
p13995
sg13
I1
sa(dp13996
g7
I41
sg8
VP50748
p13997
sg10
I3
sg11
Vrod
p13998
sg13
I1
sa(dp13999
g7
I46
sg8
g9
sg10
I7
sg11
VSLC24A1
p14000
sg13
I1
sasg24
(lp14001
(dp14002
g7
I108
sg27
VC0035309
p14003
sg10
I16
sg11
Vretinal diseases
p14004
sg13
I2
sasa(dp14005
g2
VApproximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes.
p14006
sg4
(lp14007
(dp14008
g7
I166
sg8
VP51587
p14009
sg10
I5
sg11
VBRCA2
p14010
sg13
I1
sa(dp14011
g7
I196
sg8
g9
sg10
I5
sg11
VPALB2
p14012
sg13
I1
sa(dp14013
g7
I180
sg8
g9
sg10
I3
sg11
VATM
p14014
sg13
I1
sa(dp14015
g7
I173
sg8
VP38398
p14016
sg10
I5
sg11
VBRCA1
p14017
sg13
I1
sasg24
(lp14018
(dp14019
g7
I67
sg27
VC0600139
p14020
sg10
I15
sg11
Vprostate cancer
p14021
sg13
I2
sasa(dp14022
g2
VMen who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks.
p14023
sg4
(lp14024
(dp14025
g7
I213
sg8
VP43246
p14026
sg10
I4
sg11
VMSH2
p14027
sg13
I1
sa(dp14028
g7
I197
sg8
g9
sg10
I3
sg11
VATM
p14029
sg13
I1
sa(dp14030
g7
I49
sg8
VP51587
p14031
sg10
I5
sg11
VBRCA2
p14032
sg13
I1
sa(dp14033
g7
I59
sg8
VP38398
p14034
sg10
I5
sg11
VBRCA1
p14035
sg13
I1
sa(dp14036
g7
I218
sg8
VP52701
p14037
sg10
I4
sg11
VMSH6
p14038
sg13
I1
sasg24
(lp14039
(dp14040
g7
I101
sg27
VC0001807
p14041
sg10
I10
sg11
Vaggressive
p14042
sg13
I1
sa(dp14043
g7
I112
sg27
VC0600139
p14044
sg10
I15
sg11
Vprostate cancer
p14045
sg13
I2
sasa(dp14046
g2
VThe CHEK2 gene del5395 is a founder mutation in the Latvian population, which, however, does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.
p14047
sg4
(lp14048
sg24
(lp14049
(dp14050
g7
I183
sg27
VC0600139
p14051
sg10
I15
sg11
Vprostate cancer
p14052
sg13
I2
sa(dp14053
g7
I28
sg27
VC2985435
p14054
sg10
I16
sg11
Vfounder mutation
p14055
sg13
I2
sasa(dp14056
g2
VHuman limbal neurospheres expressed the neural lineage markers, Nestin, sex determining region box-2 and N-cadherin, and the retinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2 and orthodentical homeobox-2.
p14057
sg4
(lp14058
(dp14059
g7
I250
sg8
VP52954
p14060
sg10
I10
sg11
Vhomeobox-2
p14061
sg13
I1
sa(dp14062
g7
I64
sg8
VP48681
p14063
sg10
I36
sg11
VNestin, sex determining region box-2
p14064
sg13
I5
sa(dp14065
g7
I105
sg8
VP19022
p14066
sg10
I10
sg11
VN-cadherin
p14067
sg13
I1
sa(dp14068
g7
I125
sg8
g9
sg10
I106
sg11
Vretinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2
p14069
sg13
I10
sasg24
(lp14070
(dp14071
g7
I155
sg27
VC0026010
p14072
sg10
I14
sg11
Vmicrophthalmia
p14073
sg13
I1
sasa(dp14074
g2
VMutations of orthodentricle homeobox 2 (OTX2) in human and mice often cause retinal dystrophy and nyctalopia, suggesting a role of OTX2 in mature retina, in addition to its functions in the development of the eye and retina.
p14075
sg4
(lp14076
(dp14077
g7
I40
sg8
VP32243
p14078
sg10
I4
sg11
VOTX2
p14079
sg13
I1
sa(dp14080
g7
I13
sg8
VP32243
p14081
sg10
I25
sg11
Vorthodentricle homeobox 2
p14082
sg13
I3
sa(dp14083
g7
I40
sg8
VP32243
p14084
sg10
I4
sg11
VOTX2
p14085
sg13
I1
sasg24
(lp14086
(dp14087
g7
I76
sg27
VC0854723
p14088
sg10
I17
sg11
Vretinal dystrophy
p14089
sg13
I2
sa(dp14090
g7
I98
sg27
VC0028077
p14091
sg10
I10
sg11
Vnyctalopia
p14092
sg13
I1
sasa(dp14093
g2
VTHE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: Angiotensin-converting enzyme inhibitors (ACE) affect the different mechanisms that lead to glomerulosclerosis: antihypertensive effect, with the normalisation of blood pressure having demonstrated its determining role in the production of nephrosis in various epidemiological studies; hemodynamic effect with a decrease in glomerular capillary pressure, in the filtration fraction, and inhibition of the bradykinin deterioration; antiproteinuric effect superior to that of other anti-hypertensive drugs (excepting angiotensin II-receptor antagonists).
p14094
sg4
(lp14095
(dp14096
g7
I96
sg8
VP12821
p14097
sg10
I3
sg11
VACE
p14098
sg13
I1
sa(dp14099
g7
I569
sg8
VP01019
p14100
sg10
I23
sg11
Vangiotensin II-receptor
p14101
sg13
I2
sa(dp14102
g7
I54
sg8
VP12821
p14103
sg10
I40
sg11
VAngiotensin-converting enzyme inhibitors
p14104
sg13
I3
sa(dp14105
g7
I459
sg8
VP01042
p14106
sg10
I10
sg11
Vbradykinin
p14107
sg13
I1
sasg24
(lp14108
(dp14109
g7
I294
sg27
VC0027720
p14110
sg10
I9
sg11
Vnephrosis
p14111
sg13
I1
sa(dp14112
g7
I146
sg27
VC0178664
p14113
sg10
I18
sg11
Vglomerulosclerosis
p14114
sg13
I1
sasa(dp14115
g2
VTo investigate whether the reduction in proteinuria is due to decreased generation of angiotensin II (AngII) or to decreased degradation of bradykinin, four series of experiments in established adriamycin nephrosis were performed.
p14116
sg4
(lp14117
(dp14118
g7
I140
sg8
VP01042
p14119
sg10
I10
sg11
Vbradykinin
p14120
sg13
I1
sa(dp14121
g7
I102
sg8
VP01019
p14122
sg10
I5
sg11
VAngII
p14123
sg13
I1
sa(dp14124
g7
I86
sg8
VP01019
p14125
sg10
I14
sg11
Vangiotensin II
p14126
sg13
I2
sasg24
(lp14127
(dp14128
g7
I205
sg27
VC0027720
p14129
sg10
I9
sg11
Vnephrosis
p14130
sg13
I1
sasa(dp14131
g2
VThere were few reports demonstrating behavior of kinin and kininogen in the nephrotic syndrome.
p14132
sg4
(lp14133
(dp14134
g7
I49
sg8
VP01042
p14135
sg10
I19
sg11
Vkinin and kininogen
p14136
sg13
I3
sasg24
(lp14137
(dp14138
g7
I76
sg27
VC0027726
p14139
sg10
I18
sg11
Vnephrotic syndrome
p14140
sg13
I2
sasa(dp14141
g2
VIn this paper, coagulation factors related to contact activation, such as factor XII (FXII), factor XI (FXI), prekallikrein (PK), high molecular weight kininogen (HMWKG), and kinins were measured in 15 cases of nephrotic syndrome, and clinical significance of these results were discussed.
p14142
sg4
(lp14143
(dp14144
g7
I74
sg8
VP00748
p14145
sg10
I28
sg11
Vfactor XII (FXII), factor XI
p14146
sg13
I5
sa(dp14147
g7
I86
sg8
g9
sg10
I3
sg11
VFXI
p14148
sg13
I1
sa(dp14149
g7
I110
sg8
VP03952
p14150
sg10
I51
sg11
Vprekallikrein (PK), high molecular weight kininogen
p14151
sg13
I6
sasg24
(lp14152
(dp14153
g7
I211
sg27
VC0027726
p14154
sg10
I18
sg11
Vnephrotic syndrome
p14155
sg13
I2
sasa(dp14156
g2
VIt was concluded that kinin formation in the nephrotic syndrome was not due to the activation of intrinsic coagulation system but due to release of kinin from low molecular weight kininogen.
p14157
sg4
(lp14158
sg24
(lp14159
(dp14160
g7
I45
sg27
VC0027726
p14161
sg10
I18
sg11
Vnephrotic syndrome
p14162
sg13
I2
sasa(dp14163
g2
VTo investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh).
p14164
sg4
(lp14165
(dp14166
g7
I45
sg8
VP98066
p14167
sg10
I5
sg11
VTSG-6
p14168
sg13
I1
sa(dp14169
g7
I76
sg8
VP08254
p14170
sg10
I5
sg11
VMMP-3
p14171
sg13
I1
sa(dp14172
g7
I66
sg8
VP03956
p14173
sg10
I5
sg11
VMMP-1
p14174
sg13
I1
sasg24
(lp14175
(dp14176
g7
I126
sg27
VC0878693
p14177
sg10
I19
sg11
Vconjunctivochalasis
p14178
sg13
I1
sa(dp14179
g7
I147
sg27
VC0878693
p14180
sg10
I3
sg11
VCCh
p14181
sg13
I1
sasa(dp14182
g2
VDirect sequencing analyses were performed in 19 genes, including ALS/frontotemporal lobar degeneration (FTLD)-related genes (SOD2, SOD3, ALS2/alsin, SMN1, PGRN, ANG, VEGF, VCP, VAPB, DCTN1, CHMP2B, and TARDBP or TDP-43), tauopathy-related gene (GSK3beta), and parkinsonism-related genes (alpha-synuclein, LRRK2, parkin, DJ-1, PINK1, and ATP13A2).
p14183
sg4
(lp14184
(dp14185
g7
I305
sg8
g9
sg10
I5
sg11
VLRRK2
p14186
sg13
I1
sa(dp14187
g7
I260
sg8
VP01893
p14188
sg10
I26
sg11
Vparkinsonism-related genes
p14189
sg13
I2
sa(dp14190
g7
I202
sg8
g9
sg10
I6
sg11
VTARDBP
p14191
sg13
I1
sa(dp14192
g7
I183
sg8
g9
sg10
I5
sg11
VDCTN1
p14193
sg13
I1
sa(dp14194
g7
I125
sg8
VP04179
p14195
sg10
I4
sg11
VSOD2
p14196
sg13
I1
sa(dp14197
g7
I288
sg8
VP37840
p14198
sg10
I15
sg11
Valpha-synuclein
p14199
sg13
I1
sa(dp14200
g7
I190
sg8
g9
sg10
I6
sg11
VCHMP2B
p14201
sg13
I1
sa(dp14202
g7
I177
sg8
g9
sg10
I4
sg11
VVAPB
p14203
sg13
I1
sa(dp14204
g7
I149
sg8
g9
sg10
I4
sg11
VSMN1
p14205
sg13
I1
sa(dp14206
g7
I320
sg8
g9
sg10
I4
sg11
VDJ-1
p14207
sg13
I1
sa(dp14208
g7
I172
sg8
VP55072
p14209
sg10
I3
sg11
VVCP
p14210
sg13
I1
sa(dp14211
g7
I137
sg8
g9
sg10
I4
sg11
VALS2
p14212
sg13
I1
sa(dp14213
g7
I142
sg8
g9
sg10
I5
sg11
Valsin
p14214
sg13
I1
sa(dp14215
g7
I212
sg8
g9
sg10
I6
sg11
VTDP-43
p14216
sg13
I1
sa(dp14217
g7
I326
sg8
g9
sg10
I5
sg11
VPINK1
p14218
sg13
I1
sa(dp14219
g7
I337
sg8
g9
sg10
I7
sg11
VATP13A2
p14220
sg13
I1
sa(dp14221
g7
I131
sg8
VP08294
p14222
sg10
I4
sg11
VSOD3
p14223
sg13
I1
sa(dp14224
g7
I161
sg8
VP03950
p14225
sg10
I3
sg11
VANG
p14226
sg13
I1
sasg24
(lp14227
(dp14228
g7
I137
sg27
VC1859807
p14229
sg10
I4
sg11
VALS2
p14230
sg13
I1
sa(dp14231
g7
I104
sg27
VC0751072
p14232
sg10
I4
sg11
VFTLD
p14233
sg13
I1
sa(dp14234
g7
I260
sg27
VC0242422
p14235
sg10
I12
sg11
Vparkinsonism
p14236
sg13
I1
sa(dp14237
g7
I221
sg27
VC0949664
p14238
sg10
I9
sg11
Vtauopathy
p14239
sg13
I1
sa(dp14240
g7
I65
sg27
VC0751072
p14241
sg10
I37
sg11
VALS/frontotemporal lobar degeneration
p14242
sg13
I3
sasa(dp14243
g2
VThis patient broadens the phenotypic spectrum of the 22q11.2 microduplication syndrome and raises the possibility that TUBA8 and USP18 may play an important role in the pathogenesis of amyoplasia.
p14244
sg4
(lp14245
(dp14246
g7
I119
sg8
g9
sg10
I5
sg11
VTUBA8
p14247
sg13
I1
sa(dp14248
g7
I129
sg8
g9
sg10
I5
sg11
VUSP18
p14249
sg13
I1
sasg24
(lp14250
(dp14251
g7
I169
sg27
VC0699748
p14252
sg10
I12
sg11
Vpathogenesis
p14253
sg13
I1
sa(dp14254
g7
I78
sg27
VC0039082
p14255
sg10
I8
sg11
Vsyndrome
p14256
sg13
I1
sasa(dp14257
g2
VDespite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials.
p14258
sg4
(lp14259
sg24
(lp14260
(dp14261
g7
I199
sg27
VC0677886
p14262
sg10
I25
sg11
Vepithelial ovarian cancer
p14263
sg13
I3
sa(dp14264
g7
I226
sg27
VC0677886
p14265
sg10
I3
sg11
VEOC
p14266
sg13
I1
sasa(dp14267
g2
VTo redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'.
p14268
sg4
(lp14269
sg24
(lp14270
(dp14271
g7
I25
sg27
VC1140680
p14272
sg10
I14
sg11
VOvarian Cancer
p14273
sg13
I2
sasa(dp14274
g2
VTo test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia.
p14275
sg4
(lp14276
sg24
(lp14277
(dp14278
g7
I28
sg27
VC1140680
p14279
sg10
I14
sg11
Vovarian cancer
p14280
sg13
I2
sa(dp14281
g7
I222
sg27
VC0917801
p14282
sg10
I8
sg11
Vinsomnia
p14283
sg13
I1
sa(dp14284
g7
I197
sg27
VC0011581
p14285
sg10
I10
sg11
Vdepression
p14286
sg13
I1
sasa(dp14287
g2
VProgression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial.
p14288
sg4
(lp14289
sg24
(lp14290
(dp14291
g7
I190
sg27
VC1140680
p14292
sg10
I14
sg11
Vovarian cancer
p14293
sg13
I2
sasa(dp14294
g2
VDespite increased recognition of the value of including patient-reported outcomes (PROs) as important end points in phase III clinical trials, there has been a lack of pre-specified PRO hypotheses and shortcomings with the analyses and interpretation of PROs in many ovarian cancer trials.
p14295
sg4
(lp14296
sg24
(lp14297
(dp14298
g7
I267
sg27
VC1140680
p14299
sg10
I14
sg11
Vovarian cancer
p14300
sg13
I2
sasa(dp14301
g2
VPromoting the importance of hypothesis-driven PROs in ovarian cancer clinical trials will lead to improvements in the design of these trials and the interpretation of their results.
p14302
sg4
(lp14303
sg24
(lp14304
(dp14305
g7
I54
sg27
VC1140680
p14306
sg10
I14
sg11
Vovarian cancer
p14307
sg13
I2
sasa(dp14308
g2
VWe conducted the Surgery in Ovarian Cancer Quality of life Evaluation Research study (SOCQER 1), a prospective study investigating the feasibility of collection of serial PROs in patients who had extensive surgery and standard surgery for ovarian cancer.
p14309
sg4
(lp14310
sg24
(lp14311
(dp14312
g7
I28
sg27
VC1140680
p14313
sg10
I14
sg11
VOvarian Cancer
p14314
sg13
I2
sa(dp14315
g7
I239
sg27
VC1140680
p14316
sg10
I14
sg11
Vovarian cancer
p14317
sg13
I2
sasa(dp14318
g2
VThere is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials.
p14319
sg4
(lp14320
sg24
(lp14321
(dp14322
g7
I133
sg27
VC1140680
p14323
sg10
I14
sg11
Vovarian cancer
p14324
sg13
I2
sasa(dp14325
g2
VThe results were included in and combined with an expert consensus-building process to identify the most salient PROs for ovarian cancer clinical trials.
p14326
sg4
(lp14327
sg24
(lp14328
(dp14329
g7
I122
sg27
VC1140680
p14330
sg10
I14
sg11
Vovarian cancer
p14331
sg13
I2
sasa(dp14332
g2
VWe identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.
p14333
sg4
(lp14334
(dp14335
g7
I23
sg8
VP07225
p14336
sg10
I4
sg11
VPROs
p14337
sg13
I1
sasg24
(lp14338
(dp14339
g7
I132
sg27
VC0013395
p14340
sg10
I11
sg11
Vindigestion
p14341
sg13
I1
sa(dp14342
g7
I165
sg27
VC0042963
p14343
sg10
I8
sg11
Vvomiting
p14344
sg13
I1
sa(dp14345
g7
I72
sg27
VC1291077
p14346
sg10
I8
sg11
Vbloating
p14347
sg13
I1
sa(dp14348
g7
I56
sg27
VC0000737
p14349
sg10
I14
sg11
Vabdominal pain
p14350
sg13
I2
sa(dp14351
g7
I100
sg27
VC1458156
p14352
sg10
I10
sg11
Vrecurrence
p14353
sg13
I1
sa(dp14354
g7
I111
sg27
VC0242656
p14355
sg10
I19
sg11
Vdisease progression
p14356
sg13
I2
sa(dp14357
g7
I40
sg27
VC1140680
p14358
sg10
I14
sg11
Vovarian cancer
p14359
sg13
I2
sa(dp14360
g7
I145
sg27
VC0036877
p14361
sg10
I18
sg11
Vsexual dysfunction
p14362
sg13
I2
sa(dp14363
g7
I82
sg27
VC1446787
p14364
sg10
I8
sg11
Vcramping
p14365
sg13
I1
sasa(dp14366
g2
VFindings of the review and consensus process provide good support for use of these ovarian cancer-specific PROs in ovarian cancer clinical trials.
p14367
sg4
(lp14368
sg24
(lp14369
(dp14370
g7
I83
sg27
VC1140680
p14371
sg10
I14
sg11
Vovarian cancer
p14372
sg13
I2
sa(dp14373
g7
I83
sg27
VC1140680
p14374
sg10
I14
sg11
Vovarian cancer
p14375
sg13
I2
sasa(dp14376
g2
VMutations within this gene are responsible for kinesigenic paroxysmal dyskinesias (PKD) as well as for benign familial infantile epilepsy (BFIE), a disease associating infantile convulsions and choreoathetosis (ICCA), a form of familial hemiplegic migraine (FHM type 4), paroxysmal benign torticollis of childhood, and episodic ataxia.
p14377
sg4
(lp14378
sg24
(lp14379
(dp14380
g7
I319
sg27
VC1720189
p14381
sg10
I15
sg11
Vepisodic ataxia
p14382
sg13
I2
sa(dp14383
g7
I83
sg27
VC1868682
p14384
sg10
I3
sg11
VPKD
p14385
sg13
I1
sa(dp14386
g7
I258
sg27
VC1832894
p14387
sg10
I3
sg11
VFHM
p14388
sg13
I1
sa(dp14389
g7
I59
sg27
VC0752210
p14390
sg10
I22
sg11
Vparoxysmal dyskinesias
p14391
sg13
I2
sa(dp14392
g7
I211
sg27
VC1865926
p14393
sg10
I4
sg11
VICCA
p14394
sg13
I1
sa(dp14395
g7
I289
sg27
VC0040485
p14396
sg10
I11
sg11
Vtorticollis
p14397
sg13
I1
sa(dp14398
g7
I228
sg27
VC0338484
p14399
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14400
sg13
I3
sa(dp14401
g7
I129
sg27
VC0014544
p14402
sg10
I8
sg11
Vepilepsy
p14403
sg13
I1
sa(dp14404
g7
I168
sg27
VC1865926
p14405
sg10
I41
sg11
Vinfantile convulsions and choreoathetosis
p14406
sg13
I4
sasa(dp14407
g2
VFHM type 4 is attributed to mutations in the PRRT2 gene, which encodes a proline-rich transmembrane protein of as yet unknown function.
p14408
sg4
(lp14409
(dp14410
g7
I45
sg8
g9
sg10
I10
sg11
VPRRT2 gene
p14411
sg13
I2
sasg24
(lp14412
(dp14413
g7
I0
sg27
VC1832894
p14414
sg10
I3
sg11
VFHM
p14415
sg13
I1
sasa(dp14416
g2
VTwo PRRT2 mutations were in familial hemiplegic migraine or episodic ataxia, one SLC2A1 family had episodic ataxia and one PNKD family had familial hemiplegic migraine alone.
p14417
sg4
(lp14418
(dp14419
g7
I123
sg8
g9
sg10
I11
sg11
VPNKD family
p14420
sg13
I2
sa(dp14421
g7
I4
sg8
g9
sg10
I15
sg11
VPRRT2 mutations
p14422
sg13
I2
sa(dp14423
g7
I81
sg8
VP11166
p14424
sg10
I6
sg11
VSLC2A1
p14425
sg13
I1
sasg24
(lp14426
(dp14427
g7
I60
sg27
VC1720189
p14428
sg10
I15
sg11
Vepisodic ataxia
p14429
sg13
I2
sa(dp14430
g7
I28
sg27
VC0338484
p14431
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14432
sg13
I3
sa(dp14433
g7
I28
sg27
VC0338484
p14434
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14435
sg13
I3
sa(dp14436
g7
I60
sg27
VC1720189
p14437
sg10
I15
sg11
Vepisodic ataxia
p14438
sg13
I2
sasa(dp14439
g2
VSLC2A1 mutations were associated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia and myotonia and we identified a novel PNKD gene deletion in familial hemiplegic migraine.
p14440
sg4
(lp14441
(dp14442
g7
I197
sg8
g9
sg10
I9
sg11
VPNKD gene
p14443
sg13
I2
sa(dp14444
g7
I0
sg8
VP11166
p14445
sg10
I6
sg11
VSLC2A1
p14446
sg13
I1
sasg24
(lp14447
(dp14448
g7
I142
sg27
VC1720189
p14449
sg10
I15
sg11
Vepisodic ataxia
p14450
sg13
I2
sa(dp14451
g7
I68
sg27
VC1868682
p14452
sg10
I33
sg11
Vparoxysmal kinesigenic dyskinesia
p14453
sg13
I3
sa(dp14454
g7
I202
sg27
VC1442161
p14455
sg10
I13
sg11
Vgene deletion
p14456
sg13
I2
sa(dp14457
g7
I91
sg27
VC0013384
p14458
sg10
I10
sg11
Vdyskinesia
p14459
sg13
I1
sa(dp14460
g7
I219
sg27
VC0338484
p14461
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14462
sg13
I3
sasa(dp14463
g2
VWe assessed the clinical features of both FHM families and performed direct sequencing of all coding exons (and adjacent sequences) of the CACNA1A, ATP1A2, PRRT2 and SCN1A genes.
p14464
sg4
(lp14465
(dp14466
g7
I148
sg8
VP50993
p14467
sg10
I6
sg11
VATP1A2
p14468
sg13
I1
sa(dp14469
g7
I166
sg8
VP35498
p14470
sg10
I11
sg11
VSCN1A genes
p14471
sg13
I2
sa(dp14472
g7
I42
sg8
VP19883
p14473
sg10
I12
sg11
VFHM families
p14474
sg13
I2
sa(dp14475
g7
I156
sg8
g9
sg10
I5
sg11
VPRRT2
p14476
sg13
I1
sasg24
(lp14477
(dp14478
g7
I42
sg27
VC1832894
p14479
sg10
I3
sg11
VFHM
p14480
sg13
I1
sasa(dp14481
g2
VIn 2012, PRRT2 has been identified as the fourth FHM gene, and encodes an axonal protein associated to the exocytosis complex.
p14482
sg4
(lp14483
(dp14484
g7
I9
sg8
g9
sg10
I5
sg11
VPRRT2
p14485
sg13
I1
sasg24
(lp14486
(dp14487
g7
I49
sg27
VC1832894
p14488
sg10
I3
sg11
VFHM
p14489
sg13
I1
sasa(dp14490
g2
VTo characterise the phenotype of a family with paroxysmal exercise induced dystonia (PED) and migraine and establish whether it is linked to the paroxysmal non-kinesigenic dyskinesia (PNKD) locus on chromosome 2q33-35, the familial hemiplegic migraine (FHM) locus on chromosome 19p, or the familial infantile convulsions and paroxysmal choreoathetosis (ICCA syndrome) locus on chromosome 16.
p14491
sg4
(lp14492
sg24
(lp14493
(dp14494
g7
I172
sg27
VC0013384
p14495
sg10
I10
sg11
Vdyskinesia
p14496
sg13
I1
sa(dp14497
g7
I253
sg27
VC1832894
p14498
sg10
I3
sg11
VFHM
p14499
sg13
I1
sa(dp14500
g7
I309
sg27
VC0009951
p14501
sg10
I11
sg11
Vconvulsions
p14502
sg13
I1
sa(dp14503
g7
I358
sg27
VC0039082
p14504
sg10
I8
sg11
Vsyndrome
p14505
sg13
I1
sa(dp14506
g7
I75
sg27
VC0393593
p14507
sg10
I8
sg11
Vdystonia
p14508
sg13
I1
sa(dp14509
g7
I223
sg27
VC0338484
p14510
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14511
sg13
I3
sa(dp14512
g7
I58
sg27
VC0239313
p14513
sg10
I16
sg11
Vexercise induced
p14514
sg13
I2
sa(dp14515
g7
I94
sg27
VC0149931
p14516
sg10
I8
sg11
Vmigraine
p14517
sg13
I1
sa(dp14518
g7
I353
sg27
VC1865926
p14519
sg10
I4
sg11
VICCA
p14520
sg13
I1
sa(dp14521
g7
I325
sg27
VC1868682
p14522
sg10
I26
sg11
Vparoxysmal choreoathetosis
p14523
sg13
I2
sasa(dp14524
g2
VHaplotypes were reconstructed for all the available family members by typing several microsatellite markers spanning the PNKD, FHM, and ICCA loci.
p14525
sg4
(lp14526
(dp14527
g7
I121
sg8
g9
sg10
I4
sg11
VPNKD
p14528
sg13
I1
sasg24
(lp14529
(dp14530
g7
I127
sg27
VC1832894
p14531
sg10
I3
sg11
VFHM
p14532
sg13
I1
sa(dp14533
g7
I136
sg27
VC1865926
p14534
sg10
I4
sg11
VICCA
p14535
sg13
I1
sasa(dp14536
g2
VLinkage of the disease to the PNKD, FHM, or ICCA loci was excluded as no common haplotype was shared by all the affected members for each locus.
p14537
sg4
(lp14538
(dp14539
g7
I30
sg8
g9
sg10
I4
sg11
VPNKD
p14540
sg13
I1
sasg24
(lp14541
(dp14542
g7
I44
sg27
VC1865926
p14543
sg10
I4
sg11
VICCA
p14544
sg13
I1
sa(dp14545
g7
I36
sg27
VC1832894
p14546
sg10
I3
sg11
VFHM
p14547
sg13
I1
sasa(dp14548
g2
VThis family presented with the classic phenotype of PED and is not linked to the PNKD, FHM, or ICCA loci.
p14549
sg4
(lp14550
(dp14551
g7
I81
sg8
g9
sg10
I4
sg11
VPNKD
p14552
sg13
I1
sasg24
(lp14553
(dp14554
g7
I87
sg27
VC1832894
p14555
sg10
I3
sg11
VFHM
p14556
sg13
I1
sa(dp14557
g7
I95
sg27
VC1865926
p14558
sg10
I4
sg11
VICCA
p14559
sg13
I1
sasa(dp14560
g2
VThe (FZr-EUl/FZl-EUr) and (FZr-EUr)/(FZl-EUl) were used for the patients with unicoronal craniosynostosis.
p14561
sg4
(lp14562
sg24
(lp14563
(dp14564
g7
I78
sg27
VC0432124
p14565
sg10
I27
sg11
Vunicoronal craniosynostosis
p14566
sg13
I2
sasa(dp14567
g2
VOur findings indicated that all evaluated parameters (epididymal sperm profile, Johnsen score, Plzf, GfrAlfa-1, Scp-1, Tekt-1 expressions, and histopathological profile) were significantly decreased following testicular torsion (group 3) when compared to the control group (p &lt;= 0.05).
p14568
sg4
(lp14569
(dp14570
g7
I112
sg8
g9
sg10
I5
sg11
VScp-1
p14571
sg13
I1
sasg24
(lp14572
(dp14573
g7
I209
sg27
VC0037856
p14574
sg10
I18
sg11
Vtesticular torsion
p14575
sg13
I2
sasa(dp14576
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare type of pigmentary genodermatosis, which is autosomal dominantly inherited with high penetrance.
p14577
sg4
(lp14578
sg24
(lp14579
(dp14580
g7
I39
sg27
VC0406775
p14581
sg10
I3
sg11
VDSH
p14582
sg13
I1
sa(dp14583
g7
I73
sg27
VC0037277
p14584
sg10
I14
sg11
Vgenodermatosis
p14585
sg13
I1
sa(dp14586
g7
I0
sg27
VC0406775
p14587
sg10
I37
sg11
VDyschromatosis symmetrica hereditaria
p14588
sg13
I3
sasa(dp14589
g2
VThe onset of DSH is typically during infancy or childhood.
p14590
sg4
(lp14591
(dp14592
g7
I13
sg8
VP55265
p14593
sg10
I3
sg11
VDSH
p14594
sg13
I1
sasg24
(lp14595
(dp14596
g7
I13
sg27
VC0406775
p14597
sg10
I3
sg11
VDSH
p14598
sg13
I1
sasa(dp14599
g2
VAdditionally, there have been few significant non-cutaneous complications reported with DSH.
p14600
sg4
(lp14601
(dp14602
g7
I88
sg8
VP55265
p14603
sg10
I3
sg11
VDSH
p14604
sg13
I1
sasg24
(lp14605
(dp14606
g7
I88
sg27
VC0406775
p14607
sg10
I3
sg11
VDSH
p14608
sg13
I1
sasa(dp14609
g2
VThe present study reported two sporadic cases of patients born with DSH, confirmed by the identification of ADAR1 mutations.
p14610
sg4
(lp14611
(dp14612
g7
I68
sg8
VP55265
p14613
sg10
I3
sg11
VDSH
p14614
sg13
I1
sa(dp14615
g7
I108
sg8
VP55265
p14616
sg10
I5
sg11
VADAR1
p14617
sg13
I1
sasg24
(lp14618
(dp14619
g7
I68
sg27
VC0406775
p14620
sg10
I3
sg11
VDSH
p14621
sg13
I1
sasa(dp14622
g2
VAdditionally, comorbidity of DSH, congenital heart disease (CHD) and hemangioma disease were first reported.
p14623
sg4
(lp14624
(dp14625
g7
I29
sg8
VP55265
p14626
sg10
I3
sg11
VDSH
p14627
sg13
I1
sasg24
(lp14628
(dp14629
g7
I69
sg27
VC0018916
p14630
sg10
I10
sg11
Vhemangioma
p14631
sg13
I1
sa(dp14632
g7
I60
sg27
VC0152021
p14633
sg10
I3
sg11
VCHD
p14634
sg13
I1
sa(dp14635
g7
I34
sg27
VC0152021
p14636
sg10
I24
sg11
Vcongenital heart disease
p14637
sg13
I3
sa(dp14638
g7
I29
sg27
VC0406775
p14639
sg10
I3
sg11
VDSH
p14640
sg13
I1
sasa(dp14641
g2
VIn the patient with isolated DSH from birth, a nonsense mutation (p.Y1192X) was identified, whereas in the second patient with DSH, CHD and hemangioma from birth, a frameshift mutation (p.Glu673ValfsX652) in ADAR1 was identified.
p14642
sg4
(lp14643
(dp14644
g7
I208
sg8
VP55265
p14645
sg10
I5
sg11
VADAR1
p14646
sg13
I1
sa(dp14647
g7
I29
sg8
VP55265
p14648
sg10
I3
sg11
VDSH
p14649
sg13
I1
sasg24
(lp14650
(dp14651
g7
I47
sg27
VC0544885
p14652
sg10
I17
sg11
Vnonsense mutation
p14653
sg13
I2
sa(dp14654
g7
I140
sg27
VC0018916
p14655
sg10
I10
sg11
Vhemangioma
p14656
sg13
I1
sa(dp14657
g7
I29
sg27
VC0406775
p14658
sg10
I3
sg11
VDSH
p14659
sg13
I1
sa(dp14660
g7
I29
sg27
VC0406775
p14661
sg10
I3
sg11
VDSH
p14662
sg13
I1
sa(dp14663
g7
I165
sg27
VC0079380
p14664
sg10
I19
sg11
Vframeshift mutation
p14665
sg13
I2
sasa(dp14666
g2
VTo the best of the authors' knowledge, &gt;120 mutations in ADAR1 have been reported to cause DSH; however, no previous studies have reported mutations in ADAR1 in DSH at birth, with CHD and hemangioma.
p14667
sg4
(lp14668
(dp14669
g7
I60
sg8
VP55265
p14670
sg10
I5
sg11
VADAR1
p14671
sg13
I1
sa(dp14672
g7
I94
sg8
VP55265
p14673
sg10
I3
sg11
VDSH
p14674
sg13
I1
sa(dp14675
g7
I60
sg8
VP55265
p14676
sg10
I5
sg11
VADAR1
p14677
sg13
I1
sasg24
(lp14678
(dp14679
g7
I191
sg27
VC0018916
p14680
sg10
I10
sg11
Vhemangioma
p14681
sg13
I1
sa(dp14682
g7
I94
sg27
VC0406775
p14683
sg10
I3
sg11
VDSH
p14684
sg13
I1
sa(dp14685
g7
I94
sg27
VC0406775
p14686
sg10
I3
sg11
VDSH
p14687
sg13
I1
sasa(dp14688
g2
VThe novel variants described in the current study add to the current knowledge of ADAR1 mutations in DSH.
p14689
sg4
(lp14690
(dp14691
g7
I101
sg8
VP55265
p14692
sg10
I3
sg11
VDSH
p14693
sg13
I1
sa(dp14694
g7
I82
sg8
VP55265
p14695
sg10
I5
sg11
VADAR1
p14696
sg13
I1
sasg24
(lp14697
(dp14698
g7
I101
sg27
VC0406775
p14699
sg10
I3
sg11
VDSH
p14700
sg13
I1
sa(dp14701
g7
I50
sg27
VC0004269
p14702
sg10
I3
sg11
Vadd
p14703
sg13
I1
sasa(dp14704
g2
VPathogenic molecular variants in the ADAR gene are a known cause of rare diseases, autosomal recessive Aicardi- Goutieres syndrome type 6, severe infantile encephalopathy with intracranial calcifications and dominant dyschromatosis symmetrica hereditaria, demonstrated mainly in Asian adults.
p14705
sg4
(lp14706
(dp14707
g7
I37
sg8
VP55265
p14708
sg10
I9
sg11
VADAR gene
p14709
sg13
I2
sasg24
(lp14710
(dp14711
g7
I122
sg27
VC0039082
p14712
sg10
I8
sg11
Vsyndrome
p14713
sg13
I1
sa(dp14714
g7
I217
sg27
VC0406775
p14715
sg10
I37
sg11
Vdyschromatosis symmetrica hereditaria
p14716
sg13
I3
sa(dp14717
g7
I68
sg27
VC0678236
p14718
sg10
I13
sg11
Vrare diseases
p14719
sg13
I2
sa(dp14720
g7
I156
sg27
VC0085584
p14721
sg10
I14
sg11
Vencephalopathy
p14722
sg13
I1
sasa(dp14723
g2
VTo identify potential mutation of the ADAR1 gene in a Chinese family and a sporadic case affected with dyschromatosis symmetrica hereditaria(DSH).
p14724
sg4
(lp14725
(dp14726
g7
I38
sg8
VP55265
p14727
sg10
I10
sg11
VADAR1 gene
p14728
sg13
I2
sasg24
(lp14729
(dp14730
g7
I141
sg27
VC0406775
p14731
sg10
I3
sg11
VDSH
p14732
sg13
I1
sa(dp14733
g7
I103
sg27
VC0406775
p14734
sg10
I37
sg11
Vdyschromatosis symmetrica hereditaria
p14735
sg13
I3
sasa(dp14736
g2
VThe frame-shift mutation c.2638delG (p.Asp880ThrfsX15) and the nonsense mutation c.2867C&gt;A (p.Ser956X) in the ADAR1 gene probably underlie the DSH in our patients.
p14737
sg4
(lp14738
(dp14739
g7
I146
sg8
VP55265
p14740
sg10
I3
sg11
VDSH
p14741
sg13
I1
sa(dp14742
g7
I113
sg8
VP55265
p14743
sg10
I10
sg11
VADAR1 gene
p14744
sg13
I2
sasg24
(lp14745
(dp14746
g7
I146
sg27
VC0406775
p14747
sg10
I3
sg11
VDSH
p14748
sg13
I1
sa(dp14749
g7
I63
sg27
VC0544885
p14750
sg10
I17
sg11
Vnonsense mutation
p14751
sg13
I2
sasa(dp14752
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene.
p14753
sg4
(lp14754
(dp14755
g7
I155
sg8
VP55265
p14756
sg10
I5
sg11
VADAR1
p14757
sg13
I1
sa(dp14758
g7
I119
sg8
VP55265
p14759
sg10
I34
sg11
Vadenosine deaminase acting on RNA1
p14760
sg13
I5
sasg24
(lp14761
(dp14762
g7
I39
sg27
VC0406775
p14763
sg10
I3
sg11
VDSH
p14764
sg13
I1
sa(dp14765
g7
I73
sg27
VC0037274
p14766
sg10
I18
sg11
Vcutaneous disorder
p14767
sg13
I2
sa(dp14768
g7
I0
sg27
VC0406775
p14769
sg10
I37
sg11
VDyschromatosis symmetrica hereditaria
p14770
sg13
I3
sasa(dp14771
g2
VWe present a clinical and genetic study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of ADAR1 gene.
p14772
sg4
(lp14773
(dp14774
g7
I96
sg8
VP55265
p14775
sg10
I3
sg11
VDSH
p14776
sg13
I1
sa(dp14777
g7
I145
sg8
VP55265
p14778
sg10
I10
sg11
VADAR1 gene
p14779
sg13
I2
sasg24
(lp14780
(dp14781
g7
I96
sg27
VC0406775
p14782
sg10
I3
sg11
VDSH
p14783
sg13
I1
sasa(dp14784
g2
VADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.
p14785
sg4
(lp14786
(dp14787
g7
I0
sg8
VP55265
p14788
sg10
I10
sg11
VADAR1 gene
p14789
sg13
I2
sasg24
(lp14790
(dp14791
g7
I81
sg27
VC0406775
p14792
sg10
I3
sg11
VDSH
p14793
sg13
I1
sasa(dp14794
g2
VWe describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop mutation p.Stop1227R, which was firstly reported in ADAR1 gene.
p14795
sg4
(lp14796
(dp14797
g7
I39
sg8
VP55265
p14798
sg10
I10
sg11
VADAR1 gene
p14799
sg13
I2
sa(dp14800
g7
I39
sg8
VP55265
p14801
sg10
I10
sg11
VADAR1 gene
p14802
sg13
I2
sasg24
(lp14803
(dp14804
g7
I75
sg27
VC0406775
p14805
sg10
I3
sg11
VDSH
p14806
sg13
I1
sasa(dp14807
g2
VA three-generation family exhibiting phenotypic variability with a single germline ADAR1 mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.
p14808
sg4
(lp14809
(dp14810
g7
I165
sg8
VP55265
p14811
sg10
I3
sg11
VDSH
p14812
sg13
I1
sa(dp14813
g7
I83
sg8
VP55265
p14814
sg10
I5
sg11
VADAR1
p14815
sg13
I1
sasg24
(lp14816
(dp14817
g7
I165
sg27
VC0406775
p14818
sg10
I3
sg11
VDSH
p14819
sg13
I1
sa(dp14820
g7
I112
sg27
VC0008058
p14821
sg10
I9
sg11
Vchilblain
p14822
sg13
I1
sasa(dp14823
g2
VAll patients underwent upper endoscopy and subsequently liver CT. Three radiologists independently evaluated the presence of high-risk esophageal varices with transverse images alone and with three orthogonal multiplanar reformation (MPR) images, respectively.
p14824
sg4
(lp14825
sg24
(lp14826
(dp14827
g7
I135
sg27
VC0014867
p14828
sg10
I18
sg11
Vesophageal varices
p14829
sg13
I2
sasa(dp14830
g2
VTo study the correlation between changes in portosystemic collaterals, evaluated by multidetector-row computed tomography imaging using multiplanar reconstruction (MDCT-MPR), and prognosis in patients with hemorrhagic esophageal varices (EV) after endoscopic treatment.
p14831
sg4
(lp14832
(dp14833
g7
I164
sg8
g9
sg10
I8
sg11
VMDCT-MPR
p14834
sg13
I1
sa(dp14835
g7
I84
sg8
g9
sg10
I78
sg11
Vmultidetector-row computed tomography imaging using multiplanar reconstruction
p14836
sg13
I7
sasg24
(lp14837
(dp14838
g7
I238
sg27
VC0014867
p14839
sg10
I2
sg11
VEV
p14840
sg13
I1
sa(dp14841
g7
I218
sg27
VC0014867
p14842
sg10
I18
sg11
Vesophageal varices
p14843
sg13
I2
sasa(dp14844
g2
VThe purpose of our study was to assess the relationship between hemodynamic changes in portosystemic collaterals and the prognosis of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction (MPR) MDCT images.
p14845
sg4
(lp14846
sg24
(lp14847
(dp14848
g7
I148
sg27
VC0014867
p14849
sg10
I18
sg11
Vesophageal varices
p14850
sg13
I2
sasa(dp14851
g2
VMPR MDCT images on portosystemic collaterals can accurately predict relapse of esophageal varices after endoscopic injection sclerotherapy.
p14852
sg4
(lp14853
sg24
(lp14854
(dp14855
g7
I68
sg27
VC0277556
p14856
sg10
I7
sg11
Vrelapse
p14857
sg13
I1
sa(dp14858
g7
I79
sg27
VC0014867
p14859
sg10
I18
sg11
Vesophageal varices
p14860
sg13
I2
sasa(dp14861
g2
VTTD is caused by mutations in DNA repair/transcription genes XPD, XPB or TTDA, and in TTDN1, a gene of unknown function.
p14862
sg4
(lp14863
(dp14864
g7
I66
sg8
VP19447
p14865
sg10
I3
sg11
VXPB
p14866
sg13
I1
sa(dp14867
g7
I61
sg8
VP18074
p14868
sg10
I3
sg11
VXPD
p14869
sg13
I1
sa(dp14870
g7
I73
sg8
g9
sg10
I4
sg11
VTTDA
p14871
sg13
I1
sa(dp14872
g7
I86
sg8
g9
sg10
I5
sg11
VTTDN1
p14873
sg13
I1
sasg24
(lp14874
(dp14875
g7
I66
sg27
VC0268136
p14876
sg10
I3
sg11
VXPB
p14877
sg13
I1
sa(dp14878
g7
I61
sg27
VC0268138
p14879
sg10
I3
sg11
VXPD
p14880
sg13
I1
sa(dp14881
g7
I86
sg27
VC1961117
p14882
sg10
I5
sg11
VTTDN1
p14883
sg13
I1
sasa(dp14884
g2
VTo date, four genes have been identified as responsible for TTD: XPD, XPB, p8/TTDA, and TTDN1.
p14885
sg4
(lp14886
(dp14887
g7
I65
sg8
VP18074
p14888
sg10
I3
sg11
VXPD
p14889
sg13
I1
sa(dp14890
g7
I70
sg8
VP19447
p14891
sg10
I3
sg11
VXPB
p14892
sg13
I1
sa(dp14893
g7
I88
sg8
g9
sg10
I5
sg11
VTTDN1
p14894
sg13
I1
sa(dp14895
g7
I78
sg8
g9
sg10
I4
sg11
VTTDA
p14896
sg13
I1
sasg24
(lp14897
(dp14898
g7
I65
sg27
VC0268138
p14899
sg10
I3
sg11
VXPD
p14900
sg13
I1
sa(dp14901
g7
I70
sg27
VC0268136
p14902
sg10
I3
sg11
VXPB
p14903
sg13
I1
sa(dp14904
g7
I88
sg27
VC1961117
p14905
sg10
I5
sg11
VTTDN1
p14906
sg13
I1
sasa(dp14907
g2
VWe analysed the gene expression and protein distribution of different members of the Hsp27, Hsp70, and Hsp90 families in the central nervous system of sheep naturally infected with scrapie.
p14908
sg4
(lp14909
(dp14910
g7
I92
sg8
VP34932
p14911
sg10
I5
sg11
VHsp70
p14912
sg13
I1
sa(dp14913
g7
I103
sg8
VP19883
p14914
sg10
I14
sg11
VHsp90 families
p14915
sg13
I2
sa(dp14916
g7
I85
sg8
g9
sg10
I5
sg11
VHsp27
p14917
sg13
I1
sasg24
(lp14918
(dp14919
g7
I181
sg27
VC0036457
p14920
sg10
I7
sg11
Vscrapie
p14921
sg13
I1
sa(dp14922
g7
I133
sg27
VC0027769
p14923
sg10
I7
sg11
Vnervous
p14924
sg13
I1
sasa(dp14925
g2
VWe have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions.
p14926
sg4
(lp14927
(dp14928
g7
I114
sg8
VP08107
p14929
sg10
I5
sg11
VHsp72
p14930
sg13
I1
sasg24
(lp14931
(dp14932
g7
I30
sg27
VC0036457
p14933
sg10
I7
sg11
Vscrapie
p14934
sg13
I1
sa(dp14935
g7
I47
sg27
VC1524043
p14936
sg10
I19
sg11
Vmouse neuroblastoma
p14937
sg13
I2
sasa(dp14938
g2
VIn scrapie-infected N2a (ScN2a) cells, Hsp72 and Hsp28 were not induced by heat shock, sodium arsenite, or an amino acid analog, in contrast to uninfected control N2a cells, while other inducible Hsps were increased by these treatments.
p14939
sg4
(lp14940
(dp14941
g7
I39
sg8
VP08107
p14942
sg10
I5
sg11
VHsp72
p14943
sg13
I1
sa(dp14944
g7
I196
sg8
VP08107
p14945
sg10
I4
sg11
VHsps
p14946
sg13
I1
sa(dp14947
g7
I25
sg8
g9
sg10
I5
sg11
VScN2a
p14948
sg13
I1
sa(dp14949
g7
I3
sg8
g9
sg10
I20
sg11
Vscrapie-infected N2a
p14950
sg13
I2
sasg24
(lp14951
(dp14952
g7
I3
sg27
VC0036457
p14953
sg10
I7
sg11
Vscrapie
p14954
sg13
I1
sasa(dp14955
g2
VWe have identified Receptor-interacting serine/threonine protein kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC).
p14956
sg4
(lp14957
(dp14958
g7
I75
sg8
VP57078
p14959
sg10
I4
sg11
VRIP4
p14960
sg13
I1
sa(dp14961
g7
I19
sg8
g9
sg10
I54
sg11
VReceptor-interacting serine/threonine protein kinase 4
p14962
sg13
I5
sasg24
(lp14963
(dp14964
g7
I99
sg27
VC0027651
p14965
sg10
I5
sg11
Vtumor
p14966
sg13
I1
sa(dp14967
g7
I124
sg27
VC0152013
p14968
sg10
I19
sg11
Vlung adenocarcinoma
p14969
sg13
I2
sasa(dp14970
g2
VAltogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells, promoting the expression of ECM remodeling genes and cancer dedifferentiation.
p14971
sg4
(lp14972
(dp14973
g7
I129
sg8
g9
sg10
I20
sg11
VECM remodeling genes
p14974
sg13
I3
sa(dp14975
g7
I63
sg8
VP40763
p14976
sg10
I5
sg11
VSTAT3
p14977
sg13
I1
sa(dp14978
g7
I49
sg8
VP57078
p14979
sg10
I4
sg11
VRIP4
p14980
sg13
I1
sasg24
(lp14981
(dp14982
g7
I82
sg27
VC0684249
p14983
sg10
I11
sg11
Vlung cancer
p14984
sg13
I2
sa(dp14985
g7
I87
sg27
VC0006826
p14986
sg10
I6
sg11
Vcancer
p14987
sg13
I1
sa(dp14988
g7
I161
sg27
VC0002793
p14989
sg10
I17
sg11
Vdedifferentiation
p14990
sg13
I1
sasa(dp14991
g2
VIn conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.
p14992
sg4
(lp14993
(dp14994
g7
I43
sg8
g9
sg10
I4
sg11
VEZH2
p14995
sg13
I1
sa(dp14996
g7
I37
sg8
VP57078
p14997
sg10
I5
sg11
VRIPK4
p14998
sg13
I1
sasg24
(lp14999
(dp15000
g7
I110
sg27
VC0302592
p15001
sg10
I15
sg11
Vcervical cancer
p15002
sg13
I2
sasa(dp15003
g2
VTo investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
p15004
sg4
(lp15005
(dp15006
g7
I78
sg8
VP57078
p15007
sg10
I5
sg11
VRIPK4
p15008
sg13
I1
sa(dp15009
g7
I39
sg8
g9
sg10
I37
sg11
Vreceptor-interacting kinase protein 4
p15010
sg13
I4
sasg24
(lp15011
(dp15012
g7
I140
sg27
VC1527249
p15013
sg10
I17
sg11
Vcolorectal cancer
p15014
sg13
I2
sa(dp15015
g7
I159
sg27
VC1527249
p15016
sg10
I3
sg11
VCRC
p15017
sg13
I1
sasa(dp15018
g2
VIn colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135).
p15019
sg4
(lp15020
(dp15021
g7
I31
sg8
VP57078
p15022
sg10
I9
sg11
VRIPK4 RCN
p15023
sg13
I2
sasg24
(lp15024
(dp15025
g7
I3
sg27
VC0699790
p15026
sg10
I12
sg11
Vcolon cancer
p15027
sg13
I2
sa(dp15028
g7
I146
sg27
VC0015624
p15029
sg10
I3
sg11
VRFS
p15030
sg13
I1
sasa(dp15031
g2
VIn rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738).
p15032
sg4
(lp15033
(dp15034
g7
I27
sg8
VP57078
p15035
sg10
I9
sg11
VRIPK4 RCN
p15036
sg13
I2
sasg24
(lp15037
(dp15038
g7
I3
sg27
VC0007113
p15039
sg10
I13
sg11
Vrectal cancer
p15040
sg13
I2
sa(dp15041
g7
I73
sg27
VC0015624
p15042
sg10
I3
sg11
VRFS
p15043
sg13
I1
sasa(dp15044
g2
VRIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.
p15045
sg4
(lp15046
(dp15047
g7
I0
sg8
VP57078
p15048
sg10
I9
sg11
VRIPK4 RCN
p15049
sg13
I2
sasg24
(lp15050
(dp15051
g7
I60
sg27
VC0699790
p15052
sg10
I12
sg11
Vcolon cancer
p15053
sg13
I2
sa(dp15054
g7
I60
sg27
VC0699790
p15055
sg10
I12
sg11
Vcolon cancer
p15056
sg13
I2
sasa(dp15057
g2
VAberrant expression of receptor interacting protein kinase 4 (RIPK4), a crucial regulatory protein of Wnt/Beta-catenin signaling, has recently been reported to be involved in several cancers.
p15058
sg4
(lp15059
(dp15060
g7
I62
sg8
VP57078
p15061
sg10
I5
sg11
VRIPK4
p15062
sg13
I1
sa(dp15063
g7
I23
sg8
g9
sg10
I37
sg11
Vreceptor interacting protein kinase 4
p15064
sg13
I5
sasg24
(lp15065
(dp15066
g7
I183
sg27
VC0006826
p15067
sg10
I7
sg11
Vcancers
p15068
sg13
I1
sasa(dp15069
g2
VHere, we report the potential clinical implication and biological functions of RIPK4 in cervical squamous cell carcinoma (CSCC).
p15070
sg4
(lp15071
(dp15072
g7
I79
sg8
VP57078
p15073
sg10
I5
sg11
VRIPK4
p15074
sg13
I1
sasg24
(lp15075
(dp15076
g7
I122
sg27
VC0279671
p15077
sg10
I4
sg11
VCSCC
p15078
sg13
I1
sa(dp15079
g7
I88
sg27
VC0279671
p15080
sg10
I32
sg11
Vcervical squamous cell carcinoma
p15081
sg13
I4
sasa(dp15082
g2
VRIPK4 expression increased significantly with disease progression from 3.2% in chronic cervicitis, 19.3% in LSILs and 85.1% in HSILs to 94.4% in CSCCs (P &lt; 0.001).
p15083
sg4
(lp15084
(dp15085
g7
I0
sg8
VP57078
p15086
sg10
I5
sg11
VRIPK4
p15087
sg13
I1
sasg24
(lp15088
(dp15089
g7
I79
sg27
VC0269062
p15090
sg10
I18
sg11
Vchronic cervicitis
p15091
sg13
I2
sa(dp15092
g7
I46
sg27
VC0242656
p15093
sg10
I19
sg11
Vdisease progression
p15094
sg13
I2
sasa(dp15095
g2
VKnockdown of RIPK4 reduced cell migration and invasion via inhibition of Vimentin, MMP2 and Fibronectin expression in cervical cancer cells.
p15096
sg4
(lp15097
(dp15098
g7
I83
sg8
VP08253
p15099
sg10
I4
sg11
VMMP2
p15100
sg13
I1
sa(dp15101
g7
I13
sg8
VP57078
p15102
sg10
I5
sg11
VRIPK4
p15103
sg13
I1
sasg24
(lp15104
(dp15105
g7
I118
sg27
VC0302592
p15106
sg10
I15
sg11
Vcervical cancer
p15107
sg13
I2
sa(dp15108
g7
I46
sg27
VC2699153
p15109
sg10
I8
sg11
Vinvasion
p15110
sg13
I1
sasa(dp15111
g2
VRIPK4 might act as a potential diagnostic and independent prognostic biomarker for CSCC patients.
p15112
sg4
(lp15113
(dp15114
g7
I0
sg8
VP57078
p15115
sg10
I5
sg11
VRIPK4
p15116
sg13
I1
sasg24
(lp15117
sa(dp15118
g2
VWe previously showed that protein kinase C-associated kinase (PKK, also known as DIK/RIP4), which belongs to the receptor-interacting protein (RIP) kinase family, mediates the B cell activating factor of the TNF family (BAFF)-induced NF-KB activation in diffuse large B cell lymphoma (DLBCL) cell lines.
p15119
sg4
(lp15120
(dp15121
g7
I113
sg8
g9
sg10
I28
sg11
Vreceptor-interacting protein
p15122
sg13
I2
sa(dp15123
g7
I26
sg8
VP17252
p15124
sg10
I34
sg11
Vprotein kinase C-associated kinase
p15125
sg13
I4
sa(dp15126
g7
I176
sg8
g9
sg10
I42
sg11
VB cell activating factor of the TNF family
p15127
sg13
I8
sa(dp15128
g7
I85
sg8
VP52594
p15129
sg10
I3
sg11
VRIP
p15130
sg13
I1
sa(dp15131
g7
I81
sg8
VP57078
p15132
sg10
I3
sg11
VDIK
p15133
sg13
I1
sa(dp15134
g7
I62
sg8
VP57078
p15135
sg10
I3
sg11
VPKK
p15136
sg13
I1
sa(dp15137
g7
I85
sg8
VP57078
p15138
sg10
I4
sg11
VRIP4
p15139
sg13
I1
sa(dp15140
g7
I220
sg8
g9
sg10
I4
sg11
VBAFF
p15141
sg13
I1
sasg24
(lp15142
(dp15143
g7
I285
sg27
VC0079744
p15144
sg10
I5
sg11
VDLBCL
p15145
sg13
I1
sa(dp15146
g7
I254
sg27
VC0079744
p15147
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p15148
sg13
I5
sasa(dp15149
g2
VSuppression of PKK expression by RNA interference inhibits phosphorylation of IKKAlfa and IKKBeta as well as activation of NF-KB in human cancer cell lines.
p15150
sg4
(lp15151
(dp15152
g7
I90
sg8
g9
sg10
I7
sg11
VIKKBeta
p15153
sg13
I1
sa(dp15154
g7
I15
sg8
VP57078
p15155
sg10
I3
sg11
VPKK
p15156
sg13
I1
sasg24
(lp15157
(dp15158
g7
I0
sg27
VC0221103
p15159
sg10
I11
sg11
VSuppression
p15160
sg13
I1
sa(dp15161
g7
I138
sg27
VC0006826
p15162
sg10
I6
sg11
Vcancer
p15163
sg13
I1
sasa(dp15164
g2
VWe propose that PKK may provide a critical link between IKK activation and various upstream signaling cascades, and may represent a potential target for inhibiting abnormal NF-KB activation in human cancers.
p15165
sg4
(lp15166
(dp15167
g7
I16
sg8
VP57078
p15168
sg10
I3
sg11
VPKK
p15169
sg13
I1
sa(dp15170
g7
I56
sg8
g9
sg10
I3
sg11
VIKK
p15171
sg13
I1
sasg24
(lp15172
(dp15173
g7
I199
sg27
VC0006826
p15174
sg10
I7
sg11
Vcancers
p15175
sg13
I1
sasa(dp15176
g2
VTo assess RIPK4 expression in various differentiated TSCC and to determine its basic biological function.
p15177
sg4
(lp15178
(dp15179
g7
I10
sg8
VP57078
p15180
sg10
I5
sg11
VRIPK4
p15181
sg13
I1
sasg24
(lp15182
sa(dp15183
g2
VA significantly higher level of RIPK4 was found in well-differentiated TSCC samples than in the poorly differentiated ones (p&lt;0.01).
p15184
sg4
(lp15185
(dp15186
g7
I32
sg8
VP57078
p15187
sg10
I5
sg11
VRIPK4
p15188
sg13
I1
sasg24
(lp15189
sa(dp15190
g2
VIn the present work we found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender.
p15191
sg4
(lp15192
(dp15193
g7
I51
sg8
VP57078
p15194
sg10
I5
sg11
VRIPK4
p15195
sg13
I1
sasg24
(lp15196
sa(dp15197
g2
VThe better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.
p15198
sg4
(lp15199
(dp15200
g7
I55
sg8
VP57078
p15201
sg10
I5
sg11
VRIPK4
p15202
sg13
I1
sasg24
(lp15203
(dp15204
g7
I107
sg27
VC0558353
p15205
sg10
I13
sg11
Vtongue cancer
p15206
sg13
I2
sasa(dp15207
g2
VInterestingly, maladaptive ECM remodeling was observed in early AVM without AVD and worsened with late AVD, as evidenced by increased MMP-2 and MMP-9 expression and activity, as well as abnormalities in ADAMTS-mediated versican processing.
p15208
sg4
(lp15209
(dp15210
g7
I144
sg8
VP14780
p15211
sg10
I5
sg11
VMMP-9
p15212
sg13
I1
sa(dp15213
g7
I134
sg8
VP08253
p15214
sg10
I5
sg11
VMMP-2
p15215
sg13
I1
sasg24
(lp15216
(dp15217
g7
I64
sg27
VC0003857
p15218
sg10
I3
sg11
VAVM
p15219
sg13
I1
sasa(dp15220
g2
VIn patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients.
p15221
sg4
(lp15222
(dp15223
g7
I209
sg8
VP04275
p15224
sg10
I3
sg11
VvWF
p15225
sg13
I1
sa(dp15226
g7
I216
sg8
g9
sg10
I8
sg11
VADAMTS13
p15227
sg13
I1
sasg24
(lp15228
(dp15229
g7
I174
sg27
VC0040053
p15230
sg10
I10
sg11
Vthrombosis
p15231
sg13
I1
sa(dp15232
g7
I40
sg27
VC0019061
p15233
sg10
I25
sg11
Vhemolytic-uremic syndrome
p15234
sg13
I2
sa(dp15235
g7
I17
sg27
VC0003507
p15236
sg10
I15
sg11
Vaortic stenosis
p15237
sg13
I2
sasa(dp15238
g2
VThe gene and protein expression profiles and protein distribution of six potential genetic biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and terminal stages of scrapie in five different brain regions.
p15239
sg4
(lp15240
(dp15241
g7
I109
sg8
g9
sg10
I5
sg11
VCAPN6
p15242
sg13
I1
sa(dp15243
g7
I139
sg8
VP02795
p15244
sg10
I4
sg11
VMT2A
p15245
sg13
I1
sa(dp15246
g7
I148
sg8
VP49286
p15247
sg10
I6
sg11
VMTNR1B
p15248
sg13
I1
sasg24
(lp15249
(dp15250
g7
I217
sg27
VC0036457
p15251
sg10
I7
sg11
Vscrapie
p15252
sg13
I1
sasa(dp15253
g2
VThe distribution of the GALA1 was identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports.
p15254
sg4
(lp15255
(dp15256
g7
I216
sg8
VP02795
p15257
sg10
I4
sg11
VMT2A
p15258
sg13
I1
sasg24
(lp15259
(dp15260
g7
I83
sg27
VC0036457
p15261
sg10
I7
sg11
Vscrapie
p15262
sg13
I1
sasa(dp15263
g2
VIn conclusion, this study of gene transcription and protein expression and distribution confirm CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.
p15264
sg4
(lp15265
(dp15266
g7
I110
sg8
VP49286
p15267
sg10
I6
sg11
VMTNR1B
p15268
sg13
I1
sa(dp15269
g7
I96
sg8
g9
sg10
I5
sg11
VCAPN6
p15270
sg13
I1
sa(dp15271
g7
I121
sg8
VP02795
p15272
sg10
I4
sg11
VMT2A
p15273
sg13
I1
sasg24
(lp15274
(dp15275
g7
I159
sg27
VC0162534
p15276
sg10
I13
sg11
Vprion disease
p15277
sg13
I2
sasa(dp15278
g2
VLincRNA-p21 could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1.
p15279
sg4
(lp15280
(dp15281
g7
I88
sg8
VP04216
p15282
sg10
I5
sg11
VThy-1
p15283
sg13
I1
sa(dp15284
g7
I8
sg8
VP42857
p15285
sg10
I3
sg11
Vp21
p15286
sg13
I1
sasg24
(lp15287
(dp15288
g7
I26
sg27
VC0034069
p15289
sg10
I18
sg11
Vpulmonary fibrosis
p15290
sg13
I2
sa(dp15291
g7
I48
sg27
VC0035222
p15292
sg10
I4
sg11
VARDS
p15293
sg13
I1
sasa(dp15294
g2
VLPS-induced pulmonary fibrosis was related with activation of HDAC, deacetylation of histone H3 and H4 and Thy-1 gene silencing.
p15295
sg4
(lp15296
(dp15297
g7
I107
sg8
VP04216
p15298
sg10
I10
sg11
VThy-1 gene
p15299
sg13
I2
sa(dp15300
g7
I85
sg8
g9
sg10
I10
sg11
Vhistone H3
p15301
sg13
I2
sa(dp15302
g7
I62
sg8
VP56524
p15303
sg10
I4
sg11
VHDAC
p15304
sg13
I1
sasg24
(lp15305
(dp15306
g7
I12
sg27
VC0034069
p15307
sg10
I18
sg11
Vpulmonary fibrosis
p15308
sg13
I2
sa(dp15309
g7
I0
sg27
VC0175697
p15310
sg10
I3
sg11
VLPS
p15311
sg13
I1
sasa(dp15312
g2
VHDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.
p15313
sg4
(lp15314
(dp15315
g7
I0
sg8
VP56524
p15316
sg10
I4
sg11
VHDAC
p15317
sg13
I1
sa(dp15318
g7
I147
sg8
VP62805
p15319
sg10
I10
sg11
Vhistone H4
p15320
sg13
I2
sa(dp15321
g7
I0
sg8
VP56524
p15322
sg10
I4
sg11
VHDAC
p15323
sg13
I1
sasg24
(lp15324
(dp15325
g7
I44
sg27
VC0034069
p15326
sg10
I18
sg11
Vpulmonary fibrosis
p15327
sg13
I2
sa(dp15328
g7
I32
sg27
VC0175697
p15329
sg10
I3
sg11
VLPS
p15330
sg13
I1
sasa(dp15331
g2
VSSc patients with pulmonary fibrosis (P = 0.006) and patients with PAH (P &lt; 0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc.
p15332
sg4
(lp15333
sg24
(lp15334
(dp15335
g7
I18
sg27
VC0034069
p15336
sg10
I18
sg11
Vpulmonary fibrosis
p15337
sg13
I2
sa(dp15338
g7
I67
sg27
VC0152171
p15339
sg10
I3
sg11
VPAH
p15340
sg13
I1
sasa(dp15341
g2
VOsteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive genetic disorder characterised by congenital blindness and osteoporosis, caused by biallelic mutations in the LRP5 gene.
p15342
sg4
(lp15343
(dp15344
g7
I183
sg8
g9
sg10
I9
sg11
VLRP5 gene
p15345
sg13
I2
sasg24
(lp15346
(dp15347
g7
I73
sg27
VC0019247
p15348
sg10
I16
sg11
Vgenetic disorder
p15349
sg13
I2
sa(dp15350
g7
I107
sg27
VC0005754
p15351
sg10
I20
sg11
Vcongenital blindness
p15352
sg13
I2
sa(dp15353
g7
I26
sg27
VC0039082
p15354
sg10
I8
sg11
Vsyndrome
p15355
sg13
I1
sa(dp15356
g7
I132
sg27
VC0029456
p15357
sg10
I12
sg11
Vosteoporosis
p15358
sg13
I1
sa(dp15359
g7
I0
sg27
VC0432252
p15360
sg10
I25
sg11
VOsteoporosis pseudoglioma
p15361
sg13
I2
sasa(dp15362
g2
VMolecular genetic examination detected the LRP5 gene for FEVR.
p15363
sg4
(lp15364
(dp15365
g7
I43
sg8
g9
sg10
I9
sg11
VLRP5 gene
p15366
sg13
I2
sasg24
(lp15367
sa(dp15368
g2
VThe majority of mutations identified in FEVR are found within four genes that encode the receptor complex (FZD4, LRP5, and TSPAN12) and ligand (NDP) of a molecular pathway that controls angiogenesis, the Norrin-Beta-catenin signaling pathway.
p15369
sg4
(lp15370
(dp15371
g7
I211
sg8
VP35222
p15372
sg10
I12
sg11
VBeta-catenin
p15373
sg13
I1
sa(dp15374
g7
I107
sg8
g9
sg10
I4
sg11
VFZD4
p15375
sg13
I1
sa(dp15376
g7
I113
sg8
g9
sg10
I4
sg11
VLRP5
p15377
sg13
I1
sa(dp15378
g7
I123
sg8
g9
sg10
I7
sg11
VTSPAN12
p15379
sg13
I1
sa(dp15380
g7
I204
sg8
g9
sg10
I6
sg11
VNorrin
p15381
sg13
I1
sa(dp15382
g7
I40
sg8
g9
sg10
I4
sg11
VFEVR
p15383
sg13
I1
sasg24
(lp15384
sa(dp15385
g2
VPrimers were designed to amplify the coding exons and adjacent intronic regions of the FEVR-causing genes FZD4, LRP5, NDP and TSPAN12.
p15386
sg4
(lp15387
(dp15388
g7
I112
sg8
g9
sg10
I4
sg11
VLRP5
p15389
sg13
I1
sa(dp15390
g7
I126
sg8
g9
sg10
I7
sg11
VTSPAN12
p15391
sg13
I1
sa(dp15392
g7
I106
sg8
g9
sg10
I4
sg11
VFZD4
p15393
sg13
I1
sa(dp15394
g7
I118
sg8
g9
sg10
I3
sg11
VNDP
p15395
sg13
I1
sasg24
(lp15396
sa(dp15397
g2
VWe identified five LRP5 mutations: three novel heterozygous mutations-p.M181R, p.R399S and p.G503R and two known mutations that were never reported in FEVR patients: p.R494Q and p.G876S.
p15398
sg4
(lp15399
(dp15400
g7
I19
sg8
g9
sg10
I14
sg11
VLRP5 mutations
p15401
sg13
I2
sasg24
(lp15402
sa(dp15403
g2
VSurprisingly, we then found mutations in familial exudative vitreoretinopathy (FEVR) genes; low-density lipoprotein receptor-related protein 5 mutations (six families), tetraspanin 12 mutations (two families), and NDP mutations (two families).
p15404
sg4
(lp15405
(dp15406
g7
I214
sg8
g9
sg10
I13
sg11
VNDP mutations
p15407
sg13
I2
sa(dp15408
g7
I92
sg8
g9
sg10
I60
sg11
Vlow-density lipoprotein receptor-related protein 5 mutations
p15409
sg13
I6
sa(dp15410
g7
I169
sg8
g9
sg10
I14
sg11
Vtetraspanin 12
p15411
sg13
I2
sasg24
(lp15412
(dp15413
g7
I79
sg27
VC0339539
p15414
sg10
I4
sg11
VFEVR
p15415
sg13
I1
sa(dp15416
g7
I41
sg27
VC0339539
p15417
sg10
I36
sg11
Vfamilial exudative vitreoretinopathy
p15418
sg13
I3
sasa(dp15419
g2
VTherefore, this study aimed to determine the role of the Mdm2 SNIP 309 polymorphism in the gastric mucosal morphological patterns in patients with Helicobacter pylori associated gastritis.
p15420
sg4
(lp15421
(dp15422
g7
I57
sg8
g9
sg10
I9
sg11
VMdm2 SNIP
p15423
sg13
I2
sasg24
(lp15424
(dp15425
g7
I178
sg27
VC0017152
p15426
sg10
I9
sg11
Vgastritis
p15427
sg13
I1
sasa(dp15428
g2
VTherefore, this study aimed to determine the correlation between the patterns of Mdm2 SNIP 309 and the inflammation grading of Helicobacter pylori associated gastritis in a Thai population.
p15429
sg4
(lp15430
(dp15431
g7
I81
sg8
g9
sg10
I13
sg11
VMdm2 SNIP 309
p15432
sg13
I3
sasg24
(lp15433
(dp15434
g7
I158
sg27
VC0017152
p15435
sg10
I9
sg11
Vgastritis
p15436
sg13
I1
sa(dp15437
g7
I103
sg27
VC0021368
p15438
sg10
I12
sg11
Vinflammation
p15439
sg13
I1
sasa(dp15440
g2
VGastric mucosa from 100 patients with Helicobacter pylori associated gastritis was analyzed for MDM2 SNP309 using real-time PCR hybridization (light-cycler) probes.
p15441
sg4
(lp15442
sg24
(lp15443
(dp15444
g7
I69
sg27
VC0017152
p15445
sg10
I9
sg11
Vgastritis
p15446
sg13
I1
sasa(dp15447
g2
VWhile planning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature.
p15448
sg4
(lp15449
(dp15450
g7
I168
sg8
g9
sg10
I6
sg11
VCDKAL1
p15451
sg13
I1
sa(dp15452
g7
I131
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15453
sg13
I1
sa(dp15454
g7
I118
sg8
g9
sg10
I6
sg11
VKCNJ11
p15455
sg13
I1
sa(dp15456
g7
I176
sg8
VP51787
p15457
sg10
I5
sg11
VKCNQ1
p15458
sg13
I1
sa(dp15459
g7
I162
sg8
g9
sg10
I4
sg11
VHHEX
p15460
sg13
I1
sa(dp15461
g7
I112
sg8
g9
sg10
I4
sg11
VP12A
p15462
sg13
I1
sa(dp15463
g7
I106
sg8
g9
sg10
I5
sg11
VPPARG
p15464
sg13
I1
sa(dp15465
g7
I126
sg8
g9
sg10
I3
sg11
VFTO
p15466
sg13
I1
sa(dp15467
g7
I140
sg8
g9
sg10
I5
sg11
VDUSP9
p15468
sg13
I1
sasg24
(lp15469
(dp15470
g7
I56
sg27
VC0011860
p15471
sg10
I15
sg11
Vtype 2 diabetes
p15472
sg13
I3
sasa(dp15473
g2
VAssociations between insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs11705701, insulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene polymorphisms with prediabetes and type 2 diabetes (T2D) have not been evaluated in the Han Chinese population.
p15474
sg4
(lp15475
(dp15476
g7
I74
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15477
sg13
I1
sa(dp15478
g7
I21
sg8
VP01308
p15479
sg10
I51
sg11
Vinsulin-like growth factor 2 mRNA-binding protein 2
p15480
sg13
I7
sa(dp15481
g7
I95
sg8
VP35568
p15482
sg10
I140
sg11
Vinsulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene
p15483
sg13
I17
sasg24
(lp15484
(dp15485
g7
I271
sg27
VC0011860
p15486
sg10
I15
sg11
Vtype 2 diabetes
p15487
sg13
I3
sa(dp15488
g7
I255
sg27
VC0362046
p15489
sg10
I11
sg11
Vprediabetes
p15490
sg13
I1
sa(dp15491
g7
I288
sg27
VC0011860
p15492
sg10
I3
sg11
VT2D
p15493
sg13
I1
sasa(dp15494
g2
VA breakdown analysis by gender revealed a significant association of IGF2BP2 rs11705701 with prediabetes under the dominant genetic model in females following application of the Bonferroni correction (odds ratio = 0.26; 95% confidence interval = 0.10-0.67; P=0.005).
p15495
sg4
(lp15496
(dp15497
g7
I69
sg8
g9
sg10
I18
sg11
VIGF2BP2 rs11705701
p15498
sg13
I2
sasg24
(lp15499
(dp15500
g7
I2
sg27
VC1265875
p15501
sg10
I9
sg11
Vbreakdown
p15502
sg13
I1
sa(dp15503
g7
I93
sg27
VC0362046
p15504
sg10
I11
sg11
Vprediabetes
p15505
sg13
I1
sasa(dp15506
g2
VThe present case-control study reveals a significant association between IGF2BP2 rs11705701 and prediabetes in female patients.
p15507
sg4
(lp15508
(dp15509
g7
I73
sg8
g9
sg10
I18
sg11
VIGF2BP2 rs11705701
p15510
sg13
I2
sasg24
(lp15511
(dp15512
g7
I96
sg27
VC0362046
p15513
sg10
I11
sg11
Vprediabetes
p15514
sg13
I1
sasa(dp15515
g2
VGenome-wide association studies (GWAS) found that IGF2BP2 rs4402960 and rs1470579 polymorphisms were associated with type 2 diabetes mellitus (T2DM) risk.
p15516
sg4
(lp15517
(dp15518
g7
I50
sg8
g9
sg10
I7
sg11
VIGF2BP2
p15519
sg13
I1
sasg24
(lp15520
(dp15521
g7
I117
sg27
VC0011860
p15522
sg10
I24
sg11
Vtype 2 diabetes mellitus
p15523
sg13
I4
sa(dp15524
g7
I143
sg27
VC0011860
p15525
sg10
I4
sg11
VT2DM
p15526
sg13
I1
sasa(dp15527
g2
VDecreased expression of CHC1L is linked to pathogenesis and progression of both prostate cancer and multiple myeloma.
p15528
sg4
(lp15529
(dp15530
g7
I24
sg8
g9
sg10
I5
sg11
VCHC1L
p15531
sg13
I1
sasg24
(lp15532
(dp15533
g7
I43
sg27
VC0699748
p15534
sg10
I12
sg11
Vpathogenesis
p15535
sg13
I1
sa(dp15536
g7
I80
sg27
VC0600139
p15537
sg10
I15
sg11
Vprostate cancer
p15538
sg13
I2
sa(dp15539
g7
I100
sg27
VC0026764
p15540
sg10
I16
sg11
Vmultiple myeloma
p15541
sg13
I2
sasa(dp15542
g2
VRecent studies of the RAN (6p21), ZHX-2 (8q24.3), CHC1L (13q14.3) loci highlight the importance of these genes in multiple myeloma (MM) prognosis and therapeutic applications.
p15543
sg4
(lp15544
(dp15545
g7
I34
sg8
g9
sg10
I36
sg11
VZHX-2 (8q24.3), CHC1L (13q14.3) loci
p15546
sg13
I5
sasg24
(lp15547
(dp15548
g7
I114
sg27
VC0026764
p15549
sg10
I16
sg11
Vmultiple myeloma
p15550
sg13
I2
sasa(dp15551
g2
VLow expression levels of RAN, ZHX-2, and CHC1L were observed in myeloma patients, compared with peripheral blood lymphocytes and MOLP-8 cells.
p15552
sg4
(lp15553
(dp15554
g7
I41
sg8
g9
sg10
I5
sg11
VCHC1L
p15555
sg13
I1
sasg24
(lp15556
(dp15557
g7
I64
sg27
VC0026764
p15558
sg10
I7
sg11
Vmyeloma
p15559
sg13
I1
sasa(dp15560
g2
VRAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
p15561
sg4
(lp15562
(dp15563
g7
I22
sg8
g9
sg10
I5
sg11
VCHC1L
p15564
sg13
I1
sa(dp15565
g7
I5
sg8
g9
sg10
I4
sg11
VZHX2
p15566
sg13
I1
sa(dp15567
g7
I14
sg8
g9
sg10
I6
sg11
VRCBTB2
p15568
sg13
I1
sasg24
(lp15569
(dp15570
g7
I271
sg27
VC0026470
p15571
sg10
I50
sg11
Vmonoclonal gammopathy of undetermined significance
p15572
sg13
I5
sa(dp15573
g7
I340
sg27
VC0023418
p15574
sg10
I10
sg11
Vleukaemias
p15575
sg13
I1
sa(dp15576
g7
I192
sg27
VC0026764
p15577
sg10
I16
sg11
Vmultiple myeloma
p15578
sg13
I2
sa(dp15579
g7
I152
sg27
VC1136085
p15580
sg10
I23
sg11
Vmonoclonal gammopathies
p15581
sg13
I2
sasa(dp15582
g2
VBCCIP deficiency impaired embryonic and postnatal neural development, causing severe ataxia, cerebral and cerebellar defects, and microcephaly.
p15583
sg4
(lp15584
sg24
(lp15585
(dp15586
g7
I17
sg27
VC0684336
p15587
sg10
I8
sg11
Vimpaired
p15588
sg13
I1
sa(dp15589
g7
I130
sg27
VC0025958
p15590
sg10
I12
sg11
Vmicrocephaly
p15591
sg13
I1
sa(dp15592
g7
I85
sg27
VC0004134
p15593
sg10
I6
sg11
Vataxia
p15594
sg13
I1
sasa(dp15595
g2
VPhosphorylation also links HS1 to multiple signaling proteins, including Lck, PLCgamma1, and Vav1, and is essential for the stable recruitment of Vav1 to the IS.
p15596
sg4
(lp15597
(dp15598
g7
I93
sg8
VP15498
p15599
sg10
I4
sg11
VVav1
p15600
sg13
I1
sa(dp15601
g7
I27
sg8
VP27348
p15602
sg10
I3
sg11
VHS1
p15603
sg13
I1
sa(dp15604
g7
I78
sg8
VP19174
p15605
sg10
I9
sg11
VPLCgamma1
p15606
sg13
I1
sa(dp15607
g7
I93
sg8
VP15498
p15608
sg10
I4
sg11
VVav1
p15609
sg13
I1
sasg24
(lp15610
(dp15611
g7
I27
sg27
VC2674218
p15612
sg10
I3
sg11
VHS1
p15613
sg13
I1
sa(dp15614
g7
I131
sg27
VC0271510
p15615
sg10
I11
sg11
Vrecruitment
p15616
sg13
I1
sasa(dp15617
g2
VOn the other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b.
p15618
sg4
(lp15619
(dp15620
g7
I83
sg8
VP27348
p15621
sg10
I3
sg11
VHS1
p15622
sg13
I1
sa(dp15623
g7
I161
sg8
VP48023
p15624
sg10
I4
sg11
VFasL
p15625
sg13
I1
sa(dp15626
g7
I154
sg8
g9
sg10
I5
sg11
VSam68
p15627
sg13
I1
sa(dp15628
g7
I167
sg8
VP22681
p15629
sg10
I5
sg11
Vc-Cbl
p15630
sg13
I1
sa(dp15631
g7
I75
sg8
g9
sg10
I6
sg11
VADAM15
p15632
sg13
I1
sa(dp15633
g7
I54
sg8
VP63244
p15634
sg10
I17
sg11
VSH3 binding sites
p15635
sg13
I3
sa(dp15636
g7
I54
sg8
VP63244
p15637
sg10
I17
sg11
VSH3 binding sites
p15638
sg13
I3
sa(dp15639
g7
I88
sg8
g9
sg10
I5
sg11
VSLP76
p15640
sg13
I1
sa(dp15641
g7
I178
sg8
g9
sg10
I5
sg11
VCbl-b
p15642
sg13
I1
sasg24
(lp15643
(dp15644
g7
I83
sg27
VC2674218
p15645
sg10
I3
sg11
VHS1
p15646
sg13
I1
sasa(dp15647
g2
VThe SH2 domains of ZAP70, SHP-1 and PLC gamma 1 and the SH3 domains of lck, vav and HS1 did not bind to pp85--90.
p15648
sg4
(lp15649
(dp15650
g7
I84
sg8
VP27348
p15651
sg10
I3
sg11
VHS1
p15652
sg13
I1
sa(dp15653
g7
I76
sg8
VP15498
p15654
sg10
I3
sg11
Vvav
p15655
sg13
I1
sa(dp15656
g7
I36
sg8
VP98160
p15657
sg10
I11
sg11
VPLC gamma 1
p15658
sg13
I3
sa(dp15659
g7
I19
sg8
VP43403
p15660
sg10
I5
sg11
VZAP70
p15661
sg13
I1
sa(dp15662
g7
I26
sg8
VP29350
p15663
sg10
I5
sg11
VSHP-1
p15664
sg13
I1
sasg24
(lp15665
(dp15666
g7
I84
sg27
VC2674218
p15667
sg10
I3
sg11
VHS1
p15668
sg13
I1
sasa(dp15669
g2
VThese analyses identified several cellular proteins inside HIV-1: elongation factor 1alpha, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein, Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43.
p15670
sg4
(lp15671
(dp15672
g7
I59
sg8
g9
sg10
I31
sg11
VHIV-1: elongation factor 1alpha
p15673
sg13
I4
sa(dp15674
g7
I140
sg8
VP30086
p15675
sg10
I40
sg11
Vphosphatidylethanolamine-binding protein
p15676
sg13
I2
sa(dp15677
g7
I182
sg8
g9
sg10
I4
sg11
VPin1
p15678
sg13
I1
sa(dp15679
g7
I193
sg8
VP22392
p15680
sg10
I7
sg11
VNm23-H1
p15681
sg13
I1
sa(dp15682
g7
I229
sg8
VP16150
p15683
sg10
I4
sg11
VCD43
p15684
sg13
I1
sa(dp15685
g7
I92
sg8
VP04406
p15686
sg10
I40
sg11
Vglyceraldehyde-3-phosphate dehydrogenase
p15687
sg13
I2
sasg24
(lp15688
(dp15689
g7
I59
sg27
VC0019693
p15690
sg10
I3
sg11
VHIV
p15691
sg13
I1
sasa(dp15692
g2
VWe find that the Src homology 3 domains of Grb2 directly associate, in vitro and in vivo, with murine hemopoietic specific protein 1 (HS1), a protein identical to Lck-binding protein 1.
p15693
sg4
(lp15694
(dp15695
g7
I43
sg8
VP62993
p15696
sg10
I4
sg11
VGrb2
p15697
sg13
I1
sa(dp15698
g7
I163
sg8
VP14222
p15699
sg10
I21
sg11
VLck-binding protein 1
p15700
sg13
I3
sa(dp15701
g7
I95
sg8
VP14222
p15702
sg10
I37
sg11
Vmurine hemopoietic specific protein 1
p15703
sg13
I5
sa(dp15704
g7
I17
sg8
VP12931
p15705
sg10
I14
sg11
VSrc homology 3
p15706
sg13
I3
sa(dp15707
g7
I134
sg8
VP27348
p15708
sg10
I3
sg11
VHS1
p15709
sg13
I1
sasg24
(lp15710
(dp15711
g7
I102
sg27
VC2674218
p15712
sg10
I30
sg11
Vhemopoietic specific protein 1
p15713
sg13
I4
sa(dp15714
g7
I134
sg27
VC2674218
p15715
sg10
I3
sg11
VHS1
p15716
sg13
I1
sasa(dp15717
g2
VBecause HS1 associates with the p56(lck) and p59(lyn) tyrosine kinases in vitro and in vivo, and becomes tyrosine phosphorylated upon various receptor stimulations, our present data suggest that HS1 mediates linkage between Lck or Lyn and Grb2 in lymphoid lineage cells.
p15718
sg4
(lp15719
(dp15720
g7
I8
sg8
VP27348
p15721
sg10
I3
sg11
VHS1
p15722
sg13
I1
sa(dp15723
g7
I49
sg8
VP07948
p15724
sg10
I3
sg11
Vlyn
p15725
sg13
I1
sa(dp15726
g7
I231
sg8
VP07948
p15727
sg10
I3
sg11
VLyn
p15728
sg13
I1
sa(dp15729
g7
I32
sg8
VP62191
p15730
sg10
I3
sg11
Vp56
p15731
sg13
I1
sa(dp15732
g7
I239
sg8
VP62993
p15733
sg10
I4
sg11
VGrb2
p15734
sg13
I1
sa(dp15735
g7
I45
sg8
g9
sg10
I3
sg11
Vp59
p15736
sg13
I1
sa(dp15737
g7
I54
sg8
VP29401
p15738
sg10
I16
sg11
Vtyrosine kinases
p15739
sg13
I2
sasg24
(lp15740
(dp15741
g7
I8
sg27
VC2674218
p15742
sg10
I3
sg11
VHS1
p15743
sg13
I1
sa(dp15744
g7
I8
sg27
VC2674218
p15745
sg10
I3
sg11
VHS1
p15746
sg13
I1
sasa(dp15747
g2
VWith this method, we previously isolated an Lck tyrosine kinase-associated protein, LckBP1, which is identical to HS1 (Kitamura et al., 1989, 1995; Takemoto et al., 1995).
p15748
sg4
(lp15749
(dp15750
g7
I84
sg8
VP14317
p15751
sg10
I6
sg11
VLckBP1
p15752
sg13
I1
sa(dp15753
g7
I48
sg8
VP29401
p15754
sg10
I34
sg11
Vtyrosine kinase-associated protein
p15755
sg13
I3
sasg24
(lp15756
(dp15757
g7
I114
sg27
VC2674218
p15758
sg10
I3
sg11
VHS1
p15759
sg13
I1
sasa(dp15760
g2
VWe have previously found that purine-rich element binding protein, PURalpha, was significantly repressed in androgen-independent prostate cancer cell lines in comparison to an androgen-dependent line.
p15761
sg4
(lp15762
(dp15763
g7
I30
sg8
g9
sg10
I35
sg11
Vpurine-rich element binding protein
p15764
sg13
I4
sa(dp15765
g7
I67
sg8
g9
sg10
I8
sg11
VPURalpha
p15766
sg13
I1
sasg24
(lp15767
(dp15768
g7
I129
sg27
VC0600139
p15769
sg10
I15
sg11
Vprostate cancer
p15770
sg13
I2
sasa(dp15771
g2
VMoreover, over-expressing PURalpha in androgen-independent prostate cancer cells attenuated their cell proliferation.
p15772
sg4
(lp15773
(dp15774
g7
I26
sg8
g9
sg10
I8
sg11
VPURalpha
p15775
sg13
I1
sasg24
(lp15776
(dp15777
g7
I103
sg27
VC0334094
p15778
sg10
I13
sg11
Vproliferation
p15779
sg13
I1
sa(dp15780
g7
I59
sg27
VC0600139
p15781
sg10
I15
sg11
Vprostate cancer
p15782
sg13
I2
sasa(dp15783
g2
VThese findings suggest that regulation of PURalpha expression in prostate cancer cells may serve as a therapeutic target for hormone refractory prostate cancer.
p15784
sg4
(lp15785
(dp15786
g7
I42
sg8
g9
sg10
I8
sg11
VPURalpha
p15787
sg13
I1
sasg24
(lp15788
(dp15789
g7
I125
sg27
VC1328504
p15790
sg10
I34
sg11
Vhormone refractory prostate cancer
p15791
sg13
I4
sa(dp15792
g7
I65
sg27
VC0600139
p15793
sg10
I15
sg11
Vprostate cancer
p15794
sg13
I2
sasa(dp15795
g2
VWe investigated the effects of the DNA damage-inducing cancer chemotherapeutic agent cisplatin on mouse embryo fibroblasts (MEFs) from PURA(-/-) knockout mice that lack Puralpha.
p15796
sg4
(lp15797
(dp15798
g7
I169
sg8
g9
sg10
I8
sg11
VPuralpha
p15799
sg13
I1
sasg24
(lp15800
(dp15801
g7
I55
sg27
VC0006826
p15802
sg10
I6
sg11
Vcancer
p15803
sg13
I1
sa(dp15804
g7
I35
sg27
VC0012860
p15805
sg10
I10
sg11
VDNA damage
p15806
sg13
I2
sasa(dp15807
g2
VMoreover, PURalpha was decreased in its expression both at the protein and mRNA levels in the androgen-independent prostate cancer cell lines, PC3 and DU145 in comparison to LNCaP cells.
p15808
sg4
(lp15809
(dp15810
g7
I10
sg8
g9
sg10
I8
sg11
VPURalpha
p15811
sg13
I1
sasg24
(lp15812
(dp15813
g7
I115
sg27
VC0600139
p15814
sg10
I15
sg11
Vprostate cancer
p15815
sg13
I2
sasa(dp15816
g2
VFrequent SIs were pneumonia (15.9%), cellulitis (9.9%), and sepsis (5.0%).
p15817
sg4
(lp15818
sg24
(lp15819
(dp15820
g7
I18
sg27
VC0032285
p15821
sg10
I9
sg11
Vpneumonia
p15822
sg13
I1
sa(dp15823
g7
I60
sg27
VC0243026
p15824
sg10
I6
sg11
Vsepsis
p15825
sg13
I1
sa(dp15826
g7
I37
sg27
VC0007642
p15827
sg10
I10
sg11
Vcellulitis
p15828
sg13
I1
sasa(dp15829
g2
VWe additionally show that pulmonary fibrosis in MyD88-KO mice was associated with the accumulation of pro-fibrotic regulatory T lymphocytes (T regs) and pro-fibrotic cytokine expression (TGF-Beta, IL-10 and PDGF-B), not with T helper (Th) 17 cell influx.
p15830
sg4
(lp15831
(dp15832
g7
I187
sg8
VP18075
p15833
sg10
I8
sg11
VTGF-Beta
p15834
sg13
I1
sa(dp15835
g7
I207
sg8
VP01127
p15836
sg10
I6
sg11
VPDGF-B
p15837
sg13
I1
sa(dp15838
g7
I48
sg8
g9
sg10
I8
sg11
VMyD88-KO
p15839
sg13
I1
sasg24
(lp15840
(dp15841
g7
I26
sg27
VC0034069
p15842
sg10
I18
sg11
Vpulmonary fibrosis
p15843
sg13
I2
sasa(dp15844
g2
VThe aim of our investigation was to analyze the pattern of interleukin-1 (IL-1) family compounds: IL-1 beta, IL-1 receptor accessory protein (Acp), IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type II (IL-1RII) in the serum and cerebrospinal fluid (CSF) from 67 multiple sclerosis (MS) patients and 31 controls.
p15845
sg4
(lp15846
(dp15847
g7
I209
sg8
g9
sg10
I7
sg11
VIL-1RII
p15848
sg13
I1
sa(dp15849
g7
I109
sg8
g9
sg10
I31
sg11
VIL-1 receptor accessory protein
p15850
sg13
I4
sa(dp15851
g7
I59
sg8
VP60568
p15852
sg10
I13
sg11
Vinterleukin-1
p15853
sg13
I1
sa(dp15854
g7
I148
sg8
g9
sg10
I24
sg11
VIL-1 receptor antagonist
p15855
sg13
I3
sa(dp15856
g7
I174
sg8
VP18510
p15857
sg10
I6
sg11
VIL-1Ra
p15858
sg13
I1
sa(dp15859
g7
I235
sg8
VP04141
p15860
sg10
I25
sg11
Vcerebrospinal fluid (CSF)
p15861
sg13
I3
sa(dp15862
g7
I142
sg8
VP13686
p15863
sg10
I3
sg11
VAcp
p15864
sg13
I1
sa(dp15865
g7
I74
sg8
VP01584
p15866
sg10
I4
sg11
VIL-1
p15867
sg13
I1
sa(dp15868
g7
I98
sg8
VP01584
p15869
sg10
I9
sg11
VIL-1 beta
p15870
sg13
I2
sa(dp15871
g7
I186
sg8
g9
sg10
I21
sg11
VIL-1 receptor type II
p15872
sg13
I4
sasg24
(lp15873
(dp15874
g7
I123
sg27
VC0394005
p15875
sg10
I17
sg11
Vaccessory protein
p15876
sg13
I2
sa(dp15877
g7
I142
sg27
VC0394005
p15878
sg10
I3
sg11
VAcp
p15879
sg13
I1
sa(dp15880
g7
I289
sg27
VC0026769
p15881
sg10
I2
sg11
VMS
p15882
sg13
I1
sa(dp15883
g7
I269
sg27
VC0026769
p15884
sg10
I18
sg11
Vmultiple sclerosis
p15885
sg13
I2
sasa(dp15886
g2
VPartial loss of IFT80 function leads Jeune asphyxiating thoracic dystrophy (JATD) or short-rib polydactyly (SRP) syndrome type III, displaying narrow thoracic cavity and multiple cartilage anomalies.
p15887
sg4
(lp15888
(dp15889
g7
I16
sg8
g9
sg10
I5
sg11
VIFT80
p15890
sg13
I1
sasg24
(lp15891
(dp15892
g7
I56
sg27
VC0729233
p15893
sg10
I8
sg11
Vthoracic
p15894
sg13
I1
sa(dp15895
g7
I95
sg27
VC0152427
p15896
sg10
I11
sg11
Vpolydactyly
p15897
sg13
I1
sa(dp15898
g7
I43
sg27
VC0265275
p15899
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p15900
sg13
I3
sa(dp15901
g7
I113
sg27
VC0039082
p15902
sg10
I8
sg11
Vsyndrome
p15903
sg13
I1
sa(dp15904
g7
I159
sg27
VC0011334
p15905
sg10
I6
sg11
Vcavity
p15906
sg13
I1
sasa(dp15907
g2
VPartial mutation of intraflagellar transport 80 (IFT80) in humans causes Jeune asphyxiating thoracic dystrophy (JATD) and short-rib polydactyly (SRP) syndrome type III.
p15908
sg4
(lp15909
(dp15910
g7
I49
sg8
g9
sg10
I5
sg11
VIFT80
p15911
sg13
I1
sa(dp15912
g7
I20
sg8
g9
sg10
I27
sg11
Vintraflagellar transport 80
p15913
sg13
I3
sasg24
(lp15914
(dp15915
g7
I150
sg27
VC0039082
p15916
sg10
I8
sg11
Vsyndrome
p15917
sg13
I1
sa(dp15918
g7
I132
sg27
VC0152427
p15919
sg10
I11
sg11
Vpolydactyly
p15920
sg13
I1
sa(dp15921
g7
I79
sg27
VC0265275
p15922
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p15923
sg13
I3
sasa(dp15924
g2
VPartial mutation of IFT80 in humans causes diseases such as Jeune asphyxiating thoracic dystrophy (JATD) and short rib polydactyly (SRP) type III with abnormal skeletal development.
p15925
sg4
(lp15926
(dp15927
g7
I20
sg8
g9
sg10
I5
sg11
VIFT80
p15928
sg13
I1
sasg24
(lp15929
(dp15930
g7
I66
sg27
VC0265275
p15931
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p15932
sg13
I3
sa(dp15933
g7
I119
sg27
VC0152427
p15934
sg10
I11
sg11
Vpolydactyly
p15935
sg13
I1
sasa(dp15936
g2
VJeune's asphyxiating thoracic dystrophy (JATD) is an autosomal recessive disorder with symptoms of retinal degeneration, kidney cysts, and chondrodysplasia and results from mutations in the ift80 gene.
p15937
sg4
(lp15938
(dp15939
g7
I190
sg8
g9
sg10
I10
sg11
Vift80 gene
p15940
sg13
I2
sasg24
(lp15941
(dp15942
g7
I99
sg27
VC0035304
p15943
sg10
I20
sg11
Vretinal degeneration
p15944
sg13
I2
sa(dp15945
g7
I121
sg27
VC0268800
p15946
sg10
I12
sg11
Vkidney cysts
p15947
sg13
I2
sa(dp15948
g7
I8
sg27
VC0265275
p15949
sg10
I31
sg11
Vasphyxiating thoracic dystrophy
p15950
sg13
I3
sa(dp15951
g7
I139
sg27
VC0343284
p15952
sg10
I16
sg11
Vchondrodysplasia
p15953
sg13
I1
sasa(dp15954
g2
VIL-33 is associated with a variety of autoimmune diseases, such as sclerosis, inflammatory bowel disease, and rheumatoid arthritis.
p15955
sg4
(lp15956
sg24
(lp15957
(dp15958
g7
I38
sg27
VC0004364
p15959
sg10
I19
sg11
Vautoimmune diseases
p15960
sg13
I2
sa(dp15961
g7
I78
sg27
VC0021390
p15962
sg10
I26
sg11
Vinflammatory bowel disease
p15963
sg13
I3
sa(dp15964
g7
I67
sg27
VC0036429
p15965
sg10
I9
sg11
Vsclerosis
p15966
sg13
I1
sa(dp15967
g7
I110
sg27
VC0003873
p15968
sg10
I20
sg11
Vrheumatoid arthritis
p15969
sg13
I2
sasa(dp15970
g2
VIL-33 was significantly higher in BD patients (101.2+/-20.1pg/ml) as compared to healthy controls (31.5+/-10.5 pg/ml) but lower than rheumatoid arthritis patients (132.5+/-19.1 pg/ml).
p15971
sg4
(lp15972
sg24
(lp15973
(dp15974
g7
I133
sg27
VC0003873
p15975
sg10
I20
sg11
Vrheumatoid arthritis
p15976
sg13
I2
sasa(dp15977
g2
VIt has been shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in experimental models, and a positive correlation between cytokine concentrations in serum and synovial fluid of patients with rheumatoid arthritis and disease activity was found.
p15978
sg4
(lp15979
(dp15980
g7
I45
sg8
g9
sg10
I14
sg11
Vinterleukin-33
p15981
sg13
I1
sasg24
(lp15982
(dp15983
g7
I227
sg27
VC0003873
p15984
sg10
I20
sg11
Vrheumatoid arthritis
p15985
sg13
I2
sa(dp15986
g7
I89
sg27
VC0003864
p15987
sg10
I9
sg11
Varthritis
p15988
sg13
I1
sasa(dp15989
g2
VThis review discusses evidence for the role of interleukin-33 with a focus on rheumatoid arthritis.
p15990
sg4
(lp15991
(dp15992
g7
I47
sg8
g9
sg10
I14
sg11
Vinterleukin-33
p15993
sg13
I1
sasg24
(lp15994
(dp15995
g7
I78
sg27
VC0003873
p15996
sg10
I20
sg11
Vrheumatoid arthritis
p15997
sg13
I2
sasa(dp15998
g2
VThe antigenic protein spots reacted against sera from clonorchiasis patients and were identified as cysteine proteases, glutathione transferases, gelsolin, propionyl-CoA carboxylase (PCC), prohibitin and 14-3-3 protein (14-3-3) using LC-coupled ESI-MS/MS and an EST database for C. sinensis.
p15999
sg4
(lp16000
(dp16001
g7
I183
sg8
VP07320
p16002
sg10
I3
sg11
VPCC
p16003
sg13
I1
sa(dp16004
g7
I120
sg8
VP48637
p16005
sg10
I24
sg11
Vglutathione transferases
p16006
sg13
I2
sa(dp16007
g7
I100
sg8
VP49662
p16008
sg10
I18
sg11
Vcysteine proteases
p16009
sg13
I2
sa(dp16010
g7
I146
sg8
VP06396
p16011
sg10
I35
sg11
Vgelsolin, propionyl-CoA carboxylase
p16012
sg13
I3
sa(dp16013
g7
I189
sg8
VP35232
p16014
sg10
I10
sg11
Vprohibitin
p16015
sg13
I1
sasg24
(lp16016
(dp16017
g7
I54
sg27
VC0009021
p16018
sg10
I13
sg11
Vclonorchiasis
p16019
sg13
I1
sa(dp16020
g7
I183
sg27
VC1832526
p16021
sg10
I3
sg11
VPCC
p16022
sg13
I1
sa(dp16023
g7
I22
sg27
VC0015230
p16024
sg10
I5
sg11
Vspots
p16025
sg13
I1
sa(dp16026
g7
I156
sg27
VC1832526
p16027
sg10
I25
sg11
Vpropionyl-CoA carboxylase
p16028
sg13
I2
sasa(dp16029
g2
VTo report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).
p16030
sg4
(lp16031
sg24
(lp16032
(dp16033
g7
I78
sg27
VC0039446
p16034
sg10
I14
sg11
Vtelangiectasia
p16035
sg13
I1
sasa(dp16036
g2
VTo identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-Beta (TGF-Beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.
p16037
sg4
(lp16038
(dp16039
g7
I45
sg8
VP21781
p16040
sg10
I26
sg11
Vkeratinocyte growth factor
p16041
sg13
I3
sa(dp16042
g7
I112
sg8
VP29279
p16043
sg10
I4
sg11
VCTGF
p16044
sg13
I1
sa(dp16045
g7
I155
sg8
VP18075
p16046
sg10
I8
sg11
VTGF-Beta
p16047
sg13
I1
sa(dp16048
g7
I73
sg8
VP21781
p16049
sg10
I3
sg11
VKGF
p16050
sg13
I1
sa(dp16051
g7
I79
sg8
VP29279
p16052
sg10
I31
sg11
Vconnective tissue growth factor
p16053
sg13
I4
sa(dp16054
g7
I122
sg8
VP18075
p16055
sg10
I31
sg11
Vtransforming growth factor-Beta
p16056
sg13
I3
sasg24
(lp16057
(dp16058
g7
I184
sg27
VC0751039
p16059
sg10
I3
sg11
VCsA
p16060
sg13
I1
sa(dp16061
g7
I168
sg27
VC0751039
p16062
sg10
I14
sg11
Vcyclosporine-A
p16063
sg13
I1
sasa(dp16064
g2
VKeratinocyte growth factor (KGF) and scatter factor (SF) are fibroblast-derived growth factors with potent mitogenic and motogenic effects on epithelial cells, and, therefore, could be involved in the pathogenesis of gingival overgrowth.
p16065
sg4
(lp16066
(dp16067
g7
I0
sg8
VP21781
p16068
sg10
I26
sg11
VKeratinocyte growth factor
p16069
sg13
I3
sa(dp16070
g7
I28
sg8
VP21781
p16071
sg10
I3
sg11
VKGF
p16072
sg13
I1
sasg24
(lp16073
(dp16074
g7
I201
sg27
VC0699748
p16075
sg10
I12
sg11
Vpathogenesis
p16076
sg13
I1
sasa(dp16077
g2
VThese results suggest that KGF and SF may have an important role in cyclosporin-induced gingival overgrowth.
p16078
sg4
(lp16079
(dp16080
g7
I27
sg8
VP21781
p16081
sg10
I3
sg11
VKGF
p16082
sg13
I1
sasg24
(lp16083
sa(dp16084
g2
VOn return to the district to calve, 54% of calves from herd 1 and 30% of calves from herd 2 were affected with congenital arthrogryposis or hydranencephaly caused by Akabane virus infection.
p16085
sg4
(lp16086
sg24
(lp16087
(dp16088
g7
I122
sg27
VC0003886
p16089
sg10
I14
sg11
Varthrogryposis
p16090
sg13
I1
sa(dp16091
g7
I140
sg27
VC0020225
p16092
sg10
I15
sg11
Vhydranencephaly
p16093
sg13
I1
sa(dp16094
g7
I174
sg27
VC0042769
p16095
sg10
I15
sg11
Vvirus infection
p16096
sg13
I2
sasa(dp16097
g2
VTwelve patients with classic radiologic and histologic features of MO, 6 with brown tumors, and 5 with cherubism diagnosed at our institution were studied for the presence of USP6 rearrangements using fluorescence in situ hybridization with probes flanking the USP6 locus on chromosome 17p13.
p16098
sg4
(lp16099
(dp16100
g7
I175
sg8
VP35125
p16101
sg10
I19
sg11
VUSP6 rearrangements
p16102
sg13
I2
sa(dp16103
g7
I261
sg8
VP35125
p16104
sg10
I10
sg11
VUSP6 locus
p16105
sg13
I2
sasg24
(lp16106
(dp16107
g7
I103
sg27
VC0008029
p16108
sg10
I9
sg11
Vcherubism
p16109
sg13
I1
sa(dp16110
g7
I78
sg27
VC0029405
p16111
sg10
I12
sg11
Vbrown tumors
p16112
sg13
I2
sasa(dp16113
g2
VNone of the patients with brown tumor or cherubism demonstrated USP6 rearrangements.
p16114
sg4
(lp16115
(dp16116
g7
I64
sg8
VP35125
p16117
sg10
I19
sg11
VUSP6 rearrangements
p16118
sg13
I2
sasg24
(lp16119
(dp16120
g7
I26
sg27
VC0029405
p16121
sg10
I11
sg11
Vbrown tumor
p16122
sg13
I2
sa(dp16123
g7
I41
sg27
VC0008029
p16124
sg10
I9
sg11
Vcherubism
p16125
sg13
I1
sasa(dp16126
g2
VIn contrast, no USP6 rearrangements were found in patients with cherubism or brown tumor, supporting the prevailing view that these lesions are distinct biologic entities.
p16127
sg4
(lp16128
(dp16129
g7
I16
sg8
VP35125
p16130
sg10
I19
sg11
VUSP6 rearrangements
p16131
sg13
I2
sasg24
(lp16132
(dp16133
g7
I64
sg27
VC0008029
p16134
sg10
I9
sg11
Vcherubism
p16135
sg13
I1
sa(dp16136
g7
I77
sg27
VC0029405
p16137
sg10
I11
sg11
Vbrown tumor
p16138
sg13
I2
sasa(dp16139
g2
VConsistent with findings in mice, marked alterations in nuclear envelope morphology, abnormal localization of RanGAP1, and nuclear accumulation of mRNA were found in cortex of Huntington's disease patients.
p16140
sg4
(lp16141
(dp16142
g7
I110
sg8
VP46060
p16143
sg10
I7
sg11
VRanGAP1
p16144
sg13
I1
sasg24
(lp16145
(dp16146
g7
I176
sg27
VC0020179
p16147
sg10
I20
sg11
VHuntington's disease
p16148
sg13
I2
sasa(dp16149
g2
VDouble immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.
p16150
sg4
(lp16151
(dp16152
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16153
sg13
I1
sa(dp16154
g7
I92
sg8
VP46060
p16155
sg10
I7
sg11
VRanGap1
p16156
sg13
I1
sa(dp16157
g7
I174
sg8
VP57740
p16158
sg10
I6
sg11
VNup107
p16159
sg13
I1
sa(dp16160
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16161
sg13
I1
sa(dp16162
g7
I105
sg8
g9
sg10
I6
sg11
VNup205
p16163
sg13
I1
sa(dp16164
g7
I113
sg8
g9
sg10
I5
sg11
VGp210
p16165
sg13
I1
sasg24
(lp16166
(dp16167
g7
I281
sg27
VC0002736
p16168
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p16169
sg13
I3
sasa(dp16170
g2
VDetection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.
p16171
sg4
(lp16172
(dp16173
g7
I205
sg8
VP98173
p16174
sg10
I3
sg11
VDLD
p16175
sg13
I1
sa(dp16176
g7
I200
sg8
g9
sg10
I3
sg11
VLDH
p16177
sg13
I1
sa(dp16178
g7
I188
sg8
VP63261
p16179
sg10
I10
sg11
VBeta-ACTIN
p16180
sg13
I1
sa(dp16181
g7
I221
sg8
VP01768
p16182
sg10
I9
sg11
VCaM genes
p16183
sg13
I2
sa(dp16184
g7
I210
sg8
g9
sg10
I6
sg11
VPRPF19
p16185
sg13
I1
sasg24
(lp16186
(dp16187
g7
I89
sg27
VC0024623
p16188
sg10
I14
sg11
Vgastric cancer
p16189
sg13
I2
sa(dp16190
g7
I89
sg27
VC0024623
p16191
sg10
I14
sg11
Vgastric cancer
p16192
sg13
I2
sa(dp16193
g7
I221
sg27
VC1861821
p16194
sg10
I3
sg11
VCaM
p16195
sg13
I1
sasa(dp16196
g2
VStable coronary artery disease (SCAD) patients scheduled for PCI were randomized to one of the three study arms: 1) genotyping, 2) PFT, and 3) control and evaluated by the CYP2C19 allele genotyping and PFT with P2Y12 assay.
p16197
sg4
(lp16198
(dp16199
g7
I172
sg8
VP33261
p16200
sg10
I14
sg11
VCYP2C19 allele
p16201
sg13
I2
sasg24
(lp16202
(dp16203
g7
I0
sg27
VC0342783
p16204
sg10
I30
sg11
VStable coronary artery disease
p16205
sg13
I4
sa(dp16206
g7
I107
sg27
VC0206655
p16207
sg10
I4
sg11
Varms
p16208
sg13
I1
sa(dp16209
g7
I32
sg27
VC0342783
p16210
sg10
I4
sg11
VSCAD
p16211
sg13
I1
sasa(dp16212
g2
VTo assess the association of CYP2C19 G681A, P2RY12 H1/H2, and ITGB3 T1565C polymorphisms with the extent of platelet aggregation in patients with coronary heart disease (CHD) during antiplatelet therapy.
p16213
sg4
(lp16214
(dp16215
g7
I44
sg8
g9
sg10
I12
sg11
VP2RY12 H1/H2
p16216
sg13
I2
sa(dp16217
g7
I29
sg8
VP33261
p16218
sg10
I13
sg11
VCYP2C19 G681A
p16219
sg13
I2
sa(dp16220
g7
I62
sg8
VP05106
p16221
sg10
I12
sg11
VITGB3 T1565C
p16222
sg13
I2
sasg24
(lp16223
(dp16224
g7
I170
sg27
VC0010054
p16225
sg10
I3
sg11
VCHD
p16226
sg13
I1
sa(dp16227
g7
I146
sg27
VC0010054
p16228
sg10
I22
sg11
Vcoronary heart disease
p16229
sg13
I3
sasa(dp16230
g2
VThis shortening of the HuR mRNA 3'-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells.
p16231
sg4
(lp16232
(dp16233
g7
I148
sg8
VP33240
p16234
sg10
I5
sg11
VCSTF2
p16235
sg13
I1
sa(dp16236
g7
I23
sg8
g9
sg10
I15
sg11
VHuR mRNA 3'-UTR
p16237
sg13
I3
sa(dp16238
g7
I154
sg8
VP33240
p16239
sg10
I7
sg11
VCstF-64
p16240
sg13
I1
sa(dp16241
g7
I130
sg8
g9
sg10
I16
sg11
Vfactor subunit 2
p16242
sg13
I3
sasg24
(lp16243
(dp16244
g7
I198
sg27
VC0678222
p16245
sg10
I13
sg11
Vbreast cancer
p16246
sg13
I2
sasa(dp16247
g2
VMoreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the prognosis of bladder cancer patient.
p16248
sg4
(lp16249
(dp16250
g7
I24
sg8
VP30519
p16251
sg10
I5
sg11
VHMOX2
p16252
sg13
I1
sa(dp16253
g7
I17
sg8
VP09884
p16254
sg10
I5
sg11
VPOLA1
p16255
sg13
I1
sa(dp16256
g7
I35
sg8
VP52799
p16257
sg10
I5
sg11
VEFNB2
p16258
sg13
I1
sa(dp16259
g7
I10
sg8
VP33240
p16260
sg10
I5
sg11
VCSTF2
p16261
sg13
I1
sasg24
(lp16262
(dp16263
g7
I81
sg27
VC0699885
p16264
sg10
I14
sg11
Vbladder cancer
p16265
sg13
I2
sasa(dp16266
g2
VAccordingly, RNAi-induced silencing of CSTF2 decreased the proliferative rate of cancer cells.
p16267
sg4
(lp16268
(dp16269
g7
I39
sg8
VP33240
p16270
sg10
I5
sg11
VCSTF2
p16271
sg13
I1
sasg24
(lp16272
(dp16273
g7
I81
sg27
VC0006826
p16274
sg10
I6
sg11
Vcancer
p16275
sg13
I1
sa(dp16276
g7
I59
sg27
VC0334094
p16277
sg10
I13
sg11
Vproliferative
p16278
sg13
I1
sasa(dp16279
g2
VImmunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value.
p16280
sg4
(lp16281
(dp16282
g7
I125
sg8
VP33240
p16283
sg10
I13
sg11
VCSTF2 protein
p16284
sg13
I2
sasg24
(lp16285
(dp16286
g7
I71
sg27
VC0242379
p16287
sg10
I12
sg11
Vlung cancers
p16288
sg13
I2
sasa(dp16289
g2
VA role of CSTF2 in cancer cell growth was examined by siRNA experiments.
p16290
sg4
(lp16291
(dp16292
g7
I10
sg8
VP33240
p16293
sg10
I5
sg11
VCSTF2
p16294
sg13
I1
sasg24
(lp16295
(dp16296
g7
I19
sg27
VC1516170
p16297
sg10
I18
sg11
Vcancer cell growth
p16298
sg13
I3
sasa(dp16299
g2
VImmunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.
p16300
sg4
(lp16301
(dp16302
g7
I85
sg8
VP33240
p16303
sg10
I5
sg11
VCSTF2
p16304
sg13
I1
sa(dp16305
g7
I85
sg8
VP33240
p16306
sg10
I5
sg11
VCSTF2
p16307
sg13
I1
sasg24
(lp16308
(dp16309
g7
I139
sg27
VC0007131
p16310
sg10
I26
sg11
Vnon-small cell lung cancer
p16311
sg13
I4
sasa(dp16312
g2
VIn addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
p16313
sg4
(lp16314
(dp16315
g7
I28
sg8
VP33240
p16316
sg10
I5
sg11
VCSTF2
p16317
sg13
I1
sa(dp16318
g7
I28
sg8
VP33240
p16319
sg10
I5
sg11
VCSTF2
p16320
sg13
I1
sasg24
(lp16321
(dp16322
g7
I71
sg27
VC1516170
p16323
sg10
I18
sg11
Vcancer cell growth
p16324
sg13
I3
sa(dp16325
g7
I13
sg27
VC0221103
p16326
sg10
I11
sg11
Vsuppression
p16327
sg13
I1
sa(dp16328
g7
I149
sg27
VC2699153
p16329
sg10
I8
sg11
Vinvasion
p16330
sg13
I1
sasa(dp16331
g2
VImmunohistochemistry analysis of cellular immune parameters (CD4+ or CD8+ T cells, CIITA, MHC-II and CD68) was performed on NMU-induced rat mammary tumor nodules, followed by evaluation of the serum level of 34 cytokines using the cytokine antibody array.
p16332
sg4
(lp16333
(dp16334
g7
I90
sg8
VP13747
p16335
sg10
I6
sg11
VMHC-II
p16336
sg13
I1
sa(dp16337
g7
I69
sg8
VP01732
p16338
sg10
I4
sg11
VCD8+
p16339
sg13
I1
sa(dp16340
g7
I83
sg8
VP33076
p16341
sg10
I5
sg11
VCIITA
p16342
sg13
I1
sa(dp16343
g7
I61
sg8
VP01730
p16344
sg10
I4
sg11
VCD4+
p16345
sg13
I1
sa(dp16346
g7
I101
sg8
VP34810
p16347
sg10
I4
sg11
VCD68
p16348
sg13
I1
sasg24
(lp16349
(dp16350
g7
I154
sg27
VC0028259
p16351
sg10
I7
sg11
Vnodules
p16352
sg13
I1
sa(dp16353
g7
I140
sg27
VC1458155
p16354
sg10
I13
sg11
Vmammary tumor
p16355
sg13
I2
sasa(dp16356
g2
VImmunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.
p16357
sg4
(lp16358
(dp16359
g7
I106
sg8
VP34810
p16360
sg10
I4
sg11
VCD68
p16361
sg13
I1
sa(dp16362
g7
I142
sg8
VP01765
p16363
sg10
I3
sg11
VTIL
p16364
sg13
I1
sa(dp16365
g7
I93
sg8
VP01732
p16366
sg10
I3
sg11
VCD8
p16367
sg13
I1
sa(dp16368
g7
I98
sg8
VP01730
p16369
sg10
I3
sg11
VCD4
p16370
sg13
I1
sa(dp16371
g7
I111
sg8
VP01765
p16372
sg10
I29
sg11
Vtumor-infiltrating leucocytes
p16373
sg13
I2
sasg24
(lp16374
(dp16375
g7
I54
sg27
VC0027651
p16376
sg10
I5
sg11
Vtumor
p16377
sg13
I1
sa(dp16378
g7
I54
sg27
VC0027651
p16379
sg10
I5
sg11
Vtumor
p16380
sg13
I1
sa(dp16381
g7
I117
sg27
VC0332448
p16382
sg10
I12
sg11
Vinfiltrating
p16383
sg13
I1
sa(dp16384
g7
I166
sg27
VC0006142
p16385
sg10
I14
sg11
Vbreast cancers
p16386
sg13
I2
sasa(dp16387
g2
VThese findings demonstrate, for the first time, a novel capacity of a P-Alexa647-FA conjugate to colocalize to CD11b+CD68+ TAMs in both primary and metastatic breast tumors.
p16388
sg4
(lp16389
(dp16390
g7
I111
sg8
VP11215
p16391
sg10
I16
sg11
VCD11b+CD68+ TAMs
p16392
sg13
I2
sasg24
(lp16393
(dp16394
g7
I159
sg27
VC1458155
p16395
sg10
I13
sg11
Vbreast tumors
p16396
sg13
I2
sasa(dp16397
g2
VWe used breast tumor tissues from each patient to make tissue microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and CD163 using immunohistochemical techniques.
p16398
sg4
(lp16399
(dp16400
g7
I151
sg8
VP35900
p16401
sg10
I4
sg11
VCD20
p16402
sg13
I1
sa(dp16403
g7
I173
sg8
g9
sg10
I5
sg11
VCD163
p16404
sg13
I1
sa(dp16405
g7
I146
sg8
VP01732
p16406
sg10
I3
sg11
VCD8
p16407
sg13
I1
sa(dp16408
g7
I157
sg8
VP01589
p16409
sg10
I4
sg11
VCD25
p16410
sg13
I1
sa(dp16411
g7
I163
sg8
VP34810
p16412
sg10
I4
sg11
VCD68
p16413
sg13
I1
sa(dp16414
g7
I141
sg8
VP01730
p16415
sg10
I3
sg11
VCD4
p16416
sg13
I1
sasg24
(lp16417
(dp16418
g7
I8
sg27
VC1458155
p16419
sg10
I12
sg11
Vbreast tumor
p16420
sg13
I2
sasa(dp16421
g2
VFurthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage.
p16422
sg4
(lp16423
(dp16424
g7
I29
sg8
g9
sg10
I6
sg11
VCD163+
p16425
sg13
I1
sa(dp16426
g7
I40
sg8
VP34810
p16427
sg10
I5
sg11
VCD68+
p16428
sg13
I1
sasg24
(lp16429
(dp16430
g7
I67
sg27
VC1140680
p16431
sg10
I14
sg11
Vovarian cancer
p16432
sg13
I2
sasa(dp16433
g2
VThe number of CD68+CD163+ M2-like macrophages was significantly higher in breast cancer tissues than in benign tissues.
p16434
sg4
(lp16435
(dp16436
g7
I14
sg8
VP34810
p16437
sg10
I19
sg11
VCD68+CD163+ M2-like
p16438
sg13
I2
sasg24
(lp16439
(dp16440
g7
I74
sg27
VC0678222
p16441
sg10
I13
sg11
Vbreast cancer
p16442
sg13
I2
sasa.